Post on 14-Apr-2022
UsetheselinkstorapidlyreviewthedocumentTABLEOFCONTENTSINDEXTOFINANCIALSTATEMENTS
TableofContents
As filed with the Securities and Exchange Commission on May 17, 2019
Registration No. 333-
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-4 REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
Elanco Animal Health Incorporated (Exactnameofregistrantasspecifiedinitscharter)
2500 Innovation Way Greenfield, Indiana 46140
(877) 352-6261 (Address,IncludingZipCode,andTelephoneNumber,IncludingAreaCode,ofRegistrant'sPrincipalExecutiveOffices)
Michael-Bryant Hicks, Esq. 2500 Innovation Way
Greenfield, Indiana 46140 (877) 352-6261
(Name,Address,IncludingZipCode,andTelephoneNumber,IncludingAreaCode,ofAgentForService)
Copies to:
Taavi Annus, Esq. Bryan Cave Leighton Paisner LLP
One Metropolitan Square 211 N. Broadway, Suite 3600
St. Louis, Missouri 63102 Tel: (314) 259-2000 Fax: (314) 259-2020
Approximate date of commencement of proposed sale of the securities to the public: As soon as practicable after the effectiveness of this registration statement.
IfthesecuritiesbeingregisteredonthisFormarebeingofferedinconnectionwiththeformationofaholdingcompanyandthereiscompliancewithGeneralInstructionG,checkthefollowingbox.o
IfthisFormisfiledtoregisteradditionalsecuritiesforanofferingpursuanttoRule462(b)undertheSecuritiesAct,checkthefollowingboxandlisttheSecuritiesActregistrationstatementnumberoftheearliereffectiveregistrationstatementforthesameoffering.o
IfthisFormisapost-effectiveamendmentfiledpursuanttoRule462(d)undertheSecuritiesAct,checkthefollowingboxandlisttheSecuritiesActregistrationstatementnumberoftheearliereffectiveregistrationstatementforthesameoffering.o
Indicatebycheckmarkwhethertheregistrantisalargeacceleratedfiler,anacceleratedfiler,anon-acceleratedfiler,asmallerreportingcompanyoranemerginggrowthcompany.Seethedefinitionsof"largeacceleratedfiler,""acceleratedfiler,""smallerreportingcompany"and"emerginggrowthcompany"inRule12b-2oftheExchangeAct.
Ifanemerginggrowthcompany,indicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiodforcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttoSection7(a)(2)(B)oftheSecuritiesAct.o
Ifapplicable,placeanXintheboxtodesignatetheappropriateruleprovisionrelieduponinconductingthistransaction:
ExchangeActRule13e-4(i)(Cross-BorderIssuerTenderOffer)o
ExchangeActRule14d-1(d)(Cross-BorderThird-PartyTenderOffer)o
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered
Amount to be Registered(1)
Proposed maximum offering price per
share
Proposed maximum aggregate offering
price Amount of
registration fees(3)
3.912%SeniorNotesdue2021 $500,000,000 100% $500,000,000 $60,600.00
4.272%SeniorNotesdue2023 $750,000,000 100% $750,000,000 $90,900.00
4.900%SeniorNotesdue2028 $750,000,000 100% $750,000,000 $90,900.00
Total $2,000,000,000(2) $242,400.00
(1) Representstheaggregateprincipalamountofeachseriesofnotestobeofferedintheexchangeofferstowhichtheregistrationstatementrelates.
(2) Representsthemaximumaggregateofferingpriceofallnotestobeofferedintheexchangeofferstowhichtheregistrationstatementrelates.
(3) ComputedinaccordancewithRule457(f)undertheSecuritiesAct.
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter becomeeffective in accordance with Section 8(a) of the Securities Act or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
Indiana (StateorOtherJurisdictionofIncorporationorOrganization)
2834 (PrimaryStandardIndustrialClassificationCodeNumber)
82-5497352 (I.R.S.Employer
IdentificationNumber)
Largeacceleratedfilero Acceleratedfilero Non-acceleratedfilerý SmallerreportingcompanyoEmerginggrowthcompanyo
TableofContents
The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. Thisprospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED MAY 17, 2019
Elanco Animal Health Incorporated
Offer to Exchange
up to $500,000,000 principal amount of our 3.912% Senior Notes due 2021 registered under the Securities Act, for any and all of its outstanding 3.912% Senior Notes due 2021;
up to $750,000,000 principal amount of our 4.272% Senior Notes due 2023 registered under the Securities Act, for any and all of its outstanding 4.272% Senior Notes due 2023; and
up to $750,000,000 principal amount of our 4.900% Senior Notes due 2028 registered under the Securities Act, for any and all outstanding unregistered 4.900% Senior Notes due 2028
Weareoffering,uponthetermsandsubjecttotheconditionssetforthinthisprospectusandtheaccompanyinglettersoftransmittal,toexchangeupto$500,000,000aggregateprincipalamountofournew3.912%SeniorNotesdue2021(the"2021ExchangeNotes")foralikeamountofouroutstandingunregistered3.912%SeniorNotesdue2021(the"2021OriginalNotes"),upto$750,000,000aggregateprincipalamountofournew4.272%SeniorNotesdue2023(the"2023ExchangeNotes")foralikeamountofouroutstandingunregistered4.272%SeniorNotesdue2023(the"2023OriginalNotes"),andupto$750,000,000aggregateprincipalamountofournew4.900%SeniorNotesdue2028(the"2028ExchangeNotes"and,collectivelywiththe2021ExchangeNotesandthe2023ExchangeNotes,the"ExchangeNotes")foralikeamountofouroutstandingunregistered4.900%SeniorNotesdue2028(the"2028OriginalNotes"and,collectivelywiththe2021OriginalNotesandthe2023OriginalNotes,the"OriginalNotes").WerefertotheExchangeNotesandtheOriginalNotestogetherasthe"notes"inthisprospectus.Werefertotheofferstoexchange,collectively,asthe"ExchangeOffers."
Terms of the Exchange Offers:
• TheExchangeOffersexpireat5:00 p.m., New York City time, on , 2019 ,unlessextended.
• AlloutstandingOriginalNotesthatarevalidlytenderedandnotvalidlywithdrawnpriortotheexpirationoftheExchangeOfferswillbeexchanged.
• YoumaywithdrawtendersofOriginalNotesatanytimepriortotheexpirationoftheExchangeOffers.
• WeissuedtheOriginalNotesinatransactionnotrequiringregistrationundertheSecuritiesActof1933,asamended(the"SecuritiesAct").WearemakingtheExchangeOffersinordertosatisfycertainofourobligationsundertheexchangeandregistrationrightsagreemententeredintoinconnectionwiththattransaction.
• TheexchangeofOriginalNotesforExchangeNoteswillnotbeataxableeventforU.S.federalincometaxpurposes.
• WewillnotreceiveanyproceedsfromtheExchangeOffers.
• ThetermsofeachseriesofExchangeNotesaresubstantiallyidenticaltothetermsoftheapplicableseriesofOriginalNotes,except(i)theExchangeNotesareregisteredundertheSecuritiesAct,(ii)thetransferrestrictionsandregistrationrightsapplicabletotheOriginalNotesdonotapplytotheExchangeNotes,and(iii)theExchangeNoteswillnotcontainprovisionsrelatingtoadditionalinterestrelatingtoourregistrationobligations.
ThereisnoestablishedtradingmarketfortheExchangeNotesortheOriginalNotes.WedonotintendtoapplyforlistingoftheExchangeNotesonanynationalsecuritiesexchangeorforquotationthroughanyquotationsystem.
AnyOriginalNotesnottenderedintheExchangeOfferswillremainoutstandingandcontinuetobesubjecttoallthetermsandconditionsspecifiedintheindenture,includingtransferrestrictions,butwillnotretainanyrightsundertheexchangeandregistrationrightsagreement(includingtherighttoearnadditionalinterestrelatingtoourregistrationobligations)aftertheconsummationoftheExchangeOffers.ExceptinlimitedcircumstanceswithrespecttospecifictypesofholdersofOriginalNotes,wewillhavenofurtherobligationtoprovidefortheregistrationundertheSecuritiesActofsuchOriginalNotes.Ingeneral,theOriginalNotesmaynotbeofferedorsold,unlessregisteredundertheSecuritiesAct,exceptpursuanttoanexemptionfrom,orinatransactionnotsubjectto,theSecuritiesActandapplicablestatesecuritieslaws.
Eachbroker-dealerthatreceivesExchangeNotesforitsownaccountpursuanttotheExchangeOffersmustacknowledgethatitwilldeliveraprospectusinconnectionwithanyresaleofsuchExchangeNotes.Theletteroftransmittalstatesthatbysoacknowledgingandbydeliveringaprospectus,abroker-dealerwillnotbedeemedtoadmitthatitisan"underwriter"withinthemeaningoftheSecuritiesAct.Thisprospectus,asitmaybeamendedorsupplementedfromtimetotime,maybeusedbyabroker-dealerinconnectionwithresalesofExchangeNotesreceivedinexchangeforOriginalNoteswheresuchOriginalNoteswereacquiredbysuchbroker-dealerasaresultofmarket-makingactivitiesorothertradingactivities.Wehaveagreedthat,foraperiodof180daysaftertheexpirationoftheExchangeOffers,wewillmakethisprospectusavailabletoanybroker-dealerforuseinconnectionwithanysuchresale.See"PlanofDistribution."
For a discussion of factors you should consider in determining whether to tender your Original Notes, see the information under "Risk Factors" beginning on page 15 of this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2019
TableofContents
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
WehavenotauthorizedanyonetogiveanyinformationortomakeanyrepresentationsconcerningtheseExchangeOffersexceptthatwhichisinthisprospectus,orwhichisreferredtounder"WhereYouCanFindMoreInformation."Ifanyonegivesormakesanyotherinformationorrepresentation,youshouldnotrelyonit.Thisprospectusisnotanoffertosellorasolicitationofanoffertobuysecuritiesinanycircumstancesinwhichtheofferorsolicitationisunlawful.Youshouldnotinterpretthedeliveryofthisprospectus,oranysaleofsecurities,asanindicationthattherehasbeennochangeinouraffairssincethedateofthisprospectus.Youshouldalsobeawarethatinformationinthisprospectusmaychangeafterthisdate.
WehavefiledwiththeSecuritiesandExchangeCommission,ortheSEC,aregistrationstatementonFormS-4withrespecttotheExchangeNotes.Thisprospectus,whichformspartofthisregistrationstatement,doesnotcontainalltheinformationincludedintheregistrationstatement,includingitsexhibitsandschedules.Forfurtherinformationaboutusandthenotesdescribedinthisprospectus,youshouldrefertotheregistrationstatementanditsexhibitsandschedules.Statementswemakeinthisprospectusaboutcertaincontractsorotherdocumentsarenotnecessarilycomplete.Whenwemakesuchstatements,wereferyoutothecopiesofthecontractsordocumentsthatarefiledasexhibitstotheregistrationstatement,becausethosestatementsarequalifiedinallrespectsbyreferencetothoseexhibits.Theregistrationstatement,includingtheexhibitsandschedules,isavailableattheSEC'swebsiteatwww.sec.gov .
i
AboutthisProspectus iCautionaryStatementConcerningForward-LookingStatements 1WhereYouCanFindMoreInformation 2ProspectusSummary 3RiskFactors 15UseofProceeds 42UnauditedProFormaCondensedConsolidatedandCombinedStatementofOperations 43Management'sDiscussionandAnalysisofFinancialConditionandResultsofOperations 47Industry 71Business 75Management 95ExecutiveCompensation 100CertainRelationshipsandRelatedPartyTransactions 134SecurityOwnershipofCertainBeneficialOwnersandManagement 144TheExchangeOffers 146DescriptionoftheExchangeNotes 157Book-EntrySettlementandClearance 171DescriptionofCertainOtherIndebtedness 174MaterialU.S.FederalIncomeTaxConsequences 175PlanofDistribution 176LegalMatters 178Experts 178SECPositiononIndemnificationforSecuritiesActLiabilities 178IndextoFinancialStatements F-1
TableofContents
Youmayalsoobtainthisinformationwithoutchargebywritingortelephoningusatthefollowingaddressandtelephonenumber:
ElancoAnimalHealthIncorporated2500InnovationWay
Greenfield,Indiana46140(877)352-6261
Attn:GeneralCounselandCorporateSecretary
If you would like to request copies of these documents, please do so by , 2019 (which is five business days before the scheduled expiration of the exchange offers) in order to receive thembefore the expiration of the Exchange Offers.
Asusedinthisprospectus,unlessthecontextrequiresotherwise,(i)referencesto"Elanco,"the"Company,""we,""us"or"our"refertoElancoAnimalHealthIncorporated,anIndianacorporationanditssubsidiariesand(ii)referencesto"Lilly"refertoEliLillyandCompany,anIndianacorporation,anditssubsidiaries,exceptElancoandElanco'ssubsidiariesshallnotbedeemedpartofLillyduringtheperiodsbeforeMarch11,2019,whenthemajorityofElanco'sshareswerecontrolledbyLilly.
Unlessotherwiseindicated,informationcontainedinthisprospectusconcerningElanco'sindustryandthemarketsinwhichElancooperates,includinggeneralexpectationsandmarketpositions,marketopportunityandmarketshare,isbasedoninformationfromthird-partysourcesandestimatesofElanco'smanagement.Certainstatements,whereindicated,arebasedoninformationpublishedbyVetnosisLimited("Vetnosis"),aresearchandconsultingfirmspecializinginglobalanimalhealthandveterinarymedicine,andestimatesofElanco'smanagement.Managementestimatesarederivedfrompubliclyavailableinformation,knowledgeofElanco'sindustryandassumptionsbasedonsuchinformationandknowledge,whichElancobelievestobereasonable.Managementestimateshavenotbeenverifiedbyanyindependentsource.Inaddition,assumptionsandestimatesofElanco'sanditsindustry'sfutureperformancesarenecessarilysubjecttoahighdegreeofuncertaintyandriskduetoavarietyoffactors,includingthosedescribedin"RiskFactors."TheseandotherfactorscouldcausefutureperformancetodiffermateriallyfromElanco'sassumptionsandestimates.See"CautionaryStatementConcerningForward-LookingStatements."
ii
TableofContents
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
Thisprospectuscontainsforward-lookingstatements,including,withoutlimitation,statementsconcerningtheExchangeOffers,ourindebtedness,ourabilitytomakeinterestandprincipalpaymentsonourindebtedness,ourabilitytosatisfythecovenantscontainedinourindebtedness,theredemptionofthenotes,ourindustryandouroperations,performanceandfinancialcondition,includinginparticular,statementsrelatingtoourbusiness,growthstrategies,productdevelopmentefforts,andfutureexpenses.Forward-lookingstatementscanbeidentifiedbywordssuchas"anticipates,""intends,""plans,""seeks,""believes,""estimates,""expects,"andsimilarreferencestofutureperiods,orbytheinclusionofforecastsorprojections.Examplesofforward-lookingstatementsinclude,butarenotlimitedto,statementswemakeregardingtheoutlookforourfuturebusinessandfinancialperformance,suchasthosecontainedin"Management'sDiscussionandAnalysisofFinancialConditionandResultsofOperations."
Forward-lookingstatementsarebasedonourcurrentexpectationsandassumptionsregardingourbusiness,theeconomy,andotherfutureconditions.Becauseforward-lookingstatementsrelatetothefuture,bytheirnature,theyaresubjecttoinherentuncertainties,risks,andchangesincircumstancesthataredifficulttopredict.Asaresult,ouractualresultsmaydiffermateriallyfromthosecontemplatedbytheforward-lookingstatements.Importantfactorsthatcouldcauseactualresultstodiffermateriallyfromthoseintheforward-lookingstatementsincluderegional,nationalorglobalpolitical,economic,business,competitive,marketandregulatoryconditionsandthefollowing:
• heightenedcompetition,includingfrominnovationorgenerics;
• theimpactofdisruptiveinnovationsandadvancesinveterinarymedicalpractices,animalhealthtechnologiesandalternativestoanimal-derivedprotein;
• changesinregulatoryrestrictionsontheuseofantibioticsinfoodanimals;
• impactofgenericproducts;
• ourabilitytoimplementourbusinessstrategiesorachievetargetedcostefficienciesandgrossmarginimprovements;
• consolidationofourcustomersanddistributors;
• anoutbreakofinfectiousdiseasecarriedbyfoodanimals;
• thesuccessofourR&Dandlicensingefforts;
• ourabilitytocompleteacquisitionsandsuccessfullyintegratethebusinessesweacquire;
• misuseoroff-labeluseofourproducts;
• unanticipatedsafety,qualityorefficacyconcernsassociatedwithourproducts;
• theimpactofweatherconditionsandtheavailabilityofnaturalresources;
• risksrelatedtoourpresenceinemergingmarkets;
• changesinU.S.foreigntradepolicy,impositionoftariffsortradedisputes;
• theimpactofglobalmacroeconomicconditions;and
• theeffectonourbusinessofthetransactionsinvolvingtheseparationofourbusinessfromthatofLillyandthedistributionofLilly'sinterestinustoitsshareholdersthroughanexchangeofferconsummatedonMarch11,2019.
See"RiskFactors"forafurtherdescriptionoftheseandotherfactors.Althoughwehaveattemptedtoidentifyimportantriskfactors,theremaybeotherriskfactorsnotpresentlyknowntous
1
TableofContents
orthatwepresentlybelievearenotmaterialthatcouldcauseactualresultsanddevelopmentstodiffermateriallyfromthosemadeinorsuggestedbytheforward-lookingstatementscontainedinthisprospectus.Ifanyoftheserisksmaterialize,orifanyoftheaboveassumptionsunderlyingforward-lookingstatementsproveincorrect,actualresultsanddevelopmentsmaydiffermateriallyfromthosemadeinorsuggestedbytheforward-lookingstatementscontainedinthisprospectus.Forthereasonsdescribedabove,wecautionyouagainstrelyingonanyforward-lookingstatements,whichshouldalsobereadinconjunctionwiththeothercautionarystatementsthatareincludedelsewhereinthisprospectus.Anyforward-lookingstatementmadebyusinthisprospectusspeaksonlyasofthedatethereof.Factorsoreventsthatcouldcauseouractualresultstodiffermayemergefromtimetotime,anditisnotpossibleforustopredictallofthem.Weundertakenoobligationtopubliclyupdateortoreviseanyforward-lookingstatement,whetherasaresultofnewinformation,futuredevelopments,orotherwise,exceptasmayberequiredbylaw.Comparisonsofresultsforcurrentandanypriorperiodsarenotintendedtoexpressanyfuturetrendsorindicationsoffutureperformance,unlessspecificallyexpressedassuch,andshouldbeviewedashistoricaldata.
WHERE YOU CAN FIND MORE INFORMATION
Wefileannual,quarterlyandcurrentreports,proxystatementsandotherinformationwiththeSEC.YoumayaccessthisinformationontheSEC'swebsite,whichcontainsreports,proxystatementsandotherinformationthatwefileelectronicallywiththeSEC.Theaddressofthatwebsiteiswww.sec.gov .YoumayalsoconsultourwebsiteformoreinformationaboutElanco.Ourwebsiteiswww.elanco.com .Informationincludedonthiswebsiteisnotincorporatedbyreferenceintothisprospectus.
2
TableofContents
PROSPECTUS SUMMARY
This summary highlights selected information appearing elsewhere in this prospectus and is, therefore, qualified in its entirety by the more detailed information appearing elsewhere in this prospectus. It may notcontain all the information that is important to you. We urge you to read carefully this entire prospectus and the other documents to which it refers to understand fully the terms of the Exchange Notes and theExchange Offers. You should pay special attention to "Risk Factors" and "Cautionary Statement Concerning Forward-Looking Statements."
Our Company
Elancoisapremieranimalhealthcompanythatinnovates,develops,manufacturesandmarketsproductsforcompanionandfoodanimals.HeadquarteredinGreenfield,Indiana,Elancoisthefourthlargestanimalhealthcompanyintheworld,withrevenueof$3.1billionfortheyearendedDecember31,2018.Globally,Elancois#1inmedicinalfeedadditives,#2inpoultryand#3incattle,measuredby2017revenue,accordingtoVetnosis.Elancoalsohasoneofthebroadestportfoliosofpetparasiticidesinthecompanionanimalsector.Elancooffersadiverseportfolioofmorethan125brandsthatmakeitatrustedpartnertoveterinariansandfoodanimalproducersinmorethan90countries.
OnSeptember24,2018,Elanco'sinitialpublicoffering(the"IPO")wascompleted,pursuanttowhichElancoissuedandsold19.8%ofElanco'stotaloutstandingshares.OnSeptember20,2018,ElancocommonstockbegantradingontheNYSEunderthesymbol"ELAN."OnSeptember24,2018,immediatelyprecedingthecompletionoftheIPO,LillytransferredtoElancosubstantiallyallofitsanimalhealthbusinessesinexchangefor(i)allofthenetproceeds($1,659.7million)ElancoreceivedfromthesaleofElancocommonstockintheIPO,includingthenetproceedsitreceivedasaresultoftheexerciseinfulloftheunderwriters'optiontopurchaseadditionalshares,(ii)allofthenetproceeds(approximately$2,000million)ElancoreceivedintheSeniorNotesOffering(asdefinedbelow)and(iii)allofthenetproceeds($498.6million)ElancoreceivedfromtheentryintotheTermFacility(asdefinedbelow).
OnMarch11,2019,Lillycompletedthedispositionofitsremaininginterestinusthroughatax-freeexchangeofferpursuanttowhichittransferreditsremainingholdingsinustoitsshareholdersinexchangeforsharesofLillycommonstock.Werefertothistransactioninthisprospectusasthe"Split-Off."FollowingtheSplit-Off,Lillynolongerownsanysharesinus,andweareanindependentpubliclytradingcompany.
Inaddition,immediatelypriortothecompletionoftheIPO,ElancoandLillyenteredintocertainagreementsthatprovideaframeworkforElanco'songoingrelationshipwithLilly,whichagreementsremainineffectfollowingthecompletionoftheSplit-Off.Formoreinformation,see"CertainRelationshipsandRelatedPartyTransactions—RelationshipbetweenElancoandLilly."
Elanco'svisionistoenrichthelivesofpeoplethroughfood—makingproteinmoreaccessibleandaffordable—andthroughpetcompanionship—helpingpetslivelonger,healthierlives.Elancoadvancesitsvisionbyofferingproductsinfourprimarycategories:
• Companion Animal Disease Prevention ("CA Disease Prevention"). Elancohasoneofthebroadestparasiticideportfoliosinthecompanionanimalsectorbasedonindications,speciesandformulations,withproductsthatprotectpetsfromworms,fleasandticks.Combiningitsparasiticideportfoliowithitsvaccinespresence,ElancoisaleaderintheU.S.inthediseasepreventioncategorybasedonshareofrevenue.
• Companion Animal Therapeutics ("CA Therapeutics"). Elancohasabroadpainandosteoarthritisportfolioacrossspecies,modesofaction,indicationsanddiseasestages.Petownersareincreasinglytreatingosteoarthritisintheirpets,andElanco'sGalliprant productisoneofthe
3
TableofContents
fastestgrowingosteoarthritistreatmentsintheU.S.Elancoalsohastreatmentsforotitis(earinfections),aswellascardiovascularanddermatologyindications.
• Food Animal Future Protein & Health ("FA Future Protein & Health"). Elanco'sportfoliointhiscategory,whichincludesvaccines,nutritionalenzymesandanimal-onlyantibiotics,servesthegrowingdemandforproteinandincludesinnovativeproductsinpoultryandaquacultureproduction,wheredemandforanimalhealthproductsisoutpacingoverallindustrygrowth.Elancoisfocusedondevelopingfunctionalnutritionalhealthproductsthatpromotefoodanimalhealth,includingenzymes,probioticsandprebiotics.Elancoisaleaderinprovidingvaccinesasalternativestoantibioticstopromoteanimalhealthbasedonshareofrevenue.
• Food Animal Ruminants& Swine ("FA Ruminants & Swine"). Elancohasdevelopedarangeoffoodanimalproductsusedextensivelyinruminant(e.g.,cattle,sheepandgoats)andswineproduction.
Corporate Information
ElancoAnimalHealthIncorporatedwasincorporatedinIndianaonMay3,2018.Elanco'sprincipalexecutiveofficesarelocatedat2500InnovationWay,Greenfield,Indiana46140,andthetelephonenumberis(877)352-6261.Thecorporatewebsiteaddressiswww.elanco.com .Elanco'swebsiteandtheinformationcontainedon,orthatcanbeaccessedthrough,thewebsiteisnotdeemedtobeincorporatedbyreferencein,andisnotconsideredpartof,thisprospectus.YoushouldnotrelyonanysuchinformationinmakingyourdecisionwhethertoparticipateintheExchangeOffers.
4
TableofContents
The Exchange Offers
The following summary contains basic information about the Exchange Offers. It does not contain all of the information that may be important to you. For a more complete description of the terms of theExchange Offers, see "The Exchange Offers."
5
TheExchangeOffers Weareoffering,uponthetermsandsubjecttotheconditionssetforthinthisprospectusandtheaccompanyinglettersoftransmittal,toexchange:
• upto$500,000,000aggregateprincipalamountofthe2021ExchangeNoteswhichhavebeenregisteredundertheSecuritiesActforalikeamountoftheunregistered2021OriginalNotes,
• upto$750,000,000aggregateprincipalamountofthe2023ExchangeNoteswhichhavebeenregisteredundertheSecuritiesActforalikeamountoftheunregistered2023OriginalNotes,and
• upto$750,000,000aggregateprincipalamountofthe2028ExchangeNoteswhichhavebeenregisteredundertheSecuritiesActforalikeamountoftheunregistered2028OriginalNotes.
ToexchangeyourOriginalNotes,youmustproperlytenderthem,andwemustacceptthem.WewillacceptandexchangeallOriginalNotesthatyouvalidlytenderanddonotvalidlywithdrawpriortotheexpirationoftheExchangeOffers.WewillissueregisteredExchangeNotespromptlyaftertheexpirationoftheExchangeOffer.
ResaleofExchangeNotes BasedoninterpretationsbythestaffoftheSECasdetailedinaseriesofno-actionlettersissuedtothirdparties,webelievethat,aslongasyouarenotabroker-dealer,theExchangeNotesofferedintheExchangeOffersmaybeofferedforresale,resoldorotherwisetransferredbyyouwithoutcompliancewiththeregistrationandprospectusdeliveryrequirementsoftheSecuritiesActaslongas:
• youareacquiringtheExchangeNotesintheordinarycourseofyourbusiness;
• youarenotparticipating,donotintendtoparticipateinandhavenoarrangementorunderstandingwithanypersontoparticipateina"distribution"oftheExchangeNotes;and
• youarenotan"affiliate"ofourswithinthemeaningofRule405oftheSecuritiesAct.
TableofContents
6
IfanyoftheseconditionsisnotsatisfiedandyoutransferanyExchangeNotesissuedtoyouintheExchangeOfferswithoutdeliveringaproperprospectusorwithoutqualifyingforaregistrationexemption,youmayincurliabilityundertheSecuritiesAct.Moreover,ourbeliefthattransfersofExchangeNoteswouldbepermittedwithoutregistrationorprospectusdeliveryundertheconditionsdescribedaboveisbasedonSECinterpretationsgiventoother,unrelatedissuersinsimilarExchangeOffers.WecannotassureyouthattheSECwouldmakeasimilarinterpretationwithrespecttoourExchangeOffers.WewillnotberesponsiblefororindemnifyyouagainstanyliabilityyoumayincurundertheSecuritiesAct.
Anybroker-dealerthatacquiresExchangeNotesforitsownaccountinexchangeforOriginalNotesmustrepresentthattheOriginalNotestobeexchangedfortheExchangeNoteswereacquiredbyitasaresultofmarket-makingactivitiesorothertradingactivitiesandacknowledgethatitwilldeliveraprospectusmeetingtherequirementsoftheSecuritiesActinconnectionwithanyoffertoresell,resaleorotherretransferoftheExchangeNotes.However,bysoacknowledgingandbydeliveringaprospectus,suchparticipatingbroker-dealerwillnotbedeemedtoadmitthatitisan"underwriter"withinthemeaningoftheSecuritiesAct.Duringtheperiodending180daysaftertheconsummationoftheExchangeOffers,subjecttoextensioninlimitedcircumstances,aparticipatingbroker-dealermayusethisprospectusforanoffertosell,aresaleorotherretransferofExchangeNotesreceivedinexchangeforOriginalNoteswhichitacquiredthroughmarket-makingactivitiesorothertradingactivities.
ExpirationDate TheExchangeOfferswillexpireat5:00p.m.,NewYorkCitytime,on,2019,unlessweextendtheexpirationdate.
AccruedInterestontheExchangeNotesandtheOriginalNotes TheExchangeNoteswillbearinterestfromthemostrecentdatetowhichinteresthasbeenpaidontheOriginalNotes.IfyourOriginalNotesareacceptedforexchange,thenyouwillreceiveinterestontheExchangeNotesandnotontheOriginalNotes.AnyOriginalNotesnottenderedwillremainoutstandingandcontinuetoaccrueinterestaccordingtotheirterms.
TableofContents
7
Conditions OurobligationtoconsummatetheExchangeOffersisnotsubjecttoanyconditions,otherthanthattheapplicableExchangeOfferdoesnotviolateanyapplicablelaworSECstaffinterpretation.See"TheExchangeOffers—Conditions."Wereservetherighttoterminateoramendtheexchangeoffersatanytimepriortotheexpirationdateif,amongotherthings,thereshallhavebeenproposed,adoptedorenactedanylaw,statute,rule,regulationorSECstaffinterpretationwhich,inourjudgment,couldreasonablybeexpectedtomateriallyimpairourabilitytoproceedwiththeExchangeOffers.
ProceduresforTenderingOriginalNotes EachholderofOriginalNotesthatwishestotendertheirOriginalNotesmusteither:
• properlycomplete,signanddatetheletteroftransmittal,includingallotherdocumentsrequiredbytheletteroftransmittal;havethesignatureontheletteroftransmittalguaranteediftheletteroftransmittalsorequires;anddeliverthatletteroftransmittalandotherrequireddocumentstotheexchangeagentonorbeforetheexpirationdate;
• iftheOriginalNotesaretenderedunderthebook-entrytransferprocedures,transmittotheexchangeagent,onorbeforetheexpirationdate,an"agent'smessage;"or
• complywiththeproceduressetforthbelowunder"—GuaranteedDeliveryProcedures."
EachholderofOriginalNotesthattenderstheirOriginalNotesintheExchangeOffersmustrepresenttousthatthefollowingaretrue:
• anyExchangeNotesthattheholderreceiveswillbeacquiredintheordinarycourseofitsbusiness;
• theholderhasnoarrangementorunderstandingwithanypersonorentitytoparticipateinthedistribution(withinthemeaningoftheSecuritiesAct)oftheExchangeNotes;
• theholderisnotan"affiliate"ofuswithinthemeaningofRule405oftheSecuritiesAct;and
• iftheholderisabroker-dealerthatwillreceiveExchangeNotesforitsownaccountinexchangeforOriginalNotesthatwereacquiredasaresultofmarket-makingorothertradingactivities,thensuchholderwilldeliveraprospectusinconnectionwithanyresaleoftheExchangeNotes.
TableofContents
8
SpecialProceduresforBeneficialOwners Ifyoubeneficiallyownoriginalnotesregisteredinthenameofabroker,dealer,commercialbank,trustcompanyorothernomineeandwishtotenderyourbeneficiallyownedoriginalnotesintheExchangeOffers,youshouldcontacttheregisteredholderpromptlyandinstructittotendertheoriginalnotesonyourbehalfandcomplywiththeinstructionssetforthinthisprospectusandtheletteroftransmittal.
GuaranteedDeliveryProcedures IfyoudesiretotenderyourOriginalNotes,but:
• ourOriginalNotesarenotimmediatelyavailable;
• youcannotdeliveryourOriginalNotes,theletteroftransmittaloranyotherdocumentsrequiredbytheletteroftransmittaltotheexchangeagentpriortotheexpirationdate;or
• theproceduresforbook-entrytransferofyourOriginalNotescannotbecompletedpriortotheexpirationdate,
youmaytenderyourOriginalNotespursuanttotheproceduresdescribedin"TheExchangeOffers—ProceduresforTenderingOriginalNotes—GuaranteedDelivery."
WithdrawalRights YoumaywithdrawyourtenderofOriginalNotesundertheExchangeOffersatanytimebeforetheapplicableExchangeOfferexpires.Anywithdrawalmustbeinaccordancewiththeproceduresdescribedin"TheExchangeOffers—WithdrawalRights."
ConsequencesofFailuretoExchangeOriginalNotes AnyOriginalNotesnottenderedintheExchangeOfferswillremainoutstandingandcontinuetobesubjecttoallthetermsandconditionsspecifiedintheindenture,includingtransferrestrictions,butwillnotretainanyrightsundertheexchangeandregistrationrightsagreement(includingtherighttoearnadditionalinterestrelatingtoourregistrationobligations)aftertheconsummationoftheExchangeOffers.ExceptinlimitedcircumstanceswithrespecttospecifictypesofholdersofOriginalNotes,wewillhavenofurtherobligationtoprovidefortheregistrationundertheSecuritiesActofsuchOriginalNotes.Ingeneral,theOriginalNotesmaynotbeofferedorsold,unlessregisteredundertheSecuritiesAct,exceptpursuanttoanexemptionfrom,orinatransactionnotsubjectto,theSecuritiesActandapplicablestatesecuritieslaws.
AnytradingmarketfortheOriginalNotescouldbeadverselyaffectedifsomebutnotalloftheOriginalNotesaretenderedandacceptedintheExchangeOffers.
TableofContents
9
AccountingTreatment TheExchangeNoteswillberecordedatthesamecarryingvalueastheOriginalNotes,asreflectedinouraccountingrecordsonthedateofexchange.Accordingly,wewillrecognizenogainorlossforaccountingpurposesupontheclosingoftheExchangeOffers.TheexpensesoftheExchangeOfferswillbeexpensedasincurred.
MaterialU.S.FederalIncomeTaxConsequences YourexchangeofOriginalNotesforExchangeNoteswillnotbetreatedasataxableeventforU.S.federalincometaxpurposes.See"MaterialU.S.FederalIncomeTaxConsequences."
UseofProceeds WewillnotreceiveanyproceedsfromtheExchangeOffersortheissuanceoftheExchangeNotes.BecausetheExchangeNoteshavesubstantiallyidenticaltermsastheOriginalNotes,theissuanceoftheExchangeNoteswillnotresultinanyincreaseinourindebtedness.TheExchangeOffersareintendedtosatisfyourobligationsundertheexchangeandregistrationrightsagreement.
ExchangeAgent DeutscheBankTrustCompanyAmericasisservingastheexchangeagentinconnectionwiththeExchangeOffers.Theaddress,telephonenumberandfacsimilenumberoftheexchangeagentissetforthunder"TheExchangeOffers—ExchangeAgent."
TableofContents
The Exchange Notes
ThetermsofeachseriesofExchangeNotesaresubstantiallyidenticaltothetermsoftheapplicableseriesofOriginalNotes,except(i)theExchangeNotesareregisteredundertheSecuritiesAct,(ii)thetransferrestrictionsandregistrationrightsapplicabletotheOriginalNotesdonotapplytotheExchangeNotes,and(iii)theExchangeNoteswillnotcontainprovisionsrelatingtoadditionalinterestrelatingtoourregistrationobligations.EachseriesofExchangeNoteswillevidencethesamedebtasthecorrespondingseriesofOriginalNotesandwillbeissuedunderthesameindentureasthecorrespondingseriesofOriginalNotes.
ThefollowingsummarycontainsbasicinformationabouttheExchangeNotesandisnotintendedtobecomplete.Itdoesnotcontainalltheinformationthatisimportanttoyou.ForamorecompleteunderstandingoftheExchangeNotes,pleaseread"DescriptionoftheExchangeNotes."
10
Issuer ElancoAnimalHealthIncorporated
ExchangeNotesOffered $500,000,000aggregateprincipalamountof3.912%SeniorNotesdue2021
$750,000,000aggregateprincipalamountof4.272%SeniorNotesdue2023
$750,000,000aggregateprincipalamountof4.900%SeniorNotesdue2028
InterestRates;InterestPaymentDates;Maturities The2021ExchangeNoteswillbearinterestatarateof3.912%perannumandwillmatureonAugust27,2021.Wewillpayinterestonthe2021ExchangeNotesonFebruary27andAugust27ofeachyearuntilmaturity.
The2023ExchangeNoteswillbearinterestatarateof4.272%perannumandwillmatureonAugust28,2023.Wewillpayinterestonthe2023ExchangeNotesonFebruary28andAugust28ofeachyearuntilmaturity.
The2028ExchangeNoteswillbearinterestatarateof4.900%perannumandwillmatureonAugust28,2028.Wewillpayinterestonthe2028ExchangeNotesonFebruary28andAugust28ofeachyearuntilmaturity.
InterestontheExchangeNoteswillaccruefromthemostrecentdatetowhichinterestontheOriginalNoteshasbeenpaid.
InterestRateAdjustment TheinterestratepayableoneachseriesofnoteswillbesubjecttoadjustmentfromtimetotimeifS&PorMoody's(or,ifapplicable,asubstituteratingagency)downgrades(orsubsequentlyupgrades)itsratingassignedtotherespectiveseriesofnotes.See"DescriptionoftheExchangeNotes—InterestRateAdjustment."
TableofContents
11
RepurchaseUponChangeofControl Upontheoccurrenceofachangeofcontroltriggeringevent,wewill,incertaincircumstances,berequiredtomakeanoffertopurchaseeachofthenotesatapriceequalto101%oftheaggregateprincipalamountofthenotestogetherwithaccruedandunpaidinterestto,butexcluding,thedateofrepurchase.See"DescriptionoftheExchangeNotes—ChangeofControl."
OptionalRedemption Wemayredeemthenotesofanyseries,inwholeorinpart,atanytimeattheredemptionpricesdescribedin"DescriptionoftheExchangeNotes—OptionalRedemption."
Ranking Thenotesareourseniorunsecuredobligationsandrankequallywithallofourexistingandfutureseniorunsecuredindebtedness.FollowingtheSeparation,substantiallyallofourassetsarethecapitalstockofoursubsidiariesandthenotesarenotguaranteedbyoursubsidiaries.Asaresult,thenotesarestructurallysubordinatedtoalldebtandotherliabilities,includingtradeandotherpayables,ofoursubsidiaries.
NoPriorMarket ThereiscurrentlynoestablishedmarketfortheExchangeNotes.Accordingly,wecannotassureyouastothedevelopmentorliquidityofanymarketfortheExchangeNotes.WedonotintendtoapplyforlistingoftheExchangeNotesonanysecuritiesexchange.
FormandDenomination WewillissuetheExchangeNotesintheformofoneormoreglobalnotesindefinitive,fullyregisteredbook-entryform.TheglobalnoteswillbedepositedwithoronbehalfofDTCandregisteredinthenameofCede&Co.,asnomineeofDTC.TheExchangeNoteswillbeissuedinminimumdenominationsof$2,000and$1,000integralmultiplesinexcessthereof.
RiskFactors YoushouldconsidercarefullyalloftheinformationsetforthinthisprospectuspriortoexchangingyourOriginalNotes.Inparticular,weurgeyoutoconsidercarefullythefactorssetforthundertheheading"RiskFactors."
TableofContents
Selected Historical and Pro Forma Financial Data
ElancoreportsitsfinancialresultsinaccordancewithU.S.generallyacceptedaccountingprinciples("U.S.GAAP").ThesummaryhistoricalconsolidatedandcombinedstatementsofoperationsdataforthethreemonthsendedMarch31,2019and2018andthesummaryhistoricalcombinedbalancesheetdataasofMarch31,2019presentedbelowhavebeenderivedfromourunauditedcombinedfinancialstatementsincludedelsewhereinthisprospectus.ThesummaryhistoricalconsolidatedandcombinedstatementsofoperationsdatafortheyearsendedDecember31,2018,2017and2016andtheconsolidatedandcombinedbalancesheetdataasofDecember31,2018and2017presentedbelowhavebeenderivedfromElanco'sauditedconsolidatedandcombinedfinancialstatementsincludedelsewhereinthisprospectus.TheselectedhistoricalcombinedstatementofoperationsdatafortheyearendedDecember31,2015andthecombinedbalancesheetdataasofDecember31,2016presentedbelowhavebeenderivedfromElanco'sauditedcombinedfinancialinformationnotincludedelsewhereinthisprospectus.TheselectedhistoricalcombinedstatementofoperationsdatafortheyearendedDecember31,2014andthecombinedbalancesheetdataasofDecember31,2015and2014presentedbelowhavebeenderivedfromElanco'sunauditedcombinedfinancialinformationnotincludedelsewhereinthisprospectus.
Elanco'scombinedfinancialstatementsfortheperiodspriortotheIPOincludetheattributionofcertainassetsandliabilitiesthathavehistoricallybeenheldattheLillycorporatelevelbutwhicharespecificallyidentifiableorattributabletoElanco.Elanco'scombinedfinancialstatementsfortheperiodpriortotheIPOalsoincludeexpenseallocationsrelatedtocertainLillycorporatefunctions,includingexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations.TheseexpenseshavebeenallocatedtoElancobasedondirectusageorbenefitwherespecificallyidentifiable,withtheremainderallocatedprimarilyonaproratabasisofrevenue,headcountorothermeasures.Elancobelievesthatthisexpensemethodology,andtheresultsthereof,isreasonableforallperiodspresented.However,theallocationsmaynotbeindicativeoftheactualexpensethatwouldhavebeenincurredifElancohadoperatedasanindependent,publiclytradedcompanyfortheperiodspresented.ItisimpracticaltoestimatewhatElanco'sstandalonecostswouldhavebeenforthehistoricalperiodspresented.
TheselectedunauditedproformacondensedconsolidatedandcombinedstatementofoperationsdatafortheyearendedDecember31,2018presentedbelowhavebeenderivedfromElanco'sunauditedproformacondensedconsolidatedandcombinedstatementofoperationsincludedelsewhereinthisprospectus.TheunauditedproformainformationsetforthbelowreflectsElanco'shistoricalconsolidatedandcombinedstatementofoperations,asadjustedtogiveeffecttotheTransactions(asdefinedbelow)asiftheyhadoccurredasofJanuary1,2018.TheunauditedproformainformationisillustrativeandnotintendedtorepresentwhatElanco'sresultsofoperationsorfinancialpositionwouldhavebeenhadtheTransactionsoccurredonthedateindicatedortoprojectElanco'sresultsofoperationsorfinancialpositionforanyfutureperiod.ForanunderstandingoftheproformastatementofoperationsthatgiveproformaeffecttotheTransactions,see"UnauditedProFormaCondensedConsolidatedandCombinedStatementofOperations"includedelsewhereinthisprospectus.
ThefinancialstatementsincludedinthisprospectusmaynotbeindicativeofElanco'sfutureperformanceanddonotnecessarilyreflectwhatElanco'sfinancialpositionandresultsofoperationswouldhavebeenhadElancooperatedasanindependent,publiclytradedcompanyfortheentiretyoftheperiodspresented,includingchangesthatoccurredandwilloccurinElanco'soperationsandcapitalstructureasaresultoftheIPOandtheseparation.
12
TableofContents
Theunauditedproformacondensedconsolidatedandcombinedstatementofoperationsgiveseffecttothefollowingtransactions,whicharereferredto,collectively,asthe"Transactions,"asiftheyeachhadoccurredonJanuary1,2018:
• theimpactoftheentryintotheCreditFacilitiesandtheSeniorNotesOffering(the"DebtTransactions")andtheuseoftheproceedstherefrom.
Duetolocalregulatoryandoperationalrequirements,incertainnon-U.S.jurisdictions,thetransferofcertainassetsandliabilitiesofLilly'sanimalhealthbusinesseswilloccurfollowingthedateofthisprospectus.Elancohasnotadjustedtheaccompanyingunauditedproformacondensedconsolidatedandcombinedstatementofoperationsforthepotentialimpactofsuchdelayedtransfersbecauseanyimpactofthesetransfersisnotmaterialtoitsunauditedproformacondensedconsolidatedandcombinedstatementofoperations,individuallyorintheaggregate.
Youshouldreadtheinformationsetforthbelowtogetherwith"UnauditedProFormaCondensedConsolidatedandCombinedStatementofOperations,""Management'sDiscussionandAnalysisofFinancialConditionandResultsofOperation"andElanco'sconsolidatedandcombinedfinancialstatementsandtherelatednotestheretoincludedelsewhereinthisprospectus.
13
Three Months Ended
March 31, Year Ended December 31,
Historical
Historical
Pro Forma
2018
2019 2018 2018 2017 2016 2015 2014 (In millions, except per share data) Statement of Operations Data: Revenue $ 731.1 $ 736.2 $ 3,066.8 $ 3,066.8 $ 2,889.0 $ 2,913.5 $ 2,909.1 $ 2,066.0Costs,expensesandother: Costofsales 343.8 360.0 1,573.8 1,573.8 1,493.9 1,409.0 1,533.7 932.6Researchanddevelopment 64.1 65.2 246.6 246.6 251.7 265.8 291.0 208.5Marketing,sellingandadministrative 181.1 180.0 735.2 735.2 779.8 784.8 916.0 561.2Amortizationofintangibleassets 49.0 49.2 197.4 197.4 221.2 170.7 163.0 57.6Assetimpairment,restructuringandotherspecialcharges 24.9 2.4 128.8 128.8 375.1 308.4 263.3 38.8Interestexpense,netofcapitalizedinterest 20.8 — 110.7 29.6 — — — —Other(income)expense,net 2.6 1.9 41.3 41.3 (0.1) (2.8) 1.6 1.4Income(loss)beforeincometaxes 44.8 77.5 33.0 114.1 (232.6) (22.4) (259.5) 265.9Incometaxexpense(benefit) 13.3 4.8 8.1 27.6 78.1 25.5 (48.7) 101.0Netincome(loss) $ 31.5 $ 72.7 $ 24.9 $ 86.5 $ (310.7) $ (47.9) $ (210.8) $ 164.9Netincome(loss)asapercentofrevenue 4% 10% 1% 3% (11)% (2)% (7)% 8%Netincome(loss)pershare—basicanddiluted $ 0.09 $ 0.25 $ 0.08 $ 0.28 $ (1.06) $ (0.16) $ (0.72) $ 0.56Weightedaveragesharesoutstanding—basic(1) 365.7 293.3 313.7 313.7 293.3 293.3 293.3 293.3Weightedaveragesharesoutstanding—diluted(1) 366.0 293.3 313.7 313.7 293.3 293.3 293.3 293.3
(1) TheweightedaveragesharesfortheperiodspriortotheIPOrepresentssharesofElancocommonstockheldbyLillyasifsuchshareshadbeenoutstandingfortheentireperiod.
TableofContents
14
As of December 31,
As of
March 31,
Historical 2019 2018 2017 2016 2015 2014 (In millions, except per share data) Balance Sheet Data: Totalassets $ 8,747.4 $ 8,956.7 $ 8,940.3 $ 8,099.7 $ 8,433.6 $ 2,980.6Totalliabilities 708.2 3,759.2 1,160.0 1,082.3 1,004.1 551.5Long-termdebt 2,436.6 2,443.3 — — — —Totalequity 5,196.2 5,197.5 7,780.3 7,017.4 $ 7,429.5 $ 2,429.1Cash dividends declared per common share — — — — — —Book value per common share (2) 14.20 $ 14.22 — — — —
(2) RepresentsElancoshareholders'equitydividedbytheactualnumberofoutstandingshares.
TableofContents
RISK FACTORS
You should carefully consider the risks described below and all of the information contained in this prospectus before making a decision on whether or not to participate in the Exchange Offers. The occurrence of theevents described below could have a material adverse effect on Elanco's businesses, prospects, financial condition, results of operations and/or cash flows. In addition, other unknown or unpredictable economic, business,competitive, regulatory, geopolitical or other factors could have material adverse effects on our businesses, prospects, financial condition, results of operations and/or cash flows. Please read "Cautionary StatementRegarding Forward-Looking Statements" in this prospectus.
Risks Related to Elanco's Business and Industry
The animal health industry is highly competitive.
Theanimalhealthindustryishighlycompetitive.Elanco'scompetitorsincludestandaloneanimalhealthbusinesses,theanimalhealthbusinessesoflargepharmaceuticalcompanies,specialtyanimalhealthbusinessesandcompaniesthatmainlyproducegenericproducts.ElancobelievesmanyofitscompetitorsareconductingR&DactivitiesinareasservedbyElanco'sproductsandinareasinwhichitisdevelopingproducts.Severalnewstart-upcompaniesalsocompeteintheanimalhealthindustry.Elancoalsofacescompetitionfrommanufacturersofdrugsglobally,aswellasproducersofnutritionalhealthproducts.Thesecompetitorsmayhaveaccesstogreaterfinancial,marketing,technicalandotherresources.Asaresult,theymaybeabletodevotemoreresourcestodeveloping,manufacturing,marketingandsellingtheirproducts,initiatingorwithstandingsubstantialpricecompetitionormorereadilytakingadvantageofacquisitionsorotheropportunities.Further,consolidationintheanimalhealthindustrycouldresultinexistingcompetitorsrealizingadditionalefficienciesorimprovingportfoliobundlingopportunities,therebypotentiallyincreasingtheirmarketshareandpricingpower,whichcouldleadtoadecreaseinElanco'srevenueandprofitabilityandanincreaseincompetition.Forexample,manyofElanco'scompetitorshaverelationshipswithkeydistributorsand,becauseoftheirsize,theabilitytoofferattractivepricingincentives,whichmaynegativelyimpactorhinderElanco'srelationshipswiththesedistributors.Inadditiontocompetitionfromestablishedmarketparticipants,newentrantstotheanimalhealthmedicinesandvaccinesindustrycouldsubstantiallyreduceElanco'smarketshare,renderElanco'sproductsobsoleteordisruptElanco'sbusinessmodel.
TotheextentthatanyofElanco'scompetitorsaremoresuccessfulwithrespecttoanykeycompetitivefactor,orElancoisforcedtoreduce,orisunabletoraise,thepriceofanyofitsproductsinordertoremaincompetitive,itsbusiness,financialconditionandresultsofoperationscouldbemateriallyadverselyaffected.Competitivepressurecouldarisefrom,amongotherthings,morefavorablesafetyandefficacyproductprofiles,limiteddemandgrowthorasignificantnumberofadditionalcompetitiveproductsbeingintroducedintoaparticularmarket,pricereductionsbycompetitors,theabilityofcompetitorstocapitalizeontheireconomiesofscale,theabilityofcompetitorstoproduceorotherwiseprocureanimalhealthproductsatlowercoststhanElancoandtheabilityofcompetitorstoaccessmoreornewertechnologythanElanco.
Disruptive innovation and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein could negatively affect the market for Elanco's products.
ThemarketsforElanco'sproductsareregularlyimpactedbytheintroductionand/orbroadmarketacceptanceofnewly-developedoralternativeproductsthataddressthediseasesandconditionsforwhichElancosellsproducts,including"green"or"holistic"healthproducts,speciallybreddisease-resistantanimalsorreplacementsformeat,milk,eggsorfishfromalternativenaturalorsyntheticsources.Forexample,themarketforElanco'scompanionanimaltherapeuticshasbeenparticularlyaffectedbyinnovationinnewmoleculesanddeliveryformulationsinrecentyears.TechnologicalbreakthroughsbyothersmayrenderobsoleteElanco'sproductsandreduceoreliminate
15
TableofContents
themarketforitsproducts.IntroductionoracceptanceofcompetinganimalhealthproductsandinnovationordisruptiveproteinalternativescouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Regulatory restrictions and bans on the use of antibiotics and productivity products in food animals, as well as changing market demand, may continue to negatively affect demand for certain of Elanco's food animalproducts.
Overthepastfewyears,Elanco'soperationalresultshavebeen,andwillcontinuetobe,affectedbyregulationsandchangingmarketdemand.Incertainmarkets,includingtheU.S.,salesofcertainofElanco'sfoodanimalproductshavebeennegativelyaffectedbyanincreaseinconsumersentimentforproteinsanddairyproductsproducedwithouttheuseofantibioticsorotherproductsintendedtoincreaseanimalproduction.
Therearetwoclassesofantibioticsusedinanimalhealth:shared-class,ormedicallyimportant,antibiotics,whichareusedtotreatinfectiousdiseasecausedbypathogensthatoccurinbothhumansandanimals;andanimal-onlyantibiotics,whichareusedtotreatinfectiousdiseasecausedbypathogensthatoccurinanimalsonly.See"BusinessofElanco—Products—Antibiotics."Concernsthattheuseofantibioticsinfoodanimalproductionmayleadtoincreasedantibioticresistanceofhumanpathogenshaveresultedinincreasedregulationandchangingmarketdemand.InDecember2013,theU.S.Food&DrugAdministration(the"FDA")announcedfinalguidanceestablishingproceduresforthevoluntaryphase-outintheU.S.overathree-yearperiodoftheuseofshared-classantibioticsinanimalfeedorwaterforgrowthpromotioninfoodanimalproduction.Theguidanceallowsforcontinueduseofshared-classantibioticsinfood-producinganimalsunderthesupervisionofaveterinarianfortreatment,controland,undercertaincircumstances,forpreventionofdisease.TheFDAindicatedthatittookthisactiontohelppreservetheefficacyofshared-classantibioticstotreatinfectionsinhumans.Aspartofthoseefforts,stricterguidelinesgoverningtheadministrationofshared-classantibioticshaverecentlycomeintoeffect.AsofJanuary1,2017,undertheFDA'sguidanceandtherelatedruleknownastheVeterinaryFeedDirective,theuseofshared-classantibioticsinthewaterorfeedoffood-producinganimalsrequireswrittenauthorizationbyalicensedveterinarian.Inaddition,othercountriesinwhichElancosellsorplanstosellitsproducts,suchasFranceandVietnam,havepassedrestrictionsorbansonantibioticuse.Othercountrieshaveplacedrestrictionsorbansontheuseofspecificantibioticsincertainfood-producinganimals,regardlessoftherouteofadministration(infeedorinjectable).
From2015to2018,Elanco'srevenuefromshared-classantibioticsdeclinedataCAGRof6%,excludingtheimpactofforeignexchange.Thiswasdrivenprimarilybychangingregulationsinmanymarkets,includingtheVeterinaryFeedDirective,aswellaschangingmarketdemandandElanco'stiered-approachtoantibioticstewardship,whichincludedremovinggrowthpromotionfromlabelsandrequiringveterinaryoversightintheU.S.andothermarkets.Globally,during2018,Elanco'srevenuefromshared-classantibioticsdeclined2%,excludingtheimpactofforeignexchange,andrepresented12%(4%fromsalesintheU.S.and8%fromsalesoutsidetheU.S.)oftotalrevenue,downfrom16%in2015.From2015to2018,Elanco'srevenuefromanimal-onlyantibioticsgrewataCAGRof5%,excludingtheimpactofforeignexchange,drivenbysalesoutsidetheU.S.,whichoffsetaslightdeclineintheU.S.Globally,during2018,Elanco'srevenuefromanimal-onlyantibioticsgrew8%,excludingtheimpactofforeignexchange,andrepresented25%oftotalrevenue,upfrom23%in2015.In2018,87%ofElanco'srevenuefromanimal-onlyantibioticsresultedfromthesaleofionophores.Ionophoresareaspecialclassofanimal-onlyantimicrobials,andbecauseoftheiranimal-onlydesignation,modeofactionandspectrumofactivity,theirusehasnottodatebeenimpactedbyregulationsorchangingmarketdemandinmanymarketsoutsideoftheU.S.
TheimpactofchangesinregulationsandmarketpreferencesregardingtheuseofantibioticsinfoodanimalscouldhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresults
16
TableofContents
ofoperations.IfthereisanincreasedpublicperceptionthatconsumptionoffoodderivedfromanimalsthatutilizeElanco'sproductsposesarisktohumanhealth,theremaybeafurtherdeclineintheproductionofthosefoodproductsand,inturn,demandforElanco'sproducts.Inaddition,antibioticresistanceconcernswilllikelyresultinadditionalrestrictionsorbans,expandedregulationsorpublicpressuretofurtherreducetheuseofantibioticsinfoodanimals,increaseddemandforantibiotic-freeprotein,orchangesinthemarketacceptanceorregulatorytreatmentofionophores,anyofwhichcouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Inaddition,Elanco'srevenuehasbeenimpactedbyregulatorychangesinChinaandothermarketsrestrictingtheuseofproductivityproducts,suchasthosecontainingractopamineinfoodanimals.ThishasresultedinmanyU.S.foodproducerswhoaccesssuchmarketseliminatingtheiruseofractopamine.Elanco'sFARuminants&SwineproductsOptaflexx andPaylean containractopamine.Ifmoreproducersdecidetoaccesssuchmarketsoradditionalmarketsrestricttheuseofractopamineorotherproductivityproducts,Elanco'sbusiness,financialconditionandresultsofoperationscouldbemateriallyadverselyaffected.
Generic products may be viewed as more cost-effective than Elanco's products.
Elancofacescompetitionfromproductsproducedbyothercompanies,includinggenericalternativestoElanco'sproducts.Elancodependsonpatentsandregulatorydataexclusivityperiodstoprovideitwithexclusivemarketingrightsforsomeofitsproducts.Patentsforindividualproductsexpireatdifferenttimesbasedonthedateofthepatentfiling(orsometimesthedateofpatentgrant)andthelegaltermofpatentsinthejurisdictionswheresuchpatentsareobtained.TheextentofprotectionaffordedbyElanco'spatentsvariesfromjurisdictiontojurisdictionandislimitedbythescopeoftheclaimedsubjectmatterofitspatents,thetermofthepatentandtheavailabilityandenforcementoflegalremediesintheapplicablejurisdiction.In2018,approximately72%ofElanco'srevenuewasfromproductsthatdidnothavepatentprotection,includingrevenuefromsomeofitstopproductssuchasRumensin ,Maxiban ,Denagard andTylan Premix .Otherproductsareprotectedbypatentsthatexpireoverthenextseveralyears.Forexample,certainpatentsrelatedtoTrifexis expireasearlyas2020intheU.S.,2021inJapanand2025inEuropeanterritories.Asthepatentsforabrandnameproductexpire,competitorsmaybegintointroducegenericorotheralternatives,andasaresult,Elancomayfacecompetitionfromlower-pricedalternativestomanyofitsproducts.Forexample,ElancohasexperiencedsignificantcompetitiveheadwindsfromgenericractopamineintheU.S.Inthethirdquarterof2013,alargeestablishedanimalhealthcompanyreceivedU.S.approvalforgenericractopamine.U.S.revenuefromOptaflexx ,Elanco'sractopaminebeefproduct,hasdeclinedataCAGRof24%from2015to2018asaresultofgenericcompetitionandinternationalregulatoryrestrictions.Elancomayfacesimilarcompetitioninthefutureforexistingproductsthatdonotbenefitfromexclusivity,includingRumensin ,whichhasnotbenefittedfrompatentprotectionintheU.S.forover20years,orforexistingproductswithmaterialpatentsexpiringinthefuture.See"BusinessofElanco—IntellectualProperty."
Genericcompetitorsarebecomingmoreaggressiveintermsoflaunchingproductsbeforepatentrightsexpire,and,becauseofattractivepricing,salesofgenericproductsareanincreasingpercentageofoverallanimalhealthsalesincertainregions.Althoughtheimpactofgenericcompetitionintheanimalhealthindustrytodatehasnottypicallymirroredthatseeninhumanhealth,productpricingandtheimpactofgenericcompetitioninthefuturemaymorecloselymirrorhumanhealthasaresultofchangesinindustrydynamics,suchaschannelexpansion,consolidation,anincreaseintheavailabilityanduseofpetinsuranceandthepotentialforgenericcompetitionbyestablishedanimalhealthbusinesses.Ifanimalhealthcustomersincreasetheiruseofneworexistinggenericproducts,Elanco'sbusiness,financialconditionandresultsofoperationscouldbemateriallyadverselyaffected.
17
TableofContents
Elanco may not successfully implement its business strategies or achieve targeted cost efficiencies and gross margin improvements.
Elancoispursuingstrategicinitiativesthatmanagementconsiderscriticaltoitslong-termsuccess,including,butnotlimitedto:improvingmanufacturingprocesses,reducingitsmanufacturingfootprint,achievingleaninitiatives,consolidatingitsCMOnetwork,strategicallyinsourcingprojects,pursuingcostsavingsopportunitieswithrespecttorawmaterialsthroughanewprocurementprocessandimprovingtheproductivityofitssalesforce.Elancomaypursueadditionalstrategicinitiativesinthefuturetoimprovegrossmarginsandachieveitstargetedcostefficiencies.Elancoalsohasacquiredorpartneredwithanumberofsmalleranimalhealthbusinesses,anditintendstocontinuetodosointhefuture.Therearesignificantrisksinvolvedwiththeexecutionoftheseinitiatives,includingsignificantbusiness,economicandcompetitiveuncertainties,manyofwhichareoutsideofElanco'scontrol.Accordingly,Elancomaynotsucceedinimplementingthesestrategicinitiatives.Realizingtheanticipatedbenefitsfromtheseinitiatives,ifanybenefitsareachievedatall,maytakeseveralyears.Elancomaybeunabletoachieveitstargetedcostefficienciesandgrossmarginimprovements.Additionally,Elancomayhaveinsufficientaccesstocapitaltofundinvestmentsinstrategicinitiatives,oritsbusinessstrategymaychangefromtimetotime,whichcoulddelayitsabilitytoimplementinitiativesthatitbelievesareimportanttoitsbusiness.
Consolidation of Elanco's customers and distributors could negatively affect the pricing of its products.
Third-partydistributors,veterinariansandfoodanimalproducersareElanco'sprimarycustomers.Inrecentyears,therehasbeenatrendtowardstheconcentrationofveterinariansinlargeclinicsandhospitals.Inaddition,foodanimalproducers,particularlyswineandpoultryproducers,andElanco'sdistributorshaveseenrecentconsolidationintheirindustries.Furthermore,Elancohasseentheexpansionoflargercross-bordercorporatecustomersandanincreaseintheconsolidationofbuyinggroups(cooperativesofveterinarypracticesthatleveragevolumetopursuediscountsfrommanufacturers).Thepaceofconsolidationandstructureofmarketsvariesgreatlyacrossgeographies.Ifthesetrendstowardsconsolidationcontinue,Elanco'scustomerscouldattempttoimprovetheirprofitabilitybyleveragingtheirbuyingpowertoobtainfavorablepricing.TheresultingdecreaseinElanco'spricescouldhaveamaterialadverseeffectonitsbusiness,financialconditionandresultsofoperations.
An outbreak of infectious disease carried by food animals could negatively affect the demand for, and sale and production of, Elanco's food animal products.
SalesofElanco'sfoodanimalproductscouldbemateriallyadverselyaffectedbytheoutbreakofdiseasecarriedbyfoodanimals,whichcouldleadtothewidespreaddeathorprecautionarydestructionoffoodanimalsaswellasthereducedconsumptionanddemandforanimalprotein.Inaddition,outbreaksofdiseasecarriedbyfoodanimalsmayreduceregionalorglobalsalesofparticularanimal-derivedfoodproductsorresultinreducedexportsofsuchproducts,eitherduetoheightenedexportrestrictionsorimportprohibitions,whichmayreducedemandforElanco'sfoodanimalproductsduetoreducedherdorflocksizes.
Inrecentyears,outbreaksofvariousdiseases,includingavianinfluenza,foot-and-mouthdisease,bovinespongiformencephalopathy(otherwiseknownasBSEor"madcow"disease)andporcineepidemicdiarrheavirus(otherwiseknownasPEDV),havenegativelyimpactedsalesofElanco'sanimalhealthproducts.Thediscoveryofadditionalcasesofanyofthese,ornew,diseasesmayresultinadditionalrestrictionsonanimalprotein,reducedherdorflocksizes,orreduceddemandforanimalprotein,anyofwhichmayhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresultsofoperations.Inaddition,theoutbreakofanyhighlycontagiousdiseasenearElanco'smainproductionsitescouldrequireElancotoimmediatelyhaltproductionofitsproductsatsuchsitesorforceittoincursubstantialexpensesinprocuringrawmaterialsorproductselsewhere.
18
TableofContents
Elanco's R&D, acquisition and licensing efforts may fail to generate new products or expand the use of its existing products.
Elanco'sfuturesuccessdependsonbothitsexistingproductportfolioanditspipelineofnewproducts,includingnewproductsthatitmaydevelopthroughjointventuresandproductsthatitisabletoobtainthroughlicenseoracquisition.Elancocommitssubstantialeffort,fundsandotherresourcestoR&D,boththroughitsowndedicatedresourcesandthroughcollaborationswiththirdparties.
Elancomaybeunabletodeterminewithaccuracywhenorwhetheranyofitsproductsnowunderdevelopmentwillbeapprovedorlaunched,oritmaybeunabletodevelop,licenseorotherwiseacquireproductcandidatesorproducts.Inaddition,Elancocannotpredictwhetheranyproducts,oncelaunched,willbecommerciallysuccessfulorwillachievesalesandrevenuethatareconsistentwithitsexpectations.Theanimalhealthindustryissubjecttoregionalandlocaltrendsandregulationsand,asaresult,productsthataresuccessfulinsomemarketsmaynotachievesimilarsuccesswhenintroducedintoothermarkets.Furthermore,thetimingandcostofElanco'sR&Dmayincrease,andElanco'sR&Dmaybecomelesspredictableas,amongotherthings,regulationsapplicabletoitsindustrymaymakeitmoretime-consumingand/orcostlytoresearch,developandregisterproducts.IfElancoisunabletogeneratenewproductsorexpandtheuseofitsexistingproducts,itsbusiness,financialconditionandresultsofoperationswillbemateriallyadverselyaffected.Forexample,between2015and2017,priortoElanco'sFebruary2018launchofCredelio intheU.S.,itexperiencedaninnovationlaginthecompanionanimalparasiticidespace.Intheabsenceofacompetitivecombinedoralfleaandtickproduct,Elanco'sU.S.companionanimalparasiticideportfoliorevenuedeclined15%in2017,excludingtheimpactonrevenueresultingfromareductionininventorylevelswithinElanco'sdistributionchannel.
Inaddition,someofElanco'sgrowthhasoccurredthroughLilly'sacquisitions,includingNovartisAnimalHealth,LohmannAnimalHealth,JanssenAnimalHealthandtheBIVetmedicaU.S.vaccinesportfolio.However,followingtheseparation,ElanconolongerbenefitsfromLilly'sscale,capitalbaseandfinancialstrength.
Elanco may not be able to successfully complete favorable transactions or successfully integrate acquired businesses when it pursues acquisitions, divestitures, joint ventures or other significant transactions, such as theacquisition of Aratana Therapeutics, Inc.
Fromtimetotime,Elancoevaluatespotentialacquisitions,divestituresorjointventures,suchastheacquisitionofAratanaTherapeutics,Inc.,thatwouldfurtheritsstrategicobjectives.ThecompletionofsuchtransactionsisoftensubjecttoconditionsthatmaybeoutsideElanco'scontrol,includingobtainingtherequisiteapprovalofthestockholdersofthetargetcompanyand/orgovernmentapprovalpursuanttotheHart-Scott-RodinoAntitrustImprovementsActof1976,asamended.Accordingly,Elancomaynotbeabletocompleteannouncedandsignedtransactionsandthereforenotrealizetheanticipatedbenefitstherefrom.
Aftertheclosingofanacquisition,includingthetransactionwithAratanaTherapeutics,Inc.,Elancowillberequiredtodevotesignificantmanagementattentionandresourcestointegratingtheportfolioandoperationsofthetargetcompany.PotentialdifficultiesthatElancomayencounterintheintegrationprocess,includingasaresultofdistractionofitsmanagement,includethefollowing:
• theinabilitytocombinebusinessesoftheacquiredcompanywithElanco'sinamannerthatpermitsustoachievethecostsavingsorothersynergiesanticipatedasaresultofthetransactionortoachievesuchcostsavingsorotheranticipatedsynergiesinatimelymanner,whichcouldresultinElanconotrealizingsomeanticipatedbenefitsofthetransactioninthetimeframeanticipated,oratall;
• theinabilitytorealizetheanticipatedvaluefromvariousassetsoftargetcompanies;
19
TableofContents
• lossofkeyemployees;
• potentialunknownliabilitiesandunforeseenincreasedexpenses,delaysorunfavorableconditionsinconnectionwiththeclosingofthetransactionandthesubsequentintegration;and
• performanceshortfallsatElancoorthetargetcompanyasaresultofthediversionofmanagement'sattentionfromongoingbusinessactivitiesasaresultofcompletingthetransactionandintegratingthecompanies'operations.
Futureacquisitionscouldalsoresultinpotentiallydilutiveissuancesofequitysecurities,theincurrenceofdebt,contingentliabilitiesoramortizationexpensesrelatedtointangibleassets,andincreasedoperatingexpenses,whichcouldadverselyaffectElanco'sresultsofoperationsandfinancialcondition.Furthermore,ifElancoissuesequityordebtsecuritiestoraiseadditionalfunds,Elanco'sexistingshareholdersmayexperiencesignificantdilution,andthenewequityordebtsecuritiesmayhaverights,preferencesandprivilegesseniortothoseofElanco'sexistingstockholders.Furthermore,ifElancosellsasubstantialnumberofsharesofcommonstockinthepublicmarkets,theavailabilityofthosesharesforsalecouldadverselyaffectthemarketpriceofitscommonstock.Suchsales,ortheperceptioninthemarketthatholdersofalargenumberofsharesintendtosellshares,coulddepressthemarketpriceofElanco'scommonstockandimpairitsabilitytoraisecapitalthroughthesaleofadditionalequitysecurities.
Elanco had losses in recent periods.
Inrecentperiods,Elancohasincurrednetlosses,asreportedonacombinedbasis,includinganetincome(loss)foreachoftheyearsendedDecember31,2017and2016of$(310.7)millionand$(47.9)million,respectively.See"Management'sDiscussionandAnalysisofFinancialConditionandResultsofOperationsofElanco."Elancocouldcontinuetoincurassetimpairment,restructuringandotherspecialchargesandcouldreportlossesinthefuture.Elancoalsoexpectstocontinuetoincursubstantialexpenditurestodevelop,manufactureandmarketitsproductsandimplementitsbusinessstrategies.Elancomayencounterunforeseenexpenses,difficulties,complications,delays,adverseeventsandotherunknownfactorsthatmaymateriallyadverselyaffectitsbusiness.
The misuse or off-label use of Elanco's products may harm its reputation or result in financial or other damages.
Elanco'sproductshavebeenapprovedforuseunderspecificcircumstancesforthetreatmentofcertaindiseasesandconditionsinspecificspecies.Theremaybeincreasedriskofproductliabilityclaimsifveterinarians,foodanimalproducers,petownersorothersattempttouseElanco'sproductsoff-label,includingtheuseofitsproductsinspecies(includinghumans)forwhichtheyhavenotbeenapproved.Furthermore,theuseofElanco'sproductsforindicationsotherthanthoseforwhichitsproductshavebeenapprovedmaynotbeeffective,whichcouldharmitsreputationandleadtoanincreasedriskoflitigation.IfElancoisdeemedbyagovernmentalorregulatoryagencytohaveengagedinthepromotionofanyofitsproductsforoff-labeluse,suchagencycouldrequestthatElancomodifyitstrainingorpromotionalmaterialsandpractices,andElancocouldbesubjecttosignificantfinesandpenalties,andtheimpositionofthesesanctionscouldalsoaffectitsreputationandpositionwithintheindustry.AnyoftheseeventscouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Animal health products are subject to unanticipated safety, quality or efficacy concerns, which may harm Elanco's reputation.
Unanticipatedsafety,qualityorefficacyconcernsarisefromtimetotimewithrespecttoanimalhealthproducts,whetherornotscientificallyorclinicallysupported,leadingtoproductrecalls,withdrawalsorsuspendedordecliningsales,aswellasproductliabilityandotherclaims.
20
TableofContents
Regulatoryactionsbasedonthesetypesofsafety,qualityorefficacyconcernscouldimpactall,orasignificantportion,ofaproduct'ssalesandcould,dependingonthecircumstances,materiallyadverselyaffectElanco'sresultsofoperations.
Inaddition,sinceElancodependsonpositiveperceptionsofthesafety,qualityandefficacyofitsproducts,andanimalhealthproductsgenerally,byfoodproducers,veterinariansandpetowners,anyconcernastothesafety,qualityorefficacyofElanco'sproducts,whetheractualorperceived,mayharmitsreputation.TheseconcernsandtherelatedharmtoElanco'sreputationcouldmateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations,regardlessofwhethersuchreportsareaccurate.
Elanco's business may be negatively affected by weather conditions and the availability of natural resources.
TheanimalhealthindustryanddemandformanyofElanco'sproductsinaparticularregionareaffectedbyweatherconditions,varyingweatherpatternsandweather-relatedpressuresfrompests,suchasticks.Asaresult,Elancomayexperienceregionalandseasonalfluctuationsinitsresultsofoperations.
Foodanimalproducersdependontheavailabilityofnaturalresources,includinglargesuppliesoffreshwater.Theiranimals'healthandtheirabilitytooperatecouldbeadverselyaffectediftheyexperienceashortageoffreshwaterduetohumanpopulationgrowthorfloods,droughtsorotherweatherconditions.Intheeventofadverseweatherconditionsorashortageoffreshwater,veterinariansorfoodanimalproducersmaypurchaselessofElanco'sproducts.
Further,heatwavesmaycausestressinanimalsandleadtoincreasedvulnerabilitytodisease,reducedfertilityratesandreducedmilkproduction.Droughtsmaythreatenpastureandfeedsuppliesbyreducingthequalityandamountofforageavailabletograzinglivestock,whileclimatechangemayincreasetheprevalenceofparasitesanddiseasesthataffectfoodanimals.Adverseweatherconditionsmayalsohaveamaterialimpactontheaquaculturebusiness.Changesinwatertemperaturescouldaffectthetimingofreproductionandgrowthofvariousfishspecies,aswellastriggertheoutbreakofcertainwaterbornediseases.
Inaddition,veterinaryhospitalsandpractitionersdependonvisitsfrom,andaccessto,theanimalsundertheircare.Veterinarians'patientvolumeandabilitytooperatecouldbeadverselyaffectediftheyexperienceprolongedsnow,iceorothersevereweatherconditions,particularlyinregionsnotaccustomedtosustainedinclementweather.
Elanco may not be able to realize the expected benefits of its investments in emerging markets and is subject to certain risks due to its presence in emerging markets, including political or economic instability andfailure to adequately comply with legal and regulatory requirements.
Elancohastakenstepstoincreaseitspresenceinselectemergingmarkets,includingbyexpandingitssalesorganizationandproductofferingsinthesemarkets.FailuretocontinuetomaintainandexpandElanco'sbusinessinemergingmarketscouldmateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations.
Inaddition,certainemergingmarketshavelegalsystemsthatarelessdeveloped.OtherjurisdictionsinwhichElancoconductsbusinessmayhavelegalandregulatoryregimesthatdiffermateriallyfromU.S.lawsandregulations,arecontinuouslyevolvingordonotincludesufficientjudicialoradministrativeguidancetointerpretsuchlawsandregulations.Compliancewithdiverselegalrequirementsiscostlyandtime-consumingandrequiressignificantresources.ViolationsorpossibleviolationsofapplicablelawsorregulationsbyElanco'semployeesmayresultininvestigationcosts,potentialpenaltiesandotherrelatedcostswhichinturncouldnegativelyaffectitsreputationanditsresultsofoperations.
21
TableofContents
Somecountrieswithinemergingmarketsmaybeespeciallyvulnerabletoperiodsoflocal,regionalorglobaleconomic,politicalorsocialinstabilityorcrisis.Forexample,Elanco'ssalesincertainemergingmarketshavesufferedfromextendedperiodsofdisruptionduetonaturaldisasters.Furthermore,Elancohasalsoexperiencedlowerthanexpectedsalesincertainemergingmarketsduetolocal,regionalandglobalrestrictionsonbankingandcommercialactivitiesinthosecountries.Inaddition,certainemergingmarketshavecurrenciesthatfluctuatesubstantially,whichmayimpactElanco'sfinancialperformance.Forthesereasons,amongothers,doingbusinesswithinemergingmarketscarriessignificantrisks.
Modification of foreign trade policy may harm Elanco's food animal product customers.
Changesinlaws,agreementsandpoliciesgoverningforeigntradeintheterritoriesandcountrieswhereElanco'scustomersdobusinesscouldnegativelyimpactsuchcustomers'businessesandadverselyaffectitsresultsofoperations.AnumberofElanco'scustomers,particularlyU.S.-basedfoodanimalproducers,benefitfromfreetradeagreements,suchastheNorthAmericanFreeTradeAgreement("NAFTA").InNovember2018,theU.S.negotiatedanewtradedealwithCanadaandMexicoknownastheUnitedStates-Mexico-Canada-Agreement("USMCA"),aimedatre-negotiatingandupdatingthetermsofNAFTA.TheUSMCAstillrequiresratificationbylegislativebodiesinallthreecountriesbeforeitcantakeeffect.IftheUSMCAisnotratifiedandtheU.S.weretowithdrawfromormateriallymodifyNAFTAorotherinternationaltradeagreementstowhichitisapartyoriftheU.S.weretoengageintradedisputesortheimpositionoftariffs,Elanco'scustomerscouldbeharmed,andasaresult,Elanco'sbusiness,financialconditionandresultsofoperationscouldbemateriallyadverselyaffected.
Elanco's business is subject to risk based on global economic conditions.
MacroeconomicbusinessandfinancialdisruptionscouldhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresultsofoperations.CertainofElanco'scustomersandsupplierscouldbeaffecteddirectlybyaneconomicdownturnandcouldfaceconstraintsontheavailabilityofcreditordecreasedcashflowthatcouldgiverisetopaymentdelays,increasedcreditrisk,bankruptciesandotherfinancialhardshipsthatcoulddecreasethedemandforElanco'sproductsorhinderitsabilitytocollectamountsduefromitscustomers.IfoneormoreofElanco'slargecustomers,includingdistributors,discontinuesormodifiestheirrelationshipwithitasaresultofeconomicconditionsorotherwise,itsbusiness,financialconditionandresultsofoperationsmaybemateriallyadverselyaffected.Inaddition,economicconcernsmaycausesomepetownerstoforgoordefervisitstoveterinarypracticesorcouldreducetheirwillingnesstotreatpethealthconditionsortocontinuetoownapet.Furthermore,Elanco'sexposuretocreditandcollectabilityriskishigherincertaininternationalmarketsanditsabilitytomitigatesuchrisksmaybelimited.Elanco'sproceduresintendedtomonitorandlimititsexposuretocreditandcollectabilityriskmaynoteffectivelylimitsuchriskandavoidlosses.
Elanco's results of operations are dependent upon the success of its top products.
IfanyofElanco'stopproductsexperienceissues,suchasdisruptiveinnovationsortheintroductionofmoreeffectivecompetitiveproducts,negativepublicity,changestoveterinarianorcustomerpreferences,lossofpatentprotection,materialproductliabilitylitigation,neworunexpectedsideeffects,manufacturingdisruptionsand/orregulatoryproceedings,itsrevenuecouldbenegativelyimpacted,perhapssignificantly.Elanco'stopfiveproducts,Rumensin ,Trifexis ,Maxiban ,Denagard andInterceptor Plus ,contributedapproximately31%ofitsrevenuein2018.Anyissueswiththesetopproducts,particularlyRumensin ,whichcontributedapproximately11%ofElanco'srevenuein2018,couldhaveamaterialadverseeffectonitsbusiness,financialconditionandresultsofoperations.
22
TableofContents
Elanco's business is subject to risk based on customer exposure to rising costs and reduced customer income.
Feed,fuel,transportationandotherkeycostsforfoodanimalproducersmayincreaseoranimalproteinpricesorsalesmaydecrease.EitherofthesetrendscouldcausedeteriorationinthefinancialconditionofElanco'sfoodanimalproductcustomers,potentiallyinhibitingtheirabilitytopurchaseitsproductsorpayitforproductsdelivered.Elanco'sfoodanimalproductcustomersmayoffsetrisingcostsbyreducingspendingonitsfoodanimalproducts,includingbyswitchingtolower-costalternativestoitsproducts.Inaddition,concernsaboutthefinancialresourcesofpetownerscouldcauseveterinarianstoaltertheirtreatmentrecommendationsinfavoroflower-costalternativestoElanco'sproducts,whichcouldresultinadecreaseinsalesofElanco'scompanionanimalproducts,especiallyindevelopedcountrieswherethereisahigherrateofpetownership.RisingcostsorreducedincomeforElanco'scustomerscouldhaveamaterialadverseeffectonitsbusiness,financialconditionandresultsofoperations.
For Elanco's companion animal products, increased use of alternative distribution channels, or changes within existing distribution channels, could negatively impact its market share, margins and distribution of itsproducts.
Inmostmarkets,petownerstypicallypurchasetheiranimalhealthproductsdirectlyfromveterinarians.However,petownersincreasinglyhavetheoptiontopurchaseanimalhealthproductsfromsourcesotherthanveterinarians,suchasonlineretailers,"big-box"retailstoresorotherover-the-counterdistributionchannels.Thistrendhasbeendemonstratedbythesignificantshiftawayfromtheveterinariandistributionchannelinthesaleoffleaandtickproductsinrecentyears.Petownersalsocoulddecreasetheirrelianceon,andvisitsto,veterinariansastheyrelymoreoninternet-basedanimalhealthinformation.BecauseElancomarketsitscompanionanimalprescriptionproductsprimarilythroughtheveterinariandistributionchannel,anydecreaseinvisitstoveterinariansbypetownerscouldreduceitsmarketshareforsuchproductsandmateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations.Inaddition,petownersmaysubstitutehumanhealthproductsforanimalhealthproductsifhumanhealthproductsaredeemedtobelower-costalternatives.
LegislationhasalsobeenproposedintheU.S.,andmaybeproposedintheU.S.orabroadinthefuture,thatcouldimpactthedistributionchannelsforElanco'scompanionanimalproducts.Forexample,suchlegislationmayrequireveterinarianstoprovidepetownerswithwrittenprescriptionsanddisclosurethatthepetownermayfillprescriptionsthroughathirdparty,whichmayfurtherreducethenumberofpetownerswhopurchasetheiranimalhealthproductsdirectlyfromveterinarians.SuchrequirementsmayleadtoincreaseduseofgenericalternativestoElanco'sproductsortheincreasedsubstitutionofitscompanionanimalproductswithotheranimalhealthproductsorhumanhealthproductsifsuchotherproductsaredeemedtobelower-costalternatives.ManystatesalreadyhaveregulationsrequiringveterinarianstoprovideprescriptionstopetownersuponrequestandtheAmericanVeterinaryMedicalAssociationhaslong-standingpoliciesinplacetoencouragethispractice.
Overtime,theseandothercompetitiveconditionsmayincreaseElanco'suseofonlineretailers,"big-box"retailstoresorotherover-the-counterdistributionchannelstosellitscompanionanimalproducts.Elancomaynotbeadequatelypreparedorabletodistributeitscompanionanimalproductsifanincreasedportionofitssalesoccursthroughthesechannels.Also,Elancomayrealizelowermarginsonsalesthroughthesedistributionchannelsthanitdoesonsalesthroughveterinarians.AnyoftheseeventscouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Inaddition,ifoneormoreofElanco'scompanionanimaldistributorsdiscontinuesormodifiestheirrelationshipwithit,Elanco'sbusiness,financialconditionandresultsofoperationsmaybemateriallyadverselyaffected.Forexample,in2017,achangeinElanco'sU.S.inventorymanagementpracticesresultedinarevenuelagasexistinginventorywassolddown,whichmanagementestimatesdecreaseditsrevenuebyapproximately$35million.
23
TableofContents
Loss of Elanco's executive officers or other key personnel could disrupt its operations.
Elancodependsontheeffortsofitsexecutiveofficersandotherkeypersonnel.Elanco'sexecutiveofficersandotherkeypersonnelarenotcurrently,andarenotexpectedtobe,subjecttonon-competeprovisions.Inaddition,Elancohasnotenteredintoemploymentagreementswithitsexecutiveofficersorotherkeypersonnel.Anyunplannedturnoveroritsfailuretodevelopanadequatesuccessionplanforoneormoreofitsexecutiveofficerorotherkeypersonnelpositionscoulddepleteitsinstitutionalknowledgebaseanderodeitscompetitiveadvantage.ThelossorlimitedavailabilityoftheservicesofoneormoreofElanco'sexecutiveofficersorotherkeypersonnel,oritsinabilitytorecruitandretainqualifiedexecutiveofficersorotherkeypersonnelinthefuture,could,atleasttemporarily,haveamaterialadverseeffectonitsbusiness,financialconditionandresultsofoperations.
Elanco may be required to write down goodwill or identifiable intangible assets.
UnderU.S.GAAP,ifElancodeterminesgoodwilloridentifiableintangibleassetsareimpaired,itwillberequiredtowritedowntheseassetsandrecordanon-cashimpairmentcharge.AsofDecember31,2018,Elancohadrecordedonitsbalancesheetgoodwillof$3.0billionandidentifiableintangibleassetsof$2.5billion.Identifiableintangibleassetsconsistprimarilyofmarketedproductsacquiredorlicensedfromthirdparties,licensedplatformtechnologiesthathavealternativefutureusesinR&D,manufacturingtechnologies,andcustomerrelationshipsfrombusinesscombinations.Elancoalsohasindefinite-livedintangibleassets,whichconsistofacquiredin-processR&Dprojectsfrombusinesscombinationsthataresubjecttoimpairmentandnon-cashimpairmentcharges.
Determiningwhetheranimpairmentexistsandtheamountofthepotentialimpairmentinvolvesquantitativedataandqualitativecriteriathatarebasedonestimatesandassumptionsrequiringsignificantmanagementjudgment.Futureeventsornewinformationmaychangemanagement'svaluationofanintangibleassetinashortamountoftime.ThetimingandamountofimpairmentchargesrecordedinElanco'sconsolidatedandcombinedstatementsofoperationsandwrite-downsrecordedinitsconsolidatedandcombinedbalancesheetscouldvaryifitsmanagement'sconclusionschange.AnyimpairmentofgoodwilloridentifiableintangibleassetscouldhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresultsofoperations.
As a standalone public company, Elanco may expend additional time and resources to comply with rules and regulations that did not previously apply to it, and failure to comply with such rules may lead investors tolose confidence in Elanco's financial data.
Asastandalonepubliccompany,ElancoissubjecttothereportingrequirementsoftheExchangeAct,theSarbanes-OxleyAct,theDodd-FrankWallStreetReformandConsumerProtectionActandregulationsoftheNYSE.ElancohasestablishedalloftheproceduresandpracticesrequiredasasubsidiaryofLilly,butitmustcontinuetoimplementothersasaseparate,standalonepubliccompany.ContinuingtoestablishandexpandsuchproceduresandpracticeswillincreaseElanco'slegal,accountingandfinancialcompliancecosts,willmakesomeactivitiesmoredifficult,time-consumingandcostlyandcouldbeburdensomeonElanco'spersonnel,systemsandresources.Elancoisdevotingandwillcontinuetodevotesignificantresourcestoaddressthesepubliccompanyrequirements,includingcomplianceprogramsandinvestorrelations,aswellasElanco'sfinancialreportingobligations.Asaresult,Elancohasandwillcontinuetoincursignificantlegal,accountingandotherexpensesthatitdidnotpreviouslyincurtocomplywiththeserulesandregulations.Furthermore,theneedtoestablishthecorporateinfrastructurenecessaryforastandalonepubliccompanymaydivertsomeofElancomanagement'sattentionfromoperatingElanco'sbusinessandimplementingitsstrategy.However,themeasuresElancotakesmaynotbesufficienttosatisfyitsobligationsasapubliccompany.Inaddition,Elancocannotpredictorestimatetheamountofadditionalcostsitmayincurinordertocomplywiththeserequirements.
24
TableofContents
Elancohasmade,andwillcontinuetomake,changestoitsinternalcontrolsandproceduresforfinancialreportingandaccountingsystemstomeetitsreportingobligations.Inparticular,asapubliccompany,ElancomanagementisrequiredtoconductanannualevaluationofElanco'sinternalcontrolsoverfinancialreportingandincludeareportofmanagementonElanco'sinternalcontrolsinitsannualreportsonForm10-K.Undercurrentrules,ElancowillbesubjecttotheserequirementsbeginningwithitsannualreportonForm10-KfortheyearendingDecember31,2019.Inaddition,ElancowillberequiredtohaveitsindependentregisteredpublicaccountingfirmattesttotheeffectivenessofElanco'sinternalcontrolsoverfinancialreportingpursuanttoAuditingStandardNo.5beginningwithElanco'sannualreportonForm10-KfortheyearendingDecember31,2019.IfElancoisunabletoconcludethatithaseffectiveinternalcontrolsoverfinancialreporting,orifElanco'sregisteredpublicaccountingfirmisunabletoprovideElancowithanattestationandanunqualifiedreportastotheeffectivenessofElanco'sinternalcontrolsoverfinancialreporting,investorscouldloseconfidenceinthereliabilityofElanco'sfinancialstatements,whichcouldresultinadecreaseinthevalueofitscommonstock.
Elanco's R&D relies on evaluations of animals, which may become subject to bans, additional restrictive regulations or increased attention from activism movements.
Asananimalhealthmedicinesandvaccinesbusiness,Elancoisrequiredtoevaluatetheeffectofitsexistingandnewproductsinanimalsinordertoregistersuchproducts.Animaltestingincertainindustrieshasbeenthesubjectofcontroversyandadversepublicity.Someorganizationsandindividualshaveattemptedtobananimaltestingorencouragetheadoptionofnewregulationsapplicabletoanimaltesting.Totheextentthattheactivitiesofsuchorganizationsandindividualsaresuccessful,Elanco'sR&D,andbyextensionitsbusiness,financialconditionandresultsofoperations,couldbemateriallyadverselyaffected.Inaddition,negativepublicityaboutElancooritsindustrycouldharmitsreputation.
Manufacturing problems and capacity imbalances may cause product launch delays, inventory shortages, recalls or unanticipated costs.
Inordertosellitsproducts,Elancomustbeabletoproduceandshipsufficientquantitiestoitscustomers.Elancoownsandoperates12internalmanufacturingsiteslocatedinninecountries.Elancoalsoemploysanetworkofapproximately100third-partyCMOs.ManyofElanco'sproductsinvolvecomplexmanufacturingprocessesandaresole-sourcedfromcertainmanufacturingsites.
MinordeviationsinElanco'smanufacturingorlogisticalprocesses,suchastemperatureexcursionsorimproperpackagesealing,couldresult,andhaveinthepastresultedin,delays,inventoryshortages,unanticipatedcosts,productrecalls,productliabilityand/orregulatoryaction.Inaddition,anumberoffactorscouldcauseproductioninterruptions,including:
• thefailureofElancooranyofitsvendorsorsuppliers,includinglogisticalserviceproviders,tocomplywithapplicableregulationsandqualityassuranceguidelines;
• mislabeling;
• constructiondelays;
• equipmentmalfunctions;
• shortagesofmaterials;
• laborproblems;
• naturaldisasters;
• poweroutages;
25
TableofContents
• criminalandterroristactivities;
• changesinmanufacturingproductionsitesandlimitstomanufacturingcapacityduetoregulatoryrequirements,changesintypesofproductsproduced,shippingdistributionsorphysicallimitations;and
• theoutbreakofanyhighlycontagiousdiseasesnearElanco'sproductionsites.
Theseinterruptionscouldresultinlaunchdelays,inventoryshortages,recalls,unanticipatedcostsorissueswithElanco'sagreementsunderwhichitsuppliesthirdparties,whichmaymateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations.
Elanco'smanufacturingnetworkmaybeunabletomeetthedemandforitsproductsoritmayhaveexcesscapacityifdemandforitsproductschanges.Theunpredictabilityofaproduct'sregulatoryorcommercialsuccessorfailure,theleadtimenecessarytoconstructhighlytechnicalandcomplexmanufacturingsitesandshiftingcustomerdemand(includingasaresultofmarketconditionsorentryofbrandedorgenericcompetition)increasethepotentialforcapacityimbalances.Inaddition,constructionofsitesisexpensive,andElanco'sabilitytorecovercostswilldependonthemarketacceptanceandsuccessoftheproductsproducedatthenewsites,whichisuncertain.
Elanco relies on third parties to provide it with materials and services and are subject to increased labor and material costs and potential disruptions in supply.
ThematerialsusedtomanufactureElanco'sproductsmaybesubjecttoavailabilityconstraintsandpricevolatilitycausedbychangesindemand,weatherconditions,supplyconditions,governmentregulations,economicclimateandotherfactors.Inaddition,laborcostsmaybesubjecttovolatilitycausedbythesupplyoflabor,governmentalregulations,economicclimateandotherfactors.Increasesinthedemandfor,availabilityorthepriceof,materialsusedtomanufactureElanco'sproductsandincreasesinlaborcostscouldincreasethecoststomanufactureitsproducts,resultinproductdeliverydelaysorshortages,andimpactitsabilitytolaunchnewproductsonatimelybasisoratall.Elancomaynotbeabletopassalloramaterialportionofanyhighermaterialorlaborcostsontoitscustomers,whichcouldmateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations.
Elancomaybeunabletomeetdemandforcertainofitsproductsifanyofitsthird-partysuppliersceaseorinterruptoperations,failtorenewcontractswithitorotherwisefailtomeettheirobligationstoit.
Elanco may incur substantial costs and receive adverse outcomes in litigation and other legal matters.
Elanco'sbusiness,financialconditionandresultsofoperationscouldbemateriallyadverselyaffectedbyunfavorableresultsinpendingorfuturelitigationmatters.Thesemattersmayinclude,amongotherthings,allegationsofviolationofU.S.andforeigncompetitionlaw,laborlaws,consumerprotectionlawsandenvironmentallawsandregulations,aswellasclaimsorlitigationrelatingtoproductliability,intellectualproperty,securities,breachofcontractandtort.Inaddition,changesintheinterpretationsoflawsandregulationstowhichElancoissubject,orinlegalstandardsinoneormoreofthejurisdictionsinwhichElancooperates,couldincreaseitsexposuretoliability.Forexample,intheU.S.,attemptshavebeenmadetoallowdamagesforemotionaldistressandpainandsufferinginconnectionwiththelossof,orinjuryto,acompanionanimal.Ifsuchattemptsweresuccessful,Elanco'sexposurewithrespecttoproductliabilityclaimscouldincreasematerially.
Litigationmatters,regardlessoftheirmeritsortheirultimateoutcomes,arecostly,divertmanagement'sattentionandmaymateriallyadverselyaffectElanco'sreputationanddemandforitsproducts.Elancocannotpredictwithcertaintytheeventualoutcomeofpendingorfuturelitigationmatters.AnadverseoutcomeoflitigationorlegalmatterscouldresultinElancobeingresponsiblefor
26
TableofContents
significantdamages.AnyofthesenegativeeffectsresultingfromlitigationmatterscouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Elanco's business is subject to substantial regulation.
Asaglobalcompany,Elancoissubjecttovariousstate,federalandinternationallawsandregulations,includingregulationsrelatingtothedevelopment,qualityassurance,manufacturing,importation,distribution,marketingandsaleofitsproducts.Changesinapplicablefederal,state,localandforeignlawsandregulationscouldhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresultsofoperations.Inaddition,Elanco'smanufacturingfacilities,includingthemanufacturingfacilitiesoperatedbyitsCMOs,aresubjecttoperiodicinspectionsbyregulatoryagencies.Aninspectionmayreportconditionsorpracticesthatindicatepossibleviolationsofregulatoryrequirements.Elanco'sfailure,orthefailureofthirdpartiesitrelieson,includingCMOs,tocomplywiththeseregulatoryrequirements,allegationsofsuchnon-complianceorthediscoveryofpreviouslyunknownproblemswithaproductormanufacturercouldresultin,amongotherthings,inspectionobservationnotices,warninglettersorsimilarregulatorycorrespondence,fines,apartialortotalshutdownofproductioninoneormoreofElanco'sfacilitieswhileanallegedviolationisremediated,withdrawalsorsuspensionsofcurrentproductsfromthemarket,andcivilorcriminalprosecution,aswellasdecreasedsalesasaresultofnegativepublicityandproductliabilityclaims.AnyoneoftheseconsequencescouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Inaddition,Elancowillnotbeabletomarketnewproductsunlessanduntilithasobtainedallrequiredregulatoryapprovalsineachjurisdictionwhereitproposestomarketthoseproducts.Evenafteraproductreachesmarket,itmaybesubjecttore-reviewandmayloseitsapprovals.Elanco'sfailuretoobtainapprovals,delaysintheapprovalprocess,oritsfailuretomaintainapprovalsinanyjurisdiction,maypreventitfromsellingproductsinthatjurisdictionuntilapprovalorre-approvalisobtained,ifever.
The illegal distribution and sale by third parties of counterfeit or illegally compounded versions of Elanco's products or of stolen, diverted or relabeled products could have a negative impact on Elanco's reputation andbusiness.
ThirdpartiesmayillegallydistributeandsellcounterfeitorillegallycompoundedversionsofElanco'sproductsthatdonotmeettheexactingstandardsofElanco'sdevelopment,manufacturinganddistributionprocesses.Counterfeitorillegallycompoundedmedicinesposeasignificantrisktoanimalhealthandsafetybecauseoftheconditionsunderwhichtheymaybemanufacturedandthelackofregulationoftheircontents.Counterfeitorillegallycompoundedproductsarefrequentlyunsafeorineffectiveandcanbepotentiallylife-threateningtoanimals.Elanco'sreputationandbusinesscouldsufferharmasaresultofcounterfeitorillegallycompoundedproductswhichareallegedtobeequivalentand/orwhicharesoldunderElanco'sbrandname.Inaddition,productsstolenorunlawfullydivertedfrominventory,warehouses,plantsorwhileintransit,whicharenotproperlystoredorwhichhaveanexpiredshelflifeandwhichhavebeenrepackagedorrelabeledandwhicharesoldthroughunauthorizedchannels,couldadverselyimpactanimalhealthandsafety,Elanco'sreputationanditsbusiness.Publiclossofconfidenceintheintegrityofvaccinesand/orpharmaceuticalproductsasaresultofcounterfeiting,illegalcompoundingortheftcouldhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresultsofoperations.
Elanco is subject to complex environmental, health and safety laws and regulations.
Elancoissubjecttovariousfederal,state,localandforeignenvironmental,healthandsafetylawsandregulations.Theselawsandregulationsgovernmatterssuchastheemissionanddischargeofhazardousmaterialsintotheground,airorwater;thegeneration,use,storage,handling,treatment,
27
TableofContents
packaging,transportation,exposuretoanddisposalofhazardousandbiologicalmaterials,includingrecordkeeping,reportingandregistrationrequirements;andthehealthandsafetyofElanco'semployees.DuetoElanco'soperations,theselawsandregulationsalsorequireittoobtain,andcomplywith,permits,registrationsorotherauthorizationsissuedbygovernmentalauthorities.TheseauthoritiescanmodifyorrevokeElanco'spermits,registrationsorotherauthorizationsandcanenforcecompliancethroughfinesandinjunctions.
GiventhenatureofElanco'sbusiness,ithasincurred,iscurrentlyincurringandmayinthefutureincurliabilitiesfortheinvestigationandremediationofcontaminatedlandundertheU.S.ComprehensiveEnvironmentalResponse,CompensationandLiabilityActof1980,asamended,orunderotherfederal,state,localandforeignenvironmentalcleanuplaws,withrespecttoElanco'scurrentorformersites,adjacentornearbythird-partysites,oroffsitedisposallocations.Elancocouldbesubjecttoliabilityfortheinvestigationandremediationoflegacyenvironmentalcontaminationcausedbyhistoricalindustrialactivityonsitesthatitownsoronwhichitoperates.ThecostsassociatedwithfuturecleanupactivitiesthatElancomayberequiredtoconductorfinancecouldbematerial.Additionally,Elancomaybecomeliabletothirdpartiesfordamages,includingpersonalinjury,propertydamageandnaturalresourcedamages,resultingfromthedisposalorreleaseofhazardousmaterialsintotheenvironment.SuchliabilitycouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Furthermore,regulatoryagenciesareshowingincreasingconcernovertheimpactofanimalhealthproductsandfoodanimaloperationsontheenvironment.Thisincreasedregulatoryscrutinyhasinthepastandmayinthefuturenecessitatethatadditionaltimeandresourcesbespenttoaddresstheseconcernsinbothnewandexistingproducts.
Elanco'sfailuretocomplywiththeenvironmental,healthandsafetylawsandregulationstowhichitissubject,includinganypermitsissuedthereunder,mayresultinenvironmentalremediationcosts,lossofpermits,fines,penaltiesorotheradversegovernmentalorprivateactions,includingregulatoryorjudicialordersenjoiningorcurtailingoperationsorrequiringcorrectivemeasures,installationofpollutioncontrolequipmentorremedialmeasures.Elancocouldalsobeheldliableforanyandallconsequencesarisingoutofhumanexposuretohazardousmaterials,environmentaldamageorsignificantenvironmental,healthandsafetyissuesthatmightariseatamanufacturingorR&Dfacility.Environmentallawsandregulationsarecomplex,changefrequently,havetendedtobecomemorestringentandstringentlyenforcedovertimeandmaybesubjecttonewinterpretation.ItispossiblethatElanco'scostsofcomplyingwithcurrentandfutureenvironmental,healthandsafetylaws,anditsliabilitiesarisingfrompastorfuturereleasesof,orexposureto,hazardousmaterialscouldmateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations.
The actual or purported intellectual property rights of third parties may negatively affect Elanco's business.
AthirdpartymaysueElanco,oritsdistributorsorlicensors,includingLilly,orotherwisemakeaclaim,alleginginfringementorotherviolationofsuchthird-party'spatents,trademarks,tradedress,copyrights,tradesecrets,domainnamesorotherintellectualpropertyrights.IfElanco,itsdistributorsorlicensorsdonotprevailinthistypeoflitigation,Elancomayberequiredto:
• paymonetarydamages;
• obtainalicenseinordertocontinuemanufacturingormarketingtheaffectedproducts,whichmaynotbeavailableoncommerciallyreasonableterms,oratall;or
• stopactivities,includinganycommercialactivities,relatingtotheaffectedproducts,whichcouldincludearecalloftheaffectedproductsand/oracessationofsalesinthefuture.
ThecostsofdefendinganintellectualpropertyclaimcouldbesubstantialandcouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations,evenifElanco
28
TableofContents
successfullydefendssuchclaim.Moreover,evenifElancobelievesthatitdoesnotinfringeavalidlyexistingthird-partypatent,Elancomaychoosetolicensesuchpatent,whichwouldresultinassociatedcostsandobligations.Elancomayalsoincurcostsinconnectionwithanobligationtoindemnifyadistributor,licensororotherthirdparty.
Theintellectualpropertypositionsofanimalhealthmedicinesandvaccinesbusinessesfrequentlyinvolvecomplexlegalandfactualquestions,andanissuedpatentdoesnotguaranteeElancotherighttopracticethepatentedtechnologyordevelop,manufactureorcommercializethepatentedproduct.Forexample,whileElancogenerallyentersintoproprietaryinformationagreementswithitsemployeesandthirdpartieswhichassignintellectualpropertyrightstoElanco,theseagreementsmaynotbehonoredormaynoteffectivelyassignintellectualpropertyrightstoElancounderthelocallawsofsomecountriesorjurisdictions.ElancocannotbecertainthatacompetitororotherthirdpartydoesnothaveorwillnotobtainrightstointellectualpropertythatmaypreventElancofrommanufacturing,developingormarketingcertainofitsproducts,regardlessofwhetherElancobelievessuchintellectualpropertyrightsarevalidandenforceableoritbelievesitwouldotherwisebeabletodevelopamorecommerciallysuccessfulproduct,whichmaymateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations.
If Elanco's intellectual property rights are challenged or circumvented, competitors may be able to take advantage of Elanco's research and development efforts or harm the value of Elanco's brands.
Elanco'slong-termsuccessdependsonitsabilitytomarketinnovative,competitiveproducts.Elancoreliesandexpectstocontinuetorelyonacombinationofintellectualproperty,includingpatent,trademark,tradedress,copyright,tradesecretanddomainnameprotection,aswellasconfidentialityandlicenseagreementswithElanco'semployeesandothers,toprotectitsintellectualpropertyandproprietaryrights.IfElancofailstoobtainandmaintainadequateintellectualpropertyprotection,itmaynotbeabletopreventthirdpartiesfromusingitsproprietarytechnologiesorfrommarketingproductsthatareverysimilaroridenticaltoElanco's.
Elanco'scurrentlypendingorfuturepatentapplicationsmaynotresultinissuedpatents,orbeapprovedonatimelybasis,ifatall.Similarly,anytermextensionsthatElancoseeksmaynotbeapprovedonatimelybasis,ifatall.Inaddition,Elanco'sissuedpatents,oranypatentsthatmayissueinthefuture,maynotcontainclaimssufficientlybroadtoprotectitagainstthirdpartieswithsimilartechnologiesorproductsorprovideitwithanycompetitiveadvantage,includingexclusivityinaparticularproductarea.
ThevalidityandscopeofElanco'spatentclaimsalsomayvarybetweencountries,asindividualcountrieshavetheirownpatentlaws.Forexample,somecountriesonlypermittheissuanceofpatentscoveringanovelchemicalcompounditself,anditsfirstuse,andthusfurthermethodsofuseforthesamecompoundmaynotbepatentable.Thevalidity,enforceability,scopeandeffectivetermofpatentscanbehighlyuncertainandofteninvolvecomplexlegalandfactualquestionsandproceedingsthatvarybasedonthelocallawoftherelevantjurisdiction.Elanco'sabilitytoenforceitspatentsalsodependsonthelawsofindividualcountriesandeachcountry'spracticewithrespecttoenforcementofintellectualpropertyrights.Patentprotectionmustbeobtainedonajurisdiction-by-jurisdictionbasis,andElancoonlypursuespatentprotectionincountrieswhereitthinksitmakescommercialsenseforthegivenproduct.Inaddition,ifElancoisunabletomaintainitsexistinglicenseagreementsorotheragreementspursuanttowhichthirdpartiesgrantitrightstointellectualproperty,includingbecausesuchagreementsterminate,Elanco'sfinancialconditionandresultsofoperationscouldbemateriallyadverselyaffected.
PatentlawreformintheU.S.andothercountriesmayalsoweakenElanco'sabilitytoenforceitspatentrights,ormakesuchenforcementfinanciallyunattractive.Forinstance,inSeptember2011,theU.S.enactedtheAmericaInventsAct,whichpermitsenhancedthird-partyactionsforchallenging
29
TableofContents
patentsandimplementsafirst-to-inventsystem.ThesereformscouldresultinincreasedcoststoprotectElanco'sintellectualpropertyorlimititsabilitytoobtainandmaintainpatentprotectionforitsproductsinthesejurisdictions.Additionally,certainforeigngovernmentshaveindicatedthatcompulsorylicensestopatentsmaybegrantedinthecaseofnationalemergencies,whichcoulddiminishoreliminatesalesandprofitsfromthoseregionsandmateriallyadverselyaffectElanco'sfinancialconditionandresultsofoperations.
Elanco'strademarksandbrandsmayprovideitwithacompetitiveadvantageinthemarketastheymaybeknownortrustedbyconsumers.Inordertomaintainthevalueofsuchbrands,Elancomustbeabletoenforceanddefenditstrademarks.ElancohaspursuedandwillpursuetheregistrationoftrademarksandservicemarksintheU.S.andinternationally;however,enforcingrightsagainstthosewhoknowinglyorunknowinglydiluteorinfringeElanco'sbrandscanbedifficult.Effectivetrademark,servicemark,tradedressorrelatedprotectionsmaynotbeavailableineverycountryinwhichElanco'sproductsandservicesareavailable.Enforcementisespeciallydifficultinfirst-to-filecountrieswhere"trademarksquatters"canpreventElancofromobtainingadequateprotectionsforitsbrands.TherecanbenoassurancethatthestepsElancohastakenandwilltaketoprotectitsproprietaryrightsinitsbrandsandtrademarkswillbeadequateorthatthirdpartieswillnotinfringe,diluteormisappropriateElanco'sbrands,trademarks,tradedressorothersimilarproprietaryrights.
ManyofElanco'sproductsarebasedonorincorporateproprietaryinformation.Elancoactivelyseekstoprotectitsproprietaryinformation,includingitstradesecretsandproprietaryknow-how,bygenerallyrequiringitsemployees,consultants,otheradvisorsandotherthirdpartiestoexecuteproprietaryinformationandconfidentialityagreementsuponthecommencementoftheiremployment,engagementorotherrelationship.Despitetheseeffortsandprecautions,Elancomaybeunabletopreventathirdpartyfromcopyingorotherwiseobtainingandusingitstradesecretsoritsotherintellectualpropertywithoutauthorizationandlegalremediesmaynotadequatelycompensateitforthedamagescausedbysuchunauthorizeduse.Further,othersmayindependentlyandlawfullydevelopsubstantiallysimilaroridenticalproductsthatcircumventElanco'sintellectualpropertybymeansofalternativedesignsorprocessesorotherwise.
Elanco could be subject to changes in its tax rates, the adoption of new U.S. or foreign tax legislation or exposure to additional tax liabilities.
ElancoissubjecttoincometaxesintheU.S.andnumerousforeignjurisdictions.Changesintherelevanttaxlaws,regulations,administrativepractices,principlesandinterpretationscouldadverselyaffectElanco'sfutureeffectivetaxrates.Asdiscussedfurtherbelow,theU.S.recentlyenactedtaxreformlegislationsignificantlyrevisingU.S.taxlaw,andanumberofothercountriesareactivelyconsideringorenactingtaxchanges.Otherorganizations,suchastheOrganisationforEconomicCooperationandDevelopmentandtheEuropeanCommission,arealsoactiveconcerningtax-relatedmatters,whichcouldinfluenceinternationaltaxpolicyincountriesinwhichElancooperates.Whileoutcomesoftheseinitiativescontinuetodevelopandremainuncertain,modificationstokeyelementsoftheU.S.orinternationaltaxframeworkcouldhaveamaterialadverseeffectonElanco'sconsolidatedresultsofoperationsandcashflows.
InDecember2017,thePresidentoftheUnitedStatessignedintolawtheTaxCutsandJobsAct(the"2017TaxAct").The2017TaxActincludedsignificantchangestotheU.S.corporateincometaxsystem,suchasthereductioninthecorporateincometaxrate,transitiontoamodifiedterritorialtaxsystem,changestobusinessrelatedexclusions,deductionsandcredits,andmodificationstointernationaltaxprovisions.TheU.S.TreasuryDepartmentandtheIRSbegantoissuemajorproposedregulationsrelatedtothe2017TaxActduringthesecondhalfof2018andareexpectedtocontinueissuingsuchregulations.Theproposedregulationsaregenerallysubjecttocommentbeforebeingfinalized;however,oncefinalized,theseregulationsmayrequireElancotomakeadjustments,inparticular,asaresultofcertaincomplexinternationalprovisionscontainedinthe2017TaxAct.Such
30
TableofContents
adjustmentscouldmateriallyimpactElanco'sprovisionforincometaxesandeffectivetaxrateintheperiodinwhichtheadjustmentsaremadeandcouldalsoimpactElanco'snetincome,earningspershare,consolidatedcashflowsandliquidity.
Inaddition,Elanco'seffectivetaxrateissubjecttopotentialrisksthatvarioustaxingauthoritiesmaychallengethepricingofElanco'scross-borderarrangementsandsubjectElancotoadditionaltax,adverselyimpactingElanco'seffectivetaxrateanditstaxliability.ElancoisalsosubjecttotheexaminationofitstaxreturnsandothertaxmattersbytheInternalRevenueService(the"IRS")andothertaxauthoritiesandgovernmentalbodies.Elancoregularlyassessesthelikelihoodofanadverseoutcomeresultingfromtheseexaminationstodeterminetheadequacyofitsprovisionfortaxes.Therecanbenoassuranceastotheoutcomeoftheseexaminations.IfElanco'seffectivetaxratesweretoincrease,particularlyintheU.S.orothermaterialforeignjurisdictions,oriftheultimatedeterminationofElanco'staxesowedisforanamountinexcessofamountspreviouslyaccrued,Elanco'sbusiness,financialconditionandresultsofoperationscouldbemateriallyadverselyaffected.
Significant portions of Elanco's operations are conducted in foreign jurisdictions, including jurisdictions presenting a high risk of bribery and corruption, and are subject to the economic, political, legal and businessenvironments of the countries in which Elanco does business.
Elanco'sinternationaloperationscouldbelimitedordisruptedbyanyofthefollowing:
• volatilityintheinternationalfinancialmarkets;
• compliancewithgovernmentalcontrols;
• difficultiesenforcingcontractualandintellectualpropertyrights;
• paralleltradeinElanco'sproducts(importationofElanco'sproductsfromEuropeanUnion("EU")countrieswhereElanco'sproductsaresoldatlowerpricesintoEUcountrieswheretheproductsaresoldathigherprices);
• compliancewithawidevarietyoflawsandregulations,suchastheU.S.ForeignCorruptPracticesAct(the"FCPA")andsimilarnon-U.S.lawsandregulations;
• compliancewithforeignlaborlaws;
• burdenstocomplywithmultipleandpotentiallyconflictingforeignlawsandregulations,includingthoserelatingtoenvironmental,healthandsafetyrequirements;
• changesinlaws,regulations,governmentcontrolsorenforcementpracticeswithrespecttoElanco'sbusinessandthebusinessesofitscustomers,includingtheimpositionoflimitsonitsprofitability;
• politicalandsocialinstability,includingcrime,civildisturbance,terroristactivitiesandarmedconflicts;
• traderestrictionsandrestrictionsondirectinvestmentsbyforeignentities,includingrestrictionsadministeredbytheOfficeofForeignAssetsControloftheU.S.DepartmentoftheTreasuryandtheEU,inrelationtoElanco'sproductsortheproductsoffarmersandothercustomers;
• governmentlimitationsonforeignownership;
• governmenttakeoverornationalizationofbusiness;
• changesintaxlawsandtariffs;
• impositionofanti-dumpingandcountervailingdutiesorothertrade-relatedsanctions;
31
TableofContents
• costsanddifficultiesandcompliancerisksinstaffing,managingandmonitoringinternationaloperations,includingintheuseofoverseasthird-partygoodsandserviceproviders;
• corruptionriskinherentinbusinessarrangementsandregulatorycontactswithforeigngovernmententities;
• longerpaymentcyclesandincreasedexposuretocounterpartyrisk;and
• additionallimitationsontransferringpersonalinformationbetweencountriesorotherrestrictionsontheprocessingofpersonalinformation.
Inaddition,internationaltransactionsmayinvolveincreasedfinancialandlegalrisksduetodifferinglegalsystemsandcustoms.CompliancewiththeserequirementsmayprohibittheimportorexportofcertainproductsandtechnologiesormayrequireElancotoobtainalicensebeforeimportingorexportingcertainproductsortechnologies.Afailuretocomplywithanyoftheselaws,regulationsorrequirementscouldresultincivilorcriminallegalproceedings,monetaryornon-monetarypenalties,orboth,disruptionstoElanco'sbusiness,limitationsonElanco'sabilitytoimportandexportproducts,anddamagetoElanco'sreputation.Inaddition,variationsinthepricingofElanco'sproductsbetweenjurisdictionsmayresultintheunauthorizedimportationorunauthorizedre-importationofitsproductsbetweenjurisdictionsandmayalsoresultintheimpositionofanti-dumpingandcountervailingdutiesorothertrade-relatedsanctions.Whiletheimpactofthesefactorsisdifficulttopredict,anyofthemcouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Further,changesinanyoftheselaws,regulationsorrequirements,orthepoliticalenvironmentinaparticularcountry,mayaffectElanco'sabilitytoengageinbusinesstransactionsincertainmarkets,includinginvestment,procurementandrepatriationofearnings.
Significant portions of Elanco's operations are conducted in Europe and could be impacted by the withdrawal of the United Kingdom ("UK") from the EU, commonly referred to as "Brexit."
InJune2016,votersintheUKapprovedanadvisoryreferendumtowithdrawfromtheEU,commonlyreferredtoasBrexit.OnMarch29,2017,theUKPrimeMinisterformallynotifiedtheEuropeanCounciloftheUK'sintentiontowithdrawfromtheEUunderArticle50oftheTreatyofLisbon.Thenoticebeganatwo-yearnegotiationperiodtoestablishthewithdrawalterms.InApril2019,theEUextendedtheenddateofthenegotiationperiodtoOctober31,2019,althoughtheUKcouldleavetheEUsooner,dependingonpoliticaldevelopments.Thereferendumandnoticecreatedpolitical,regulatoryandeconomicuncertainty,particularlyintheUKandtheEU,andthisuncertaintymaypersistforyearsifthewithdrawalbecomeseffectivewithoutclarificationastowhethertheUKwillcontinuetobepartytotheEUFreeTradeAgreements("FTA")attheendofthenegotiationperiod.
Elanco'sbusinessissubjecttosubstantialregulation.IftheUKwithdrawsfromtheEUwithoutanagreementandmutualrecognitionoftheFTAs,ElancomaynotbeabletomarketcertainproductsthatenteredtheEUmarketfollowingmarketingauthorizationbyUKauthoritiesinallthenationsthatarepartiestoFTAswiththeEUunlessanduntilElancohasobtainedallrequiredregulatoryapprovalsineachjurisdictionwhereitproposestomarketthoseproducts.
Inaddition,theuncertaintyrelatedtoBrexithascausedforeignexchangeratefluctuationsinthepast,includingthestrengtheningoftheU.S.dollarrelativetotheeuroandBritishpoundimmediatelyfollowingtheannouncementofBrexit.Theimplementationof,orfurtherdevelopmentswithrespectto,Brexitcouldfurtherimpactforeignexchangerates,whichcouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Awithdrawalwithnoagreementinplacecouldsignificantlydisruptthefreemovementofgoods,services,andpeoplebetweentheUKandtheEU,andresultinincreasedlegalandregulatorycomplexities,aswellaspotentialhighercostsofconductingbusinessinEuropeanddeclininggross
32
TableofContents
domesticproductinmanyEuropeanmarkets.TheUK'svotetoexittheEUcouldalsoresultinsimilarreferendumsorvotesinotherEuropeancountriesinwhichElancodoesbusiness.
IfnoagreementisreachedattheendoftheextendednegotiationperiodonOctober31,2019andtheUK'sseparationbecomeseffective,unlesstheremainingEUmembersunanimouslyagreetoanextension,theuncertaintysurroundingthetermsoftheUK'swithdrawalanditsconsequencescouldadverselyimpactconsumerandinvestorconfidence,andcouldaffectsalesorregulationofElanco'sproducts.Anyoftheseeffects,amongothers,couldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Foreign exchange rate fluctuations and potential currency controls affect Elanco's results of operations, as reported in its financial statements.
Elancoconductsoperationsinmanyareasoftheworld,involvingtransactionsdenominatedinavarietyofcurrencies.In2018,Elancogeneratedapproximately52%ofitsrevenueincurrenciesotherthantheU.S.dollar,principallytheeuro,Britishpound,Brazilianreal,Australiandollar,Japaneseyen,CanadiandollarandChineseyuan.Elancoissubjecttocurrencyexchangeraterisktotheextentthatitscostsaredenominatedincurrenciesotherthanthoseinwhichitearnsrevenue.Inaddition,becauseElanco'sfinancialstatementsarereportedinU.S.dollars,changesincurrencyexchangeratesbetweentheU.S.dollarandothercurrencieshavehad,andwillcontinuetohave,animpactonElanco'sresultsofoperations.
Elancoalsofacesrisksarisingfromcurrencydevaluationsandtheimpositionofcashrepatriationrestrictionsandexchangecontrols.Currencydevaluationsresultinadiminishedvalueoffundsdenominatedinthecurrencyofthecountryinstitutingthedevaluation.CashrepatriationrestrictionsandexchangecontrolsmaylimitElanco'sabilitytoconvertforeigncurrenciesintoU.S.dollarsortoremitdividendsandotherpaymentsbyElanco'sforeignsubsidiariesorbusinesseslocatedinorconductedwithinacountryimposingrestrictionsorcontrols.WhileElancocurrentlyhasnoneed,anddoesnotintend,torepatriateorconvertcashheldincountriesthathavesignificantrestrictionsorcontrolsinplace,shouldElanconeedtodosotofunditsoperations,itmaybeunabletorepatriateorconvertsuchcash,ormaybeunabletodosowithoutincurringsubstantialcosts.
Elancoalsobearsforeignexchangeriskassociatedwiththefuturecashsettlementofanexistingnetinvestmenthedge("NIH").InOctober2018,Elancoenteredintoafixedinterestrate,5-year,750millionSwissfrancNIHagainstSwissfrancassets.TheNIHisexpectedtogenerateapproximately$25millionincashandcontrainterestexpenseperyear;however,thereispotentialforsignificant2023settlementexposureonthe750millionSwissfrancnotionaliftheU.S.dollardevaluesversustheSwissfranc.
Elanco depends on sophisticated information technology and infrastructure.
Elancoreliesonvariousinformationsystemstomanageitsoperations,anditincreasinglydependsonthirdpartiestooperateandsupportitsinformationtechnologysystems,includingbywayofvirtualandcloud-basedoperations.Thesethirdpartiesincludelargeestablishedvendorsaswellassmall,privatelyownedcompanies.FailurebyanyprovidertoadequatelyserviceElanco'soperations,orachangeincontrolorinsolvencyofoneormoreproviders,maymateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.Priortotheseparation,ElancoreliedonLillytonegotiateandmanagemanyofElanco'srelationshipsandcontractswiththesethirdparties.
InconnectionwiththeIPOandtheseparation,Elancosubstantiallychanged,andwillcontinuetodevelop,anumberofitsbusinessprocesses,includingitsfinancialreportingandsupplychainprocessesandwithrespecttowhereandfromwhomitobtainsinformationtechnologysystems.InordertosupportthenewbusinessprocessesunderthetermsofElanco'stransitionalservicesagreementwithLilly,Elancowillmakesignificantconfiguration,processanddatachangeswithinmanyofthe
33
TableofContents
informationtechnologysystemsituses.IfElanco'sinformationtechnologysystemsandprocessesarenotsufficienttosupportElanco'sbusinessandfinancialreportingfunctions,orifElancofailstoproperlyimplementitsnewbusinessprocesses,Elanco'sfinancialreportingmaybedelayedorinaccurateand,asaresult,Elanco'sbusiness,financialconditionandresultsofoperationsmaybemateriallyadverselyaffected.EvenifElancoisabletosuccessfullyconfigureandchangeitssystems,alltechnologysystems,evenwithimplementationofsecuritymeasures,arevulnerabletodisability,failuresorunauthorizedaccess.IfElanco'sinformationtechnologysystemsweretofailorbebreached,thiscouldmateriallyadverselyaffectElanco'sreputationanditsabilitytoperformcriticalbusinessfunctions,andsensitiveandconfidentialdatacouldbecompromised.
Breaches of Elanco's information technology systems or improper disclosure of confidential company or personal data could have a material adverse effect on Elanco's reputation and operations, or Elanco may fail tocomply with privacy laws, regulations and its contractual obligations.
Elancoreliesoninformationtechnologysystemstoprocess,transmitandstoreelectronicinformationinitsday-to-dayoperations,includingcustomer,employeeandcompanydata.Thesecureprocessing,maintenanceandtransmissionofthisinformationiscriticaltoElanco'soperationsandthelegalenvironmentsurroundinginformationsecurity,storage,use,processing,disclosureandprivacyisdemanding,withthefrequentimpositionofnewandchangingrequirements.Elancoalsostorescertaininformationwiththirdparties.Elanco'sinformationsystemsandthoseofElanco'sthird-partyvendorsaresubjectedtocomputervirusesorothermaliciouscodes,unauthorizedaccessattempts,andcyber-orphishing-attacksandalsoarevulnerabletoanincreasingthreatofcontinuallyevolvingcybersecurityrisksandexternalhazards,aswellasimproperorinadvertentstaffbehavior,allofwhichcouldexposeconfidentialcompanyandpersonaldatasystemsandinformationtosecuritybreaches.AnysuchbreachcouldcompromiseElanco'snetworks,andtheinformationstoredthereincouldbeaccessed,publiclydisclosed,lostorstolen.SuchattackscouldresultinElanco'sintellectualpropertyandotherconfidentialinformationbeinglostorstolen,disruptionofElanco'soperations,andothernegativeconsequences,suchasincreasedcostsforsecuritymeasuresorremediationcosts,anddiversionofmanagementattention.Anyactualorperceivedaccess,disclosureorotherlossofinformationoranysignificantbreakdown,intrusion,interruption,cyber-attackorcorruptionofcustomer,employeeorcompanydataorElanco'sfailuretocomplywithfederal,state,localandforeignprivacylawsorcontractualobligationswithcustomers,vendors,paymentprocessorsandotherthirdparties,couldresultinlegalclaimsorproceedings,liabilityunderlawsorcontractsthatprotecttheprivacyofpersonalinformation,regulatorypenalties,disruptionofElanco'soperations,anddamagetoElanco'sreputation,allofwhichcouldmateriallyadverselyaffectElanco'sbusiness,revenueandcompetitiveposition.WhileElancowillcontinuetoimplementadditionalprotectivemeasurestoreducetheriskofanddetectcyber-incidents,cyber-attacksarebecomingmoresophisticatedandfrequent,andthetechniquesusedinsuchattackschangerapidly.Elanco'sprotectivemeasuresmaynotprotectitagainstattacksandsuchattackscouldhaveasignificantimpactonElanco'sbusinessandreputation.Inaddition,priortotheseparation,ElancoreliedonLillyforcertainprivacyandcompliancefunctionsandpersonnelandmayexperiencedifficultiesmaintainingandimplementingallpoliciesandpracticesfollowingcompletionoftheseparation.
Increased regulation or decreased governmental financial support relating to the raising, processing or consumption of food animals could reduce demand for Elanco's food animal products.
Companiesinthefoodanimalsectoraresubjecttoextensiveandincreasinglystringentregulations.See"BusinessofElanco—Regulatory."Iffoodanimalproducersareadverselyaffectedbynewregulationsorchangestoexistingregulations,theymayreduceherdorflocksizesorbecomelessprofitableand,asaresult,theymayreducetheiruseofElanco'sproducts,whichmaymateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.Also,manyfoodanimalproducersbenefitfromgovernmentalsubsidies,andifsuchsubsidiesweretobereducedoreliminated,
34
TableofContents
thesecompaniesmaybecomelessprofitableand,asaresult,mayreducetheiruseofElanco'sfoodanimalproducts.Morestringentregulationofthefoodanimalsector,includingregardingtheuseoffoodanimalproducts,couldhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresultsofoperations.
Elanco's business could be materially adversely affected by labor disputes, strikes or work stoppages.
SomeofElanco'semployeesaremembersofunions,workscouncils,tradeassociationsorareotherwisesubjecttocollectivebargainingagreementsincertainjurisdictions,includingtheU.S.Asaresult,Elancoissubjecttotheriskoflabordisputes,strikes,workstoppagesandotherlabor-relationsmatters.Elancomaybeunabletonegotiatenewcollectivebargainingagreementsonsimilarormorefavorabletermsandmayexperienceworkstoppages,higherongoinglaborcostsorotherlaborproblemsinthefutureatitssites.Elancomayalsoexperiencedifficultyordelaysinimplementingchangestoitsworkforceincertainmarkets.TheserisksmaybeincreasedbytheseparationbecauseElancowillnolongerbeabletobenefitfromLilly'spriorrelationshipsandnegotiationsrelatingtosuchagreements.
Further,labor-relatedissues,includingatElanco'ssuppliersorCMOs,couldcauseadisruptionofElanco'soperations,whichcouldhaveamaterialadverseeffectonitsbusiness,financialconditionandresultsofoperations,potentiallyresultingincancelledordersbycustomers,unanticipatedinventoryaccumulationorshortagesandreducedrevenueandnetincome.
The anticipated benefits of the separation may not be achieved.
Elancomaynotbeabletoachievethefullstrategicandfinancialbenefitsexpectedtoresultfromtheseparation.Further,suchbenefits,ifultimatelyachieved,maybedelayed.Thesebenefitsincludethefollowing:
• improvingstrategicandoperationalflexibilityandstreamliningdecision-makingbyprovidingtheflexibilitytoimplementElanco'sstrategicplanandtorespondmoreeffectivelytodifferentcustomerneedsandthechangingeconomicandindustryenvironment;
• allowingElancotoadopttheinvestmentpolicyanddividendpolicybestsuitedtoitsfinancialprofileandbusinessneeds,andallowingittoraisecapitalasanindependentbusiness;
• creatinganindependentequitystructurethatmakespossiblefutureacquisitionsutilizingElanco'scommonstockaswellascompensationarrangements;and
• facilitatingincentivecompensationarrangementsforemployeesmoredirectlytiedtotheperformanceofElanco'sbusiness,andenhancingemployeehiringandretentionby,amongotherthings,improvingthealignmentofmanagementandemployeeincentiveswithperformanceandgrowthobjectivesofElanco'sbusiness.
Elancomaynotachievetheanticipatedbenefitsoftheseparationforavarietyofreasons,whichcouldmateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperations.
Elanco has underfunded pension plan liabilities. Elanco will require current and future operating cash flow to fund these shortfalls reducing the cash available for other uses.
Elancohascertaindefinedbenefitpensionplans,predominantlyoutsideoftheU.S.,thatElanco'semployeesparticipateinthatareeitherdedicatedtoElanco'semployeesorwheretheplanassetsandliabilitiesthatrelatetoElanco'semployeeswerelegallyrequiredtotransfertoElancoatthetimeoftheseparation.Thefundedstatusandnetperiodicpensioncostfortheseplansismateriallyaffectedbythediscountrateusedtomeasurepensionobligations,thelongevityandactuarialprofileofElanco'sworkforce,thelevelofplanassetsavailabletofundthoseobligationsandtheactualandexpected
35
TableofContents
long-termrateofreturnonplanassets.Significantchangesininvestmentperformanceorachangeintheportfoliomixofinvestedassetscanresultincorrespondingincreasesanddecreasesinthevaluationofplanassetsorinachangeintheexpectedrateofreturnonplanassets.AsofDecember31,2018,forpensionplanswithprojectedbenefitobligationsinexcessofplanassets,theprojectedbenefitobligationwas$229.2millionwithplanassetsof$124.1million.Anychangesinthediscountratecouldresultinasignificantincreaseordecreaseinthevaluationofpensionobligations,affectingthereportedfundedstatusofElanco'spensionplansaswellasthenetperiodicpensioncostinthefollowingyears.Similarly,changesintheexpectedreturnonplanassetscanresultinsignificantchangesinthenetperiodicpensioncostinthefollowingyears.TheneedtomakeadditionalcashcontributionswilldivertresourcesfromElanco'soperationsandmayhaveamaterialadverseeffectonElanco'sbusiness,financialconditionandresultsofoperations.
Risks Related to Elanco's Relationship with Lilly
As a result of the separation, Elanco will lose Lilly's brand, reputation, capital base and other resources.
ElancobelievesitsassociationwithLillyhascontributedtoElanco'sbuildingrelationshipswithElanco'scustomersduetoLilly'sgloballyrecognizedbrandandperceivedhigh-qualityproducts.TheseparationcouldadverselyaffectElanco'sabilitytoattractandretaincustomers,whichcouldresultinreducedsalesofitsproducts.
ThelossofLilly'sscale,capitalbaseandfinancialstrengthmayalsopromptsupplierstoreprice,modifyorterminatetheirrelationshipswithElanco.Inaddition,Lilly'sdispositionofitsownershipofElancocouldpotentiallycausesomeofElanco'sexistingagreementsandlicensestobeterminated.ElancocannotpredictwithcertaintytheeffectthattheseparationwillhaveonElanco'sbusiness,Elanco'sclients,vendorsorotherpersons,orwhethertheElancobrandwillbeacceptedinthemarketplace.
Further,becauseElancohasnotoperatedasastandalonecompanyinthepast,itmayhavedifficultydoingso.ElancomayneedtoacquireassetsandresourcesinadditiontothoseprovidedbyLilly,andinconnectionwiththeseparation,mayalsofacedifficultyinseparatingElanco'sassetsfromLilly'sassetsandintegratingnewlyacquiredassetsintoElanco'sbusiness.Elanco'sbusiness,financialconditionandresultsofoperationscouldbemateriallyadverselyaffectedifithasdifficultyoperatingasastandalonecompany,failstoacquireassetsthatprovetobeimportanttoElanco'soperationsorincursunexpectedcostsinseparatingitsassetsfromLilly'sassetsorintegratingnewly-acquiredassets.
Lilly may compete with Elanco.
LillyisnotrestrictedfromcompetingwithElancointheanimalhealthbusiness.AlthoughLillyhasinformedElancoithasnocurrentintentiontocompetewithitintheanimalhealthbusiness,ifLillyinthefuturedecidestoengageinthetypeofbusinessElancoconducts,itmayhaveacompetitiveadvantageoverElanco,whichmaycauseElanco'sbusiness,financialconditionandresultsofoperationstobemateriallyadverselyaffected.
To preserve the tax-free treatment to Lilly and its shareholders of the Split-Off and certain related transactions, Elanco may not be able to engage in certain transactions.
Topreservethetax-freetreatmenttoLillyanditsshareholdersoftheSplit-Offandcertainrelatedtransactions,underthetaxmattersagreement,Elancoisrestrictedfromtakinganyactionthatpreventssuchtransactionsfrombeingtax-freeforU.S.federalincometaxpurposes.TheserestrictionsmaylimitElanco'sabilitytopursuecertainstrategictransactionsorengageinothertransactions,includingusingElanco'scommonstocktomakeacquisitionsandinconnectionwithequitycapitalmarkettransactionsthatmightincreasethevalueofElanco'sbusiness.See"CertainRelationshipsandRelatedPartyTransactions—RelationshipbetweenElancoandLilly—TaxMattersAgreement."
36
TableofContents
Lilly's rights as licensor under the intellectual property and technology license agreement could limit Elanco's ability to develop and commercialize certain products.
Priortotheseparation,ElancohadtheabilitytoleveragecertainofLilly'sintellectualproperty.Aspartoftheseparation,Elancoenteredintoanintellectualpropertyandtechnologylicenseagreement.Pursuanttotheintellectualpropertyandtechnologylicenseagreement,LillylicensestoElancocertainofitsintellectualproperty(excludingtrademarks)relatedtotheanimalhealthbusinessandalsograntsalicenseforElancotouseLilly'sproprietarycompoundlibraryforaperiodoftwoyearsplusuptothreeadditionalone-yearperiods,eachsuchperiodtobegrantedunderLilly'ssolediscretion.IfElancofailstocomplywithitsobligationsunderthisagreementandLillyexercisesitsrighttoterminateit,Elanco'sabilitytocontinuetoresearch,developandcommercializeproductsincorporatingthatintellectualpropertywillbelimited.Inaddition,thisagreementincludeslimitationsthataffectElanco'sabilitytodevelopandcommercializecertainproducts,includingincircumstanceswhereLillyhasaninterestinthelicensedintellectualpropertyinconnectionwithitshumanhealthdevelopmentprograms.Theselimitationsandterminationrightsmaymakeitmoredifficult,timeconsumingorexpensiveforElancotodevelopandcommercializecertainnewproducts,ormayresultinElanco'sproductsbeinglatertomarketthanthoseofitscompetitors.Forasummarydescriptionofthetermsoftheintellectualpropertyandtechnologylicenseagreement,see"CertainRelationshipsandRelatedPartyTransactions—RelationshipbetweenElancoandLilly—IntellectualPropertyandTechnologyLicenseAgreement."
Elanco's historical consolidated and combined financial data is not necessarily representative of the results it would have achieved as a standalone company and may not be a reliable indicator of its future results.
Elanco'shistoricalconsolidatedandcombinedfinancialdataincludedinthisprospectusdoesnotreflectthefinancialcondition,resultsofoperationsorcashflowsitwouldhaveachievedasastandalonecompanyduringtheperiodspresentedorthoseitwillachieveinthefuture.Thisisprimarilytheresultofthefollowingfactors:
• Elanco'shistoricalconsolidatedandcombinedfinancialdatadoesnotreflecttheseparation;
• Elanco'shistoricalconsolidatedandcombinedfinancialdatareflectsexpenseallocationsforcertainsupportfunctionsthatareprovidedonacentralizedbasiswithinLilly,suchasexpensesforexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelationsthatmaybehigherorlowerthanthecomparableexpensesElancowouldhaveactuallyincurred,orwillincurinthefuture,asastandalonecompany;
• Elanco'scostofdebtandElanco'scapitalstructureisdifferentfromthatreflectedinitshistoricalconsolidatedandcombinedfinancialstatements;
• significantincreasesmayoccurinElanco'scoststructureasaresultofElancobeingastandalonepubliccompany,includingcostsrelatedtopubliccompanyreporting,investorrelationsandcompliancewiththeSarbanes-OxleyAct;and
• lossofeconomiesofscaleasaresultofElanconolongerbeingapartofLilly.
Elanco'sfinancialconditionandfutureresultsofoperations,aftergivingeffecttotheseparation,willbemateriallydifferentfromamountsreflectedinElanco'shistoricalconsolidatedandcombinedfinancialstatementsincludedinthisprospectus.Asaresultoftheseparation,itmaybedifficultforinvestorstocompareElanco'sfutureresultstohistoricalresultsortoevaluateElanco'srelativeperformanceortrendsinElanco'sbusiness.
37
TableofContents
Elanco has incurred and will continue to incur significant charges in connection with the separation and incremental costs as a standalone public company.
Elancowillneedtoreplicateorreplacecertainfunctions,systemsandinfrastructuretowhichElanconolongerhasthesameaccessaftertheseparation.ElancomayalsoneedtomakeinvestmentsorhireadditionalemployeestooperatewithoutthesameaccesstoLilly'sexistingoperationalandadministrativeinfrastructure.Theseinitiativesmaybecostlytoimplement.Duetothescopeandcomplexityoftheunderlyingprojectsrelativetotheseefforts,theamountoftotalcostscouldbemateriallyhigherthanElanco'sestimate,andthetimingoftheincurrenceofthesecostsissubjecttochange.
Priortotheseparation,LillyperformedorsupportedmanyimportantcorporatefunctionsforElanco.Elanco'sconsolidatedandcombinedfinancialstatementsreflectchargesfortheseservicesonanallocatedbasis.Followingtheseparation,manyoftheseservicesaregovernedbyElanco'stransitionalservicesagreementwithLilly.UnderthetransitionalservicesagreementElancoisabletousetheseLillyservicesforafixedtermestablishedonaservice-by-servicebasis.PartialreductionintheprovisionofanyserviceorterminationofaservicepriortotheexpirationoftheapplicablefixedtermrequiresLilly'sconsent.Inaddition,eitherpartyisabletoterminatetheagreementduetoamaterialbreachoftheotherparty,uponpriorwrittennotice,subjecttolimitedcureperiodsoriftheotherpartyundergoesachangeofcontrol.
ElancopaysLillymutuallyagreed-uponfeesfortheseservices,whicharebasedonLilly'scosts(includingthird-partycosts)ofprovidingtheservicesthroughMarch31,2021andsubjecttoamark-upof7%thereafter,withadditionalinflation-basedescalationbeginningJanuary1,2022.However,sinceElanco'stransitionalservicesagreementwasnegotiatedinthecontextofaparent-subsidiaryrelationship,thetermsoftheagreement,includingthefeeschargedfortheservices,maybehigherorlowerthanthosethatwouldbeagreedtobypartiesbargainingatarm'slengthforsimilarservicesandmaybehigherorlowerthanthecostsreflectedintheallocationsinElanco'shistoricalconsolidatedandcombinedfinancialstatements.Inaddition,whiletheseservicesarebeingprovidedtoElancobyLilly,Elanco'soperationalflexibilitytomodifyorimplementchangeswithrespecttosuchservicesortheamountsElancopaysforthemwillbelimited.
Elancomaynotbeabletoreplacetheseservicesorenterintoappropriatethird-partyagreementsontermsandconditions,includingcost,comparabletothosethatElancoreceivedfromLillyunderthetransitionalservicesagreement.Additionally,afterthetransitionalservicesagreementterminates,ElancomaybeunabletosustaintheservicesatthesamelevelsorobtainthesamebenefitsaswhenElancowasreceivingsuchservicesandbenefitsfromLilly.WhenElancobeginstooperatethesefunctionsseparately,ifElancodoesnothaveitsownadequatesystemsandbusinessfunctionsinplace,orisunabletoobtainthemfromotherproviders,itmaynotbeabletooperateitsbusinesseffectivelyoratcomparablecosts,anditsprofitabilitymaydecline.Inaddition,ElancohashistoricallyreceivedinformalsupportfromLilly,whichmaynotbeaddressedinthetransitionalservicesagreement.Thelevelofthisinformalsupportmaydiminishorbeeliminatedinthefuture.
Inaddition,Elanco'shistoricalconsolidatedandcombinedfinancialstatementsincludetheattributionofcertainassetsandliabilitiesthathistoricallyhavebeenheldattheLillycorporatelevelbutwhicharespecificallyidentifiableorattributabletothebusinessesthatweretransferredtoElancoinconnectionwiththeseparation.ThevalueoftheassetsandliabilitiesElancoassumedinconnectionwiththeseparationcouldultimatelybemateriallydifferentthansuchattributions,whichcouldhaveamaterialadverseeffectonElanco'sfinancialcondition.
38
TableofContents
Risks Related to Elanco's Indebtedness
Elanco has substantial indebtedness.
Elancohasasignificantamountofindebtedness,whichcouldmateriallyadverselyaffectitsbusiness,financialconditionandresultsofoperations.AsofMarch31,2019,Elancohasincurredapproximately$2.5billionaggregateprincipalamountofseniorindebtedness,consistingofthenotesandtheTermFacility.Elancohasanadditional$750millionofborrowingcapacity($1,000millionifcertainconditionsaremet)undertheRevolvingFacility(asdefinedbelow).See"DescriptionofCertainOtherIndebtedness."
Elancomayincursubstantialadditionaldebtfromtimetotimetofinanceworkingcapital,capitalexpenditures,investments,acquisitionsorforotherpurposes.IfElancodoesso,therisksrelatedtoitshighlevelofdebtcouldintensify.Specifically,Elanco'shighlevelofdebtcouldhaveimportantconsequences,including:
• makingitmoredifficultforElancotosatisfyitsobligationswithrespecttoitsdebt;
• limitingElanco'sabilitytoobtainadditionalfinancingtofundfutureworkingcapital,capitalexpenditures,businessdevelopmentorothergeneralcorporaterequirements,includingdividends;
• increasingElanco'svulnerabilitytogeneraladverseeconomicandindustryconditions;
• exposingElancototheriskofincreasedinterestratesascertainofitsborrowingsareandmayinthefuturebeatvariableratesofinterest;
• limitingElanco'sflexibilityinplanningforandreactingtochangesintheanimalhealthindustry;
• impactingElanco'seffectivetaxrate;and
• increasingElanco'scostofborrowing.
Elanco may not be able to generate sufficient cash to service all of its indebtedness and may be forced to take other actions to satisfy its obligations under its indebtedness, which may not be successful.
Elanco'sabilitytomakescheduledpaymentsonorrefinanceitsdebtobligationsdependsonitsfinancialconditionandoperatingperformance,whicharesubjecttoprevailingeconomicandcompetitiveconditionsandtocertainfinancial,business,legislative,regulatoryandotherfactorsbeyonditscontrol.Elancomaybeunabletomaintainalevelofcashflowsfromoperatingactivitiessufficienttopermitittopaytheprincipalandinterestonitsindebtedness.
IfElanco'scashflowsandcapitalresourcesareinsufficienttofunditsdebtserviceobligations,itcouldfacesubstantialliquidityproblemsandcouldbeforcedtoreduceordelayinvestmentsandcapitalexpenditures,ortodisposeofmaterialassetsoroperations,alteritsdividendpolicy,seekadditionaldebtorequitycapitalorrestructureorrefinanceitsindebtedness.Elancomaynotbeabletoeffectanysuchalternativemeasuresoncommerciallyreasonabletermsoratalland,evenifsuccessful,thosealternativeactionsmaynotallowittomeetitsscheduleddebtserviceobligations.TheinstrumentsthatwillgovernElanco'sindebtednessmayrestrictitsabilitytodisposeofassetsandmayrestricttheuseofproceedsfromthosedispositionsandmayalsorestrictitsabilitytoraisedebtorequitycapitaltobeusedtorepayotherindebtednesswhenitbecomesdue.Elancomaynotbeabletoconsummatethosedispositionsortoobtainproceedsinanamountsufficienttomeetanydebtserviceobligationswhendue.
Inaddition,Elancoconductsitsoperationsthroughitssubsidiaries.Accordingly,repaymentofElanco'sindebtednesswilldependonthegenerationofcashflowbyitssubsidiaries,includingcertaininternationalsubsidiaries,andtheirabilitytomakesuchcashavailabletoElanco,bydividend,debt
39
TableofContents
repaymentorotherwise.Elanco'ssubsidiariesmaynothaveanyobligationtopayamountsdueonElanco'sindebtednessortomakefundsavailableforthatpurpose.Elanco'ssubsidiariesmaynotbeableto,ormaynotbepermittedto,makeadequatedistributionstoenableElancotomakepaymentsinrespectofitsindebtedness.Eachsubsidiaryisadistinctlegalentityand,undercertaincircumstances,legal,taxandcontractualrestrictionsmaylimitElanco'sabilitytoobtaincashfromitssubsidiaries.IntheeventthatElancodoesnotreceivedistributionsfromitssubsidiaries,itmaybeunabletomakerequiredprincipalandinterestpaymentsonitsindebtedness.
Elanco'sinabilitytogeneratesufficientcashflowstosatisfyitsdebtobligations,ortorefinanceitsindebtednessoncommerciallyreasonabletermsoratall,maymateriallyadverselyaffectElanco'sbusiness,financialconditionandresultsofoperationsanditsabilitytosatisfyitsobligationsunderitsindebtedness.
The notes are unsecured and are effectively junior to any secured indebtedness.
Thenotesareourunsecuredgeneralobligations.Holdersofanyfuturesecuredindebtednesswillhaveclaimsthatarepriortoyourclaimsasholdersofthenotes,totheextentoftheassetssecuringsuchindebtedness.Intheeventofabankruptcy,liquidation,dissolution,reorganizationorsimilarproceeding,ourpledgedassetswouldbeavailabletosatisfyobligationsofoursecuredindebtednessbeforeanypaymentcouldbemadeonthenotes.Totheextentthatsuchassetscannotsatisfyinfulloursecuredindebtedness,theholdersofsuchindebtednesswouldhaveaclaimforanyshortfallthatwouldrankequallyinrightofpaymentwiththenotes.Inanyoftheforegoingevents,wecannotassureyouthattherewillbesufficientassetstopayamountsdueonthenotes.Asaresult,holdersofthenotesmayreceiveless,ratably,thanholdersofanysecuredindebtedness.AsofMarch31,2019,wehadapproximately$2.5billionoflong-termdebtnetoforiginalissuedebtdiscount.
Risks Relating to Participation in the Exchange Offers
Our board of directors has not made a recommendation as to whether you should tender your Original Notes in exchange for Exchange Notes in the Exchange Offers, and we have not obtained a third-partydetermination that the Exchange Offers are fair to holders of our Original Notes.
Ourboardofdirectorshasnotmade,andwillnotmake,anyrecommendationastowhetherholdersofOriginalNotesshouldtendertheirOriginalNotesinexchangeforExchangeNotespursuanttotheExchangeOffers.Wehavenotretained,anddonotintendtoretain,anyunaffiliatedrepresentativetoactsolelyonbehalfoftheholdersoftheOriginalNotesforpurposesofnegotiatingthetermsoftheseExchangeOffers,orpreparingareportormakinganyrecommendationconcerningthefairnessoftheseExchangeOffers.Therefore,ifyoutenderyourOriginalNotes,youmaynotreceivemorethanorasmuchvalueasifyouchosetokeepthem.HoldersofOriginalNotesmustmaketheirownindependentdecisionsregardingtheirparticipationintheExchangeOffers.
If you fail to exchange your Original Notes, they will continue to be restricted securities and may become less liquid.
OriginalNotesthatyoudonottenderorthatwedonotacceptwill,followingtheExchangeOffers,continuetoberestrictedsecurities,andyoumaynotoffertosellthemexceptpursuanttoanexemptionfrom,orinatransactionnotsubjectto,theSecuritiesActandapplicablestatesecuritieslaw.WewillissueExchangeNotesinexchangefortheOriginalNotespursuanttotheExchangeOffersonlyfollowingthesatisfactionoftheproceduresandconditionssetforthin"TheExchangeOffers—Conditions"and"TheExchangeOffers—ProceduresforTenderingOriginalNotes".TheseproceduresandconditionsincludetimelyreceiptbytheExchangeAgentofsuchOriginalNotes(oraconfirmationofbook-entrytransfer)andofaproperlycompletedanddulyexecutedletteroftransmittal(oranagent'smessagefromDTC).
40
TableofContents
BecauseweanticipatethatmostholdersofOriginalNoteswillelecttoexchangetheirOriginalNotes,weexpectthattheliquidityofthemarketforanyOriginalNotesremainingafterthecompletionoftheExchangeOfferswillbesubstantiallylimited.AnyOriginalNotestenderedandexchangedintheExchangeOfferswillreducetheaggregateprincipalamountoftheapplicableseriesofOriginalNotesoutstanding.FollowingtheExchangeOffers,ifyoudonottenderyourOriginalNotes,yougenerallywillnothaveanyfurtherregistrationrights,andyourOriginalNoteswillcontinuetobesubjecttocertaintransferrestrictions.Accordingly,theliquidityofthemarketfortheOriginalNotescouldbeadverselyaffected.
If an active trading market does not develop for the Exchange Notes, you may be unable to sell the Exchange Notes or to sell them at a price you deem sufficient.
TheExchangeNotesareanewissueofsecuritiesforwhichthereiscurrentlynopublictradingmarket.WedonotintendtolisttheExchangeNotesonanynationalsecuritiesexchange.Accordingly,therecanbenoassurancesthatanactivetradingmarketwilldevelopuponcompletionoftheExchangeOffersor,ifitdevelops,thatsuchmarketwillbesustained,orastotheliquidityofanymarket.Ifanactivetradingmarketdoesnotdeveloporisnotsustained,themarketpriceandtheliquidityoftheExchangeNotesmaybeadverselyaffected.Inaddition,theliquidityofthetradingmarketfortheExchangeNotes,ifitdevelops,andthemarketpricequotedfortheExchangeNotes,maybeadverselyaffectedbychangesintheoverallmarketforthosesecuritiesandbychangesinourfinancialperformanceorprospectsorintheprospectsforcompaniesinourindustrygenerally.
41
TableofContents
USE OF PROCEEDS
WewillnotreceiveanycashproceedsfromtheissuanceoftheExchangeNotespursuanttotheExchangeOffers.InconsiderationforissuingtheExchangeNotesascontemplatedinthisprospectus,wewillreceiveinexchangealikeprincipalamountofOriginalNotes,thetermsofwhichareidenticalinallmaterialrespectstotheExchangeNotes,exceptthattheExchangeNoteswillnotcontaintermswithrespecttotransferrestrictions,registrationrightsandadditionalinterestforfailuretoobservecertainobligationsintheexchangeandregistrationrightsagreement.TheOriginalNotessurrenderedinexchangefortheExchangeNoteswillberetiredandcancelledandcannotbereissued.Accordingly,theissuanceoftheExchangeNoteswillnotresultinanychangeinourcapitalization.
42
TableofContents
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF OPERATIONS
Thefollowingunauditedproformacondensedconsolidatedandcombinedstatementofoperationsshouldbereadinconjunctionwiththesectionentitled"Management'sDiscussionandAnalysisofFinancialConditionandResultsofOperations"andElanco'sconsolidatedandcombinedfinancialstatementsandaccompanyingnotesincludedelsewhereinthisprospectus.
Elanco'sunauditedproformacondensedconsolidatedandcombinedstatementofoperationsisbasedonandhasbeenderivedfromElanco'shistoricalconsolidatedandcombinedfinancialstatementsincludedelsewhereinthisprospectus.
Inmanagement'sopinion,theunauditedproformacondensedconsolidatedandcombinedstatementofoperationsreflectcertainadjustmentsthatarenecessarytopresentfairlyElanco'sunauditedproformacondensedconsolidatedandcombinedresultsofoperationsfortheperiodindicated.Theproformaadjustmentsgiveeffecttoeventsthatare(i)directlyattributabletothetransactionsdescribedbelow,(ii)factuallysupportable,and(iii)expectedtohaveacontinuingimpactonElanco.TheproformaadjustmentsarebasedonassumptionsthatElanco'smanagementbelievesarereasonablegiventhebestinformationcurrentlyavailable.
TheunauditedproformacondensedconsolidatedandcombinedstatementofoperationsisforillustrativeandinformationalpurposesonlyandisnotintendedtorepresentwhatElanco'sresultsofoperationswouldhavebeenhaditoperatedasanindependent,publiclytradedcompanyduringtheperiodpresentedorifthetransactionsdescribedbelowhadactuallyoccurredasofthedateindicated.TheunauditedproformacondensedconsolidatedandcombinedstatementofoperationsalsoshouldnotbeconsideredindicativeofElanco'sfutureresultsofoperationsasanindependent,publiclytradedcompany.
Theunauditedproformacondensedconsolidatedandcombinedstatementofoperationsgiveeffecttothefollowingtransactions,whicharereferredtoasthe"Transactions,"asiftheyeachhadoccurredonJanuary1,2018:
• theimpactoftheDebtTransactionsandtheuseoftheproceedstherefrom.
Duetolocalregulatoryandoperationalrequirements,incertainnon-U.S.jurisdictions,thetransferofcertainassetsandliabilitiesofLilly'sanimalhealthbusinesseshavenotlegallyoccurred.Elancohasnotadjustedtheaccompanyingunauditedproformacondensedconsolidatedandcombinedstatementofoperationsforthepotentialimpactofthedelayedtransfersbecauseanyimpactofthesetransfersisnotmaterialtoitsunauditedproformacondensedconsolidatedandcombinedstatementofoperations,individuallyorintheaggregate.
Elanco'scondensedconsolidatedandcombinedstatementofoperationsincludesexpenseallocationsrelatedtocertainLillycorporatefunctionspriortotheIPO,including,butnotlimitedto,executiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations.TheseexpenseshavebeenallocatedtoElancobasedondirectusageorbenefitwherespecificallyidentifiable,withtheremainderallocatedprimarilyonaproratabasisofrevenue,headcountorothermeasures.Elanco'smanagementbelievesthatthisexpensemethodology,andtheresultsthereof,isreasonableforallperiodspresented.However,theallocationsmaynotbeindicativeoftheactualexpensethatwouldhavebeenincurredifElancowouldhaveoperatedasanindependent,publiclytradedcompanyfortheentiretyoftheperiodpresented.LillycontinuestoprovideElancowithsomeoftheservicesrelatedtothesefunctionsonatransitionalbasisinexchangeforagreed-uponfeesandElancoexpectstoincurothercoststoreplacetheservicesandresourcesthatwillnotbeprovidedbyLilly.Elancowillalsocontinuetoincurnewcostsrelatingtoitspublicreportingandcomplianceobligationsasanindependent,publiclytradedcompany.Theaccompanyingunauditedproformacondensedconsolidatedandcombinedstatementofoperationshas
43
TableofContents
notbeenadjustedforanychangeinsuchcosts,astheyareprojectedamountsbasedonestimatesandarenotfactuallysupportable.
Theunauditedproformacondensedconsolidatedandcombinedstatementofoperationsexcludescertainadjustmentsfornon-recurringcoststhatElancohasincurredorexpectstoincurrelatedtotheseparation,including,amongotherthings,thecreationofastandaloneinfrastructureinareassuchasinformationtechnology,facilitiesmanagement,distribution,humanresources,manufacturing,financeandotherfunctions.Elancocurrentlyestimatesthesecostsintheaggregatetobeinarangefrom$240millionto$290million,netofpotentialrealestatedispositions,ofwhichaportionwillbecapitalizedandtheremainderwillbeexpensed.
44
TableofContents
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED AND COMBINED STATEMENT OF OPERATIONS
YEAR ENDED DECEMBER 31, 2018
SeeaccompanyingNotestoUnauditedProFormaCondensedConsolidatedandCombinedStatementofOperations.
45
Historical Pro Forma
Adjustments Notes Pro Forma (In millions, except per share data) Revenue $ 3,066.8 — $ 3,066.8Costs,expensesandother: Costofsales 1,573.8 — 1,573.8Researchanddevelopment 246.6 — 246.6Marketing,sellingandadministrative 735.2 — 735.2Amortizationofintangibleassets 197.4 — 197.4Assetimpairment,restructuringandotherspecialcharges 128.8 — 128.8Interestexpense,netofcapitalizedinterest 29.6 81.1 (a) 110.7Other(income)expense,net 41.3 — 41.3
Income/(loss)beforeincometaxexpense 114.1 (81.1) 33.0Incometaxexpense(benefit) 27.6 (19.5) (b) 8.1Netloss $ 86.5 $ (61.6) $ 24.9Netlosspershare—basicanddiluted $ 0.28 $ 0.08Weightedaveragesharesoutstanding—basicanddiluted 313.7 313.7
TableofContents
Notes to Unaudited Pro Forma Condensed Consolidated and Combined Statement of Operations.
(a) ReflectsinterestexpenserelatedtotheSeniorNotesOffering,TermLoanandamortizationoftheassociateddeferreddebtissuancecosts.TheinterestexpensehasbeencalculatedbasedonthefixedinterestratesforthenotesissuedintheSeniorNotesOfferingandforborrowingsundertheTermLoan,alongwithanestimated$24.5millionofdebtissuancecostsamortizedoverthetermofthedebt,calculatedasfollows:
(b) ReflectstheimpactoftheproformaadjustmentsonincometaxcalculatedusingElanco'sU.S.effectivetaxrateof24%fortheyearendedDecember31,2018.
46
Principal Interest Rate
Year Ended December 31,
2018 (Dollars in millions) Seniornotes: 3year $ 500.0 3.912%$ 19.65year 750.0 4.272% 32.010year 750.0 4.900% 36.8
Termloan* 500.0 3.772% 18.9Debtissuancecost 24.5 — 4.8Totalcost $ 2,524.5 — $ 112.1Less:Historicalinterestpayment** — — (31.0)Proformaadjustment — — $ 81.1
* RepresentsinterestrateasofDecember31,2018
** Interestexpenseincludedwithin"Interestexpense,netofcapitalizedinterest"financialstatementlineitem.
TableofContents
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following is a discussion and analysis of Elanco's financial condition and results of operations as of, and for, the periods presented. You should read the following discussion and analysis of Elanco's financialcondition and results of operations together with the sections entitled "Prospectus Summary—Selected Historical and Pro Forma Financial Data," "Risk Factors," "Cautionary Statement Concerning Forward-LookingStatements," "Unaudited Pro Forma Condensed Consolidated and Combined Statement of Operations" and Elanco's consolidated and combined financial statements and related notes thereto included elsewhere in thisprospectus.
Overview
Foundedin1954aspartofEliLillyandCompany,Elancoisapremieranimalhealthcompanythatinnovates,develops,manufacturesandmarketsproductsforcompanionandfoodanimals.HeadquarteredinGreenfield,Indiana,Elancoisthefourthlargestanimalhealthcompanyintheworld,withrevenueof$3.1billionfortheyearendedDecember31,2018.Globally,itis#1inmedicinalfeedadditives,#2inpoultryand#3incattle,measuredby2017revenue,accordingtoVetnosis.Elancoalsohasoneofthebroadestportfoliosofpetparasiticidesinthecompanionanimalsector.Elancooffersadiverseportfolioofmorethan125brandsthatmakeitatrustedpartnertoveterinariansandfoodanimalproducersinmorethan90countries.
Elancooperatesitsbusinessinasinglesegmentdirectedatfulfillingitsvisionofenrichingthelivesofpeoplethroughfood—makingproteinmoreaccessibleandaffordable—andthroughpetcompanionship—helpingpetslivelonger,healthierlives.Elancoadvancesitsvisionbyofferingproductsinfourprimarycategories:
• Companion Animal Disease Prevention ("CA Disease Prevention"). Elancohasoneofthebroadestparasiticideportfoliosinthecompanionanimalsectorbasedonindications,speciesandformulations,withproductsthatprotectpetsfromworms,fleasandticks.Combiningitsparasiticideportfoliowithitsvaccinespresence,ElancoisaleaderintheU.S.inthediseasepreventioncategorybasedonshareofrevenue.
Companion Animal Therapeutics ("CA Therapeutics"). Elancohasabroadpainandosteoarthritisportfolioacrossspecies,modesofaction,indicationsanddiseasestages.Petownersareincreasinglytreatingosteoarthritisintheirpets,andElanco'sGalliprant productisoneofthefastestgrowingosteoarthritistreatmentsintheU.S.Elancoalsohastreatmentsforotitis(earinfections),aswellascardiovascularanddermatologyindications.
• Food Animal Future Protein & Health ("FA Future Protein & Health"). Elanco'sportfoliointhiscategory,whichincludesvaccines,nutritionalenzymesandanimal-onlyantibiotics,servesthegrowingdemandforproteinandincludesinnovativeproductsinpoultryandaquacultureproduction,wheredemandforanimalhealthproductsisoutpacingoverallindustrygrowth.Elancoisfocusedondevelopingfunctionalnutritionalhealthproductsthatpromotefoodanimalhealth,includingenzymes,probioticsandprebiotics.Elancoisaleaderinprovidingvaccinesasalternativestoantibioticstopromoteanimalhealthbasedonshareofrevenue.
• Food Animal Ruminants & Swine ("FA Ruminants & Swine"). Elancohasdevelopedarangeoffoodanimalproductsusedextensivelyinruminant(e.g.,cattle,sheepandgoats)andswineproduction.
ForthethreemonthsendedMarch31,2019and2018,Elanco'srevenuewas$731.1millionand$736.2million,respectively,andfortheyearsendedDecember31,2018,2017and2016,Elanco'srevenuewas$3.1billion,$2.9billionand$2.9billion,respectively.ForthethreemonthsendedMarch31,2019and2018,Elanco'snetincomewas$31.5millionand$72.7million,respectively,and
47
TableofContents
fortheyearsendedDecember31,2018,2017and2016,Elanco'snetincome(loss)was$86.5million,$(310.7)millionand$(47.9)million,respectively.
Key Trends and Conditions Affecting Elanco's Results of Operations
Industry Trends
Theanimalhealthindustry,whichfocusesonbothfoodanimalsandcompanionanimals,isagrowingindustrythatbenefitsbillionsofpeopleworldwide.
Asdemandforanimalproteingrows,foodanimalhealthisbecomingincreasinglyimportant.Factorsinfluencinggrowthindemandforfoodanimalmedicinesandvaccinesinclude:
• oneinthreepeopleneedsimprovednutrition;
• increasedglobaldemandforprotein,particularlypoultryandaquaculture;
• naturalresourceconstraints,suchasscarcityofarableland,freshwaterandincreasedcompetitionforcultivatedland,drivingtheneedformoreefficientfoodproduction;
• lossofproductivityduetofoodanimaldiseaseanddeath;
• increasedfocusonfoodsafetyandfoodsecurity;and
• humanpopulationgrowth,increasedstandardsofliving,particularlyinmanyemergingmarkets,andincreasedurbanization.
Growthinfoodanimalnutritionalhealthproducts(enzymes,probioticsandprebiotics)isinfluenced,amongotherfactors,bydemandforantibioticalternativesthatcanpromoteanimalhealthandincreaseproductivity.
Factorsinfluencinggrowthindemandforcompanionanimalmedicinesandvaccinesinclude:
• increasedpetownershipglobally;
• petslivinglonger;and
• increasedpetspendingaspetsareviewedasmembersofthefamilybyowners.
Product Development and New Product Launches
AkeyelementofElanco'stargetedvaluecreationstrategyistodrivegrowththroughportfoliodevelopmentandproductinnovation,primarilyinitsthreetargetedgrowthcategories:CADiseasePrevention,CATherapeuticsandFAFutureProtein&Health.Elanco'selevenproductlaunchesbetween2015andDecember31,2018havehadasignificantpositiveimpactonitsrevenueoverthoseperiods,andElancoexpectsnewproductsandinnovationwillcontinuetohaveapositiveimpactonrevenueinthefuture.Revenuefromtheseproductlaunchescontributed$274.2milliontorevenuefortheyearendedDecember31,2018and$97.8milliontorevenueforthethreemonthsendedMarch31,2019.Elancocontinuestopursuethedevelopmentofnewchemicalandbiologicalmoleculesthroughitsapproachtoinnovation.Elanco'sfuturegrowthandsuccessdependsonbothitspipelineofnewproducts,includingnewproductsthatitmaydevelopthroughjointventuresandproductsthatitisabletoobtainthroughlicenseoracquisition,andtheexpansionoftheuseofitsexistingproducts.ElancobelievesitisanindustryleaderinanimalhealthR&D,withatrackrecordofproductinnovation,businessdevelopmentandcommercialization.
48
TableofContents
Impact of Changing Market Demand for Antibiotics
Inrecentyears,Elanco'soperationalresultshavebeen,andwillcontinuetobe,affectedbyregulationsandchangingmarketdemandrelatingtotheuseofantibioticsandotherproductsintendedtoincreasefoodanimalproduction.
Therearetwoclassesofantibioticsusedinanimalhealth,shared-class,ormedicallyimportant,antibioticsandanimal-onlyantibiotics.Shared-classantibioticsareusedtotreatinfectiousdiseasecausedbypathogensthatoccurinbothhumansandanimals.AspartofElanco'santibioticstewardshipplanandincompliancewithFDAguidance,shared-classantibioticsarelabeledonlyforthetreatmentofanestablishedneedinanimalsandonlywithveterinarianoversight.However,notallpathogensthatcausediseaseinanimalsareinfectiousinhumans,andaccordinglyanimal-onlyantibioticsarenotusedinhumanmedicine(i.e.,notmedicallyimportant).From2015to2018,Elanco'srevenuefromshared-classantibioticsdeclinedataCAGRof6%,excludingtheimpactofforeignexchange.Thiswasdrivenprimarilybychangingregulationsinmanymarkets,includingtheVeterinaryFeedDirective,aswellaschangingmarketdemandandElanco'stiered-approachtoantibioticstewardship,whichincludedremovinggrowthpromotionfromlabelsandrequiringveterinaryoversightintheU.S.andothermarkets.Globally,during2018,Elanco'srevenuefromshared-classantibioticsdeclined2%,excludingtheimpactofforeignexchange,andrepresented12%(4%fromsalesintheU.S.and8%fromsalesoutsideoftheU.S.)oftotalrevenue,downfrom16%in2015.From2015to2018,Elanco'srevenuefromanimal-onlyantibioticsgrewataCAGRof5%,excludingtheimpactofforeignexchange,drivenbysalesoutsidetheU.S.,whichoffsetaslightdeclineintheU.S.Globally,during2018,Elanco'srevenuefromanimal-onlyantibioticsgrew8%,excludingtheimpactofforeignexchange,andrepresented25%oftotalrevenue,upfrom23%in2015.During2018,87%ofElanco'srevenuefromanimal-onlyantibioticsresultedfromthesaleofionophores.Ionophoresareaspecialclassofanimal-onlyantimicrobials,andbecauseoftheiranimal-onlydesignation,modeofactionandspectrumofactivity,theirusehasnottodatebeenimpactedbyregulationsorchangingmarketdemandinmanymarketsoutsideoftheU.S.
Elancohasintentionallyshiftedawayfromshared-classantibiotics,andisfocusingonanimal-onlyantibiotics,aswellasantibiotic-freesolutions.Whenananimal-onlyantibioticexists,Elancobelievesitshouldbethefirst,preferredantibiotictreatment.Antibioticresistanceconcerns,orotherhealthconcernsregardingfoodanimalproducts,mayresultinadditionalrestrictions,expandedregulationsorchangesinmarketdemandtofurtherreducetheuseofantibioticsinfoodanimals.Elancobelievesitisimportanttoprotectthebenefitsofantibioticsinhumanmedicine,whileresponsiblyprotectingthehealthoffoodanimalsandthesafetyofourfoodsupply.
Impact of Competition
Theanimalhealthindustryiscompetitive.Establishedanimalhealthcompanieswhoconsistentlydeliverhighqualityproductsenjoybrandloyaltyfromtheircustomers,whichoftencontinuesafterthelossofpatent-basedorregulatoryexclusivity.In2018,approximately72%ofElanco'srevenuewasfromproductsthatdidnothavepatentprotection.Inanimalhealth,whilepotentiallysignificant,erosionfromgenericcompetitionisoftennotassteepasinhumanhealth,withtheoriginatoroftenretainingasignificantmarketshare.WhileElanco'slargestproduct,Rumensin ,hasbeensubjecttogenericcompetitionfrommonensinoutsidetheU.S.formorethan10years,revenuefromRumensin salesoutsidetheU.S.grewataCAGRof5%from2015to2018.However,genericcompetitioncanneverthelesssignificantlyaffectElanco'sresults.ElancohasexperiencedsignificantcompetitiveheadwindsfromgenericractopamineintheU.S.Inthethirdquarterof2013,alarge,establishedanimalhealthcompanyreceivedU.S.approvalforgenericractopamine.U.S.revenueforOptaflexx ,Elanco'sractopaminebeefproduct,hasdeclinedataCAGRof24%from2015to2018asaresultofgenericcompetitionandtheimpactofinternationalregulatoryrestrictions.In2018,Elancohadan
49
TableofContents
estimated70%marketshareofallU.S.ractopamine-treatedbeefcattlebasedonElancomanagementestimates.
AlthoughElancobelievesbrandloyaltyisanimportantcontributortoaproduct'songoingsuccess,theanimalhealthindustryisalsoimpactedbyinnovation.Elancoexperiencedaninnovationlaginthecompanionanimalparasiticidespacefrom2015to2017.Intheabsenceofacompetitivecombinedoralfleaandtickproduct,Elanco'sU.S.companionanimalparasiticideportfoliorevenuedeclined15%in2017,excludingtheimpactonrevenueresultingfromareductionininventorylevelswithinElanco'sdistributionchannel.InFebruary2018,ElancolaunchedCredelio intheU.S.forthetreatmentoffleasandticks.SincethelaunchofCredelio ,Elanco'ssalesofparasiticidesintheU.S.havebeguntogrowagain.
Productivity
Elanco'sresultsduringtheperiodspresentedhavebenefittedfromoperationalandproductivityinitiativesimplementedfollowingrecentacquisitionsandinresponsetochangingmarketdemandforantibioticsandotherheadwinds.Elancoestimatesthattheseinitiativeshavegeneratedmorethan$500millioninannualizedcostsavingsfromthebeginningof2015throughtheendof2017.
Elanco'sacquisitionsofLohmannAnimalHealthin2014,NovartisAnimalHealthin2015andtheBIVetmedicaU.S.vaccinesportfolioin2017addedintheaggregate$1.4billioninrevenue,4,500full-timeemployees,12manufacturingandeightR&Dsites.Inaddition,from2015to2018,changingmarketdemandforantibioticsandotherheadwinds,suchascompetitionwithgenericsandinnovation,affectedsomeofElanco'shighestgrossmarginproducts,resultinginachangetoElanco'sproductmixanddrivingoperatingmarginlower.Inresponse,Elancoimplementedanumberofinitiativesacrossmanufacturing,R&Dandmarketing,sellingandadministrative,suchasrationalizationofstockkeepingunits,reductionofcontractmanufacturingorganizations,implementationofleanmanufacturingprinciplesandprocurementinitiatives.
Foreign Exchange Rates
SignificantportionsofElanco'srevenueandcostsareexposedtochangesinforeignexchangerates.Elanco'sproductsaresoldinmorethan90countriesand,asaresult,itsrevenueisinfluencedbychangesinforeignexchangerates.ForthethreemonthsendedMarch31,2019and2018,approximately42%and47%,respectively,ofElanco'srevenuewasdenominatedinforeigncurrencies.FortheyearsendedDecember31,2018and2017,approximately52%and50%,respectively,ofElanco'srevenuewasdenominatedinforeigncurrencies.Elancoseekstomanageforeignexchangerisk,inpart,throughoperationalmeans,includingmanagingsame-currencyrevenueinrelationtosame-currencycosts,andsame-currencyassetsinrelationtosame-currencyliabilities.AsElancooperatesinmultipleforeigncurrencies,includingtheeuro,Britishpound,Brazilianreal,Australiandollar,Japaneseyen,Canadiandollar,Chineseyuan,andothercurrencies,changesinthosecurrenciesrelativetotheU.S.dollarwillimpactitsrevenue,costofgoodsandexpenses,andconsequently,netincome.ExchangeratefluctuationsinemergingmarketsmayalsohaveanimpactbeyondElanco'sreportedfinancialresultsanddirectlyimpactoperations.ThesefluctuationsmayalsoaffecttheabilitytobuyandsellElanco'sproductsbetweenmarketsimpactedbysignificantexchangeratevariances.TherehasbeenlimitedimpactonElanco'srevenueduetocurrencymovementsduringthethreemonthsendedMarch31,2019and2018.Foreignexchangerateshadanegligibleeffectonrevenuefrom2016to2018.
General Economic Conditions
Inadditiontoindustry-specificfactors,Elanco,likeotherbusinesses,faceschallengesrelatedtoglobaleconomicconditions.Growthinboththefoodanimalandcompanionanimalsectorsisdrivenin
50
TableofContents
partbyoveralleconomicdevelopmentandrelatedgrowth,particularlyinmanyemergingmarkets.Inrecentyears,certainofElanco'scustomersandsuppliershavebeenaffecteddirectlybyeconomicdownturns,whichdecreasedthedemandforElanco'sproducts.
ThecostofElanco'sproductstofoodanimalproducersissmallrelativetotheirotherproductioncosts,includingfeed,andtheuseofElanco'sproductsisintendedtoimproveeconomicoutcomesforfoodanimalproducers.Similarly,industrysourceshavereportedthatpetownersindicatedapreferenceforreducingspendingonotheraspectsoftheirlifestyle,includingentertainment,clothingandhouseholdgoods,beforereducingspendingonpetcare.Whilethesefactorshavemitigatedtheimpactofrecentdownturnsintheglobaleconomy,furthereconomicchallengescouldincreasecostsensitivityamongElanco'scustomers,whichmayresultinreduceddemandforElanco'sproductsandcouldhaveamaterialadverseeffectonElanco'sfinancialconditionandresultsofoperations.
Weather Conditions and the Availability of Natural Resources
TheanimalhealthindustryanddemandformanyofElanco'sanimalhealthproductsinaparticularregionareaffectedbyweatherconditions,varyingweatherpatternsandweather-relatedpressuresfrompests,suchasfleasandticks.Asaresult,Elancomayexperienceregionalandseasonalfluctuationsinitsresultsofoperations.
Foodanimalproducersdependontheavailabilityofnaturalresources,includinglargesuppliesoffreshwater.Theiranimals'healthandtheirabilitytooperatecouldbeadverselyaffectediftheyexperienceashortageoffreshwaterduetohumanpopulationgrowthorfloods,droughtsorotherweatherconditions.
Droughtconditionscouldnegativelyimpact,amongotherthings,thesupplyofcornandtheavailabilityofgrazingpastures.Adecreaseinharvestedcornresultsinhighercornprices,whichcouldnegativelyimpacttheprofitabilityoffoodanimalproducersofruminants,porkandpoultry.Highercornpricesandreducedavailabilityofgrazingpasturescontributetoreductionsinherdorflocksizesthatinturnresultinlessspendingonanimalhealthproducts.Assuch,aprolongeddroughtcouldhaveamaterialadverseeffectonElanco'sfinancialconditionandresultsofoperations.FactorsinfluencingthemagnitudeandtimingofeffectsofadroughtonElanco'sperformanceinclude,butmaynotbelimitedto,weatherpatternsandherdmanagementdecisions.
Inaddition,veterinaryhospitalsandpractitionersdependonvisitsfromandaccesstotheanimalsundertheircare.Veterinarians'patientvolumeandabilitytooperatecouldbeadverselyaffectediftheyexperienceprolongedsnow,iceorothersevereweatherconditions,particularlyinregionsnotaccustomedtosustainedinclementweather.AdverseweatherconditionsorashortageoffreshwatermaycauseveterinariansandfoodanimalproducerstopurchaselessofElanco'sproducts.
Disease Outbreaks
SalesofElanco'sfoodanimalproductscouldbeadverselyaffectedbytheoutbreakofdiseasecarriedbyanimals.Outbreaksofdiseasemayreduceregionalorglobalsalesofparticularanimal-derivedfoodproductsorresultinreducedexportsofsuchproducts,eitherduetoheightenedexportrestrictionsorimportprohibitions,whichmayreducedemandforElanco'sproducts.Also,theoutbreakofanyhighlycontagiousdiseasenearElanco'smainproductionsitescouldrequireElancotoimmediatelyhalttheproductionofproductsatsuchsitesorforceElancotoincursubstantialexpensesinprocuringrawmaterialsorproductselsewhere.Alternatively,salesofproductsthattreatspecificdiseaseoutbreaksmayincrease.
51
TableofContents
Manufacturing and Supply
InordertosellElanco'sproducts,Elancomustbeabletoreliablyproduceandshipproductsinsufficientquantities.ManyofElanco'sproductsinvolvecomplexmanufacturingprocessesandaresole-sourcedfromcertainmanufacturingsites.
MinordeviationsinElanco'smanufacturingorlogisticalprocesses,unpredictabilityofaproduct'sregulatoryorcommercialsuccessorfailure,theleadtimenecessarytoconstructhighlytechnicalandcomplexmanufacturingsites,andshiftingcustomerdemandincreasethepotentialforcapacityimbalances.
Components of Revenue and Costs and Expenses
Revenue
Elanco'srevenueisprimarilyderivedfromsalesofitsproductstothird-partydistributors,anddirectlytofoodproducersandveterinarians.ForadditionalinformationregardingElanco'sproducts,includingdescriptionsofitsproducts,see"BusinessofElanco—Products."
Elancoaggregatesitsproductsintofivecategoriestounderstandrevenuegrowth:
• CA Disease Prevention includesparasiticidesandvaccineproductsfordogsandcats;
• CA Therapeutics includesproductsforthetreatmentofpain,osteoarthritis,otitis,cardiovascularanddermatologyindicationsindogsandcats;
• FA Future Protein & Health includesvaccines,antibiotics,parasiticidesandotherproductsusedinpoultryandaquacultureproduction,aswellasfunctionalnutritionalhealthproducts,includingenzymes,probioticsandprebiotics;
• FA Ruminants & Swine includesvaccines,antibiotics,implants,parasiticides,andotherproductsusedinruminantsandswineproduction,aswellascertainotherfoodanimalproducts;and
• Strategic Exits includesbusinessactivitiesthatElancohaseitherexitedormadethestrategicdecisiontoexit,includingthetransitionalcontractmanufacturingactivitythatitacquiredinconnectionwithitsacquisitionoftheBIVetmedicaU.S.vaccinesportfolio,twoterminatedlegacyU.S.distributionagreements,aterminateddistributionagreementoutsidetheU.S.,anequineproductnotcoretoitsbusinessandtransitionalcontractmanufacturingactivityassociatedwiththesupplyofhumangrowthhormonetoLilly.
Costs, Expenses and Other
Cost of sales consistsprimarilyofcostofmaterials,facilitiesandotherinfrastructureusedtomanufactureElanco'sproducts,shippingandhandling,inventorylossesandexpiredproducts.
Marketing, selling and administrative expensesconsistof,amongotherthings,thecostsofmarketing,promotionandadvertisingandthecostsofadministration(businesstechnology,facilities,legal,finance,humanresources,businessdevelopment,externalaffairsandprocurement).
Amortization of intangible assetsconsistoftheamortizationexpenseforintangibleassetsthathavebeenacquiredthroughbusinesscombinations.
R&D expensesconsistofprojectcostsspecifictonewproductR&Dandproductlifecyclemanagement,overheadcostsassociatedwithR&Doperations,regulatory,productregistrationsandinvestmentsthatsupportlocalmarketclinicaltrialsforapprovedindications.ElancomanagesoverallR&DbasedonitsstrategicopportunitiesanddoesnotdisaggregateitsR&Dexpensesincurredbynatureorbyproductasitdoesnotuseormaintainsuchinformationinmanagingitsbusiness.
52
TableofContents
Asset impairment, restructuring and other special charges consistsprimarilyofimpairmentoflong-termassets,restructuringcharges,costsassociatedwithacquiringandintegratingbusinesses,andcertainnon-recurringexpenses,includingcostsrelatedtothebuildoutofprocessesandsystemstosupportfinanceandglobalsupplyandlogistics,amongothers,asElancobecomesanindependentcompany.
Other—(income) expense, net consistsofnetinterest(income)/expense,realizedorunrealizedforeignexchangelossesandlossorimpairmentonotherinvestments.
Comparability of Historical Results
Elanco'shistoricalresultsofoperationsfortheperiodspresentedmaynotbecomparablewithpriorperiodsorwithitsresultsofoperationsinthefutureduetomanyfactors,includingbutnotlimitedtothefactorsidentifiedin"—KeyTrendsandConditionsAffectingElanco'sResultsofOperations."
Elanco's Relationship with Lilly and Additional Standalone Costs
PriortotheIPO,Elanco'sbusinessoperatedaspartofadivisionofLilly.Elanco'sconsolidatedandcombinedfinancialstatementshavebeenderivedfromLilly'sconsolidatedfinancialstatementsandaccountingrecordsfortheperiodspriortotheIPO.Elanco'sconsolidatedandcombinedfinancialstatementsreflectitsfinancialposition,resultsofoperationsandcashflowsofthebusinessthatweretransferredatthetimeoftheseparationanddonotpurporttoreflectwhattheresultsofoperations,comprehensiveincome/(loss),financialposition,equityorcashflowswouldhavebeenhadElancooperatedasanindependent,publiclytradedcompanyduringtheperiodspresentedpriortotheIPO.
Elanco'shistoricalresultsreflectanallocationofcostsforcertainLillycorporatecostsfortheperiodspriortotheIPO,including,amongothers,executiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations.TheseallocationsarenotnecessarilyindicativeoftheexpensesElancomayincurasastandalonepubliccompany.AlthoughElancoenteredintocertainagreementswithLillyinconnectionwiththeIPOandtheseparation,theamountandcompositionofitsexpensesmayvaryfromhistoricallevelssincethefeeschargedfortheservicesundertheagreementmaybehigherorlowerthanthecostsreflectedinthehistoricalallocations.ThetotalallocationsincludedinElanco'sresultsforthethreemonthsendedMarch31,2019and2018were$0.0millionand$35.6million,respectively.ThetotalallocationsincludedinElanco'sresultsfortheyearsendedDecember31,2018,2017and2016were$105.2million,$151.7millionand$145.3million,respectively.SeeNote19:RelatedPartyAgreementsandTransactionstoElanco'sauditedconsolidatedandcombinedfinancialstatementsandNote15:RelatedPartyAgreementsandTransactionstoElanco'sunauditedconsolidatedandcombinedfinancialstatements.
Elancoiscurrentlyinvestinginexpandingitsownadministrativefunctions,including,butnotlimitedto,informationtechnology,facilitiesmanagement,distribution,humanresourcesandmanufacturing,toreplaceservicespreviouslyprovidedbyLilly.Becauseofinitialstand-upcostsandoverlapswithservicespreviouslyprovidedbyLilly,Elancohasincurredandexpectstocontinuetoincurcertaintemporary,duplicativeexpensesinconnectionwiththeseparation.Elancoalsoincurredandexpectstocontinuetoincurcostsrelatedtothebuildoutofprocessesandsystemstosupportfinanceandglobalsupplyandlogistics,amongothers.Elancocurrentlyestimatesthesecoststakentogethertobeinarangefrom$240millionto$290million,netofpotentialrealestatedispositions,ofwhichaportionwillbecapitalizedandtheremainderwillbeexpensed.See"CertainRelationshipsandRelatedPartyTransactions—RelationshipbetweenLillyandElanco."
53
TableofContents
LillyutilizesacentralizedtreasurymanagementsystemofwhichElancowaspartuntilitsIPO.ForperiodspriortotheIPO,Elanco'sconsolidatedandcombinedfinancialstatementsreflectcashheldonlyinbankaccountsinitslegalnameandnoallocationofcombinedcashpositions.Elanco'sconsolidatedandcombinedfinancialstatementsdonotreflectanallocationofLilly'sdebtoranyassociatedinterestexpense.InconnectionwiththeIPO,Elancoincurred$2.5billionoflong-termborrowings.Elanco'shistoricalresultsreflect$29.6millionofinterestexpenseduringtheyearendedDecember31,2018duetothetimingoftheborrowings,incomparisonto$20.8millionforthethreemonthsendedMarch31,2019.Elancohasestimatedinterestexpenseofapproximately$85milliononanannualbasis.
FortheperiodspriortotheIPO,Elanco'sconsolidatedandcombinedfinancialstatementsreflectincometaxexpense(benefit)computedonaseparatecompanybasis,asifoperatingasastandaloneentityoraseparateconsolidatedgroupineachmaterialjurisdictioninwhichElancooperates.Elanco'sconsolidatedandcombinedfinancialstatementsfortheperiodspriortotheIPOalsoreflectcertaindeferredtaxassetsandliabilitiesandincometaxespayablebasedonthisapproachthatdidnottransfertoElancoupontheseparation,astheunderlyingtaxattributeswereusedbyLillyorretainedbyLilly.AsaresultofpotentialchangestoElanco'sbusinessmodelandthefactthatcertaindeferredtaxassetsandliabilitiesandincometaxespayabledidnottransfertoElanco,incometaxexpense(benefit)includedintheconsolidatedandcombinedfinancialstatementsmaynotbeindicativeofElanco'sfutureexpectedtaxrate.
Elanco'shistoricalresultspriortotheIPOalsodonotreflecttheimpactofcostsElancohasincurredandexpectstocontinuetoincurasaconsequenceofbecomingastandalonecompany,includingincrementalcostsassociatedwithbeingapubliclytradedcompany.
Elancoisseekingtoinstitutecompetitivecompensationpoliciesandprogramsasastandalonepubliccompany,theexpenseforwhichmaydifferfromthecompensationexpenseallocatedbyLillyinElanco'sconsolidatedandcombinedfinancialstatements.
AsaresultoftheIPO,ElancobecamesubjecttothereportingrequirementsoftheExchangeActandtheSarbanes-OxleyAct.Elancohasadditionalproceduresandpracticestoestablishorexpandasastandalonepubliccompany.Asaresult,Elancowillcontinuetoincuradditionalcostsasastandalonepubliccompany,includinginternalaudit,externalaudit,investorrelations,stockadministration,stockexchangefeesandregulatorycompliancecosts.
Recent Significant Acquisitions
Elanco'sfinancialresultshavebeenimpactedbyacquisitionsandintegrations.Fortheperiodspresented,theseincludeprimarilytheacquisitionsandintegrationsofNovartisAnimalHealth,whichclosedonJanuary1,2015,certainrightstodevelop,manufacture,marketandcommercializeGalliprant outsidetheU.S.andco-promoteitintheU.S.acquiredfromAratanaTherapeutics,Inc.,whichclosedonApril22,2016,andBIVetmedicaU.S.vaccinesportfolio,whichclosedonJanuary3,2017.Formoreinformation,seeNote6:AcquisitionstoElanco'sconsolidatedandcombinedfinancialstatements.
OnApril26,2019,Elancoenteredintoanagreement(theMergerAgreement)toacquireAratanaTherapeutics,Inc.(Aratana).Aratanaisapettherapeuticscompanyfocusedoninnovativetherapiesfordogsandcats,andcreatorofthecanineosteoarthritismedicine,Galliprant®,therightstowhichElancoacquiredin2016.SubjecttothetermsandconditionssetforthintheMergerAgreement,upontheconsummationofthemerger,eachshareofAratanacommonstockwillbeconvertedintotherighttoreceive0.1481sharesofElanco'scommonstockplusonecontingentvalueright,whichshallrepresenttherighttoreceiveacontingentpaymentof$0.25incashupontheachievementofaspecifiedmilestoneasoutlinedintheMergerAgreement.BasedontheclosingpriceofashareofElancocommonstockonApril24,2019,thedateonwhichtheexchangeratiowasset,thestockportionofthemergerconsiderationrepresentedapproximately$234million.Themaximumaggregate
54
TableofContents
contingentpaymentisapproximately$12million.Thetransactionisexpectedtocloseinthemiddleof2019,subjecttocustomaryclosingconditions,includingtheregistrationofsharesofElancocommonstockissuableinthemerger,receiptofregulatoryapprovals,andapprovalbythestockholdersofAratana.
Asset Impairment, Restructuring and Other Special Charges
DuringtheyearsendedDecember31,2018,2017and2016includinginconnectionwiththeproductivityinitiativesdescribedaboveunder"—KeyTrendsandConditionsAffectingElanco'sResultsofOperations—Productivity,"Elancoincurredchargesrelatedtoassetimpairment,restructuringandotherspecialcharges,includingintegrationofacquiredbusinesses.ThesechargesincludeseverancecostsresultingfromactionstakentoreduceElanco'scosts,assetimpairmentchargesprimarilyrelatedtocompetitivepressuresforcertaincompanionanimalproducts,productrationalizations,siteclosures,andintegrationcostsrelatedtoacquiredbusinesses,primarilyNovartisAnimalHealth,andcostsrelatedtothebuildoutofprocessesandsystemstosupportfinanceandglobalsupplyandlogistics,amongothers,asElancobecomesanindependentcompany.
Formoreinformationonthesecharges,seeNote7:AssetImpairment,RestructuringandOtherSpecialChargestoElanco'sconsolidatedandcombinedfinancialstatements.
Results of Operations
ThefollowingdiscussionandanalysisofElanco'sconsolidatedandcombinedstatementsofoperationsshouldbereadalongwithElanco'sconsolidatedandcombinedfinancialstatementsandthenotestheretoincludedelsewhereinthisprospectus,whichreflecttheresultsofoperationsofthebusinesstransferredtoElancofromLilly.Formoreinformation,seeNote2:BasisofPresentationtoElanco'sauditedconsolidatedandcombinedfinancialstatementsandElanco'sunauditedconsolidatedandcombinedfinancialstatements.
55
Three Months Ended
March 31, % Change Year Ended December 31, % Change (Dollars in millions) 2019 2018 19/18 2018 2017 2016 18/17 17/16 Revenue $ 731.1 736.2 (1)% $ 3,066.8 $ 2,889.0 $ 2,913.5 6% (1)%Costs,expensesandother: Costofsales 343.8 360.0 (5)% 1,573.8 1,493.9 1,409.0 5% 6%%ofrevenue 47% 49% (2)% 51% 52% 48%
Researchanddevelopment 64.1 65.2 (2)% 246.6 251.7 265.8 (2)% (5)%%ofrevenue 9% 9% —% 8% 9% 9% Marketing,sellingandadministrative 181.1 180.0 1% 735.2 779.8 784.8 (6)% (1)%%ofrevenue 25% 24% 1% 24% 27% 27%
Amortizationofintangibleassets 49.0 49.2 —% 197.4 221.2 170.7 (11)% 30%%ofrevenue 7% 7% —% 6% 8% 6% Assetimpairment,restructuringandotherspecialcharges 24.9 2.4 938% 128.8 375.1 308.4 (66)% 22%Interestexpense,netofcapitalizedinterest 20.8 — 100% 29.6 — — NM NMOther(income)expense,net 2.6 1.9 NM 41.3 (0.1) (2.8) NM NM
Income(loss)beforetaxes 44.8 77.5 NM 114.1 $ (232.6) $ (22.4) NM NM%ofrevenue 6% 11% (5)% 4% (8)% (1)% NM NM
Incometaxexpense 13.3 4.8 177% 27.6 78.1 25.5 NM NMNetincome(loss) $ 31.5 $ 72.7 NM $ 86.5 $ (310.7) $ (47.9) NM NM
Certainamountsandpercentagesmayreflectroundingadjustments.
TableofContents
Revenue
Onaglobalbasis,Elanco'srevenuewithinElanco'sproductcategorieswasasfollows:
Onaglobalbasis,theeffectofprice,foreignexchangeratesandvolumesonrevenuewasasfollows:
Revenue
Total revenue
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Totalrevenuedecreased$5.1millionor1%forthethreemonthsendedMarch31,2019ascomparedtothethreemonthsendedMarch31,2018,reflectinga2%increaseduetohighervolumeswhichweremorethanoffsetbya3%unfavorableforeignexchangerateimpactandzeroimpactduetoprices.
56
Three Months Ended
March 31, % Change Year Ended December 31, % Change (Dollars in millions) 2019 2018 19/18 2018 2017 2016 18/17 17/16 CADiseasePrevention $ 185.9 201.3 (8)% $ 804.6 $ 660.2 $ 628.4 22% 5%CATherapeutics(a) 81.4 62.3 31% 283.1 260.8 255.6 9% 2%FAFutureProtein&Health 167.2 166.7 —% 711.2 649.2 630.8 10% 3%FARuminants&Swine 274.1 282.5 (3)% 1,174.0 1,175.0 1,309.2 (0)% (10)%Subtotal 708.6 712.8 (1)% 2,972.9 $ 2,745.2 $ 2,824.0 8% (3)%StrategicExits(a) 22.5 23.4 (4)% 93.9 143.8 89.5 (35)% 61%Total $ 731.1 $ 736.2 (1)% $ 3,066.8 $ 2,889.0 $ 2,913.5 6% (1)%
(a) RepresentsrevenuefrombusinessactivitiesthatElancohaseitherexitedormadeastrategicdecisiontoexit.OnJune30,2018,Elancomadethedecisiontoexitanequineproductnotcoretoitsbusiness.RevenuefromthisproductisreflectedinStrategicExitsfortheyearendedDecember31,2018andinCATherapeuticsfortheyearsendedDecember31,2017and2016.Revenuefromthisproductwas$1.6million,$3.4millionand$3.7million,fortheyearsendedDecember31,2018,2017and2016,respectively.
Full year 2018 Revenue Price FX Rate Volume Total CER* (in millions) CADiseasePrevention $ 804.6 8% 0% 14% 22% 22%CATherapeutics 283.1 7% 1% 0% 9% 7%FAFutureProtein&Health 711.2 4% (0)% 6% 10% 10%FARuminants&Swine 1,174.0 (1)% (0)% 1% (0)% (0)%Subtotal $ 2,972.9 3% 0% 5% 8% 8%StrategicExits 93.9 (0)% 0% (34)% (35)% (35)%Total $ 3,066.8 3% 0% 3% 6% 6%
Certainamountsandpercentagesmayreflectroundingadjustments.
* CER=Constantexchangerate
TableofContents
Insummary,thetotalrevenuedecreasewasdueprimarilyto:
• anincreaseinrevenueof$21.4millionor34%fromCATherapeuticsproducts,excludingtheimpactofforeignexchangerates;
• anincreaseinrevenueof$9.0millionor5%fromFAFutureProtein&Healthproducts,excludingtheimpactforeignexchangerates;and
morethanoffsetby:
• adecreaseinrevenueof$12.2millionor6%fromCADiseasePreventionproducts,excludingtheimpactofforeignexchangerates;
• adecreaseinrevenueof$1.3millionfromFARuminants&Swineproducts,excludingtheimpactofforeignexchangerates;
• adecreaseinrevenueof$0.9millionfromStrategicExits,excludingtheimpactofforeignexchangerates;and
• adecreaseinrevenueof$21.2millionduetothenegativeimpactofforeignexchangerates.
Thedetailedchangeinrevenuebyproductcategorywasasfollows:
• CADiseasePreventionrevenuedecreasedby$15.4millionor8%,primarilydrivenbylowervolumeandprice,aswellasunfavorableimpactfromforeignexchangerates.DeclinesinoldergenerationparasiticideproductsandCompanionAnimalvaccineswerepartiallyoffsetbycontinuedgrowthinCredelio,InterceptorPlusandcertainover-the-counterparasiticideproducts.
• CATherapeuticsrevenueincreasedby$19.1millionor31%,drivenbyincreasedvolumeandtoalesserextentprice,partiallyoffsetbytheimpactofforeignexchangerates.TherevenueincreasewasprimarilydrivenbythesalesofGalliprantandAtopica.Inthequarter,backordersofGalliprantinthechannelwereresolvedandtheproductwaslaunchedinseveralEuropeanmarkets.
• FAFutureProtein&Healthrevenuewasflatforthequarter,drivenbybothincreasedvolumeandprice,fullyoffsetbyanunfavorableimpactfromforeignexchangerate.Growthwasdrivenbytheaquaportfolioandpoultryvaccines,offsetbytimingofinternationalpurchasingpatternsforpoultryanimal-onlyantibiotics.
• FARuminants&Swinerevenuedecreasedby$8.4millionor3%withflatvolumenegativelyimpactedbyforeignexchangeratesanddecreasedprice.Excludingtheimpactofforeignexchangerates,theincreaseinrevenueforElanco'sU.S.businessanddecreaseinrevenueforitsinternationalbusinesslargelyoffseteachother.TheU.S.ruminantsbusinessprimarilybenefittedfromthereplenishmentofthechannelforMicotil®afterthestockoutagein2018aswellaspurchasingpatternsforRumensin.Theinternationalbusinesssawsoftnessinswineantibiotics,particularlyinAsiaprimarilydrivenbytheimpactofAfricanSwineFever,continuedimplementationofantimicrobialpoliciesacrosstheregionandproductionrationalizationsalignedwithElanco'sproductivityagenda.
• StrategicExitsrevenuedecreasedby$0.9millionor4%andrepresented3%oftotalrevenue.
2018vs.2017
Totalrevenueincreased$177.8millionor6%in2018ascomparedto2017,reflectinga3%increaseduetohigherrealizedpricesanda3%increaseduetohighervolumes.
57
TableofContents
Insummary,thetotalrevenueincreasewasdueprimarilyto:
• anincreaseinrevenueof$142.1millionor22%fromCADiseasePreventionproducts,excludingtheimpactofforeignexchangerates;
• anincreaseinrevenueof$18.4millionor7%fromCATherapeuticsproducts,excludingtheimpactofforeignexchangerates;
• anincreaseinrevenueof$63.8millionor10%fromFAFutureProtein&Healthproducts,excludingtheimpactofforeignexchangerates;
partiallyoffsetby:
• adecreaseinrevenueof$0.8millionor0%fromFARuminants&Swine,excludingtheimpactofforeignexchangerates;and
• adecreaseinrevenueof$49.9millionor35%fromStrategicExits,excludingtheimpactofforeignexchangerates.
Thedetailedchangeinrevenuebyproductcategorywasasfollows:
• CADiseasePreventionrevenueincreasedby$144.4millionor22%dueprimarilytoareductioninchannelinventoryin2017providingafavorableyear-on-yearcomparison,continueduptakeofCredelio andInterceptor Plus ,aswellasrealizedpriceincreasesprimarilyimpactingTrifexis ,Capstar (afleatreatment)andComfortis ,partiallyoffsetbyvolumedeclinesincertainparasiticides,primarilyTrifexis andComfortis volumes.
• CATherapeuticsrevenueincreasedby$22.3millionor9%dueprimarilytothecontinueduptakeofGalliprant andOsurnia ,aswellasincreaseddemandforOnsior ,partiallyoffsetbyatemporarysupplyshortageofPercorten V usedforthetreatmentofcanineAddison'sDisease.
• FAFutureProtein&Healthrevenueincreasedby$62.0millionor10%dueprimarilytothelaunchofImvixa andthegrowthinpoultryanimal-onlyantibioticsandpoultryvaccines.
• FARuminants&Swinerevenuedecreasedby$1.0milliondueprimarilytocompetitiveheadwindsforractopaminebasedproducts,offsetbygrowthinanimal-onlyantibiotics,primarilyincattle.
• StrategicExitsrevenuedecreasedby$49.9millionor35%dueprimarilytotheterminationofalegacyU.S.distributionagreementinthethirdquarterof2017,partiallyoffsetbyrevenuefromthecontractmanufacturingagreementtosupplyhumangrowthhormonetoLilly.
2017vs.2016
Totalrevenuedecreased$24.5millionor1%in2017ascomparedto2016,duetolowervolumes.
Insummary,thetotalrevenuedecreasewasdueprimarilyto:
• adeclineinrevenueof$133.6millionor10%fromFARuminants&Swineproducts,excludingtheimpactofforeignexchangesrates;and
• adeclineinrevenueof$113.6millionor18%fromCADiseasePreventionproducts,excludingtheimpactofacquisitionandforeignexchangerates;
partiallyoffsetby:
• theacquisitionoftheBIVetmedicaU.S.vaccinesportfoliowhichcontributed$216.7millionin2017;and
58
TableofContents
• anincreaseinrevenueof$18.7millionor3%fromFAFutureProtein&Healthproducts,excludingtheimpactofforeignexchangerates.
Thedetailedchangeinrevenuebyproductcategorywasasfollows:
• CADiseasePreventionrevenueincreasedby$31.8millionor5%.ExcludingproductrevenuefromtheacquisitionoftheBIVetmedicaU.S.vaccinesportfolioandtheimpactofforeignexchangerates,revenuedeclined$113.6millionor18%dueprimarilytocompetitionincertainparasiticides,primarilyimpactingTrifexis andComfortis ,andareductionininventorylevelswithinElanco'sU.S.companionanimaldistributionchannelpartiallyoffsetbythegrowthofInterceptor Plus .
• CATherapeuticsrevenueincreasedby$5.2millionor2%dueprimarilytothelaunchofGalliprant ,partiallyoffsetbyvolumedeclinesfromcompetitioninElanco'sdermatologyportfolio.
• FAFutureProtein&Healthrevenueincreasedby$18.4millionor3%dueprimarilytogrowthinpoultryproducts,includinganimal-onlyantibiotics,enzymesandvaccines,andtoalesserextentaquacultureproducts.
• FARuminants&Swinerevenuedecreasedby$134.2millionor10%dueprimarilytocompetitionfromgenericractopamine-basedproducts,aswellasdeclinesinshared-classantibioticsandareductionininventorylevelswithinElanco'sChinadistributionchannel,partiallyoffsetbygrowthinanimal-onlyantibiotics.
• StrategicExitsrevenueincreasedby$54.3millionor61%dueprimarilytotheacquisitionofatransitionalcontractmanufacturingarrangementatFortDodgeaspartoftheBIVetmedicaU.S.vaccinesportfolioacquisition,partiallyoffsetbytheterminationinthethirdquarterof2017ofalegacyU.S.distributionagreementacquiredaspartofElanco'sNovartisAnimalHealthacquisition.
Costs, Expenses and Other
Cost of sales
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Costofsalesdecreased$16.2millioninthethreemonthsendedMarch31,2019ascomparedtothethreemonthsendedMarch31,2018dueprimarilytomanufacturingproductivityimprovements,partiallyoffsetbytheimpactofforeignexchangerates,unfavorableproductmix,andhigheraffiliatelossesandlogisticscosts.
2018vs.2017
Costofsalesincreased$79.9millionin2018ascomparedto2017primarilydueto:
• increasedvolumeofproductssold;and
• thewrite-offofinventoryrelatedtothesuspensionofactivitiesforImrestor in2018;
partiallyoffsetby:
• non-recurringcostsincurredin2017associatedwithfairvalueadjustmentstoinventoryacquiredintheBIVetmedicaU.S.vaccinesportfolioacquisitionandsubsequentlysold.
59
TableofContents
2017vs.2016
Costofsalesincreased$84.9millionin2017ascomparedto2016dueprimarilyto:
• theadditionofapproximately$134.1millionofcostsin2017relatedtotheacquisitionoftheBIVetmedicaU.S.vaccinesportfolio,including$54.0millionassociatedwithStrategicExitscontractmanufacturingobligationsandapproximately$42.7millioninnon-recurringcostsassociatedwiththeincrementalpurchaseaccountingchargesrelatedtothefairvalueadjustmentstoinventoryacquiredthatwassubsequentlysold;
• anunfavorableproductmixasaresultofdisproportionalrevenuedecreasesofhighermarginproductsprimarilyresultingfromchangingmarketdemandforantibioticsandcompetitionheadwinds;and
• contractualincreasesinthird-partymanufacturingagreements;
partiallyoffsetby:
• operationalefficienciesandcostsavingsassociatedwithmanufacturingfootprintconsolidationandoverallcostreductions.
Research and development
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
R&Dexpensesdecreased$1.1millionforthethreemonthsendedMarch31,2019ascomparedtothethreemonthsendedMarch31,2018primarilydrivenbynormalprojectspendfluctuationsandexternalinnovationmilestonepaymentsinthefirstquarterof2018thatcreatedafavorablecomparison.
2018vs.2017
R&Dexpensesdecreased$5.1millionfor2018ascomparedto2017dueprimarilytocostcontrolmeasuresandtimingofprojectsleadingtolowerspendin2018.
2017vs.2016
R&Dexpensesdecreased$14.1millionin2017ascomparedto2016dueprimarilytosavingsrealizedfromtheconsolidationofacquiredR&Dsitesandoperations,aswellastheterminationofcertainR&Dprojects.ThisdecreasewaspartiallyoffsetbyexpensesincurredinconnectionwiththeacquisitionoftheBIVetmedicaU.S.vaccinesportfolioin2017.
Marketing, selling and administrative
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Marketing,sellingandadministrativeexpensesincreased$1.1millionforthethreemonthsendedMarch31,2019ascomparedtothethreemonthsendedMarch31,2018dueprimarilytoincreasedexpensesasaresultofoperatingasapubliccompany,whichwerepartiallyoffsetbycontinuedproductivityinitiativesandcostcontrolmeasuresacrossthebusiness.
2018vs.2017
Marketing,sellingandadministrativeexpensesdecreased$44.6millionfor2018ascomparedto2017dueprimarilytoproductivityinitiativesinsalesandadministrativefunctionsandreduceddirecttoconsumerprogramscombinedwithnewproductlaunchesin2017.
60
TableofContents
2017vs.2016
Marketing,sellingandadministrativeexpensesdecreased$5.0millionin2017ascomparedto2016dueprimarilytosavingsfromproductivityinitiativesrelatedtosalesforce,marketingandadministrativefunctions,morethanoffsettingtheincreasefromtheacquisitionoftheBIVetmedicaU.S.vaccinesportfolio.
Amortization of intangible assets
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Amortizationofintangibleassetsdecreased$0.2millionforthethreemonthsendedMarch31,2019ascomparedtothethreemonthsendedMarch31,2018duetoanumberofassetsbecomingfullyamortizedduring2018.
2018vs.2017
Amortizationofintangibleassetsdecreased$23.8millionfor2018ascomparedto2017dueprimarilytotheaccelerationofamortizationrelatedtocertainproductexitsin2017.
2017vs.2016
Amortizationofintangibleassetsincreased$50.5millionin2017ascomparedto2016dueprimarilytotheimpactoftheacquisitionoftheBIVetmedicaU.S.vaccinesportfolioand,toalesserextent,theaccelerationofamortizationrelatedtocertainproductexits.
Asset impairment, restructuring and other special charges
ForadditionalinformationregardingElanco'sassetimpairment,restructuringandotherspecialcharges,seeNote7:AssetImpairment,RestructuringandOtherSpecialChargestoElanco'sauditedconsolidatedandcombinedfinancialstatementsandNote6:AssetImpairment,RestructuringandOtherSpecialChargestoElanco'sunauditedconsolidatedandcombinedfinancialstatements.
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Assetimpairment,restructuringandotherspecialchargesincreased$22.5millionforthethreemonthsendedMarch31,2019ascomparedtothethreemonthsendedMarch31,2018primarilyduetointegrationcostsassociatedwiththeimplementationofnewsystems,programs,andprocessesduetotheSeparationfromLilly.
2018vs.2017
Assetimpairment,restructuringandotherspecialchargesdecreased$246.3millionfortheyearendedDecember31,2018ascomparedtotheyearendedDecember31,2017primarilyduetoadecreaseinseverancerelatedtotheU.S.voluntaryearlyretirementprogramofferedin2017aswellasadecreaseinintegrationcostsrelatedtotheacquisitionoftheBIVetmedicaU.S.vaccinesportfolioin2017,partiallyoffsetbyagainonthe2017disposalofasitethatwaspreviouslyclosedaspartoftheacquisitionandintegrationofNovartisAnimalHealth.
2017vs.2016
Assetimpairment,restructuringandotherspecialchargesincreased$66.7millionin2017ascomparedto2016dueprimarilytohigherseverancecostsrecognizedin2017duetotheU.S.voluntaryearlyretirementprogramofferedtoElanco'semployees,partiallyoffsetbylowerintegrationcostsrelatingtoElanco'sacquiredbusinesses.
61
TableofContents
Interest expense, net of capitalized interest
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Interestexpense,netofcapitalizedinterest,was$20.8millionforthethreemonthsendedMarch31,2019duetoElanco'sissuanceofdebtinthethirdquarterof2018.TherewasnointerestexpenseinthethreemonthsendedMarch31,2018.
2018vs.2017
Interestexpensewas$29.6millionfortheyearendedDecember31,2018duetoElanco'sissuanceofdebtinthethirdquarterof2018.Therewasnointerestexpensein2017andprioryears.
Other (income) expense, net
2018vs.2017
Other(income)expense,netwasexpenseof$41.3millionin2018comparedtoincomeof$0.1millionin2017.TheincreaseinexpenseisprimarilyduetotheincreaseintheAratanaTherapeutics,Inc.contingentconsiderationliabilityof$37.6millionassociatedwiththeGalliprant acquisition.
2017vs.2016
Other(income)expense,netwasflatwhencomparing2017to2016withincomeof$0.1millionin2017comparedtoincomeof$2.8millionin2016,adecreaseof$2.7million.
Income tax expense
Elanco'shistoricalincometaxexpensemaynotbeindicativeofitsfutureexpectedtaxrate.See"—ComparabilityofHistoricalResults—Elanco'sRelationshipwithLillyandAdditionalStandaloneCosts."
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Incometaxexpenseincreased$8.5millionforthethreemonthsendedMarch31,2019ascomparedtothethreemonthsendedMarch31,2018primarilyduetothebenefitreceivedinthethreemonthsendedMarch31,2018fromthereleaseofcertainvaluationallowancesrelatedtonetoperatinglossesgeneratedinpriorperiodsofElanco'sseparatecompanyfinancialstatements.SeeNote11:IncomeTaxestoElanco'sunauditedconsolidatedandcombinedfinancialstatementsforfurtherinformation.
2018vs.2017
Incometaxexpensedecreased$50.5millionfortheyearendedDecember31,2018ascomparedtotheyearendedDecember31,2017primarilyduetoadecreaseintheU.S.valuationallowancewhichwasrecordedin2017baseduponthepre-IPOseparatereturnmethodology(seeNote2:BasisofPresentationtoElanco'sconsolidatedandcombinedfinancialstatements).
2017vs.2016
Incometaxexpenseincreased$52.6milliondueprimarilytoanincreaseinunrecognizeddeferredtaxassetsin2017duetoavaluationallowanceandthetaxeffectofassetimpairment,restructuringandotherspecialcharges,partiallyoffsetbyanincometaxbenefitrelatedtoU.S.taxreform.
62
TableofContents
Quarterly Results of Operations
ThefollowingtablespresentElanco'squarterlyresultsfortheyearsendedDecember31,2018,2017and2016.
Liquidity and Capital Resources
Elanco'sprimarysourcesofliquidityarecashonhand,cashflowsfromoperationsandfundsavailableunderitsCreditFacilities.AsasignificantportionofElanco'sbusinessisconductedoutsidetheU.S.,ElancoholdsasignificantportionofcashoutsideoftheU.S.Elancomonitorsandadjuststheamountofforeigncashbasedonprojectedcashflowrequirements.Elanco'sabilitytouseforeigncash
63
First
Quarter Second Quarter
Third Quarter
Fourth Quarter
(In millions, except per share data) 2018: Revenue 736.2 770.2 761.1 799.3Costs,expensesandother(a) 654.4 733.4 656.4 708.8Assetimpairment,restructuringandotherspecialcharges 2.4 68.0 12.4 46.0Netincome(loss) 72.7 (62.8) 60.2 16.4Earnings(loss)pershare:Basicanddiluted 0.25 (0.21) 0.20 0.04Weightedaveragesharesoutstanding:Basicanddiluted(b) 293.3 293.3 301.9 365.6
First
Quarter Second Quarter
Third Quarter
Fourth Quarter
2017: Revenue 704.8 732.8 697.1 754.3Costs,expensesandother(a) 650.8 687.4 684.4 724.0Assetimpairment,restructuringandotherspecialcharges 106.8 58.8 23.7 185.8Netincome(loss) (98.3) (30.2) (20.7) (161.5)Earnings(loss)pershare:Basicanddiluted (0.34) (0.10) (0.07) (0.55)Weightedaveragesharesoutstanding:Basicanddiluted(b) 293.3 293.3 293.3 293.3
First
Quarter Second Quarter
Third Quarter
Fourth Quarter
2016: Revenue 689.2 794.3 648.9 781.1Costs,expensesandother(a) 670.4 693.3 595.7 670.9Assetimpairment,restructuringandotherspecialcharges 130.2 59.8 45.7 72.7Netincome(loss) (117.9) 45.7 6.0 18.3Earnings(loss)pershare:Basicanddiluted (0.40) 0.16 0.02 0.06Weightedaveragesharesoutstanding:Basicanddiluted(b) 293.3 293.3 293.3 293.3
(a) ExcludesAssetimpairment,restructuringandotherspecialcharges;other(income)expense,net;interestexpense,netofcapitalizedinterest;andincometaxexpense.
(b) PriortotheIPO,thisrepresentsanaggregateof293,290,000sharesofElancocommonstockheldbyLilly(whichrepresentsthe100sharesofElancocommonstockheldbyLillypriortogivingeffecttothe2,932,900-for-1stocksplitthatoccurredonSeptember19,2018).InconnectionwiththecompletionoftheIPO,72,335,000additionalsharesofElancocommonstockwereissued.Elancohascalculatedearningspersharebasedon365,625,000sharesofElancocommonstockoutstandingforthefullperiodpost-IPOandweightedaveragefor2018year-to-date.
TableofContents
tofundcashflowrequirementsintheU.S.maybeimpactedbylocalregulationsand,toalesserextent,followingU.S.taxreforms,theincometaxesassociatedwithtransferringcashtotheU.S.See"BusinessofElanco."Elancocurrentlyintendstoindefinitelyreinvestforeignearningsforcontinueduseinitsforeignoperations.AsElanco'sstructureevolvesasastandalonecompany,Elancomaychangethatstrategy,particularlytotheextentitidentifiestaxefficientreinvestmentalternativesforitsforeignearningsorchangeitscashmanagementstrategy.
Elanco'sprincipalliquidityneedsgoingforwardincludefundingexistingmarketedandpipelineproducts,capitalexpenditures,businessdevelopmentinitstargetedareas,interestexpenseandananticipateddividend.
Elancobelievesitscashandcashequivalentsonhand,itsoperatingcashflowsanditsexistingfinancingarrangementswillbesufficienttosupportitscashneedsfortheforeseeablefuture,includingforatleastthenext12months.
Elanco'sabilitytomeetfuturefundingrequirementsmaybeimpactedbymacroeconomic,businessandfinancialvolatility.Asmarketschange,Elancowillcontinuetomonitoritsliquidityposition.However,achallengingeconomicenvironmentoraneconomicdownturnmayimpactElanco'sliquidityorabilitytoobtainfuturefinancing.See"CautionaryStatementConcerningForward-LookingStatements"and"RiskFactors—RisksRelatedtoElanco'sIndebtedness—Elancomaynotbeabletogeneratesufficientcashtoserviceallofitsindebtednessandmaybeforcedtotakeotheractionstosatisfyitsobligationsunderitsindebtedness,whichmaynotbesuccessful."
AsofDecember31,2018,cashandcashequivalentswas$474.8million,anincreaseof$151.4million,comparedto$323.4millionatDecember31,2017.Elancoalsoheld$202.7millionofrestrictedcashatDecember31,2018,whichisavailablesolelytopaytheremainderofthepurchasepriceforElanco'sbusinessestoLilly.ElancohasacorrespondingliabilityrecordedonitsbalancesheetandincludedinPayabletoLilly.SeeElanco'sconsolidatedandcombinedstatementsofcashflowsforadditionaldetailsonthesignificantsourcesandusesofcashfortheyearsendedDecember31,2018andDecember31,2017.
AsofMarch31,2019,cashandcashequivalentswas$272.1million,adecreaseof$202.7million,comparedto$474.8millionatDecember31,2018.Elancoalsoheld$28.5millionofrestrictedcashatMarch31,2019,whichisavailablesolelytopaytheremainderofthepurchasepriceforElanco'sbusinessestoLilly.Elancohasareceivableof$35.5millionduefromLillyrecordedonitsbalancesheetasofMarch31,2019.
Revolving and Term Credit Facilities
OnSeptember5,2018,ElancoenteredintotheRevolvingFacilitywithasyndicateofbanksprovidingforafive-year$750.0millionseniorunsecuredrevolvingcreditfacility.TheRevolvingFacilitybearsinterestatavariablerateplusspecifiedmarginasdefinedintheagreementandispayablequarterly.TherewerenoborrowingsoutstandingundertheRevolvingFacilityatMarch31,2019.TheRevolvingFacilityispayableinfullattheendoftheterm.
OnSeptember5,2018Elancoalsoenteredintothe$500.0millionthree-yearTermFacilitywithasyndicateofbanks.TheTermFacilitybearsinterestatavariablerateplusmarginasdefinedinTermFacility(3.75%atMarch31,2019).Interestispaidmonthly,while1.5%ofprincipalispayablequarterly.TheTermFacilityalsorequiresaquarterlyprincipalpaymentequalto1.5%oftheaggregateinitialprincipallessanyprepayment.TheTermFacilityispayableinfullattheendoftheterm.
TheCreditFacilitiesaresubjecttovariousfinancialandothercovenantsincludingrestrictionsonthelevelofborrowingsbasedonaconsolidatedleverageratioandaconsolidatedinterestcoverageratio.ElancowasincompliancewithallsuchcovenantsasofMarch31,2019.SeeNote8:DebttoElanco'sunauditedconsolidatedandcombinedfinancialstatements.
64
TableofContents
Senior Notes
OnAugust28,2018,Elancoissued$2.0billionofSeniorNotesintheSeniorNotesOffering.TheSeniorNotesarecomprisedof$500.0millionof3.912%SeniorNotesdueAugust27,2021,$750.0millionof4.272%SeniorNotesdueAugust28,2023,and$750.0millionof4.900%SeniorNotesdueAugust28,2028.ElancowasincompliancewithallcovenantsundertheindenturegoverningtheSeniorNotesasofMarch31,2019.Long-termdebtasofDecember31,2017wasnotmaterial.SeeNote9:DebttoElanco'sauditedconsolidatedandcombinedfinancialstatementsandNote8:DebttoElanco'sunauditedconsolidatedandcombinedfinancialstatements.
Capitalexpenditureswere$134.5millionduring2018,anincreaseof$35.9millioncomparedto2017.
Cash Flows
Thefollowingtableprovidesasummaryofcashflowsfromoperating,investingandfinancingactivitiesfortheperiodspresented:
Operating activities
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Elanco'scashprovidedbyoperatingactivitiesdecreasedby$41.4million,from$47.0millionforthethreemonthsendedMarch31,2018to$5.6millionforthethreemonthsendedMarch31,2019.Thedecreaseinoperatingcashflowswasprimarilyattributableto:
• adecreaseinnetincome;
• anincreaseinaccountsreceivable;and
• adecreaseinaccountspayable.
TheimpactoftheaboveitemswaspartiallyoffsetbyanincreaseintheamountduetoLillyforcertainservicesandbackofficefunctionsthataresharedbyElancoandLilly(seeNote15:RelatedPartyAgreementsandTransactionsinElanco'sunauditedconsolidatedandcombinedfinancialstatementsforfurtherdiscussion).
2018vs.2017
Elanco'scashflowfromoperatingactivitiesincreasedby$313.5millionfrom$173.8millionfortheyearendedDecember31,2017to$487.3millionfortheyearendedDecember31,2018.Theincreaseisaresultofanincreaseinnetincome,whichwaspartiallyoffsetbycashusedtofinanceworkingcapital,primarilyfocusedonaccountsreceivableandinventory.
65
Three Months Ended
March 31, % Change Year Ended December 31, % Change (Dollars in millions) 2019 2018 19/18 2018 2017 2016 18/17 17/16 Netcashprovidedby/(usedin): Operatingactivities $ 5.6 $ 47.0 (88)% $ 487.3 $ 173.8 $ 155.9 180% 11%Investingactivities (28.5) (34.4) (17)% (127.0) (964.6) (182.1) (87)% 430%Financingactivities (339.5) (76.5) 344% (35.2) 847.5 (149.6) (104)% (667)%
Effectofexchange-ratechangesoncashandcashequivalents (14.5) 3.9 (472)% 29.0 7.9 (26.0) 267% (130)%Netincreaseincash,cashequivalentsandrestrictedcash $ (376.9) $ (60.0) 528% $ 354.1 $ 64.6 $ (201.8) 448% (132)%
TableofContents
2017vs.2016
Elanco'snetcashprovidedbyoperatingactivitieswas$173.8millionin2017ascomparedtocashprovidedbyoperatingactivitiesof$155.9millionin2016.Thisincreaseinoperatingcashflowswasprimarilyattributableto:
• adecreaseinreceivablesin2017ascomparedtoanincreasein2016duetoaone-timeimpactofstandardizingpaymenttermsacrossElanco'sacquiredbusinessesaswellaspaymentreceipttimingduetointegrationofacquiredassets;
• adecreaseinotherassetsin2017ascomparedtoanincreasein2016primarilyduetothetimingoftaxpayments;and
• asmallerincreaseininventorylevelsin2017ascomparedto2016;
partiallyoffsetby:
• increasednetlosses.
Investing activities
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Elanco'scashusedforinvestingactivitiesdecreased$5.9million,to$(28.5)millionforthethreemonthsendedMarch31,2019comparedto$(34.4)millionforthethreemonthsendedMarch31,2018.Thechangewasprimarilydrivenbyadecreaseincapitalexpendituresfrom2018to2019.
2018vs.2017
Elanco'scashflowusedininvestingactivitiesdecreasedfrom$964.6millionfortheyearendedDecember31,2017to$127.0millionfortheyearendedDecember31,2018.Elanco'snetcashusedininvestingactivitiesfortheyearendedDecember31,2017included$882.1millionrelatedtotheacquisitionoftheBIVetmedicaU.S.vaccinesportfolioin2017.Thisdecreasewasoffsetbyanetincreaseof$35.9millionincapitalexpendituresfrom2017to2018.
2017vs.2016
Elanco'snetcashusedininvestingactivitieswas$964.6millionin2017ascomparedtocashusedininvestingactivitiesof$182.1millionin2016.ThisincreaseinnetcashflowsusedininvestingactivitieswasprimarilyattributabletotheacquisitionoftheBIVetmedicaU.S.vaccinesportfolioin2017.
Financing activities
ThreemonthsendedMarch31,2019vs.threemonthsendedMarch31,2018
Elanco'scashusedforfinancingactivitiesincreased$263.0million,from$76.5millionforthethreemonthsendedMarch31,2018to$339.5millionforthethreemonthsendedMarch31,2019.Theincreasewasprimarilyattributableto$174.2millionofrestrictedcashpaidtoLillyinconnectionwiththeSeparationduringthethreemonthsendedMarch31,2019andotherfinancingwithLillyduringtheperiod.
AspartofElanco'sseparationfromLilly,foraperiodoftime,Elancocontinuestooperatethroughasingletreasurysettlementprocessandincertaininstances(asdescribedabove)continuedtotransactthroughLilly'sprocesses.Asaresultoftheseactivities,therewasacertainamountoffinancingthatoccurredbetweenLillyandElancoduringthethree-monthperiodendedMarch31,
66
TableofContents
2019.Thisresultedinanetfinancingcashoutflowduringtheperiodof$156.4million,whichwillberepaidtoElancointhesecondquarterof2019.
2018vs.2017
Elanco'scashfromfinancingactivitieswasauseofcashof$35.2millionin2018comparedtocashprovidedbyfinancingactivitiesof$847.5millionin2017,achangeof$882.7million.Thecashflowsin2017relatetonetcashprovidedbytransactionswithLillyof$848.3millioncomparedtocashusedintransactionswithLillyof$154.4millionin2018,areductioninfinancingofcashflowsbetweenperiodsof$1.0billion.This,inadditiontotheconsiderationpaidtoLillyinconnectionwiththeseparation,waspartiallyoffsetbynetcashprovidedfromfinancingtransactionsrelatedtotheseparationincludingtheproceedsfromlong-termdebtandtheIPO.TheremainderoftheproceedsfromthefinancingrelatedtotheseparationwillbepaidtoLillyinfutureperiodsandisreflectedasrestrictedcashinElanco'sconsolidatedbalancesheet.
2017vs.2016
Elanco'snetcashprovidedbyfinancingactivitieswas$847.5millionin2017ascomparedtocashusedinfinancingactivitiesof$149.6millionin2016.ThisincreaseinnetcashprovidedwasprimarilyattributabletofinancingprovidedbyLillyfortheacquisitionoftheBIVetmedicaU.S.vaccinesportfolioin2017.
Contractual Obligations
PaymentsdueundercontractualobligationsasofDecember31,2018,aresetforthbelow:
Off-Balance Sheet Arrangements
Elancohasnooff-balancesheetarrangementsthathaveamaterialcurrenteffectorthatarereasonablylikelytohaveamaterialfutureeffectonElanco'sfinancialcondition,changesinfinancialcondition,revenueorexpenses,resultsofoperations,liquidity,capitalexpendituresorcapitalresources.
Critical Accounting Policies
ThepreparationoffinancialstatementsinaccordancewithU.S.GAAPrequiresElancotomakeestimatesandjudgmentsthataffectthereportedamountsofassets,liabilities,revenuesandexpenses.CertainofElanco'saccountingpoliciesareconsideredcriticalbecausethesepoliciesarethemostimportanttothedepictionofElanco'sfinancialstatementsandrequiresignificant,difficultorcomplexjudgmentsbyElanco,oftenrequiringtheuseofestimatesabouttheeffectsofmattersthatare
67
Years
(Dollars in millions) Total (2) Less Than
1 Year 1 - 3 Years 4 - 5 Years More Than
5 Years Long-termdebtobligations $ 2,958.4 $ 79.9 $ 1,137.9 $ 829.7 $ 910.9Operatingleases 95.6 25.2 33.6 18.3 18.5Purchaseobligations(1) 1,207.9 1,108.9 42.8 39.8 16.4Otherlong-termliabilities 12.3 0.5 10.8 0.1 0.9Total $ 4,274.2 $ 1,214.5 $ 1,225.1 $ 887.9 $ 946.7
(1) RepresentsopenpurchaseordersasofDecember31,2018andcontractualpaymentobligationswitheachofElanco'ssignificantvendorsthatarenoncancelableandarenotcontingent.
(2) Elancoexcludeddeferredtaxesbecauseitcannotreasonablyestimatethetimingoffuturecashoutflowsassociatedwiththoseliabilities.
TableofContents
inherentlyuncertain.ActualresultsthatdifferfromElanco'sestimatescouldhaveanunfavorableeffectonElanco'sfinancialpositionandresultsofoperations.Elancoappliesestimationmethodologiesconsistentlyfromyeartoyear.TherehavebeennosignificantchangesintheapplicationofElanco'scriticalaccountingpoliciesduringthethreemonthsendedMarch31,2019,asidefromitsadoptionofASC842,Leases ,onJanuary1,2019.SeeNote10:LeasesinElanco'sunauditedconsolidatedandcombinedfinancialstatementsforfurtherinformation.ThefollowingisasummaryofaccountingpoliciesthatElancoconsiderscriticaltotheconsolidatedandcombinedfinancialstatements.
Revenue Recognition
Elanco'sgrossproductrevenueissubjecttodeductionsthataregenerallyestimatedandrecordedinthesameperiodthattherevenueisrecognizedandprimarilyrepresentsrevenueincentives(rebatesanddiscounts)andsalesreturns.Forexample:
• forrevenueincentives,Elancousesitshistoricalexperiencewithsimilarincentivesprogramsandcurrentsalesdatatoestimatetheimpactofsuchprogramsonrevenueandcontinuallymonitortheimpactofthisexperienceandadjustasnecessary;and
• forsalesreturns,Elancoconsidersitemssuchas:localreturnspoliciesandpractices;returnsasapercentageofrevenue;anunderstandingofthereasonsforpastreturns;estimatedshelflifebyproduct;andestimateoftheamountoftimebetweenshipmentandreturntoestimatetheimpactofsalesreturns.
Ifanyoftheseratios,factors,assessments,experiencesorjudgmentsarenotindicativeoraccuratepredictorsofElanco'sfutureexperience,Elanco'sresultscouldbemateriallyaffected.
Althoughtheamountsrecordedfortheserevenuedeductionsaredependentonestimatesandassumptions,historicallyElanco'sadjustmentstoactualresultshavenotbeenmaterial.ThesensitivityofElanco'sestimatescanvarybyprogram,typeofcustomerandgeographiclocation.Amountsrecordedforrevenuedeductionscanresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesandcanrelyonestimatesandassumptions.
Acquisitions and Fair Value
Elancoaccountsfortheassetsacquiredandliabilitiesassumedinanacquisitionbasedonthefairvaluesasoftheacquisitiondate.Theexcessofthepurchasepriceoverthefairvalueoftheacquirednetassets,whereapplicable,isrecordedasgoodwill.
Thejudgmentsmadeindeterminingestimatedfairvaluesassignedtoassetsacquiredandliabilitiesassumedinabusinesscombination,aswellasestimatedassetlives,canmateriallyaffectElanco'sconsolidatedresultsofoperations.Thefairvaluesofintangibleassetsarere-determinedusinginformationavailableneartheacquisitiondatebasedonexpectationsandassumptionsthataredeemedreasonablebyElanco'smanagement.Dependingonthefactsandcircumstances,Elancomaydeemitnecessarytoengageanindependentvaluationexperttoassistinvaluingsignificantassetsandliabilities.
Thefairvalueofanycontingentconsiderationliabilitythatresultsfromabusinesscombinationisdeterminedusingamarketapproachbasedonquotedmarketvalues,significantotherobservableinputsforidenticalorcomparableassetsorliabilities,oradiscountedcashflowanalysis.Estimatingthefairvalueofcontingentconsiderationrequirestheuseofsignificantestimatesandjudgments,including,butnotlimitedto,revenueandthediscountrateandwillberemeasuredeveryreportingperiod.
Impairment of Indefinite-Lived and Long-Lived Assets
Elancoreviewsthecarryingvalueoflong-livedassets(bothintangibleandtangible)forpotentialimpairmentonaperiodicbasisandwhenevereventsorchangesincircumstancesindicatethecarrying
68
TableofContents
valueofanasset(orassetgroup)maynotberecoverable.Elancoidentifiesimpairmentbycomparingtheprojectedundiscountedcashflowstobegeneratedbytheasset(orassetgroup)toitscarryingvalue.Ifanimpairmentisidentified,alossisrecordedequaltotheexcessoftheasset'snetbookvalueoveritsfairvalueutilizingadiscountedcashflowanalysis,andthecostbasisisadjusted.
Goodwillandindefinite-livedintangibleassetsarereviewedforimpairmentatleastannuallyandwhencertainimpairmentindicatorsarepresent.Whenrequired,acomparisonoffairvaluetothecarryingamountofassetsisperformedtodeterminetheamountofanyimpairment.
TheestimatedcashflowsandfairvaluesusedinElanco'simpairmentreviewsrequiresignificantjudgmentwithrespecttofuturevolume;useofworkingcapital;foreigncurrencyexchangerates;theselectionofappropriatediscountrates;productmix;incometaxratesandotherassumptionsandestimates.SuchestimatesandassumptionsaredeterminedbaseduponElanco'sbusinessplansandwhenapplicable,marketparticipants'viewsofElancoandothersimilarcompanies.ElancomakesthesejudgmentsbasedonElanco'shistoricalexperience,relevantmarketsize,historicalpricingofsimilarproductsandexpectedindustrytrends.Theseassumptionsaresubjecttochangeinfutureperiodsbecauseof,amongotherthings,additionalinformation,financialinformationbasedonfurtherhistoricalexperience,changesincompetition,Elanco'sinvestmentdecisions,volatilityinforeigncurrencyexchangerates,andresultsofresearchanddevelopment.Achangeintheseassumptionsortheuseofalternativeestimatesandassumptionscouldhaveasignificantimpactontheestimatedfairvaluesoftheassets,andmayresultinanimpairmentoftheexistingassetsinafutureperiod.
DuringtheyearsendedDecember31,2018,2017and2016,Elancorecordedassetimpairmentsof$81.9million,$110.6millionand$98.3million,respectively,duetochangesinestimatesorjudgmentsrelatedtotheuseoftheassets.FormoreinformationrelatedtoElanco'simpairmentcharges,seeNote7:AssetImpairment,RestructuringandOtherSpecialChargestoElanco'sconsolidatedandcombinedfinancialstatements.
DuringthethreemonthsendedMarch31,2019,Elancorecordedanassetimpairmentof$4.0millionwhichresultedfromtheadjustmenttofairvalueofintangibleassetsthatweresubjecttoproductrationalization.
Deferred Tax Asset Valuation Allowances
Elancomaintainsvaluationallowancesunlessitismorelikelythannotthatalloraportionofthedeferredtaxassetwillberealized.ChangesinvaluationallowancesareincludedinElanco'staxprovisionintheperiodofchange.Indeterminingwhetheravaluationallowanceiswarranted,Elancoevaluatesfactorssuchaspriorearningshistory,expectedfutureearnings,carrybackandcarryforwardperiods,andtaxstrategiesthatcouldpotentiallyenhancethelikelihoodofrealizationofadeferredtaxasset.Therealizabilityassessmentsmadeatagivenbalancesheetdatearesubjecttochangeinthefuture,particularlyifearningsofasubsidiaryaresignificantlyhigherorlowerthanexpected,orifElancotakesoperationalortaxplanningactionsthatcouldimpactthefuturetaxableearningsofasubsidiary.AchangeintheseassumptionsmayresultinanincreaseordecreaseintherealizabilityofElanco'sexistingdeferredtaxassets,andthereforeachangeinthevaluationallowance,infutureperiods.AsofDecember31,2018and2017,Elancohadvaluationallowancesof$21.4millionand$127.7million,respectively.
AsofMarch31,2019,Elancohadavaluationallowanceof$19.8million.
Qualitative and Quantitative Disclosures About Market Risk
Foreign Exchange Risk
Elancooperatesonaglobalbasisandisexposedtotheriskthatitsearnings,cashflowsandequitycouldbeadverselyimpactedbyfluctuationsinforeignexchangerates.Elancoisprimarilyexposedto
69
TableofContents
foreignexchangeriskwithrespecttonetassetsdenominatedintheeuro,Britishpound,Canadiandollar,AustraliandollarandBrazilianreal.Lillymaintainsaforeigncurrencyriskmanagementprogramthroughacentralsharedentity,whichentersintoderivativecontractstohedgeforeigncurrencyriskassociatedwithforecastedtransactionsfortheentirecompany,includinghistoricallyforElanco'soperations.GainsandlossesonderivativecontractsenteredintobyLillyhavebeenallocatedtoElanco'sresultstotheextenttheyweretocoverexposurerelatedtoElanco'sbusinessandoffsetgainsandlossesonunderlyingforeigncurrencyexposures.Elancointendstoimplementitsownforeigncurrencyriskmanagementprogrambytheendofthesecondquarterof2019.
ElancoalsofacescurrencyexposurethatarisesfromtranslatingtheresultsofitsglobaloperationstotheU.S.dollaratexchangeratesthathavefluctuatedfromthebeginningoftheperiod.Elancomayenterintoforeigncurrencyforwardoroptionderivativecontractstoreducetheeffectoffluctuatingcurrencyexchangeratesinfutureperiods,butitshistoricalresultsdonotreflecttheimpactofanysuchderivativesrelatedtoitsexposuretoforeigncurrencyimpactsontranslation.
Elancoestimatesthatahypothetical10%adversemovementinallforeigncurrencyexchangeratesrelatedtothetranslationoftheresultsofElanco'sforeignoperationswoulddecreaseitsnetincomebyapproximately$11.9millionforthethreemonthsendedMarch31,2019.
Elancoalsobearsforeignexchangeriskassociatedwiththefuturecashsettlementofanexistingnetinvestmenthedge.InOctober2018,Elancoenteredintoafixedinterestrate,5-year,750millionSwissfrancNIHagainstSwissfrancassets.TheNIHisexpectedtogenerateapproximately$25millionincashandcontrainterestexpenseperyear;however,thereispotentialforsignificant2023settlementexposureonthe750millionSwissfrancnotionaliftheU.S.dollardevaluesversustheSwissfranc.
Interest Risk
Elancoisexposedtointerestrateriskonthelong-termdebtElancoincurredinconnectionwithitsIPO.PriortotheIPO,Elancodidnothaveanyinterestrateexposure.Elancohascashflowriskassociatedwithits$485.0millionofborrowingsthatpayinterestbasedonvariablerates.Elancoactivelymonitorsitsexposureandmayenterintofinancialinstrumentsforthepurposeoflimitingitsexposurebasedonitsassessmentofrisk.
Recently Issued Accounting Pronouncements
FordiscussionofElanco'snewaccountingstandards,seeNote4:SummaryofSignificantAccountingPolicies—ImplementationofNewFinancialAccountingPronouncementstoElanco'sauditedconsolidatedandcombinedfinancialstatementsandNote4:ImplementationofNewFinancialAccountingPronouncementstoElanco'sunauditedconsolidatedandcombinedfinancialstatements.
70
TableofContents
INDUSTRY
Overview
GlobalanimalhealthindustryrevenueisprojectedtogrownominallyataCAGRof5%from2017to2023,accordingtoVetnosis.Importantly,thisgrowingindustry,whichincludesbothfoodandcompanionanimals,benefitsbillionsofpeopleworldwide.Thefoodanimalsectorfocusesonspeciesraisedtoprovideanimalprotein,suchascattle,otherruminants(e.g.,sheepandgoats),swine,poultryandaqua.Thecompanionanimal—orpet—sectorfocusesprimarilyondogsandcats.
Animalhealthmedicines,vaccinesandfunctionalnutritionalsrepresentanestimatedglobalmarketof$34.3billion,basedon2017revenue,accordingtoindustrysources.Medicinesandvaccinesrepresentaglobalmarketof$32.0billion,basedon2017revenue,andgrewataCAGRof4%from2007to2017,accordingtoVetnosis.Elanco'smanagementexpectsthistrendtocontinuethroughatleast2023basedonindustryprojections.Functionalnutritionals(specificallyenzymes,probioticsandprebiotics)usedinfoodanimalproductionrepresentaglobalmarketof$2.3billion,accordingtoindustrysources.Basedonindustryprojections,Elanco'smanagementexpectsfunctionalnutritionalstogrowfasterthanthemedicinesandvaccinesmarket.
Food Animal. Foodanimalmedicinesandvaccines,includingaquaculture,represented$21.2billionofrevenuein2017andgrewataCAGRof4%from2007to2017,accordingtoVetnosis.
Factorsinfluencinggrowthindemandforfoodanimalmedicinesandvaccinesinclude:
• oneinthreepeopleneedsimprovednutrition;
• increasedglobaldemandforprotein,particularlypoultryandaquaculture;
• naturalresourceconstraints,suchasscarcityofarableland,freshwaterandincreasedcompetitionforcultivatedland,drivingtheneedformoreefficientfoodproduction;
• lossofproductivityduetofoodanimaldiseaseanddeath;
• increasedfocusonfoodsafetyandfoodsecurity;and
• humanpopulationgrowth,increasedstandardsofliving,particularlyinmanyemergingmarkets,andincreasedurbanization.
Functionalnutritionalsusedinfoodanimalproductionrepresentanadditionalmarketestimatedat$2.3billion.Growthinfunctionalnutritionalsisinfluenced,amongotherfactors,bydemandforantibioticalternativesthatcanpromoteanimalhealthandincreaseproductivity.
Companion Animal. Companionanimalmedicinesandvaccinesrepresented$10.8billionofrevenuein2017andgrewataCAGRof4%from2007to2017,accordingtoVetnosis.
Factorsinfluencinggrowthindemandforcompanionanimalmedicinesandvaccinesinclude:
• increasedpetownershipglobally;
• petslivinglonger;and
• increasedpetspendingaspetsareviewedasmembersofthefamilybyowners.
Food Animal Sector
Food Animal Growth Drivers
Theglobalfoodanimalsectorisprimarilyfocusedontheproductionofcattle(bothdairyandbeef),otherruminants,swine,poultryandfish.Theseanimalsarethebasisformostoftheworldwideconsumptionofanimal-basedprotein.
71
TableofContents
Animalproteinnowconstitutesalargerpercentageoftheaveragehumandietthaneverbefore.Annualmeatproductionwouldneedtoriseby74%,orover200milliontons,toreach470milliontonsby2050tomeetexpectedglobaldemand.Thegrowthinanimalproteinconsumptionisbeinginfluencedinpartbyagrowingmiddleclassindevelopingcountries,theglobalindustrializationoffoodanimalproductionandeasieraccesstosafeandaffordablemeatproducts.Withbillionsofpeoplecurrentlyreceivinginsufficientdailynutrition,Elancoexpectsthedemandforfoodanimalproteintocontinuetorisetoaddressthisunmetneed.
Tomeetthegrowingdemandforanimalprotein,additionaloutputisnecessary.Simplyaddinglivestockstrainstheenvironmentandresultsintheoveruseofnaturalresources.Inordertomeettheincreaseddemandforanimalprotein,producersareincreasinglylookingforwaystodriveefficiencyandpromoteanimalhealththroughtheuseofmedicinesandvaccines.
Industrysourcesestimatethat20%ofproductionanimalsarelosttodiseaseanddeath.Byimprovinghealthandloweringmortalityratesoffoodanimals—predominantlybyactivelypreventingcommonparasites,diseasesandviruses—producersareabletoincreaseproductionyieldsandpromotemoreefficientfeeding.Elancobelievesmostfoodproducersfindthatthepositiveimpactofthesetherapiesoutweighstheirprice,especiallyastheyrepresentasmallportionofthetotalcostofproduction.Consequently,Elancoexpectsthatuseofthesetreatmentswillcontinue.
Food Animal Product Categories
Foodanimalmedicines,vaccinesandfunctionalnutritionalsaredividedintotwomaincategories:FARuminants&SwineandFAFutureProtein&Health.
FA Ruminants & Swine
Ruminantsandswine,whichiscomprisedofbeefanddairycattle,sheep,goatsandpigs,constitutedapproximatelythreequartersofthefoodanimalsectorrevenuebyspeciesin2017,representinganestimated$15.5billionofrevenue,accordingtoVetnosis.Ruminantsandswineareimportantsourcesofanimalproteinthroughouttheworld,andElancobelievesitwillcontinuetobeamaterialcategorygoingforward.Managementbelievesthiscategorywillcontinuetogrow,albeitataslowerpacethanFAFutureProtein&Health,andthatmedicinesandvaccineswillcontinuetoplayaprominentroleinthehealthandproductivityoffoodanimals.
FA Future Protein & Health (Poultry, Aquaculture and Functional Nutritionals)
Poultryandfishareamongthefastestgrowingproteinsinthefoodanimalsector.Therapidgrowthoftheseproteinsisexpectedtocontinue.
Fishisthefastestgrowinganimalproteinglobally.Aquaculture—thefarmingofaquaticorganismssuchasfishandcrustaceans—remainsanimmaturemarketwherelowproductionyieldsandhighcostsduetomortalityandbiologicalchallengeshavelimitedmarketgrowth.Thesefactorshaveledtoincreasedexpendituresonaquaculture-specificanimalhealthproducts.
Theuseoffunctionalnutritionalstopromoteanimalhealthandimmunityisanotherpathtohelpproducersmaximizeanimalproductionefficiencyandlimituseofantibiotics.Enzymes,prebioticsandprobioticsarebeingstudiedandusedacrossfoodanimalspeciestoday.Enzymesinanimalfeedacttoimprovefeeddigestibilityandreducegutinflammation,improvingnutrientabsorptionandreducingcostforproducers.Prebioticsarenon-digestiblefunctionalingredientsfermentedinthelargecolonthatfeedthebeneficialbacteriaintheanimal'sgutandsupportmicrobiomehealth.Probioticsarelivebacteriaaddedtofeedinordertomanagethemicrobiomeandpreventinfections.Thiscategoryisexpectedtogrowfasterthanthefoodanimalmedicinesandvaccinesmarket.TheFAFutureProtein&Healthmarketrepresentedanestimated$7.9billionofrevenuein2017.
72
TableofContents
Companion Animal Sector
Companion Animal Growth Drivers
Petsarebecomingalargerpartoftheaveragefamilydynamicandareincreasinglyviewedas"membersofthefamily."ThenumberofpetsownedintheU.S.hasincreasedinrecentyears,andin2017,68%ofallU.S.householdsownedapet.Withpetslivinglonger,consumersarespendingmoredisposableincometogivetheir"familymember"ahealthier,morecomfortablelife.Mostveterinaryexpendituresarepaidoutofpocket.Evenintimesofrecession,petownersarelesssensitivetotheoverallpriceofpetcarethantootheraspectsoftheirlifestyle.Asnewinnovationsemerge,petownersnowhaveagreaterabilitytoextendthelifeoftheirpetbytreatingchronicdiseasesandailmentsassociatedwitholdage.
TheU.S.petownershiptrendisbeingechoedinotherpartsoftheworld.OutsidetheU.S.,thenumberofdogsandcatsreceivinghealthcareisgrowingwiththeincreasingmiddleclass.Inemergingmarkets,from2003to2016,catanddogpetownershipgrewbyapproximately50%.
Companion Animal Product Categories
Companionanimalmedicinesandvaccinesaredividedintotwomaincategories:CADiseasePreventionandCATherapeutics.
CA Disease Prevention
CADiseasePreventionconsistsprimarilyofparasiticides,whichpredominantlytargetfleas,ticks,heartworms,roundworms,hookworms,whipwormsandtapeworms;andvaccines,whichtargetrabies,rhinotracheitis,felineleukemia,hepatitis,parainfluenzaandotherconditions.Aspetownersbecomeincreasinglywillingtospendmoneyontheirpets,theyareextendingthelivesandqualityoflifeoftheirpetsthroughpreventativecare,mirroringhumanhealthtrends.Preventionoffleas,ticks,wormsandotherparasites,aswellasvaccinationagainstinfection,havebecomewidelyadoptedbyconsumers.TheCADiseasePreventionmarketrepresentedanestimated$6.4billionofrevenuein2017.
CA Therapeutics
CATherapeuticsconsistsofproductsusedtotreatormanagechronicdiseaseinpets.Examplesincludeproductsforpain,inflammation,arthritis,cardiovascularissues,otitis(earinfections),dermatologyconditions,diabetesandmanyothers.Thesetherapies,whichofferahigherqualityoflifeforpets,aregrowing,drivenbyinnovationinnewmoleculesandimproveddeliveryformulations.Aspetslivelongerandowners'willingnesstoprovidethemwithmedicaltreatmentstrengthens,innovationhasfurtherexpandedwiththerapiesinfluencedbyhumanhealth,offeringthepotentialfordevelopmentofnewanimalhealthmedicinesandcapabilities.TheCATherapeuticsmarketrepresentedanestimated$4.4billioninrevenuein2017.
Key Structural Characteristics of the Animal Health Industry
• Brands often have long, sustainable value. Brandedanimalhealthproductsoftenretainsignificant,andoccasionallyincreased,marketshareaftermanyyearsonthemarket,evenafterthelossofpatentprotection.Asanexample,fiveofElanco'stop10products,basedon2018revenue,havebeenonthemarketforover25years.Inthefoodanimalsector,thelevelofcompetitionisinfluencedbymacro-economicfactors,brandloyalty,distributionmodelsandtheabsenceofgovernmentalorthird-partypayersystems.Inthecompanionanimalsector,competitionisinfluencedbybrandloyalty,newinnovation,relationshipswithveterinarians,channelexpansionandtheoverallgrowthinpetownership.
73
TableofContents
• Diversified product portfolios. Animalhealthcompaniesoftenderivetheirrevenuefromdozens,ifnothundreds,ofproductsandarefrequentlynotdependentonaselectfewflagshipproducts.Forexample,Elanco'stop10productsaccountedforonly42%ofrevenuein2018.Elancobelievescompanieswithdiversifiedglobalcompanionandfoodanimalproductportfolioscanbemoreresilienttochangingmarketdynamicsandarestructuredtobetterbalancepotentialgeographic,productandspeciesvolatility.
• Deep customer relationships. Directcustomermodelsallowanimalhealthsalesrepresentativesandveterinaryconsultantstodevelopadeepunderstandingofcustomerneeds,whichoftenfacilitatestrongandimpactfulrelationships.Representativesandconsultantsfrequentlypartnerwithcustomersthroughproductsupportandanalytics,drivingadditionalvalueforthecustomer.
• Fast and efficient R&D model. Productapprovalstypicallyrequirealimitednumberoftargetedstudiesinanimals,whichmoderatesresearchexpenses.Theapprovalprocessisgenerallypredictablegiventhenumberofstudiesrequired,leadingtoaveragetimelinesfrominitiationofdevelopmenttoapprovalofthreetosevenyearsatacostof$50millionto$100million.
• Self-pay market. Foodanimalproducers,petownersandveterinarianstypicallypayforproductsoutofpocket,makingthemtheprimarydecisionmakers.Thisresultsinmanufacturersbeingabletopriceproductsbasedprimarilyontheendcustomer'srealizedvalue.
74
TableofContents
BUSINESS
Overview
Elancoisapremieranimalhealthcompanythatinnovates,develops,manufacturesandmarketsproductsforcompanionandfoodanimals.HeadquarteredinGreenfield,Indiana,Elancoisthefourthlargestanimalhealthcompanyintheworld,withrevenueof$3.1billionfortheyearendedDecember31,2018.Globally,Elancois#1inmedicinalfeedadditives,#2inpoultryand#3incattle,measuredby2017revenue,accordingtoVetnosis.Elancoalsohasoneofthebroadestportfoliosofpetparasiticidesinthecompanionanimalsector.Elancooffersadiverseportfolioofmorethan125brandsthatmakeitatrustedpartnertoveterinariansandfoodanimalproducersinmorethan90countries.
OnSeptember24,2018,theIPOwascompleted,pursuanttowhichElancoissuedandsold19.8%ofElanco'stotaloutstandingshares.OnSeptember20,2018,ElancocommonstockbegantradingontheNYSEunderthesymbol"ELAN."OnSeptember24,2018,immediatelyprecedingthecompletionoftheIPO,LillytransferredtoElancosubstantiallyallofitsanimalhealthbusinessesinexchangefor(i)allofthenetproceeds($1,659.7million)ElancoreceivedfromthesaleofElancocommonstockintheIPO,includingthenetproceedsitreceivedasaresultoftheexerciseinfulloftheunderwriters'optiontopurchaseadditionalshares,(ii)allofthenetproceeds(approximately$2,000million)ElancoreceivedintheSeniorNotesOfferingand(iii)allofthenetproceeds($498.6million)ElancoreceivedfromtheentryintotheTermFacility.
OnMarch11,2019,Lillycompletedthedispositionofitsremaininginterestinusthroughatax-freeexchangeofferpursuanttowhichittransferreditsremainingholdingsinustoitsshareholdersinexchangeforsharesofLillycommonstock.Werefertothistransactioninthisprospectusasthe"Split-Off."FollowingtheSplit-Off,Lillynolongerownsanysharesinus,andweareanindependentpubliclytradingcompany.
Inaddition,immediatelypriortothecompletionoftheIPO,ElancoandLillyenteredintocertainagreementsthatprovideaframeworkforElanco'songoingrelationshipwithLilly,whichagreementsremainineffectfollowingthecompletionoftheSplit-Off.Formoreinformation,see"CertainRelationshipsandRelatedPartyTransactions—RelationshipbetweenElancoandLilly."
Elanco'svisionistoenrichthelivesofpeoplethroughfood—makingproteinmoreaccessibleandaffordable—andthroughpetcompanionship—helpingpetslivelonger,healthierlives.Elancoadvancesitsvisionbyofferingproductsinfourprimarycategories:
• Companion Animal Disease Prevention ("CA Disease Prevention"). Elancohasoneofthebroadestparasiticideportfoliosinthecompanionanimalsectorbasedonindications,speciesandformulations,withproductsthatprotectpetsfromworms,fleasandticks.Combiningitsparasiticideportfoliowithitsvaccinespresence,ElancoisaleaderintheU.S.inthediseasepreventioncategorybasedonshareofrevenue.
• Companion Animal Therapeutics ("CA Therapeutics"). Elancohasabroadpainandosteoarthritisportfolioacrossspecies,modesofaction,indicationsanddiseasestages.Petownersareincreasinglytreatingosteoarthritisintheirpets,andElanco'sGalliprant productisoneofthefastestgrowingosteoarthritistreatmentsintheU.S.Elancoalsohastreatmentsforotitis(earinfections),aswellascardiovascularanddermatologyindications.
• Food Animal Future Protein & Health ("FA Future Protein & Health"). Elanco'sportfoliointhiscategory,whichincludesvaccines,nutritionalenzymesandanimal-onlyantibiotics,servesthegrowingdemandforproteinandincludesinnovativeproductsinpoultryandaquacultureproduction,wheredemandforanimalhealthproductsisoutpacingoverallindustrygrowth.Elancoisfocusedondevelopingfunctionalnutritionalhealthproductsthatpromotefoodanimal
75
TableofContents
health,includingenzymes,probioticsandprebiotics.Elancoisaleaderinprovidingvaccinesasalternativestoantibioticstopromoteanimalhealthbasedonshareofrevenue.
• Food Animal Ruminants & Swine ("FA Ruminants & Swine"). Elancohasdevelopedarangeoffoodanimalproductsusedextensivelyinruminant(e.g.,cattle,sheepandgoats)andswineproduction.
Elancohasatopfourpresenceinallfourkeyindustrygeographicregions:NorthAmerica("NA");Europe,theMiddleEastandAfrica("EMEA");LatinAmerica("LATAM");andAsia-Pacific("APAC"),asmeasuredby2017revenue,accordingtoVetnosis.ThefollowinggraphsdemonstrateElanco'srevenuefortheyearendedDecember31,2018byproductcategory,geographyanditshighestrevenueproducts:
Percentage of 2018 Revenue By Product Category (1)
(1) Certainpercentagesmayreflectroundingadjustments.
(2) StrategicExitsincludesrevenuefromthird-partymanufacturing,distributionandothercontractualarrangements,aswellasanequineproductnotcoretoElanco'sbusinessandtransitionalcontractmanufacturingactivityassociatedwiththesupplyofhumangrowthhormonetoLilly,whichElancohaseitherexitedormadethedecisiontoexit.
76
TableofContents
Percentage of 2018 Revenue By Region (1)
(1) Certainpercentagesmayreflectroundingadjustments.
(2) LATAMincludesaquacultureinallregions.
Throughitsglobalsalesforceofapproximately1,475salesrepresentatives,itsveterinaryconsultantsanditskeydistributors,Elancoseekstobuildstrongcustomerrelationshipsandfulfilldemandforitsfoodanimalproductsprimarilywithfoodanimalproducers,veterinariansandnutritionists,andforElanco'scompanionanimalproductsprimarilywithveterinariansand,insomemarkets,petowners.Elancoisalsoexpandingintoretailchannelsinordertomeetpetownerswheretheywanttopurchase.
Elanco'sinclusiveapproachtosourcinginnovationhelpsitidentify,attract,fundanddevelopnewideasthatenhanceitspipelineandreduceriskascomparedtoanin-houseonlyapproach.Elancohaslaunchedelevenproductsfrom2015to2018thatdelivered$24.7millionofrevenuein2015,$97.9millionofrevenuein2016,$143.8millionofrevenuein2017and$274.2millionofrevenuein2018.
Elancobelievesithasanexperiencedleadershipteamthatfostersanadaptive,purpose-drivencultureamongapproximately5,780employeesworldwideasofDecember31,2018andthatElanco'semployeesshareadeepconvictionforachievingitsvisionoffoodandcompanionship,enrichinglife.
ForthethreemonthsendedMarch31,2019and2018,Elanco'srevenuewas$731.1millionand$736.2million,respectively,andfortheyearsendedDecember31,2018,2017and2016,Elanco'srevenuewas$3.1billion,$2.9billionand$2.9billion,respectively.ForthethreemonthsendedMarch31,2019and2018,Elanco'snetincomewas$31.5millionand$72.7million,respectively,andfortheyearsendedDecember31,2018,2017and2016,Elanco'snetincome(loss)was$86.5million,$(310.7)millionand$(47.9)million,respectively.
Products
Elancohasadiverseportfolioofproductsmarketedundermorethan125brands,includingproductsforbothfoodanimalsandcompanionanimals.
77
TableofContents
Elanco'sfoodanimalproductsaredesignedtoenableproducerstokeepanimalshealthyanddelivermorefoodwhileusingfewerresources.Elanco'santibacterials,anticoccidials,vaccinesandparasiticidesaimtomakefoodsaferbypreventingandcontrollingdisease.Elancooffersproductsandsupporttoenhancetheintegrityofthefoodsupply,whileElanco'sproductivityenhancershelpmakefoodmoreaffordableandabundantbyincreasingtheamountofmeat,milkoreggsananimalcansupply.Furthermore,Elanco'sexpertiseanddataanalyticshelpitscustomersimproveproductionefficiencyandbusinessperformance.Foodanimalproductsrepresentedapproximately61%ofElanco'srevenuefortheyearendedDecember31,2018.
Elanco'scompanionanimalproductshelpveterinariansbettercareforpets.Elancopartnerswithpetownersandveterinariansforthepurposeofprovidingaconsistentflowofinnovativeandeffectiveproductsandsupport.Elanco'sR&Dfocusesonproductsthatpreventandtreatdisease,improveandextendqualityoflifeandimprovethetypeofcarereceivedbypets.Elancoalsopartnerscloselywithveterinarianstoprovidetechnicalsupportandcasemanagementforitsproducts.Companionanimalproductsrepresentedapproximately35%ofElanco'srevenuefortheyearendedDecember31,2018.
Elancogroupsitsproductsintofourprincipalcategories:
• CA Disease Prevention: includesparasiticidesandvaccineproductsforcaninesandfelines.
• CA Therapeutics: includesproductsforthetreatmentofpain,osteoarthritis,otitis,cardiovascularanddermatologyindicationsincaninesandfelines.
• FA Future Protein & Health: includesvaccines,antibiotics,parasiticidesandotherproductsusedinpoultryandaquacultureproduction,aswellasfunctionalnutritionalhealthproducts,includingenzymes,probioticsandprebiotics.
• FA Ruminants & Swine: includesvaccines,antibiotics,implants,parasiticidesandotherproductsusedinruminantsandswineproduction,aswellascertainotherfoodanimalproducts.
Elanco'srevenuebyproductcategoryfortheyearsendedDecember31,2018,2017,2016and2015wasthefollowing:
Elancopursuesthedevelopmentofnewchemicalandbiologicalmoleculesthroughitsinnovationstrategy.Since2015,Elancohaslaunchedthefollowingelevenproducts:
• InCADiseasePrevention,Credelio andInterceptor Plus .
• InCATherapeutics,Galliprant andOsurnia.
• InFAFutureProtein&Health,Inteprity ,Imvixa ,Clynav and Correlink .
• InFARuminants&Swine,Imrestor, Kavault and Prevacent .
Inthesecondquarterof2018,ElancosuspendedcommercializationofImrestor andplanstopursueadditionalindications.
78
Year Ended December 31, 2018 2017 2016 2015 CADiseasePrevention $ 804.6 $ 660.2 $ 628.4 $ 591.2CATherapeutics 283.1 260.8 255.6 245.2FAFutureProtein&Health 711.2 649.2 630.8 633.2FARuminants&Swine 1,174.0 1,175.0 1,309.2 1,356.6Other $ 93.9 143.8 89.5 82.9TotalRevenue $ 3,066.8 $ 2,889.0 $ 2,913.5 $ 2,909.1
TableofContents
In2016,ElancoannouncedthecreationofitsNutritionalHealthorganization,whichfocusesonfunctionalnutritionproducts,includingenzymes,probioticsandprebiotics,whichimpactanimalmicrobiomesandotherdietaryfactorstoreducediseaseincidence,improveguthealthandenhancefeeddigestibility.Elancofirstfocusedonnutritionalhealthin2012,withtheacquisitionofChemGenandtheHemicell brand.In2016,ElancoenteredintoanagreementwithAgroBiosciences,Inc.tocommercializeCorrelink —anoveldirect-fedmicrobial(probiotic)productoutsidetheU.S.Inearly2018,Elancoannouncedanewglobal,exclusivein-licensingagreementwithAbEDiscoverytofurtherdevelopandbringtothemarketaninfeedantibodyproductfocusedonreducingandcontrollingcoccidiosis.
Rumensin ,Elanco'stopsellingproduct,contributedapproximately11%ofitsrevenuein2018and10%ofitsrevenuein2017,2016and2015.Nootherproductcontributed10%ormoreofElanco'srevenue.Elanco'stopfivesellingproducts,Rumensin ,Trifexis ,Maxiban ,Denagard andInterceptor Plus ,collectivelycontributedapproximately31%ofits2018revenue.Elanco'stop10productscollectivelycontributed42%ofits2018revenue.
SetforthbelowisinformationregardingElanco'sprincipalproducts.
CA Disease Prevention Products
79
Product Description Primary Species
Bronchi Shield III andBronchi Shield Oral (vaccines) BronchiShieldIII—Toprotectagainstadenovirus,parainfluenzaandBordetellabronchiseptica(Bb)indogs. Dogs
BronchiShieldOral—ToprotectagainstBbindogs.
Comfortis (spinosad)
Tokillfleasandpreventandtreatfleainfestations(Ctenocephalides felis )incats14weeksofageorolderandweighingatleast4.1lbs.anddogs14weeksofageorolderandweighingatleast5.0lbs.
Cats,Dogs
Credelio (lotilaner)
Tokilladultfleasandtotreatfleainfestations(Ctenocephalides felis )andtreatandcontroltickinfestations(Amblyommaamericanum (lonestartick),Dermacentor variabilis (Americandogtick),Ixodes scapularis (black-leggedtick)andRhipicephalus sanguineus (browndogtick))foronemonthindogsandpuppies8weeksofageorolderandweighingatleast4.4lbs.
Dogs
Duramune (vaccines)
Includesmultipleproductsthatcollectivelyprotectagainstdistemper,adenovirus,parvovirus,corona,parainfluenza,leptospiracanicola,andotherdiseasesindogs.
Dogs
Rabvac (vaccines)
Toprotectagainstrabies,includesa1-yearand3-yearshot.
Cats,Dogs
Fel-O-Vax (vaccines)
IncludesmultipleproductsthatcollectivelyprotectagainstLeukemia,rhinovirus,calicivirus,panleukopenia,andchlamydiaincats.
Cats
Fel-O-Guard (vaccines)
IncludesmultipleproductsthatcollectivelyprotectagainstLeukemia,rhinovirus,calicivirus,panleukopenia,andchlamydiaincats.
Cats
TableofContents
CA Therapeutics Products
80
Product Description Primary Species
Interceptor Plus (milbemycinoxime/praziquantel) TopreventheartwormdiseasecausedbyDirofilaria immitis andforthetreatmentandcontrolofadultroundworm(Toxocaracanis andToxascaris leonina ),adulthookworm(Ancylostoma caninum ),adultwhipworm(Trichuris vulpis ),andadulttapeworm(Taenia pisiformis ,Echinococcus multilocularis ,andEchinococcus granulosus )infectionsindogsandpuppiesweighingatleast2lbs.and6weeksofageorolder.Interceptor Plus isarelaunchofapreviouslyapprovedformula.
Dogs
Milbemax (milbemycinoxime+praziquantel)
Totreatandcontrolparasiticinfectionsduetoadulthookworm,adultroundwormandadulttapewormandtopreventheartwormdiseasecausedbyDirofilaria immitis incatsanddogs.
Cats,Dogs
Trifexis (spinosad+milbemycinoxime)
Topreventheartwormdisease(Dirofilaria immitis )andtokillfleas.Trifexis isindicatedforthepreventionandtreatmentoffleainfestations(Ctenocephalides felis ),andthetreatmentandcontrolofadulthookworm(Ancylostoma caninum) ,adultroundworm(Toxocara canis andToxascaris leonina )andadultwhipworm(Trichuris vulpis )infectionsindogsandpuppies8weeksofageorolderandweighingatleast5lbs.
Dogs
Product Description Primary Species
Atopica (cyclosporineA) Tocontrolatopicdermatitisindogsweighingatleast4lbs. Dogs
Fortekor Plus (benazepril+pimobendan)
Totreatcongestiveheartfailureduetoatrioventricularvalveinsufficiencyordilatedcardiomyopathyindogs.
Dogs
Galliprant (grapiprant)
Tocontrolpainandinflammationassociatedwithosteoarthritisindogs.
Dogs
Onsior (robenacoxib)
Tocontrolpostoperativepainandinflammationassociatedwithsofttissuesurgeryindogsweighingatleast5.5lbs.and4monthsofageorolderandcontrolpostoperativepainandinflammationassociatedwithorthopedicsurgery,ovariohysterectomyandcastrationincatsweighingatleast5.5lbs.and6monthsofageorolder;foruptoamaximumof3days.
Cats,Dogs
Osurnia (terbinafine+florfenicol+betamethasoneacetate)
Totreatotitisexternaindogsassociatedwithsusceptiblestrainsofbacteria(Staphylococcus pseudintermedius )andyeast(Malassezia pachydermatis ).
Dogs
TableofContents
FA Future Protein & Health
FA Ruminants & Swine
81
Product Description Primary Species
AviPro (vaccines) IncludesmultipleproductsthatcollectivelyprotectagainstNewcastledisease,infectiousbronchitis,fowlcholera,paramyxovirusType3,BursalDisease,otherdiseasesandfoodbornepathogenslikeSalmonellainpoultry.
Poultry
Clynav (plasmiddeoxyribonucleicacidvaccine)ToimmunizeAtlanticsalmontoreduceimpaireddailyweightgain,andreducemortality,andcardiac,pancreaticandskeletalmusclelesionscausedbypancreasdiseasefollowinginfectionwithsalmonidalphavirussubtype3(SAV3).
Fish(Salmon)
Coban /Elancoban (monensin)Toaidinthepreventionofcoccidiosisinbroilerandreplacementchickens(causedbyEimeria necatrix, E. tenella, E. acervulina,E. brunetti, E. mivati ,andE. maxima ),inturkeys(causedbyEimeria adenoeides, E. meleagrimitis andE. gallopavonis )andingrowingBobwhitequail(causedbyEimeria dispersa andE. lettyae ).Coban/Elancobanisananimal-onlyantibioticandanionophore.
Poultry
Hemicell (endo-1,4-b-mannanase)Enzymesupplementforpoultryandswinefeedsthatcontainasourceofb-mannanase,whichhydrolysestheb-mannanspresentinsoybeanandcornmeal.
Poultry,Swine
Imvixa (lufenuron)Topreventandcontrolinfestationcausedbysealice,Caligus reogercresseyi, infarmedsalmon.
Fish(Salmon)
Maxiban (narasin+nicarbazin)TopreventcoccidiosisinbroilerchickenscausedbyEimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati andE.maxima. Maxiban isananimal-onlyantibioticandanionophore.
Poultry
Monteban (narasin)TopreventcoccidiosisinbroilerchickenscausedbyEimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati andE.maxima. Monteban isananimal-onlyantibioticandanionophore.
Poultry
Surmax / Maxus / Inteprity (avilamycin)TopreventmortalitycausedbynecroticenteritisassociatedwithClostridium perfringens inbroilerchickens.Surmax, Maxis andInteprity areanimal-onlyantibiotics.
Poultry
Product Description Primary Species
Denagard (tiamulin) TotreatSwineDysenteryassociatedwithSerpulina hyodysenteriae susceptibletotiamulinandfortreatmentofswinebacterialenteritiscausedbyEscherichia coli andSalmonella choleraesuis sensitivetochlortetracyclineandtreatmentofbacterialpneumoniacausedbyPasteurellamultocidasensitivetochlortetracycline.Denagard isashared-classantibiotic.
Swine
TableofContents
82
Product Description Primary Species
Optaflexx / Paylean (ractopaminehydrochloride) Toincreaserateofweightgain,improvefeedefficiencyandincreasecarcassleanness,andusedasatopdressfeedtoincreaserateofweightgainandimprovefeedefficiencyincattlefedinconfinementforslaughterduringthelast28to42daysonfeed.Ractopamine,theactiveingredientinPaylean and Optaflexx, isabetaadrenoreceptoragonist.
Cattle,Swine
Pulmotil (tilmicosin)Forswine:TocontrolswinerespiratorydiseaseassociatedwithActinobacillus pleuropneumoniae andPasteurellamultocida.
Cattle,Swine
Forcattle:Tocontrolbovinerespiratorydisease(BRD)associatedwithMannheimia haemolytica, Pasteurella multocidaandHistophilus somni ingroupsofbeefandnon-lactatingdairycattle,whereactiveBRDhasbeendiagnosedinatleast10%oftheanimalsinthegroup.Pulmotil isashared-classantibiotic.
Rumensin (monensin)Forcattlefedinconfinementforslaughter:ToimprovefeedefficiencyandpreventandcontrolcoccidiosisduetoEimeriabovis andEimeria zuernii .
Cattle
Fordairycows:Toincreasemilkproductionefficiency(productionofmarketablesolids-correctedmilkperunitoffeedintake).
Forgrowingcattleonpastureorindrylot(stockerandfeederanddairyandbeefreplacementheifers):ToincreaserateofweightgainandtopreventandcontrolcoccidiosisduetoEimeria bovis andEimeria zuernii .
Formaturereproducingbeefcows:ToimprovefeedefficiencywhenreceivingsupplementalfeedandtopreventandcontrolcoccidiosisduetoEimeria bovis andEimeria zuernii .
Forgoats:TopreventcoccidiosisduetoEimeria crandallis, Eimeria christenseni andEimeria ninakohlyakimovae ingoatsmaintainedinconfinement.
Forcalves(excludingvealcalves):TopreventandcontrolcoccidiosisduetoEimeria bovis andEimeria zuernii.
Rumensin isananimal-onlyantibioticandanionophore.
Tylan Premix (tylosinphosphate)TocontrolporcineproliferativeenteropathiesassociatedwithLawsonia intracellularis andtocontrolporcineproliferativeenteropathiesassociatedwithLawsonia intracellularis immediatelyaftermedicatingwithTylan Soluble (tylosintartrate)indrinkingwater.Tylan Premix isashared-classantibiotic.
Swine,Cattle,Poultry
TableofContents
Antibiotics
Antimicrobialresistanceinhumans,ortheriskthathumanpathogensevolveorotherwiseemergethatareresistanttoantibioticsorotherantimicrobials,isasignificanthealthconcern,andanimalagriculturecanplayaroleinmitigatingthisrisk.Asacompanydedicatedtothehealthandwell-beingofanimals,Elancoseekstohelpveterinariansandfarmersresponsiblyuseantibioticswhentreatinganimals.Initseffortstoaddressantibioticresistancewhileprotectinganimalhealth,Elancointroducedaglobalantibioticstewardshipplanfocusingonincreasingresponsibleantibioticuse;reducingtheneedforshared-classantibiotics;andreplacingantibioticswithalternativestohelplivestockproducerstreatandpreventanimaldisease.Antibiotics,usedresponsibly,alongwithgoodanimalcarepractices,helpenhancefoodsafetyandanimalwell-being.
Therearetwoclassesofantibioticsusedinanimalhealth:
• Animal-only antibiotics and ionophores: Notallpathogensthatcausediseaseinanimalsareinfectiousinhumans,andaccordinglyanimal-onlyantibioticsarenotusedinhumanmedicine(i.e.,notmedicallyimportant).Ionophoresareaspecialclassofanimal-onlyantimicrobialsuniquelydevelopedonlyforuseinanimals.InEuropeandcertainotherjurisdictions,ionophoresarenotcurrentlyclassifiedasantibiotics.Becauseoftheiranimal-onlydesignation,modeofaction,andspectrumofactivity,theiruseisnotconsideredtocreatethesameriskofresistanceinhumanpathogens.
• Shared-class antibiotics: Theseareusedinbothhumansandanimals.Someantibioticsareusedtotreatinfectiousdiseasecausedbypathogensthatoccurinbothhumansandanimals.Ofthe18majorantibioticresistancethreatsthattheCentersforDiseaseControlandPreventiontracks,twoareassociatedwithinfectiousdiseaseinanimals.AspartofElanco'sglobalantibioticstewardshipplanandincompliancewithFDAguidance,shared-classantibioticsarelabeledonlyforthetreatmentofanestablishedneedinanimalsandonlywithveterinarianoversight.
Elancohasintentionallyshiftedawayfromshared-classantibiotics,andisfocusingonanimal-onlyantibiotics,aswellasantibiotic-freesolutions.In2018,12%ofElanco'srevenuewasfromproductsclassifiedasshared-classantibiotics,ofwhich4%ofitsrevenuewasintheU.S.and8%wasoutsidetheU.S.,whereas25%ofElanco'srevenuewasfromanimal-onlyantibioticsandionophores,ofwhichionophoresconstituted21%ofitsrevenue.ThroughElanco'spoliciesandeffortsinthisarea,itseekstoprotectthebenefitsofantibioticsinhumanmedicine,whileresponsiblyprotectingthehealthoffoodanimalsandthesafetyofourfoodsupply.
Sales and Marketing
Elanco'ssalesorganizationincludessalesrepresentatives,veterinaryconsultantsandothervalueaddedspecialists.InmarketswhereElancodoesnothaveadirectcommercialpresence,itgenerallycontractswithdistributorsthatprovidelogisticsandsalesandmarketingsupportforitsproducts.
Elanco'ssalesrepresentativesvisititscustomers,includingconsultants,veterinarians,foodanimalproducers,andresellers,toinform,promoteandsellElanco'sproductsandtosupportcustomers.Elanco'sveterinaryconsultantsprovidescientificconsultingfocusedondiseasemanagementandherdmanagement,trainingandeducationondiversetopics,includingresponsibleproductuse,andgenerallyhaveadvanceddegreesinveterinarymedicine,veterinarynutritionorotheragriculture-relatedfields.
83
Product Description Primary Species
Vira Shield (vaccines) Includesmultipleproductsthatprotectagainstinfection,bovinerhinotracheitis,bovineviraldiarrhea,bovinerespiratorysyncytialvirus,bovinerespiratorydisease,leptospiracanicolaandotherdiseasesincattle.
Cattle
TableofContents
ThesedirectrelationshipswithcustomersallowElancotounderstandtheirneeds.Additionally,Elanco'ssalesrepresentativesandveterinaryconsultantsfocusoncollaboratingwithitscustomerstoeducateandsupportthemontopicssuchaslocaldiseaseawarenessandtohelpthemadoptnewandmoresophisticatedanimalhealthsolutions,includingthroughtheuseofElanco'sproducts.Asaresultoftheserelationships,Elanco'ssalesandconsultingvisitsprovideitwithaccesstocustomerdecisionmakers.Inaddition,Elanco'ssalesandmarketingorganizationprovidesenhancedvaluebyprovidingsupporttofoodanimalproducerstohelpmaximizetheiryieldsandreducecosts.Elanco'sanalyticshelpcustomersanalyzelargeamountsofhealthandproductiondata.AsofDecember31,2018,Elancohadapproximately1,475salesrepresentatives.
Customers
Elancoprimarilysellsitsfoodanimalproductstothird-partydistributorsanddirectlytoadiversesetoffoodanimalproducers,includingbeefanddairyfarmersaswellaspork,poultryandaquacultureoperations.Elancoprimarilysellsitscompanionanimalproductstothird-partydistributors,aswellasdirectlytoveterinariansthattypicallythensellElanco'sproductstopetowners.Elancoisalsoexpandingintoretailchannelsinordertomeetpetownerswheretheywanttopurchase.Elanco'slargestcustomer,anaffiliateofAmerisourceBergenCorp.,isathird-partyveterinarydistributorandrepresentedapproximately12%ofElanco'srevenuefortheyearendedDecember31,2018.Elanco'snextlargestcustomerrepresentedapproximately7%ofitsrevenuefortheyearendedDecember31,2018andnoothercustomerrepresentedmorethan5%ofElanco'srevenueforthesameperiod.
Research and Development
Elanco'sR&Dorganizationiscomprisedofinternalresearch,globaldevelopment,globalregulatoryandexternalinnovationcollaborationsandventureinvesting.AsofDecember31,2018,Elancoemployedapproximately690employeesinitsglobalR&DandRegulatoryAffairsorganizations.Elanco'sR&DheadquartersislocatedinGreenfield,Indiana.ElancohasR&DfacilitiesinBasel,Switzerland;PrinceEdwardIsland,Canada;andYarrandoo,AustraliaandR&Dfacilitiesco-locatedwithmanufacturingsitesinFortDodge,Iowa;andCuxhaven,Germany.AdditionalR&DoperationsarelocatedinSaoPaulo,Brazil;Shanghai,China;andBangalore,India.ElancoincurredR&Dexpensesof$246.6millionin2018,$251.7millionin2017and$265.8millionin2016.
NewproductinnovationisacorepartofElanco'sbusinessstrategy.Elanco'sR&Dinvestmentisfocusedonprojectsthattargetnovelproductintroductions,aswellasnewindications,presentations,combinationsandspeciesexpansion.Elanco'sapproachisabuild,buy,orallystrategytodevelopcompellingtargetsandconceptsthatoriginatefromitsscientistsandinnovators,academia,agribusiness,orhumanpharmaceuticalandbiotechnologyatallstagesofR&D.TheabilitytosourceitsconceptsfromdifferentareasallowsElancotocreateapipelinethatcanbecompetitiveinthecategoriesinwhichithaschosentocompete,whilereducingitsriskbynotowningandfundingallaspectsofitsR&Dprojects.
ElancoseekstoconcentrateitsresourcesinareaswhereitbelievesthescienceandElanco'scapabilitiesbestmatchtheopportunitiesintheanimalhealthmarket.Specifically,Elanco'sR&Dfocusesonsixareasacrosscompanionanimalsandfoodanimals.Forcompanionanimals,ElancohasR&Dactivitiesintherapeutics,vaccinesandparasiticides,whileinfoodanimalsElancoispursuingpharmaceuticals,vaccinesandnutritionalhealth.
84
TableofContents
Elanco'sR&Deffortsconsistofmorethan100activeprogramsbalancedacrossspeciesandtechnologyplatforms.Forbothfoodanimalsandcompanionanimals,Elancoappliesbothlargeandsmallmoleculeapproaches.Invaccines,Elanco'seffortsencompassafullrangeofmodifiedlive,inactivatedandnucleicacidstrategies.Innutritionalhealth,Elancofocusesonproductsbasedonenzymes,probiotics,prebioticsandotherapproachesthatmodulatebiologicalactivityintheanimaldigestivetract.Additionally,Elancoemploysvariousdeliverystrategiesforproductsincludingin-feed,injectable,oralandtopicalformulationsdevelopedinconjunctionwithitsmanufacturingteamtoassureproductionthatmaximizesthecapabilitieswithinElanco'sinternalandexternalmanufacturingnetwork.
ElancoengagesinlicensingandbusinessdevelopmenttoacquireassetsforitspipelineandnewR&DplatformsandtoestablishstrategicR&Dcollaborations.Elancomakesandmaintainscapitalinvestmentsinventurecapitalvehiclesthatfocusonagribusinessandanimalhealth,andElancoengagesinrisksharingcollaborationstoexpanditsexternalcapitalsourcestoaugmentinternalinvestments.TosupportcollaborationswithinnovationsourcesfocusedonhumanhealthElancohasdevelopedcapabilitiestoconducttranslationalcomparativemedicalresearchtrialsinanimalswithnaturallyoccurringconditionsthatmimicahumandiseaseordisorder.Thistypeofcollaborationde-risksunprovenorlesswell-validatedhumanhypotheseswhilepotentiallydefiningaclinicallyvalidatednewapproachinveterinarymedicine.
Elanco'sR&DandcommercialleadershipallocateR&Dinvestmentannuallywiththegoalofaligningnear-andlong-termstrategicopportunitiesandobjectives.Portfolioinvestmentdecisionsaremadebasedontheprobabilityoftechnicalsuccessandregulatoryapproval,timingofapproval/launchandearliermilestones,feasibilityandcostofdevelopmentandmanufacture,intellectualpropertyprotectionandmarketattractiveness/commercialforecast.R&DprojectsaresupportedbypharmaceuticalprojectmanagementapproachesandElancoaimsforallofitssupportingR&Dfunctionalcapabilitiesandcapacitiestobemanagedandmatchedtotheevolvingdemandsofthepipeline.ElancobelievesthisoverallR&Dmanagementsystemhasenabledittoconsistentlygainproductapprovalswhilemaintainingclearvisibilitytopipelinebreadthanddepthtosupportsustainedlaunchesintothefuture.
Manufacturing and Supply Chain
Priortotheseparation,Elanco'sproductsweremanufacturedatbothsitesoperatedbyElancoandsitesoperatedbythird-partyCMOs.
Elancoownsandoperates12internalmanufacturingsites,fourofwhichfocusonvaccines,sixofwhichfocusonotheranimalhealthproductsandtwoofwhichareregionalsitesthatfocusonpackaging:
Elancowillcontinuetomanufactureoneproduct,humangrowthhormone,forLillyatoneofthesesitesforaperiodoftwoyearsfollowingthedateoftheseparation.Lillyhastheoptiontoextendforthreeadditionalyears.
Elanco'sglobalmanufacturingandsupplychainisalsosupportedbyanetworkofCMOs.AsofDecember31,2018,thisnetworkwascomprisedofapproximately100CMOs.Elanco'sExternal
85
Site Location Site LocationClinton Indiana,U.S. Winslow Maine,U.S.Speke Liverpool,U.K. FortDodge Iowa,U.S.KansasCity Kansas,U.S. Cuxhaven GermanyHuningue France Chungli TaiwanWusi China Barueri BrazilTerreHaute Indiana,U.S. PrinceEdwardIsland Canada
TableofContents
ManufacturingNetworkcentrallygovernsitsglobalCMOrelationshipsandprovidesoversighttotheseCMOsthroughfourhubs.
ElancoselectsCMOsbasedonseveralfactors:(i)theirabilitytoreliablysupplyproductsormaterialsthatmeetElanco'squalitystandardsatanoptimizedcost;(ii)theiraccesstospecialtyproductsandtechnologies;(iii)capacity;and(iv)financialanalyses.Elanco'sExternalManufacturingNetworkseekstoensurethatalloftheCMOsElancousesadheretoitsstandardsofmanufacturingquality.
Elancopurchasescertainrawmaterialsnecessaryforthecommercialproductionofitsproductsfromavarietyofthird-partysuppliers.Elancoutilizeslogisticsserviceprovidersasapartofitsglobalsupplychain,primarilyforshippingandlogisticssupport.
Elancoservesaglobalcustomerbasethroughthird-partydistributionrelationshipsandadirectcommercialpresence.Elancointendstomaintainsuchcommercialpresencein50orfewercountriesbytheendofthe2019,reducedfrom70countriesin2015.Elancointendstocontinueitsefficiencyimprovementprogramsinitsmanufacturingandsupplychainorganization.Elancohasstronggloballymanagedandcoordinatedqualitycontrolandqualityassuranceprogramsinplaceatallinternalmanufacturingsitesandexternalmanufacturinghubs,anditregularlyinspectsandauditsitsinternalsitesandCMOlocations.Elancorecentlyconductedareviewofitsglobalmanufacturingandsupplynetworktoimproveefficiency.AsaresultofthisreviewandElanco'soperationalefficiencyprogram,since2015,ElancohasexitedownershipofitsmanufacturingsitesinVacaville,California;Dundee,Scotland;Sligo,Ireland;Larchwood,Iowa;andCali,Colombia,reducedheadcountfromapproximately3,500toapproximately2,300employeesandeliminatedover2,800stockkeepingunits,orSKUs.Elancocurrentlysuppliesapproximately4,500SKUs.
Elanco'smanufacturingsitesexperiencedapproximately200externalregulatoryinspectionsgloballyfrom2015to2018,forwhichsuchregulatorsmadenomaterialcriticalfindings.
Competition
Elancofacesintensecompetitioninthesectorsandregionsonwhichitfocuses.Principalmethodsofcompetitionvarydependingontheparticularregion,species,productcategory,orindividualproduct.Someofthesemethodsincludenewproductdevelopment,quality,price,serviceandpromotion.
Elanco'sprimarycompetitorsincludeanimalhealthmedicinesandvaccinescompaniessuchasZoetisInc.;BoehringerIngelheimVetmedica,Inc.,theanimalhealthdivisionofBoehringerIngelheimGmbH;MerckAnimalHealth,theanimalhealthdivisionofMerck&Co.,Inc.;andBayerAnimalHealth,theanimalhealthdivisionofBayerAG.Elancoalsofacescompetitiongloballyfrommanufacturersofgenericdrugs,aswellasfromproducersofnutritionalhealthproducts,suchasDSMNutritionalProductsAGandDaniscoAnimalNutrition,theanimalhealthdivisionofE.I.duPontdeNemoursandCompany,asubsidiaryofDowDuPont,Inc.Therearealsoseveralnewstart-upcompaniesworkingintheanimalhealtharea.Inaddition,Elancocompeteswithnumerousotherproducersofanimalhealthproductsthroughouttheworld.
Intellectual Property
Elanco'stechnology,brandsandotherintellectualpropertyareimportantelementsofitsbusiness.Elancoreliesonpatent,trademark,copyrightandtradesecretlaws,aswellasregulatoryexclusivityperiodsandnon-disclosureagreementstoprotectitsintellectualpropertyrights.Elanco'spolicyistovigorouslyprotect,enforceanddefenditsrightstoitsintellectualproperty,asappropriate.
Elanco'sproductportfolioandcertainproductcandidatesenjoytheprotectionofapproximately3,000patentsandapplications,filedinover50countries,withconcentrationinElanco'smajormarket
86
TableofContents
countriesaswellasothercountrieswithstrongpatentsystems,suchasAustralia,Brazil,Canada,Europe,JapanandtheU.S.ManyofthepatentsandpatentapplicationsinElanco'sportfolioaretheresultofitsownwork,whileotherpatentsandpatentapplicationsinitsportfoliowereatleastpartiallydeveloped,andlicensedtoElanco,bythirdparties.AsubsetofElanco'scurrentproductsorproductcandidatesarecoveredbypatentsandpatentapplicationsinitsportfolio.
Patentsforindividualproductsexpireatdifferenttimesbasedonthedateofthepatentfiling(orsometimesthedateofpatentgrant)andthelegaltermofpatentsinthecountrieswheresuchpatentsareobtained.Forexample,Galliprant's activeingredient,grapiprant,isencompassedbybothcompoundandphysicalformpatentsintheU.S.,Europe,Canadaandotherkeymarkets,withtermsthatexpirebetweenatleastOctober2021andMarch2026.Variousformulationandmethodofusepatentsencompassthespinosadpesticideproducts,Comfortis andTrifexis .TheComfortis formulationpatentextendsthroughAugust2020intheU.S.,CanadaandAustralia,and,upongrantofapplicablesupplementingprotectioncertificate("SPC"),throughAugust2025inEurope.TheTrifexis formulationandmethodofusepatentsextendsthroughSeptember2021intheU.S.,CanadaandAustralia,and,upongrantofapplicableSPC,throughSeptember2026inEurope.Elancotypicallymaintainsallofitspatentsandassertsitspatentrightsagainstthirdpartiesasappropriate.
Additionally,manyofElanco'svaccineproducts,includingtheDuramune familyofvaccines,arebasedonproprietaryorpatentedmasterseedsandformulations.Elancoactivelyseekstoprotectitsproprietaryinformation,includingitstradesecretsandproprietaryknow-how,throughavarietyofmeansincludingbyseekingtorequireElancoemployees,consultants,advisorsandpartnerstoenterintoconfidentialityagreementsandotherarrangementsuponthecommencementoftheiremploymentorengagement.
InordertofacilitatetheseparationandallowLilly'sandElanco'soperationstocontinuewithminimalinterruption,LillylicensedtoElancotherighttousecertainintellectualpropertyrightsintheanimalhealthfield.Inaddition,LillyhasgrantedElancoatransitionallicensetousecertainofLilly'strademarksforaperiodoftimefollowingtheIPO.See"CertainRelationshipsandRelatedPartyTransactions—RelationshipbetweenElancoandLilly—TransitionalTrademarkLicenseAgreement."
Elancoseekstofileandmaintaintrademarksaroundtheworldbasedoncommercialactivitiesinmostregionswhereithas,ordesirestohave,abusinesspresenceforaparticularproduct.Elancocurrentlymaintainsmorethan9,000trademarkapplicationsandregistrationsinmajorregions,primarilyidentifyingproductsdedicatedtothecareoflivestockandcompanionanimals.
Regulatory
ThesaleofanimalhealthproductsisgovernedbythelawsandregulationsspecifictoeachcountryinwhichElancosellsitsproducts.Tomaintaincompliancewiththeseregulatoryrequirements,Elancohasestablishedprocesses,systemsanddedicatedresourceswithend-to-endinvolvementfromproductconcepttolaunchandmaintenanceinthemarket.Elanco'sregulatoryfunctionactivelyseekstoengageindialoguewithvariousglobalagenciesregardingtheirpoliciesthatrelatetoanimalhealthproducts.InthemajorityofElanco'smarkets,therelevanthealthauthorityisseparatefromthosegoverninghumanmedicinalproducts.
United States
U.S. Food and Drug Administration. TheregulatorybodythatisresponsiblefortheregulationofanimalhealthpharmaceuticalsintheU.S.istheCenterforVeterinaryMedicine,adivisionoftheFDA.Allmanufacturersofanimalhealthpharmaceuticalsmustdemonstratetheirproductstobesafe,effectiveandproducedbyaconsistentmethodofmanufactureasdefinedundertheFederalFood,Drug,andCosmeticAct(the"FFDCA").TheFDA'sbasisforapprovinganewanimaldrugapplicationisdocumentedinaFreedomofInformationSummary.Post-approvalmonitoringofproductsis
87
TableofContents
requiredbylaw,withreportsbeingprovidedtotheCVM'sOfficeofSurveillanceandCompliance.Reportsofproductqualitydefects,adverseeventsorunexpectedresultsaremaintainedandsubmittedinaccordancewiththelaw.Additionally,aspartofthedrugexperiencereport,Elancoisrequiredtosubmitallnewinformationpertainingtothesafetyoreffectivenessofaproduct,regardlessofthesource.
U.S. Department of Agriculture. TheregulatorybodyintheU.S.forveterinarybiologicalsistheU.S.DepartmentofAgriculture(the"USDA").TheCenterforVeterinaryBiologicswithintheAnimalandPlantHealthInspectionServiceintheUSDAisresponsiblefortheregulationofanimalhealthbiologicals,whichincludesbutisnotlimitedtovaccines,bacterins,allergens,antibodies,antitoxins,toxoids,immunostimulants,certaincytokines,antigenicorimmunizingcomponentsoflivemicroorganisms,anddiagnosticcomponentsofnaturalorsyntheticorigin,orthatarederivedfromsynthesizingoralteringvarioussubstancesorcomponentsofsubstancessuchasmicroorganisms,genesorgeneticsequences,carbohydrates,proteins,antigens,allergensorantibodies.Allmanufacturersofanimalhealthbiologicalsmustshowtheirproductstobepure,safe,effectiveandproducedbyaconsistentmethodofmanufactureasdefinedundertheVirusSerumToxinAct.Post-approvalmonitoringofproductsisrequired.Reportsofproductqualitydefects,adverseeventsorunexpectedresultsaremaintainedandsubmittedinaccordancewiththeagencyrequirements.
Environmental Protection Agency. ThemainregulatorybodyintheU.S.forveterinarypesticidesistheEnvironmentalProtectionAgency(the"EPA").TheEPA'sOfficeofPesticideProgramsisresponsiblefortheregulationofmostpesticideproductsappliedtoanimalsinaccordancewithamemorandumofunderstandingbetweentheFDAandEPAforproductsthataresubjecttoregulationunderboththeFFDCAandtheFederalInsecticide,FungicideandRodenticideAct.Allmanufacturersofanimalhealthpesticidesmustshowtheirproductswillnotcauseunreasonableadverseeffectstomanortheenvironmentasstatedintheact.WithintheU.S.,individualstatepesticideauthoritiesmust,beforedistributioninthatstate,alsoapprovepesticideproductsthatareapprovedbytheEPA.Post-approvalmonitoringofproductsisrequired,withreportsprovidedtotheEPAandsomestateregulatoryagencies.
Food Safety Inspection Service. TheFDAisauthorizedtodeterminethesafetyofsubstances(including"generallyrecognizedassafe"substances,foodadditivesandcoloradditives),aswellasprescribetheirsafeconditionsofuse.However,althoughtheFDAhastheresponsibilityfordeterminingthesafetyofsubstances,theFoodSafetyandInspectionService,thepublichealthagencyintheUSDA,retains,underthetenetsoftheFederalMeatInspectionActandthePoultryProductsInspectionActandtheirimplementingregulations,theauthoritytodeterminethatnewsubstancesandnewusesofpreviouslyapprovedsubstancesaresuitableforuseinmeatandpoultryproducts.
Inaddition,theFCPAprohibitsU.S.corporationsandtheirrepresentativesfromoffering,promising,authorizingormakingpaymentstoanyforeigngovernmentofficial,governmentstaffmember,politicalpartyorpoliticalcandidateinanattempttoobtainorretainbusinessabroad.ThescopeoftheFCPAincludesinteractionswithcertainhealthcareprofessionalsinmanycountries.Othercountrieshaveenactedsimilaranti-corruptionlawsand/orregulations.InsomecountriesinwhichElancooperates,thepharmaceuticalandlifesciencesindustriesareexposedtoahighriskofcorruptionassociatedwithsalestohealthcareprofessionalsandinstitutions.NotwithstandingElanco'sreasonableeffortstoconductitsoperationsinmaterialcompliancewiththeFCPA,Elanco'sinternationalbusinesscouldexposeittopotentialliabilityundertheFCPA,whichmayresultinElancoincurringsignificantcriminalandcivilpenalties,andtopotentialliabilityundertheanti-corruptionlawsandregulationsofotherjurisdictionsinwhichitoperates.Inaddition,thecostsElancomayincurindefendingagainstanFCPAinvestigationcouldbesignificant.
88
TableofContents
Outside of the United States
European Union (EU). ElancoisgovernedbythefollowingEUregulatorybodies:
• TheEuropeanMedicinesAgency("EMA")isacentralizedagencyoftheEU,currentlylocatedinLondon,England.DuetothedecisionoftheUKtoleavetheEU,theagencywillrelocatetoAmsterdam.TheagencyisresponsibleforthescientificevaluationofVeterinaryMedicinalProducts("VMP")developedbypharmaceuticalcompaniesforuseintheEU.Theagencyhasaveterinaryreviewsectiondistinctfromthemedicalreviewsectionforhumanproducts.TheCommitteeforVeterinaryMedicinalProducts("CVMP")isresponsibleforscientificreviewofthesubmissionsforVMPandImmunologicalVeterinaryMedicinalProducts.IftheCVMPconcludesthatallrequirementsforquality,safetyandefficacyaremet,theyissueapositiveopinionthatisforwardedtotheEuropeanCommission,whotakesthefinaldecisionfollowingtheEuropeancomitologyprocedure.Thecentralizedmarketingauthorization(commissiondecision)oftheEuropeanCommissionisvalidinalloftheEU.AllcountriesthatarenotpartoftheEUbutbelongtotheEuropeanEconomicArea("EEA"),i.e.,Norway,IcelandandLiechtenstein,arepartofthescientificassessmentdonebytheCVMP.ThesecountriesissueanationalmarketingapprovalinaccordancewiththeCommissionDecision.Aseriesofregulations,directives,guidelines,EUPharmacopeiaMonographsandotherlegislationprovidetherequirementsforapprovalintheEU.Ingeneral,theserequirementsaresimilartothoseintheU.S.,requiringdemonstratedevidenceofpurity,safety,efficacyandconsistencyofmanufacturingprocesses.
Ifapprovalissoughtforproductsthateithercannotordonotneedtofollowthecentralizedprocedure,approvalcanalsobeachievedbynationalapprovalinanEEAcountryagency.ThisnationalauthorizationcanbemutuallyrecognizedbyotherEEAcountries/EUmemberstates(MutualRecognitionProcedure).Inaddition,nationalandmutualrecognitioncanbedoneinacombinedprocedure(DecentralizedProcedure).
• TheEuropeanFoodSafetyAuthority("EFSA")istheagencyoftheEUthatprovidesscientificadviceandcommunicateswithrespecttoexistingandemergingrisksassociatedwiththefoodchain.EFSAwasestablishedinFebruary2002andisbasedinParma,Italy.BasedonEFSA'smandate,theagencyevaluatesapplicationsforfeedadditives,includingenzymesandseveralnutritionalsforanimals.
• TheEuropeanChemicalAgency("ECHA")istheagencyoftheEUforthesafeuseofchemicals.ECHAwasfoundedin2007andisbasedinHelsinki,Finland.BasedonECHA'smandate,theagencyconductstheevaluationofbiocidesfortheEU.
InregardtoBrexit,theEUandtheUKarecontinuingtoworkonplansfordealingwiththewithdrawaloftheUKfromtheEU,currentlyscheduledforMarch29,2019.Post-separation,theUKhasindicatedtheywilllooktocontinueworkingcloselywiththeEMA,andthatexistingagreementsbetweentheEMAandothercountriessuchasSwitzerland,theU.S.andCanadaprovideaprecedentonwhichtheUKcouldbuild.
Brazil. TheMinistryofAgriculture,LivestockProductionandSupply("MAPA")istheregulatorybodyinBrazilthatisresponsiblefortheregulationandcontrolofpharmaceuticals,biologicalsandmedicinalfeedadditivesforanimaluse.MAPA'sregulatoryactivitiesareconductedthroughtheSecretaryofAgriculturalDefenseanditsLivestockProductsInspectionDepartment.Inaddition,regulatoryactivitiesareconductedatalocallevelthroughtheFederalAgricultureSuperintendence.Theseactivitiesincludetheinspectionandlicensingofbothmanufacturingandcommercialestablishmentsforveterinaryproducts,aswellasthesubmission,reviewandapprovalofpharmaceuticals,biologicalsandmedicinalfeedadditives.MAPAisoneofthemostactiveregulatoryagenciesinLatinAmerica,havingpermanentseatsatseveralinternationalanimalhealthforums,such
89
TableofContents
asCodexAlimentarius,WorldOrganizationforAnimalHealthandCommitteeofVeterinaryMedicinesfortheAmericas.MAPAwasalsorecentlyinvitedtobeaLatinAmericanrepresentativeatInternationalCooperationonHarmonisationofTechnicalRequirementsforRegistrationofVeterinaryMedicinalProducts("VICH")meetings.SeveralnormativeinstructionsissuedbyMAPAhavesetregulatorytrendsinLatinAmerica.
Japan. TheMinistryofAgriculture,ForestryandFishery("MAFF")istheregulatorybodyinJapanthatisresponsiblefortheregulationandcontrolofpharmaceuticals(includingbiologicalsandpesticide/disinfectant)andfeedadditive/feedforanimaluse.MAFF'sregulatoryactivitiesareconductedthroughtheLivestock&AquacultureProductSafetyControlDivisionundertheConsumerSafetyBureau.Theanimaldrugreviewsandapprovals,reexaminationreviews,GxPcompliancechecks,GxPsiteinspectionsandproductassaychecks(includingvaccinenationalassays)aredonebyNationalVeterinaryAssayLaboratory("NVAL").MAFFcoordinateswithotheragenciessuchasMinistryofHealth,LaborandWelfare("MHLW")andFoodSafetyCommission("FSC")toperformvariouslicensecompliancechecks(e.g.,marketingauthorizationholder,manufacturerandoverseasiteaccreditation)andensuregoodpromotionalactivities.Routineinspections,antimicrobialfeedadditivenationalassaysandmanufacturinginspectionsaredonebytheFood&AgricultureMaterialInspectionCenter.Forfoodanimalproducts,animaldrugreviewisdonebyNVALbutthehumanfoodsafetyreviewisdonebyFSC(acceptabledailyintakeestablishmentandantimicrobialriskassessment)andMHLW(maximumresiduelimitestablishment).Thesethreeagencies(NVAL,FSCandMHLW)worktogethertoapprovefoodanimalproducts.Inadditiontothosecentralgovernmentagencies,variouslicensesaredelegatedtothelocalmunicipalgovernment,suchasanimaldrugwholesalerandretailerlicensesandfeedadditivedistributorlicenses.
China. TheMinistryofAgriculture("MOA")istheregulatorybodythatisresponsiblefortheregulationandcontrolofpharmaceuticals,biologicals,disinfectants,medicinalfeedadditives,pesticideandfeed/feedadditivesforanimaluse.TherearethreeorganizationsundertheMOAthatregulateanimalhealth:
• TheInstituteofVeterinaryDrugControlisresponsiblefortheevaluationofnewapplications,renewals,variations,manufacturers,qualitymethodsandtissueresiduemethodsforpharmaceuticals,biologicals,disinfectantsandmedicinalfeedadditives.
• TheFeed/FeedAdditiveOfficeisresponsiblefortheregistrationandrenewaloffeedandfeedadditives.
• ThePesticideBureauisresponsiblefortheregistrationandrenewalofpesticideproducts.
Australia. TheAustralianPesticidesandVeterinaryMedicinesAuthority("APVMA")isanAustraliangovernmentstatutoryauthorityestablishedin1993tocentralizetheregistrationofallagriculturalandveterinaryproductsintotheAustralianmarketplace.Previously,eachstateandterritorygovernmenthaditsownsystemofregistration.TheAPVMAassessesapplicationsfromcompaniesandindividualsseekingregistrationsotheycansupplytheirproducttothemarketplace.ApplicationsundergorigorousassessmentusingtheexpertiseoftheAPVMA'sscientificstaffanddrawingonthetechnicalknowledgeofotherrelevantscientificorganizations,Commonwealthgovernmentdepartmentsandstateagriculturedepartments.Iftheproductworksasintendedandthescientificdataconfirmsthatwhenusedasdirectedontheproductlabelitwillhavenoharmfulorunintendedeffectsonpeople,animals,theenvironmentorinternationaltrade,theAPVMAwillregistertheproduct.Aswellasregisteringnewagriculturalandveterinaryproducts,theAPVMAreviewsolderproductsthathavebeenonthemarketforasubstantialperiodoftimetoensuretheystilldothejobusersexpectandaresafetouse.TheAPVMAalsoreviewsregisteredproductswhenparticularconcernsareraisedabouttheirsafetyandeffectiveness.Thereviewofaproductmayresultinconfirmationofitsregistrationoritmayseeregistrationcontinuewithsomechangestothewaytheproductcanbeused.Insomecases
90
TableofContents
thereviewmayresultintheregistrationofaproductbeingcancelledandtheproducttakenoffthemarket.
Rest of world. Country-specificregulatorylawstypicallyhaveprovisionsthatincluderequirementsforcertainlabeling,safety,efficacyandmanufacturers'qualitycontrolprocedures(toassuretheconsistencyoftheproducts),aswellascompanyrecordsandreports.Othercountries'regulatoryagenciestypicallyeitherrefertotheFDA,USDA,EUorotherinternationalanimalhealthentities,includingtheWorldOrganizationforAnimalHealth,CodexAlimentariusandVICH(seebelow),inestablishingstandardsandregulationsforveterinarypharmaceuticalsandvaccines,orreviewthequality,safetyandeffectivenessoftheproductsthemselvesaccordingtotheirownnationalrequirements.
Global policy and guidance
Joint FAO/WHO Expert Committee on Food Additives. TheJointFAO/WHOExpertCommitteeonFoodAdditives("JECFA")isaninternationalexpertscientificcommitteethatisadministeredjointlybytheFoodandAgricultureOrganizationoftheUnitedNations("FAO")andtheWorldHealthOrganization("WHO").Theyprovideariskassessment/safetyevaluationofresiduesofveterinarydrugsinanimalproducts,exposureandresiduedefinitionandmaximumresiduelimitproposalsforveterinarydrugs.Similarly,theJointFAO/WHOMeetingonPesticideResidues("JMPR")isaninternationalexpertscientificgroupadministeredjointlybytheFAOandWHO.JMPRreviewsresiduesandanalyticalaspectsofthepesticides,estimatethemaximumresiduelevels,reviewtoxicologicaldataandestimateacceptabledailyintakesforhumansofthepesticidesunderconsideration.Elancoworkswiththesecommitteestoestablishacceptablesafelevelsofresidualproductinfood-producinganimalsaftertreatmentwithveterinarydrugsorpesticides.ThisinturnenablesthecalculationofappropriatewithdrawaltimesforElanco'sproductspriortoananimalenteringthefoodchain.
Advertising and promotion review. Promotionofethicalanimalhealthproductsiscontrolledbyregulationsinmanycountries.Theserulesgenerallyrestrictadvertisingandpromotiontothoseclaimsandusesthathavebeenreviewedandendorsedbytheapplicableagency.Elancoconductsareviewofpromotionmaterialforcompliancewiththelocalandregionalrequirementsinthemarketswhereitsellsanimalhealthproducts.
Import and Export of Products. Theimportationandexportationofanimalhealthproductsiscontrolledbyregulationsinmanycountries.Insomejurisdictionsthismayincludeobtainingseparatepermitsorlicensesbyproductorbycompanyorfilingnoticeswithapplicableregulatoryagenciespriortoimportorexportofproduct.Elancoensurescompliancewithlocalandglobalregulationsinthemarketswhereitimports/exportsitsanimalhealthproducts.
International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products. VICHisatrilateral(EU-Japan-USA)programlaunchedin1996aimedatharmonizingtechnicalrequirementsforveterinaryproductregistration.Severalothercountrieshaveobtainedobserverstatus,forexample,Canada,NewZealand,AustraliaandSouthAfrica,orarelinkedtoVICHonbasisoftheVICHOutreachForum,aVICHinitiativewiththemainobjectiveofprovidingabasisforwiderinternationalharmonizationoftechnicalrequirements.Inaddition,theWorldOrganizationforAnimalHealthisanassociatememberofVICH.
TheobjectivesoftheVICHareasfollows:
• EstablishandimplementharmonizedtechnicalrequirementsfortheregistrationofveterinarymedicinalproductsintheVICHregions,whichmeethighquality,safetyandefficacystandardsandminimizetheuseoftestanimalsandcostsofproductdevelopment.
91
TableofContents
• ProvideabasisforwiderinternationalharmonizationofregistrationrequirementsthroughtheVICHOutreachForum.
• MonitorandmaintainexistingVICHguidelines,takingparticularnoteoftheworkprogramofthecorrespondinghumandruggroupand,wherenecessary,updatetheseVICHguidelines.
• EnsureefficientprocessesformaintainingandmonitoringconsistentinterpretationofdatarequirementsfollowingtheimplementationofVICHguidelines.
• Bymeansofaconstructivedialoguebetweenregulatoryauthoritiesandindustry,providetechnicalguidanceenablingresponsetosignificantemergingglobalissuesandsciencethatimpactregulatoryrequirementswithintheVICHregions.
Employees
AsofDecember31,2018,Elancoemployedapproximately5,590fulltimeemployees.Inaddition,Elancoemployedapproximately190fixed-durationemployees,whichareindividualshiredforapre-definedlengthoftime(onetofouryears).Together,theytotalapproximately5,780worldwide.Ofthe5,780employeesglobally,approximately2,440areU.S.-basedandapproximately3,340areemployedinotherjurisdictions.Someoftheseemployeesaremembersofunions,workscouncils,tradeassociationsorareotherwisesubjecttocollectivebargainingagreements,includingapproximately150unionemployeesintheU.S.locatedatElanco'sFortDodge,Iowamanufacturing/R&Dfacility.Approximately40%ofElanco'sglobalpopulationisincustomer-facingroles,includingbutnotlimitedto,traditionalsalesroles,technicalconsultants,accountmanagersandcommercialandgeneralmanagers.
Property
ElancohasR&Doperationsco-locatedwithcertainofitsmanufacturingsitesintheU.S.tofacilitatetheefficienttransferofproductionprocessesfromElanco'slaboratoriestomanufacturingsites.Inaddition,ElancomaintainsR&Doperationsatnon-manufacturinglocationsintheU.S.,Switzerland,Australia,BrazilandChina.Aspartoftheseparation,LillytransferredtoElancoitsinterestineachoftheseR&Dfacilities.Elanco'slargestR&DfacilityisitsU.S.R&DsitelocatedinFortDodge,Iowa,whichhasapproximately0.3millionsquarefeet.
TheaddressofElanco'sprincipalexecutiveofficesiscurrentlyc/oElanco,2500InnovationWay,GreenfieldIN,46140.
Elanco'sglobalmanufacturingnetworkiscomprisedof12manufacturingsites.ThelargestmanufacturingsiteinElanco'sglobalmanufacturingnetworkisitsmanufacturingsitelocatedinClinton,Indiana,whichhasapproximately0.7millionsquarefeet.Inaddition,Elanco'sglobalmanufacturingnetworkwillcontinuetobesupplementedbyapproximately100CMOs.See"—ManufacturingandSupplyChain."
Elancoownsorleasesvariousadditionalpropertiesforotherbusinesspurposesincludingofficespace,warehousesandlogisticscenters.Inaddition,underthetransitionalservicesagreement,LillyprovidesElancowithcontinuedaccesstocertainofLilly'spremisescurrentlyoccupiedbyElanco'semployeesforuptotwoyearsfromthedateoftheseparation.
Elancobelievesthatitsexistingproperties,assupplementedbyCMOsandaccesstoLillyfacilitiesthatareprovidedunderthetransitionalservicesagreement,areadequateforElanco'scurrentrequirementsandforitsoperationsinthenearfuture.
92
TableofContents
Environmental, Health and Safety
Elancoissubjecttovariousfederal,state,localandforeignenvironmental,healthandsafety("EHS")lawsandregulations.Theselawsandregulationsgovernmatterssuchastheemissionanddischargeofhazardousmaterialsintotheground,airorwater;thegeneration,use,storage,handling,treatment,packaging,transportation,exposureto,anddisposalofhazardousandbiologicalmaterials,includingrecordkeeping,reportingandregistrationrequirements;andthehealthandsafetyofElanco'semployees.DuetoElanco'soperations,theselawsandregulationsalsorequireittoobtain,andcomplywith,permits,registrationsorotherauthorizationsissuedbygovernmentalauthorities.TheseauthoritiescanmodifyorrevokeElanco'spermits,registrationsorotherauthorizationsandcanenforcecompliancethroughfinesandinjunctions.
Certainenvironmentallawsimposejointandseveralliability,withoutregardtofault,forcleanupcostsonpersonswhohavedisposedoforreleasedhazardoussubstancesintotheenvironment,includingatthird-partysitesoroffsitedisposallocations,orthatcurrentlyownoroperate(orformerlyownedoroperated)siteswheresuchareleaseoccurred.ElancocouldbesubjecttoliabilityfortheinvestigationandremediationoflegacyenvironmentalcontaminationcausedbyhistoricalindustrialactivityatsitesthatElancoownsoronwhichitoperates.Inadditiontoclean-upactionsbroughtbyfederal,state,localandforeigngovernmentalentities,privatepartiescouldraisepersonalinjuryorotherclaimsagainstElancoduetothepresenceof,orexposureto,hazardousmaterialson,fromorotherwiserelatingtosuchaproperty.
Elancohasmade,andintendstocontinuetomake,necessaryexpendituresforcompliancewithapplicableEHSlawsandregulations.Elancoisalsomonitoringandinvestigatingenvironmentalcontaminationfrompastindustrialactivityatcertainsites.WhileElancocannotpredictwithcertaintyitsfuturecapitalexpendituresoroperatingcostsforenvironmentalcomplianceortheinvestigationandremediationofcontaminatedsites,ElancoanticipateshavingcapitalandoperationalexpendituresfortheyearsendingDecember31,2019and2020forenvironmentalcompliancepurposesandforthemonitoring,investigationorclean-upofcertainpastindustrialactivitiesasfollows:
• environmental-relatedcapitalexpenditures—$0.7million;and
• otherenvironmental-relatedexpenditures—$0.7million.
Inconnectionwithpastacquisitionsanddivestitures,Elancohasundertakencertainindemnificationobligationsthatmayrequireitinthefuture,toconductorfinanceenvironmentalcleanupsatsitesthatitnolongerownsoroperates.Elancohasalsoenteredintoindemnificationagreementsinwhichitisormaybeindemnifiedforvariousenvironmentalcleanups;however,suchindemnitiesarelimitedinbothtimeandscopeandmaybefurtherlimitedinthepresenceofnewinformation,ormaynotbeavailableatall.
Legal Proceedings
Elancoisfromtimetotimesubjecttoclaimsandlitigationarisingintheordinarycourseofbusiness.Theseclaimsandlitigationmayinclude,amongotherthings,allegationsofviolationofU.S.andforeigncompetitionlaw,laborlaws,consumerprotectionlawsandenvironmentallawsandregulations,aswellasclaimsorlitigationrelatingtoproductliability,intellectualproperty,securities,breachofcontractandtort.Elancooperatesinmultiplejurisdictionsand,asaresult,aclaiminonejurisdictionmayleadtoclaimsorregulatorypenaltiesinotherjurisdictions.Elancointendstovigorouslydefendagainstanypendingorfutureclaimsandlitigation,asappropriate.
Atthistime,intheopinionofElanco'smanagement,thelikelihoodisremotethattheimpactofsuchproceedings,eitherindividuallyorintheaggregate,wouldhaveamaterialadverseeffectonElanco'scombinedresultsofoperations,financialconditionorcashflows.However,oneormoreunfavorableoutcomesinanyclaimorlitigationagainstElancocouldhaveamaterialadverseeffectfor
93
TableofContents
theperiodinwhichtheyareresolved.Inaddition,regardlessoftheirmeritsortheirultimateoutcomes,suchmattersarecostly,divertmanagement'sattentionandmaymateriallyadverselyaffectElanco'sreputation,evenifresolvedinitsfavor.
Available Information
Elanco'swebsiteaddressiswww.elanco.com .OnElanco'swebsite,thecompanymakesavailable,freeofcharge,itsannual,quarterlyandcurrentreports,includingamendmentstosuchreports,assoonasreasonablypracticableafterthecompanyelectronicallyfilessuchmaterialwith,orfurnishessuchmaterialto,theSEC.
InformationrelatingtocorporategovernanceatElanco,includingElanco'sCorporateGovernanceGuidelines,CodeofConduct,FinancialCodeofEthics,ArticlesofIncorporation,Bylaws,CommitteeCharters;informationconcerningElanco'sexecutiveofficersandmembersofitsboardofdirectors;andwaystocommunicateareavailableonElanco'swebsite.ElancowillprovideanyoftheforegoinginformationwithoutchargeuponwrittenrequesttoElanco'sCorporateSecretary,Elanco,2500InnovationWay,Greenfield,Indiana46140.InformationrelatingtoshareholderservicesisalsoavailableonElanco'swebsite.TheinformationcontainedonElanco'swebsitedoesnotconstituteapartofthisprospectus.
94
TableofContents
MANAGEMENT
Directors and Executive Officers
Thefollowingtablesetsforththenames,ages,asofMay10,2019,andtitlesofElanco'sexecutiveofficersandmembersofElanco'sboardofdirectors.Certainbiographicalinformationwithrespecttothoseexecutiveofficersanddirectorsfollowsthetable.
Jeffrey N. Simmons hasservedasElanco'sPresidentandChiefExecutiveOfficerandasadirectoronElanco'sboardsinceJuly2018.Mr.SimmonsservedasthePresidentoftheElancoAnimalHealthdivisionofLillyandSeniorVicePresidentofLillyfrom2008untilSeptember2018.Priorto2008,Mr.SimmonsheldvariousleadershiprolesforElanco,includingDistrictSalesManager,InternationalMarketingManager,CountryDirectorforBrazil,AreaDirectorforWesternEuropeandExecutiveDirectorforU.S.andGlobalResearch&Development.
Mr.Simmons'experiencedescribedabove,includinghisknowledgeofElancoandtheanimalhealthindustryandhisbusinessandmanagementexperience,provideshimwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Todd S. Young hasservedasElanco'sExecutiveVicePresidentandChiefFinancialOfficersinceNovember2018.PriortojoiningElanco,Mr.YoungwastheExecutiveVicePresidentandChiefFinancialOfficeratACADIAPharmaceuticalssince2016.PriortohistimeatACADIA,Mr.YoungservedasSeniorVicePresidentandTreasurerleadingthecreationofacapitalstructureforBaxaltaupuntiltheiracquisitionbyShireinJune2016.PriortoBaxalta,Mr.Youngworkedforover14yearsatBaxterinmultipleleadershiproles,includingCorporateVicePresidentandTreasurer,VicePresident,InternationalFinance,andVicePresident,GlobalFinancialPlanningandAnalysis.
James M. Meer hasservedasElanco'sVicePresidentandChiefAccountingOfficersinceSeptember2018.PriortojoiningElanco,Mr.MeerservedastheChiefFinancialOfficerofHealthx,Inc.sinceJune2017.PriortojoiningHealthx,heservedasSeniorVicePresidentofFinanceatAppiriofrom2014to2017andasVicePresidentandCorporateControlleratSalesforce(previouslyExactTarget)from2011to2014.Priorto2011,Mr.Meerheldvariousfinancial,accountingandstrategy
95
Name Age PositionJeffreyN.Simmons 51 President,ChiefExecutiveOfficerandDirectorToddS.Young 47 ExecutiveVicePresidentandChiefFinancialOfficerJamesM.Meer 49 VicePresident,ChiefAccountingOfficerRamiroM.Cabral 47 ExecutiveVicePresident,ElancoInternationalMichael-BryantHicks 44 ExecutiveVicePresident,GeneralCounselandCorporateSecretaryDavidS.Kinard 52 ExecutiveVicePresident,HumanResourcesSarenaS.Lin 48 ExecutiveVicePresident,ElancoUSA,CorporateStrategyandGlobalMarketingAaronL.Schacht 52 ExecutiveVicePresident,Innovation,RegulatoryandBusinessDevelopmentDavidA.Urbanek 53 ExecutiveVicePresident,ManufacturingandQualityR.DavidHoover 73 Director(Chairman)KapilaK.Anand 65 DirectorJohnP.Bilbrey 62 DirectorArtA.Garcia 58 DirectorMichaelJ.Harrington 56 DirectorDeborahT.Kochevar 63 DirectorLawrenceE.Kurzius 61 DirectorKirkMcDonald 52 DirectorDeniseScots-Knight 60 Director
TableofContents
positionsat3M(previouslyAearoTechnologiesInc.),Hill-Rom,HillenbrandIndustriesandErnst&YoungLLP.Mr.Meerisacertifiedpublicaccountant.
Ramiro M. Cabral hasservedasElanco'sExecutiveVicePresident,ElancoInternationalsinceJanuary2019.Mr.CabralservedasExecutiveVicePresident,ElancoInternationalandGlobalCustomerValuefromJuly2018toDecember2018andasVicePresidentandChiefMarketingOfficeroftheElancoAnimalHealthdivisionofLillyfrom2017untilSeptember2018.Mr.CabraljoinedLillyin2005andheldvariousleadershippositionsforElanco,includingVicePresidentandHeadofOperationsforElancoEMEAfrom2013to2017andSeniorDirector,U.S.BeefBusinessUnitfrom2011to2013.
Michael-Bryant Hicks hasservedasElanco'sExecutiveVicePresident,GeneralCounselandCorporateSecretarysinceJuly2018.Mr.HicksservedasGeneralCounseloftheElancoAnimalHealthdivisionofLillyfromMay2018toSeptember2018.PriortojoiningElanco,Mr.Hicksservedinvariouslegalroles,includingGeneralCounselatMallinckrodtPublicLiabilityCompanyfrom2016to2018,SeniorVicePresident,GeneralCounselandCorporateStrategyatTheProvidenceServiceCorporationfrom2014to2016andasAssistantGeneralCounselatDaVitaInc.from2011to2013.
David S. Kinard hasservedasElanco'sExecutiveVicePresident,HumanResourcessinceJanuary2019.Mr.KinardservedasElanco'sExecutiveVicePresident,HumanResourcesandCorporateAffairsfromJuly2018toDecember2018andasVicePresidentofHumanResourcesandGlobalLearningandDevelopmentfortheElancoAnimalHealthdivisionofLillyfromMay2018toSeptember2018.PriortoMay2018,Mr.KinardservedinvariousleadershiprolesforLilly,includingVicePresidentofHumanResourcesforavarietyofLillybusinesses,includingLillyInternationalin2017,Bio-MedicinesandEmergingMarketsfrom2015to2017andLillyDiabetesandGlobalEmployeeRelations/HROperationsfrom2011to2015.
Sarena S. Lin hasservedasElanco'sExecutiveVicePresident,ElancoUSA,CorporateStrategyandGlobalMarketingsinceJanuary2019.Ms.LinservedasExecutiveVicePresident,ElancoUSAandGlobalStrategyfromJuly2018toDecember2018andasSeniorVicePresidentofNorthAmericanOperationsandStrategyattheElancoAnimalHealthdivisionofLillyfromJanuary2018toSeptember2018.PriortojoiningLilly,Ms.LinservedasPresidentofCargillFeed&Nutritionfrom2014to2017.Priorto2014,Ms.LinservedasGlobalHeadofStrategyandBusinessDevelopmentforCargillfrom2011to2014.Ms.Linservedontheboardofdirectorsfortheanimalhealthanddentaldistributor,PattersonCompanies,from2014to2018.
Aaron L. Schacht hasservedasElanco'sExecutiveVicePresident,Innovation,RegulatoryandBusinessDevelopmentsinceJuly2018.Mr.SchachtservedastheVicePresidentofglobalresearchanddevelopmentoftheElancoAnimalHealthdivisionofLillyfrom2015toSeptember2018.Priorto2015,Mr.SchachtservedinvariousleadershiprolesforLilly,includingGlobalBrandDevelopmentLeaderofPaininLillyBioMedicinesin2014,SeniorAdvisorofStrategy&BusinessDevelopmentforLillyBioMedicinesfrom2012to2014andExecutiveDirectorofGlobalExternalR&DatLillyfrom2008to2012.
David A. Urbanek hasservedasElanco'sExecutiveVicePresident,ManufacturingandQualitysinceJuly2018.Mr.UrbanekservedasVicePresidentofManufacturingattheElancoAnimalHealthdivisionofLillyfromNovember2017toSeptember2018.Priortothat,Mr.UrbanekservedinvariousleadershiprolesforLilly'sManufacturingdivision,includingSeniorDirectorofEmergingMarketsManufacturingfrom2013to2017,SeniorDirectorofGlobalDiabetesManufacturingfrom2011to2013andSeniorDirectorofExternalDrugProductsOperationsfrom2009to2011.
R. David Hoover hasservedasthechairmanofElanco'sboardsinceMay2018.Mr.Hooverhasbeenretiredsince2013.Priortothat,Mr.HooverservedinvariousrolesatBallCorporation,includingChairmanfrom2002to2013,ChiefExecutiveOfficerfrom2010to2011,PresidentandChief
96
TableofContents
ExecutiveOfficerfrom2001to2010,ChiefOperatingOfficerfrom2000to2001andChiefFinancialOfficerfrom1998to2000.Mr.HoovercurrentlyservesontheboardsofdirectorsofBallCorporationandEdgewellPersonalCareCompany.
Mr.Hoover'sexperiencedescribedabove,includinghisextensivemanagementexperienceasChiefExecutiveOfficerandChiefFinancialOfficeratBallCorporationandcorporategovernanceexperiencethroughhisserviceonotherpublicboards,includingnineyearshepreviouslyservedasadirectorforLilly,provideshimwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Kapila K. Anand hasservedasadirectoronElanco'sboardsinceSeptember2018.Ms.AnandhasservedasaSeniorAdvisortoKPMGLLPsince2016.Priortothat,Ms.AnandservedinvariousleadershiprolesasapartneratKPMGLLP,includingIndustrySegmentLeader—Travel,LeisureandHospitalityfrom2011to2017,PartnerinCharge—PublicPolicyBusinessInitiativesfrom2009to2013,KPMGLLPBoardmemberfrom2005to2010,AdvisoryLeader—PrivateEquity,RealEstateandHospitalityfrom2002to2009andAuditPartner—RealEstateandHospitalityfrom1989to2002.Ms.AnandcurrentlyservesontheboardsofdirectorsofExtendedStayAmerica,Inc.andOmegaHealthcareInvestors,Inc.
Ms.Anand'sexperiencedescribedabove,includingherextensivefinancial,managerialandcorporategovernanceexperience,providesherwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
John P. Bilbrey ,alsoknownasJ.P.,hasservedasamemberoftheBoardsinceMarch2019.HeservedastheCEOandPresidentofTheHersheyCompany,amultinationalconsumerfoodcompany,from2011untilhisretirementin2017,andasChairmanoftheBoardfrom2015until2018.Previously,Mr.BilbreyservedinvariousrolesatTheHersheyCompany,includingastheChiefOperatingOfficerandEVPfrom2010to2011,thePresidentofNorthAmericafrom2007to2010,thePresidentofInternationalCommercialgroupfrom2005to2007.PriortojoiningTheHersheyCompany,heheldleadershippositionsatMissionFoods,DanoneWatersofNorthAmerica,Inc.,BilbreyFarmsandRanchandProcter&GambleCompany.Mr.BilbreycurrentlyservesontheboardofdirectorsofColgate-PalmoliveCompanyandhaspreviouslyservedontheboardsofdirectorsofTheHersheyCompanyandMcCormick&Company,Incorporated.
Mr.Bilbrey'sexperiencedescribedabove,includingtheuniquecombinationoflivestockproduction,foodindustryandconsumerinsightsexperience,provideshimwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Art A. Garcia hasservedasamemberoftheBoardsinceMay2019.Mr.GarciaservedinvariousleadershiprolesatRyderSystems,Inc.,includingExecutiveVicePresidentandChiefFinancialOfficerfrom2010untilhisretirementinApril2019,SeniorVicePresidentandControllerfrom2005to2010andVicePresidentandControllerfrom2002to2005.Mr.Garciaisacertifiedpublicaccountant.Mr.GarciacurrentlyservesontheboardofdirectorsofABMIndustriesIncorporated.
Mr.Garcia'sexperiencedescribedaboveandhisextensivestrategic,financialandtechnicalexpertise,aswellasstrongfocusongrowth,provideshimwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Michael J. Harrington hasservedasadirectoronElanco'sboardsinceSeptember2018.Mr.HarringtonhasservedastheSeniorVicePresidentandGeneralCounselforLillysinceJanuary2013.Priorto2013,Mr.HarringtonservedinvariouslegalrolesforLilly,includingVicePresidentandDeputyGeneralCounselofGlobalPharmaceuticalOperationsfrom2010to2012andVicePresidentandGeneralCounsel,Corporatefrom2004to2010.
97
TableofContents
Mr.Harrington'sexperiencedescribedabove,includinghisknowledgeofElancoandtheanimalhealthindustryandhisbusinessandmanagementexperience,provideshimwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Deborah T. Kochevar ,D.V.M.,Ph.D.,DACVCP,hasservedasamemberoftheBoardsinceMarch2019.Dr.KochevarhasservedhasservedastheprovostandseniorvicepresidentadinterimatTuftsUniversitysince2018.SheservedastheDeanoftheCummingsSchoolofVeterinaryMedicineatTuftsUniversityfrom2006through2018.Previously,Dr.Kochevarwasalong-timefacultymemberandadministratorattheCollegeofVeterinaryMedicineandBiomedicalSciences,TexasA&MUniversity,wheresheheldtheWileyChairofVeterinaryMedicalEducation.Dr.Kochevarisapast-presidentoftheAssociationofAmericanVeterinaryMedicalCollegesandAmericanCollegeofVeterinaryClinicalPharmacology.Dr.KochevarisactiveintheAmericanVeterinaryMedicalAssociation,havingchaireditsCouncilonEducationandtheEducationalCommissionforForeignVeterinaryGraduates.Dr.KochevarcurrentlyservesontheboardofdirectorsofCharlesRiverLaboratoriesInternational,Inc.
Dr.Kochevar'sexperiencedescribedabove,includingherdeepanimalhealthexpertiseandOneHealthapproach,willaddtoElanco'sfocusondeliveringbest-in-classinnovationacrosstheportfolioandprovidesherwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Lawrence E. Kurzius hasservedasadirectoronElanco'sboardsinceSeptember2018.Mr.KurziushasservedinvariousleadershiprolesatMcCormick&Company,includingdirectorsince2015andChairmanoftheBoardofDirectorssince2017,ChiefExecutiveOfficersince2016,Presidentsince2015,ChiefOperatingOfficerfrom2015to2016,ChiefAdministrativeOfficerfrom2013to2015,President,InternationalBusinessesfrom2008to2013,President,Europe,MiddleEastandAfricafrom2007to2008andPresident,U.S.ConsumerFoodsfrom2005to2006.
Mr.Kurzius'experiencedescribedabove,includinghisextensivemanagementexperienceandcorporategovernanceexperience,provideshimwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Kirk McDonald hasservedasamemberoftheBoardsinceMarch2019.Mr.McDonaldhasservedastheChiefMarketingOfficerofXandr,AT&T'sAdvertisingandAnalyticscompany,sinceNovember2017.PriortoXandr,McDonaldservedasthePresidentofPubMatic,acompanydevelopingandimplementingonlineadvertisingsoftwareandstrategies,since2011.BeforejoiningPubMatic,hewasPresidentofDigitalatTimeInc.,from2009to2011andtheChiefAdvertisingOfficeroftheFortune--MoneyGroup.HehasalsoservedastheSVPofSales,MarketingandClientServicesforDRIVEpmandAtlas,bothunitsofMicrosoft'sadvertisingbusiness,aswellasinvariousrolesatCNET,ZiffDavisandCondéNast.McDonaldservesonseveralprofessionalandnot-for-profitboards.HewasaformeradvisorontheLUMAPartnersboardandiscurrentlytheChairmanofanon-profit,CodeInteractive,whichisfocusedoninspiringthenextgenerationoftechnologyleadersfromunderservedcommunities.
Mr.McDonald'sexperiencedescribedabove,includinghisproficiencydrivingdigitaltransformation,marketingcapabilityandknow-howinusingcutting-edgetechnologytoconnectwithtoday'scustomers,provideshimwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Denise Scots-Knight ,PhD,hasservedasamemberoftheBoardsinceMarch2019.Dr.Scots-Knightwastheco-founderof,andhasservedastheChiefExecutiveOfficerandmemberoftheboardofMereoBioPharmaGroupplc,aspecialtybiopharmaceuticalcompany,since2015.From2010until2015,shewastheManagingPartnerofPhase4PartnersLtd.,agloballifescienceventurecapitalfirm.From2004to2010,Dr.Scots-KnightwasheadofNomuraPhase4Ventures,aventurecapitalaffiliateofNomuraInternationalplc,aleadingJapanesefinancialinstitution.Dr.Scots-Knighthasservedon
98
TableofContents
theboardsofdirectorsofOncomedPharmaceuticals,Inc.,IdenixPharmaceuticals,Inc.andNabrivaTherapeuticsAG.
Dr.Scots-Knight'sexperiencedescribedabove,includingherextensivepreviousboardleadership,historyleadinganinnovationandgrowth-orientedcompany,andexpertisebuildinginnovationmodelsandpartnerships,providesherwiththequalificationsandskillstoserveasadirectoronElanco'sboard.
Board of Directors
Elanco'sbusinessandaffairsaremanagedunderthedirectionofitsboardofdirectors.Elanco'samendedandrestatedarticlesofincorporationandamendedandrestatedbylawsprovidethatitsboardofdirectorswillconsistofnotlessthanfivedirectors.AsofMay10,2019,Elanco'sboardofdirectorsiscomposedof10directors.CertainindividualswhoservedasElanco'sdirectorswhowereofficersoremployeesofLillyresigneduponthecompletionoftheSplit-Off,andatsuchtimeweappointedadditionalindependentdirectors.
Elanco'sboardisdividedintothreeclasses,denominatedasClassI,ClassIIandClassIII,witheachclassholdingofficeforstaggeredthree-yearterms.AteachannualmeetingofElanco'sshareholdersbeginningin2019,thesuccessorstothedirectorswhosetermexpiresatthatmeetingwillbeelectedtoserveuntilthethirdannualmeetingaftertheirelectionoruntiltheirsuccessorshavebeenelectedandqualified.Currentlythemembersofeachclassinclude:
ClassI(termsexpiringatthe2022annualmeeting):KapilaK.Anand,JohnP.Bilbrey,R.DavidHooverandLawrenceE.Kurzius.
ClassII(termsexpiringatthe2020annualmeeting):MichaelJ.Harrington,DeborahT.KochevarandKirkMcDonald.
ClassIII(termsexpiringatthe2021annualmeeting):ArtA.Garcia,DeniseScots-KnightandJeffreyN.Simmons.
Director Independence
Theboardannuallydetermines,takingintoconsiderationtherecommendationsoftheNominatingandCorporateGovernanceCommittee,anddisclosestheindependenceofdirectors.Nodirectorisconsideredindependentunlesstheboardhasdetermined,basedonallrelevantfactsandcircumstances,thatheorshehasnomaterialrelationshipwiththecompany,eitherdirectlyorasapartner,significantshareholder,orofficerofanorganizationthathasamaterialrelationshipwiththecompany.TheboardhasadoptedthecategoricalindependencestandardsfordirectorsestablishedintheNYSElistingstandards.
OntherecommendationoftheNominatingandCorporateGovernanceCommittee,theboardhasdeterminedthateachofKapilaK.Anand,JohnP.Bilbrey,ArtA.Garcia,R.DavidHoover,DeborahT.Kochevar,LawrenceE.Kurzius,KirkMcDonaldandDeniseScots-KnightisindependentundertheapplicablerulesoftheNYSEandtheExchangeAct.TheboardalsodeterminedthateachofthemembersoftheAuditCommittee,theCompensationCommittee,andtheNominatingandCorporateGovernanceCommitteealsomeetourindependencestandards.Theboarddeterminedthatnoneofthenon-employeedirectors,otherthanMichaelJ.Harrington,hashadduringthelastthreeyears(i)anyoftherelationshipsidentifiedinthecompany'scategoricalindependencestandardsor(ii)anyothermaterialrelationshipwiththecompanythatwouldcompromisehisorherindependence.
Compensation Committee Interlocks and Insider Participation
Elancodoesnothaveanyinterlockingrelationshipsbetweenanymembersofitscompensationcommitteeandanyofitsexecutiveofficersthatwouldrequiredisclosureundertheapplicablerulespromulgatedunderthefederalsecuritieslaws.
99
TableofContents
EXECUTIVE COMPENSATION
Compensation Discussion and Analysis
Introduction
Thiscompensation,discussionandanalysis("CD&A")providesdetailedinformationregardingElanco'sChiefExecutiveOfficer,ChiefFinancialOfficer,formerChiefFinancialOfficer,formerActingChiefFinancialOfficerandthreemosthighly-compensatedexecutiveofficerswhoarenamedbelow(collectively,the"NamedExecutiveOfficers")withrespectto2018compensation:
PriortotheIPO,Elanco'sbusinessoperatedaspartofadivisionofLilly.Asaresult,thediscussioninthisCD&AasitrelatestoElanco'scompensationprogramspriortotheIPO,relatestoLilly'scompensationphilosophybecauseLillyestablishedandmanagedthecompensationforalloftheNamedExecutiveOfficersuntilthecompletionoftheIPOonSeptember24,2018.BecauseMs.LinandMessrs.Montarce,Jensen,KinardandUrbanekwerenotexecutiveofficersofLilly,theircompensationpriortotheIPOwasdeterminedbyLilly'sseniormanagementconsistentwithLilly'scompensationphilosophy,butwasnotspecificallydeterminedorreviewedbytheLillycompensationcommittee.AsaLillyexecutiveofficerpriortotheIPO,Mr.Simmons'compensationwasreviewedanddeterminedbyLilly'scompensationcommittee,withtheadviceofthecompensationconsultantengagedbyLilly'scompensationcommittee.
InconnectionwiththeIPO,theElancoboardofdirectorsapprovedthepaypackagesfortheexecutiveofficersofElanco,includingcertainoftheNamedExecutiveOfficers.InconnectionwithhishiringfollowingtheIPO,Mr.Young'scompensationwasreviewedandapprovedbytheElancocompensationcommittee.ThisElancocompensationfor2018ismorefullydescribedbelowunder"ElancoCompensationProgram—CompensationArrangements."
ThisCD&AdiscussesthecompensationprogramsapplicabletoNamedExecutiveOfficersandtheircompensationthereunderin2018,includingadescriptionofLilly'scompensationphilosophy,theelementsofeachcompensationprogram,thefactorsthatLillyconsideredinsettingcompensation,andhowresultsaffectedincentivepayoutsfor2018performanceforeachoftheNamedExecutiveOfficerswithrespecttotheperiodpriortotheIPO.ThisCD&AalsodescribescertainelementsofElanco'scompensationprogramsandpoliciesfollowingtheIPOthroughDecember31,2018,whichlargelyreflectElanco'sdeterminationtogenerallymaintainLilly'scompensationphilosophyandotherelementsofLilly'scompensationprogramsandpoliciesthroughtheSplit-Off,withcertainadjustments
100
Name TitleJeffreyN.Simmons President,ChiefExecutiveOfficerandDirectorToddS.Young(1) ExecutiveVicePresidentandChiefFinancialOfficerSarenaS.Lin ExecutiveVicePresident,ElancoUSA,CorporateStrategyandGlobalMarketingDavidA.Urbanek ExecutiveVicePresident,ManufacturingandQualityDavidS.Kinard ExecutiveVicePresident,HumanResourcesChristopherW.Jensen(2) FormerChiefFinancialOfficerLucasE.Montarce(3) FormerActingChiefFinancialOfficer
(1) Mr.YounghasservedasElanco'sChiefFinancialOfficersinceNovember1,2018.
(2) Mr.JensenservedasElanco'sChiefFinancialOfficerbeginningonApril23,2018,butbeganamedicalleaveofabsenceonoraboutAugust1,2018anddidnotreturntohisposition.
(3) Mr.MontarcewasnamedActingChiefFinancialOfficeronAugust1,2018andservedinthatrolethroughOctober31,2018.
TableofContents
topaypackagesinconnectionwiththeIPOasdescribedunder"ElancoCompensationProgram"below.
Lilly's Philosophy on Compensation
Lilly'scompensationprogramsaredesignedtohelpachievethegoalsofattracting,engagingandretaininghighlytalentedindividualswhoarecommittedtoitscorevaluesofintegrity,excellenceandrespectforpeoplewhilebalancingthelong-terminterestsofitsshareholdersandcustomers.
Lilly'scompensationandbenefitsprogramsarebasedonthefollowingobjectives:
• Reflect individual and company performance. Lillyreinforcesahigh-performanceculturebylinkingpaywithindividualperformanceandcompanyperformance.AsLillyemployeesassumegreaterlevelsofresponsibility,theproportionoftotalcompensationbasedoncompanyperformanceandshareholderreturnsincreases.Lillyperformsanannualreviewtoensureitsprogramsprovideincentivestodeliverlong-term,sustainablebusinessresultswhilediscouragingexcessiverisk-takingorotheradversebehaviors.
• Attract and retain talented employees. LillyaimsforcompensationopportunitiesatLillytobecompetitivewithitspeergroupandreflectthelevelofjobimpactandresponsibility.Retentionoftalentisanimportantfactorinthedesignofitscompensationandbenefitprograms.
• Implement broad-based programs. Whiletheamountofcompensationpaidtoemployeesvaries,theoverallstructureofLilly'scompensationandbenefitprogramsisbroadlysimilaracrosstheorganizationtoencourageandrewardallemployeeswhocontributetoitssuccess.
• Consider shareholder input. LillymanagementandtheLillycompensationcommitteeconsidertheresultsofitsannualsay-on-payvoteandothersourcesofshareholderfeedbackwhendesigningLilly'scompensationandbenefitprograms.
ForthetimebetweenthecompletionoftheIPOandtheendoftheperformanceperiodonDecember31,2018,ElancogenerallycontinuedLilly'scompensationphilosophy.TheElancocompensationcommitteewillfurtherreviewandadjustthisphilosophyasitdeemsappropriatein2019.
Compensation Processes and Analysis
Process for Setting Compensation
TheLillycompensationcommitteeconsideredindividualperformanceassessments,compensationrecommendationsfromseniorleadership,Lilly'scompanyperformance,Elancoperformance(asapplicable),Lilly'speergroupdata,inputfromitscompensationconsultantanditsownjudgmentwhendeterminingcompensationforitsexecutiveofficers.WhendeterminingthecompensationforemployeeswhowerenotexecutiveofficersofLilly,Lilly'sseniormanagementconsideredsimilarfactorsconsistentwithLilly'sphilosophy,focusingonindividualperformanceassessments,compensationrecommendationsfromseniorleadership,Elanco'sperformance(asapplicable)andtheirownjudgment.
• Assessment of individual performance. TheapplicableNamedExecutiveOfficer'sindividualperformanceassessmentwasbasedonachievementofobjectivesestablishedatthestartofeachyear,includingthedemonstrationofLillyvaluesandleadershipbehaviors.
• Assessment of company performance. LillycompanyperformanceandElancoperformance,asapplicable,wereconsideredintwoways:
• Overallperformanceoftheprioryearbasedonavarietyofmetrics,whichwasafactorinestablishingtargetcompensation.
101
TableofContents
• Specificperformancegoalswereestablishedatthebeginningofeachperformanceyeartodeterminepayoutsundercashandequityincentiveprograms.
• Peer group analysis. Lillyuseddatafromitspeergroupasamarketcheckforcompensationdecisions,butdidnotusethisdataasthesolebasisforitscompensationtargets.
• Input from an independent compensation consultant concerning executive pay. Lilly'scompensationcommitteereceivedtheadviceofitsindependentcompensationconsultant,FredericW.Cook&Co.,Inc.,whensettingLillyexecutiveofficercompensation.
Lilly Peer Group
Lilly'speergroupfor2018wascomprisedofcompaniesthatdirectlycompetedwithLilly,operatedinasimilarbusinessmodelandemployedpeoplewiththeuniqueskillsrequiredtooperateanestablishedbiopharmaceuticalcompany.Lilly'scompensationcommitteeselectedapeergroupwhosemedianmarketcapandrevenueswerebroadlysimilartoLilly's.Lilly'speergroupfor2018consistedofthefollowingcompanies:
WiththeexceptionofJohnson&Johnson,NovartisandPfizer,peercompanieswerenogreaterthanthreetimesLilly'ssizeonbothmeasures.Lilly'scompensationcommitteeincludedthesethreecompaniesdespitetheirsizebecausetheycompetedirectlywithLilly,havesimilarbusinessmodelsandseektohirefromthesamepoolofmanagementandscientifictalent.
Components of Executive Compensation
TheexecutivecompensationprogramfortheNamedExecutiveOfficersfor2018,bothbeforeandaftertheIPO,wasprimarilycomprisedofbasesalary,annualcashbonusandequityawards.
• PriortotheIPO,theannualcashbonusprogramsincluded:
• ElancoCorporateBonusPlan("ElancoBonusPlan"),underwhichbonusesarecalculatedbasedonElanco'sperformanceascomparedtoElanco'sinternaltargetsforrevenueandoperatingmargin,Elanco'sinnovationprogressandLilly'sperformanceunderTheEliLillyandCompanyBonusPlan("LillyBonusPlan").Mr.Simmons'bonuspayoutundertheElancoBonusPlanwasalsosubjecttothetermsoftheLillyExecutiveOfficerIncentivePlan(EOIP)throughthedateoftheIPO;and
• LillyBonusPlan,underwhichbonusesarecalculatedbasedonLilly'sperformanceascomparedtoLilly'sinternaltargetsforrevenue,earningspershare("EPS"),andLillyinnovationprogress.
• FollowingtheIPO,ElancomaintainedtheElancoBonusPlanwiththesamemetricsandeligibilityfortheremainderof2018,butadjustedtheannualbonustargetsforcertainNamedExecutiveOfficers.Mr.Simmons'bonuspayoutfortheperiodfollowingtheIPOwasnolongersubjecttotheEOIP.See"2018Compensation—SettingTargetCompensation—AnnualCashBonusTargets"below.
102
Abbvie Celgene MerckAmgen Gilead NovartisAstraZeneca GlaxoSmithKline PfizerBaxter Hoffman-LaRoche Sanofi-AventisBiogen Johnson&Johnson ShireBristol-MyersSquibb Medtronic
TableofContents
• PriortotheIPO,equityincentivesincluded:
• Performanceawards("LillyPAs"),whichareLillyequityawardswithaperformancecomponentmeasuringLilly'stwo-yeargrowthinEPSrelativetotheexpectedpeergroupgrowth.ForperformanceawardsgrantedtoLillyexecutiveofficers("ExecutiveOfficerPAs"),includingMr.Simmons,thetwo-yearperformanceperiodisimmediatelyfollowedbyathirteen-monthservice-vestingperiod;
• Shareholdervalueawards("LillySVAs"),whichareLillyequityawardswithaperformancecomponentmeasuringabsoluteLillystockpricegrowthoverathree-yearperformanceperiod.ForshareholdervalueawardsgrantedtoLillyexecutiveofficers("ExecutiveOfficerSVAs"),includingMr.Simmons,Lillyalsoappliesameasureoftotalshareholderreturn("TSR")relativetopeersandaone-yearholdingperiod;and
• LillyRestrictedStockUnits("LillyRSUs"),whichareLillytime-vestedequityawardsissuedtoexecutivesforpurposesofretentionortopartiallyoffsetoutstandingawardsthatwereforfeitedwhentransitioningtheiremploymenttoLilly.
• FollowingtheIPO,equityawardsincluded:
• Elancostockoptions("ElancoOptions"),whichareElancononqualifiedstockoptionswithathree-yearvestingperiodfollowedbyaseven-yearexerciseperiod.ElancoOptionswereissuedtocertainexecutiveofficersofElanco,includingourNamedExecutiveOfficers(otherthanMr.MontarceandMr.Young,whojoinedElancoonNovember1,2018);and
• ElancoRestrictedStockUnits("ElancoRSUs"),whichareElancotime-vestingequityawardsissuedtocertainexecutiveofficersofElanco,includingourNamedExecutiveOfficers(otherthanMr.Montarce).
LillyemployeespriortotheIPO,whichincludedtheNamedExecutiveOfficers(otherthanMr.Young),alsoreceivedacompanybenefitspackage,describedbelowunder"OtherCompensationPracticesandInformation—EmployeeBenefits."FollowingtheIPO,Elancoemployees,includingtheNamedExecutiveOfficers,receivedbenefitsthatweresubstantiallysimilartotheLillybenefitspackagepriortotheIPO.
1. Base Salary
BasesalariesforLillyemployees,includingfortheNamedExecutiveOfficerswhowereLillyemployeespriortotheIPO,werereviewedandestablishedannuallybyLillyandmaybeadjusteduponpromotion,followingachangeinjobresponsibilitiesortomaintainmarketcompetitiveness.Salariesarebasedoneachperson'slevelofcontribution,responsibility,expertiseandcompetitivenesswithLillypeergroupdata.
Basesalaryincreasesfor2018wereestablishedbaseduponaLillycorporatebudgetforsalaryincreases,whichweresetconsideringLillyperformanceovertheprioryear,expectedLillyperformanceforthefollowingyearandgeneralexternaltrends.Insettingsalaries,Lillyseekstoretain,motivateandrewardsuccessfulperformers,whilemaintainingaffordabilitywithinthecompany'sbusinessplan.
InconnectionwiththeIPO,thebasesalariesofcertainoftheNamedExecutiveOfficerswereadjustedasdescribedunder"ElancoCompensationProgram"below.
2. Annual Cash Bonus
TheNamedExecutiveOfficersparticipatedintheElancoBonusPlanduring2018,whichwasadministeredbyLillypriortotheIPOandbyElancofortheperiodfromthecompletionoftheIPOthroughDecember31,2018.TheElancoBonusPlanfor2018wasdesignedtorewardtheachievement
103
TableofContents
ofElanco'sfinancialgoals,innovationobjectivesandcontributionstoLilly'soverallfinancialsuccessfortheyear.Thebonusisbasedonfourareasthataremeasuredrelativetointernaltargets:Elancorevenue,Elancooperatingmargin,ElancoinnovationprogressandLillycorporateobjectivesasmeasuredundertheLillyBonusPlan(referredtoastheLillyBonusPlanMultiple).
Mr.KinardalsoparticipatedintheLillyBonusPlanthroughApril2018afterwhichheparticipatedintheElancoBonusPlan.Mr.MontarceparticipatedintheElancoBonusPlanthroughOctober2018,atwhichtimehesteppeddownfromserviceasElanco'sActingCFOtoreturntoLilly,afterwhichheparticipatedintheLillyBonusPlan.TheLillyBonusPlanisdesignedtorewardtheachievementofLilly'sfinancialgoalsandinnovationobjectives.Thebonusisbasedonthreeareasthataremeasuredrelativetointernaltargets:Lillyrevenue,LillyEPSandLillyinnovationprogress.
ElancoandLillyperformancegoalsundertheElancoBonusPlanandtheLillyBonusPlanandindividualbonustargetsaresetatthebeginningofeachyear.Actualpayoutcanrangefrom0%to200%ofanindividual'sbonustarget.Performancetargetsandtheassessmentoftherelativeweightingforeachobjectiveisbaseduponannualoperatingplanswithathreshold,targetandmaximumsetforeachobjective(withstraightlineinterpolationforachievementbetweenrelevantlevels).The2018weightingswereasfollows:
Elanco Bonus Plan
Basedonthisweighting,theElancoBonusPlanmultipleiscalculatedasfollows:
(0.25 × revenue multiple) + (0.25 × operating margin multiple) + (0.25 × innovation multiple) + (0.25 × Lilly Bonus Plan Multiple) = Elanco Bonus Plan multiple
TheannualElancoBonusPlanpayoutforeachindividualiscalculatedasfollows:
Elanco Bonus Plan multiple × individual bonus target × base salary earnings = payout
Lilly Bonus Plan
Basedonthisweighting,theLillyBonusPlanmultipleiscalculatedasfollows:
(0.25 × revenue multiple) + (0.50 × EPS multiple) + (0.25 × innovation multiple) = Lilly Bonus Plan multiple
TheannualLillyBonusPlanpayoutforeachindividualiscalculatedasfollows:
Lilly Bonus Plan multiple × individual bonus target × base salary earnings = payout
ForMr.Simmons,whowasaLillyexecutiveofficerpriortotheIPO,theannualbonuswassubjecttothetermsoftheLillyExecutiveOfficerIncentivePlan(EOIP).UndertheEOIP,themaximumannualcashbonusallowableiscalculatedbasedonLilly'snon-GAAPnetincomefortheyear.ForMr.Simmons,themaximumamountfor2018was0.15%ofnon-GAAPnetincome,whichwouldonly
104
Elanco Goals Weighting Elancorevenueperformance 25%Elancooperatingmarginperformance 25%Elancoinnovationprogress 25%LillyBonusPlanMultiple 25%
Lilly Goals Weighting Lillyrevenueperformance 25%LillyEPSperformance 50%Lillyinnovationprogress 25%
TableofContents
applyfortheportionoftheyearduringwhichhewasaLillyexecutiveofficer.NoneoftheLillyexecutiveofficers,whichincludedMr.SimmonspriortotheIPO,receiveanannualcashbonuspaymentunlessLillyhaspositivenon-GAAPnetincomefortheyear.
UndertheEOIP,oncethemaximumpayoutforMr.Simmonshasbeendetermined,theLillycompensationcommitteehasthediscretiontoreduce(butnotincrease)theamounttobepaid.Inexercisingthisdiscretion,thecommittee'sintentistoawardthelesserof(i)thebonusMr.SimmonswouldhavereceivedundertheElancoBonusPlanor(ii)theEOIPmaximumpayout.Accordingly,for2018,theLillycompensationcommittee,initsdiscretion,reducedMr.Simmons'bonuspayoutundertheEOIPtoalevelthatwasbasedentirelyonElancoperformance,whichwaspro-ratedfortheperiodpriortotheIPOduringwhichhewasaLillyexecutiveofficer.FordetailregardingElancoBonusPlanpayoutsbeforeandaftertheIPO,see"2018CompensationPayouts—ElancoBonusPlan"below.
3. Equity Incentives
Lillyprimarilygrantstwotypesofequityincentivestoexecutivesandcertainotheremployeesduringitsannualcycle—LillyPAsandLillySVAs.LillyPAsaredesignedtofocusleadersonmulti-yearoperationalperformancerelativetopeercompanies.LillySVAsalignearnedcompensationwithlong-termgrowthinLillyshareholdervalue.TheLillycompensationcommitteehasthediscretiontoadjustdownward(butnotupward)anyequityawardpayout,includingLillyexecutiveofficer'spayoutfromtheamountyieldedbytheapplicableformula.
ExecutiveOfficerPAsandExecutiveOfficerSVAsareawardedtoLillyexecutiveofficers,whichincludedMr.SimmonspriortotheIPO.TheElancoequityawardsgrantedtotheNamedExecutiveOfficersfollowingtheIPOaredescribedunder"ElancoCompensationProgram"below.
InconnectionwiththeSplit-Off,allthen-unvestedLillyequityawardsheldbytheNamedExecutiveOfficers(otherthanMr.Montarce,whowillremainemployedbyLilly)wereforfeitedfornoconsideration.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.See"2019Compensation"below.
Performance Awards (Lilly PAs and Executive Officer PAs)
Messrs.Kinard,Montarce,andUrbanekreceivedLillyPAsthatvestovertwoyears.PotentialLillysharesarebasedonachievingLillyEPSgrowthtargetsoveratwo-yearperformanceperiod.Thegrowth-ratetargetsaresetrelativetothemedianexpectedEPSgrowthforLilly'speergroup.Theseawardsdonotaccumulatedividends.
Lillyexecutiveofficers,includingMr.Simmons,receivedtheExecutiveOfficerPAs,whichusethesametwo-yearEPSgrowth-ratetargetsastheLillyPAsfordeterminingthenumberofLillyshares;however,theperformanceperiodisfollowedbyanadditionalthirteen-monthservice-vestingperiodduringwhichtheawardisheldintheformofLillyrestrictedstockunits.Executiveofficersaccumulatedividendequivalentunitsduringthethirteen-monthservicevestingperiodwhicharepaiduponthevestingoftheunderlyingaward.
TheLillycompensationcommitteebelievesEPSgrowthisaneffectivemeasureofoperationalperformancebecauseitiscloselylinkedtoshareholdervalue,isbroadlycommunicatedtothepublic,iseasilyunderstoodbyitsemployeesandallowsforobjectivecomparisonstoitspeergroupperformance.Consistentwithitscompensationobjectives,Lillycompanyperformanceexceedingtheexpectedpeergroupmedianresultsinabove-targetpayouts,whileLillycompanyperformancelaggingtheexpectedpeergroupmedianresultsinbelow-targetpayouts.Possiblepayoutsrangefrom0%to150%ofthetarget,dependingonLillyEPSgrowthovertheperformanceperiod.
105
TableofContents
Shareholder Value Awards (Lilly SVAs and Executive Officer SVAs)
Messrs.Kinard,MontarceandUrbanekreceivedLillySVAs.TheseawardsarebasedonLilly'ssharepriceappreciationoverathree-yearperformanceperiod.LillySVAspayabovetargetifLilly'sstockoutperformsanexpectedrateofreturnandbelowtargetifLilly'sstockunderperformsthatexpectedrateofreturn.Theexpectedrateofreturnisbasedonthethree-yearTSRthatareasonableinvestorwouldconsiderappropriatewheninvestinginabasketoflarge-capU.S.companies,asdeterminedbytheLillycompensationcommittee.TheminimumpricetoachievetargetiscalculatedbymultiplyingthestartingsharepriceofLilly'sstockbythethree-yearcompoundedexpectedrateofreturnlessLilly'sdividendyield.
Lillyexecutiveofficers,includingMr.Simmons,receivedExecutiveOfficerSVAs.TheseawardsarethesameasLillySVAsexceptexecutiveofficersreceivenopayoutifLilly'sTSRforthethree-yearperiodiszeroornegative,andamodifierbasedonLilly'sthree-yearcumulativeTSRrelativetoitspeercompanies'medianTSRperformancewillbeappliedtopayouts.IfLilly'sTSRisabovethemedianofLilly'speers,thepayoutisincreasedby1%foreverypercentagepointthatLilly'sTSRexceedsthemedian(uptoamaximumof20%).Likewise,ifLilly'sTSRisbelowthemedian,thepayoutwillbereducedbyuptoamaximumof20%.AddingtherelativeTSRmodifiertotheExecutiveOfficerSVAshelpsensureLillyexecutiveofficers'rewardsalignwithshareholderexperiencewhilealsorewardingstrongperformancerelativetoourpeergroup.
2018 Compensation
Setting Target Compensation
TheNamedExecutiveOfficers'2017compensationand2018compensationthroughSeptember19,2018wereapprovedbyLilly'scompensationcommitteeormanagement,asapplicable,fortheperiodsthatsuchpersonswereemployedbyLilly.TheNamedExecutiveOfficers'compensationfromSeptember20,2018throughDecember31,2018wasapprovedbytheElancoboardofdirectors,exceptforMr.Young,whojoinedElancoonNovember1,2018andwhosecompensationwasapprovedbytheElancocompensationcommittee.
Theactualcompensationreceivedin2018issummarizedbelowin"2018CompensationPayouts."
Base Salary
ThefollowingtableincludestheactualannualsalaryearnedbytheNamedExecutiveOfficersin2017and2018,asreflectedintheSummaryCompensationTableinthesectionentitled"ExecutiveCompensationTables"below.
106
Name 2017 Annual Base Salary
2018 Annual Base Salary
Mr.Simmons $ 688,118 $ 775,185(1)Mr.Young N/A $ 91,667Ms.Lin N/A $ 500,556(1)Mr.Urbanek $ 297,174 $ 381,885(1)Mr.Kinard $ 405,632 $ 420,972(1)Mr.Jensen N/A $ 390,345Mr.Montarce $ 280,673 $ 335,175
(1) RepresentsablendofsalarypriortotheIPOandasalaryincreaseinconnectionwiththeIPO.See"ElancoCompensationProgram"below.
TableofContents
Annual Cash Bonus Targets
Bonustargetsfor2017and2018areshowninthetablebelowasapercentageoftheNamedExecutiveOfficer'sactualbasesalaryearnings.ElancocontinuedtheexistingElancoBonusPlanforalloftheNamedExecutiveOfficersfortheperiodfromthecompletionoftheIPOthroughDecember31,2018andtheElancoboardofdirectorsadjustedbonustargetsforcertainoftheNamedExecutiveOfficersforthatperiod.
Lilly Equity Program—Target Grant Values
For2018pre-IPOequitygrants,LillysetthetotaltargetvalueforMessrs.Simmons,Urbanek,KinardandMontarcebasedoninternalpayequity,LillyandElanco(asapplicable)performance,individualperformanceandLillypeergroupdata(asapplicable).Mr.Simmonshad60%ofhisequitytargetallocatedtoExecutiveOfficerSVAsand40%toExecutiveOfficerPAs.Messrs.Urbanek,KinardandMontarcehad50%oftheirequityallocatedtoLillySVAsand50%toLillyPAs.Totaltargetvaluesforthe2017and2018equitygrantstotheapplicableNamedExecutiveOfficerswereasfollows:
107
Name
2017 Bonus Target
(1)
Pre-IPO 2018
Bonus Target
Post-IPO 2018 Bonus
Target
Weighted 2018 Bonus Target (2)
Mr.Simmons 80% 80% 120% 91%Mr.Young N/A N/A 70% 70%Ms.Lin N/A 55% 60% 56%Mr.Urbanek 35% 45% 60% 49%Mr.Kinard 45% 45% 60% 49%Mr.Jensen N/A 70% 70% 70%Mr.Montarce 34% 40% 40% 40%
(1) The2017bonustargetsforMessrs.MontarceandUrbanekareaweightedaverageresultedfromchangesinpositionsheldduringtheyear.
(2) The2018bonustargetsforMs.LinandMessrs.Simmons,Urbanek,andKinardrepresentaweightedaverageoftheamountsapprovedbyLillymanagementfortheperiodpriortotheIPOandamountsapprovedbytheElancoboardofdirectorsinconnectionwiththeIPO.Foradditionaldetail,see"ElancoCompensationProgram"below.
Name 2017 Annual Equity Grant
2018 Annual Equity Grant
(1) Mr.Simmons $ 2,000,000 $ 1,200,000Mr.Young N/A N/AMs.Lin N/A N/AMr.Urbanek $ 80,000 $ 500,000Mr.Kinard $ 415,000 $ 400,000Mr.Jensen N/A N/AMr.Montarce $ 90,000 $ 300,000
(1) Ms.LinandMessrs.YoungandJensenwerenoteligibleforanannualLillyequitygrantsincetheywerenotactiveemployeesonJanuary1,2018.
TableofContents
Performance Goals for 2018 Lilly Incentive Programs
Annual Bonus Goals
PerformancetargetsfortheElancoBonusPlanandtheLillyBonusPlanwerebasedonthe2018operatingplanforeachofElancoandLilly,respectively.Thesetargetsaredescribedbelowunder"2018CompensationPayouts."
Performance Award (Lilly PAs and Executive Officer PAs)
InFebruary2018,theLillycompensationcommitteeestablishedacumulative,compoundedtwo-yearLillyEPSgrowthtargetof8.1%peryearforthe2018-2019performanceperiod,basedoninvestmentanalysts'growthestimatesforLilly'speergroupcompaniesatthattime.Payoutsforthe2018-2019LillyPAsand2018-2020ExecutiveOfficerPAsrangefrom0%to150%ofthetarget,asillustratedbelow:
Shareholder Value Award (Lilly SVAs and Executive Officer SVAs)
ForpurposesofestablishingtheLillystockpricetargetforthe2018-2020LillySVAs,thestartingpricewas$84.70pershare,theaverageLillyclosingstockpriceforalltradingdaysinNovemberandDecember2017.TheLillytargetsharepricewasestablishedusingtheexpectedannualrateofreturnforlarge-capcompanies(8%),lessanassumedLillydividendyieldof2.66%.Todeterminepayouts,theendingpricewillbetheaverageoftheclosingpricesofLillystockforalltradingdaysinNovemberandDecember2020.
Lilly SVA
Messrs.Kinard,MontarceandUrbanekreceivedLillySVAswiththepossiblepayoutsonsharepricerangesillustratedinthegridbelow:
108
Ending Stock Price Less than
$42.35 $42.35 to
$88.19 $88.20 to
$99.01 $99.02 to $109.83
$109.84 to $120.65
Greater than $120.65
CompoundedAnnualSharePriceGrowthRate(excludingdividends) Lessthan(20.6%) (20.6%)to1.4% 1.4%to5.3% 5.3%to9.0% 9.1%to12.5% Greaterthan12.5%PercentofTarget 0% 50% 75% 100% 125% 150%
TableofContents
Executive Officer SVA
TheExecutiveOfficerSVAisdesignedtodelivernopayoutifthetotalshareholderreturn(includingprojecteddividends)iszeroornegative.Mr.SimmonsreceivedExecutiveOfficerSVAswithpayoutsbasedonsharepricerangesillustratedinthegridbelow:
Mr.Simmons'ExecutiveOfficerSVAsaresubjecttoarelativeTSRmodifier,asoutlinedinthegridbelow.ThenumberofLillysharestobepaidwillincreaseordecreaseby1%foreverypercentagepointLilly'sthree-yearTSRdeviatesfromLilly'speergroup'smedianthree-yearTSR,cappedat20%.
2018 Compensation Payouts
TheinformationinthissectionreflectstheamountspaidtotheNamedExecutiveOfficersundertheElancoBonusPlan,LillyBonusPlanandinrespectofLillyequityawardsgrantedinprioryearsforwhichtherelevantperformanceperiodendedin2018,asapplicable.
Elanco Performance
In2018,Elancoexceededitsannualoperatingmarginby0.1%;however,itmisseditsannualrevenuetargetby0.9%.Elancomadestrongprogressonitsinnovationgoals,andendedwithaninnovationratingabovetargetat3.6.ThetwomajorapprovalswereGalliprantintheEUandCredeliointheU.S.Inaddition,Elancomadesignificantprogressonitslong-termstrategicagenda,improvingcoststructure,reducingglobalheadcount,rationalizingkeyassetsandproductsandacceleratingimportantpipelineprojects.The2018resultsdescribedbelowreflectElanco's2018performancewithrespecttotheElancoBonusPlantargetsandarenotpresentedonthesamebasisas,andarenotdirectlycomparableto,ourcombinedfinancialresultspresentedinthisprospectus.
109
Ending Stock Price Less than
$77.38 $77.38 to
$88.19 $88.20 to
$99.01 $99.02 to $109.83
$109.84 to $120.65
Greater than $120.65
CompoundedAnnualSharePriceGrowthRate(excludingdividends) Lessthan(3.0)% (3.0)%to1.4% 1.4%to5.3% 5.3%to9.0% 9.1%to12.5% Greaterthan12.5%PercentofTarget 0% 50% 75% 100% 125% 150%
TableofContents
Elanco Bonus Plan
Elanco'sperformancecomparedtothe2018targetsforrevenue,operatingmargin,innovationprogressandtheLillyCompanyBonusMultiple,aswellastheresultingbonusmultiple,issetforthbelow.
Elanco's2018innovationtargetwas3.0onascaleof1.0to5.0.Elanco'sinnovationmultipleiscomprisedofthefollowingfactors:(i)achievementofproductapprovals,(ii)entrantsintoearlyandlatestagedevelopment,(iii)adherencetoapprovaltimelinesand(iv)aqualitativeassessmentbyElanco'sheadofR&Dofoverallperformance.Basedontheweightedoutcomesofthesefactors,Elancoachieveda3.60score,whichcorrelatestoa1.30innovationmultipleforuseintheElancobonuscalculation.
Whencombined,theElancorevenue,operatingmargininnovationandLillyCorporateBonusmultiplesyieldeda2018ElancoBonusPlanmultipleof:
(0.25 × 0.85) + (0.25 × 1.10) + (0.25 × 1.30) + (0.25 × 1.73) = 1.24 bonus multiple
The2018bonusestobepaidtotheapplicableNamedExecutiveOfficersundertheElancoBonusPlanareasfollows:
110
2018
Elanco Target 2018
Elanco Results Multiple Revenue $ 3.171B $ 3.143B 0.85OperatingMargin 20.0% 20.2% 1.10Innovation 3.00 3.60 1.30LillyCompanyBonusMultiple 1.73ResultingElancoBonusMultiple 1.24
Name 2018 Bonus ($) Mr.Simmons $ 907,450(2)Mr.Young(1) $ 79,567Ms.Lin(1) $ 350,552(3)Mr.Urbanek $ 233,083(3)Mr.Kinard(1) $ 180,180(3)Mr.Jensen(1) $ 222,439Mr.Montarce(1) $ 138,404
(1) Pro-ratedbasedupontheactualtime-periodworkedatElanco.
TableofContents
Lilly Performance
In2018,LillyexceededbothitsannualrevenueandEPStargets.Lillyalsomadesignificantprogressonitspipeline,meetingorexceedingallofitspipelinetargets.KeypipelinehighlightsincludefirstregulatoryapprovalforEmgality,alongwithelevenothernewapprovals,indicationsorlineextensions.
Lilly Bonus Plan
Lilly'sperformancecomparedtoits2018targetsforrevenue,EPSandpipelineprogress,aswellastheresultingbonusmultiple,isillustratedbelow.
Lilly'sScienceandTechnologyCommitteeassessedLilly'sprogresstowardachievingproductpipelinegoalsbasedonthefollowingfactors:(i)achievementofproductapprovals,(ii)newchemicalentityentrantsintoPhase1andPhase3clinicaltrials,(iii)newindicationorlineextensionentrantsintoPhase3clinicaltrials,(iv)speedofdevelopment,(v)adherencetotimelinesand(iv)aqualitativeassessmentofoverallperformance.BasedontherecommendationoftheScienceandTechnologyCommittee,Lilly'scompensationcommitteecertifiedapipelinescoreof3.90,resultinginapipelinemultipleof1.45.
111
(2) Representsthesumofapro-ratedEOIPpayoutof$492,050throughSeptember19,2018,whichreflectsthereductionofMr.Simmons'bonuspayoutundertheEOIPbytheLillycompensationcommittee,initsdiscretion,toalevelthatwasbasedentirelyonElancoperformanceandthatwaspro-ratedfortheperiodpriortotheIPOduringwhichMr.SimmonswasaLillyexecutiveofficer,andtheElancoBonusPlanpayoutof$415,400fortheremainderof2018.See"AnnualCashBonusTargets"above.
(3) RepresentsaweightedaverageoftheamountsapprovedbyLillymanagementfortheperiodpriortotheIPOandamountsapprovedbytheElancoboardofdirectorsinconnectionwiththeIPO.
2018
Lilly Target 2018
Adjusted Results Multiple Revenue $ 23.457B $ 24.556B 1.48EPS $ 4.91 $ 5.49 2.00PipelineScore 3.00 3.90 1.45ResultingLillyBonusMultiple 1.73
TableofContents
Whencombined,theLillyrevenue,EPS,andpipelinemultiplesyieldeda2018LillyBonusPlanmultipleof:
(0.25 × 1.48) + (0.50 × 2.00) + (0.25 × 1.45) = 1.73 bonus multiple
The2018bonusespaidtoMessrs.MontarceandKinardundertheLillyBonusPlanwereasfollows:
Performance Awards (Lilly PAs and Executive Officer PAs)
ThetargetcumulativeLillyEPSforthe2017-2018LillyPAsandthe2017-2019ExecutiveOfficerPAswassetinthefirstquarterof2017,reflectingexpectedindustrygrowthof5.3%eachyearoverthetwo-yearperformanceperiodof2017-2018.Lilly'sactualannualEPSgrowthforthetwo-yearperiodwas22.5%.ThisoutcomewaslargelydrivenbyvolumegrowthfromnewerLillyproducts.
FortheNamedExecutiveOfficers,thenumberofLillysharesearnedunderthe2017-2018LillyPAsor,forMr.Simmons,the2017-2019ExecutiveOfficerPAs,issetforthinthetablebelow.Mr.Simmons'sharesearnedunderthe2017-2019ExecutiveOfficerPAaresubjecttoanadditionalthirteen-monthservice-vestingperiodatLillyorElancofollowingvesting.
112
Name 2018 Bonus ($) Mr.Kinard $ 107,498Mr.Montarce $ 38,845
Name Target Shares Shares Earned Mr.Simmons 10,878 16,317Mr.Young(1) N/A N/AMs.Lin(1) N/A N/AMr.Urbanek 544 816Mr.Kinard 2,822 4,233Mr.Jensen(1) N/A N/AMr.Montarce 612 918
(1) Ms.LinandMessrs.YoungandJensenwerenoteligiblefora2017-2018LillyPAsincetheywerenotactiveLillyemployeesonJanuary1,2017.
TableofContents
Shareholder Value Award (Lilly SVAs and Executive Offer SVAs)
ThetargetLillystockpricerangeof$98.55to$109.06(17.7%to30.2%stockpricegrowth)forthe2016-2018LillySVAswassetin2016basedonabeginningLillystockpriceof$83.74,whichwastheaverageclosingpriceforLillystockforalltradingdaysinNovemberandDecember2015.TheendingLillystockpriceof$112.38representsastockpricegrowthofapproximately34.2%overtherelevantthree-yearperiod.Lilly'sperformancecomparedtotargetfor2016-2018LillySVAsisshownbelow.
Theperformancemultipleof1.25wasmodifiedforMr.Simmonsbytherelativetotalshareholderreturnmetric.ThecumulativetotalshareholderreturnmedianfortheLillypeergroupwas16.6%,andLilly'stotalshareholderreturnoverthesameperiodwas44.9%asdepictedonthechartbelow:
Giventhispositiverelativeperformance,theExecutiveOfficerSVApayoutmultiplewasincreasedby20%makingthefinalperformancemultiplea1.50.
ThesharesearnedbytheNamedExecutiveOfficersduring2018underthe2016-2018LillySVAs(ExecutiveOfficerSVAsforMr.Simmons)wereasfollows:
113
Name Target Shares Shares Paid Out Mr.Simmons 29,190 43,785Mr.Young(1) N/A N/AMs.Lin(1) N/A N/AMr.Urbanek 819 1,024Mr.Kinard 3,854 4,818Mr.Jensen(1) N/A N/AMr.Montarce 1,012 1,265
(1) Ms.LinandMessrs.YoungandJensenwerenoteligiblefora2016-2018LillySVAgrantsincetheywerenotactiveLillyemployeesonJanuary1,2016.
TableofContents
Other Lilly Compensation Practices and Information
Lilly Employee Benefits
Lillyofferscoreemployeebenefitscoverageto:
• providetheLillyworkforcewithareasonableleveloffinancialsupportintheeventofillnessorinjury;
• providepost-retirementincome;and
• enhanceproductivityandjobsatisfactionthroughbenefitprogramsthatfocusonoverallwell-being.
ThebenefitsthatwereavailabletotheNamedExecutiveOfficersduringtheiremploymentwithLillyweregenerallythesameasthoseavailabletoallU.S.Lillyemployeesandincludedmedicalanddentalinsurance,disabilityinsuranceandlifeinsurance.Inaddition,TheLillyEmployee401(k)plan("Lilly401(k)Plan")andTheLillyRetirementPlanprovideU.S.Lillyemployeesareasonablelevelofretirementincomereflectingemployees'careerswithLilly.
TotheextentthatanyLillyemployee'sretirementbenefitexceedsInternalRevenueService(IRS)limitsforamountsthatcanbepaidthroughaqualifiedplan,Lillyalsooffersanonqualifiedpensionplanandanonqualifiedsavingsplan.TheNamedExecutiveOfficersparticipatedinthesenonqualifiedplansin2018.TheseplansprovideonlythedifferencebetweenthecalculatedbenefitsandtheIRSlimits,andtheformulaisthesameforallU.S.Lillyemployees.ThecostofLillyemployeebenefitsispartiallybornebytheemployee,whichincludedtheNamedExecutiveOfficerswhoreceivedLillyemployeebenefits.
The Lilly Deferred Compensation Plan
Lillyexecutiveofficers,which,priortotheIPO,includedMr.Simmons,maydeferreceiptofallorpartoftheircashcompensation.OtherU.S.LillyexecutivesmaydeferreceiptofallorpartoftheircashbonusunderTheLillyDeferredCompensationPlan,whichallowsparticipantstosaveforretirementinatax-effectivewayatminimalcosttoLilly.Underthisunfundedplan,amountsdeferredbytheparticipantarecreditedataninterestrateof120%oftheapplicablefederallong-termrate,asdescribedinmoredetailfollowingthe"NonqualifiedDeferredCompensationin2018"table.
Elanco Compensation Program
ThefollowingsectiondescribesElanco'scurrentcompensationprogram,whichcontinuestobedevelopedbytheElancocompensationcommittee.
Elanco Compensation Committee
Elanco'scompensationcommitteedeterminesandapprovesexecutiveofficercompensationandprovidesoversightofElanco'scompensationphilosophy.TheElancocompensationcommitteewillannuallyreviewandevaluateElanco'sexecutivecompensationplansandprogramstoensuretheyarealignedwithitscompensationphilosophy.TheElancocompensationcommitteedeterminedtogenerallymaintainLilly'scompensationphilosophythroughtheSplit-OffandanticipatesreviewingitsphilosophyandpayprogramsfollowingtheSplit-Off.
114
TableofContents
Elanco Peer Group
BasedontheadviceofWillisTowersWatson,thecompensationconsultantengagedbyLillymanagementtoprovideadviceontheElancopeergroupinconnectionwiththeIPO,thefollowinggroupof18companieswereidentifiedasElanco's"core"peers:
TodeterminetheelementsofElanco'scompensationprogramsforitsNamedExecutiveOfficers,theElancoboardapprovedcompensationpackagesderivedfromfollowingbenchmarks,amongothers:
• Proxystatementdataforthe"core"peergroupasdisclosedineachcompany'sprioryearcompensationdiscussionandanalysisandexecutivecompensationtables;and
• Surveydatafromsimilarly-sizedcompanieswithinthelifesciencesindustry,inparticular,fromtheWillisTowersWatsonsurveythatencompassedlife-sciencecompanieswithannualrevenuesoflessthanorequalto$20billion.
TheElancocompensationcommitteeexpectstoperiodicallyreviewthepeergroupandmakeadjustmentstoitssizeandcomposition,whenappropriate,withinitsdiscretion.
Compensation Arrangements
InconnectionwiththeIPO,theElancoboardofdirectorsapprovednewpaypackagesforeachofMessrs.Simmons,Urbanek,KinardandMs.Lin.Mr.Jensen'spaypackagewasnotmodifiedashejoinedElancoinMarch2018andbeganamedicalleaveonoraboutAugust1,2018.Mr.JensendidnotreturntohispositionwithElancofollowinghismedicalleave.FollowinghisdeathonDecember14,2018,Mr.Jensen'sestatereceivedbenefitspursuanttothetermsofhisemploymentarrangementwithElanco(see"PaymentsUponTerminationorChangeinControl(asofDecember31,2018)"below).
Mr.MontarcewasnamedActingChiefFinancialOfficerfromAugust1,2018throughOctober31,2018,duringwhichtimehispaypackagealsodidnotchange.AsofNovember1,2018,Mr.MontarcereturnedtohispositionatLillyandreceivedaone-timecashawardof$200,000fromLillyinconnectionwiththetransitiontohisnewrole.Mr.Young'scompensationwasdeterminedbytheElancocompensationcommitteeinconnectionwithhishiringonNovember1,2018.
ThefollowingpaypackagesoftheNamedExecutiveOfficersweredevelopedbasedontheexperienceprofileoftheexecutiveandcompetitivepositioningagainstpeergroupbenchmarkingasdescribedabove.AlloftheNamedExecutiveOfficers'compensationpackagesreflecttheconsiderationofbenchmarkingdatafromtheWillisTowersWatsonlifesciencessurveyregressedforrelativecompany
115
AgilentTechnologies EndoInternational PerkinElmerAlexionPharmaceuticals Hologic PerrigoCompanyBostonScientific IDEXXLaboratories SterisCatalent JazzPharmaceuticals VarianMedicalSystemsDENTSPLYSIRONA Mallinckrodt WestPharmaceuticalServicesEdwardsLifesciences OPKOHealth Zoetis
TableofContents
size,andthecompensationpackageforMr.Simmonswasalsobenchmarkedagainstthecompensationofthe18corepeercompanieslistedabove.
2018 Founders Awards
ElancoNamedExecutiveOfficers,exceptMessrs.MontarceandYoung,receivedaFoundersAwardonOctober20,2018.TheFounders'Awardswereallocatedevenly(basedongrantdatefairvalue)betweenElancoRSUsandElancoOptionsthateachvestonthatdatethatisthreeyearsafterthegrantdate,subjecttocontinuedservice.Thenumberofsharesgrantedareassetforthbelow:
Stock Ownership and Holding Requirements
Elanco'sboardofdirectorshasadoptedequityownershiprequirementsforexecutiveofficers,whichrequiretheChiefExecutiveOfficerofElancotoholdthenumberofsharesofElancocommonstockequaltosixtimes(6x)hisorherbasesalaryandotherofficerstoholdthenumberofsharesofElancocommonstockequaltothreetimes(3x)theirbasesalaries.AllNamedExecutiveOfferswere
116
Mr.Simmons: AsthePresidentandChiefExecutiveOfficer,Mr.Simmonsreceives$1,000,000inbasesalaryandiseligibletoparticipateintheElancoBonusPlanwithatargetof120%ofbasesalary.
Mr.Young: AstheChiefFinancialOfficer,Mr.Youngreceives$550,000inbasesalaryandiseligibletoparticipateintheElancoBonusPlanwithatargetof70%ofbasesalary.Mr.Youngreceivedaone-timecashpaymentof$200,000lessapplicabletaxesuponstartinghisElancoemployment.Healsoreceivedaone-timeequityawardof$300,000inDecember2018inconnectionwithjoiningElanco.
Ms.Lin: AstheExecutiveVicePresident,ElancoUSA,CorporateStrategyandGlobalMarketing,Ms.Linreceives$530,000inbasesalaryandiseligibletoparticipateintheElancoBonusPlanwithatargetof60%ofbasesalary.Ms.Linreceivedaone-timecashpaymentof$500,000lessapplicabletaxesuponstartingherElancoemployment.Shealsoreceivedaone-timeequityawardof$900,000inFebruary2018inconnectionwithjoiningElanco.
Mr.Urbanek: AstheExecutiveVicePresident,ManufacturingandQuality,Mr.Urbanekreceives$385,000inbasesalaryandiseligibletoparticipateintheElancoBonusPlanwithatargetof60%ofbasesalary.
Mr.Kinard: AstheExecutiveVicePresident,HumanResources,Mr.Kinardreceives$430,000inbasesalaryandiseligibletoparticipateintheElancoBonusPlanwithatargetof60%ofbasesalary.
Mr.Montarce: Mr.Montarcereceives$336,810inbasesalaryandparticipatesinanannualcashincentiveprogramwithatargetof40%.Mr.Montarce'scompensationwasnotadjustedduringthetimeheservedasActingChiefFinancialOfficerofElanco.
Name Elanco RSUs Elanco Options Mr.Simmons 36,287 109,642Ms.Lin 6,979 21,086Mr.Urbanek 6,979 21,086Mr.Kinard 6,979 21,086Mr.Jensen 19,449 58,766
TableofContents
compliantwiththeannualawardshareretentionguideline,whichrequirestheretentionof50%ofallequityawardsuntiltheirstockownershiprequirementsaresatisfied,astheyeachbuildtowardtheirrespectiveownershiprequirements.Mr.Montarcehasaholdingrequirementof5,000LillysharesundertheLillyshareownershipandretentionguidelinesandhewascompliantwiththeLillyshareretentionguidelineashebuilttowardhisrespectiveownershiprequirement.
Hedging/Pledging Policy
Elanco'scompensationcommitteeadoptedahedgingandpledgingpolicyunderwhichournon-employeedirectorsandemployeesarenotpermittedtohedgetheireconomicexposurestoElancostockthroughshortsalesorderivativetransactions.Non-employeedirectorsandallmembersofseniormanagementareprohibitedfrompledginganyElancostock(i.e.,usingElancostockascollateralforaloanortradingsharesonmargin).
Executive Compensation Recovery Policy
AllElancoincentiveawardsgenerallyaresubjecttoforfeitureuponterminationofemploymentpriortotheendoftheperformanceorvestingperiodorfordisciplinaryreasons.Inaddition,theElancocompensationcommitteehasadoptedanElancoexecutivecompensationrecoverypolicythatgivestheElancocompensationcommitteebroaddiscretiontoclawbackElancoincentivepayoutsfromanymemberofElancoseniormanagement,whichincludesourNamedExecutiveOfficers,whosemisconductresultsinamaterialviolationoflaworcompanypolicythatcausessignificantharmtoElancoorwhofailsinhisorhersupervisoryresponsibilitytopreventsuchmisconductbyothers.TheElancorecoverypolicycoversanyElancoincentivecompensationawardedorpaidtoanemployeeatatimewhenheorsheisamemberofElancoseniormanagement.Subsequentchangesinstatus,includingretirementorterminationofemployment,donotaffectElanco'srightstorecovercompensationunderthepolicy.RecoveriesundertheElancoplancanextendbackasfarasthreeyears.
2019 Compensation
TheElancocompensationcommitteeapprovedthecontinuanceoftheexistingElancoBonusPlanforalloftheNamedExecutiveOfficersfortheperiodfromthecompletionoftheIPOthroughDecember31,2018.ThecompensationcommitteesubsequentlyadoptedanewElancoBonusPlanfor2019thatincludesthreemeasures:Revenue(30%),EBIT(40%)andprogressoftheinnovationpipeline(30%).
LillyequityawardspreviouslygrantedtotheNamedExecutiveOfficerscontinuedtovestinaccordancewiththeirterms,withtheirservicetoElancocountingasservicetoLillyforallpurposesuntiltheSplit-Off.UpontheSplit-Off,unvestedLillyequityawardsterminatedinaccordancewiththeirtermsfornoconsiderationpaidtotheNamedExecutiveOfficers(otherthanMr.Montarce,whoremainsemployedbyLilly).TheElancocompensationcommitteeauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationsubjecttotherequirementsofapplicablelawandthetermsofthe2018ElancoStockPlanandapplicableawardagreements.
Elancoprovidesretirementincometoeligibleemployees,whichincludestheNamedExecutiveOfficers,throughTheElanco401(k)Plan,adefinedcontributionplanqualifiedunderSections401(a)and401(k)oftheInternalRevenueCode.Participantsmayelecttocontributeaportionoftheirbasesalarytotheplan,andElancoprovidesmatchingcontributionsonemployees'contributionsupto6%ofbasesalaryuptoIRSlimits.Inaddition,Elancoprovidesanon-electivecontributionintheamountof3%ofbasesalary,pendingactiveemploymentonDecember31ofeachyear.Theemployeecontributions,ElancocontributionsandearningsthereonarepaidoutinaccordancewithelectionsmadebytheparticipantunderthetermsandconditionsofthePlan.
117
TableofContents
NeitherElanconoritssubsidiariessponsor(1)adefinedbenefitretirementplanforU.S.employees,however,eligibleemployeesmayreceivetransitionservicecreditforvestingandeligibilitypurposesundercertainretirementplanssponsoredbyEliLillyandCompanyor(2)anonqualifieddeferredcompensationplanor(3)anonqualifiedsavingsplan.
Executive Compensation Tables
AllamountsincludedinthetablesbelowrepresentcompensationpaidtoorearnedbytheapplicableNamedExecutiveOfficersfor2018ortheyearindicatedintheapplicabletable.Ms.LinandMessrs.YoungandJensenjoinedElancoin2018andthereforedonothaveanycompensationfromLillyin2017.
Summary Compensation Table
118
Name and Principal Position Year Salary
($) Bonus ($) (1)
Stock Awards
($) (2)
Option Awards
($) (3)
Non-Equity Incentive
Plan Compensation
($) (4)
Change in Pension Value
and Nonqualified
Deferred Compensation
Earnings ($) (5)
All Other Compensation
($) (6)
Total Compensation
($) JeffreySimmons 2018 $ 775,185 $ 0 $ 2,530,654 $ 1,119,445 $ 907,450 $ 0 $ 46,511 $ 5,379,245PresidentandChief 2017 $ 688,118 $ 0 $ 2,400,000 $ 0 $ 379,841 $ 1,261,845 $ 41,287 $ 4,771,091ExecutiveOfficer
ToddYoung
2018 $ 91,667 $ 200,000 $ 300,032 $ 0 $ 79,567 $ 1,102 $ 8,285 $ 680,653ExecutiveVicePresidentand 2017 N/A N/A N/A N/A N/A N/A N/A N/AChiefFinancialOfficer
SarenaLin
2018 $ 500,556 $ 500,000 $ 1,115,384 $ 215,288 $ 350,552 $ 5,742 $ 171,338 $ 2,858,860ExecutiveVicePresident, 2017 N/A N/A N/A N/A N/A N/A N/A N/AElancoUSA,CorporateStrategyandGlobalMarketing
DavidUrbanek
2018 $ 381,885 $ 0 $ 825,302 $ 215,288 $ 233,083 $ 202,856 $ 22,913 $ 1,881,328ExecutiveVicePresident, 2017 $ 297,174 $ 0 $ 300,040 $ 0 $ 76,887 $ 333,402 $ 17,830 $ 1,025,333ManufacturingandQuality
DavidKinard
2018 $ 420,972 $ 0 $ 703,302 $ 215,288 $ 180,180 $ 0 $ 25,258 $ 1,652,499ExecutiveVicePresident, 2017 $ 405,632 $ 0 $ 518,750 $ 0 $ 244,596 $ 379,379 $ 24,338 $ 1,572,696HumanResources
ChristopherJensen
2018 $ 390,345 $ 200,000 $ 600,002 $ 600,001 $ 222,439 $ 7,135 $ 75,676 $ 2,095,597FormerChiefFinancial 2017 N/A N/A N/A N/A N/A N/A N/A N/AOfficer
LucasMontarce
2018 $ 335,175 $ 200,000 $ 616,019 $ 0 $ 138,404 $ 5,5674 $ 20,111 $ 1,354,228FormerActingChief 2017 $ 280,673 $ 0 $ 112,500 $ 0 $ 83,976 $ 24,896 $ 16,200 $ 518,245FinancialOfficer
(1) Ms.LinandMessrs.YoungandJensenreceivedone-timecashbonuspaymentsof$500,000,$200,000and$200,000,respectively,aspartoftheiremploymentoffers.Mr.Montarcereceivedaone-timecashbonuspaymentof$200,000fromLillyinconnectionwithhistransitionfromElancotohisnewroleatLillyasofNovember1,2018.
(2) ThiscolumnshowsthegrantdatefairvalueoftheLillyPAs,ExecutiveOfficerPAs,LillySVAs,ExecutiveOfficerSVAs,LillyRSUsandElancoRSUs,asapplicable,awardedtotheNamedExecutiveOfficersin2017and2018computedinaccordancewithFASBASCTopic718,basedupontheprobableoutcomeoftheperformanceconditionsasofthegrantdateandtheassumptionsinNote13:Stock-BasedCompensationtoElanco'sconsolidatedandcombinedfinancialstatementsincludedelsewhereinthisprospectus,"Note11:Stock-BasedCompensation"footnotetotheconsolidatedfinancialstatementsintheAnnualReportonForm10-KforthefiscalyearendedDecember31,2018filedbyLillyonFebruary19,2019,and"Note11—StockBasedCompensation"footnotetotheconsolidatedfinancialstatementsintheAnnualReportonForm10-KforthefiscalyearendedDecember31,2017,filedbyLillyonFebruary20,2018.ThegrantdatefairvaluefortheLillyPAs,ExecutiveOfficerPAs,LillySVAsandExecutiveOfficerSVAsincludedinthe"StockAwards"columnarebasedontheprobablepayoutoutcomeanticipatedatthetimeofgrant,whichfortheLillyPAsandExecutiveOfficerPAswasat144%oftargetandfortheLillySVAsandExecutiveOfficerSVAswastargetvalue.
The"StockAwards"columnalsoincludesone-timeLillyRSUandElancoRSUawardsasfollows:
• Ms.LinreceivedaLillyRestrictedStockUnitaward,whichwasgrantedonFebruary1,2018withagrantdatefairvalueof$900,082.Shereceivedthisasaone-timeawardtopartiallyoffsetcompensationforfeitedfromapreviousemployer.One-thirdofhergrantisscheduledvestonFebruary1,2019,one-thirdonFebruary1,2020andtheremainingone-thirdonFebruary1,2021.
TableofContents
Grants of Plan-Based Awards During 2018
Thefollowingtablereflectsgrantsofplan-basedawardsdescribedintheCD&Aundereachofthefollowingplans:theElancoBonusPlanandLillyBonusPlan(eachplanisanon-equityincentiveplan),
119
• Mr.YoungreceivedanElancoRestrictedStockUnitaward,whichwasgrantedonDecember3,2018withagrantdatefairvalueof$300,032.Hereceivedthisasaone-timeawardtopartiallyoffsetcompensationforfeitedfromapreviousemployer.One-halfofthisgrantwillvestonDecember3,2019andtheremainingone-halfwillvestonDecember3,2020.
• Mr.MontarcereceivedaLillyRestrictedStockUnitaward,whichwasgrantedonMay1,2018withagrantdatefairvalueof$250,019.HereceivedthisawardinrecognitionofhiscontributionstoLillyandtohelpsecurehisservicesasvicepresident,CFOLillyInternationalthroughMay2023.One-thirdofhisgrantwillvestonMay1,2021andtheremainingtwo-thirdswillvestonMay1,2023.
Theseone-timerestrictedstockunitawardswillbeforfeitedifMs.LinorMessrs.YoungorMontarceterminateemploymentwithLillyorElanco,asapplicable,priortothevestingdates,otherthantheeventofcertainqualifyingterminations.
The"StockAwards"columnalsoincludesFounders'AwardElancoRSUsforMs.LinandMessrs.Simmons,Urbanek,KinardandJensen.TheseawardsweregrantedaftertheIPOonOctober20,2018,whichwillvestonOctober20,2021.Thegrantdatefairvalueswere$1,119,454forMr.Simmonsand$215,302forMs.LinandMessrs.UrbanekandKinard.
ThesupplementaltablebelowshowsthetotaltargetgrantdatefairvaluesoftheannualequityawardsapprovedbytheLillycompensationcommitteeforMr.SimmonsandapprovedbyLillymanagementfortheremainingNamedExecutiveOfficers,asapplicable:
Name 2017
Total Equity 2018
Total Equity Mr.Simmons $ 2,000,000 $ 1,200,000Mr.Young* N/A N/AMs.Lin* N/A N/AMr.Urbanek $ 80,000 $ 500,000Mr.Kinard $ 415,000 $ 400,000Mr.Jensen* N/A N/AMr.Montarce $ 90,000 $ 300,000
* Ms.LinandMessrs.YoungandJensenwerenoteligibleforanannualLillyequitygrantsincetheywerenotactiveemployeesofLillyonJanuary1,2018.
Thetablebelowshowstheminimum,targetandmaximumpayouts(usingthegrantdatefairvalue)forthe2018-2019LillyPAs(2018-2020ExecutiveOfficerPAforMr.Simmons)includedinthiscolumnofthe"SummaryCompensationTable."
Name Payout
Date Minimum
Payout Target Payout
Maximum Payout
Mr.Simmons January2021 $ 0 $ 480,000 $ 720,000Mr.Urbanek January2020 $ 0 $ 250,000 $ 375,000Mr.Kinard January2020 $ 0 $ 200,000 $ 300,000Mr.Montarce January2020 $ 0 $ 150,000 $ 225,000
Thetablebelowshowstheminimum,targetandmaximumpayouts(usingthegrantdatefairvalue)forthe2018-2020LillySVAs(2018-2020ExecutiveOfficerSVAsforMr.Simmons)includedinthiscolumnofthe"SummaryCompensationTable."
Name Payout
Date Minimum
Payout Target Payout
Maximum Payout
Mr.Simmons January2021 $ 0 $ 720,000 $ 1,296,000Mr.Urbanek January2021 $ 0 $ 250,000 $ 375,000Mr.Kinard January2021 $ 0 $ 200,000 $ 300,000Mr.Montarce January2021 $ 0 $ 150,000 $ 225,000
(3) The"OptionAwards"columnincludesFounders'AwardsofElancooptionsforMs.LinandMessrs.Simmons,Urbanek,KinardandJensen.ThesenonqualifiedstockoptionawardsweregrantedaftertheIPOonOctober20,2018.Generally,theyvestonthethirdanniversaryofthegrantdate,followedbyaseven-yearexerciseperiod,exceptforMr.JensenwhoseoptionawardimmediatelyvesteduponhisdeathonDecember14,2018andexpiredonMarch14,2019.Thegrantdatefairvalueswere$1,119,445forMr.Simmons,$600,001forMr.Jensenand$215,288forMs.LinandMessrs.UrbanekandKinard.
(4) ThiscolumnshowspaymentsundertheElancoBonusPlanand/ortheLillyBonusPlanforperformancein2018.See"—2018CompensationPayouts"abovefordetailson2018payoutsfortheNamedExecutiveOfficersundertheapplicablecashbonusplan.
(5) TheamountsinthiscolumnreflectthechangeinLillypensionvalue,calculatedbyLilly'sactuary,andareaffectedbyadditionalserviceaccrualsandpayearned,aswellasactuarialassumptionchanges.The2018changeinpensionvalueswasdriventoalargeextentbyahigherdiscountratewhichdecreasedthenetpresentvalueoftheapplicableNamedExecutiveOfficers'pension.Thedesignofthepensionbenefitdidnotchange.See"—PensionBenefits"belowforinformationabouttheactuarialassumptionsused.NoneoftheNamedExecutiveOfficersreceivedanypreferentialorabove-marketearningsondeferredcompensation.
(6) TheamountsinthiscolumnconsistsolelyofLillymatchingcontributionsforeachindividual's401(k)planandnonqualifiedsavingsplancontributions.Therewerenoreportableperquisites,personalbenefitsortaxreimbursementsorgross-upspaidtoanyoftheNamedExecutiveOfficersfor2018.
TableofContents
the2002LillyStockPlan(whichprovidesforthegrantofperformanceawards(PAs),shareholdervalueawards(SVAs),restrictedstockunits(RSUs)andthe2018ElancoStockPlan.ToreceiveapayoutundertheLillyPAs,ExecutiveOfficerPAs,LillySVAsorExecutiveOfficerSVAs,aparticipantmustremainemployedwithLillythroughtheendoftherelevantawardperiod(exceptinthecaseofdeath,disability,retirementorredundancy).Nodividendsaccrueoneitherperformanceawardsorshareholdervalueawardsduringtheperformanceperiod.FortheExecutiveOfficerPAs,dividendequivalentsunitsaccrueduringthethirteen-monthservice-vestingperiod(followingthetwo-yearperformanceperiod)andarepaiduponvesting.InconnectionwiththeSplit-Off,allthen-unvestedLillyequityawardsheldbytheNamedExecutiveOfficers(otherthanMr.Montarce,whowillremainemployedbyLilly)wereforfeitedfornoconsideration.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
120
All Other Stock
Awards:Number
of Shares
of Stock
or Units
(#)
Lilly/ Elanco
compensation committee
Estimated Future Payouts Under Non-Equity Incentive
Plan Awards(1)
Estimated Future Payouts Under Equity Incentive Plan
Awards
All Other Option
Awards: Number of Securities Underlying
Options
Grant Date Fair Value of
Stock and Option
Awards (9)
Exerciseor Base Price of Option Awards
Name Award Grant Date (2)
Action Date
Threshold($)
Target ($)
Maximum ($)
Threshold(#)
Target (#)
Maximum(#)
Mr.Simmons ElancoBonusPlan $ 182,954 $ 731,815 $ 1,463,629
2018-2020Executive
OfficerPAs(3) 2/9/2018 12/11/2017 3,351 6,701 10,052 $ 691,200
2018-2020Executive
OfficerSVAs(4) 2/9/2018 12/11/2017 6,988 17,471 31,448 $ 720,000 ElancoRSUs(5) 10/20/2018 9/5/2018 36,287 $ 1,119,454 ElancoOptions(5) 10/20/2018 9/5/2018 109,642 $ 31.61 $ 1,119,445
Mr.Young ElancoBonusPlan $ 16,042 $ 64,167 $ 128,333 ElancoRSUs(6) 12/3/2018 11/12/2018 8,983 $ 300,032
Ms.Lin ElancoBonusPlan $ 70,676 $ 282,703 $ 565,407 LillyRSU(7) 2/1/2018 N/A 10,922 $ 900,082 ElancoRSUs(5) 10/20/2018 9/5/2018 6,979 $ 215,302 ElancoOptions(5) 10/20/2018 9/5/2018 21,086 $ 31.61 $ 215,288
Mr.Urbanek ElancoBonusPlan $ 46,993 $ 187,970 $ 375,940
2018-2020LillyPAs(3) 2/9/2018 N/A 1,745 3,490 5,235 $ 360,000
2018-2020LillySVAs(4) 2/9/2018 N/A 2,442 4,883 7,325 $ 250,000
ElancoRSUs(5) 10/20/2018 9/5/2018 6,979 $ 215,302 ElancoOptions(5) 10/20/2018 9/5/2018 21,086 $ 31.61 $ 215,288
Mr.Kinard ElancoBonusPlan $ 36,327 $ 145,306 $ 290,612 LillyBonusPlan $ 15,534 $ 62,138 $ 124,275
2018-2020LillyPAs(3) 2/9/2018 N/A 1,396 2,792 4,188 $ 288,000
2018-2020LillySVAs(4) 2/9/2018 N/A 1,953 3,906 5,859 $ 200,000
ElancoRSUs(5) 10/20/2018 9/5/2018 6,979 $ 215,302 ElancoOptions(5) 10/20/2018 9/5/2018 21,086 $ 31.61 $ 215,288
Mr.Jensen ElancoBonusPlan $ 44,847 $ 179,386 $ 358,772 ElancoRSUs(5) 10/20/2018 9/5/2018 19,449 $ 600,002 ElancoOptions(5) 10/20/2018 9/5/2018 58,766 $ 31.61 $ 600,001
Mr.Montarce ElancoBonusPlan $ 27,904 $ 111,616 $ 223,232 LillyBonusPlan $ 5,614 $ 22,454 $ 44,908
2018-2020LillyPAs(3) 2/9/2018 N/A 1,047 2,094 3,141 $ 216,000
2018-2020LillySVAs(4) 2/9/2018 N/A 1,465 2,930 4,395 $ 150,000
LillyRSU(8) 5/1/2018 N/A 3,162 $ 250,019
(1) Thesecolumnsshowthethreshold,targetandmaximumpayoutsforperformanceundertheElancoBonusPlanand/orLillyBonusPlan.Bonuspayoutsrangefrom0%to200%oftarget.Thethreshold,targetandmaximumamountsrepresentsaweightedaverageoftheamountsapprovedbyLillymanagementfortheperiodpriortotheIPOandamountsapprovedbytheElancoboardofdirectorsorcompensationcommittee,asapplicable,inconnectionwiththeIPO.
(2) Toassuregranttimingisnotmanipulatedforemployeegain,theannualgrantdateforLillyawardsisestablishedinadvancebytheLillycompensationcommittee.Lillyequityawardstonewhiresandotheroff-cyclegrantsaregenerallyeffectiveonthefirsttradingdayofthefollowingmonth.
(3) Thisrowshowsthepossiblepayoutsfor2018-2019LillyPAsandthe2018-2020ExecutiveOfficerPAs,rangingfrom0%to150%oftarget.TheLillyPAs,totheextentearnedandvested,willpayoutinJanuary2020,andtheExecutiveOfficerPAs,totheextentearnedandvested,willpayoutinJanuary2021.ThegrantdatefairvalueoftheLillyPAsandExecutiveOfficerPAsisbasedontheprobablepayoutoutcomeatthetimeofgrant,whichassumespayoutat144%oftargetvalue.
TableofContents
121
ThetargetandmaximumvaluesarelistedfortheseawardsinNote2totheSummaryCompensationTable,above.ForallNamedExecutiveOfficersotherthanMr.Montarce(whowillremainemployedbyLilly),theseawardswereforfeitedfornoconsiderationinconnectionwiththeSplit-Off.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationoftheforfeitedawardsfollowingtheSplit-Off.
(4) Thisrowshowstherangeofpayoutsfor2018-2020LillySVAsandthe2018-2020ExecutiveOfficerSVAs.TheseshareholdervalueawardswillpayoutinJanuary2021,withpayoutsforthe2018-2020LillySVAsrangingfrom0%to150%andthepayoutsforthe2018-2020ExecutiveOfficerSVAsrangingfrom0%to180%oftarget.LillymeasuresthefairvalueofLillySVAsandtheExecutiveOfficerSVAawardsonthegrantdateusingaMonteCarlosimulationmodel.Thegrantdatefairvalueoftheseshareholdervalueawardsisbasedontheprobablepayoutoutcomeatthetimeofgrant,whichassumespayoutatthetargetvalue.ThetargetandmaximumvaluesarelistedfortheseawardsinNote2totheSummaryCompensationTable,above.ForallNamedExecutiveOfficersotherthanMr.Montarce(whowillremainemployedbyLilly),theseawards,totheextentnotthenvested,wereforfeitedfornoconsiderationinconnectionwiththeSplit-Off.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
(5) FollowingtheIPO,Ms.LinandMessrs.Simmons,Urbanek,KinardandJensenreceivedaFounder'sAwardintheformof50%ElancoOptionsand50%ElancoRSUs.Generally,theElancoOptionswillvestinthreeyears,followedbyaseven-yearexerciseperiodandtheElancoRSUswillvestonOctober20,2021,exceptforMr.Jensen,whoseFounders'Awardsaccelerateduponhisdeath.
(6) TheElancoRSUrepresentsaone-timeawardtopartiallyoffsetcompensationforfeitedfromapreviousemployer.Mr.YoungwasgrantedtheawardonDecember3,2018;one-halfofthisgrantwillvestonDecember3,2019andtheremainingone-halfwillvestonDecember3,2020.
(7) TheLillyRSUrepresentsaone-timeawardtopartiallyoffsetcompensationforfeitedfromapreviousemployer.Ms.LinwasgrantedonFebruary1,2018;one-thirdofthisgrantwillvestonFebruary1,2019,one-thirdwillvestonFebruary1,2020andtheremainingone-thirdwillvestonFebruary1,2021.InconnectionwiththeSplit-Off,thethen-unvestedportionofthisawardwereforfeitedfornoconsideration.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
(8) TheLillyRSUrepresentstheawardMr.MontarcereceivedinrecognitionofhiscontributionstoEliLillyandCompanyandtohelpsecurehisservicesthroughMay2023.TheawardwasgrantedonMay1,2018;one-thirdofthisgrantwillvestonMay1,2021,andtheremainingtwo-thirdswillvestonMay1,2023.Thegrantdatefairvalueoftheawardwas$250,019.
(9) ThiscolumnshowsthegrantdatefairvalueoftheLillyPAs,ExecutiveOfficerPAs,LillySVAsandExecutiveOfficerSVAscomputedinaccordancewithFASBASCTopic718,basedupontheprobableoutcomeoftheperformanceconditionsasofthegrantdateaswellasthegrantdatefairvalueoftheLillyRSUandElancoRSUawardsgrantedtoMs.LinandMessrs.YoungandMontarce.Seenotes3through8tothistable.
TableofContents
Outstanding Lilly and Elanco Equity Awards at December 31, 2018
The2018Elancoclosingstockpriceof$31.53andtheLillyclosingstockpriceof$115.72wereusedtocalculatethevaluesinthetablebelow.
122
Stock Awards
Equity Incentive Plan
Awards: Market or
Payout Value of
Unearned Shares, Units,
or Other Rights
That Have Not Vested
($)
Equity Incentive Plan
Awards: Number of Unearned
Shares, Units, or Other
Rights That Have Not
Vested (#)
Option Awards
Number ofShares
or Units of
Stock That Have Not Vested
(#)
Name Award
Number of Securities Underlying
Options Exercisable
(#)
Number of Securities
Underlying Options
Unexercisable(#)
Option Exercise
Price
Option Expiration
Date
Market Value of Shares or
Units of Stock That Have Not
Vested ($)
Mr.Simmons 2018-2020ExecutiveOfficerSVA 31,448(1) $ 3,639,163
2017-2019ExecutiveOfficerSVA 33,074(2) $ 3,827,323
2018-2020ExecutiveOfficerPA 10,052(3) $ 1,163,217
2017-2019ExecutiveOfficerPA 16,317(4) $ 1,888,203
2016-2018ExecutiveOfficerPA 11,111(5) $ 1,285,765
ElancoRSUs 36,287(6) $ 1,144,129 ElancoOptions 109,642(7) $ 31.61 10/20/2028
Mr.Young
ElancoRSUs 8,983(8) $ 283,234
Ms.Lin
LillyRSUs 10,922(9) $ 1,263,894 ElancoRSUs 6,979(6) $ 220,048 ElancoOptions 21,086(7) $ 31.61 10/20/2028
Mr.Urbanek
2018-2020LillySVA 7,325(1) $ 847,649 2017-2019LillySVA 902(2) $ 104,379 2018-2020LillyPA 5,235(3) $ 605,794 LillyRSU 2,498(10) $ 289,069 ElancoRSUs 6,979(6) $ 220,048 ElancoOptions 21,086(7) $ 31.61 10/20/2028
Mr.Kinard
2018-2020LillySVA 5,859(1) $ 678,003 2017-2019LillySVA 4,676(2) $ 541,107 2018-2020LillyPA 4,188(3) $ 484,635 ElancoRSUs 6,979(6) $ 220,048 ElancoOptions 21,086(7) $ 31.61 10/20/2028
Mr.Jensen
ElancoOptions 58,766(11) $ 31.61 3/14/2019
Mr.Montarce
2018-2020LillySVA 4,395(1) $ 508,589 2017-2019LillySVA 1,014(2) $ 117,340 2018-2020LillyPA 3,141(3) $ 363,477 LillyRSUs 3,162(12) $ 365,907
(1) LillySVAsandExecutiveOfficerSVAsgrantedforthe2018-2020performanceperiod,totheextentearned,arescheduledtovestonDecember31,2020.ThenumberofLillysharesreportedreflectsthemaximumpayout,whichwillbemadeiftheaverageclosingLillystockpriceinNovemberandDecember2020isover$120.65.Actualpayoutsmayvaryfrom0%to180%oftargetfortheExecutiveOfficerSVAsand0%to150%fortheLillySVAs.NetLillysharesreceivedinrespectofExecutiveOfficerSVApayoutsmustbeheldbyMr.Simmonsforaminimumofoneyear.ForallNamedExecutiveOfficersotherthanMr.Montarce(whowillremainemployedbyLilly),theseawards,totheextentnotthenvested,wereforfeitedfornoconsiderationinconnectionwiththeSplit-Off.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
(2) LillySVAsandExecutiveOfficerSVAsgrantedforthe2017-2019performanceperiodarescheduledtovestonDecember31,2019.ThenumberofLillysharesreportedreflectsthemaximumpayout,whichwillbemadeiftheaverageclosingLillystockpriceinNovemberandDecember2018isover$101.79.Actualpayoutsmayvaryfrom0%to180%oftargetfortheExecutiveOfficerSVAand0%to150%fortheLillySVA.NetLillysharesfromanypayoutmustbeheldbytheapplicableNamedExecutiveOfficerforaminimumofoneyear.ForallNamedExecutiveOfficersotherthanMr.Montarce(whowillremainemployedbyLilly),theseawards,totheextentnotthenvested,wereforfeitedfornoconsiderationinconnectionwiththeSplit-Off.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
TableofContents
Lilly and Elanco Stock Vested in 2018
123
(3) ForMr.Simmons,thisnumberrepresentsthemaximumvalueofExecutiveOfficerPAsharesthatcouldpayoutfor2018-2019performanceperiodprovidedperformancegoalsaremet.OncethecombinedcumulativeLillyEPSresultandassociatedpayoutlevelisdeterminedattheendoftheperformanceperiod,theresultantnumberofsharesowedtoMr.SimmonswillbeissuedasLillyRSUsthatvestinFebruary2021.ForMessrs.Urbanek,KinardandMontarce,thisnumberrepresentsthemaximumvalueofLillyPAsharesthatcouldpayoutfor2018-2019performanceperiodprovidedperformancegoalsaremet.ActualpayoutsforbothLillyPAsandExecutiveOfficerPAsmayvaryfrom0%to150%oftarget.ForallNamedExecutiveOfficersotherthanMr.Montarce(whowillremainemployedbyLilly),theseawards,totheextentnotthenvested,wereforfeitedfornoconsiderationinconnectionwiththeSplit-Off.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
(4) TheperformanceperiodendingDecember31,2018forthe2017-2019ExecutiveOfficerPAresultedinMr.SimmonsbeingissuedLillyRSUsfor150%oftargetshares.TheRSUsarescheduledtovestinFebruary2020.
(5) RSUsvestinginFebruary2019fromthe2016-2018ExecutiveOfficerPA,whichoccurredpriortotheSplit-Off.
(6) ElancoRSUsgrantmadeafterElanco'sIPOwithathree-yearvestvestingonOctober20,2021.
(7) ElancononqualifiedstockoptionsgrantmadeafterElanco'sIPOwithathree-yearvestvestingonOctober20,2021followedbyaseven-yearexerciseperiodendingOctober20,2028.
(8) ElancoRSUgrantedonDecember3,2018.One-halfofthisgrantwillvestonDecember3,2019andtheremainingone-halfwillvestonDecember3,2020.
(9) LillyRSUgrantedonFebruary1,2018.One-thirdofthisgrantvestedonFebruary1,2019,one-thirdwillvestonFebruary1,2020andtheremainingone-thirdwillvestonFebruary1,2021.Thisaward,totheextentnotthenvested,wasforfeitedfornoconsiderationinconnectionwiththeSplit-Off.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
(10) LillyRSUgrantmadein2017outsideofthenormalannualcycle.ThisgrantwillvestonSeptember1,2020.Thisaward,totheextentnotthenvested,wasforfeitedfornoconsiderationinconnectionwiththeSplit-Off.TheElancocompensationcommitteehasauthorizedtheissuanceofElancoequityawardsofsimilarvalueanddurationtotheforfeitedawardsfollowingtheSplit-Off.
(11) UponMr.Jensen'sdeath,thisElancononqualifiedstockoptiongrantmadeafterElanco'sIPOimmediatelyvestedonDecember14,2018.TheoptiontoexercisethisoptionexpiredonMarch14,2019.
(12) LillyRSUgrantmadeonMay1,2018outsideofthenormalannualcycle.One-thirdofthisgrantwillvestonMay1,2021,andtheremainingtwo-thirdswillvestonMay1,2023.
Lilly Stock Awards Elanco Stock Awards
Name
Number of Shares
Acquired on Vesting (#)
Value Realized on
Vesting ($) (1)
Number of Shares
Acquired on Vesting (#)
Value Realized on Vesting ($)
(1) Mr.Simmons 20,000(2) $ 1,621,400 — —
21,326(3) $ 1,737,003 — — 43,785(4) $ 5,261,643 — —
Mr.Young — — — —Ms.Lin — — — —Mr.Urbanek 816(5) $ 98,059 — —
1,024(6) $ 123,054 — —Mr.Kinard 4,233(5) $ 508,680 — —
4,818(6) $ 578,979 — — 6,726(7) $ 718,001 — —
Mr.Jensen — — 19,449(8) $ 629,564Mr.Montarce 918(5) $ 110,316 — —
1,265(6) $ 152,015 — —
(1) AmountsreflectthemarketvalueoftheLillystockonthedaytheLillystockvestedorthemarketvalueoftheElancostockonthedaytheElancostockvestedasapplicable.
(2) Thelastinstallmentofaone-timeRSUawardedtoMr.Simmonsin2008outsideofthenormalgrantcycle.
(3) Lillyrestrictedstockunitsresultingfromthe2015-2017ExecutiveOfficerPAthatvestedinFebruary2018.
TableofContents
Retirement Benefits
LillyprovidesretirementincometoeligibleU.S.Lillyemployees,whichincludedcertainoftheNamedExecutiveOfficerspriortotheIPO,throughthefollowingplans:
• TheLilly401(k)Plan,adefinedcontributionplanqualifiedunderSections401(a)and401(k)oftheInternalRevenueCode.Participantsmayelecttocontributeaportionoftheirbasesalarytotheplan,andLillyprovidesmatchingcontributionsonemployees'contributionsupto6%ofbasesalaryuptoIRSlimits.Theemployeecontributions,Lillycontributionsandearningsthereonarepaidoutinaccordancewithelectionsmadebytheparticipant.Seethe"AllOtherCompensation"columnintheSummaryCompensationTableforinformationaboutLillycontributionsunderthe401(k)PlanfortheapplicableNamedExecutiveOfficers.
• TheLillyRetirementPlan,atax-qualifieddefinedbenefitplanthatprovidesmonthlybenefitstoretirees.SeethePensionBenefitstablebelowforadditionalinformationaboutthevalueofthesepensionbenefits.
Sections401and415oftheCodegenerallylimittheamountofannualpensionthatcanbepaidfromatax-qualifiedplanto$275,000in2018aswellastheamountofannualearningsthatcanbeusedtocalculateapensionbenefit.However,since1975LillyhasmaintainedanonqualifiedpensionplanthatpaysretireesthedifferencebetweentheamountpayableundertheRetirementPlanandtheamounttheywouldhavereceivedwithouttheCodelimits.TheLillynonqualifiedpensionplanisunfundedandsubjecttoforfeitureintheeventofbankruptcy.Likewise,Lillymaintainsanonqualifiedsavingsplanthatallowsparticipantstocontributeupto6%ofbasesalaryexceedingtheIRSlimit.Lillymatchesthesecontributionsasdescribedinthe401(k)Plan.Formoreinformation,seethedisclosureimmediatelyfollowingthefootnotestotheNonqualifiedDeferredCompensationin2018table.
ThefollowingtableshowsbenefitsthattheapplicableNamedExecutiveOfficershaveaccruedundertheLillyRetirementPlanandtheLillynonqualifiedpensionplan.
124
(4) Payoutofthe2016-2018ExecutiveOfficerSVAat125%oftargetwith+20%TSRmodifier,resultinginanoverall150%payout.
(5) Payoutofthe2017-2018LillyPAat150%oftarget.
(6) Payoutofthe2016-2018LillySVAat125%oftarget.
(7) Thelastinstallmentofaone-timeRSUawardedtoMr.Kinardin2008outsideofthenormalgrantcycle.
(8) PayoutofMr.Jensen'sElancoRSUusingtheclosingpriceofElancostockonDecember14,2018of$32.37.
TableofContents
Pension Benefits
TheLillyRetirementPlanbenefitsshowninthetablearenetpresentvalues.Thebenefitsarenotpayableasalumpsum;theyaregenerallypaidasamonthlyannuityforthelifeoftheretireeand,ifelected,anyqualifyingsurvivor.TheannualbenefitundertheLillyretirementplaniscalculatedusingyearsofserviceandtheaverageoftheannualearnings(salaryplusbonus)forthehighestfiveoutofthelast10calendaryearsofservice(finalaverageearnings).
125
Name Plan
Number of Years of Credited Service
Present Value of
Accumulated Benefit ($) (1)
Payments During
Last Fiscal
Year ($) Mr.Simmons Lillyretirementplan(pre-2010) 21 $ 1,019,096
Lillyretirementplan(post-2009) 9 $ 207,040 Lillynonqualifiedplan(pre-2010) 21 $ 4,344,161 Lillynonqualifiedplan(post-2009) 9 $ 849,148 $ 6,419,745 $ 0
Mr.Young Lillyretirementplan(post-2009) 0 $ 551 Lillynonqualifiedplan(post-2009) 0 $ 551 $ 1,102 $ 0
Ms.Lin Lillyretirementplan(post-2009) 1 $ 3.300 Lillynonqualifiedplan(post-2009) 1 $ 2.442 $ 5,742 $ 0
Mr.Urbanek Lillyretirementplan(pre-2010) 22 $ 1,113,304 Lillyretirementplan(post-2009) 9 $ 223,687 Lillynonqualifiedplan(pre-2010) 22 $ 467,061 Lillynonqualifiedplan(post-2009) 9 $ 88,407 $ 1,892,459 $ 0
Mr.Kinard Lillyretirementplan(pre-2010) 13 $ 488,132 Lillyretirementplan(post-2009) 9 $ 207,040 Lillynonqualifiedplan(pre-2010) 13 $ 738,879 Lillynonqualifiedplan(post-2009) 9 $ 301,492 $ 1,735,543 $ 0
Mr.Jensen Lillyretirementplan(post-2009) 1 $ 3.300 Lillynonqualifiedplan(post-2009) 1 $ 3,835 $ 7,135 $ 0
Mr.Montarce Lillyretirementplan(post-2009) 6 $ 18,675 Lillynonqualifiedplan(post-2009) 6 $ 3,556 $ 22,231 $ 0
(1) ThefollowingactuarialassumptionswereusedtocalculatethepresentvalueoftheapplicableNamedExecutiveOfficer'saccumulatedpensionbenefit:
Discountrate: 4.52%forthequalifiedplanand4.36%fornon-qualifiedplanMortality(post-retirementdecrementonly): RP2006withgenerationalprojectionusingScaleMP2018Pre-2010jointandsurvivorbenefit(%ofpension): 50%untilage62;25%thereafterPost-2009benefitpaymentform: lifeannuity
TableofContents
Post-2009 Lilly Plan Information: FollowingamendmentoftheLillyRetirementPlanformulas,employeeshiredbyLillyonorafterFebruary1,2008haveaccruedretirementbenefitsonlyunderthenewLillyplanformula.EmployeeshiredbeforethatdatehaveaccruedbenefitsunderboththeoldLillyandnewLillyplanformulas.Alleligibleemployees,includingthosehiredonorafterFebruary1,2008,canretireatage65withatleastfiveyearsofserviceandreceiveanunreducedbenefit.TheannualbenefitunderthenewLillyplanformulaisequalto1.2%offinalaverageearningsmultipliedbyyearsofservice.EarlyretirementbenefitsunderthisLillyplanformulaarereduced6%foreachyearunderage65.Transitionbenefitswereaffordedtoemployeeswith50points(ageplusservice)ormoreasofDecember31,2009.ThesebenefitswereintendedtoeasethetransitiontothenewLillyretirementformulaforthoseemployeeswhowereclosertoretirementorhadbeenwithLillylongeratthetimetheLillyplanwaschanged.Forthetransitiongroup,earlyretirementbenefitsarereduced3%foreachyearfromage65toage60and6%foreachyearunderage60.Messrs.Simmons,UrbanekandKinardareinthistransitiongroup.
Pre-2010 Lilly Plan Information: EmployeeshiredbyLillypriortoFebruary1,2008,accruedbenefitsunderbothLillyplanformulas.Fortheseemployees,benefitsthataccruedbeforeJanuary1,2010werecalculatedundertheoldLillyplanformula.TheamountofthebenefitiscalculatedusingactualyearsofservicethroughDecember31,2009,whiletotalyearsofserviceisusedtodetermineeligibilityandearlyretirementreductions.Thebenefitamountisincreased(butnotdecreased)proportionately,basedonfinalaverageearningsatterminationcomparedtofinalaverageearningsatDecember31,2009.Fullretirementbenefitsareearnedbyemployeeswith90ormorepoints(thesumofhisorherageplusyearsofservice).Employeeselectingearlyretirementreceivereducedbenefitsasdescribedbelow:
• ThebenefitforLillyemployeeswithbetween80and90pointsisreducedby3%foreachyearunder90pointsorage62.
• ThebenefitforLillyemployeeswhohavefewerthan80points,butwhoreachedage55andhaveatleast10yearsofservice,isreducedasdescribedaboveandisfurtherreducedby6%foreachyearunder80pointsorage65.
126
TableofContents
Nonqualified Deferred Compensation
TheNonqualifiedDeferredCompensationtableaboveshowsinformationabouttwoLillyprograms:theLillynonqualifiedsavingsplanandtheLillyDeferredCompensationPlan.TheLillynonqualifiedsavingsplanisdesignedtoalloweachemployeetocontributeupto6%ofhisorherbasesalaryandreceiveaLillycompanymatchbeyondthecontributionlimitsprescribedbytheIRSwithregardto401(k)plans.TheLillyplanisadministeredinthesamemannerasthe401(k)Plan,withthesameparticipationandinvestmentelections.LillyexecutiveofficersmaydeferreceiptofallorpartoftheircashcompensationandotherU.S.LillyexecutivesmaydeferreceiptofallorpartoftheircashbonusundertheLillyDeferredCompensationPlan.AmountsdeferredbyexecutivesundertheLillyplanarecreditedwithinterestat120%oftheapplicablefederallong-termrateasestablishedtheprecedingDecemberbytheU.S.TreasuryDepartmentunderSection1274(d)oftheCodewithmonthlycompounding,whichwas3.1%for2018.Participantsmayelecttoreceivethefundsinalumpsumorinupto10annualinstallmentsfollowingterminationofemployment,butmaynotmakewithdrawalswhileemployedbyLilly,exceptintheeventofhardshipasapprovedbytheLillycompensationcommittee.Alldeferralelectionsandassociateddistributionschedulesareirrevocable.BothLillyplansareunfundedandsubjecttoforfeitureintheeventofbankruptcy.
127
Name Plan
Executive Contributions in Last Fiscal
Year ($) (1)
Registrant (Lilly)
Contributions in Last Fiscal
Year ($) (2)
Aggregate Earnings in Last Fiscal Year
($)
Aggregate Withdrawals/ Distributions
in Last Fiscal Year
($)
Aggregate Balance at Last Fiscal Year End
($) Mr.Simmons Lillynonqualifiedsavings $ 30,011 $ 30,011 $ 21,215 $ 0 $ 803,403
Lillydeferredcompensation $ 0 $ 0 $ 54,151 $ 1,789,759 Total $ 30,011 $ 30,011 $ 75,366 $ 0 $ 2,593,162
Mr.Young Lillynonqualifiedsavings $ 0 $ 0 $ 0 $ 0 $ 0 Lillydeferredcompensation $ 0 $ 0 $ 0 $ 0 Total $ 0 $ 0 $ 0 $ 0 $ 0
Ms.Lin Lillynonqualifiedsavings $ 13,533 $ 13,533 $ (2,092) $ 0 $ 24,974 Lillydeferredcompensation $ 0 $ 0 $ 0 $ 0 Total $ 13,533 $ 13,533 $ (2,092) $ 0 $ 24,974
Mr.Urbanek Lillynonqualifiedsavings $ 6,413 $ 6,413 $ (51) $ 0 $ 16,034 Lillydeferredcompensation $ 0 $ 0 $ 0 $ 0 Total $ 6,413 $ 6,413 $ (51) $ 0 $ 16,034
Mr.Kinard Lillynonqualifiedsavings $ 8,758 $ 8,758 $ (7,196) $ 0 $ 181,348 Lillydeferredcompensation $ 61,149 $ 0 $ 20,957 $ 703,833 Total $ 69,907 $ 8,758 $ 13,761 $ 0 $ 885,181
Mr.Jensen Lillynonqualifiedsavings $ 5,796 $ 5,796 $ (456) $ 0 $ 11,136 Lillydeferredcompensation $ 0 $ 0 $ 0 $ 0 Total $ 5,796 $ 5,796 $ (546) $ 0 $ 11,136
Mr.Montarce Lillynonqualifiedsavings $ 3,611 $ 3,611 $ (131) $ 0 $ 7,090 Lillydeferredcompensation $ 0 $ 0 $ 0 $ 0 Total $ 3,611 $ 3,611 $ (131) $ 0 $ 7,090
(1) TheamountsinthiscolumnarealsoincludedintheSummaryCompensationTable,inthe"Salary"column(nonqualifiedsavings)orthe"LillyNon-EquityIncentivePlanCompensation"column(deferredcompensation).
(2) TheamountsinthiscolumnarealsoincludedintheSummaryCompensationTable,inthe"AllOtherCompensation"columnasaportionofthesavingsplanmatch.
TableofContents
Payments Upon Termination or Change in Control (as of December 31, 2018)
ThefollowingtabledescribesthepotentialpaymentsandbenefitsunderElanco'scompensationandbenefitplansandarrangementstowhichtheapplicableNamedExecutiveOfficerswouldhavebeenentitleduponahypotheticalterminationofemploymentonDecember31,2018inthecircumstancesdescribedinthetable.ThenarrativefollowingthetabulardisclosurebelowcontainsmoredetailsonthetreatmentofcertainequityawardsuponaqualifyingterminationofemploymentfortheNamedExecutiveOfficers.Otherthanthepaymentsandbenefitsdescribedbelow,anyagreementtoprovideseverancepaymentsorbenefits(otherthanfollowingachangeincontrol)wouldbeatthediscretionofourcompensationcommittee.
128
Cash Severance Payment (1)
Continuation of Medical /
Welfare Benefits (present
value)
Value of Acceleration
of Equity Awards
Total Termination
Benefits Mr.Simmons • Involuntaryretirementorterminationwithoutcause $ 0 $ 0 $ 4,318,097(3) $ 4,318,097• Involuntaryorgoodreasonterminationafterchangeincontrol $ 4,400,000 $ 47,892(2) $ 12,341,104(5) $ 16,788,996Mr.Young • Involuntaryretirementorterminationwithoutcause $ 0 $ 0 $ 283,234(4) $ 283,234• Involuntaryorgoodreasonterminationafterchangeincontrol $ 1,870,000 $ 47,892(2) $ 283,234(4) $ 2,201,126Ms.Lin • Involuntaryretirementorterminationwithoutcause $ 0 $ 0 $ 1,483,942(3) $ 1,483,942• Involuntaryorgoodreasonterminationafterchangeincontrol $ 1,696,000 $ 31,039(2) $ 1,483,942(5) $ 3,210,981Mr.Urbanek • Involuntaryretirementorterminationwithoutcause $ 0 $ 0 $ 509,116(3) $ 509,116• Involuntaryorgoodreasonterminationafterchangeincontrol $ 1,232,000 $ 47,892(2) $ 1,925,558(5) $ 3,205,450Mr.Kinard • Involuntaryretirementorterminationwithoutcause $ 0 $ 0 $ 220,048(3) $ 220,048• Involuntaryorgoodreasonterminationafterchangeincontrol $ 1,376,000 $ 41,386(2) $ 1,810,735(5) $ 3,228,121
(1) AsofDecember31,2018,theNamedExecutiveOfficers(otherthanMessrs.MontarceandJensen),wereentitledtoseveranceunderTheElancoChange-in-ControlSeverancePayPlanforSelectEmployeesuponaninvoluntaryretirementorterminationwithoutcause(seebelow).
(2) See"ElancoChange-in-ControlSeverancePayPlanforSelectEmployees"belowforadiscussionofpaymentsfollowingachangeincontrol.
(3) IncludesamountsforMr.Simmonsthatwouldbepaidunderthe2016-2018ExecutiveOfficerPAs,2017-2019ExecutiveOfficerPAsandthefounders'awardElancoRSUs.ForMs.Lin,theamountincludesthefounders'awardElancoRSUsandtheLillyRSUgrantedonFebruary1,2018.ForMr.Urbanek,theamountincludesthefounders'awardElancoRSUsandtheLillyRSUgranted
TableofContents
Former Chief Financial Officer and Acting Chief Financial Officer
InconnectionwithMr.Jensen'sdeathonDecember14,2018,hisestatebecameentitledtocertainbenefits,includingalifeinsuranceanddeathbenefitof$1,300,000underTheEliLillyandCompanyLifeInsuranceandDeathBenefitPlan,whichgenerallyprovidesforabenefitequaltotwotimesanemployee'sbasesalaryandwasavailabletoallLillyandElancoemployeesin2018.Mr.Jensen'sElancoRSUawardwasaccelerated,whichresultedintheimmediatevestingof19,449sharesofElancostockwithavalueof$629,564,andhisElancooptionawardwasacceleratedandremainedexercisableuntilMarch14,2019.Inaddition,thematchingofhisaccountsunderTheLillyEmployee401(k)PlanandTheLillyExcessSavingsPlanwasacceleratedentitlinghisestatetopaymentsof$13,886and$5,796,respectively.Mr.Jensen'sspouseanddependentsareentitledtoCOBRAforaperiodofsixmonths.
Mr.MontarcewasnotentitledtoanyterminationpaymentsfromElancoinconnectionwithhistransitioninemploymentfromElancotoLillyonNovember1,2018.
Equity Acceleration in Connection with a Change-in-Control
UponaLillychangeincontrol,anythenoutstandingandunvestedLillySVAs,ExecutiveSVAs,PAsandExecutivePAswouldconvertintorestrictedstockunitsofthenewcompany,withthenumberofLillysharesearnedunderanyperformance-basedawardsbasedonactualperformanceatthetimeofthetransaction.TheseconvertedrestrictedstockunitsandotherLillyrestrictedstockunitawards(whichwouldalsoconvertintorestrictedstockunitsofthenewcompany)willcontinuetovestandpayoutupontheearlierofthecompletionoftheoriginalawardperiod,uponacoveredterminationofemployment(generallythesameasisdescribedbelowforElanco),orifthesuccessorentitydoesnotassume,substituteorotherwisereplacetheaward.
UponanElancochangeincontrol,unvestedElancoRSUsandoptionswillcontinuetovestandpayoutupontheearlierofthecompletionoftheoriginalawardperiod,uponacoveredterminationofemploymentasdescribedbelow,orifthesuccessorentitydoesnotassume,substituteorotherwisereplacetheaward.
Elanco Change-in-Control Severance Pay Plan for Select Employees
InconnectionwiththeIPO,Elanco'sboardofdirectorsadoptedElancochange-in-controlseverancepayplansfornearlyallElancoemployees,includingaplanthatappliestotheNamedExecutiveOfficers.TheElancoplansareintendedtopreserveElancoemployeemoraleandproductivityandencourageretentioninthefaceofthedisruptiveimpactofanactualorrumoredchangeincontrol.Inaddition,theElancoplansareintendedtoalignparticipatingElancoemployee
129
in2017.ForMr.Kinard,theamountincludesthefounders'awardElancoRSUs.Doesnotincludeamountsthatwouldbepaidunderthe2018-2020LillyPAs,2018-2020ExecutiveOfficerPA,2017-2019LillySVAs,2017-2019ExecutiveOfficerSVA,2018-2020LillySVAsor2018-2020ExecutiveOfficerSVAs,whichwouldresultinthefollowingestimatedamounts,ifcalculatedattarget,asofDecember31,2018:Mr.Simmons:$2,479,127;Mr.Urbanek:$436,650andMr.Kinard:$552,679.See"OutstandingLillyandElancoEquityAwardsatDecember31,2018"tableabove.
(4) IncludestheaccelerationofElancoRSUsrelatedtotheone-timeElancoRSUawardMr.Youngreceivedaspartofhishiringupontheeventofcertainqualifyingterminations.
(5) IncludestheaccelerationofElancoRSUsandoptionsandofLillySVAs,ExecutiveOfficerSVAs,PAs,ExecutiveOfficerPAsandRSUs,ineachcase,upontheeventofcertainqualifyingterminationsfollowingachange-in-control.
TableofContents
andElancoshareholderinterestsbyenablingexecutivestoevaluatecorporatetransactionsthatmaybeinthebestinterestsoftheElancoshareholdersandotherconstituentsofElancowithoutundueconcernoverwhetherthetransactionswouldjeopardizetheparticipatingemployee'sownemployment.Outsideofachangeincontrol,ElancowasnotobligatedtopayseverancetoitsNamedExecutiveOfficersuponterminationofemployment,butseverancecouldhavebeenpaidatthediscretionoftheElancocompensationcommittee.
ThebasicelementsoftheselectplanapplicabletotheNamedExecutiveOfficersinclude:
• Doubletrigger.Unlike"singletrigger"plansthatpayoutimmediatelyuponachangeincontrol,theselectplanrequiresa"doubletrigger"—achangeincontrolfollowedbyaninvoluntarylossofemploymentwithintwoyears.ThisisconsistentwithElanco'sintenttoprovideemployeeswithfinancialprotectionuponlossofemployment.
• Coveredterminations.OurparticipatingNamedExecutiveOfficersareeligibleforpaymentsunderourselectplanif,withintwoyearsofthechangeincontrol,theiremploymentisterminated(i)withoutcausebyElancoor(ii)forgoodreasonbytheemployee,eachasisdefinedintheplan.
• Severancepayment.NamedExecutiveOfficersareeligibleforuptotwoyears'basesalaryplustwotimestheirtargetbonusforthethen-currentyear.
• Benefitcontinuation.Basicemployeebenefitssuchashealthandlifeinsurancewouldcontinuefor18monthsfollowingaparticipatingNamedExecutiveOfficer'sterminationofemployment,unlesstheybecomeeligibleforcoveragewithanewemployerbeforethen.
• Nogross-ups.Insomecircumstances,thepaymentsorotherbenefitsreceivedbyaparticipatingemployeeinconnectionwithachangeincontrolcouldexceedlimitsestablishedunderSection280GoftheCoderesultinginanexcisetaxpayment.Elancowouldnotreimburseorgross-upemployeesforthesetaxes.However,theamountofchangeincontrol-relatedbenefitswouldbereducedtothemaximumamountthatwouldnotresultinanexcisetaxiftheeffectwouldbetodeliveragreaterafter-taxbenefitthantheemployeewouldreceiveifhisorherbenefitswerenotsoreduced.
Director Compensation
Elanco Non-Employee Director Compensation Program
DirectorswhoareemployedbyElancooranyofitsaffiliatesarenoteligibletoreceivecompensationfortheirserviceontheBoard.In2018,directorswhowereemployedbyLillyoritsaffiliatesweresimilarlynoteligibletoreceivecompensationfortheirserviceonourBoard.Currently,allmembersoftheBoard,otherthanthoseemployedbyElanco,receiveanannualretentionfeeof$70,000incashandanannualequityawardgrantedundertheElancoDirectors'DeferralPlaninthenumberofsharesofourcommonstockhavingagrantdatevalueequalto$180,000.ThechairmanofElanco'sboardofdirectorsalsoreceivesanannualretentionfeeof$100,000incash,thechairmanoftheElancoAuditCommitteealsoreceivesanannualretentionfeeof$18,000incash,andthechairmanoftheCompensationCommittee,FinanceCommitteeandNominatingandCorporateGovernanceCommitteeeachalsoreceiveanannualretentionfeeof$16,000incash.TheannualequityawardsgrantedtodirectorsaresubjecttomandatorydeferralundertheElancoDirectors'DeferralPlanandthecashcompensationissubjecttoelectivedeferralundersuchplan,asdescribedbelow.
Elanco'sdirectorsmaybereimbursedforreasonableout-of-pockettravelexpensesincurredinconnectionwithattendanceatboardandcommitteemeetingsandotherboard-relatedactivities.TheElancocompensationcommitteewillreviewdirectorcompensationfromtimetotimeandmakerecommendationstotheboardofdirectors.
130
TableofContents
2018 Director Compensation
ElancodirectorswhoarenotalsoemployeesofLillyorElancoreceivedthefollowingcompensationfortheirservicein2018,whichrepresentsproratedamountsfromthetimeoftheIPOthroughDecember31,2018unlessotherwiseindicated:
Director Letter Agreement with Chairman
InconnectionwiththeappointmentofR.DavidHooverasadirectorandchairmanofElanco'sboardofdirectors,ElancoenteredintoaletteragreementwithMr.Hoover,whichprovided,inpart,thatMr.Hooverwouldassistintheidentificationandrecruitmentofpotentialcandidatestoserveontheboardofdirectors.Undertheletteragreement,Mr.Hooverwasentitledtoapaymentof$10,000permonthpriortotheIPO.SincetheIPO,Mr.Hooverhasbeencompensatedinthesamemannerastheothernon-employeedirectorsasdescribedunder"ElancoNon-EmployeeDirectorCompensationProgram"above.
Elanco Directors' Deferral Plan
PriortotheIPO,theboardofdirectorsandLilly,asElanco'ssoleshareholder,approvedtheElancoDirectors'DeferralPlan(the"Directors'DeferralPlan"),whichbecameeffectiveonSeptember18,2018.UndertheElancoDirectors'DeferralPlan,non-employeedirectors'equitycompensation(butnomorethanthelesserof30,000sharesorthenumberofsharesequalinvalueto$800,000(asoftheapplicablevaluationdate)lessthedirectors'cashcompensationfortheapplicableplanyear)arecreditedannuallyinadeferredstockaccount(asdescribedbelow).TheElanco
131
Name*
Fees Earned or Paid in
Cash ($)
Stock Awards
($) (1)
All Other Compensation
Payments ($)
Total ($)
R.DavidHoover $ 62,000(2) $ 60,004 $ 0 $ 122,004LawrenceKurzius $ 28,667(3) $ 60,004 $ 0 $ 88,671KapilaAnand $ 29,333(4) $ 60,004 $ 0 $ 89,337
* During2018,inadditiontothedirectorslistedandJeffreyN.Simmonswhosecompensationisdisclosedinthe"SummaryCompensationTable,"ourboardalsoincludedMichaelJ.Harrington,CarlL.McMillian,DavidA.Ricks,AartiS.ShahandJoshuaL.Smiley,eachofwhomwasalsoanemployeeofLillyanddidnotreceiveanycompensationfromusfortheirserviceasourdirector.
(1) Eachnon-employeedirectorreceivedanawardofstockvaluedat$60,004(1,796shares),representingapro-ratedawardforapartialyearofservice,whichawardsaremandatorilydeferredandnotissueduntilthesecondJanuaryfollowingthedirector'sdeparturefromserviceundertheElancoDirectors'DeferralPlan.Thecolumnshowsthegrantdatefairvalueforeachdirector'sstockawardcomputedinaccordancewithFASBASCTopic718basedupontheclosingpriceonthegrantdateandtheassumptionsinNote13:Stock-BasedCompensationtoElanco'sconsolidatedandcombinedfinancialstatementsincludedelsewhereinthisprospectus.
(2) Alsoincludesafeeof$10,000permonthfromthedateofMr.Hoover'sappointmentasChairmanoftheboardofdirectorsfromMay26,2018throughtheIPO.See"DirectorLetterAgreementwithChairman"below.
(3) Includespro-ratedfeeforserviceasthechairmanoftheElancocompensationcommittee.
(4) Includespro-ratedfeeforserviceasthechairmanoftheElancoauditcommittee.
TableofContents
Directors'DeferralPlanalsoallowsnon-employeedirectorstodeferreceiptofallorpartoftheircashcompensationuntilaftertheirserviceonourboardofdirectorshasended.Eachdirectorcanchoosetoinvesttheirdeferredcashcompensationinoneorbothofthefollowingtwoaccounts:
Deferred Stock Account. Thisaccountallowsthedirector,ineffect,toinvesthisorherdeferredcashcompensationincompanystock.Fundsinthisaccountarecreditedashypotheticalsharesofcompanystockbasedontheclosingstockpriceonpre-setdates.Thenumberofsharescreditedinrespectofdeferredcashcompensationiscalculatedbytheamountdeferreddividedbytheclosingstockpriceonpre-setdates.Inaddition,theannualstockcompensationawardsdescribedaboveisalsocreditedtothisaccount.Deferredstockaccountsarealsocreditedfordividendsasifthecreditedshareswereactualshares,withsuchcrediteddividendscreditedinadditionalshares.
Deferred Compensation Account. Fundsinthisaccountearninteresteachyearatarateof120percentoftheapplicablefederallong-termrate,compoundedmonthly,asestablishedtheprecedingDecemberbytheU.S.TreasuryDepartmentunderSection1274(d)oftheInternalRevenueCodeof1986(theInternalRevenueCode).
BothaccountsmaygenerallyonlybepaidinalumpsuminJanuaryofthesecondplanyearfollowingtheplanyearinwhichthedirectorseparatesfromserviceorinannualinstallmentsoverbetweentwoand10years,beginningatthesametimethelumpsumpaymentwouldbemade.Amountscreditedtothedirector'sdeferredstockaccountwouldgenerallybepaidinsharesofcompanystockandamountscreditedtothedirector'sdeferredcompensationaccountwouldbepaidincash.
Stock Ownership Guidelines
Pursuanttoourcorporategovernanceguidelines,directorsshouldholdmeaningfulequityownershippositionsinthecompany.Accordingly,asignificantportionofdirectorcompensationismadeintheformofcompanyequity.Theboardwillconsiderfromtimetotimeequityownershiprequirementsfornon-employeedirectors.
Hedging/Pledging Policy
Elanco'sCompensationCommitteeadoptedahedgingandpledgingpolicyunderwhichournon-employeedirectorsandemployeesarenotpermittedtohedgetheireconomicexposurestoElancostockthroughshortsalesorderivativetransactions.Non-employeedirectorsandallmembersofseniormanagementareprohibitedfrompledginganyElancostock(i.e.,usingElancostockascollateralforaloanortradingsharesonmargin).
132
TableofContents
Securities Authorized for Issuance under Equity Compensation Plans
ThefollowingtablesummarizesinformationasofDecember31,2018relatingtoElanco'sequitycompensationplansunderwhichequitysecuritiesareauthorizedforissuance:
.
133
Number of securities to be
issued upon exercise of
outstanding options, warrants
and rights
Weighted-average exercise price of
outstanding options, warrants
and rights
Number of securities
remaining available for future issuance
under equity compensation plans
(excluding securities reflected
in column (a)) Plan Category (a) (b) (c) EquityCompensationPlansapprovedbysecurityholders 550,855(1) $ 31.61(2) 4,940,145EquityCompensationPlansnotapprovedbysecurityholders — — —Total 559,855 $ 31.61 4,940,145
(1) Includes421,297stockoptions,133,170sharesunderlyingRSUsgrantedunderthe2018ElancoStockPlanand5,388deferredRSUsgrantedundertheDirectors'DeferralPlan.
(2) Theweighted-averageexercisepriceisonlyapplicabletostockoptions.
TableofContents
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Relationship between Elanco and Lilly
OnSeptember24,2018,immediatelypriortothecompletionoftheIPO,ElancoenteredintoamasterseparationagreementandanumberofotheragreementswithLillytoeffecttheseparationofElanco'sbusinessfromLillyandtoprovideaframeworkforElanco'songoingrelationshipwithLillyaftertheIPOandtheseparation,eachofwhichremainineffectfollowingthecompletionoftheSplit-Off.ThefollowingisasummaryofthetermsofthemasterseparationagreementandothermaterialagreementsbetweenusandLilly,whicharefiledasexhibitstotheregistrationstatementofwhichthisprospectusisapart.ThesesummariessetforththetermsoftheagreementsthatElancobelievesarematerialandarequalifiedintheirentiretybyreferencetothefulltextofsuchagreements.
Master Separation Agreement
ElancoenteredintoamasterseparationagreementwithLillyimmediatelypriortothecompletionoftheIPO.Themasterseparationagreementgovernscertainpre-IPOtransactions,aswellastheongoingrelationshipbetweenLillyandElancofollowingtheIPOandtheseparation.
The separation of Elanco's business; contribution of entities. ThemasterseparationagreementgenerallyallocatescertainassetsandliabilitiesbetweenElancoandLillyaccordingtothebusinesstowhichsuchassetsorliabilitiesrelate.PriortothecompletionoftheIPO,Lillyoritsaffiliates,asapplicable,conveyed,contributed,assigned,distributed,deliveredorotherwisetransferredownershipofsubstantiallyalloftheassetsthatareusedexclusivelyin,relateexclusivelyto,orariseexclusivelyoutof,theoperationorconductofitsanimalhealthbusinesses,tocertaindirectandindirectsubsidiariesofLilly.
EffectiveasoftheclosingoftheIPOonSeptember24,2018,LillycontributedtoElanco,pursuanttothemasterseparationagreement,theequityinterestsofcertainentitiesthatheld,eitherdirectlyorindirectlythroughtheequityownershipofadditionalentities,substantiallyalloftheassetsofLilly'sanimalhealthbusinesses,whichnowformstheElancobusiness.ThemasterseparationagreementalsogenerallyprovidesfortheassumptionbyElancoortheentitiesthatarenowitssubsidiariespursuanttoforegoingcontribution,asapplicable,ofallhistoricalandfutureliabilitiestotheextentrelatingto,arisingoutoforresultingfromtheownershiporoperationofsuchanimalhealthbusiness.InexchangeforthetransfertoElancooftheentitiesholdingsubstantiallyalloftheassetsandliabilitiesofLilly'sanimalhealthbusinesses,Lillyreceived(i)allofthenetproceeds($1,659.7million)thatElancoreceivedfromthesaleofElancocommonstockintheIPO,includingthenetproceedsreceivedasaresultoftheexerciseoftheunderwriters'optiontopurchaseadditionalshares,(ii)allofthenetproceeds(approximately$2,000million)receivedintheSeniorNotesOfferingand(iii)allofthenetproceeds($498.6million)receivedfromtheentrybyElancointoatermloanfacility.FollowingtheIPO,ElancomadeapaymenttoLillyof$359.9millionpursuanttothetermsofthemasterseparationagreement,whichrequiredthatElancopayadditionalamountstoLillytotheextentthatElanco'stotalunrestrictedcashforworkingcapitalandothergeneralcorporatepurposesexceeded$300millionfollowingthecompletionoftheIPO.AportionofthetotalconsiderationtobepaidtoLillywastemporarilyretainedbyElancoasrestrictedcashinconnectionwiththeanticipatedtransfertoElancofromLillyofcertainanimalhealthassetsincertainjurisdictions.
Exceptasexpresslysetforthinanyofthetransactiondocuments,orasrequiredbylaw,theassetsthathavebeenorwillbeconveyed,contributedorassigned,transferred,distributedordeliveredtoElancooritssubsidiaries(includingentitiestheequityinterestsofwhichhavebeenorwillbetransferredtoElancobyLilly)arebeingsotransferredonan"asis,""whereis"basis,withoutanyrepresentationsorwarranties,andElancohasagreedtobeartheeconomicandlegalrisksthatanyconveyancewasinsufficienttovestinitgoodtitle,freeandclearofanysecurityinterest,thatany
134
TableofContents
necessaryconsentsorapprovalswerenotobtainedorthatanyconveyancewasnotdoneincompliancewithanyrequirementsoflaworjudgments.
Delayed transfers and further assurances. TotheextentthatthetransfersoftheassetsandtheassumptionsoftheliabilitiesallocatedtoElancounderthemasterseparationagreementwerenotcompletedonorpriortotheIPO,ElancoandLillyagreedtocooperatewitheachotherandusecommerciallyreasonableeffortstoeffectsuchtransfersandassumptionsaspromptlyaspracticablethereafteroratsuchothertimeasElancoandLillyhaveagreed.Underthemasterseparationagreement,untilthetransferofsuchassetsandtheassumptionofsuchliabilitieshaveoccurred,thebenefitsandburdensrelatingtoanysuchassetsandliabilitiesgenerallywillinure,aftertheIPO,totheentitywhowouldhavereceivedsuchassetorliability,haditbeentransferredpriortocompletionoftheIPO,including,inthecaseofthejurisdictionsinwhichLillyandElancohaveagreedtodefertheapplicabletransfersandassumptions,bycalculatingtheneteconomicbenefitanddetrimentattributabletosuchassetsandliabilitiesandmakingpaymentsinconnectiontherewithinthemanneragreeduponbyElancoandLilly.If,despiteLillyandElanco'scooperatingwithoneanotherandusingtheirrespectivecommerciallyreasonableefforts,thetransfersandassumptionsoftheapplicableassetsandliabilitiesinoneormoreofsuchjurisdictionshasnotoccurredonorpriortothedatepreviouslyagreeduponinwritingbyElancoandLilly,thenLillyshallbepaidanyremainingconsiderationretainedbyElancoasrestrictedcash,andshallbeentitledtoretain,sell,transferorotherwisedisposeofanysuchremainingassetorliability,initssolediscretion.
ElancoandLillyhaveagreedtocooperatewitheachotherandusetheirrespectivecommerciallyreasonableeffortstotakeorcausetobetakenallactions,andtodo,orcausetobedone,allthingsreasonablynecessary,properoradvisableunderapplicablelaw,regulationsandagreementstoconsummateandmakeeffectivethetransactionscontemplatedbythemasterseparationagreementandtheothertransactiondocuments.
Distribution. ThemasterseparationagreementprovidesthatElancowouldcooperatewithLillyinallrespectstomakeadistributiontoitsshareholdersofalloraportionofitsequityinterestsinElanco,includinginconnectionwiththeSplit-Off.
Insurance. FollowingthetimethatLillyholds50%orlessofElanco'scommonstock,subjecttocertainexceptions,ElancowillarrangeforitsowninsurancepoliciesandwillnolongerseekbenefitfromanyofLilly'soritsaffiliates'insurancepoliciesthatmayprovidecoverageforclaimsrelatingtotheanimalhealthbusinesspriortothedateonwhichElancoobtainsitsowninsurancecoverage.ThemasterseparationagreementcontainsproceduresfortheadministrationofinsuredclaimsandallocatestherighttoclaimcoverageandcontrolovertheprosecutionanddefenseofclaimsbetweenElancoandLilly.
Mutual releases and indemnification. Exceptforeachparty'sobligationsunderthemasterseparationagreement,theothertransactiondocumentsandcertainotherspecifiedliabilities,underthemasterseparationagreement,ElancoandLillyhavereleasedanddischargedtheotherfromanyandallliabilitiesexistingorarisingfromactsoreventsthatoccurred(orfailedtooccur)priortothecompletionofIPO.
Elancowillindemnify,defendandholdharmlessLilly,eachofitsaffiliatesandeachofitsandtheirrespectivedirectors,officers,managers,members,employeesandagentsfromandagainstanyandalllossesrelatingto,arisingoutoforresultingfrom,amongothers:
• theliabilitiesoftheanimalhealthbusinessesthatareallocatedtoElanco;
• anybreachbyElancooritssubsidiariesofthemasterseparationagreementoranyothertransactiondocument;
135
TableofContents
• anyuntruestatementoromissionofamaterialfactinLilly'sgovernmentalorpublicfilings,totheextentcausedbyinformationfurnishedbyElancoorincorporatedbyreferencefromElanco'spublicfilings;or
• anyuntruestatementoromissionofamaterialfactinElanco'sgovernmentalorpublicfilings,totheextentnotcausedbyinformationfurnishedbyLilly.
Lillywillindemnify,defendandholdharmlessElanco,eachofitsaffiliatesandeachofitsandtheirrespectivedirectors,officers,managers,members,employeesandagentsfromandagainstanyandalllossesrelatingto,arisingoutoforresultingfrom,amongothers:
• theliabilitiesallocatedtoLillyunderthemasterseparationagreement;
• anybreachbyLillyoritssubsidiariesofthemasterseparationagreementoranyothertransactiondocument;
• anyuntruestatementoromissionofamaterialfactinElanco'sgovernmentalorpublicfilings,totheextentcausedbyinformationfurnishedbyLillyorincorporatedbyreferencefromLilly'spublicfilings;or
• anyuntruestatementoromissionofamaterialfactinLilly'sgovernmentalorpublicfilings,totheextentnotcausedbyinformationfurnishedbyElanco.
Exchange of Information. ThemasterseparationagreementprovidesforthemutualsharingofinformationbetweenLillyandElancoinordertocomplywithapplicablelaw,reporting,filing,auditortaxrequirementsorotherapplicableobligations,orforuseinjudicialorotherproceedings.
Financial Reporting Covenants. Underthemasterseparationagreement,ElancoagreedtocomplywithcertaincovenantsrelatingtoitsfinancialreportingforsolongasLillywasrequiredtoconsolidateElanco'sresultsofoperationsandfinancialpositionortoaccountforitsinvestmentinElancoundertheequitymethodofaccounting.
Elancohasalsoagreedthat,forsolongasLillyprovidesElancoservicesunderthetransitionalservicesagreement,Elancowillnotchangeitsauditor,norwillElancoengageitsauditorforanynon-auditservices,ineachcase,withoutLilly'spriorconsent,andElancowillgenerallyimplementandmaintainLilly'sbusinesspracticesandstandardsinaccordancewithcertainpoliciesandproceduresspecifiedbyLilly,subjecttoappropriatematerialitythresholds.
Other covenants and approval rights. ThemasterseparationagreementalsocontainedcertainothercovenantsthatplacedrestrictionsonElanco'sactions,orrequiredLilly'spriorwrittenapprovaltosuchactions,untilLillydisposedofitsElancosharesintheSplit-Off.
Board representation. Themasterseparationagreementprovidedthat,forsolongasLillyanditsaffiliatesbeneficiallyownedatleast10%ofElancovotingshares,LillywasentitledtodesignatefornominationcertainrepresentativesontheBoard.FollowingthecompletionoftheSplit-Off,Lillynolongerhassuchrights.
No solicitation of employees. Subjecttocertaincustomaryexceptions,foraperiodof12monthsfollowingthedateonwhichLillyanditsaffiliatesnolongerownamajorityofElanco'soutstandingsharesofcommonstock,neitherElancooritsaffiliates,norLillyoritsaffiliates,willdirectlyorindirectlysolicitorencourageanyemployeeoftheotherpartyatthelevelofseniordirectorandabovetoleavehisorheremploymentwithoutthepriorwrittenconsentoftheotherparty.
Dispute resolution. ThemasterseparationagreementprovidesthatElancoandLillywillusetheirrespectivecommerciallyreasonableeffortstoresolvedisputesexpeditiouslyandonamutuallyacceptablenegotiatedbasisbyourrespectiveseniorlevelrepresentatives.Anydisputesunabletobe
136
TableofContents
resolvedthroughsuchprocesswillbereferredtomediation,fornon-bindingresolution.Subjecttocompliancewiththetermsofthemasterseparationagreement,eitherElancoorLilly,followingtheescalationandmediationproceduresinthemasterseparationagreement,maysubmitadisputetoacourtofcompetentjurisdictioninIndiana.
Term. ThemasterseparationagreementwillcontinueunlessterminatedbythemutualconsentofElancoandLilly,althoughcertainrightsandobligationsterminateduponareductioninLilly'sownershipofElanco'soutstandingcommonstock.
Transitional Services Agreement
Historically,LillyhasprovidedElancosignificantsharedservicesandresourcesrelatedtocorporatefunctionssuchasexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations,whicharereferredtocollectivelyasthe"LillyServices."ThetransitionalservicesagreementbecameoperativeasofthecompletionofIPOandtheagreementwillcontinueuntiltheexpirationorterminationofthelastLillyServicetoexpireorbeterminated,unlesstheagreementisearlierterminatedaccordingtoitsterms.
Underthetransitionalservicesagreement,ElancoisabletouseLillyServicesforafixedtermestablishedonaservice-by-servicebasis.PartialreductionintheprovisionofanyLillyServiceorterminationofaLillyServicepriortotheexpirationoftheapplicablefixedtermrequiresLilly'sconsent.Inaddition,eitherpartycanterminatetheagreementduetoamaterialbreachoftheotherparty,uponpriorwrittennotice,subjecttolimitedcureperiodsoriftheotherpartyundergoesachangeofcontrol.
ElancowillpayLillymutuallyagreed-uponfeesfortheLillyServicesprovidedunderthetransitionalservicesagreement,whichwillbebasedonLilly'scost(includingthird-partycosts)ofprovidingtheLillyServicesthroughMarch31,2021andsubjecttoamark-upof7%thereafter,withadditionalinflation-basedescalationbeginningJanuary1,2020.
Tax Matters Agreement
Allocation of taxes. ElancoenteredintoataxmattersagreementwithLillyimmediatelyprecedingthecompletionoftheIPOthatgovernstheparties'respectiverights,responsibilitiesandobligationswithrespecttotaxliabilitiesandbenefits,taxattributes,thepreparationandfilingoftaxreturns,thecontrolofauditsandothertaxproceedingsandothermattersregardingtaxes.Ingeneral,undertheagreement:
• LillyisresponsibleforanyU.S.federal,state,localorforeigntaxes(andanyrelatedinterest,penaltiesorauditadjustmentsandincludingthosetaxesattributabletoElanco'sbusiness)reportableonaconsolidated,combinedorunitaryreturnthatincludesLillyoranyofitssubsidiaries(andElancoand/oranyofitssubsidiaries)foranyperiodsorportionsthereofendingonorpriortothedateoftheclosingoftheIPO.Elancoisresponsiblefortheportionofanysuchtaxesforperiodsorportionsthereofbeginningaftersuchdate,aswouldbeapplicabletoElancoifitfiledtherelevanttaxreturnsonastandalonebasis.
• ElancoisresponsibleforanyU.S.federal,state,localorforeigntaxes(andanyrelatedinterest,penaltiesorauditadjustments)thatarereportableonreturnsthatincludeonlyElancoand/oranyofitssubsidiaries,foralltaxperiodswhetherbeforeorafterthecompletionoftheIPO.
• LillyisresponsibleforcertaintaxesimposedonLillyand/oranyofitssubsidiariesandElancoand/oranyofitssubsidiariesarisingfrom,orattributableto,certaintransfersofassetsorliabilitiesintheseparation.
137
TableofContents
ElancoisnotgenerallyentitledtoreceivepaymentfromLillyinrespectofanyofElanco'staxattributesortaxbenefitsoranyreductionoftaxesofLilly.Neitherparty'sobligationsundertheagreementarelimitedinamountorsubjecttoanycap.Theagreementalsoassignsresponsibilitiesforadministrativematters,suchasthefilingofreturns,paymentoftaxesdue,retentionofrecordsandconductofaudits,examinationsorsimilarproceedings.Inaddition,theagreementprovidesforcooperationandinformationsharingwithrespecttotaxmatters.
LillyisprimarilyresponsibleforpreparingandfilinganytaxreturnwithrespecttotheLillyaffiliatedgroupforU.S.federalincometaxpurposesandwithrespecttoanyconsolidated,combined,unitaryorsimilargroupforU.S.stateorlocalorforeigntaxpurposesthatincludesLillyoranyofitssubsidiaries(includingthosethatalsoincludeElancoand/oranyofitssubsidiaries),aswellasanytaxreturnthatincludesonlyLillyand/oranyofitssubsidiaries(includingsuchtaxreturnsthatreflecttaxesattributabletoElanco'sbusiness).ElancoisgenerallyresponsibleforpreparingandfilinganytaxreturnsthatincludeonlyElancoand/oranyofitssubsidiaries.
Thepartyresponsibleforpreparingandfilingagiventaxreturngenerallyhasexclusiveauthoritytocontroltaxcontestsrelatedtoanysuchtaxreturn.ElancogenerallyhasexclusiveauthoritytocontroltaxcontestswithrespecttotaxreturnsthatincludeonlyElancoand/oranyofitssubsidiaries.
Preservation of the tax-free status of certain aspects of the separation. ElancoandLillyintendtheseparation,thetransferofnetcashproceedsfromtheIPOandcertainrelatedfinancingtransactions(whichwerefertoastheDebtTransactions)toLillyandtheSplit-Offtoqualifyasatax-freetransactionunderSection355,Section368(a)(1)(D)andrelatedprovisionsoftheCode.Inaddition,ElancoandLillyintendfortheseparation,thetransferofnetcashproceedsfromtheIPOandtheDebtTransactionstoLilly,theSplit-Offandcertainrelatedtransactionstoqualifyfortax-freetreatmentunderU.S.federal,stateandlocaltaxlawand/orforeigntaxlaw.
InconnectionwithcertainopinionsobtainedbyLillyfromitsoutsidetaxattorneysandadvisors,Elancohasmaderepresentationsregardingthepastandfutureconductofitsbusinessandcertainothermatters.Elancohasalsoagreedtocertaincovenantsthatcontainrestrictionsintendedtopreservethetax-freestatusoftheseparation,thetransferofnetcashproceedsfromtheIPOandtheDebtTransactionstoLilly,theSplit-Offandcertainrelatedtransactions.ElancomaytakecertainactionsprohibitedbythesecovenantsonlyifLillyreceivesaprivateletterrulingfromtheIRSorElancoobtainsandprovidestoLillyanopinionfromaU.S.taxcounseloraccountantofrecognizednationalstanding,ineithercaseacceptabletoLillyinitssoleandabsolutediscretion,totheeffectthatsuchactionwouldnotjeopardizethetax-freestatusofthesetransactions.Elancoisbarredfromtakinganyaction,orfailingtotakeanyaction,wheresuchactionorfailuretoactadverselyaffectsorcouldreasonablybeexpectedtoadverselyaffectthetax-freestatusofthesetransactions,foralltimeperiods.Inaddition,duringthetimeperiodendingtwoyearsafterthedateoftheSplit-OffthesecovenantsincludespecificrestrictionsonElanco's:
• issuanceorsaleofstockorothersecurities(includingsecuritiesconvertibleintoElancostockbutexcludingcertaincompensatoryarrangements);
• salesofassetsoutsidetheordinarycourseofbusiness;and
• enteringintoanyothercorporatetransactionwhichwouldcauseElancotoundergoa40%orgreaterchangeinitsstockownership.
ElancohasgenerallyagreedtoindemnifyLillyanditsaffiliatesagainstanyandalltax-relatedliabilitiesincurredbythemrelatingtotheseparation,thetransferofnetcashproceedsfromtheIPOandtheDebtTransactionstoLilly,theSplit-Offand/orcertainrelatedtransactionstotheextentcausedbyanacquisitionofElancostockorassetsorbyanyotheractionundertakenbyElanco.ThisindemnificationprovisionappliesevenifLillyhaspermittedElancototakeanactionthatwouldotherwisehavebeenprohibitedunderthetax-relatedcovenantsdescribedabove.
138
TableofContents
Employee Matters Agreement
ElancoenteredintoanemployeemattersagreementwithLillyimmediatelypriortothecompletionofIPO.TheemployeemattersagreementgovernsLilly's,Elanco'sandtheparties'respectivesubsidiaries'andaffiliates'rights,responsibilitiesandobligationsaftertheIPOwithrespecttoemployees,compensation,employment,employeebenefitplansandrelatedmatters.Belowisasummaryofthetermsoftheemployeemattersagreement.
Benefit plans generally. PriortothecompletionoftheIPO,exceptwithrespecttoanycashbonusorequitycompensationplans,ElancowasaparticipatingemployerintheLillybenefitplansinwhichElanco'semployeesparticipatedatsuchtime,totheextentpermittedundertheplans.Exceptasotherwiseagreedtobytheparties,ElancoceasedtobeaparticipatingemployerintheLillyplansandadopteditsownbenefitplansonJanuary1,2019,whichisreferredtoasthe"PlanTransitionDate."AnappropriateallocationofElancocostsincurredundertheLillybenefitplanspriortothePlanTransitionDateshallbechargedbacktoElanco.Lillywillretaintherighttoamendorterminateitsplans.AsofthecompletionoftheIPO,Elancoadoptedorretained,asapplicable,cashbonusandequitycompensationplansforitsemployees.Underthecashbonusplans,ElancopaysitsemployeesongenerallythesamebasisasineffectpriortotheIPOfortheperformanceperiodwhichincludestheIPOandwillassumeanyliabilityforthepaymentofbonusesunderLilly'sbonusplans,totheextentapplicable.AsofthePlanTransitionDate,ElancohasestablishedorwillestablishbenefitplansthataregenerallycomparabletotheLillyplansinwhichitsemployeesparticipatedpriortothePlanTransitionDate.TheemployeemattersagreementdoesnotobligateElancotoestablishanydefinedbenefitpensionplan,retireemedicalplanornonqualifiedplanforitsU.S.employees,unlessrequiredbylaworanapplicablecollectivebargainingagreement,andallliabilitiesrelatingtoanysuchplanmaintainedbyLillyshallremainwithLilly(otherthanasprovidedforunder"—Non-U.S.retirementbenefitarrangements").
Employment. PriortothecompletionoftheIPO,ElancogenerallyofferedemploymenttocertainemployeeswhoprovidedservicestoitsbusinessandwhodidnototherwisetransfertoElancoentitiesbyoperationoflaw.ThedateonwhichanysuchtransferringemployeeisconsideredtobeemployedbyElanco(eitherbyoperationoflaworofanoffer)forpurposesoftheemployeemattersagreementisreferredtoasthe"EmployeeTransferDate."TotheextentthatseveranceorterminationobligationsweretriggeredbyorasaresultofsuchtransfersorElanco'sfailuretomakeoffersorcontinueemploymentasrequiredbytheemployeemattersagreementorarerequiredtobepaidunderapplicablelaworaLillyplan,LillywilladministertheseverancepayorterminationpayobligationsinaccordancewiththetermsandconditionsoftheapplicableLillyseverancepayorterminationpayplanorpolicy,orasotherwiserequiredbyapplicablelaw,andElancowillindemnifyLillyforsuchliability.IfanyofElanco'sU.S.employeesbeganreceivinglong-termdisabilityleavebenefitsunderLilly'sdisabilityplanbeforetheapplicablePlanTransitionDate,suchemployeesremaineligibleforsuchbenefitsafterthePlanTransitionDate,subjecttoallapplicablerequirementsofthedisabilityplan.FortheperiodstartingasofthecompletionoftheIPOandendingonDecember31,2019,Elancoemployeeswillbeentitledtoreceive:(A)(i)atleastthesamesalaryorwages,andcashbonusopportunitiesattarget,(ii)equityincentivecommitmentsequaltotheequitybudgetvalueand(iii)othermaterialtermsandconditionsofemploymentassuchemployeeswereprovidedimmediatelybeforeJanuary1,2019;and(B)employeebenefitsandperquisites(otherthancashbonusopportunities,equityincentivecommitments,definedbenefitpension,retireemedicalandnonqualifiedbenefits)thataresubstantiallycomparableintheaggregatetotheemployeebenefitsandperquisitesthatsuchemployeeswereprovidedunderapplicableplansofLillybeforeJanuary1,2019.Elancowillusereasonableeffortstoassume,asoftheEmployeeTransferDate,anyapplicableemploymentagreementsorotherindividualbenefitorcompensationagreemententeredintobetweenLillyandatransferringemployeeandwillindemnifyLillyforallliabilitiesundersuchagreements.Inaddition,Elancoexpectstoprovidetoanyofitsemployeeswhoseemploymentisterminatedduringtheperiod
139
TableofContents
endingonDecember31,2019,alevelofseverancebenefitsthatisequaltothegreaterof(i)theseverancebenefitstheemployeewouldhavereceivedundertheapplicableLillyplansineffectimmediatelybeforeJanuary1,2019,or(ii)theseverancebenefitsprovidedunderElanco'sseverancearrangementsapplicabletosimilarly-situatedemployees,ineachcase,calculatedbasedontheemployee'scompensationandservice.
Unions and collective bargaining agreements. Thepartieswillcooperatetoinformandconsultwithanyapplicablerepresentativeofalaborunion,orsimilarorganization,coveringanytransferringemployee,totheextentrequiredbylawortheapplicablecollectivebargainingagreementorsimilararrangement.AsoftheEmployeeTransferDate,Elancowillassumeanycollectivebargaining,orsimilar,agreementsorarrangementscoveringanysuchemployeesandindemnifyLillyforallrelatedliabilities.
Credited service. Elancowillcauseitsemployeebenefitplanstocredititsemployees,withoutduplicationofbenefits,forservicewithLillyonorpriortotheEmployeeTransferDate,andforservicewithElancoonorfollowingtheEmployeeTransferDate,forpurposesofeligibilityandvestingunderallofElanco'semployeebenefitplansandarrangementsandcomputationofvacation,sickdaysorseverancebenefits,orasmayotherwiseberequiredbyapplicablelaw.
U.S. defined benefit and retiree medical plans. FollowingthePlanTransitionDate,U.S.employeeswillgenerallybeeligibletoreceivecreditforservicewithElancoforvestingandeligibilityservice(butnotbenefitservice)undertheEliLillyRetirementPlanandtheEliLillyandCompanyRetireeHealthPlanthroughadatenotlaterthanDecember31,2023,totheextentpermittedbyandsubjecttothetermsofsuchplans.
U.S. defined contribution plans. Elancoestablisheda401(k)planforitsU.S.employeeseffectiveasofthePlanTransitionDatewithtermsthataresubstantiallysimilartoLilly's401(k)plan,exceptthatitwillprovidefora6%companymatchand3%non-electivecompanycontribution.AnytransferringemployeewhoseEmployeeTransferDatewasonorbeforeJanuary1,2019is100%vestedinElanco's401(k)plan.ElancoacceptedthetransferfromtheU.S.LillyqualifieddefinedcontributionplantoitsqualifieddefinedcontributionplanofanyassetsandliabilitiesallocabletotheparticipantstransferringtoElanco.Elanco'semployeesare100%vestedintheiraccountbalancesundertheLillyqualifieddefinedcontributionbenefitplanasofthePlanTransitionDate,andceasedbeingeligibletoreceiveanyemployercontributionsfromLillyeffectiveDecember31,2018.
U.S. Lilly nonqualified plans. AsofthePlanTransitionDate,anytransferringemployeeceasedbeingeligibleforcontributionsfromLillyundertheEliLillyExcessSavingsPlanandDeferredCompensationPlanforservicesrenderedafterDecember31,2018.FollowingthePlanTransitionDate,U.S.employeeswillgenerallybeeligibletoreceivecreditforservicewithElancoforvestingandeligibilityservice(butnotbenefitservice)undertheEliLillyExcessBenefitRetirementPlanthroughadatenotlaterthanDecember31,2023,totheextentpermittedbyandsubjecttothetermsoftheplan.
Non-U.S. retirement benefit arrangements. TheemployeemattersagreementprovidesforthetransferfromLillytoElancoofanyretirementbenefitarrangementcoveringElancoemployeeslocatedoutsideoftheU.S.andofanyrelatedobligationsorliabilities,unlessotherwiseagreedbytheparties.
Lilly equity compensation. Theemployeemattersagreementprovidesthat,priortothecompletionoftheIPO,theboardofdirectorsofLillywoulddeterminehowanyLillyequity,equity-relatedandlong-termperformanceawardsgrantedtoElanco'stransferringemployeeswillbetreatedundertheapplicableLillyplans.
140
TableofContents
Toll Manufacturing and Supply Agreement
ElancoenteredintoatollmanufacturingandsupplyagreementwithLillyimmediatelypriortothecompletionoftheIPO.LillyhashistoricallymanufacturedHumatrope drugsubstanceforuseinthehumanhealthfieldatitsSpekemanufacturingsite,whichsiteisbeingtransferredtoElancoinconnectionwiththeseparation.Underthetollmanufacturingandsupplyagreement,ElancowillcontinuetoexclusivelymanufactureHumatrope forLillyattheSpekesiteuntilDecember31,2020;provided,however,thatsuchobligationmaycontinuethroughDecember31,2023(throughtheexerciseofthreeone-yearextensions)ifLilly'sreplacementthirdpartysupplierofHumatrope hasnotreceivedallnecessarygovernmentalapprovalsorcannotmeetLilly'svolumerequirements.
ThetollingfeethatElancochargesLillyfortheprovisionofsuchmanufacturingandsupplyservicesisbasedonlocalvalueaddedplusareasonablearm'slengthmark-up.ByOctober1ofeachcalendaryearduringthetermofthetollmanufacturingandsupplyagreement,Elancowillmutuallyagreeuponanewtollingfeetobeeffectiveforthefollowingcalendaryear.
Underthetollmanufacturingandsupplyagreement,ElancoagreesnottomanufactureorsellanyproductthatiscompetitivetoHumatrope foraperiodoffiveyearsaftertheexpirationorterminationoftheagreement.Inaddition,duringthetermoftheagreement,ElancoagreesnottomanufactureanyproductotherthanHumatrope atcertainbuildingsoftheSpekemanufacturingsitewithoutLilly'sconsent.
Intellectual Property and Technology License Agreement
ElancoenteredintoanintellectualpropertyandtechnologylicenseagreementwithLillyimmediatelypriortothecompletionoftheIPO.Undertheintellectualpropertyandtechnologylicenseagreement,LillygrantedElancoanexclusive,perpetuallicensetoexploitproductsintheanimalhealthfieldthatutilizeorusecertainofLilly'sintellectualproperty(excludingtrademarks).Inaddition,LillygrantedElancoanon-exclusive,non-sublicenseablelicensetoscreencertaincompoundsinLilly'scompoundlibrariestoexploitproductsintheanimalhealthfieldthatutilizeorusecertainofLilly'sintellectualproperty.Thisscreeninglicensehasaninitialtermoftwoyears,subjecttothreeone-yearextensions,eachofwhichrequiresLilly'sconsent.
IfElancomakesanyimprovementstothelicensedintellectualproperty,ElancoshallretainownershipofsuchimprovementsandprovideLillywithanon-exclusive,perpetuallicensetousetheintellectualpropertyinfieldsoutsideanimalhealth(includinghumanhealth).
Foraperiodoftwoyearsfollowingtheeffectivedateoftheintellectualpropertyandtechnologylicenseagreement,eachpartyhasarightoffirstofferwithrespecttothird-partyoffersthattheotherpartyreceivestolicensesuchotherparty'sintellectualpropertyinthefirstparty'sfield(animalhealthversushumanhealth).Inconnectionwithsuchright,Elancowillnegotiateexclusivelyastosuchofferfortheuseoftheotherparty'sintellectualpropertyinthefirstparty'sfield.
Undertheintellectualpropertyandtechnologylicenseagreement,ElancowillprovidequarterlyreportstoLillydescribinganyknow-howgeneratedundertheagreement,includinginventions,patentablesubjectmatter,discoveries,andtechnicaldata.Elancowillretainownershipofsuchgeneratedknow-howandwillprovideLillywithanon-exclusive,perpetuallicensetousetheknow-howinfieldsoutsideanimalhealth(includinghumanhealth).
Transitional Trademark License Agreement
ElancoenteredintoatransitionaltrademarklicenseagreementwithLillyimmediatelypriortothecompletionoftheIPO.Underthetransitionaltrademarklicenseagreement,LillygrantedElancoatransitionallicensetousecertainofLilly'strademarksforaperiodoftimefollowingtheIPO.Suchlicenseisnon-exclusiveandroyalty-free,andallowsElancotousecertainofLilly'strademarkson
141
TableofContents
Elanco'sproductpackaging,anyadvertisingmaterialsusedinconnectionwiththesaleanddistributionofElancoproducts,andgenerallyinconnectionwiththesaleanddistributionofitsproductsandintheday-to-dayoperationofitsbusiness(includinginElanco'sbooksandrecords).
Suchlicensewillterminateonaproduct-by-productandcountry-by-countrybasis.Thetermofthelicensewillnotextendbeyondfouryears;provided,however,thatthelicensecanextendforoneadditionalyear(beyondsuchfouryears)ifthepartiesmutuallyagreeuponsuchextension.Lillycanterminatethetransitionaltrademarklicenseagreementduetoourbreachofsuchagreement,uponpriorwrittennotice,subjecttoalimitedcureperiod.
Registration Rights Agreement with Lilly
ElancoenteredintoaregistrationrightsagreementwithLillyimmediatelypriortothecompletionoftheIPO,pursuanttowhichElancoagreedthat,upontherequestofLilly,ElancowoulduseitsreasonablebesteffortstoeffecttheregistrationunderapplicablefederalandstatesecuritieslawsofanysharesofElancocommonstockretainedbyLillyfollowingtheIPO.PriortothecommencementoftheexchangeofferrelatedtotheSplit-Off,wefiledaregistrationstatementonFormS-4registeringthesharesofourcommonstockexchangedbyLillyintheSplit-Off.Pursuanttotheregistrationrightsagreement,weweregenerallyresponsibleforallregistrationexpensesinconnectionwiththeperformanceofourobligationsundertheregistrationrightsprovisionsintheregistrationrightsagreement.Lillyisresponsibleforitsowninternalfeesandexpenses,anyapplicableunderwritingdiscountsorcommissionsandanystocktransfertaxes.TheagreementcontainsindemnificationandcontributionprovisionsbyusforthebenefitofLillyand,inlimitedsituations,byLillyforthebenefitofuswithrespecttotheinformationprovidedbyorfailedtobeprovidedbyLillyincludedoromitted,asapplicable,intheregistrationstatement,prospectusorrelateddocument.
Policy Concerning Related Person Transactions
Elanco'sboardofdirectorshasadoptedawrittenpolicy,whichisreferredtoasthe"relatedpersontransactionpolicy",forthereviewofanytransaction,arrangementorrelationshipinwhichElancoisaparticipant,iftheamountinvolvedexceeds$120,000andoneofElanco'sexecutiveofficers,directors,directornomineesorbeneficialholdersofmorethan5%ofElanco'stotalequity(ortheirimmediatefamilymembers),eachofwhomisreferredtoasa"relatedperson",hasadirectorindirectmaterialinterest.ThispolicywasnotineffectwhenElancoenteredintothetransactionsdescribedabove.
EachoftheagreementsbetweenElancoandLillyanditssubsidiariesthatwereenteredintopriortothecompletionoftheIPO,andanytransactionscontemplatedthereby,weredeemedtobeapprovedandnotsubjecttothetermsofsuchpolicy.Ifarelatedperson,otherthanLillyanditsaffiliates,proposestoenterintosuchatransaction,arrangementorrelationship,whichisreferredtoasa"relatedpersontransaction",therelatedpersonmustreporttheproposedrelatedpersontransactiontoElanco'sAuditCommittee.Thepolicycallsfortheproposedrelatedpersontransactiontobereviewedand,ifdeemedappropriate,approvedbytheAuditCommittee.Inapprovingorrejectingsuchproposedtransactions,theAuditCommitteewillberequiredtoconsiderrelevantfactsandcircumstances.TheAuditCommitteewillapproveonlythosetransactionsthat,inlightofknowncircumstances,aredeemedtobeinElanco'sbestinterests.IntheeventthatanymemberoftheAuditCommitteeisnotadisinterestedpersonwithrespecttotherelatedpersontransactionunderreview,thatmemberwillbeexcludedfromthereviewandapprovalorrejectionofsuchrelatedpersontransaction;provided,however,thatsuchAuditCommitteemembermaybecountedindeterminingthepresenceofaquorumatthemeetingoftheAuditCommitteeatwhichsuchtransactionisconsidered.IfElancobecomesawareofanexistingrelatedpersontransactionwhichhasnotbeenapprovedunderthepolicy,thematterwillbereferredtotheAuditCommittee.TheAuditCommitteewillevaluatealloptionsavailable,includingratification,revisionorterminationofsuchtransaction.Intheeventthat
142
TableofContents
managementdeterminesthatitisimpracticalorundesirabletowaituntilameetingoftheAuditCommitteetoconsummatearelatedpersontransaction,thechairmanoftheAuditCommitteemayapprovesuchtransactioninaccordancewiththerelatedpersontransactionpolicy.AnysuchapprovalmustbereportedtotheAuditCommitteeatitsnextregularlyscheduledmeeting.
AcopyofElanco'srelatedpersontransactionpolicyisavailableonElanco'swebsiteatinvestor.elanco.com under"Governance."
143
TableofContents
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Common Stock Ownership by 5% Beneficial Owners, Directors and Executive Officers
Thefollowingtablesetsforth,asofMay13,2019,beneficialownershipofsharesofElancocommonstockbyeachElancodirector,eachofElanco'snamedexecutiveofficersandalldirectorsandexecutiveofficersasagroup,aswellastheirtotalstock-basedholdings,andeachpersonorgroupknowntoElancotobethebeneficialownerofmorethan5%ofoutstandingsharesofElancocommonstock.Sharesarebeneficiallyownedwhenanindividualhasvotingand/orinvestmentpoweroverthesharesorcouldobtainvotingand/orinvestmentpowerovertheshareswithin60days.Votingpowerincludesthepowertodirectthevotingofthesharesandinvestmentpowerincludesthepowertodirectthedispositionoftheshares.Percentageofbeneficialownershipisbasedon365,707,234sharesofcommonstockoutstandingasofMay13,2019.
Unlessotherwiseindicated,theaddressforeachholderlistedbelowis2500InnovationWay,Greenfield,Indiana46140.Exceptasnotedbyfootnote,andsubjecttocommunitypropertylawswhereapplicable,ElancobelievesbasedontheinformationprovidedtoitthatthepersonsandentitiesnamedinthetablebelowhavesolevotingandinvestmentpowerwithrespecttoallsharesofElanco'scommonstockshownasbeneficiallyownedbythem.
NoneoftheElancodirectorsandexecutiveofficers,individuallyorasagroup,beneficiallyownsgreaterthan1%ofElanco'soutstandingsharesofElancocommonstock.Beneficialownershiprepresentinglessthan1%isdenotedwithanasterisk(*).
144
Shares of common stock beneficially owned
Directors' and officers' total stock-based holdings (2)
Name Number of shares (1)
Percentage of shares
T.RowePriceAssociates,Inc.(3) 38,678,903 10.57% N/APRIMECAPManagementCompany(4) 30,607,906 8.37% N/A
JeffreyN.Simmons 59,301 * 503,898DavidS.Kinard 10,477 * 77,883SarenaS.Lin 20,000 * 82,899LucasE.Montarce — — —DavidA.Urbanek 2,521 * 70,519ToddS.Young — — 18,883R.DavidHoover 30,920(5) * 34,959KapilaK.Anand 1,200 * 5,779JohnP.Bilbrey 7,750(6) — 10,533ArtA.Garcia — — —MichaelJ.Harrington — — 2,783DeborahT.Kochevar — — 2,783LawrenceE.Kurzius 10,000 * 14,579KirkMcDonald — — 2,783DeborahScots-Knight — — 2,783All directors and executive officers as a group (18 persons) 151,248 * 1,014,430
(1) IncludessharesofcommonstockbeneficiallyownedascalculatedunderSECrules,includingsharesthatmaybeacquireduponsettlementofRSUswithin60days,oruponexerciseofstockoptionsthatarecurrentlyexercisableorwillbecomeexercisablewithin60days.AsofMay13,2019,nosuchRSUsoroptionswereoutstanding.
TableofContents
145
(2) Thiscolumnshowstheindividual'stotalElancostock-basedholdings,includingsecuritiesshowninthe"Sharesofcommonstockbeneficiallyowned"columns(asdescribedabove),plusstock-basedholdingsthatcannotbeconvertedintosharesofElanco'scommonstockwithin60days,including,asapplicable,RSUssubjecttotime-basedvestingconditions,stockoptions,anddeferredstockunitsheldbydirectors.Thenumberdoesnotinclude(i)performance-basedawardsgrantedtoexecutiveofficersthataresubjecttoperformance-basedvestingconditions,or(ii)theannualawardofdeferredstockunitstobecreditedtonon-employeedirectorsinNovember2019undertheDirectors'DeferralPlanbasedonserviceduring2019.
(3) TheaddressforT.RowePriceAssociates,Inc.is100E.PrattStreet,Baltimore,MD21202.Ithassolevotingpowerwithrespectto12,897,118ofitssharesandsoledispositivepowerwithrespectto38,678,903ofitsshares.TheshareinformationisbasedsolelyonaSchedule13GfiledbyT.RowePriceAssociates,Inc.withtheSEConApril10,2019.
(4) TheaddressforPRIMECAPManagementCompanyis177E.ColoradoBlvd.,11thFloor,Pasadena,CA91105.Ithassolevotinganddispositivepowerwithrespectto30,607,906ofitsshares.TheshareinformationisbasedsolelyonaSchedule13GfiledbyPRIMECAPManagementCompanywiththeSEConMay7,2019.
(5) Includes920sharesheldintrustoverwhichMr.Hooversharesvotingandinvestmentpower.
(6) Includes7,750sharesownedbytheJohnP.BilbreyRevocableTrust.
TableofContents
THE EXCHANGE OFFERS
Purpose of the Exchange Offers
OnAugust28,2018,weissued$500,000,000aggregateprincipalamountofthe2021OriginalNotes,$750,000,000aggregateprincipalamountofthe2023OriginalNotesand$750,000,000aggregateprincipalamountofthe2028OriginalNotesinaprivateplacement.InconnectionwiththesaleoftheOriginalNotes,weenteredintoanexchangeandregistrationrightsagreementwiththerepresentativesoftheinitialpurchasers.Undertheexchangeandregistrationrightsagreementweagreed,forthebenefitoftheholdersoftheOriginalNotes,to:
• useourcommerciallyreasonableeffortsto(i)causetobefiledwiththeSECaregistrationstatementcoveringofferstotheholdersoftheOriginalNotesfortheExchangeNotesand(ii)havesuchregistrationstatementbecomeandremaineffectiveuntil180daysafterthelastdateofacceptanceforexchange;
• commencetheexchangeofferforeachseriesofOriginalNotespromptlyaftertheexchangeofferregistrationstatementisdeclaredeffectivebytheSEC;and
• useourcommerciallyreasonableeffortstocompletetheexchangeofferforeachseriesofOriginalNotesnotlaterthan60daysaftertheexchangeofferregistrationstatementbecomeseffective.
Asdescribedin"—RegistrationRights;AdditionalInterestonOriginalNotes,"wehavealsoagreedtofileashelfregistrationstatementfortheresaleofthenotesifwecannoteffecttheexchangeofferbyAugust28,2019andinothercircumstances.Youwillbeentitledtothepaymentofadditionalinterestifwedonotcomplywiththeseobligationswithinthattimeperiod.
WearemakingtheExchangeOffersinrelianceonthepositionoftheSECasdescribedinpreviousno-actionlettersissuedtothirdparties,includinginExxonCapitalHoldingsCorporation(April13,1988),MorganStanley&Co.,Inc.(June5,1991),Shearman&Sterling(July2,1993)andsimilarno-actionletters.However,wehavenotsoughtourownno-actionletter.BasedupontheseinterpretationsbytheSEC,webelievethataholderwhoexchangesOriginalNotesforExchangeNotesintheExchangeOffersgenerallymayoffertheExchangeNotesforresale,selltheExchangeNotesandotherwisetransfertheExchangeNoteswithoutfurtherregistrationundertheSecuritiesActandwithoutdeliveryofaprospectusthatsatisfiestherequirementsofSection10oftheSecuritiesAct.Theprecedingsentencedoesnotapply,however,toaholderwhoisour"affiliate"withinthemeaningofRule405oftheSecuritiesAct.Wealsobelievethataholdermayoffer,sellortransfertheExchangeNotesonlyiftheholderacknowledgesthattheholderisacquiringtheExchangeNotesintheordinarycourseofitsbusinessandisnotparticipating,doesnotintendtoparticipateandhasnoarrangementorunderstandingwithanypersontoparticipateina"distribution,"asdefinedintheSecuritiesAct,oftheExchangeNotes.WehavenotenteredintoanyarrangementorunderstandingwithanypersonwhowillreceiveExchangeNotesintheexchangeoffertodistributesuchExchangeNotesfollowingcompletionoftheexchangeoffer,and,tothebestofourinformationandbelief,wearenotawareofanypersonthatwillparticipateintheExchangeOfferswithaviewtodistributetheExchangeNotes.AholderwhoexchangesRestrictedNotesforExchangeNotesintheexchangeofferforthepurposeofdistributingsuchExchangeNotescannotrelyontheinterpretationsofthestaffoftheSECintheaforementionedno-actionletters,mustcomplywiththeregistrationandprospectusdeliveryrequirementsoftheSecuritiesActinconnectionwithanysecondaryresaleoftheExchangeNotesandmustbeidentifiedasanunderwriterintheprospectus.
Eachbroker-dealerthatreceivestheExchangeNotesforitsownaccountinexchangefortheOriginalNotes,wheretheOriginalNoteswereacquiredbyitasaresultofmarket-makingactivitiesorothertradingactivities,mustacknowledgethatitwilldeliveraprospectusthatmeetstherequirementsoftheSecuritiesActinconnectionwithanyresaleoftheExchangeNotesandthatithasnotentered
146
TableofContents
intoanyagreementorunderstandingwithusoranyofour"affiliates,"asdefinedinRule405undertheSecuritiesAct,toparticipateina"distribution,"asdefinedundertheSecuritiesAct,oftheExchangeNotes.Bysoacknowledgingandbydeliveringaprospectus,abroker-dealerwillnotbedeemedtoadmitthatitisan"underwriter"withinthemeaningoftheSecuritiesAct.See"PlanofDistribution."
TheExchangeOffersareintendedtosatisfyourobligationsundertheexchangeandregistrationrightsagreement.Thesummaryoftheexchangeandregistrationrightsagreementisnotcomplete.Youareencouragedtoreadthefulltextoftheexchangeandregistrationrightsagreement,whichhasbeenfiledasanexhibittotheregistrationstatementthatincludesthisprospectus.
Registration Rights; Additional Interest on Original Notes
IntheeventthatwedeterminethataregisteredexchangeofferisnotavailableormaynotbecompletedassoonaspracticableafterthelastdateforacceptanceofnotesforexchangebecauseitwouldviolateanyapplicablelaworapplicableinterpretationsofthestaffoftheSECor,iftheexchangeofferisnotforanyotherreasoncompletedbyAugust28,2019,or,incertaincircumstances,anyinitialpurchasersorequestsinconnectionwithanyofferorsaleofnotes,wewilluseourcommerciallyreasonableeffortstofileandtohavebecomeeffectiveashelfregistrationstatementrelatingtoresalesofthenotesandtokeepthatshelfregistrationstatementeffectiveuntilthedatethatthenotesceasetobe"registrablesecurities"(asdefinedintheexchangeandregistrationrightsagreement),includingwhenallnotescoveredbytheshelfregistrationstatementhavebeensoldpursuanttotheshelfregistrationstatement.Wewill,intheeventofsuchashelfregistration,providetoeachparticipatingholderofnotescopiesofaprospectus,notifyeachparticipatingholderofnoteswhentheshelfregistrationstatementhasbecomeeffectiveandtakecertainotheractionstopermitresalesofthenotes.Aholderofnotesthatsellsnotesundertheshelfregistrationstatementgenerallywillberequiredtomakecertainrepresentationstous(asdescribedintheexchangeandregistrationrightsagreement),tobenamedasasellingsecurityholderintherelatedprospectusandtodeliveraprospectustopurchasers,willbesubjecttocertainofthecivilliabilityprovisionsundertheSecuritiesActinconnectionwiththosesalesandwillbeboundbytheprovisionsoftheexchangeandregistrationrightsagreementthatareapplicabletosuchaholderofnotes(includingcertainindemnificationobligations).Holdersofnoteswillalsoberequiredtosuspendtheiruseoftheprospectusincludedintheshelfregistrationstatementunderspecifiedcircumstancesuponreceiptofnoticefromus.
Ifa"registrationdefault"(asdefinedintheexchangeandregistrationrightsagreement)withrespecttoaseriesofregistrablesecuritiesoccurs,thenadditionalinterestshallaccrueontheprincipalamountofthenotesofaparticularseriesthatare"registrablesecurities"atarateof0.25%perannum(whichratewillbeincreasedbyanadditional0.25%perannumforeachsubsequent90-dayperiodthatsuchadditionalinterestcontinuestoaccrue,providedthattherateatwhichsuchadditionalinterestaccruesmayinnoeventexceed1.00%perannum).Theadditionalinterestwillceasetoaccruewhentheregistrationdefaultiscured.Aregistrationdefaultoccursif(1)wehavenotexchangedExchangeNotesforallnotesvalidlytenderedinaccordancewiththetermsoftheexchangeofferonorpriortoAugust28,2019or,ifashelfregistrationstatementisrequiredandisnotdeclaredeffectivebythelaterofthelaterof90daysfromsuchshelfrequestAugust28,2019or(2)ifapplicable,ashelfregistrationstatementcoveringresalesofthenoteshasbeendeclaredeffectiveandsuchshelfregistrationstatementceasestobeeffectiveortheprospectuscontainedthereinceasestobeusable(a)onmorethantwooccasionsinany12-monthperiodduringtherequiredeffectivenessperiodor(b)atanytimeinany12-monthperiodduringtherequiredeffectivenessperiod,andsuchfailuretoremaineffectiveorbeusableexistsformorethan30days(whetherornotconsecutive)inany12-monthperiod.Aregistrationdefaultiscuredwithrespecttoaseriesofnotes,andadditionalinterestceasestoaccrueonanyregistrablesecuritiesofaseriesofnotes,whentheexchangeofferiscompletedortheshelf
147
TableofContents
registrationstatementisdeclaredeffectiveortheprospectusagainbecomesusable,asapplicable,orsuchnotesceasetobe"registrablesecurities."
Thenoteswillceasetoberegistrablesecuritiesupontheearliertooccurofthefollowing:(1)whenaregistrationstatementwithrespecttosuchnoteshasbecomeeffectiveandsuchnoteshavebeenexchangedordisposedofpursuanttosuchregistrationstatement,(2)whensuchnotesceasetobeoutstandingor(3)exceptinthecaseofnotesthatotherwiseremainregistrablesecuritiesandthatareheldbyaninitialpurchaserandthatareineligibletobeexchangedintheexchangeoffer,whentheexchangeofferisconsummated.
Terms of the Exchange Offers
Weareofferingtoexchange:
• upto$500,000,000aggregateprincipalamountofthe2021ExchangeNoteswhichhavebeenregisteredundertheSecuritiesActforalikeamountoftheunregistered2021OriginalNotes,
• upto$750,000,000aggregateprincipalamountofthe2023ExchangeNoteswhichhavebeenregisteredundertheSecuritiesActforalikeamountoftheunregistered2023OriginalNotes,and
• upto$750,000,000aggregateprincipalamountofthe2028ExchangeNoteswhichhavebeenregisteredundertheSecuritiesActforalikeamountoftheunregistered2028OriginalNotes.
Uponthetermsandsubjecttotheconditionssetforthinthisprospectusandintheaccompanyingletteroftransmittal,wewillacceptallOriginalNotesvalidlytenderedandnotwithdrawnbefore5:00p.m.,NewYorkCitytime,ontheexpirationdateoftheExchangeOffers.Wewillissue$1,000principalamountofExchangeNotesinexchangeforeach$1,000principalamountofoutstandingOriginalNotesweacceptintheExchangeOffers.HoldersmaytendersomeoralloftheirOriginalNotespursuanttotheExchangeOffersindenominationsof$2,000andintegralmultiplesof$1,000inexcessthereof.TheExchangeOffersarenotconditioneduponanyminimumamountofOriginalNotesbeingtendered.
TheformandtermsoftheExchangeNoteswillbethesameastheformandtermsoftheOriginalNotes,exceptthat:
• theExchangeNoteswillhaveadifferentCUSIPnumberfromtheOriginalNotes;
• theExchangeNoteswillberegisteredundertheSecuritiesActandthuswillnotbesubjecttotherestrictionsontransferorbearlegendsrestrictingtheirtransfer;
• theExchangeNoteswillnotbesubjecttotheregistrationrightsrelatingtotheOriginalNotes;and
• theExchangeNoteswillnotprovideforthepaymentofadditionalinterestundercircumstancesrelatingtothetimingoftheExchangeOffers.
TheExchangeNoteswillevidencethesamedebtastheOriginalNotesandwillbeissuedunder,andbeentitledtothebenefitsof,theindenturegoverningtheOriginalNotes.TheExchangeNoteswillaccrueinterestfromthemostrecentdatetowhichinteresthasbeenpaidontheOriginalNotes.Accordingly,registeredholdersofExchangeNotesontherecorddateforthefirstinterestpaymentdatefollowingthecompletionoftheExchangeOfferswillreceiveinterestaccruedfromthemostrecentdatetowhichinteresthasbeenpaidontheOriginalNotes.However,ifthatrecorddateoccurspriortocompletionoftheExchangeOffers,thentheinterestpayableonthefirstinterestpaymentdatefollowingthecompletionoftheExchangeOfferswillbepaidtotheregisteredholdersoftheOriginalNotesonthatrecorddate.
148
TableofContents
InconnectionwiththeExchangeOffers,youdonothaveanyappraisalordissenters'rightsundertheindenture.WeintendtoconducttheExchangeOffersinaccordancewiththeexchangeandregistrationrightsagreementandtheapplicablerequirementsoftheSecuritiesAct,theSecuritiesExchangeActof1934,asamended(the"ExchangeAct"),andtherulesandregulationsoftheSEC.TheExchangeOffersarenotbeingmadeto,norwillweaccepttendersforexchangefrom,aholderoftheOriginalNotesinanyjurisdictioninwhichtheExchangeOffersortheacceptancethereofwouldnotbeincompliancewiththesecuritiesorblueskylawsofthejurisdiction.
WewillbedeemedtohaveacceptedvalidlytenderedOriginalNoteswhenwehavegivenoralorwrittennoticeofouracceptancetotheexchangeagent.TheexchangeagentwillactasagentforthetenderingholdersforthepurposeofreceivingtheExchangeNotesfromus.
IfwedonotacceptanytenderedOriginalNotesbecauseofaninvalidtenderorforanyotherreason,thenwewillreturncertificatesforanyunacceptedOriginalNoteswithoutexpensetothetenderingholderaspromptlyaspracticableaftertheexpirationdate.
Expiration Date
TheExchangeOfferswillexpireat5:00p.m.,NewYorkCitytime,on,2019,unlesswe,inoursolediscretion,extendtheExchangeOffers.
IfwedeterminetoextendtheExchangeOffers,thenwewillnotifytheexchangeagentofanyextensionbyoralorwrittennoticeandgiveeachregisteredholdernoticeoftheextensionbymeansofapressreleaseorotherpublicannouncementbefore9:00a.m.,NewYorkCitytime,onthenextbusinessdayafterthepreviouslyscheduledexpirationdate.
Procedures for Tendering Original Notes
AnytenderofOriginalNotesthatisnotwithdrawnpriortotheexpirationdatewillconstituteabindingagreementbetweenthetenderingholderandusuponthetermsandsubjecttotheconditionssetforthinthisprospectusandintheaccompanyingletteroftransmittal.AholderwhowishestotenderOriginalNotesintheExchangeOffersmustdoeitherofthefollowing:
• properlycomplete,signanddatetheletteroftransmittal,includingallotherdocumentsrequiredbytheletteroftransmittal;havethesignatureontheletteroftransmittalguaranteediftheletteroftransmittalsorequires;anddeliverthatletteroftransmittalandotherrequireddocumentstotheexchangeagentattheaddresslistedbelowunder"—ExchangeAgent"onorbeforetheexpirationdate;or
• iftheOriginalNotesaretenderedunderthebook-entrytransferproceduresdescribedbelow,transmittotheexchangeagent,onorbeforetheexpirationdate,anagent'smessage.
Inaddition,oneofthefollowingmustoccur:
• theexchangeagentmustreceivecertificatesrepresentingyourOriginalNotesalongwiththeletteroftransmittalonorbeforetheexpirationdate;
• theexchangeagentmustreceiveatimelyconfirmationofbook-entrytransferoftheOriginalNotesintotheexchangeagent'saccountatDTCundertheprocedureforbook-entrytransfersdescribedbelowalongwiththeletteroftransmittaloraproperlytransmittedagent'smessage,onorbeforetheexpirationdate;or
• theholdermustcomplywiththeguaranteeddeliveryproceduresdescribedbelow.
Theterm"agent'smessage"meansamessage,transmittedbyabook-entrytransferfacilitytoandreceivedbytheexchangeagentandformingapartofthebook-entryconfirmation,whichstatesthatthebook-entrytransferfacilityhasreceivedanexpressacknowledgementfromthetenderingDTCparticipantstatingthattheparticipanthasreceivedandagreestobeboundbytheletteroftransmittalandthatwemayenforcetheletteroftransmittalagainsttheparticipant.
149
TableofContents
THE METHOD OF DELIVERY OF ORIGINAL NOTES, LETTERS OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS IS AT THE ELECTION AND RISK OF THE HOLDERS. IFTHE DELIVERY IS BY MAIL, IT IS RECOMMENDED THAT REGISTERED MAIL PROPERLY INSURED, WITH RETURN RECEIPT REQUESTED, BE USED. IN ALL CASES, SUFFICIENT TIMESHOULD BE ALLOWED TO ENSURE TIMELY DELIVERY. HOLDERS SHOULD NOT SEND ORIGINAL NOTES OR LETTERS OF TRANSMITTAL TO US.
Generally,aneligibleinstitutionmustguaranteesignaturesonaletteroftransmittaloranoticeofwithdrawalunlesstheOriginalNotesaretendered:
• byaregisteredholderoftheOriginalNoteswhohasnotcompletedtheboxentitled"SpecialIssuanceInstructions"or"SpecialDeliveryInstructions"ontheletteroftransmittal;or
• fortheaccountofaneligibleinstitution.
Ifsignaturesonaletteroftransmittaloranoticeofwithdrawalarerequiredtobeguaranteed,theguaranteemustbebyafirmwhichis:
• amemberofaregisterednationalsecuritiesexchange;
• acommercialbankortrustcompanyhavinganofficeorcorrespondentintheUnitedStates;or
• another"eligibleguarantorinstitution"withinthemeaningofRule17Ad-15undertheExchangeAct.
IftheletteroftransmittalissignedbyapersonotherthantheregisteredholderofanyoutstandingOriginalNotes,theOriginalNotesmustbeendorsedoraccompaniedbyappropriatepowersofattorney.Thepowerofattorneymustbesignedbytheregisteredholderexactlyastheregisteredholder(s)name(s)appear(s)ontheOriginalNotesandaneligibleinstitutionmustguaranteethesignatureonthepowerofattorney.
Iftheletteroftransmittal,oranyOriginalNotesorpowersofattorneyaresignedbytrustees,executors,administrators,guardians,attorneys-in-fact,officersofcorporationsorothersactinginafiduciaryorrepresentativecapacity,thesepersonsshouldsoindicatewhensigning.Unlesswaivedbyus,theyshouldalsosubmitevidencesatisfactorytousoftheirauthoritytosoact.
IfyoubeneficiallyowntheOriginalNotesregisteredinthenameofabroker,dealer,commercialbank,trustcompanyorothernomineeandwishtotenderyourbeneficiallyownedOriginalNotesintheexchangeoffer,youshouldcontacttheregisteredholderpromptlyandinstructittotendertheOriginalNotesonyourbehalf.ThebeneficialownermayalsoobtainandincludewiththeletteroftransmittaltheOriginalNotesproperlyendorsedfortransferbytheregisteredholderoraccompaniedbyaproperlycompletedbondpowerfromtheregisteredholder,withsignaturesontheendorsementorbondpowerguaranteedbyaneligibleinstitution.Ifthebeneficialownerwishestotenderdirectly,thebeneficialownermust,priortocompletingandexecutingtheletteroftransmittalandtenderingtheOriginalNotes,makeappropriatearrangementstoregisterownershipoftheOriginalNotesinthebeneficialowner'sname.Beneficialownersshouldbeawarethatthetransferofregisteredownershipmaytakeconsiderabletime.
Wewilldetermineinoursolediscretionallquestionsastothevalidity,form,eligibility,includingtimeofreceipt,andacceptanceofOriginalNotestenderedforexchange.Ourdeterminationwillbefinalandbindingonallparties.WereservetheabsoluterighttorejectanyandalltendersofOriginalNotesthatarenotproperlytenderedorOriginalNotes,ouracceptanceofwhichmight,inthejudgmentofourcounsel,beunlawful.Wealsoreservetheabsoluterighttowaiveanydefects,irregularitiesorconditionsoftenderastoanyparticularOriginalNotes.OurinterpretationofthetermsandconditionsoftheExchangeOffers,includingtheinstructionsintheletteroftransmittal,willbefinalandbindingonallparties.Unlesswaived,anydefectsorirregularitiesinconnectionwith
150
TableofContents
tendersofOriginalNotesmustbecuredwithinthetimeperiodwedetermine.NeitherwenortheexchangeagentnoranyotherpersonwillincuranyliabilityforfailuretogiveyounotificationofdefectsorirregularitieswithrespecttotendersofyourOriginalNotes.
Bytendering,eachholderofOriginalNoteswillrepresenttousthat,amongotherthings:
• anyExchangeNotesthattheholderreceiveswillbeacquiredintheordinarycourseofitsbusiness;
• theholderhasnoarrangementorunderstandingwithanypersonorentitytoparticipateinthedistribution(withinthemeaningoftheSecuritiesAct)oftheExchangeNotes;and
• theholderisnotan"affiliate"ofuswithinthemeaningofRule405oftheSecuritiesAct.
Ifanyholderoranysuchotherpersonisour"affiliate,"orisengagedinorintendstoengageinorhasanarrangementorunderstandingwithanypersontoparticipateinadistributionoftheExchangeNotestobeacquiredintheExchangeOffers,thenthatholderoranysuchotherperson:
• maynotrelyontheapplicableinterpretationsofthestaffoftheSEC;
• isnotentitledandwillnotbepermittedtotenderOriginalNotesintheExchangeOffers;and
• mustcomplywiththeregistrationandprospectusdeliveryrequirementsoftheSecuritiesActinconnectionwithanyresaletransaction.
EachbrokerdealerthatreceivesExchangeNotesforitsownaccountinexchangeforOriginalNotes,wheretheOriginalNoteswereacquiredbythebrokerdealerasaresultofmarket-makingactivitiesorothertradingactivities,mustacknowledgethatitwilldeliveraprospectusinconnectionwithanyresaleoftheExchangeNotes.Theletteroftransmittalstatesthatbysoacknowledgingandbydeliveringaprospectus,abrokerdealerwillnotbedeemedtoadmitthatitisan"underwriter"withinthemeaningoftheSecuritiesAct.
Anybroker-dealerthatacquiredOriginalNotesdirectlyfromusmaynotrelyontheapplicableinterpretationsofthestaffoftheSECandmustcomplywiththeregistrationanddeliveryrequirementsoftheSecuritiesAct(includingbeingnamedasasellingsecurityholder)inconnectionwithanyresalesoftheOriginalNotesortheExchangeNotes.
Book-Entry Transfer
WeunderstandthattheexchangeagentwillmakearequestwithintwobusinessdaysafterthedateofthisprospectustoestablishaccountsfortheOriginalNotesatDTCforthepurposeoffacilitatingtheExchangeOffers,andanyfinancialinstitutionthatisaparticipantinDTC'ssystemmaymakebook-entrydeliveryofOriginalNotesbycausingDTCtotransfertheOriginalNotesintotheexchangeagent'saccountatDTCinaccordancewithDTC'sproceduresfortransfer.AlthoughdeliveryofOriginalNotesmaybeeffectedthroughbook-entrytransferatDTC,theexchangeagentmustreceiveaproperlycompletedanddulyexecutedletteroftransmittalwithanyrequiredsignatureguarantees,oranagent'smessageinsteadofaletteroftransmittal,andallotherrequireddocumentsatitsaddresslistedbelowunder"—ExchangeAgent"onorbeforetheexpirationdate,orifyoucomplywiththeguaranteeddeliveryproceduresdescribedbelow,withinthetimeperiodprovidedunderthoseprocedures.
Guaranteed Delivery
IfyoudesiretotenderyourOriginalNotes,but:
• yourOriginalNotesarenotimmediatelyavailable;
151
TableofContents
• youcannotdeliveryourOriginalNotes,theletteroftransmittaloranyotherdocumentsrequiredbytheletteroftransmittaltotheexchangeagentpriortotheexpirationdate;or
• theproceduresforbook-entrytransferofyourOriginalNotescannotbecompletedpriortotheexpirationdate;
youmayeffectatenderaccordingtotheguaranteeddeliveryproceduressetforthintheletteroftransmittal.
Pursuanttosuchprocedures:
• yourtenderofOriginalNotesmustbemadebyorthroughaneligibleinstitutionandyoumustproperlycompleteanddulyexecuteanoticeofguaranteeddelivery(asdefinedintheletteroftransmittal);
• onorpriortotheexpirationdate,theexchangeagentmusthavereceivedfromyouandtheeligibleinstitutionaproperlycompletedanddulyexecutednoticeofguaranteeddelivery(byfacsimiletransmission,mailorhanddelivery)settingforththenameandaddressoftheholder,thecertificatenumberornumbersofthetenderedOriginalNotes,andtheprincipalamountoftenderedOriginalNotes,statingthatthetenderisbeingmadetherebyandguaranteeingthat,withinthree(3)businessdaysafterthedateofexecutionofthenoticeofguaranteeddelivery,thetenderedOriginalNotes,adulyexecutedletteroftransmittalandanyotherrequireddocumentswillbedepositedbytheeligibleinstitutionwiththeexchangeagent;and
• suchproperlycompletedandexecuteddocumentsrequiredbytheletteroftransmittalandthetenderedOriginalNotesinproperformfortransfer(orconfirmationofabook-entrytransferofsuchOriginalNotesintotheexchangeagent'saccountatDTC)mustbereceivedbytheexchangeagentwithinthree(3)businessdaysafterthedateofexecutionofthenoticeofguaranteeddelivery.
AnyholderwhowishestotendertheirOriginalNotespursuanttotheguaranteeddeliveryproceduresdescribedabovemustensurethattheexchangeagentreceivesthenoticeofguaranteeddeliveryrelatingtosuchOriginalNotespriorto5:00p.m.,NewYorkCitytime,ontheexpirationdate.
UnlessOriginalNotesbeingtenderedbytheabove-describedguaranteeddeliverymethodaredepositedwiththeexchangeagent,atenderwillbedeemedtohavebeenreceivedasofthedatewhenthetenderingholder'sproperlycompletedanddulysignedletteroftransmittal,oraproperlytransmittedagent'smessage,accompaniedbytheOriginalNotesoraconfirmationofbook-entrytransferoftheOriginalNotesintotheexchangeagent'saccountatthebook-entrytransferfacilityisreceivedbytheexchangeagent.
Withdrawal Rights
YoumaywithdrawyourtenderofOriginalNotesatanytimebeforetheExchangeOffersexpires.
Forawithdrawaltobeeffective,theexchangeagentmustreceiveawrittennoticeofwithdrawalatitsaddresslistedbelowunder"—ExchangeAgent."Thenoticeofwithdrawalmust:
• specifythenameofthepersonwhotenderedtheOriginalNotestobewithdrawn;
• identifytheOriginalNotestobewithdrawn,includingtheprincipalamount,or,inthecaseofOriginalNotestenderedbybook-entrytransfer,thenameandnumberoftheDTCaccounttobecredited,andotherwisecomplywiththeproceduresofDTC;
• besignedinthesamemannerastheoldsignatureontheletteroftransmittalbywhichtheOriginalNotesweretendered(includinganyrequiredsignatureguarantees)orbeaccompaniedbydocumentsoftransfersufficienttohavethetrusteewithrespecttotheOriginalNotes
152
TableofContents
registerthetransferoftheOriginalNotesintothenameofthepersonwithdrawingthetender;and
• ifcertificatesforOriginalNoteshavebeentransmitted,specifythenameinwhichthoseOriginalNotesareregisteredifdifferentfromthatofthewithdrawingholder.
IfcertificatesforOriginalNoteshavebeendeliveredorotherwiseidentifiedtotheexchangeagentinconnectionwiththeExchangeOffersandaretobewithdrawnthen,beforethereleaseofthesecertificatesbytheexchangeagent,theholdermustalsosubmittheserialnumbersoftheparticularcertificatestobewithdrawnandasignednoticeofwithdrawalwiththesignaturesguaranteedbyaneligibleinstitution,unlesstheholderisaneligibleinstitution.
Wewilldetermineinoursolediscretionallquestionsastothevalidity,formandeligibility,includingtimeofreceipt,ofnoticesofwithdrawal.Ourdeterminationwillbefinalandbindingonallparties.AnyOriginalNotessowithdrawnwillbedeemednottohavebeenvalidlytenderedforpurposesoftheExchangeOffers.WewillreturnanyOriginalNotesthathavebeentenderedbutthatarenotexchangedforanyreasontotheholder,withoutcost,assoonaspracticableafterwithdrawal,rejectionoftenderorterminationoftheExchangeOffers.InthecaseofOriginalNotestenderedbybook-entrytransferintotheexchangeagent'saccountatDTC,theOriginalNoteswillbecreditedtoanaccountmaintainedwithDTCfortheOriginalNotes.YoumayretenderproperlywithdrawnOriginalNotesbyfollowingoneoftheproceduresdescribedunder"—ProceduresforTenderingOriginalNotes"atanytimeonorbeforetheexpirationdate.
Conditions
NotwithstandinganyothertermoftheExchangeOffers,wewillnotberequiredtoacceptforexchange,ortoexchangeExchangeNotesfor,anyOriginalNotesif:
• theExchangeOffers,orthemakingofanyexchangebyaholderofOriginalNotes,wouldviolateanyapplicablelaworapplicableinterpretationbythestaffoftheSEC;or
• anyactionorproceedingisinstitutedorthreatenedinanycourtorbyorbeforeanygovernmentalagencywithrespecttotheExchangeOfferswhich,inourjudgment,wouldreasonablybeexpectedtoimpairourabilitytoproceedwiththeExchangeOffers.
Theconditionslistedaboveareforoursolebenefitandwemayassertthemregardlessofthecircumstancesgivingrisetoanycondition.Subjecttoapplicablelaw,wemaywaivetheseconditionsinourdiscretioninwholeorinpartatanytimeandfromtimetotime.
Weexpresslyreservetheright,atanytimeoratvarioustimes,toextendtheperiodoftimeduringwhichtheExchangeOffersareopen.Consequently,wemaydelayacceptanceofanyOriginalNotesbygivingoralorwrittennoticeofanextensiontotheirholders.Duringanextension,allOriginalNotespreviouslytenderedwillremainsubjecttotheExchangeOffers,andwemayacceptthemforexchange.
Acceptance of Original Notes for Exchange and Delivery of Exchange Notes
UponsatisfactionorwaiverofallconditionstotheExchangeOffers,wewillaccept,promptlyaftertheexpirationdate,allOriginalNotesproperlytenderedandwillissuetheExchangeNotespromptlyafteracceptanceoftheOriginalNotes.ForpurposesoftheExchangeOffers,wewillbedeemedtohaveacceptedproperlytenderedOriginalNotesforexchangewhenwehavegivenoralorwrittennoticeofthatacceptancetotheexchangeagent.ForeachOriginalNoteacceptedforexchange,youwillreceiveaNewNotehavingaprincipalamountequaltothatofthesurrenderedOriginalNote.
153
TableofContents
Inallcases,wewillissueExchangeNotesforOriginalNotesthatwehaveacceptedforexchangeundertheExchangeOffersonlyaftertheexchangeagenttimelyreceives:
• certificatesforyourOriginalNotesoratimelyconfirmationofbook-entrytransferofyourOriginalNotesintotheexchangeagent'saccountatDTC;and
• aproperlycompletedanddulyexecutedletteroftransmittalandallotherrequireddocumentsoraproperlytransmittedagent'smessage.
IfwedonotacceptanytenderedOriginalNotesforanyreasonsetforthinthetermsoftheExchangeOffersorifyousubmitOriginalNotesforagreaterprincipalamountthanyoudesiretoexchange,wewillreturntheunacceptedornon-exchangedOriginalNoteswithoutexpensetoyou.InthecaseofOriginalNotestenderedbybook-entrytransferintotheexchangeagent'saccountatDTCunderthebook-entryproceduresdescribedbelow,wewillcreditthenon-exchangedOriginalNotestoyouraccountmaintainedwithDTC.
Exchange Agent
DeutscheBankTrustCompanyAmericashasbeenappointedastheexchangeagentfortheExchangeOffers.YoushoulddirectanyquestionsandrequestsforassistanceregardingtheprocedureforexchangingyourOriginalNotesforExchangeNotesandrequestsforadditionalcopiesofthisprospectus,theletteroftransmittalorthenoticeofguaranteeddeliverytotheexchangeagentaddressedasfollows:
By Registered or Certified Mail, Overnight Delivery or Hand Delivery : DeutscheBankTrustCompanyAmericasc/oDBServicesAmericas,Inc.Attn:ReorgDept.5022GateParkway,Suite200Jacksonville,FL32256
By Facsimile Transmission : (ForEligibleInstitutionsOnly)615-866-3889Attention:ReorgDept.
Confirm by Telephone : 877-843-9767
DELIVERY TO AN ADDRESS OTHER THAN AS SET FORTH IN THE LETTER OF TRANSMITTAL, OR TRANSMISSIONS OF INSTRUCTIONS VIA A FACSIMILE NUMBER OTHER THANTHE ONE SET FORTH IN THE LETTER OF TRANSMITTAL, WILL NOT CONSTITUTE A VALID DELIVERY.
Fees and Expenses
WewillbeartheexpensesofsolicitingtenderspursuanttotheExchangeOffers.TheprincipalsolicitationfortenderspursuanttotheExchangeOffersisbeingmadebymail;however,additionalsolicitationmaybemadebytelephone,telecopy,inpersonorbyothermeansbyourofficersandregularemployeesandbyofficersandemployeesofouraffiliates.
Wehavenotretainedanydealer-managerinconnectionwiththeExchangeOffersandwillnotmakeanypaymentstobrokers,dealersorotherssolicitingacceptancesoftheExchangeOffers.However,wewillpaytheexchangeagentreasonableandcustomaryfeesforitsservicesandwillreimburseitforitsreasonableout-of-pocketexpenses.Wemayalsopaybrokeragehousesandothercustodians,nomineesandfiduciariesthereasonableout-of-pocketexpensesincurredbythemin
154
TableofContents
forwardingcopiesofthisprospectus,lettersoftransmittalandrelateddocumentstothebeneficialownersoftheOriginalNotesandinhandlingorforwardingtendersforexchange.WewillpaytheotherexpensesincurredinconnectionwiththeExchangeOffers,includingfeesandexpensesofthetrustee,accountingandlegalfeesandprintingcosts.
Transfer Taxes
Wewillpayalltransfertaxes,ifany,applicabletotheexchangeofOriginalNotespursuanttotheExchangeOffers.If,however,certificatesrepresentingExchangeNotesorOriginalNotesforprincipalamountsnottenderedoracceptedforexchangearetobedeliveredto,oraretobeissuedinthenameof,anypersonotherthantheregisteredholderoftheOriginalNotestendered,oriftenderedOriginalNotesareregisteredinthenameofanypersonotherthanthepersonsigningtheletteroftransmittal,orifatransfertaxisimposedforanyreasonotherthantheexchangeofOriginalNotespursuanttotheExchangeOffers,thentheamountofanytransfertaxes(whetherimposedontheregisteredholderoranyotherpersons)willbepayablebythetenderingholder.Ifsatisfactoryevidenceofpaymentofanytaxesorexemptiontherefromisnotsubmittedwiththeletteroftransmittal,theamountofanytransfertaxeswillbebilleddirectlytothetenderingholder.
Accounting Treatment
WewillrecordtheExchangeNotesatthesamecarryingvaluesastheOriginalNotes,asreflectedinouraccountingrecordsonthedateofexchange.Accordingly,wewillnotrecognizeanygainorlossontheexchangeofnotes.WewillamortizetheexpensesoftheExchangeOffersoverthetermoftheExchangeNotes.
Consequences of Failure to Exchange Original Notes
AnyOriginalNotesnottenderedintheExchangeOfferswillremainoutstandingandcontinuetobesubjecttoallthetermsandconditionsspecifiedintheindenture,includingtransferrestrictions,butwillnotretainanyrightsundertheexchangeandregistrationrightsagreement(includingtherighttoearnadditionalinterestrelatingtoourregistrationobligations)aftertheconsummationoftheExchangeOffers.ExceptinlimitedcircumstanceswithrespecttospecifictypesofholdersofOriginalNotes,wewillhavenofurtherobligationtoprovidefortheregistrationundertheSecuritiesActofsuchOriginalNotes.Ingeneral,theOriginalNotesmaynotbeofferedorsold,unlessregisteredundertheSecuritiesAct,exceptpursuanttoanexemptionfrom,orinatransactionnotsubjectto,theSecuritiesActandapplicablestatesecuritieslaws.
OriginalNotesthatarenotexchangedintheExchangeOfferswillremainoutstandingandcontinuetoaccrueinterestandwillbeentitledtotherightsandbenefitstheirholdershaveundertheindenturerelatingtotheOriginalNotes.HoldersoftheExchangeNotesandanyOriginalNotesthatremainoutstandingafterconsummationoftheExchangeOfferswillvoteasasingleclassforpurposesofdeterminingwhetherholdersoftherequisitepercentageoftheclasshavetakencertainactionsorexercisedcertainrightsundertheindenture.
Resales of Exchange Notes
BasedoninterpretationsofthestaffoftheSEC,assetforthinnoactionletterstothirdparties,webelievethatExchangeNotesissuedundertheExchangeOffersinexchangeforOriginalNotesmaybeofferedforresale,resoldandotherwisetransferredbyanyOriginalNoteholderwithoutfurtherregistrationundertheSecuritiesActandwithoutdeliveryofaprospectusthatsatisfiestherequirementsofSection10oftheSecuritiesActif:
• theholderisnotour"affiliate"withinthemeaningofRule405undertheSecuritiesAct;
155
TableofContents
• theExchangeNotesareacquiredintheordinarycourseoftheholder'sbusiness;and
• theholderdoesnotintendtoparticipateinadistribution(withinthemeaningoftheSecuritiesAct)oftheExchangeNotes.
AnyholderwhoexchangesOriginalNotesintheExchangeOfferswiththeintentionofparticipatinginanymannerinadistributionoftheExchangeNotesmustcomplywiththeregistrationandprospectusdeliveryrequirementsoftheSecuritiesActinconnectionwithasecondaryresaletransaction.
Thisprospectusmaybeusedforanoffertoresell,resaleorotherretransferofExchangeNotes.Withregardtobrokerdealers,onlybrokerdealersthatacquiretheOriginalNotesasaresultofmarketmakingactivitiesorothertradingactivitiesmayparticipateintheExchangeOffers.EachbrokerdealerthatreceivesExchangeNotesforitsownaccountinexchangeforOriginalNotes,wheretheOriginalNoteswereacquiredbythebrokerdealerasaresultofmarketmakingactivitiesorothertradingactivities,mustacknowledgethatitwilldeliveraprospectusinconnectionwithanyresaleoftheExchangeNotes.Pleasesee"PlanofDistribution"formoredetailsregardingthetransferofExchangeNotes.
156
TableofContents
DESCRIPTION OF THE EXCHANGE NOTES
TheOriginalNoteswereissuedandtheExchangeNoteswillbeissuedundertheindenture(the"base indenture ")datedasofAugust28,2018betweenElancoAnimalHealthIncorporatedandDeutscheBankTrustCompanyAmericas,astrustee(the"trustee "),assupplementedbythefirstsupplementalindenture(the"first supplemental indenture "and,togetherwiththebaseindenture,the"indenture ")datedasofAugust28,2018betweenElancoAnimalHealthIncorporatedandthetrustee.Thefollowingdescriptionisasummaryofselectedportionsoftheindentureanddoesnotrestatetheindenture.Theindenture,notthisdescription,willdefineyourrightsasaholderofthenotes.Youshouldreadtheindenturecarefullyforprovisionsthatmaybeimportanttoyou.ThetermsofthenotesincludethoseexpresslysetforthintheindentureandthosemadepartoftheindenturebyreferencetotheTrustIndentureActof1939,asamended.
Werefertothe2021OriginalNotesandthe2021ExchangeNotestogetherasthe"2021Notes,"the2023OriginalNotesandthe2023ExchangeNotestogetherasthe"2023Notes,"andthe2028OriginalNotesandthe2028ExchangeNotesasthe"2028Notes."Asusedinthissection,referencesto"Elanco ,"our"Company ,""we ,""us "and"our "referonlytoElancoAnimalHealthIncorporatedandnottoanyofitscurrentorfuturesubsidiaries.
Terms of the Exchange Notes
2021 Exchange Notes
Thespecifictermsofthe2021ExchangeNoteswillbeasfollows:
• Title of the note s:3.912%SeniorNotesdue2021
• Total principal amount being issued: upto$500,000,000
• Maturity date: August27,2021
• Interest rate: 3.912%
• Denomination: $2,000andintegralmultiplesof$1,000inexcessthereof
• Date interest starts accruing: FromthemostrecentdatetowhichinterestontheOriginalNoteshasbeenpaid
• Regular interest payment dates: February27andAugust27
• Regular records dates for interest: February12andAugust12
• Redemption: See"—OptionalRedemption"
2023 Exchange Notes
Thespecifictermsofthe2023ExchangeNoteswillbeasfollows:
• Title of the note s:4.272%SeniorNotesdue2023
• Total principal amount being issued: upto$750,000,000
• Maturity date: August28,2023
• Interest rate: 4.272%
• Denomination: $2,000andintegralmultiplesof$1,000inexcessthereof
• Date interest starts accruing: FromthemostrecentdatetowhichinterestontheOriginalNoteshasbeenpaid
157
TableofContents
• Regular interest payment dates: February28andAugust28
• Regular records dates for interest: February13andAugust13
• Redemption: See"—OptionalRedemption"
2028 Exchange Notes
Thespecifictermsofthe2028ExchangeNoteswillbeasfollows:
• Title of the note s:4.900%SeniorNotesdue2028
• Total principal amount being issued: upto$750,000,000
• Maturity date: August28,2028
• Interest rate: 4.900%
• Denomination: $2,000andintegralmultiplesof$1,000inexcessthereof
• Date interest starts accruing: FromthemostrecentdatetowhichinterestontheOriginalNoteshasbeenpaid
• Regular interest payment dates: February28andAugust28
• Regular records dates for interest: February13andAugust13
• Redemption: See"—OptionalRedemption"
Interestonthenoteswillbecomputedonthebasisofa360-dayyearoftwelve30-daymonths.Ifanyinterestpaymentdate,statedmaturitydateorredemptiondateofaseriesofnotesisnotaBusinessDay,thepaymentotherwiserequiredtobemadeonsuchdatemaybemadeonthenextBusinessDaywiththesameforceandeffectasifmadeonsuchinterestpaymentdate,statedmaturitydateorredemptiondate,asthecasemaybe,andnointerestshallaccrueontheamountsopayablefortheperiodfromandaftersuchinterestpaymentdate,statedmaturitydateorredemptiondate,asthecasemaybe.
Thetrustee,throughitscorporatetrustofficeintheCityofNewYork(insuchcapacity,the"paying agent ")willactasourpayingagentwithrespecttothenotes.Paymentsofprincipal,interestandpremiumwillbemadebyusthroughthepayingagenttoDTCasdescribedunder"Book-EntrySettlementandClearance."
Interest Rate Adjustment
TheinterestratepayableoneachseriesofnoteswillbesubjecttoadjustmentfromtimetotimeifS&PorMoody's(or,ifapplicable,anationallyrecognizedstatisticalratingorganizationwithinthemeaningofSection3(a)(62)oftheExchangeAct,selectedbyus(ascertifiedbyaresolutionofourboardofdirectorsoracommitteethereof)asareplacementagencyforS&PorMoody's,oranyofthem,asthecasemaybe,"asubstituteratingagency")downgrades(orsubsequentlyupgrades)itsratingassignedtotherespectiveseriesofnotes,assetforthbelow.EachofS&P,Moody'sandanysubstituteratingagencyisan"InterestRateRatingAgency,"andtogethertheyare"InterestRateRatingAgencies."
IftheratingofanyseriesofnotesfromS&P(or,ifapplicable,anysubstituteratingagency)withrespecttosuchseriesofnotesisdecreasedtoaratingsetforthintheimmediatelyfollowingtable,theinterestrateonsuchseriesofnoteswillincreasefromtheinterestratepayableonsuchseriesofnotes
158
TableofContents
onthedateoftheirinitialissuancebyanamountequaltothepercentagesetforthoppositethatrating:
IftheratingofanyseriesofnotesfromMoody's(or,ifapplicable,anysubstituteratingagency)withrespecttosuchseriesofnotesisdecreasedtoaratingsetforthintheimmediatelyfollowingtable,theinterestrateonsuchseriesofnoteswillincreasefromtheinterestratepayableonsuchseriesofnotesonthedateoftheirinitialissuancebyanamountequaltothepercentagesetforthoppositethatrating:
Eachadjustmentrequiredbyanydecreaseorincreaseinaratingsetforthabove,whetheroccasionedbytheactionofS&PorMoody's(or,inanycase,anysubstituteratingagency),shallbemadeindependentofanyandallotheradjustments.
NoadjustmentintheinterestrateonanyseriesofnotesshallbemadesolelyasaresultofanInterestRateRatingAgencyceasingtoprovidearatingonsuchseriesofnotes.IfatanytimefewerthantwoInterestRateRatingAgenciesprovidearatingonaseriesofnotesforreasonsbeyondourcontrol,wewillusecommerciallyreasonableeffortstoobtainaratingonsuchnotesfromasubstituteratingagencyforpurposesofdetermininganyincreaseordecreaseintheperannuminterestrateonaseriesofnotespursuanttothetablesabove,(1)suchsubstituteratingagencywillbesubstitutedforthelastInterestRateRatingAgencytoprovidearatingonsuchseriesofnotesbutwhichhassinceceasedtoprovidesuchrating,(2)therelativeratingsscaleusedbysuchsubstituteratingagencytoassignratingstoseniorunsecureddebtwillbedeterminedingoodfaithbyanindependentinvestmentbankinginstitutionofnationalstandingappointedbyusand,forpurposesofdeterminingtheapplicableratingsincludedintheapplicabletableabovewithrespecttosuchsubstituteratingagency,suchratingsshallbedeemedtobetheequivalentratingsusedbyS&PorMoody's,asapplicable,insuchtable,and(3)theperannuminterestrateonsuchnoteswillincreaseordecrease,asthecasemaybe,suchthattheinterestrateequalstheinterestratepayableonsuchseriesofnotesonthedateoftheirinitialissuanceplustheappropriatepercentage,ifany,setforthoppositetheratingfromsuchsubstituteratingagencyintheapplicabletableabove(takingintoaccounttheprovisionsofclause(2)above)(plusanyapplicablepercentageresultingfromadecreasedratingbytheotherInterestRateRatingAgency).Forsolongas(a)onlyoneInterestRateRatingAgencyprovidesaratingonaseriesofnotes,anyincreaseordecreaseintheinterestrateonsuchnotesnecessitatedbyareductionorincreaseintheratingbythatInterestRateRatingAgencyshallbetwicetheapplicablepercentagesetforthintheapplicabletableaboveand(b)noInterestRateRatingAgencyprovidesaratingonsuchnotes,theinterestrateonthatseriesofnoteswillincreaseto,orremainat,asthecasemaybe,2.00%abovetheinterestratepayableonsuchseriesofnotesonthedateoftheirinitialissuance.Innoevent
159
S&P's Rating* Percentage BB 0.25%BB– 0.50%B+ 0.75%Borbelow 1.00%
* Includingtheequivalentratingsofanysubstituteratingagency.
Moody's Rating* Percentage Ba1 0.25%Ba2 0.50%Ba3 0.75%B1orbelow 1.00%
* Includingtheequivalentratingsofanysubstituteratingagency.
TableofContents
shall(x)theinterestrateforaseriesofnotesbereducedtobelowtheinterestratepayableonsuchseriesofnotesonthedateoftheirinitialissuanceor(y)thetotalincreaseintheinterestrateonaseriesofnotesexceed2.00%abovetheinterestratepayableonsuchseriesofnotesonthedateoftheirinitialissuance.IfS&PorMoody'sceasestorateaseriesofnotesormakearatingofsuchnotespubliclyavailableforreasonswithinourcontrol,wewillnotbeentitledtoobtainaratingfromasubstituteratingagencyandtheincreaseordecreaseintheperannuminterestrateonthenotesofsuchseriesshallbedeterminedinthemannerdescribedaboveasifeitheronlyoneornoInterestRateRatingAgencyprovidesaratingonsuchnotes,asthecasemaybe.
IfatanytimetheinterestrateonanyseriesofnoteshasbeenadjustedupwardandanyoftheInterestRateRatingAgenciessubsequentlyincreasesitsratingofsuchnotes,theinterestrateonthenotesofthatserieswillbedecreasedsuchthattheinterestrateonsuchnotesequalstheinterestratepayableonsuchseriesofnotesonthedateoftheirinitialissuanceplustheapplicablepercentagessetforthoppositetheratingsineffectimmediatelyfollowingtheincreaseinthetablesabove;providedthatifS&P'soranysubstituteratingagencysubsequentlyincreasesitsratingonanyseriesofnotesto"BB+"(oritsequivalentifwithrespecttoanysubstituteratingagency)orhigher,andMoody'soranysubstituteratingagencysubsequentlyincreasesitsratingonsuchseriesofnotesto"Baa3"(oritsequivalentifwithrespecttoanysubstituteratingagency)orhigher,theperannuminterestrateonsuchnoteswillbedecreasedtotheinterestratepayableonsuchseriesofnotesonthedateoftheirinitialissuance.
Anyinterestrateincreaseordecreasedescribedabovewilltakeeffectfromthefirstdayofthefirstinterestpaymentperiodfollowingtheinterestpaymentperiodduringwhicharatingchangeoccursthatrequiresanadjustmentintheinterestrate.Assuch,interestwillnotaccrueatsuchincreasedordecreasedrateuntilthenextinterestpaymentdatefollowingthedateonwhicharatingchangeoccurs.
IfanyInterestRateRatingAgencychangesitsratingofanyseriesofnotesmorethanonceduringanyparticularinterestperiod,thelastsuchchangebysuchagencytooccurwillcontrolintheeventofaconflictforpurposesofanyinterestrateincreaseordecreasewithrespecttosuchseriesofnotesdescribedabove.
Theinterestratesonanyseriesofnoteswillpermanentlyceasetobesubjecttoanyadjustmentdescribedabove(notwithstandinganysubsequentdecreaseintheratingsbyanyInterestRateRatingAgency)ifsuchnotesbecomerated"BBB+"(oritsequivalent)orhigherbyS&P(oranysubstituteratingagency)and"Baa1"(oritsequivalent)orhigherbyMoody's(oranysubstituteratingagency),oroneofthoseratingsifratedbyonlyoneInterestRateRatingAgency,ineachcasewithastableorpositiveoutlook.
Iftheinterestratepayableonanyseriesofnotesisincreasedasdescribedabove,theterm"interest",asusedwithrespecttosuchseriesofnotes,willbedeemedtoincludeanysuchadditionalinterestunlessthecontextotherwiserequires.
Elancoissolelyresponsibleforcalculatinganyadjustmentoftheinterestrate.Elancoshalldeliverwrittennoticetothetrusteeandtheholdersofanychangetotheinterestrate.Inthecaseofglobalnotes,anychangetotheinterestrateshallbemadeinaccordancewiththeapplicableprovisionsofDTC.Neitherthetrusteenorthepayingagentshallhaveanydutytodeterminewhethertheinterestrateshouldbeadjustedortheamountofanysuchadjustment.
Ranking
Thenoteswillbeourseniorunsecuredobligationsandwillrankequallywithallofourexistingandfutureseniorunsecuredindebtedness.
160
TableofContents
No Listing
Thenoteswillnotbelistedonanynationalsecuritiesexchangeorbequotedonanyautomateddealerquotationsystem.
Reports
Whilethenotesremainoutstanding,andifwearenotrequiredtofilereportsundertheExchangeAct,wewillfurnishtoyouoranyprospectivepurchaserdesignatedbyyou,uponrequest,theinformationrequiredtobedeliveredpursuanttoRule144A(d)(4)undertheSecuritiesActtoallowyoutocomplywithRule144Ainconnectionwithresalesofthenotes.
Transfer and Exchange
Aholderofthenotesmaytransferorexchangenotesinaccordancewiththeindenture.Uponwrittendirectionfromus,oraccordingtotheircustomaryprocedures,theregistrarandthetrusteemayrequireaholdertofurnishappropriateendorsementsandtransferdocumentsinconnectionwithatransferofnotes.Holderswillberequiredtopayalltaxesdueontransfer.Wearenotrequiredtotransferorexchangeanynotesselectedforredemption.Also,wearenotrequiredtotransferorexchangeanynotesforaperiodof15daysbeforeaselectionofnotestoberedeemed.
Optional Redemption
Atouroption,wemayredeemthenotesofanyseries,inwholeorinpart,atanytimeandfromtimetotime.Theredemptionpricewillbeequaltothegreaterofthefollowingamounts:
• 100%oftheprincipalamountofthenotesbeingredeemedontheredemptiondate;and
• thesumofthepresentvaluesoftheremainingscheduledpaymentsofprincipalandinterestonthenotesbeingredeemed(assumingforthesepurposesthatthematuritydateforthe2023Notesandthe2028NotesistheapplicableParCallDate(asdefinedbelow))onthatredemptiondate(notincludingtheamountofaccruedandunpaidinterestto,butexcluding,theredemptiondate)discountedtotheredemptiondateonasemi-annualbasisattheTreasuryRate,asdeterminedbytheReferenceTreasuryDealer,plus 20basispointsinthecaseofthe2021Notes,25basispointsinthecaseofthe2023Notesand30basispointsinthecaseofthe2028Notes;
plus ,ineachcase,accruedandunpaidinterestonthenotesbeingredeemedto,butexcluding,theredemptiondate;provided ,however ,thatifweredeemthe2023NotesonorafterJuly28,2023(the"2023 Par Call Date"),theredemptionpricewillequal100%oftheprincipalamountofthe2023Notestoberedeemedplusaccruedandunpaidinterestontheamountbeingredeemedto,butexcluding,thedateofredemption;provided further ,however ,thatifweredeemthe2028NotesonorafterMay28,2028(the"2028 Par Call Date "andeachofthe2023ParCallDateandthe2028ParCallDate,a"Par Call Date "),theredemptionpricewillequal100%oftheprincipalamountofthe2028Notestoberedeemedplusaccruedandunpaidinterestontheamountbeingredeemedto,butexcluding,thedateofredemption.
Notwithstandingtheforegoing,installmentsofinterestonapplicablenotesthataredueandpayableoninterestpaymentdatesfallingonorpriortoaredemptiondatewillbepayableontheinterestpaymentdatetotheregisteredholdersasofthecloseofbusinessontherelevantrecorddateaccordingtotheapplicablenotesandtheindenture.Theredemptionpricewillbecalculatedonthebasisofa360-dayyearconsistingoftwelve30-daymonths.
Wewilldelivernoticeofanyredemptionatleast30daysbutnotmorethan60daysbeforetheredemptiondatetoeachregisteredholderofthenotestoberedeemed.Oncenoticeofredemptionis
161
TableofContents
mailed,thenotescalledforredemptionwillbecomedueandpayableontheredemptiondateattheapplicableredemptionprice,plusaccruedandunpaidinterestapplicabletosuchnotesto,butexcluding,theredemptiondate.
Setforthbelowarecertainofthedefinedtermsusedinthissection.
"Comparable Treasury Issue "means,foranyseriesofnotes,theUnitedStatesTreasurysecurityselectedbytheQuotationAgentashavinganactualorinterpolatedmaturitycomparabletotheremainingtermofthenotesofsuchseriestoberedeemedthatwouldbeutilized,atthetimeofselectionandinaccordancewithcustomaryfinancialpractice,inpricingnewissuesofcorporatedebtsecuritiesofcomparablematuritytotheremainingtermofthenotesofsuchseries.
"Comparable Treasury Price "means,withrespecttoanyredemptiondateandseriesofnotestoberedeemed,(A)theaverageoftheReferenceTreasuryDealerQuotationsforsuchredemptiondateandseries,afterexcludingthehighestandlowestofsuchReferenceTreasuryDealerQuotations,or(B)ifweobtainfewerthanfoursuchReferenceTreasuryDealerQuotations,theaverageofsuchquotations,or(C)ifonlyoneReferenceTreasuryDealerQuotationisreceived,suchquotation.
"Quotation Agent "meansoneoftheReferenceTreasuryDealersappointedbyustoactasthe"Quotation Agent ."
"Reference Treasury Dealer "means(A)anyofGoldmanSachs&Co.LLC,J.P.MorganSecuritiesLLCandCitigroupGlobalMarketsInc.(ortheirrespectiveaffiliatesthatarePrimaryTreasuryDealers),andtheirrespectivesuccessors;provided ,however ,thatifanyoftheforegoingshallceasetobeaprimaryU.S.GovernmentsecuritiesdealerintheUnitedStates(a"Primary Treasury Dealer "),wewillsubstitutethereforanotherPrimaryTreasuryDealer;and(B)anyotherPrimaryTreasuryDealer(s)selectedbyus.
"Reference Treasury Dealer Quotation "means,withrespecttoeachReferenceTreasuryDealerandanyredemptiondateandseriesofnotestoberedeemed,theaverage,asdeterminedbyus,ofthebidandaskedpricesfortheComparableTreasuryIssueforsuchseries(expressedineachcaseasapercentageofitsprincipalamount)quotedinwritingtousbysuchReferenceTreasuryDealerat5:00p.m.(NewYorkCitytime)onthethirdBusinessDayprecedingsuchredemptiondate.
"Treasury Rate "means,withrespecttoanyredemptiondateforanyseriesofnotes,therateperannumequaltothesemi-annualequivalentyieldtomaturity(orinterpolatedyieldtomaturityonadaycountbasis)oftheapplicableComparableTreasuryIssue,assumingapriceforsuchComparableTreasuryIssue(expressedasapercentageofitsprincipalamount)equaltotheapplicableComparableTreasuryPriceforsuchredemptiondate.
Onandaftertheredemptiondate,interestwillceasetoaccrueonthenotesoranyportionofthenotescalledforredemption(unlesswedefaultinthepaymentoftheredemptionpriceandaccruedandunpaidinterest).Onorbeforetheredemptiondate,wewilldepositwithapayingagent(orthetrustee)moneysufficienttopaytheredemptionpriceofandaccruedandunpaidinterestonthenotestoberedeemedonthatdate.Iffewerthanallofthenotesofanyseriesaretoberedeemed,thenotestoberedeemedshallbeselectedinaccordancewithDTC'sapplicableprocedures,inthecaseofnotesrepresentedbyaglobalsecurity,orbythetrusteebyamethodthetrusteedeemstobefairandappropriate,inthecaseofnotesthatarenotrepresentedbyaglobalsecurity.
Change of Control
IfaChangeofControlTriggeringEventoccurs,unlesswehaveredeemedthenotesinfullasdescribedabove,wewillmakeanoffertoeachholder(the"Change of Control Offer ")torepurchaseanyandall(equalto$2,000oranintegralmultipleof$1,000inexcessthereof)ofsuchholder'snotesatarepurchasepriceincashequalto101%oftheprincipalamountofthenotestoberepurchased
162
TableofContents
plusaccruedandunpaidinterestto,butexcluding,thedateofrepurchase(the"Change of Control Payment ").Within30daysfollowinganyChangeofControlTriggeringEvent,wewillberequiredtomailawrittennotice,withacopytothetrustee,toeachholderofnotesatitsregisteredaddressdescribingthetransactionortransactionsthatconstitutetheChangeofControlTriggeringEventandofferingtorepurchasethenotesonthedatespecifiedinthenotice,whichdatewillbenoearlierthan30daysandnolaterthan60daysfromthedatesuchnoticeismailed(the"Change of Control Payment Date "),pursuanttotheproceduresrequiredbythenotesanddescribedinsuchnotice.
WemustcomplywiththerequirementsofRule14e-1undertheExchangeActandanyothersecuritieslawsandregulationsthereundertotheextentthoselawsandregulationsareapplicableinconnectionwiththerepurchaseofthenotesasaresultofaChangeofControlTriggeringEvent.TotheextentthattheprovisionsofanysecuritieslawsorregulationsconflictwiththeChangeofControlrepurchaseprovisionsofthenotes,wewillberequiredtocomplywiththeapplicablesecuritieslawsandregulationsandwillnotbedeemedtohavebreachedourobligationsundertheChangeofControlrepurchaseprovisionsofthenotesbyvirtueofsuchconflicts.
OntheChangeofControlPaymentDate,wewillberequired,totheextentlawful,to:
• acceptforpaymentallnotesorportionsofnotesproperlytenderedpursuanttotheChangeofControlOffer;
• depositwiththepayingagentanamountequaltotheChangeofControlPaymentinrespectofallnotesorportionsofnotesproperlytendered;and
• deliverorcausetobedeliveredtothetrusteethenotesproperlyaccepted,togetherwithanofficers'certificatestatingtheprincipalamountofnotesorportionsofnotesbeingpurchased.
Setforthbelowarecertainofthedefinedtermsusedinthissection.
"Below Investment Grade Rating Event "meanstheratingsonthenotesarelowered,andthenotesareratedbelowInvestmentGradeRatingbytwoormoreoftheRatingAgencies(orifthereisoneRatingAgency,bysuchRatingAgency)onanydatecommencinguponthefirstpublicnoticebyusoftheoccurrenceofaChangeofControlandending60daysfollowingconsummationofsuchChangeofControl(whichperiodshallbeextendeduptoanadditional60days,solongastheratingofthenotesisunderpubliclyannouncedconsiderationforpossibledowngradebyanyoftheRatingAgencies);provided thataBelowInvestmentGradeRatingEventwillnotbedeemedtohaveoccurredinrespectofaparticularChangeofControl(andthuswillnotbedeemedaBelowInvestmentGradeRatingEventforpurposesofthedefinitionofChangeofControlTriggeringEvent)ifeachRatingAgencymakingthereductioninratingdoesnotpubliclyannounceorconfirmorinformusinwritingatourrequestthatthereductionwastheresult,inwholeorinpart,ofanyeventorcircumstancecomprisedoforarisingasaresultof,orinrespectof,theChangeofControl.
"Change of Control "meanstheoccurrenceofanyofthefollowing:
(i)directorindirectsale,transfer,conveyanceorotherdisposition(otherthanbywayofmergerorconsolidation),inoneoraseriesofrelatedtransactions,ofallorsubstantiallyallofthepropertiesorassetsofusandoursubsidiariestakenasawholetoany"person"(asthattermisusedinSection13(d)(3)oftheExchangeAct)otherthanLillyanditsaffiliates,usoroneofoursubsidiaries;
(ii)theconsummationofanytransaction(including,withoutlimitation,anymergerorconsolidation,butexcludingtransactionsinconnectionwiththeDistribution)asaresultofwhichany"person"(asthattermisusedinSection13(d)(3)oftheExchangeAct),otherthanLillyanditsaffiliates,becomesthe"beneficialowner"(asdefinedinRules13d-3and13d-5undertheExchangeAct),directlyorindirectly,ofmorethan50%ofouroutstandingvotingstockorothervotingstockintowhichourvotingstockisreclassified,consolidated,exchangedorchanged,
163
TableofContents
measuredbyvotingpowerratherthannumberofshares;provided,however,thatatransactionwillnotbedeemedtoinvolveaChangeofControlif(a)webecomeadirectorindirectwhollyownedsubsidiaryofaholdingcompanyand(b)(i)theholdersofthevotingstockofsuchholdingcompanyimmediatelyfollowingthattransactionaresubstantiallythesameastheholdersofourvotingstockimmediatelypriortothattransactionor(ii)no"person"(asthattermisusedinSection13(d)(3)oftheExchangeAct)becomesthe"beneficialowner"(asdefinedinRules13d-3and13d-5undertheExchangeAct),directlyorindirectly,ofmorethan50%ofthevotingpowerofthevotingstockofsuchholdingcompanyimmediatelyfollowingsuchtransaction;
(iii)weconsolidatewith,ormergewithorinto,any"person"or"group"(asthattermisusedinSection13(d)(3)oftheExchangeAct),otherthanLillyanditsaffiliates,orany"person"or"group",otherthanLillyanditsaffiliates,consolidateswith,ormergeswithorinto,us,inanysucheventpursuanttoatransactioninwhichanyofourvotingstockorthevotingstockofsuchotherpersonisconvertedintoorexchangedforcash,securitiesorotherproperty,otherthananysuchtransactionwherethesharesofourvotingstockoutstandingimmediatelypriortosuchtransactionconstitute,orareconvertedintoorexchangedfor,amajorityofthevotingstockofthesurvivingpersonoranydirectorindirectparentcompanyofthesurvivingpersonimmediatelyaftergivingeffecttosuchtransaction;
(iv)thefirstdayonwhichamajorityofthemembersofourboardofdirectorsarenotContinuingDirectors;or
(v)theadoptionofaplanrelatingtoourliquidationordissolution.
Forpurposesofthisdefinition,"voting stock "meanswithrespecttoanyspecifiedperson(asthattermisusedinSection13(d)(3)oftheExchangeAct)capitalstockofanyclassorkindtheholdersofwhichareordinarily,intheabsenceofcontingencies,entitledtovotefortheelectionofdirectors(orpersonsperformingsimilarfunctions)ofsuchperson,eveniftherighttovotehasbeensuspendedbythehappeningofsuchacontingency.
ThedefinitionofChangeofControlincludesaphraserelatingtothedirectorindirectsale,lease,transfer,conveyanceorotherdispositionof"allorsubstantiallyall"ofthepropertiesorassetsofusandoursubsidiariestakenasawhole.Althoughthereisalimitedbodyofcaselawinterpretingthephrase"substantiallyall,"thereisnopreciseestablisheddefinitionofthephraseunderapplicablelaw.Accordingly,theapplicabilityoftherequirementthatweoffertorepurchasethenotesasaresultofasale,lease,transfer,conveyanceorotherdispositionoflessthanalloftheassetsofusandoursubsidiariestakenasawholetoanotherpersonorgroupmaybeuncertain.
"Change of Control Triggering Event "meanstheoccurrenceofbothaChangeofControlandaBelowInvestmentGradeRatingEvent.
"Continuing Director "means,asofanydateofdetermination,anymemberofourboardofdirectorswho(1)wasamemberofourboardofdirectorsonthedateoftheissuanceofthenotes;or(2)wasnominatedforelectionorelectedtoourboardofdirectorswiththeapprovalofamajorityoftheContinuingDirectorswhoweremembersofsuchboardofdirectorsatthetimeofsuchnominationorelection(eitherbyspecificvoteorbyapprovalofourproxystatementinwhichsuchmemberwasnamedasanomineeforelectionasadirector).
"Fitch "meansFitchRatingsInc.,andanysuccessortoitsratingagencybusiness."Investment Grade Rating "meansaratingbyMoody'sequaltoorhigherthanBaa3(ortheequivalentunderasuccessorratingcategoryofMoody's),aratingbyS&PequaltoorhigherthanBBB–(ortheequivalentunderanysuccessorratingcategoryofS&P)oraratingbyFitchequaltoorhigherthanBBB–(ortheequivalentunderanysuccessorratingcategoryofFitch).
"Moody's "meansMoody'sInvestorsService,Inc.,andanysuccessortoitsratingsagencybusiness.
164
TableofContents
"Rating Agencies "means(1)eachofFitch,Moody'sandS&P;and(2)ifanyofFitch,Moody'sorS&Pceasestoratethenotesorfailstomakearatingofthenotespubliclyavailableforreasonsoutsideofourcontrol,a"nationallyrecognizedstatisticalratingorganization"withinthemeaningofSection3(a)(62)undertheExchangeAct,selectedbyus(ascertifiedbyaresolutionofourboardofdirectors)asareplacementagency,ifany,foranyofFitch,Moody's,S&P,oreachofthem,asthecasemaybe.
"S&P "meansStandard&Poor'sRatingsServices,aStandard&Poor'sFinancialServicesLLCbusinessandanysuccessortoitsratingagencybusiness.
Certain Covenants
Thefollowingrestrictivecovenantswillapplytoeachseriesofthenotesbeingofferedinthisoffering.Wemayalsoelecttohavethesecovenantsapplytoanyotherseriesofdebtsecuritiesissuedpursuanttotheindenture.
Limitations on liens
Weshallnot,andshallnotpermitanyRestrictedSubsidiaryto,create,assumeorsuffertoexistanyLien(an"Initial Lien "),otherthanPermittedLiens,onanyPrincipalPropertytosecureanyDebtofElancooranyRestrictedSubsidiaryunlessithasmadeorwillmakeeffectiveprovisionwherebythenotesandanyotherdebtsecuritiesofanyseriesissuedpursuanttotheindentureandhavingthebenefitofthiscovenantwillbesecuredbysuchLienequallyandratablywith(orpriorto)allotherDebtsecuredbysuchLien.AnyLiencreatedforthebenefitoftheholdersofthenotesandanyotherdebtsecuritiesofanyseriesissuedpursuanttotheindentureandhavingthebenefitofthiscovenantshallprovidebyitstermsthatsuchLienwillbeautomaticallyreleasedanddischargeduponthereleaseanddischargeoftheapplicableInitialLien.
Limitations on sale leaseback transactions
Elancoshallnot,andshallnotpermitanyRestrictedSubsidiaryto,enterintoanySaleandLeasebackTransactioncoveringanyPrincipalPropertyunless:
(a)pursuanttothecovenantdescribedunder"—LimitationsonLiens"above,itwouldbeentitledtoincurDebtsecuredbyaLienonsuchPrincipalPropertyinaprincipalamountequaltotheValueofsuchSaleandLeasebackTransactionwithoutequallyandratablysecuringthenotesandanyotherdebtsecuritiesofanyseriesissuedpursuanttotheindentureandhavingthebenefitofthiscovenant;or
(b)ElancooranyRestrictedSubsidiary,duringthe270daysfollowingtheeffectivedateoftheSaleandLeasebackTransaction,appliesanamountequaltotheValueofsuchSaleandLeasebackTransactiontothevoluntaryretirementoflong-termDebtofElancooranyRestrictedSubsidiaryofElancoortotheacquisitionofoneormorePrincipalProperties.
BecausethedefinitionofPrincipalPropertycoversonlybuildings,structuresorotherfacilitiestogetherwiththeunderlyinglandandfixturesusedprimarilyformanufacturing,processingorproductionthatweownintheUnitedStates,ourmanufacturingfacilitieselsewhereintheworldareexcludedfromtheoperationofthecovenantsdescribedabove.UponcompletionoftheSeparation,therewouldbenoLienson,oranySaleandLeasebackTransactionscovering,anypropertythatwouldpotentiallyqualifyasPrincipalPropertythatwouldrequirethenotestobesecuredequallyandratablywith(orpriorto)DebtsecuredbysuchLien(disregarding,forsuchdetermination,clause(a)ofthedefinitionof"PermittedLiens").Wedonotkeepongoingrecordsidentifyingwhichofourproperties,ifany,wouldqualifyasPrincipalProperty.TherecanbenoguaranteesthatwewillmaintainanypropertythatconstitutesaPrincipalProperty.
165
TableofContents
Definitions
Setforthbelowarecertainofthedefinedtermsusedintheindenture.
"Consolidated Net Tangible Assets "meanstheaggregateamountofassetsafterdeducting(a)allcurrentliabilities(excludinganyindebtednessmaturingwithin12monthsoftheendofthemostrecentquarterforwhichfinancialstatementsareavailable)and(b)allgoodwill,tradenames,patents,unamortizeddebtdiscountandexpenseandanyotherlikeintangibles.
"Debt "ofanyPersonmeans(a)allobligationsofsuchPersonforborrowedmoney,orevidencedbybonds,debentures,notesorothersimilarinstruments(otherthananysuchobligationstotheextentthat(i)theliabilityofsuchPersonislimitedsolelytothepropertyorassetfinancedbysuchobligationsor(ii)suchobligationsresultfromtherequirementtoreturncollateralpostedtosuchPersonbyacounterpartypursuanttooneormorehedgingcontractsorothersimilarriskmanagementcontracts)and(b)allDebtofothersguaranteedbysuchPerson.
"Equity Interests "meanssharesofcapitalstock,partnershipinterests,membershipinterestsinalimitedliabilitycompany,beneficialinterestsinatrustorotherequityownershipinterestsinaPerson,andanywarrants,optionsorotherrightsentitlingtheholderthereoftopurchaseoracquireanysuchequityinterests.
"Lien "means,withrespecttoanypropertyofanyPerson,anymortgageordeedoftrust,pledge,hypothecation,assignment,depositarrangement,securityinterest,lien,charge,easement(otherthananyeasementnotmateriallyimpairingusefulnessormarketability),encumbrance,preference,priorityorothersecurityagreementorpreferentialarrangementofanykindornaturewhatsoeveronorwithrespecttosuchproperty.
"Lilly "meansEliLillyandCompany.
"Permitted Liens "means
(a)LiensexistingonthedateofthefirstsupplementalindentureorLiensexistingonpropertyofanyPersonatthetimeitbecomesaSubsidiaryofElanco;
(b)LiensonpropertyownedbyaPersonexistingatthetimesuchPersonismergedwithorintoorconsolidatedwithusoranyofourSubsidiaries;provided thatsuchLienswerenotincurredinthecontemplationofsuchmergerorconsolidationanddonotextendtoanyassetsotherthanthoseofthePersonmergedintoorconsolidatedwithusorsuchSubsidiary;
(c)LiensonpropertyexistingatthetimeofacquisitionthereofbyusoranyofourSubsidiaries;provided thatsuchLienswerenotincurredinthecontemplationofsuchacquisitionanddonotextendtoanypropertyotherthanthepropertysoacquiredbyusorsuchSubsidiary;
(d)aLienonanyassetorimprovementtoanyassetsecuringDebtincurredorassumedforthepurposeoffinancingalloranypartofthecostofacquiringorimproving(includingconstructing)suchasset,ifsuchLienattachestosuchassetconcurrentlywithorwithin12monthsafteritsacquisitionorimprovement(includingthecompletionofconstruction)andtheprincipalamountoftheDebtsecuredbysuchLien,togetherwithallotherdebtsecuredbyaLienonsuchproperty,doesnotexceedthepurchasepriceofsuchpropertyorthecostofsuchimprovement;
(e)anyLienarisingbyreasonofdepositswith,orthegivingofanyformofsecurityto,anygovernmentalagencyoranybodycreatedorapprovedbylaworgovernmentalregulation;
(f)LienssecuringDebtofaRestrictedSubsidiaryofElancoowedtoElancooranotherRestrictedSubsidiaryofElanco;
166
TableofContents
(g)anyextension,renewalorreplacement(orsuccessiveextensions,renewalsorreplacements)inwholeorinpartofanyLienreferredtoinclauses(a)through(f)above,inclusive,solongas(i)theprincipalamountoftheDebtsecuredtherebydoesnotexceedtheprincipalamountofDebtsosecuredatthetimeoftheextension,renewalorreplacement(exceptthat,whereanadditionalprincipalamountofDebtisincurredtoprovidefundsforthecompletionofaspecificproject,theadditionalprincipalamount,andanyrelatedfinancingcosts,maybesecuredbytheLienaswell)and(ii)theLienislimitedtothesamepropertysubjecttotheLiensoextended,renewedorreplaced(andimprovementsontheproperty);and
(h)LiensonanyPrincipalPropertynotdescribedinclauses(a)through(g)abovesecuringDebtthat,togetherwith(i)theaggregateamountofallotheroutstandingDebtsecuredbyallotherLiensonPrincipalPropertynotdescribedinclauses(a)through(g)aboveand(ii)theaggregateamountofValueinrespectofallSaleandLeasebackTransactionsthatwouldotherwisebeprohibitedbythecovenantdescribedunder"—LimitationonSaleandLeasebackTransactions,"donotexceed15%ofourConsolidatedNetTangibleAssetsmeasuredasoftheendofthemostrecentquarterforwhichfinancialstatementsareavailable.
"Person "meansanindividual,acorporation,acompany,avoluntaryassociation,apartnership,atrust,ajointventure,alimitedliabilitycompanyorotherbusinessentity,anunincorporatedorganization,oragovernmentoranyagency,instrumentalityorpoliticalsubdivisionthereof.
"Principal Property "meansanybuilding,structureorotherfacilitytogetherwiththeunderlyinglandanditsfixtures,usedprimarilyformanufacturing,processingorproduction,ownedintheUnitedStatesandthenetbookvalueofsuchbuilding,structureorotherfacilityexceeds2%ofourConsolidatedNetTangibleAssetsmeasuredasoftheendofthemostrecentquarterforwhichfinancialstatementsareavailable;providedthatnobuilding,structureorotherfacilitywillbeaPrincipalPropertyif,inthegoodfaithopinionofourboardofdirectors(oracommitteethereof),suchbuilding,structureorotherfacilityisnotofmaterialimportancetoourbusinesstakenasawhole.
"Restricted Subsidiary "meansanyofourSubsidiariesthatownsaPrincipalProperty.
"Sale and Leaseback Transaction "meansanydirectorindirectarrangementrelatingtopropertynowownedorhereafteracquiredwherebyweoraRestrictedSubsidiarytransferssuchpropertytoanotherPersonandweoraRestrictedSubsidiaryleasesorrentsitfromsuchPerson(otherthan(i)leasesbetweenusandaRestrictedSubsidiaryorbetweenRestrictedSubsidiaries,(ii)temporaryleasesforaterm,includingrenewalsattheoptionofthelessee,ofnotmorethanthreeyearsand(iii)leasesofapropertyexecutedbythetimeof,orwithin90daysafterthelatestof,theacquisition,thecompletionofconstructionorimprovement,orthecommencementofcommercialoperationoftheproperty).
"Subsidiary "means,withrespecttoanyPerson,anycorporation,partnership,limitedliabilitycompanyorotherbusinessentityofwhichatleastamajorityoftheoutstandingsharesofVotingStockisatthetimedirectlyorindirectlyownedorcontrolledbysuchPersonoroneormoreoftheSubsidiariesofsuchPerson.
"Value "means,withrespecttoaSaleandLeasebackTransaction,anamountequaltothepresentvalueoftheleasepaymentswithrespecttothetermoftheleaseremainingonthedateasofwhichtheamountisbeingdetermined,withoutregardtoanyrenewalorextensionoptionscontainedinthelease,discountedattheweightedaverageinterestrateofallseriesofdebtsecuritiesissuedpursuanttotheindentureandhavingthebenefitofthecovenantsdescribedaboveunder"—LimitationonLiens"and"—LimitationonSaleandLeasebackTransactions"(includingtheeffectiveinterestrateofanyoriginalissuediscountdebtsecurities)whichareoutstandingonthedateofsuchSaleandLeasebackTransaction.
167
TableofContents
"Voting Stock "meansEquityInterestsofanyPersonhavingordinarypowertovoteintheelectionofmembersoftheboardofdirectors,managers,trusteesorothercontrollingPersonsofsuchPerson(irrespectiveofwhether,atthetime,EquityInterestsofanyotherclassorclassesofsuchentityshallhaveormighthavevotingpowerbyreasonofthehappeningofacontingency).
Theindenturecontainsnootherrestrictivecovenants,includingthosethatwouldaffordholdersofthenotesprotectionintheeventofahighly-leveragedtransactioninvolvingElancooranyofitsaffiliates,oranycovenantsrelatingtototalindebtedness,interestcoverage,stockrepurchases,recapitalizations,dividendsanddistributionstoshareholders,currentratiosoracquisitionsanddivestitures.
Further Issues
Wemay,withouttheconsentoftheholdersofnotesofanyseries,issueadditionalnoteshavingthesamerankingandthesameinterestrate,maturityandothertermsasthenotesofanyseries.Anyadditionalnoteshavingsuchsimilarterms,togetherwiththenotesoftheapplicableseries,willconstituteasingleseriesofdebtsecuritiesundertheindenture.Noadditionalnotesofanyseriesmaybeissuedifaneventofdefaulthasoccurredwithrespecttothenotesofthatseries.WewillnotissueanyadditionalnotesintendedtoformasingleserieswiththenotesofanyseriesunlesssuchfurthernoteswillbefungiblewithallnotesofthesameseriesforU.S.federalincometaxpurposes.
Consolidation, Merger or Sale
Wewillnotconsolidatewith,mergewithorinto,orsell,convey,transfer,leaseorotherwisedisposeofallorsubstantiallyallofourandoursubsidiaries'propertyandassetstakenasawhole(inonetransactionoraseriesofrelatedtransactions)to,anyperson,orpermitanypersontomergewithorintous,unless:
(a)weshallbethecontinuingperson,ortheperson(ifotherthanus)formedbysuchconsolidationorintowhichwearemergedorthatacquiredorleasedsuchpropertyandassets(the"Surviving Person "),shallbeanentityorganizedandvalidlyexistingunderthelawsoftheUnitedStatesofAmericaoranyjurisdictionthereof,andshallexpresslyassume,byasupplementalindenture,executedanddeliveredtothetrustee,allofourobligationsundertheindentureandthenotes;
(b)immediatelyaftergivingeffecttosuchtransaction,nodefaultoreventofdefault(eachasdefinedintheindenture)shallhaveoccurredandbecontinuing;and
(c)wedelivertothetrusteeanofficer'scertificateandopinionofcounsel,ineachcasestatingthatsuchconsolidation,mergerortransferandsuchsupplementalindenturecomplieswiththisprovisionandthatallconditionsprecedentprovidedforhereinrelatingtosuchtransactionhavebeencompliedwith.
TheSurvivingPersonwillsucceedto,andexceptinthecaseofalease,besubstitutedfor,usundertheindentureandthenotes.
Modification of Indenture
Undertheindenture,ifthetrusteeandweagree,wecanmodifytheindenturewithoutnotifyinganyholdersorseekingtheirconsentincertainspecifiedcircumstances,includingiftheamendmentdoesnotmateriallyadverselyaffectanyholder.Inothercircumstances,ourrightsandobligationsandtherightsoftheholdersmaybemodifiediftheholdersofamajorityinaggregateprincipalamountoftheoutstandingnotesofeachseriesaffected(votingtogetherasasingleclass)bythemodificationconsenttoit.Nomodificationofthematuritydateorprincipalorinterestpaymentterms,nomodificationofthecurrencyforpayment,noimpairmentoftherighttosuefortheenforcementof
168
TableofContents
paymentatthematurityofthenotes,nomodificationofanyconversionrightsandnomodificationreducingthepercentagerequiredformodificationsormodifyingtheforegoingrequirementsorredoingthepercentagerequiredtowaivecertainspecifiedcovenants,iseffectiveagainstanyholderwithoutitsconsent.Inconnectionwithanymodificationoftheindenture,wewilldelivertothetrusteeanopinionofcounselandanofficer'scertificate,uponwhichthetrusteemayrely,eachstatingthatsuchmodificationcomplieswiththeapplicableprovisionsoftheindenture,andallconditionsprecedentidentifiedtherein.
Events of Default
Whenweusetheterm"event of default "intheindenture,herearesomeexamplesofwhatwemean.Aneventofdefaultoccursif:
• wefailtomaketheprincipaloranypremiumpaymentonthenoteswhendue;
• wefailtopayinterestonthenotesfor30daysafterpaymentwasdue;
• wefailtoperformanyothercovenantintheindentureandthisfailurecontinuesfor90daysafterwereceivewrittennoticeofit;or
• weoracourttakecertainactionsrelatingtothebankruptcy,insolvencyorreorganizationofourcompany.
Adefaultunderoneseriesofnoteswillnotnecessarilybeadefaultunderanotherseries.Thetrusteemaywithholdnoticetotheholdersofnotesofanydefault(exceptfordefaultsthatinvolveourfailuretopayprincipalorinterest)ifitconsiderssuchwithholdingofnoticetobeinthebestinterestsoftheholders.Thetrusteeshallnotbedeemedtohavenoticeofanydefaultoreventofdefault(otherthandefaultsthatinvolveourfailuretopayprincipalorinterest)unlessanofficerofthetrusteehavingresponsibilityforadministrationoftheindenturehasreceivedwrittennoticeofsuchdefaultoreventofdefault,andsuchnoticereferencesthenotesandtheindenture.
Ifaneventofdefaultwithrespecttooutstandingnotesofanyseriesoccursandiscontinuing,thenthetrusteeortheholdersofatleast33%inprincipalamountofnotesofthatseriesmaydeclare,inawrittennotice,theprincipalamount(orspecifiedamount)plusaccruedandunpaidinterestonnotesofthatseriestobeimmediatelydueandpayable.Atanytimeafteradeclarationofaccelerationwithrespecttonotesofanyserieshasbeenmade,theholdersofamajorityinprincipalamountoftheoutstandingnotesofsuchseriesmayrescindandannultheaccelerationif:
• theholdersactbeforethetrusteehasobtainedajudgmentordecreeforpaymentofthemoneydue;
• wehavepaidordepositedwiththetrusteeasumsufficienttopayoverdueinterestandoverdueprincipalotherthantheacceleratedinterestandprincipal;and
• wehavecuredortheholdershavewaivedallEventsofDefault,otherthanthenon-paymentofacceleratedprincipalandinterestwithrespecttodebtsecuritiesofthatseries,asprovidedintheindenture.
Ifadefaultintheperformanceorbreachoftheindentureshallhaveoccurredandbecontinuing,theholdersofnotlessthanamajorityinprincipalamountoftheoutstandingsecuritiesofallseries,bywrittennoticetothetrustee,maywaiveanypasteventofdefaultoritsconsequencesundertheindenturewithrespecttosuchseriessolongascertainconditionsaremet(including,butnotlimitedto,thedepositwiththetrusteeofasumsufficienttopayallsumspaidoradvancedbythetrusteeandthereasonablecompensation,expenses,disbursementsandadvancesofthetrustee,itsagentsand
169
TableofContents
counsel).However,aneventofdefaultcannotbewaivedwithrespecttoanyseriesofsecuritiesinthefollowingtwocircumstances:
• afailuretopaytheprincipalof,andpremiumorinterestonanysecurityorinthepaymentofanysinkingfundinstallment;or
• acovenantorprovisionthatcannotbemodifiedoramendedwithouttheconsentofeachholderofoutstandingsecuritiesofthatseries.
Otherthanitsdutiesincaseofadefault,thetrusteeisnotobligatedtoexerciseanyofitsrightsorpowersundertheindentureattherequest,orderordirectionofanyholders,unlesstheholdersofferthetrusteereasonableindemnityand/orsecuritytothesatisfactionofthetrustee.Iftheyprovidethisreasonableindemnityand/orsecuritytothesatisfactionofthetrustee,theholdersofamajorityinprincipalamountoutstandingofanyseriesofnotesmay,subjecttocertainlimitations,directthetime,methodandplaceofconductinganyproceedingoranyremedyavailabletothetrustee,orexercisinganypowerconferreduponthetrustee,foranyseriesofdebtsecurities.
Wearerequiredtodelivertothetrusteeanannualstatementastoourfulfillmentofallofourobligationsundertheindenture.
No Sinking Fund
Thenotesarenotentitledtothebenefitofasinkingfund.
Defeasance
Whenweusethetermdefeasance,wemeandischargefromsomeorallofourobligationsundertheindenture.Ifwedepositwiththetrusteesufficientcashorgovernmentsecuritiestopaytheprincipal,interest,anypremiumandanyothersumsduetothestatedmaturitydateoraredemptiondateofthenotesinaparticularseries,thenatouroption:
• wewillbedischargedfromourobligationswithrespecttothenotesinsuchseries;or
• wewillnolongerbeunderanyobligationtocomplywithcertainrestrictivecovenantsundertheindenture,andcertainEventsofDefaultwillnolongerapplytous.
Ifthishappens,theholdersofthenotesoftheaffectedserieswillnotbeentitledtothebenefitsoftheindentureexceptforregistrationoftransferandexchangeofthenotesandreplacementoflost,stolenormutilatednotes.Suchholdersmaylookonlytosuchdepositedfundsorobligationsforpayment.
Toexerciseourdefeasanceoption,wemustdelivertothetrusteeanopinionofcounseltotheeffectthat,amongotherthings,thedepositandrelateddefeasancewouldnotcausetheholdersofthenotestorecognizeincome,gainorlossforU.S.federalincometaxpurposes.Weshallalsodelivertothetrusteeanofficer'scertificateandopinionofcounselstatingthatallconditionsprecedentinconnectionwiththedefeasancehavebeencompliedwith.
Governing law
TheindentureandExchangeNotesaregovernedbythelawsoftheStateofNewYork.
Regarding the Trustee
DeutscheBankTrustCompanyAmericasisthetrusteeundertheindenture.Thetrusteeoritsaffiliatesmayfromtimetotimeinthefutureprovidebankingandotherservicestousintheordinarycourseoftheirbusiness.
Paying Agent and Registrar
Thetrusteeundertheindentureinitiallyactsasthepayingagentandregistrarforthenotes.Wemaychangethepayingagentorregistrarundertheindenturewithoutpriornoticetotheholdersofthenotes,andweoranyofoursubsidiariesmayactaspayingagentorregistrarundertheindenture.
170
TableofContents
BOOK-ENTRY SETTLEMENT AND CLEARANCE
TheExchangeNotesinitiallywillberepresentedbyoneormorenotesinregistered,globalformwithoutinterestcoupons(collectively,the"GlobalNotes").TheGlobalNoteswillbedepositeduponissuancewiththetrusteeascustodianforDTC,andregisteredinthenameofDTCoritsnominee,ineachcase,forcredittoanaccountofadirectorindirectparticipantinDTCasdescribedbelow.Exceptassetforthbelow,theGlobalNotesmaybetransferred,inwholeandnotinpart,onlytoanothernomineeofDTCortoasuccessorofDTCoritsnominee.BeneficialinterestsintheGlobalNotesmaynotbeexchangedfordefinitivenotesinregisteredcertificatedform("CertificatedNotes")exceptinthelimitedcircumstancesdescribedbelow.See"—ExchangeofGlobalNotesforCertificatedNotes."Exceptinthelimitedcircumstancesdescribedbelow,ownersofbeneficialinterestsintheGlobalNoteswillnotbeentitledtoreceivephysicaldeliveryofnotesincertificatedform.TransfersofbeneficialinterestsintheGlobalNoteswillbesubjecttotheapplicablerulesandproceduresofDTCanditsdirectorindirectparticipants(including,ifapplicable,thoseofEuroclearandClearstream),whichmaychangefromtimetotime.
Depository Procedures
ThefollowingdescriptionoftheoperationsandproceduresofDTC,EuroclearandClearstreamareprovidedsolelyasamatterofconvenience.Theseoperationsandproceduresaresolelywithinthecontroloftherespectivesettlementsystemsandaresubjecttochangesbythem.Elancotakesnoresponsibilityfortheseoperationsandproceduresandurgesinvestorstocontactthesystemortheirparticipantsdirectlytodiscussthesematters.
DTChasadvisedElancothatDTCisalimited-purposetrustcompanycreatedtoholdsecuritiesforitsparticipatingorganizations(collectively,the"Participants")andtofacilitatetheclearanceandsettlementoftransactionsinthosesecuritiesbetweentheParticipantsthroughelectronicbook-entrychangesinaccountsofitsParticipants.TheParticipantsincludesecuritiesbrokersanddealers(includingtheinitialpurchasers),banks,trustcompanies,clearingcorporationsandcertainotherorganizations.AccesstoDTC'ssystemisalsoavailabletootherentitiessuchasbanks,brokers,dealersandtrustcompaniesthatclearthroughormaintainacustodialrelationshipwithaParticipant,eitherdirectlyorindirectly(collectively,the"IndirectParticipants").PersonswhoarenotParticipantsmaybeneficiallyownsecuritiesheldbyoronbehalfofDTConlythroughtheParticipantsortheIndirectParticipants.Theownershipinterestsin,andtransfersofownershipinterestsin,eachsecurityheldbyoronbehalfofDTCarerecordedontherecordsoftheParticipantsandIndirectParticipants.
DTChasalsoadvisedElancothat,pursuanttoproceduresestablishedbyit:
(1)upondepositoftheGlobalNotes,DTCwillcredittheaccountsoftheParticipantsdesignatedbytheinitialpurchaserswithportionsoftheprincipalamountoftheGlobalNotes;and
(2)ownershipoftheseinterestsintheGlobalNoteswillbeshownon,andthetransferofownershipoftheseinterestswillbeeffectedonlythrough,recordsmaintainedbyDTC(withrespecttotheParticipants)orbytheParticipantsandtheIndirectParticipants(withrespecttootherownersofbeneficialinterestsintheGlobalNotes).
AllinterestsinaGlobalNote,includingthoseheldthroughEuroclearorClearstream,maybesubjecttotheproceduresandrequirementsofDTC.ThoseinterestsheldthroughEuroclearorClearstreammayalsobesubjecttotheproceduresandrequirementsofsuchsystems.ThelawsofsomejurisdictionsmayrequirethatcertainPersonstakephysicaldeliveryindefinitiveformofsecuritiesthattheyown.Consequently,theabilitytotransferbeneficialinterestsinaGlobalNotetosuchPersonswillbelimitedtothatextent.BecauseDTCcanactonlyonbehalfoftheParticipants,whichinturnactonbehalfoftheIndirectParticipants,theabilityofaPersonhavingbeneficialinterestsinaGlobalNotetopledgesuchintereststoPersonsthatdonotparticipateintheDTCsystem,orotherwisetakeactions
171
TableofContents
inrespectofsuchinterests,maybeaffectedbythelackofaphysicalcertificateevidencingsuchinterests.
Exceptasdescribedbelow,ownersofinterestsintheGlobalNoteswillnothavenotesregisteredintheirnames,willnotreceivephysicaldeliveryofCertificatedNotesandwillnotbeconsideredtheregisteredownersor"holders"thereofundertheindentureforanypurpose.Paymentsinrespectoftheprincipalof,premiumon,ifany,andinterest,ifany,on,aGlobalNoteregisteredinthenameofDTCoritsnomineewillbepayabletoDTCinitscapacityastheregisteredholderundertheindenture.Underthetermsoftheindenture,Elancoandthetrusteewilltreatthepersonsinwhosenamesthenotes,includingtheGlobalNotes,areregisteredastheownersofthenotesforthepurposeofreceivingpaymentsandforallotherpurposes.
Consequently,noneofElanco,thetrusteeoranyagentofElancoorthetrusteehasorwillhaveanyresponsibilityorliabilityfor:
(1)anyaspectofDTC'srecordsoranyParticipant'sorIndirectParticipant'srecordsrelatingtoorpaymentsmadeonaccountofbeneficialownershipinterestsintheGlobalNotesorformaintaining,supervisingorreviewinganyofDTC'srecordsoranyParticipant'sorIndirectParticipant'srecordsrelatingtothebeneficialownershipinterestsintheGlobalNotes;or
(2)anyothermatterrelatingtotheactionsandpracticesofDTCoranyofitsParticipantsorIndirectParticipants.
DTChasadvisedElancothatitscurrentpractice,uponreceiptofanypaymentinrespectofsecuritiessuchasthenotes(includingprincipalandinterest),istocredittheaccountsoftherelevantParticipantswiththepaymentonthepaymentdateunlessDTChasreasontobelievethatitwillnotreceivepaymentonsuchpaymentdate.EachrelevantParticipantiscreditedwithanamountproportionatetoitsbeneficialownershipofaninterestintheprincipalamountoftherelevantsecurityasshownontherecordsofDTC.PaymentsbytheParticipantsandtheIndirectParticipantstothebeneficialownersofnoteswillbegovernedbystandinginstructionsandcustomarypracticesandwillbetheresponsibilityoftheParticipantsortheIndirectParticipantsandwillnotbetheresponsibilityofDTC,thetrustee,orElanco.NeitherElanconorthetrusteewillbeliableforanydelaybyDTCoranyoftheParticipantsortheIndirectParticipantsinidentifyingthebeneficialownersofthenotes,andElancoandthetrusteemayconclusivelyrelyonandwillbeprotectedinrelyingoninstructionsfromDTCoritsnomineeforallpurposes.
Subjecttothetransferrestrictionssetforthunder"NoticetoInvestors,"transfersbetweentheParticipantswillbeeffectedinaccordancewithDTC'sprocedures,andwillbesettledinsame-dayfunds,andtransfersbetweenparticipantsinEuroclearandClearstreamwillbeeffectedinaccordancewiththeirrespectiverulesandoperatingprocedures.
Subjecttocompliancewiththetransferrestrictionsapplicabletothenotesdescribedherein,cross-markettransfersbetweentheParticipants,ontheonehand,andEuroclearorClearstreamparticipants,ontheotherhand,willbeeffectedthroughDTCinaccordancewithDTC'srulesonbehalfofEuroclearorClearstream,asthecasemaybe,bytheirrespectivedepositaries;however,suchcross-markettransactionswillrequiredeliveryofinstructionstoEuroclearorClearstream,asthecasemaybe,bythecounterpartyinsuchsysteminaccordancewiththerulesandproceduresandwithintheestablisheddeadlines(Brusselstime)ofsuchsystem.EuroclearorClearstream,asthecasemaybe,will,ifthetransactionmeetsitssettlementrequirements,deliverinstructionstoitsrespectivedepositarytotakeactiontoeffectfinalsettlementonitsbehalfbydeliveringorreceivinginterestsintherelevantGlobalNoteinDTC,andmakingorreceivingpaymentinaccordancewithnormalproceduresforsame-dayfundssettlementapplicabletoDTC.EuroclearparticipantsandClearstreamparticipantsmaynotdeliverinstructionsdirectlytothedepositoriesforEuroclearorClearstream.
172
TableofContents
DTChasadvisedElancothatitwilltakeanyactionpermittedtobetakenbyaholderofnotesonlyatthedirectionofoneormoreParticipantstowhoseaccountDTChascreditedtheinterestsintheGlobalNotesandonlyinrespectofsuchportionoftheaggregateprincipalamountofthenotesastowhichsuchParticipantorParticipantshasorhavegivensuchdirection.However,ifthereisanEventofDefaultunderthenotes,DTCreservestherighttoexchangetheGlobalNotesforCertificatedNotes,andtodistributesuchnotestoitsParticipants.
AlthoughDTC,EuroclearandClearstreamhaveagreedtotheforegoingprocedurestofacilitatetransfersofinterestsintheGlobalNotesamongparticipantsinDTC,EuroclearandClearstream,theyareundernoobligationtoperformortocontinuetoperformsuchprocedures,andmaydiscontinuesuchproceduresatanytime.NoneofElanco,thetrusteeoranyoftheirrespectiveagentswillhaveanyresponsibilityfortheperformancebyDTC,EuroclearorClearstreamortheirrespectiveparticipantsorindirectparticipantsoftheirrespectiveobligationsundertherulesandproceduresgoverningtheiroperations.
Exchange of Global Notes for Certificated Notes
AGlobalNoteisexchangeableforCertificatedNotesif:
(1)DTC(a)notifiesElancothatitisunwillingorunabletocontinueasdepositaryfortheGlobalNoteor(b)hasceasedtobeaclearingagencyregisteredundertheExchangeActand,ineithercase,Elancofailstoappointasuccessordepositarywithin90days;
(2)Elanco,atitsoptionbutsubjecttoDTC'srequirements,notifiesthetrusteeinwritingthatitelectstocausetheissuanceoftheCertificatedNotes;or
(3)therehasoccurredandiscontinuinganEventofDefault,andDTCnotifiesthetrusteeofitsdecisiontoexchangesuchGlobalNoteforCertificatedNotes.
Inaddition,beneficialinterestsinaGlobalNotemaybeexchangedforCertificatedNotesuponpriorwrittennoticegiventothetrusteebyoronbehalfofDTCinaccordancewiththeindenture.Inallcases,CertificatedNotesdeliveredinexchangeforanyGlobalNoteorbeneficialinterestsinGlobalNoteswillberegisteredinthenames,andissuedinanyapproveddenominations,requestedbyoronbehalfofthedepositary(inaccordancewithitscustomaryprocedures).
Same Day Settlement and Payment
ElancowillmakepaymentsinrespectofthenotesrepresentedbytheGlobalNotesincludingprincipal,premium,ifany,andinterest,ifany,bywiretransferofimmediatelyavailablefundstotheaccountsspecifiedbyDTCoritsnominee.ThenotesrepresentedbytheGlobalNotesareexpectedtobeeligibletotradeinDTC'sSame-DayFundsSettlementSystem,andanypermittedsecondarymarkettradingactivityinsuchnoteswill,therefore,berequiredbyDTCtobesettledinimmediatelyavailablefunds.ElancoexpectsthatsecondarytradinginanyCertificatedNoteswillalsobesettledinimmediatelyavailablefunds.
Becauseoftimezonedifferences,thesecuritiesaccountofaEuroclearorClearstreamparticipantpurchasinganinterestinaGlobalNotefromaParticipantwillbecredited,andanysuchcreditingwillbereportedtotherelevantEuroclearorClearstreamparticipant,duringthesecuritiessettlementprocessingday(whichmustbeabusinessdayforEuroclearandClearstream)immediatelyfollowingthesettlementdateofDTC.DTChasadvisedElancothatcashreceivedinEuroclearorClearstreamasaresultofsalesofinterestsinaGlobalNotebyorthroughaEuroclearorClearstreamparticipanttoaParticipantwillbereceivedwithvalueonthesettlementdateofDTCbutwillbeavailableintherelevantEuroclearorClearstreamcashaccountonlyasofthebusinessdayforEuroclearorClearstreamfollowingDTC'ssettlementdate.
173
TableofContents
DESCRIPTION OF CERTAIN OTHER INDEBTEDNESS
We summarize below the principal terms of the Credit Facilities. This summary is not a complete description of all of the terms of the Credit Facilities.
Credit Facilities
OnSeptember5,2018,Elancoenteredintoarevolvingcreditfacilitywithasyndicateofbanksprovidingforafive-year$750millionseniorunsecuredrevolvingcreditfacility,withtheability(subjecttocertainconditions)toincuradditionalincrementalcommitmentsofupto$250million(the"RevolvingFacility"),andatermcreditagreementwithasyndicateofbanksprovidingforathree-yearseniorunsecuredtermcreditfacilityinanamountof$500million(the"TermFacility"and,togetherwiththeRevolvingFacility,the"CreditFacilities").TheCreditFacilitiesbecameavailableforborrowingsuponthecompletionoftheIPOand,concurrentlywiththecompletionoftheIPO,ElancoborrowedthefullamountavailableundertheTermFacility.TherearenodrawingsundertheRevolvingFacility.TheCreditFacilitiesarenotguaranteedbyElanco'ssubsidiaries.
Additionally,ElancowillpayatickingfeeonthecommitmentsofeachlenderwithrespecttotheTermFacilityduringtheperiodfromandincludingthedateofexecutionofthespecificdocumentationrelatingtotheTermFacilitybutexcludingthedateonwhichsuchcommitmentswithrespecttotheTermFacilityterminate.WithrespecttotheRevolvingFacility,ElancowillpayafacilityfeeontheaggregateamountoftheRevolvingFacility(whetherdrawnorundrawn)duringtheperiodfromandincludingthedateofexecutionofthespecificdocumentationrelatingtotheRevolvingFacilitybutexcludingthedateonwhichcommitmentsundertheRevolvingFacilityterminate.Theapplicablemargins,thetickingfeeandthefacilityfeearedeterminedbasedonpublicratingsofElanco'sseniorunsecurednon-creditenhancedcreditrating.BasedonthepublicratingsasoftheclosingdateoftheCreditFacilities,(A)theinterestrateforrevolvingloans(i)comprisingeachABRBorrowing(asdefinedintheRevolvingFacility)shallbearinterestattheAlternateBaseRate(asdefinedintheRevolvingFacility)plus0.10%and(ii)comprisingeachEurocurrencyBorrowing(asdefinedintheRevolvingFacility)shallbearinterestattheAdjustedEurocurrencyRate(asdefinedintheRevolvingFacility)fortheapplicableinterestperiodineffectforsuchborrowingplus1.10%and(B)theinterestratefortermloans(i)comprisingeachABRBorrowing(asdefinedintheTermFacility)shallbearinterestattheAlternateBaseRate(asdefinedintheTermFacility)plus0.25%and(ii)comprisingeachEurocurrencyBorrowing(asdefinedintheTermFacility)shallbearinterestattheAdjustedEurocurrencyRate(asdefinedintheTermFacility)fortheapplicableinterestperiodineffectforsuchborrowingplus1.25%.Interestonbaserateborrowings,thetickingfeeandthefacilityfeearegenerallypayablequarterlyinarrears;however,forloansbearinginterestbasedonaEurocurrencyRate,interestispayableonthelastdayoftheapplicableinterestperiodand,inthecaseofanyinterestperiodofmorethanthreemonths'duration,eachdaypriortothelastdayofsuchinterestperiodthatoccursatintervalsofthreemonths'durationafterthefirstdayofsuchinterestperiod.
Elancomayvoluntarilyprepayloansand/orreducethecommitmentundertheCreditFacilities,inwholeorinpart,withoutpenaltyorpremium,subjecttocertainminimumamountsandincrementsandthepaymentofcustomarybreakagecosts.NomandatoryprepaymentisrequiredundertheCreditFacilities.TheTermFacilityissubjecttoamortizationpayments,payableonthelastdayofeachquarter.
TheCreditFacilitiescontainafinancialcovenantrequiringElanconottoexceedamaximumconsolidatedleverageratioandafinancialcovenanttomaintainaminimuminterestcoverageratio.Inaddition,theCreditFacilitiescontaincustomaryaffirmativeandnegativecovenantsthat,amongotherthings,limitorrestrictElanco'sand/oritssubsidiaries'ability,subjecttocertainexceptions,toincurliens,merge,consolidateorsellorotherwisetransferassets,toenterintotransactionswithElanco'saffiliatesandincursubsidiaryindebtedness.TheCreditFacilitiesalsocontaincustomaryeventsofdefault.
174
TableofContents
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES
ThefollowingdiscussionisasummaryofcertainmaterialU.S.federalincometaxconsequencesrelatingtotheexchangeofOriginalNotesforExchangeNotespursuanttotheExchangeOffers,butisnotacompleteanalysisofallpotentialtaxeffects.ThesummarybelowisbasedupontheInternalRevenueCodeof1986,asamended(the"Code"),regulationsoftheTreasuryDepartment,administrativerulingsandpronouncementsoftheInternalRevenueServiceandjudicialdecisions,allofwhicharesubjecttochange,possiblywithretroactiveeffect.ThissummaryappliesonlytoaholderthatacquiredtheOriginalNotesatoriginalissueforcashandholdssuchOriginalNotesasacapitalassetwithinthemeaningofSection1221oftheCode.
ThissummarydoesnotaddressalloftheU.S.federalincometaxconsequencesthatmayberelevanttoaholderinlightofsuchholder'sparticularcircumstances.ThissummaryalsodoesnotaddresstheU.S.federalincometaxconsequencestoholderssubjecttospecialtreatmentunderU.S.federalincometaxlaws,suchastax-exemptorganizations,holderssubjecttotheU.S.federalalternativeminimumtax,dealersortradersinsecuritiesorcurrencies,financialinstitutions,insurancecompanies,regulatedinvestmentcompanies,realestateinvestmenttrusts,certainformercitizensorresidentsoftheUnitedStates,controlledforeigncorporations,passiveforeigninvestmentcompanies,partnerships,Scorporationsorotherpass-throughentities,personswhosefunctionalcurrencyisnottheU.S.dollar,foreignpersonsandentities,andpersonsholdingnotesinconnectionwithastraddle,hedging,conversionorotherrisk-reductiontransaction.Thissummarydoesnotconsidertheeffectofanyforeign,state,local,gift,estateorothertaxlawsthatmaybeapplicabletoaparticularholder.
The Exchange Offers
TheexchangeofyourOriginalNotesforExchangeNotespursuanttotheExchangeOffersshouldnotconstituteanexchangeforU.S.federalincometaxpurposesbecausetheExchangeNotesshouldnotbeconsideredtodiffermateriallyinkindorextentfromtheOriginalNotes.Accordingly,therewillbenoU.S.federalincometaxconsequencestoholderswhoexchangetheirOriginalNotesforExchangeNotesinconnectionwiththeExchangeOffersandanysuchholderwillhavethesameadjustedtaxbasisandholdingperiodintheExchangeNotesasithadintheOriginalNotesimmediatelybeforetheexchange.
The foregoing discussion of certain material U.S. federal income tax consequences does not consider the facts and circumstances of any particular holder's situation or status. Accordingly, each holder ofOriginal Notes considering the Exchange Offers should consult its own tax advisor regarding the tax consequences of the Exchange Offers to it, including those under state, foreign and other tax laws, includinggift and estate tax laws, and any treaties.
175
TableofContents
PLAN OF DISTRIBUTION
ThedistributionofthisprospectusandtheofferandsaleoftheExchangeNotesmayberestrictedbylawincertainjurisdictions.PersonswhocomeintopossessionofthisprospectusoranyoftheExchangeNotesmustinformthemselvesaboutandobserveanysuchrestrictions.Youmustcomplywithallapplicablelawsandregulationsinforceinanyjurisdictioninwhichyoupurchase,offerorselltheExchangeNotesorpossessordistributethisprospectusand,inconnectionwithanypurchase,offerorsalebyyouoftheExchangeNotes,mustobtainanyconsent,approvalorpermissionrequiredunderthelawsandregulationsinforceinanyjurisdictiontowhichyouaresubjectorinwhichyoumakesuchpurchase,offerorsale.
InrelianceoninterpretationsofthestaffoftheSECsetforthinno-actionlettersissuedtothirdpartiesinsimilartransactions,webelievethattheExchangeNotesissuedintheExchangeOffersinexchangefortheOriginalNotesmaybeofferedforresale,resoldandotherwisetransferredbyholderswithoutcompliancewiththeregistrationandprospectusdeliveryprovisionsoftheSecuritiesAct,providedthattheExchangeNotesareacquiredintheordinarycourseofsuchholders'businessandtheholdersarenotengagedinanddonotintendtoengageinandhavenoarrangementorunderstandingwithanypersontoparticipateinadistribution(withinthemeaningoftheSecuritiesAct)ofExchangeNotes.Thispositiondoesnotapplytoanyholderthatis:
• an"affiliate"ofElancowithinthemeaningofRule405undertheSecuritiesAct;or
• abroker-dealer.
Allbroker-dealersreceivingExchangeNotesintheExchangeOffersaresubjecttoaprospectusdeliveryrequirementwithrespecttoresalesoftheExchangeNotes.Eachbroker-dealerreceivingExchangeNotesforitsownaccountintheExchangeOffersmustrepresentthattheOriginalNotestobeexchangedfortheExchangeNoteswereacquiredbyitasaresultofmarket-makingactivitiesorothertradingactivitiesandacknowledgethatitwilldeliveraprospectusmeetingtherequirementsoftheSecuritiesActinconnectionwithanyoffertoresell,resaleorotherretransferoftheExchangeNotespursuanttotheExchangeOffers.However,bysoacknowledgingandbydeliveringaprospectus,theparticipatingbroker-dealerwillnotbedeemedtoadmitthatitisan"underwriter"withinthemeaningoftheSecuritiesAct.Wehaveagreedthat,foraperiodendingupontheearlierof(i)180daysaftertheconsummationoftheExchangeOffersor(ii)orwhenallExchangeNoteshavebeensold,wewilluseallcommerciallyreasonableeffortstokeeptheexchangeofferregistrationstatementeffectiveandmakethisprospectus,asamendedorsupplemented,availabletoanybroker-dealerforuseinconnectionwithsuchresales.Todate,theSEChastakenthepositionthatbroker-dealersmayuseaprospectussuchasthisonetofulfilltheirprospectusdeliveryrequirementswithrespecttoresalesofExchangeNotesreceivedinanexchangesuchastheexchangepursuanttotheExchangeOffers,iftheOriginalNotesforwhichtheExchangeNoteswerereceivedintheexchangewereacquiredfortheirownaccountsasaresultofmarket-makingorothertradingactivities.
WewillnotreceiveanyproceedsfromanysaleoftheExchangeNotesbybroker-dealers.Broker-dealersacquiringExchangeNotesfortheirownaccountsmaysellthenotesinoneormoretransactionsintheover-the-countermarket,innegotiatedtransactions,throughwritingoptionsontheExchangeNotesoracombinationofsuchmethodsofresale,atmarketpricesprevailingatthetimeofresale,atpricesrelatedtosuchprevailingmarketpricesoratnegotiatedprices.Anysuchresalemaybemadedirectlytopurchasersortoorthroughbrokersordealerswhomayreceivecompensationintheformofcommissionsorconcessionsfromanysuchbroker-dealerand/orthepurchasersofsuchExchangeNotes.
Anybroker-dealerthatheldOriginalNotesacquiredforitsownaccountasaresultofmarket-makingactivitiesorothertradingactivities,thatreceivedExchangeNotesintheExchangeOffers,andthatparticipatesinadistributionofExchangeNotesmaybedeemedtobean"underwriter"withinthe
176
TableofContents
meaningoftheSecuritiesActandmustdeliveraprospectusmeetingtherequirementsoftheSecuritiesActinconnectionwithanyresaleoftheExchangeNotes.AnyprofitontheseresalesofExchangeNotesandanycommissionsorconcessionsreceivedbyabroker-dealerinconnectionwiththeseresalesmaybedeemedtobeunderwritingcompensationundertheSecuritiesAct.Theletteroftransmittalstatesthatbyacknowledgingthatitwilldeliverandbydeliveringaprospectus,abroker-dealerwillnotadmitthatitisan"underwriter"withinthemeaningoftheSecuritiesAct.
WehaveagreedtopayallexpensesincidentaltoourparticipationintheExchangeOffers,includingthereasonablefeesandexpensesofonecounselfortheholdersofOriginalNotesandtheinitialpurchasers,otherthancommissionsorconcessionsofanybroker-dealersandwillindemnifyholdersoftheOriginalNotes,includinganybroker-dealers,againstspecifiedtypesofliabilities,includingliabilitiesundertheSecuritiesAct.Wenote,however,thatintheopinionoftheSEC,indemnificationagainstliabilitiesunderfederalsecuritieslawsisagainstpublicpolicyandmaybeunenforceable.
177
TableofContents
LEGAL MATTERS
BryanCaveLeightonPaisnerLLP,St.Louis,Missouri,willpassuponthevalidityoftheexchangenotes.BryanCaveLeightonPaisnerLLPisrelyingupontheopinionofBarnes&ThornburgLLP,Indianapolis,Indiana,astocertainmattersofIndianalaw.
EXPERTS
Ernst&YoungLLP,independentregisteredpublicaccountingfirm,hasauditedElanco'sconsolidatedandcombinedfinancialstatementsasofDecember31,2018and2017,andforeachofthethreeyearsintheperiodendedDecember31,2018,assetforthinitsreport.Elanco'sfinancialstatementsareincludedinthisprospectusandelsewhereintheregistrationstatementinrelianceonErnst&YoungLLP'sreport,givenonsaidfirm'sauthorityasexpertsinaccountingandauditing.
SEC POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
InsofarasindemnificationforliabilitiesarisingundertheSecuritiesActmaybepermittedtodirectors,officersorpersonscontrollingtheregistrantpursuanttotheforegoingprovisions,theregistranthasbeeninformedthatintheopinionoftheSECsuchindemnificationisagainstpublicpolicyasexpressedintheSecuritiesActandisthereforeunenforceable.
178
TableofContents
INDEX TO FINANCIAL STATEMENTS
F-1
PageAudited Consolidated and Combined Financial Statements of Elanco Animal Health Incorporated: ReportofIndependentRegisteredPublicAccountingFirm F-2ConsolidatedandCombinedStatementsofOperationsfortheYearsEndedDecember31,2018,2017and2016 F-3ConsolidatedandCombinedStatementsofComprehensiveIncome(Loss)fortheYearsEndedDecember31,2018,2017and2016 F-4ConsolidatedandCombinedBalanceSheetsasofDecember31,2018and2017 F-5ConsolidatedandCombinedStatementsofEquityfortheYearsEndedDecember31,2018,2017and2016 F-6ConsolidatedandCombinedStatementofCashFlowsfortheYearsEndedDecember31,2018,2017and2016 F-7NotestoConsolidatedandCombinedFinancialStatements F-8
Unaudited Condensed Combined Financial Statements of Elanco Animal Health Incorporated:
UnauditedCondensedConsolidatedandCombinedStatementsofOperationsfortheThreeMonthsEndedMarch31,2019and2018 F-50UnauditedCondensedConsolidatedandCombinedStatementsofComprehensiveIncomefortheThreeMonthsEndedMarch31,2019and2018 F-51UnauditedCondensedConsolidatedandCombinedBalanceSheetsasofMarch31,2019andDecember31,2018 F-52UnauditedCondensedConsolidatedandCombinedStatementsofEquityfortheThreeMonthsEndedMarch31,2019and2018 F-53UnauditedCondensedConsolidatedandCombinedStatementsofCashFlowsfortheThreeMonthsEndedMarch31,2019and2018 F-54NotestoUnauditedCondensedConsolidatedandCombinedFinancialStatements F-55
TableofContents
Report of Independent Registered Public Accounting Firm
TotheShareholdersandtheBoardofDirectorsofElancoAnimalHealthIncorporated
Opinion on the Financial Statements
WehaveauditedtheaccompanyingconsolidatedandcombinedbalancesheetsofElancoAnimalHealthIncorporated(theCompany)asofDecember31,2018and2017,therelatedconsolidatedandcombinedstatementsofoperations,comprehensiveincome(loss),equity,andcashflowsforeachofthethreeyearsintheperiodendedDecember31,2018,andtherelatednotes(collectivelyreferredtoasthe"consolidatedandcombinedfinancialstatements").Inouropinion,theconsolidatedandcombinedfinancialstatementspresentfairly,inallmaterialrespects,thefinancialpositionoftheCompanyatDecember31,2018and2017,andtheresultsofitsoperationsanditscashflowsforeachofthethreeyearsintheperiodendedDecember31,2018,inconformitywithU.S.generallyacceptedaccountingprinciples.
Basis for Opinion
ThesefinancialstatementsaretheresponsibilityoftheCompany'smanagement.OurresponsibilityistoexpressanopinionontheCompany'sfinancialstatementsbasedonouraudits.WeareapublicaccountingfirmregisteredwiththePublicCompanyAccountingOversightBoard(UnitedStates)(PCAOB)andarerequiredtobeindependentwithrespecttotheCompanyinaccordancewiththeU.S.federalsecuritieslawsandtheapplicablerulesandregulationsoftheSecuritiesandExchangeCommissionandthePCAOB.
WeconductedourauditsinaccordancewiththestandardsofthePCAOB.Thosestandardsrequirethatweplanandperformtheaudittoobtainreasonableassuranceaboutwhetherthefinancialstatementsarefreeofmaterialmisstatement,whetherduetoerrororfraud.TheCompanyisnotrequiredtohave,norwereweengagedtoperform,anauditofitsinternalcontroloverfinancialreporting.AspartofourauditswearerequiredtoobtainanunderstandingofinternalcontroloverfinancialreportingbutnotforthepurposeofexpressinganopinionontheeffectivenessoftheCompany'sinternalcontroloverfinancialreporting.Accordingly,weexpressnosuchopinion.
Ourauditsincludedperformingprocedurestoassesstherisksofmaterialmisstatementofthefinancialstatements,whetherduetoerrororfraud,andperformingproceduresthatrespondtothoserisks.Suchproceduresincludedexamining,onatestbasis,evidenceregardingtheamountsanddisclosuresinthefinancialstatements.Ourauditsalsoincludedevaluatingtheaccountingprinciplesusedandsignificantestimatesmadebymanagement,aswellasevaluatingtheoverallpresentationofthefinancialstatements.Webelievethatourauditsprovideareasonablebasisforouropinion.
/s/Ernst&YoungLLP
WehaveservedastheCompany'sauditorsince2017.
Indianapolis,IndianaFebruary20,2019
F-2
TableofContents
Elanco Animal Health Incorporated
Consolidated and Combined Statements of Operations
(in millions, except per-share data)
Seenotestoconsolidatedandcombinedfinancialstatements.
F-3
Year Ended December 31, 2018 2017 2016 Revenue $ 3,066.8 $ 2,889.0 $ 2,913.5Costs,expensesandother: Costofsales 1,573.8 1,493.9 1,409.0Researchanddevelopment 246.6 251.7 265.8Marketing,sellingandadministrative 735.2 779.8 784.8Amortizationofintangibleassets 197.4 221.2 170.7Assetimpairments,restructuringandotherspecialcharges(Note7) 128.8 375.1 308.4Interestexpense,netofcapitalizedinterest 29.6 — —Other(income)expense,net 41.3 (0.1) (2.8)
2,952.7 3,121.6 2,935.9Income(loss)beforeincometaxes 114.1 (232.6) (22.4)Incometaxexpense 27.6 78.1 25.5
Netincome(loss) $ 86.5 $ (310.7) $ (47.9)Earnings(loss)pershare: Basicanddiluted $ 0.28 $ (1.06) $ (0.16)
Weightedaveragesharesoutstanding: Basicanddiluted 313.7 293.3 293.3
TableofContents
Elanco Animal Health Incorporated
Consolidated and Combined Statements of Comprehensive Income (Loss)
(in millions)
Seenotestoconsolidatedandcombinedfinancialstatements.
F-4
Year Ended December 31, 2018 2017 2016 Netincome(loss) $ 86.5 $ (310.7) $ (47.9)Othercomprehensiveincome(loss): Changeinforeigncurrencytranslationgains(losses) (47.1) 210.1 (230.7)Changeindefinedbenefitpensionandretireehealthbenefitplans,netoftaxes 25.4 (9.8) (4.3)
Othercomprehensiveincome(loss),netoftaxes (21.7) 200.3 (235.0)Comprehensiveincome(loss) $ 64.8 $ (110.4) $ (282.9)
TableofContents
Elanco Animal Health Incorporated
Consolidated and Combined Balance Sheets
(in millions)
Seenotestoconsolidatedandcombinedfinancialstatements.
F-5
December 31,
2018 December 31,
2017 Assets Current Assets Cashandcashequivalents $ 474.8 $ 323.4Accountsreceivable,netofallowancesof$8.4(2018)and$9.8(2017) 651.8 567.4Otherreceivables 57.6 34.5Inventories(Note8) 1,004.1 1,062.3Prepaidexpensesandother 113.9 136.1Restrictedcash(Note19) 202.7 —
Totalcurrentassets 2,504.9 2,123.7Noncurrent Assets Investments(Note10) 15.3 12.3Goodwill(Note11) 2,958.0 2,969.2Otherintangibles,net(Note11) 2,453.0 2,672.8Othernoncurrentassets 103.1 242.0Propertyandequipment,net(Note12) 922.4 920.3
Totalassets $ 8,956.7 $ 8,940.3Liabilities and Equity Current Liabilities Accountspayable $ 205.2 $ 203.8Employeecompensation 98.9 89.3Salesrebatesanddiscounts 169.9 165.5Currentportionoflongtermdebt 29.0 —Othercurrentliabilities 199.0 184.5PayabletoLilly(Note19) 268.7 —
Totalcurrentliabilities 970.7 643.1Noncurrent Liabilities Long-termdebt(Note9) 2,443.3 —Accruedretirementbenefits(Note17) 109.1 139.0Deferredtaxes(Note14) 114.6 251.9Othernoncurrentliabilities 121.5 126.0
Totalliabilities 3,759.2 1,160.0Commitments and Contingencies (Note 15) Equity Netparentcompanyinvestment — 8,036.9Commonstock,noparvalue,5,000,000,000sharesauthorized365,643,911sharesissuedandoutstandingasofDecember31,2018 — —Additionalpaid-incapital 5,403.3 —Retainedearnings 16.4 —Accumulatedothercomprehensiveloss (222.2) (256.6)
Totalequity 5,197.5 7,780.3Totalliabilitiesandequity $ 8,956.7 $ 8,940.3
TableofContents
Elanco Animal Health Incorporated
Consolidated and Combined Statements of Equity
(in millions)
Seenotestoconsolidatedandcombinedfinancialstatements.
F-6
Accumulated Other Comprehensive
Income (Loss)
Common Stock
Defined Benefit Pension and
Retiree Health Benefit Plans
Additional Paid-in Capital
Net Parent Company Investment
Retained Earnings
Foreign Currency
Translation
Total Equity
Shares Amount Total January1,2016 293.3 $ — $ — $ 7,651.4 $ — $ (206.6) $ (15.3) $ (221.9) $ 7,429.5Netloss — — — (47.9) — — — — (47.9)Othercomprehensiveincome,netoftax — — — — — (230.7) (4.3) (235.0) (235.0)Transfers(to)/fromLilly,net — — — (129.2) — — — — (129.2)
December31,2016 293.3 — — 7,474.3 — (437.3) (19.6) (456.9) 7,017.4Net(loss) — — — (310.7) — — — — (310.7)Othercomprehensiveincome(loss),netoftax — — — — — 210.1 (9.8) 200.3 200.3Transfers(to)/fromLilly,net — — — 873.3 — — — — 873.3
December31,2017 293.3 — — 8,036.9 — (227.2) (29.4) (256.6) 7,780.3AdoptionofAccountingStandardsUpdate2016-16 — — — (0.3) — — — — (0.3)Netincome — — — 70.1 16.4 — — 86.5Othercomprehensiveincome(loss),netoftax — — — — — (47.1) 25.4 (21.7) (21.7)Transfers(to)/fromLilly,net — — — (226.3) — — — — (226.3)Separationadjustments — — — 43.5 — 56.1 — 56.1 99.6Issuanceofcommonstock 72.3 — 1,659.7 — — — — — 1,659.7ConsiderationtoLillyinconnectionwiththeSeparation — — (4,194.9) — — — — — (4,194.9)Reclassificationofnetparentcompanyinvestment — — 7,923.9 (7,923.9) — — — — —Sharedbasecompensation — — 1.8 — — — — — 1.8CapitalcontributionfromLilly — — 12.8 — — — — — 12.8December31,2018 365.6 $ — $ 5,403.3 $ — $ 16.4 $ (218.2) $ (4.0) $ (222.2) $ 5,197.5
TableofContents
Elanco Animal Health Incorporated
Consolidated and Combined Statement of Cash Flows
(in millions)
Seenotestoconsolidatedandcombinedfinancialstatements.
F-7
Year Ended December 31, 2018 2017 2016 Cash Flows from Operating Activities Netincome(loss) $ 86.5 $ (310.7) $ (47.9)Adjustmentstoreconcilenetincome(loss)tocashflowsfromoperatingactivities: Depreciationandamortization 296.0 318.4 254.4Changeindeferredincometaxes (60.7) (13.4) (5.9)Stock-basedcompensationexpense 26.0 25.0 20.4Assetimpairmentcharges 120.5 110.6 98.3Gainonsaleofassets (0.8) (19.6) —Othernon-cashoperatingactivities,net 49.0 10.0 6.0Otherchangesinoperatingassetsandliabilities,netofacquisitionsanddivestitures: Receivables (122.0) 48.4 (80.7)Inventories (20.1) (39.0) (89.1)Otherassets (3.2) 52.5 (36.7)Accountspayableandotherliabilities 116.1 (8.4) 37.1
Net Cash Provided by Operating Activities 487.3 173.8 155.9Cash Flows from Investing Activities
Purchasesofpropertyandequipment (134.5) (98.6) (110.3)Disposalsofpropertyandequipment 9.4 37.6 7.4Cashpaidforacquisitions,netofcashacquired — (882.1) (45.0)Otherinvestingactivities,net (1.9) (21.5) (34.2)
Net Cash Used for Investing Activities (127.0) (964.6) (182.1)Cash Flows from Financing Activities
Proceedsfromissuanceoflong-termdebt(Note9) 2,500.0 — —Repaymentsofborrowings (7.5) — —Proceedsfromissuanceofcommonstock(Note1) 1,659.7 — —Debtissuancecosts (24.5) — —ConsiderationpaidtoLillyinconnectionwiththeSeparation(Note1) (3,991.3) — —Otherfinancingactivities,net (17.2) (0.8) —OthernettransactionswithLilly (154.4) 848.3 (149.6)
Net Cash Provided by (Used for) Financing Activities (35.2) 847.5 (149.6)Effectofexchangeratechangesoncashandcashequivalents 29.0 7.9 (26.0)Netincreaseincash,cashequivalentsandrestrictedcash 354.1 64.6 (201.8)Cash,cashequivalentsandrestrictedcashatJanuary1 323.4 258.8 460.6Cash, cash equivalents and restricted cash at December 31 $ 677.5 $ 323.4 $ 258.8
December 31, 2018 2017 Cash and cash equivalents $ 474.8 $ 323.4Restricted cash (Note 19) 202.7 —Cash, cash equivalents and restricted cash at December 31 $ 677.5 $ 323.4
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1. Nature of Business and Organization
Nature of Business
ElancoAnimalHealthIncorporated(ElancoParent)anditssubsidiaries(collectively,Elanco,theCompany,we,usorour)wasformedasawholly-ownedsubsidiaryofEliLillyandCompany(Lilly).Elancoisaglobalanimalhealthcompanythatinnovates,develops,manufacturesandmarketsproductsforcompanionandfoodanimals.Weofferadiverseportfolioofmorethan125brandstoveterinariansandfoodanimalproducersinmorethan90countries.
Organization
ElancoParentwasformedin2018,asawholly-ownedsubsidiaryofLilly,toserveastheultimateparentcompanyofsubstantiallyalloftheanimalhealthbusinessesofLilly.
OnSeptember24,2018,ElancoParentcompletedaninitialpublicofferingresultingintheissuanceof72.3millionsharesofitscommonstock(includingsharesissuedpursuanttotheunderwriters'optiontopurchaseadditionalshares),whichrepresents19.8%oftheoutstandingshares,at$24pershare(IPO)foratotalnetproceeds,afterunderwritingdiscountsandcommissions,of$1.7billion.InconnectionwiththecompletionoftheIPO,throughaseriesofequityandothertransactions,LillytransferredtoElancoParenttheanimalhealthbusinessesthatformitsbusinessgoingforward.InexchangeElancoParenthaspaid,orwillpay,toLillyapproximately$4.2billion,whichincludesthenetproceedsfromtheIPO,thenetproceedsfromthedebtofferingcompletedbyElancoParentinAugust2018andthetermloanfacilityenteredintobyElancoParentinSeptember2018(seeNote9).AsofDecember31,2018,ElancoParenthaspaidLilly$4.0billionwiththeremainingpurchasepricereflectedinPayabletoLillyonthebalancesheet.ThesetransactionsarecollectivelyreferredtohereinastheSeparation.
Note 2. Basis of Presentation
TheaccompanyingconsolidatedandcombinedfinancialstatementshavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedintheUnitedStates(GAAP).Theaccountsofallwholly-ownedandmajority-ownedsubsidiariesareincludedintheconsolidatedfinancialstatements.Allintercompanybalancesandtransactionshavebeeneliminated.
ThepreparationoffinancialstatementsinconformitywithGAAPrequiresmanagementtomakeestimatesandassumptionsthataffectthereportedamountsofassets,liabilities,revenues,expenses,andrelateddisclosuresatthedateofthefinancialstatementsandduringthereportingperiod.Actualresultscoulddifferfromthoseestimates.WeissuedourfinancialstatementsbyfilingwiththeSecuritiesandExchangeCommissionandhaveevaluatedsubsequenteventsuptothetimeofthefiling.
DuringtheperiodendedDecember31,2018,certaincombinedbalancesheetamountsrelatedtotheprioryearhavebeenrevisedtocorrectthesalesrebatesanddiscountsliability,whichdidnotcorrectlyreflectanaccrualforrebatesrelatedtoproductheldinthewholesalers'pipeline.InaccordancewithSecuritiesandExchangeCommissionStaffAccountingBulletinNo.99,Materiality ,andAccountingStandardsCodification(ASC)250,Presentation of Financial Statements ,weassessedthematerialityofthiscorrectionandconcludedthattheaccrualfortherebaterelatedtoproductheldinthewholesalers'pipelinewasnotmaterialtopriorperiods,andtherefore,amendmentsofpreviouslyfiledreportsarenotrequired.
F-8
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 2. Basis of Presentation (Continued)
Assuch,inaccordancewithASC250,werevisedthepreviouslyreportedcombinedbalancesheetandcombinedstatementsofequity.Theadjustment,whichoriginatesinperiodspriortothosepresented,resultedina$10.5millionincreaseasofDecember31,2017intheaccrualforsalesrebatesanddiscountsof$155.0million,totalcurrentliabilitiesof$632.6millionandtotalliabilitiesof$1,149.5million.Inaddition,previouslyreportedamountsatDecember31,2017andDecember31,2016ofnetparentcompanyinvestmentof$8,047.4millionand$7,484.8million,respectively,andtotalequityof$7,790.8millionand$7,027.9million,respectively,havebeenreducedby$10.5milliontoreflectthecorrectionabove.
Fortheperiodsafterseparation,thefinancialstatementsarepreparedonaconsolidatedbasisandreflecttheresultsofoperations,comprehensiveincome,financialposition,equityandcashflowsresultingfromouroperationsasanindependentcompany.ForperiodspriortotheSeparation,ourfinancialstatementsarecombined,havebeenpreparedonastandalonebasis,andarederivedfromLilly'sconsolidatedfinancialstatementsandaccountingrecords.Theconsolidatedandcombinedfinancialstatementsreflectthefinancialposition,resultsofoperationsandcashflowsrelatedtotheanimalhealthbusinessesthatweretransferredtoElancoParentandarepreparedinconformitywithGAAP.
ThecombinedfinancialstatementsincludetheattributionofcertainassetsandliabilitiesthathistoricallyhavebeenheldattheLillycorporatelevelbutwhicharespecificallyidentifiableorattributabletothebusinessesthathavebeentransferredtoElancoParent.AllintercompanytransactionsandaccountswithinElancohavebeeneliminated.AlltransactionsbetweenusandLillyareconsideredtobeeffectivelysettledinthecombinedfinancialstatementsatthetimetheintercompanytransactionisrecorded.Thetotalneteffectofthesettlementoftheseintercompanytransactionsisreflectedinthecombinedstatementsofcashflowsasafinancingactivityandinthecombinedbalancesheetsasnetparentcompanyinvestment.
Priortotheseparation,thesecombinedfinancialstatementsincludeanallocationofexpensesrelatedtocertainLillycorporatefunctions,includingexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations,priortoIPO.Theseexpenseshavebeenallocatedtousbasedondirectusageorbenefitwherespecificallyidentifiable,withtheremainderallocatedprimarilyonaproratabasisofrevenue,headcountandothermeasures.Weconsidertheexpensesmethodologyandresultstobereasonableforallperiodspresented.However,theallocationsmaynotbeindicativeoftheactualexpensethatwouldhavebeenincurredhadweoperatedasanindependent,publiclytradedcompanyfortheperiodspresented.ItisimpracticaltoestimatewhatthestandalonecostsofElancowouldhavebeeninthehistoricalperiods.Aftertheseparation,aTSAbetweenLillyandElancowentintoeffect.UnderthetermsoftheTSA,wewillbeabletouseLillyServicesforafixedtermestablishedonaservice-by-servicebasis.WearepayingLillymutuallyagreeduponfeesfortheLillyServicesprovidedundertheTSA.OurconsolidatedandcombinedfinancialstatementsreflectthechargesforLillyServicesaftertheIPO.SeeNote19foradditionaldetails.
Theincometaxamountsinthecombinedfinancialstatementshavebeencalculatedbasedonaseparatereturnmethodologyandpresentedasifouroperationswereseparatetaxpayersintherespectivejurisdictions.WefileincometaxreturnsintheUnitedStates(U.S.)federaljurisdictionand
F-9
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 2. Basis of Presentation (Continued)
variousstate,localandnon-U.S.jurisdictions.CertainoftheseincometaxreturnsarefiledonaconsolidatedorcombinedbasiswithEliLillyandCompanyand/oritssubsidiaries.
Lillymaintainsvariousbenefitandcombinedstock-basedcompensationplansatacorporatelevelandotherbenefitplansatacountrylevel.Ouremployeesparticipateinsuchprogramsandtheportionofthecostofthoseplansrelatedtoouremployeesisincludedinourfinancialstatements.However,theconsolidatedandcombinedbalancesheetsdonotincludeanyequityissuedrelatedtostock-basedcompensationplansoranynetbenefitplanobligationsunlessthebenefitplancoversonlyourdedicatedemployeesorwherethelegalobligationassociatedwiththebenefitplanwilltransfertoElanco.
PriortoSeparation,theequitybalanceinthecombinedfinancialstatementsrepresentstheexcessoftotalassetsoverliabilities,includingintercompanybalancesbetweenusandLilly(netparentcompanyinvestment)andaccumulatedothercomprehensiveloss.NetparentcompanyinvestmentisprimarilyimpactedbycontributionsfromLillywhicharetheresultoftreasuryactivitiesandnetfundingprovidedbyordistributedtoLilly.SeeNote19forfurtherinformation.
Note 3. Impact of Separation
InconnectionwiththeSeparation,weissued$2.0billionaggregateprincipalamountofseniornotesinaprivateplacement,andwealsoenteredintoa$750.0millionseniorunsecuredrevolvingcreditfacilityand$500.0millionseniorunsecuredtermcreditfacility.SeeNote9forfurtherinformation.
InconnectionwiththeSeparation,weenteredintovariousagreementswithLilly,includingamasterseparationagreement.InconnectionwiththetermsoftheSeparation,therewerecertainassetsandliabilitiesincludedinthepre-SeparationbalancesheetthatwereretainedbyLillyandtherewerecertainassetsnotincludedinthepre-Separationbalancesheetthatweretransferredtous.Thecumulativeadjustmenttothehistoricalbalancesheetincreasednetassetsandtotalequitybyapproximately$99.6million.Theimpactonnetassetsprimarilyrepresenttheeliminationofcertainincometaxassetsandliabilitiesandthecontributionofadditionalassets.
OnFebruary8,2019,wefiledaRegistrationStatementonFormS-4withtheSECinconnectionwithLilly'sproposedexchangeoffer,wherebyLillyshareholderscanexchangesharesofLillycommonstockforsharesofourcommonstockownedbyLilly(exchangeoffer).Immediatelybeforethecommencementoftheexchangeoffer,Lillyowned293,290,000sharesofourcommonstock,representing80.2%ofouroutstandingcommonstock.Iftheexchangeofferisnotfullysubscribed,Lillyintends,fromtimetotime,tocompletesubsequentexchangeoffersand/oraprorataspin-offofitsremaininginterestinElancoParent.
Note 4. Summary of Significant Accounting Policies
Revenue recognition
Werecognizerevenuefromsalesofproductsatthetimetitleofgoodspassestothebuyerandthebuyerassumestherisksandrewardsofownership.Provisionsforreturns,discountsandrebatesareestablishedinthesameperiodtherelatedsalesarerecognized.Forarrangementswithcontract
F-10
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 4. Summary of Significant Accounting Policies (Continued)
manufacturingorganizations(CMO),werecognizerevenueovertimeoratapointintimedependingonitsevaluationofwhenthecustomerobtainscontrolofthepromisedgoodsorservice.Revenueisrecognizedovertimewhenwearecreatingorenhancinganassetthatthecustomercontrolsastheassetiscreatedorenhancedorourperformancedoesnotcreateanassetwithanalternativeuseandwehaveanenforceablerighttopaymentforperformancecompleted.
Research and development expenses and acquired in-process research and development
Researchanddevelopmentexpensesincludethefollowing:
• Researchanddevelopmentcosts,whichareexpensedasincurred.
• Milestonepaymentobligationsincurredpriortoregulatoryapprovaloftheproduct,whichareaccruedwhentheeventrequiringpaymentofthemilestoneoccurs.
• Acquiredin-processresearchanddevelopment(IPR&D)expense,whichincludestheinitialcostsofIPR&Dprojects,acquireddirectlyinatransactionotherthanabusinesscombinationthatdonothaveanalternativefutureuse.
Foreign Currency Translation
OperationsinoursubsidiariesoutsidetheUnitedStates(U.S.)arerecordedinthefunctionalcurrencyofeachsubsidiarywhichisdeterminedbyareviewoftheenvironmentwhereeachsubsidiaryprimarilygeneratesandexpendscash.TheresultsofoperationsforoursubsidiariesoutsidetheU.S.aretranslatedfromfunctionalcurrenciesintoU.S.dollarsusingtheweightedaveragecurrencyratefortheperiod.Assetsandliabilitiesaretranslatedusingtheperiodendexchangerates.TheU.S.dollareffectsthatarisefromtranslatingthenetassetsofthesesubsidiariesarerecordedinothercomprehensiveincome(loss).
Other significant accounting policies
Ourothersignificantaccountingpoliciesaredescribedintheremainingappropriatenotestothecombinedfinancialstatements.
F-11
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 4. Summary of Significant Accounting Policies (Continued)
Implementation of New Financial Accounting Pronouncements
ThefollowingtableprovidesabriefdescriptionofaccountingstandardsthatwereeffectiveJanuary1,2018andwereadoptedonthatdate:
F-12
Standard Description Effect on the financial statements
or other significant mattersAccountingStandardsUpdate2014-09andvariousotherrelatedupdates,Revenue from Contracts with Customers
Thisstandardreplacedexistingrevenuerecognitionstandardsandrequiresentitiestorecognizerevenuetodepictthetransferofpromisedgoodsorservicestocustomersinanamountthatreflectstheconsiderationtowhichtheentityexpectstobeentitledinexchangeforthosegoodsorservices.Anentitycanapplythenewrevenuestandardretrospectivelytoeachpriorreportingperiodpresentedorwiththecumulativeeffectofinitiallyapplyingthestandardrecognizedatthedateofinitialapplicationinretainedearnings.Weappliedthelatterapproach.
ApplicationofthenewstandardtoapplicablecontractshadnoimpacttonetparentcompanyinvestmentasofJanuary1,2018.DisclosuresrequiredbythenewstandardareincludedinNote5.
AccountingStandardsUpdate2016-16,Income Taxes: Intra-EntityTransfers of Assets Other Than Inventory
Thisstandardrequiresentitiestorecognizetheincometaxconsequencesofintra-entitytransfersofassetsotherthaninventoryatthetimeoftransfer.Thisstandardrequiresamodifiedretrospectiveapproachtoadoption.
Uponadoption,thecumulativeeffectofapplyingthestandardresultedinadecreasetonetparentcompanyinvestmentofapproximately$0.3million.AdoptionofthisstandarddidnotresultinamaterialchangeinnetincomeforthetwelvemonthsendedDecember31,2018.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 4. Summary of Significant Accounting Policies (Continued)
F-13
Standard Description Effect on the financial statements
or other significant mattersAccountingStandardsUpdate2017-07,Compensation-Retirement
Benefits: Improving the Presentation of Net Periodic Pension Costand Net Periodic Postretirement Benefit Cost
Thisstandardwasissuedtoimprovethetransparencyandcomparabilityamongorganizationsbyrequiringentitiestoseparatetheirnetperiodicpensioncostandnetperiodicpostretirementbenefitcostintoaservicecostcomponentandothercomponents.Previously,thecostsoftheothercomponentsalongwiththeservicecostcomponentwereclassifiedbaseduponthefunctionoftheemployee.Thisstandardrequiresentitiestoclassifytheservicecostcomponentinthesamefinancialstatementlineitemoritemsasothercompensationcostsarisingfromservicesrenderedbypertinentemployees.Theothercomponentsofnetbenefitcostarenowpresentedseparatelyfromthelineitemsthatincludetheservicecostcomponent.Whenapplicable,theservicecostcomponentisnowtheonlycomponenteligibleforcapitalization.Anentityshouldapplythenewstandardretrospectivelyfortheclassificationoftheservicecostandothercomponentsandprospectivelyforthecapitalizationoftheservicecostcomponent.
Uponadoptionofthisstandard,pensionandpostretirementbenefitcostcomponentsotherthanservicecostsarepresentedinother(income)expense,net.RetrospectiveapplicationwasnotmaterialtothecombinedstatementofoperationsforthetwelvemonthsendedDecember31,2017.Wedonotexpectapplicationofthenewstandardtohaveamaterialimpactonanongoingbasis.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 4. Summary of Significant Accounting Policies (Continued)
F-14
Standard Description Effect on the financial statements
or other significant mattersAccountingStandardsUpdate2017-12,Derivatives and Hedging Thisstandardamendsthehedgeaccountingrecognitionand
presentationrequirementsandisintendedtobetteralignhedgeaccountingwithcompanies'riskmanagementstrategies.Thisstandardeliminatestherequirementstoseparatelymeasureandreporthedgeineffectivenessandgenerallyrequiresthattheentirechangeinfairvalueofahedginginstrumentbepresentedinthesameincomestatementlineitemastherespectivehedgeditem.Thestandardalsomodifiescertaindisclosurerequirements.
WeelectedtoearlyadoptthisguidanceasofJanuary1,2018.Therewerenohedgingcontractsineffectasofthedateofadoption.Wedonotexpectapplicationofthenewstandardtohaveamaterialimpactonanongoingbasis.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 4. Summary of Significant Accounting Policies (Continued)
Thefollowingtableprovidesabriefdescriptionoftheaccountingstandardthathasnotyetbeenadoptedandcouldhaveamaterialeffectontheconsolidatedfinancialstatements:
Note 5. Revenue
EffectiveJanuary1,2018,weadoptedAccountingStandardsUpdate2014-09,Revenue from Contracts with Customers (ASU2014-09)andotherrelatedupdates.Thenewstandardhasbeenappliedtocontractsforwhichperformancehadnotbeencompletedasofthedateofadoption.Revenuepresentedforperiodspriorto2018wereaccountedforunderpreviousstandardsandhasnotbeenadjusted.RevenueandnetincomefortheyearendedDecember31,2018doesnotdiffermateriallyfromamountsthatwouldhaveresultedfromapplicationofthepreviousstandards.
F-15
Standard Description Effective Date
Effect on the financial statements or other significant matters
AccountingStandardsUpdate2016-02,Leases Thisstandardwasissuedtoincreasetransparencyandcomparabilityamongorganizationsbyrecognizingleaseassetsandleaseliabilities,includingleasesclassifiedasoperatingleasesundercurrentGAAP,onthebalancesheetandrequiringadditionaldisclosuresaboutleasingarrangements.Anentitycanapplythenewleasesstandardretrospectivelytoeachpriorreportingperiodpresentedorwiththecumulativeeffectofinitiallyapplyingthestandardrecognizedatthedateofinitialapplicationinretainedearnings.Weplantousethelatterapproach.
ThisstandardiseffectiveJanuary1,2019,withearlyadoptionpermitted.Weintendtoadoptthisstandardonthatdate.
Weexpecttorecordaright-of-useassetandleaseliabilityforoperatingleasesofapproximately$75-95milliononourconsolidatedbalancesheetonJanuary1,2019.Ouraccountingforcapitalleaseswillremainsubstantiallyunchanged.Thisstandardwillnothaveamaterialimpactonourconsolidatedstatementofoperations.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 5. Revenue (Continued)
Product Sales
Werecognizerevenueprimarilyfromproductsalestocustomers.Revenuefromsalesofproductsisrecognizedatthepointwherethecustomerobtainscontrolofthegoodsandwesatisfyourperformanceobligation,whichgenerallyisatthetimeweshiptheproducttothecustomer.Paymenttermsdifferbyjurisdictionandcustomer,butpaymenttermsinmostofourmajorjurisdictionstypicallyrangefrom30to100daysfromdateofshipment.Revenueforourproductsaleshasnotbeenadjustedfortheeffectsofafinancingcomponentasweexpect,atcontractinception,thattheperiodbetweenwhenwetransfercontroloftheproductandwhenwereceivepaymentwillbeoneyearorless.Anyexceptionsareeithernotmaterialorwecollectinterestforpaymentsmadeaftertheduedate.Provisionsforrebatesanddiscounts,andreturnsareestablishedinthesameperiodtherelatedsalesarerecognized.Wegenerally,shipproductshortlyafterordersarereceived;therefore,wegenerallyonlyhaveafewdaysofordersreceivedbutnotyetshippedattheendofanyreportingperiod.Shippingandhandlingactivitiesareconsideredtobefulfillmentactivitiesandarenotconsideredtobeaseparateperformanceobligation.Weexcludefromthemeasurementofthetransactionpricealltaxesassessedbyagovernmentalauthoritythatareimposedonoursalesofproductandcollectedfromacustomer.
Significantjudgmentsmustbemadeindeterminingthetransactionpriceforsalesofproductsrelatedtoanticipatedrebatesanddiscounts,andreturns.Thefollowingdescribethemostsignificantofthesejudgments:
Sales Rebates and Discounts—Background and Uncertainties
• Mostofourproductsaresoldtowholesaledistributors.Weinitiallyinvoiceourcustomerscontractuallistprices.Contractswithdirectandindirectcustomersmayprovideforvariousrebatesanddiscountsthatmaydifferineachcontract.Asaconsequence,todeterminetheappropriatetransactionpriceforourproductsalesatthetimewerecognizeasaletoadirectcustomer,wemustestimateanyrebatesordiscountsthatultimatelywillbeduetothedirectcustomerandothercustomersinthedistributionchainunderthetermsofourcontracts.Significantjudgmentsarerequiredinmakingtheseestimates.
• Therebateanddiscountamountsarerecordedasadeductiontoarriveatournetproductsales.Weestimatetheseaccrualsusinganexpectedvalueapproach.
• Indeterminingtheappropriateaccrualamount,weconsiderourhistoricalexperiencewithsimilarincentivesprogramsandcurrentsalesdatatoestimatetheimpactofsuchprogramsonrevenueandcontinuallymonitortheimpactofthisexperienceandadjustasnecessary.Althoughweaccruealiabilityforrebatesrelatedtotheseprogramsatthetimethesaleisrecorded,therebaterelatedtothatsaleistypicallypaiduptosixmonthsafterrebateorincentiveperiodexpires.Becauseofthistimelag,inanyparticularperiodrebateadjustmentsmayincorporaterevisionsofaccrualsforseveralperiods.
OursalesrebatesanddiscountsarebasedonspecificagreementsandthemajorityrelatetosalesintheU.S.AsofDecember31,2018and2017,liabilityforsalesrebatesanddiscountsintheU.S.representsapproximately70%and69%,respectively,ofourtotalliabilitywiththenextlargestcountryrepresentingapproximately8%ofourtotalliabilityfor2018and2017.
F-16
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 5. Revenue (Continued)
ThefollowingtablesummarizestheactivityinthesalesrebatesanddiscountsliabilityintheU.S.:
AdjustmentstorevenuerecognizedasaresultofchangesinestimatesforthejudgmentsdescribedaboveduringtheyearendedDecember31,2018forproductshippedinpreviousperiodswerenotmaterial.
Sales Returns—Background and Uncertainties
• Weestimateareserveforfutureproductreturnsrelatedtoproductsalesusinganexpectedvalueapproach.Thisestimateisbasedonseveralfactors,including:localreturnspoliciesandpractices;returnsasapercentageofrevenue;anunderstandingofthereasonsforpastreturns;estimatedshelflifebyproduct;andestimateoftheamountoftimebetweenshipmentandreturn.Adjustmentstothereturnsreservehavebeenandmayinthefutureberequiredbasedonrevisedestimatestoourassumptions,whichwouldhaveanimpactonourconsolidatedresultsofoperations.Werecordthereturnamountsasadeductiontoarriveatournetproductsales.
• Actualproductreturnshavebeenapproximately1%ofnetrevenuefortheyearendedDecember31,2018and2017andhavenotfluctuatedsignificantlyasapercentageofrevenue.
Disaggregation of Revenue
ThefollowingtablesummarizesourrevenuedisaggregatedbyproductcategoryfortheyearsendedDecember31:
Note 6. Acquisitions
During2017and2016,wecompletedtheacquisitionsofBIVIVPandcertainrightstoAratanaTherapeutics,Inc.'s(Aratana)Galliprant®,respectively.Thesetransactionswereaccountedforas
F-17
Year Ended December 31,
2018 2017 Beginningbalance $ 114.8 $ 116.1Reductionofrevenue 221.0 236.1Payments (217.3) (237.4)
Endingbalance $ 118.5 $ 114.8
2018 2017 2016 CompanionAnimalDiseasePrevention $ 804.6 $ 660.2 $ 628.4CompanionAnimalTherapeutics 283.1 260.8 255.6FoodAnimalFutureProtein&Health 711.2 649.2 630.8FoodAnimalRuminants&Swine 1,174.0 1,175.0 1,309.2Other 93.9 143.8 89.5
TotalRevenue $ 3,066.8 $ 2,889.0 $ 2,913.5
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 6. Acquisitions (Continued)
businesscombinationsundertheacquisitionmethodofaccounting.Underthismethod,theassetsacquiredandliabilitiesassumedwererecordedattheirrespectivefairvaluesasoftheacquisitiondateinourcombinedfinancialstatements.Thedeterminationofestimatedfairvaluerequiredmanagementtomakesignificantestimatesandassumptions.Theexcessofthepurchasepriceoverthefairvalueoftheacquirednetassets,whereapplicable,hasbeenrecordedasgoodwill.Theresultsofoperationsoftheseacquisitionsareincludedinourconsolidatedandcombinedfinancialstatementsfromthedatesofacquisition.
Boehringer Ingelheim Vetmedica, Inc. Vaccine Portfolio Acquisition
OnJanuary3,2017,weacquiredBIVIVPinacashtransactionfor$882.1million.Underthetermsoftheagreement,weacquiredamanufacturingandresearchanddevelopmentsite,aU.S.vaccineportfolioincludingvaccinesusedforthetreatmentofbordetella,Lymedisease,rabiesandparvovirus,amongothers.
Thefollowingtablesummarizestheamountsrecognizedforassetsacquiredandliabilitiesassumedasoftheacquisitiondate:
OurcombinedstatementofoperationsfortheyearendedDecember31,2017includedBIVIVPrevenuesof$216.7million.WeareunabletoprovidetheresultsofoperationsattributabletoBIVIVPasthoseoperationsweresubstantiallyintegratedintoourlegacybusiness.
F-18
Estimated Fair Value at January 3, 2017 Inventories(1) $ 108.6Marketedproducts(2) 297.0Propertyandequipment 148.2Otherassetsandliabilities—net 8.2Totalidentifiablenetassets 562.0Goodwill(3) 320.1Totalconsiderationtransferred—netofcashacquired $ 882.1
(1) Thefairvalueforinventoriesincludeapurchaseaccountingadjustmenttowriteuptheinventoryvalue,whichresultedinincrementalcostofsalesof$42.7millionin2017.Thefairvaluewasdeterminedbyestimatingtheexpectedsalespriceoftheinventories,reducedforallcostsexpectedtotheincurredandaprofitonthosecosts.
(2) Theseintangibleassets,whicharebeingamortizedonastraight-linebasisovertheirestimatedusefullives,wereexpectedtohaveaweightedaverageusefullifeof10years.
(3) ThegoodwillrecognizedfromthisacquisitionisattributableprimarilytoexpectedsynergiesfromcombiningtheoperationsofBIVIVPwithourlegacybusiness,futureunidentifiedprojectsandproducts,andtheassembledworkforceofBIVIVP.Thegoodwillassociatedwiththisacquisitionisdeductiblefortaxpurposes.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 6. Acquisitions (Continued)
HadBIVIVPbeenacquiredonJanuary1,2016,theunauditedproformacombinedrevenuesofElancoandBIVIVPwouldhavebeen$2.89billionand$3.14billionfortheyearsendedDecember31,2017and2016,respectively.ItisimpracticaltodeterminetheproformaimpactonlossbeforetaxattributabletoBIVIVPfor2017and2016.
Galliprant Acquisition
OnApril22,2016,weacquiredfromAratana,certainrightstoGalliprant,acaninepaintreatmentforosteoarthritisforatotalpurchasepriceof$88.6million,whichconsistedofanupfrontpaymentof$45.0millionandcontingentconsiderationof$43.6million.ThecontingentconsiderationrepresentedthefairvalueofpotentialfuturepaymentstoAratanabasedontheprobabilityofachievingcontingentmilestonesandroyalties.Atthetimeoftheacquisition,GalliprantwasapprovedintheU.S.andwasstillunderdevelopmentoutsidetheU.S.
Underthetermsoftheagreement,weweregrantedco-promotionrightsintheU.S.throughDecember31,2018,atwhichtimewewillcontrolcommercializationintheU.S.WereceivedfullcommercializationrightsoutsidetheU.S.TheagreementrequirespaymentsbyustoAratanaassociatedwithcertaindevelopment,success-basedregulatoryandsales-basedmilestonesandroyalties.AsofDecember31,2018,Aratanaiseligibletoreceiveupto$8.0millionofpotentialdevelopmentandsuccess-basedregulatorymilestones.Aratanaisalsoeligibletoreceiveupto$60.0millionofpotentialsales-basedmilestones.AratanaiseligibletoreceiveroyaltiesbasedonapercentageofnetsalesofGalliprant,dependentonthetimingandgeographyofthenetsales.Thereisnocapontheamountofroyaltiesthatmaybepaidpursuanttothisarrangement.AsofDecember31,2018,wepaidAratana$15millionrelatedtoasales-basedmilestone.
Thefollowingtablesummarizestheamountsrecognizedforassetsacquiredandliabilitiesassumedasoftheacquisitiondate:
F-19
Estimated Fair Value at April 22, 2016 Deferredtaxassets $ 15.3Acquiredin-processresearchanddevelopment 31.6Marketedproducts(1) 57.0Deferredtaxliabilities (15.3)Totalconsideration 88.6Less:Contingentconsideration (43.6)Totalcashpaid $ 45.0
(1) Theseintangibleassets,whicharebeingamortizedonastraight-linebasisovertheirestimatedusefullives,wereexpectedtohaveaweightedaverageusefullifeof20years.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 7. Asset Impairment, Restructuring and Other Special Charges
TheCompany'stotalchargesrelatedtoassetimpairment,restructuringandotherspecialcharges,includingintegrationofacquiredbusinesses,inourconsolidatedandcombinedstatementsofoperationsconsistedofthefollowingfortheyearsendedDecember31:
Restructuring
WehistoricallyparticipatedinLilly'scost-reductioninitiatives,whichresultedinrestructuringchargesintheperiodpriortoourIPO.Therestructuringchargesincludeseveranceandothercostsassociatedwiththereductionofourworkforce,includingspecialterminationbenefitsrecognizedin2017associatedwiththeU.S.voluntaryearlyretirementprogramofferedbyLilly,relatedtoouremployeesandpensioncurtailmentcostsandfacilityexitcosts.Wealsorecordedcertainimpairmentchargesrelatedtotheactivitiesasdescribedbelow.
DuringDecember2018,weinitiatedarestructuringprogramtostreamlineourinternationaloperations,includingshiftingfocusandresourcestopriorityareas.Amongotheractions,therestructuringreflectsachangefromhavingaphysicallocationtoadistributionmodelincertaincountriesinconnectionwithourseparationfromLillyandresultedintherecognitionofseverancecosts.Inaddition,aspartofourongoingactivitiestoseparatefullyfromLilly,wewroteoffcertainassetsthatwehavedeterminedwillnotbeutilizedinthebusinessonanongoingbasis.WeexpecttosubstantiallycompletetherestructuringactivitiesbyDecember2019.
Integration costs
IntegrationcostsrecognizedduringtheyearsendedDecember31,2018,2017and2016wererelatedtoourintegrationeffortsasaresultofouracquiredbusinessesandcoststostandourorganizationuptobeanindependentcompany.
Asset impairment
AssetimpairmentrecognizedduringtheyearendedDecember31,2018includes$22.5millionofintangibleassetimpairmentsand$59.4millionofotherassetimpairments.Theintangibleasset
F-20
2018 2017 2016 Cash expense: Severanceandother $ 15.5 $ 162.0 $ 42.1Integration 26.5 90.3 154.8Facilityexitcosts 5.7 31.8 13.2
Total cash expense 47.7 284.1 210.1Non-cash expense: Assetimpairment 81.9 110.6 98.3
Total non-cash expense 81.9 110.6 98.3Gainonsaleoffixedassets (0.8) (19.6) —
Total expense $ 128.8 $ 375.1 $ 308.4
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 7. Asset Impairment, Restructuring and Other Special Charges (Continued)
impairmentsprimarilyrelatedtorevisedprojectionsoffairvalueduetoproductrationalization.ThefixedassetimpairmentswereprimarilyduetothedecisiontodisposeofamanufacturingfacilityintheU.S.,thesuspensionofcommercialactivitiesforImrestor®andthewrite-offofcertainidleassetsinaU.S.manufacturingfacility.SeeNote11forfurtherdetailrelatingtointangibleassetimpairments.
AssetimpairmentrecognizedduringtheyearendedDecember31,2017resultedprimarilyfromintangibleassetimpairmentsrelatedtorevisedprojectionsoffairvalueduetoproductrationalizationandtoalesserextentcompetitivepressures.
AssetimpairmentrecognizedduringtheyearendedDecember31,2016resultedfromintangibleassetimpairmentsduetoproductrationalizationandtochargesrelatedtositeclosuresresultingfromouracquisitionandintegrationofNovartisAH,includingtheclosureofamanufacturingfacilityinIrelandin2016.
Gain on sale
ThegainonsaleoffixedassetsfortheyearendedDecember31,2017representsagainonthedisposalofasitethatwaspreviouslyclosedaspartoftheacquisitionandintegrationofNovartisAnimalHealthbeginningonJanuary1,2015.
Thefollowingtablesummarizestheactivityinourreservesestablishedinconnectionwiththeserestructuringactivities:
Substantiallyallofthereservesareexpectedtobepaidinthenexttwelvemonths.Webelievethatthereservesareadequate.
Note 8. Inventories
Westateallinventoriesatthelowerofcostormarket.Weusethelast-in,first-out(LIFO)methodforaportionofourinventorieslocatedinthecontinentalU.S.Otherinventoriesarevaluedbythefirst-in,first-out(FIFO)method.FIFOcostapproximatescurrentreplacementcost.
F-21
Exit costs Severance Total BalanceatDecember31,2016 $ 11.5 $ 26.6 $ 38.1Charges 31.8 162.0 193.8Reserveadjustment 1.4 (3.9) (2.5)Cashpaid (9.8) (141.6) (151.4)
BalanceatDecember31,2017 34.9 43.1 78.0Charges 11.7 15.5 27.2Separationadjustment (5.9) — (5.9)Reserveadjustment (6.0) — (6.0)Cashpaid (25.4) (23.5) (48.9)
BalanceatDecember31,2018 $ 9.3 $ 35.1 $ 44.4
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 8. Inventories (Continued)
InventoriesatDecember31consistedofthefollowing:
InventoriesvaluedundertheLIFOmethodcomprised$194.8millionand$231.4millionoftotalinventoriesatDecember31,2018and2017,respectively.
DuringtheyearendedDecember31,2018,werecognized$38.6millionofinventorywrite-offsincostofsalesprimarilyrelatedtothesuspensionofcommercialactivitiesforImrestor.
Note 9. Debt
Long-termdebtasofDecember31,2018consistedofthefollowing:
Long-termdebtasofDecember31,2017wasnotmaterial.
Revolving and Term Credit Facilities
OnSeptember5,2018,weenteredintoarevolvingcreditagreementwithasyndicateofbanksprovidingforafive-year$750.0millionseniorunsecuredrevolvingcreditfacility(RevolvingFacility).TheRevolvingFacilitybearsinterestatavariablerateplusspecifiedmarginasdefinedintheagreementandispayablequarterly.TherewerenoborrowingsoutstandingundertheRevolvingFacilityatDecember31,2018.TheRevolvingFacilityispayableinfullattheendoftheterm.
OnSeptember5,2018wealsoenteredintoa$500.0millionthree-yeartermloanunderatermcreditfacilitywithasyndicateofbanks(theTermFacilityandcollectivelywiththeRevolvingFacility,theCreditFacilities.)TheTermFacilitybearsinterestatavariablerateplusmarginasdefinedinTerm
F-22
2018 2017 Finishedproducts $ 400.7 $ 452.0Workinprocess 570.4 580.0Rawmaterialsandsupplies 80.4 70.4Total(approximatesreplacementcost) 1,051.5 1,102.4DecreasetoLIFOcost (47.4) (40.1)Inventories $ 1,004.1 $ 1,062.3
December 31,
2018 Termcreditfacility $ 492.53.912%SeniorNotesdue2021 500.04.272%SeniorNotesdue2023 750.04.900%SeniorNotesdue2028 750.0Otherobligations 0.5Unamortizeddebtissuancecosts (20.7)
2,472.3Lesscurrentportionoflong-termdebt (29.0)Totallong-termdebt $ 2,443.3
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 9. Debt (Continued)
Facility(3.77%atDecember31,2018)andispayablequarterly.TheTermFacilityalsorequiresaquarterlyprincipalpaymentequalto1.5%oftheaggregateinitialprincipallessanyprepayment.TheTermFacilityispayableinfullattheendoftheterm.
TheCreditFacilitiesaresubjecttovariousfinancialandothercovenantsincludingrestrictionsonthelevelofborrowingsbasedonaconsolidatedleverageratioandaconsolidatedinterestcoverageratio.WewereincompliancewithallsuchcovenantsasofDecember31,2018.
Senior Notes
OnAugust28,2018,weissued$2.0billionofseniornotes(SeniorNotes)inaprivateplacement.TheSeniorNotescomprisedof$500.0millionof3.912%SeniorNotesdueAugust27,2021,$750.0millionof4.272%SeniorNotesdueAugust28,2023,and$750.0millionof4.900%SeniorNotesdueAugust28,2028.TheinterestratepayableoneachseriesofSeniorNotesissubjecttoadjustmentifMoody'sInvestorServices,Inc.orStandard&Poor'sFinancialServicesLLCdowngrades,orsubsequentlyupgrades,itsratingsontherespectiveseriesofSeniorNotes.
TheindenturethatgovernstheSeniorNotescontainscovenants,includinglimitationsonourability,andcertainofoursubsidiaries,toincurliensorengageinsale-leasebacktransactions.Theindenturealsocontainsrestrictionsonourabilitytoconsolidate,mergeorsellsubstantiallyallofourassets,inadditiontoothercustomaryterms.WewereincompliancewithallsuchcovenantsundertheindenturegoverningtheSeniorNotesasofDecember31,2018.
WehaveenteredintoanagreementthatrequiresustousecommerciallyreasonableeffortstocausearegistrationstatementtobecomeeffectivewiththeSECbyAugust28,2019,relatingtoanoffertoexchangetheSeniorNotesforregisteredSeniorNoteshavingsubstantiallyidenticalterms,or,incertaincases,toregistertheSeniorNotesforresale.IfwedonotregisterorexchangetheSeniorNotespursuanttothetermsoftheregistrationrightsagreement,wewillberequiredtopayadditionalinteresttotheholdersoftheSeniorNotesundercertaincircumstances.
Note 10. Financial Instruments and Fair Value
Financialinstrumentsthatarepotentiallysubjecttocreditriskconsistprincipallyoftradereceivables.Collateralisgenerallynotrequired.Theriskassociatedwiththisconcentrationismitigatedbyourongoingcredit-reviewproceduresandinsurance.
Alargeportionofourcashisheldbyafewmajorfinancialinstitutions.Wemonitortheexposurewiththeseinstitutionsanddonotexpectanyoftheseinstitutionstofailtomeettheirobligations.Allhighlyliquidinvestmentswithamaturityofthreemonthsorlessfromthedateofpurchaseareconsideredtobecashequivalents.Thecostoftheseinvestmentsapproximatesfairvalue.Wealsoconsiderthecarryingvalueofrestrictedcashbalancestoberepresentativeofitsfairvalue.
AsofDecember31,2018and2017,wehad$15.3millionand$12.3million,respectively,primarilyrelatedtoequitymethodinvestments.
F-23
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 10. Financial Instruments and Fair Value (Continued)
ThefollowingtablesummarizesthefairvalueinformationatDecember31,2018and2017forcontingentconsiderationliabilitiesandnetinvestmenthedgeliabilitymeasuredatfairvalueonarecurringbasisintherespectivebalancesheetlineitems:
WedetermineourLevel1andLevel2fairvaluemeasurementsbasedonamarketapproachusingquotedmarketvalues,significantotherobservableinputsforidenticalorcomparableassetsorliabilities,ordiscountedcashflowanalysis.Level3fairvaluemeasurementsforotherinvestmentsecuritiesaredeterminedusingunobservableinputs,includingtheinvestments'costadjustedforimpairmentsandpricechangesfromorderlytransactions.Thefairvaluesofcostandequitymethodinvestmentsarenotreadilyavailable.
ContingentconsiderationliabilitiesrelatetoGalliprant forwhichthefairvaluewasestimatedusingadiscountedcashflowanalysisandLevel3inputs,includingprojectionsrepresentativeofamarketparticipantviewfortheprobabilityofachievingpotentialfuturepaymentstoAratanaTherapeutics,Inc.andanestimateddiscountrate.Theamounttobepaidisdependentuponcertaindevelopment,success-basedregulatory,andsales-basedmilestones.Inaddition,theamountofroyaltiestobepaidiscalculatedasapercentageofnetsalesdependentuponthetimingandgeographyandwill,therefore,varydirectlywithincreasesanddecreasesinnetsalesofGalliprant .Thereisnocapontheamountthatmaybepaidpursuanttothisarrangement.During2018,asaresultofanincreaseintheprojectedcashflowsrelatedtoGalliprant, weincreasedthefairvalueofthecontingentconsiderationliabilitiesby$37.6million,offsetbya$15.0millionsales-basedmilestonepayment.Theadditionalexpensewasrecognizedinother(income)expense,net.
Wehavelongtermdebtof$2.5billionthatisrecordedatamortizedcostinourconsolidatedandcombinedbalancesheetasofDecember31,2018.Weconsiderthecarryingvalueofthelongtermdebt
F-24
Fair Value Measurements Using
Financial statement line item Carrying Amount
Quoted Prices
in Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant Unobservable
Inputs (Level 3)
Fair Value
December31,2018 Othercurrentliabilities—contingentconsideration $ 5.1 $ — $ — $ 5.1 $ 5.1Othernoncurrentliabilities—contingentconsideration 69.0 — — 69.0 69.0Othernoncurrentliabilities—crosscurrencyinterestratecontractsdesignatedasnetinvestmenthedges 7.4 — 7.4 — 7.4
December31,2017 Othercurrentliabilities—contingentconsideration 1.3 — — 1.3 1.3Othernoncurrentliabilities—contingentconsideration 45.2 — — 45.2 45.2
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 10. Financial Instruments and Fair Value (Continued)
toberepresentativeofitsfairvalueasofDecember31,2018.ThefairvalueofthislongtermdebtisestimatedbasedonquotedmarketpricesofsimilarliabilitiesandisclassifiedasLevel2.AsofDecember31,2017,longtermdebtwasnotmaterial.
InOctober2018,weenteredintoacross-currencyfixedinterestrateswap,5-year,750millionSwissFranc(CHF),whichisdesignatedasaNIHagainstCHFdenominatedassetsforwhichthefairvaluewasestimatedbasedonquotedmarketvaluesofsimilarhedgesandisclassifiedasLevel2.TheNIHisexpectedtogenerateapproximately$25millionincashandanoffsettointerestexpenseonanannualbasis.DuringtheyearendedDecember31,2018,ourinterestexpensewasoffsetby$5.6millionasaresultoftheNIH.Overthelifeofthederivative,gainsorlossesduetospotratefluctuationsarerecordedincumulativetranslationadjustment.DuringtheyearendedDecember31,2018,werecordeda$5.9millionloss,netoftax,ontheNIH,whichisincludedinthechangeinthecumulativetranslationadjustmentinothercomprehensiveincome.Thereisapotentialforsignificant2023settlementexposureastheU.S.dollarfluctuatesagainsttheSwissFranc.TheriskmanagementobjectiveistomanageforeigncurrencyriskrelatingtonetinvestmentsincertainCHFdenominatedassets.ChangesinfairvalueofthederivativeinstrumentsarerecognizedinacomponentofAccumulatedOtherComprehensiveLosstooffsetthechangesinthevaluesofthenetinvestmentsbeinghedged.
Note 11. Goodwill and Intangibles
Goodwill
Goodwillwas$3.0billionasofDecember31,2018and2017.Goodwillresultsfromexcessconsiderationinabusinesscombinationoverthefairvalueofidentifiablenetassetsacquired.Goodwillisnotamortizedbutisreviewedforimpairmentatleastannuallyandwhenimpairmentindicatorsarepresent.Goodwillmaybeimpairedifthecarryingamountofareportingunitexceedsthefairvalueofthatreportingunit,calculatedasbasedondiscountedcashflows.Theimpliedfairvalueofgoodwillisthendeterminedbysubtractingthefairvalueofallidentifiablenetassetsotherthangoodwillfromthefairvalueofthereportingunit.Animpairmentchargewouldberecordedfortheexcess,ifany,ofcarryingamountofgoodwillovertheimpliedfairvalue.Theestimatedfairvalueisbasedonanumberofassumptions,includingcurrentmarketcapitalizationascorroborationoffairvalue.SeeNote6forfurtherdiscussionofgoodwillresultingfromrecentbusinesscombinations.Theremainingchangeingoodwillisprimarilytheresultofforeignexchangetranslationadjustments.
NoimpairmentsoccurredwithrespecttothecarryingvalueofgoodwillfortheyearsendedDecember31,2018,2017and2016.
F-25
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 11. Goodwill and Intangibles (Continued)
Other Intangibles
ThecomponentsofintangibleassetsotherthangoodwillatDecember31wereasfollows:
Marketedproductsconsistoftheamortizedcostoftherightstoassetsacquiredinbusinesscombinationsandapprovedformarketinginasignificantglobaljurisdiction.Fortransactionsotherthanabusinesscombination,wecapitalizemilestonepaymentsincurredatoraftertheproducthasobtainedregulatoryapprovalformarketing.
Otherfinite-livedintangiblesconsistprimarilyoftheamortizedcostoflicensedplatformtechnologiesthathavealternativefutureusesinresearchanddevelopment,manufacturingtechnologiesandcustomerrelationshipsfrombusinesscombinations.AcquiredIPR&Dconsistsoftherelatedcostscapitalized,adjustedforsubsequentimpairments,ifany.ThecostsofacquiredIPR&Dprojectsacquireddirectlyinatransactionotherthanabusinesscombinationarecapitalizediftheprojectshaveanalternativefutureuse;otherwise,theyareexpensedimmediately.ThefairvaluesofacquiredIPR&Dprojectsacquiredinbusinesscombinationsarecapitalizedasotherintangibleassets.
Severalmethodsmaybeusedtodeterminetheestimatedfairvalueofotherintangiblesacquiredinabusinesscombination.Weutilizethe"incomemethod"forotherintangibles.ThismethodisaLevel3fairvaluemeasurementandappliesaprobabilityweightingthatconsiderstheriskofdevelopmentandcommercializationtotheestimatedfuturenetcashflowsthatarederivedfromprojectedrevenuesandestimatedcosts.Theseprojectionsarebasedonfactorssuchasrelevantmarketsize,patentprotection,historicalpricingofsimilarproductsandexpectedindustrytrends.Theestimatedfuturenetcashflowsarethendiscountedtothepresentvalueusinganappropriatediscountrate.Thisanalysisisperformedforeachgroupofassetsindependently.TheacquiredIPR&Dassetsaretreatedasindefinite-livedintangibleassetsuntilcompletionorabandonmentoftheprojects,atwhichtimetheassetsaretestedforimpairmentandamortizedovertheremainingusefullifeorwrittenoff,asappropriate.
SeeNote6forfurtherdiscussionofintangibleassetsacquiredinrecentbusinesscombinations.
F-26
2018 2017
Description
Carrying Amount,
Gross Accumulated Amortization
Carrying Amount,
Net
Carrying Amount,
Gross Accumulated Amortization
Carrying Amount,
Net Finite-livedintangibleassets: Marketedproducts $ 3,193.5 $ (779.2) $ 2,414.3 $ 3,151.2 $ (599.8) $ 2,551.4Other 53.1 (34.0) 19.1 54.1 (29.9) 24.2Totalfinite-livedintangibleassets 3,246.6 (813.2) 2,433.4 3,205.3 (629.7) 2,575.6
Indefinite-livedintangibleassets: Acquiredin-processresearchanddevelopment 19.6 — 19.6 97.2 — 97.2
Otherintangibles $ 3,266.2 $ (813.2) $ 2,453.0 $ 3,302.5 $ (629.7) $ 2,672.8
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 11. Goodwill and Intangibles (Continued)
Otherindefinite-livedintangibleassetsarereviewedforimpairmentatleastannuallyandwhenimpairmentindicatorsarepresent.Thefairvalueoftheindefinitelivedintangibleassets(acquiredIPR&D)isestimatedusingthesameassumptionsasusedforgoodwillandbyapplyingaprobabilityweightingthatreflectstheriskofdevelopmentandcommercializationtotheestimatedfuturenetcashflowsthatarederivedfromprojectedrevenuesandestimatedcosts.Finite-livedintangibleassetsarereviewedforimpairmentwhenanindicatorofimpairmentispresent.Wecomparethecarryingamountsoftheassetswiththeestimatedundiscountedfuturecashflows.Intheeventthecarryingamountexceedstheundiscountedcashflows,animpairmentchargeisrecordedfortheamountbywhichthecarryingamountoftheassetexceedstheestimatedfairvalue,whichisdeterminedbasedondiscountedfuturecashflows.
During2018,werecordedimpairmentchargesof$22.5million(comprisedof$9.5millionimpairmentoffinite-livedintangibleassetsand$13.0millionimpairmentofindefinite-livedintangibleassets)whichareincludedinassetimpairment,restructuringandotherspecialchargesonthecombinedstatementsofoperations.Theimpairmentoffinite-livedintangibleassetsprimarilyrelatedtocompetitivepressuresforacertainmarketedproductresultinginareductionofprojectedcashflows.Theimpairmentofindefinite-livedintangibleassetsprimarilyrelatedtorevisedprojectionsoffairvalueduetocompetitivepressuresandtoalesserextentproductrationalization.TheincreaseinthecarryingamountoffiniteintangiblesisprimarilyduetothereceiptoffullcommercializationrightsoutsidetheU.S.forGalliprant.During2017,wehadimpairmentchargesof$94.5million(comprisedof$56.5millionimpairmentoffinite-livedintangibleassetsand$38.0millionimpairmentofindefinite-livedintangibleassets)whichareincludedinassetimpairment,restructuringandotherspecialchargesonthecombinedstatementsofoperations.Theimpairmentoffinite-livedintangibleassetsprimarilyrelatedtocompetitivepressuresforacertainmarketedproductresultinginareductionofprojectedcashflows.Theimpairmentofindefinite-livedintangibleassetsprimarilyrelatedtorevisedprojectionsoffairvalueduetocompetitivepressuresandtoalesserextentproductrationalization.During2016,werecordedimpairmentchargesof$14.0millionprimarilyrelatedtoindefinite-livedintangibleassetschargedtoassetimpairment,restructuringandotherspecialchargesonthecombinedstatementsofoperations.Theimpairmentsin2016wererelatedtoproductrationalization.
Intangibleassetswithfinitelivesarecapitalizedandareamortizedovertheirestimatedusefullives,rangingfrom3to20years.AsofDecember31,2018,theremainingweighted-averageamortizationperiodforfinite-livedintangibleassetsisapproximately14years.
Theestimatedamortizationexpenseforeachofthenextfiveyearsassociatedwithourfinite-livedintangibleassetsasofDecember31,2018isasfollows:
Note 12. Property and Equipment
Propertyandequipmentisstatedonthebasisofcost.Provisionsfordepreciationofbuildingsandequipmentarecomputedgenerallybythestraight-linemethodatratesbasedontheirestimatedusefullives(12to50yearsforbuildingsand3to25yearsforequipment).Wereviewthecarryingvalueoflong-livedassetsforpotentialimpairmentonaperiodicbasisandwhenevereventsorchangesin
F-27
2019 2020 2021 2022 2023 Estimatedamortizationexpense $ 197.9 $ 198.3 $ 198.0 $ 196.0 $ 195.8
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 12. Property and Equipment (Continued)
circumstancesindicatethecarryingvalueofanassetmaynotberecoverable.Impairmentisdeterminedbycomparingprojectedundiscountedcashflowstobegeneratedbytheassettoitscarryingvalue.Ifanimpairmentisidentified,alossisrecordedequaltotheexcessoftheasset'snetbookvalueoveritsfairvalueutilizingadiscountedcashflowanalysis,andthecostbasisisadjusted.
AtDecember31,propertyandequipmentconsistedofthefollowing:
Depreciationexpenserelatedtopropertyandequipmentandrentalexpenseforallleaseswasasfollows:
Thefutureminimumrentalcommitmentsundernon-cancelableoperatingleasesareasfollows:
Note 13. Stock-Based Compensation
Lilly Stock Compensation Plans
ForperiodspriortoIPO,webenefitedfromLilly'sstock-basedcompensationprogram.Lillymaintainsvariousstock-basedcompensationprogramsforthebenefitofitsofficers,directorsandcertainemployeesincludingemployeesoftheCompany.AswereceivetheemployeeservicesinconsiderationfortheparticipationoftheCompany'semployeesintheseplans,stock-basedcompensationexpensefortheawardsgrantedtoouremployeeshasbeenreflectedintheconsolidatedandcombinedstatementsofoperations.
Lilly'sstock-basedcompensationgrantedtoouremployeesconsistsofperformanceawards(PAs),shareholdervalueawards(SVAs)andRSUs.Thestock-basedcompensationexpensehasbeenderivedfromtheequityawardsgrantedbyLillytoouremployees.Thecompensationexpenseisbasedonthefairvalueofstock-basedawardswhichisrecognizedascompensationexpenseovertherequisiteserviceperiodoftheindividualgrantees,whichgenerallyequalsthevestingperiod.TheawardsaresettledbyLilly.
F-28
2018 2017 Land $ 27.6 $ 25.1Buildings 567.2 557.7Equipment 1,025.1 994.5Constructioninprogress 181.1 177.1
1,801 1,754.4Lessaccumulateddepreciation (878.6) (834.1)Propertyandequipment,net $ 922.4 $ 920.3
2018 2017 2016 Depreciationexpense $ 81.3 $ 79.8 $ 75.7Rentalexpense 47.5 47.1 41.8
2019 2020 2021 2022 2023 After 2023 Leasecommitments $ 25.2 $ 20.1 $ 13.5 $ 10.0 $ 8.3 $ 18.5
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 13. Stock-Based Compensation (Continued)
FortheperiodspriortoIPO,asthestock-basedcompensationplanswereLilly'splansandtheawardsweresettledbyLilly,theoffsettotheexpensewasrecognizedthroughnetparentcompanyinvestmentonthecombinedbalancesheet.
Stock-basedcompensationexpenserelatedtoouremployeesforyearsendedDecember31,2018,2017and2016was$26.0million,$25.0millionand$20.4million,respectively.
FollowingIPOanduntilthecompletionoftheexchangeoffer,theequityawardspreviouslygrantedtoouremployeesbyLillywillcontinuetovest,andservicewithElancocountstowardtheLillyaward'svestingprovisions.Uponcompletionoftheexchangeoffer,weexpectthatouremployees'unvestedLillyRSUs,PAs,andSVAswillbeforfeitedandreplacedwithElancoRSUsvaluedattheexchangeratewiththesameservicevestingperiodastheforfeitedLillyawards.
Performance Award Program
PAshavebeengrantedtocertainofourofficersandmanagementandaresettledinsharesofLilly'scommonstock.ThenumberofPAsharesactuallyissued,ifany,variesdependingontheachievementofcertainpre-establishedearnings-per-sharetargetsoveratwo-yearperiod.PAsharesareaccountedforatfairvaluebasedupontheclosingstockpriceonthedateofgrantandfullyvestattheendofthemeasurementperiod.ThefairvaluesofPAsgrantedfortheyearsendedDecember31,2018,2017and2016were$71.63,$73.54,and$72.00,respectively.ThenumberofPAsharesthatwillvestforthePAprogramisdependentuponLilly'searningsachievedduringthevestingperiod.Pursuanttothisprogram,approximately39,771shares,69,144sharesand20,329shareswereissuedbyLillytoouremployeesduringtheyearsendedDecember31,2018,2017and2016,respectively.AsofDecember31,2018,thetotalremainingunrecognizedcompensationcostrelatedtononvestedPAswas$5.8million,whichwillbeamortizedovertheweighted-averageremainingrequisiteserviceperiodof12months.
Shareholder Value Award Program
SVAshavebeengrantedtocertainofourofficersandmanagementandaresettledinsharesofLilly'scommonstock.Thenumberofsharesactuallyissued,ifany,variesdependingonLilly'sstockpriceattheendofthethree-yearvestingperiodcomparedtopre-establishedtargetstockprices.WemeasurethefairvalueoftheSVAunitonthegrantdateusingaMonteCarlosimulationmodel.Themodelutilizesmultipleinputvariablesthatdeterminetheprobabilityofsatisfyingthemarketconditionstipulatedintheawardgrantandcalculatesthefairvalueoftheaward.ExpectedvolatilitiesutilizedinthemodelarebasedonimpliedvolatilitiesfromtradedoptionsonLilly'sstock,historicalvolatilityofLilly'sstockpriceandotherfactors.Similarly,thedividendyieldisbasedonhistoricalexperienceandLilly'sestimateoffuturedividendyields.Therisk-freeinterestrateisderivedfromtheU.S.Treasuryyieldcurveineffectatthetimeofgrant.Theweighted-averagefairvaluesoftheSVAunitsgranted
F-29
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 13. Stock-Based Compensation (Continued)
duringtheyearsendedDecember31,2018,2017and2016were$49.38,$66.25and$48.68,respectively,determinedusingthefollowingassumptions:
Pursuanttothisprogram,Lillyissuedapproximately30,195shares,35,063sharesand36,071sharestoouremployeesduringtheyearsendedDecember31,2018,2017and2016,respectively.AsofDecember31,2018,thetotalremainingunrecognizedcompensationcostrelatedtononvestedSVAswas$3.5million,whichwillbeamortizedovertheweighted-averageremainingrequisiteserviceperiodof20months.
Restricted Stock Units
RSUshavebeengrantedtocertainofouremployeesandarepayableinsharesofLilly'scommonstock.RSUsharesareaccountedforatfairvaluebaseduponLilly'sclosingstockpriceonthedateofgrant.Thecorrespondingexpenseisamortizedoverthevestingperiod,typicallythreeyears.ThefairvaluesofRSUawardsgrantedduringtheyearsendedDecember31,2018,2017and2016were$70.95,$72.47and$71.46,respectively.ThenumberofsharesultimatelyissuedbyLillyfortheRSUprogramremainsconstantwiththeexceptionofforfeitures.Pursuanttothisprogram,82,025shares,57,224sharesand26,468sharesweresettledbyLillywithitsRSUstoouremployeesduringtheyearsendedDecember31,2018,2017and2016,respectively.AsofDecember31,2018,thetotalremainingunrecognizedcompensationcostrelatedtononvestedRSUswas$12.5millionwhichwillbeamortizedovertheweighted-averageremainingrequisiteserviceperiodof20months.
Elanco Stock Compensation Plans
InconnectionwithIPO,weadoptedourownstockbasedcompensationplans,includingRSUsandstockoptions.Ourstock-basedcompensationexpenseandtherelatedtaxundertheseplansfortheyearendedDecember31,2018was$1.8millionand$0.4million.
Restricted Stock Units
RSUsaregrantedtocertainemployeesandaresettledinsharesofourcommonstock.RSUsharesareaccountedforatfairvaluebasedupontheclosingstockpriceonthedateofthegrant.Thecorrespondingexpenseisamortizedoverthevestingperiod,typicallythreeyears.ThefairvalueoftheRSUawardsgrantedduringtheyearendedDecember31,2018was$31.09.ThenumberofsharesultimatelyissuedfortheRSUprogramremainsconstantwiththeexceptionofforfeitures.Pursuanttothisprogram,158,007sharesweregrantedand18,991shareswereissuedduringtheyearendedDecember31,2018.AsofDecember31,2018,thetotalremainingunrecognizedcompensationcostrelatedtononvestedRSUswas$3.9million,whichwillamortizeovertheweighted-averageremainingrequisiteserviceperiodof33months.
F-30
(Percents) 2018 2017 2016 Expecteddividendyield 2.50% 2.50% 2.00%Risk-freeinterestrate 2.31 1.38 0.92Volatility 22.26 22.91 21.68
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 13. Stock-Based Compensation (Continued)
Stock Option Program
Stockoptionsrepresenttherighttopurchasesharesofourcommonstockwithinaspecifiedperiodoftimeataspecifiedprice.Theexercisepriceforastockoptionwillbenotlessthan100%ofthefairmarketvalueofthecommonstockonthedateofthegrant.
Stockoptionsareaccountedforusingafair-valuebasedmethodatthedateofthegrantintheconsolidatedstatementofoperations.Thevaluesdeterminedthroughthisfair-value-basedmethodgenerallyareamortizedonastraight-linebasisoverthevestingterm.
Stockoptionsweregrantedin2018toourofficers,managementandboardmembersatexercisepricesequaltothefairmarketvalueofourstockatthedateofthegrant.Optionsfullyvest3yearsfromthegrantdateandhaveatermof10years.
Thefair-value-basedmethodforvaluingeachElancostockoptiongrantonthegrantdateusestheBlack-Scholes-Mertonoption-pricingmodel,whichincorporatesanumberofvaluationassumptionsnotedinthefollowingtable,shownattheirweighted-averagevaluesfortheyearendedDecember31:
StockoptionactivityduringtheyearendedDecember31,2018issummarizedbelow:
AsofDecember31,2018,theweighted-averageremainingcontractualtermoftheexercisableoptionswas9.8yearsandtheaggregateintrinsicvaluewas$0.08.
F-31
2018 Expecteddividendyield(1) 0.70%Risk-freeinterestrate(2) 3.07%Expectedstockpricevolatility(3) 28.25%Expectedterm(4)(years) 6.5
(1) Determinedusingtheexpectedquarterlydividenddividedbytheavailablethree-monthaveragestockpriceasofthevaluationdate,annualizedandcontinuouslycompounded.
(2) Determinedusingtheterm-matched,zero-couponrisk-freeratefromtheTreasuryConstantMaturityyieldcurve,continuouslycompounded
(3) Determinedusingaleverage-adjustedhistoricalvolatilityofpeercompanies
(4) DeterminedusingSECsafeharborapproach,basedona3-yearcliffvestingscheduleand10-yearcontractualterm.
Shares of Common
Stock Attributable to Options
Weighted-Average Exercise Price
of Options OutstandingatJanuary1,2018 — $ —Granted 421,297 31.61Exercised — —Forfeitedorexpired — —OutstandingatDecember31,2018 421,297 31.61ExercisableatDecember31,2018 58,766 31.61
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 14. Income Taxes
Duringtheperiodspresentedintheconsolidatedandcombinedfinancialstatements,ElancowasgenerallyincludedinthetaxgroupingofotherLillyentitieswithintherespectiveentity'staxjurisdiction;however,incertainjurisdictions,Elancofiledseparatetaxreturns.Theincometax(benefit)/expenseincludedintheseconsolidatedandcombinedfinancialstatementshasbeencalculatedusingtheseparatereturnbasis,asifElancofiledseparatetaxreturns.
2017 Tax Act
InDecember2017,thePresidentoftheU.S.signedintolawtheTaxCutsandJobsAct(2017TaxAct).The2017TaxActincludessignificantchangestotheU.S.corporateincometaxsystem,suchasthereductioninthecorporateincometaxratefrom35percentto21percent,transitiontoaterritorialtaxsystem,changestobusinessrelatedexclusions,deductionsandcredits,andmodificationstointernationaltaxprovisions,includingaone-timerepatriationtransitiontax(alsoknownasthe'TollTax')onunremittedforeignearnings.
GAAPrequiresthattheincometaxaccountingeffectsfromachangeintaxlawsortaxratesberecognizedincontinuingoperationsinthereportingperiodthatincludestheenactmentdateofthechange.Theseeffectsinclude,amongotherthings,re-measuringdeferredtaxassetsandliabilities,evaluatingdeferredtaxassetsforvaluationallowancesandassessingtheimpactoftheTollTaxandcertainotherprovisionsofthe2017TaxAct.Ouraccountingforthetaxeffectsoftheenactmentofthe2017TaxActwasnotcompleteasofDecember31,2017;however,incertaincases,wemadeareasonableestimate.Inothercases,wewereunabletomakeareasonableestimateandcontinuedtoaccountforthoseitemsbasedonourexistingaccountingmodelunderASC740,IncomeTaxesandtheprovisionsofthetaxlawsthatwereineffectimmediatelypriortoenactment.Fortheitemsforwhichwewereabletomakeareasonableestimate,werecordedaprovisionaltaxbenefitof$33.1millionin2017relatedtotheimpactsofthe2017TaxAct.
Wefinalizedouraccountingforthetaxeffectsofthe2017TaxActduring2018.Nomaterialadjustmentstoincometaxexpense(benefit)wererecorded.Weexpectthatfurtherguidancewillcontinuetobeissuedin2019whichmayimpactourinterpretationsofthe2017TaxActandcouldmateriallyaffecttheestimatesused.The2017TaxActalsoincludesanewU.S.minimumtax,globalintangiblelow-taxedincome(GILTI),ontheearningsofourforeignsubsidiaries.WehaveelectedtoaccountforthetaxrelatedtoGILTIasaperiodcostintheyearthetaxisincurred.
Deferredtaxesarerecognizedforthefuturetaxeffectsoftemporarydifferencesbetweenfinancialandincometaxreportingbasedonenactedtaxlawsandrates.Werecognizethetaxbenefitfromanuncertaintaxpositiononlyifitismorelikelythannotthatthetaxpositionwillbesustainedonexaminationbythetaxingauthorities,basedonthetechnicalmeritsoftheposition.Thetaxbenefitsrecognizedinthefinancialstatementsfromsuchapositionaremeasuredbasedonthelargestbenefitthathasagreaterthan50percentlikelihoodofbeingrealizeduponultimateresolution.
F-32
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 14. Income Taxes (Continued)
Followingisthecompositionofincome(loss)beforeincometaxexpense(benefit):
Followingisthecompositionofincometaxexpense(benefit):
F-33
2018 2017 2016 Federal $ 12.2 $ (133.2) $ (12.5)Foreign 101.9 (99.4) (9.9)
Income(loss)beforeincometaxes $ 114.1 $ (232.6) $ (22.4)
2018 2017 2016 Current: Federal $ 45.1 $ — $ —Foreign 45.5 91.6 31.1State (2.3) (0.1) 0.3Totalcurrenttaxexpense 88.3 91.5 31.4
Deferred: Federal (56.8) 42.6 18.4Foreign (5.6) (16.6) (26.8)State 1.7 (6.3) 2.52017TaxAct — (33.1) —Totaldeferredtaxbenefit (60.7) (13.4) (5.9)
Incometaxes $ 27.6 $ 78.1 $ 25.5
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 14. Income Taxes (Continued)
SignificantcomponentsofourdeferredtaxassetsandliabilitiesasofDecember31areasfollows:
Deferredtaxassetsandliabilitiesreflecttheimpactofre-measurementresultingfromthe2017TaxAct.
ThedeferredtaxassetsandrelatedvaluationallowanceamountsforU.S.federalandstatenetoperatinglossesandtaxcreditsshownabovehavebeenreducedfordifferencesbetweenfinancialreportingandtaxreturnfilings.
AtDecember31,2018,wehavetaxcreditcarryoversof$6.5millionavailabletoreducefutureincometaxes.Theamountiscomprisedofforeignandstatecredits.Foreigncreditstotal$4.1millionandifunused,willexpirebeginningin2032.Statetaxcreditsof$2.4millionarefullyreserved.
AtDecember31,2018,wehadnetoperatinglosscarryoversandothercarryoversforinternationalandU.S.stateincometaxpurposesof$156.2million:$84.6millionwillexpireby2023;$65.0millionwillexpireby2025;and$1.6millionofthecarryoverswillneverexpire.NetoperatinglossesandothercarryoversforinternationalandU.S.stateincometaxpurposesarepartiallyreserved.Deferredtaxassetsrelatedtostatenetoperatinglossesof$4.9millionarefullyreserved.
F-34
2018 2017 Deferredtaxassets: Compensationandbenefits $ 32.2 $ 34.8Accrualsandreserves 47.8 12.0Taxcreditcarryovers 1.9 19.2Taxlosscarryovers 21.7 144.9Other 23.5 26.6Totalgrossdeferredtaxassets 127.1 237.5
Valuationallowances (21.4) (127.7)Totaldeferredtaxassets 105.7 109.8
Deferredtaxliabilities: Intangibles (130.8) (165.2)Propertyandequipment (50.8) (43.1)Other (2.7) (7.4)Totaldeferredtaxliabilities (184.3) (215.7)
Deferredtaxliabilities—net $ (78.6) $ (105.9)
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 14. Income Taxes (Continued)
Themovementsinthevaluationallowanceareasfollows:
PriortotheIPO,wepreparedtheincometaxamountsandbalancesbaseduponaseparatereturnmethodology,asifwewereseparatetaxpayersfromLilly.Asaresult,certaintaxcreditandnetoperatinglosscarryoversarenotavailableforuseinfutureperiodsastheywereusedinLillyconsolidatedorcombinedtaxreturnfilings.Accordingly,asaresultoftheSeparation,thetaxcreditandnetoperatinglosscarryoversandrelatedvaluationallowancehavebeenadjustedtoreflectthebalanceafterSeparation.Theseadjustmentshadnoimpactonincometaxexpenseintheconsolidatedandcombinedfinancialstatements.Theseparationentriesrelatedtothevaluationallowancewereoffsetby$133.7million,priortotaxeffect,ofseparationentriesrelatedtotheremovalofthenetoperatinglosses.
The2017TaxActintroducedinternationaltaxprovisionsthatsignificantlychangetheU.S.taxationofforeignearnings.AtDecember31,2018,noU.S.taxesorforeignwithholdingtaxeshavebeenaccruedwithrespecttothe$464.5millioninunremittedearningsofourforeignsubsidiariesastheyareconsideredindefinitelyreinvestedforcontinueduseinourforeignoperations.Itisnotpracticabletodeterminetheunrecognizeddeferredtaxliabilityrelatedtotheseearnings.
Cashpaymentsofincometaxeswereasfollows:
F-35
2018 2017 January1 $ (127.7) $ (39.1)AdjustmentrelatedtoSeparation 110.4 —January1 (17.3) (39.1)Increase (5.8) (97.4)Release 1.7 8.8December31 $ (21.4) $ (127.7)
2018 2017 2016 Cashpaymentsofincometaxes $ 26.9 $ 35.7 $ 53.6
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 14. Income Taxes (Continued)
Thefollowingisareconciliationoftheincometaxexpense(benefit)applyingtheU.S.federalstatutoryratetoincomebeforeincometaxestoreportedincometaxexpense:
Areconciliationofthebeginningandendingamountofgrossunrecognizedtaxbenefitsisasfollows:
Thetotalamountofunrecognizedtaxbenefitsthat,ifrecognized,wouldaffecttaxexpenseby$12.8millionand$29.6millionatDecember31,2018and2017,respectively.Thereare$1.9millionof2018unrecognizedtaxbenefitswhichrelatedtotemporarydifferenceswhichwouldnot,ifrecognized,impacttheeffectivetaxrate.AdjustmentsrelatedtotheSeparationrepresentunrecognizedtaxbenefitsassumedbyLillyintheSeparationandhavenoimpactonincometaxexpenseintheconsolidatedandcombinedfinancialstatements.
WefileincometaxreturnsintheU.S.federaljurisdictionandvariousstate,localandnon-U.S.jurisdictions.CertainoftheseincometaxreturnsarefiledonaconsolidatedorcombinedbasiswithEliLillyandCompanyand/oritssubsidiaries.
WeareincludedinLilly'sU.S.taxexaminationsbytheInternalRevenueService.PursuanttotheTaxMattersAgreementweexecutedwithLillyinconnectionwiththeIPO,theliabilitiesorpotential
F-36
2018 2017 2016 IncometaxattheU.S.federalstatutorytaxrate $ 24.0 $ (81.4) $ (7.8)Add(deduct): Internationaloperationsandchangeinforeigntaxrates 11.5 55.6 8.4Statetaxes 4.4 5.4 2.8Incometaxcredits (17.3) (1.8) (1.7)Foreigninclusionitems 9.0 4.2 2.4IPOandseparationcosts 2.3 — —Otherpermanentadjustments 0.9 1.6 0.2Changeinuncertaintaxpositions (1.7) 6.2 5.2Changeinvaluationallowance (1.7) 122.2 18.12017TaxAct — (33.1) —Other (3.8) (0.8) (2.1)
Incometaxes $ 27.6 $ 78.1 $ 25.5
2018 2017 2016 BeginningbalanceatJanuary1 $ 29.6 $ 25.7 $ 25.5AdjustmentsrelatedtoSeparation (17.6) — —
BeginningbalanceatJanuary1 12.0 25.7 25.5Additionsbasedontaxpositionsrelatedtothecurrentyear 2.2 7.9 7.4Additionsfortaxpositionsofprioryears 4.0 — —Settlements (3.0) (4.0) (7.1)Changesrelatedtotheimpactofforeigncurrencytranslation (0.5) — (0.1)EndingbalanceatDecember31 $ 14.7 $ 29.6 $ 25.7
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 14. Income Taxes (Continued)
refundsattributabletopre-IPOperiodsinwhichElancowasincludedinaLillyconsolidatedorcombinedtaxreturnremainwithLilly.Consequently,althoughaU.S.examinationoftaxyears2013-2015iscurrentlyinprogress,theresultingadjustments,ifany,willnotrequireanycashtaxpaymentsbyElanco.WearenototherwisesubjecttoU.S.federal,stateandlocal,ornon-U.S.incometaxexaminationsinmostmajortaxingjurisdictionsforyearsbefore2013.
Werecognizebothaccruedinterestandpenaltiesrelatedtounrecognizedtaxbenefitsinincometaxexpense(benefit).Werecognizedincometaxexpense(benefit)relatedtointerestandpenaltiesasfollows:
AtDecember31,2018and2017,ouraccrualsforthepaymentofinterestandpenaltiestotaled$13.3millionand$15.7million,respectively.
Note 15. Contingencies
Wearepartytovariouslegalactionsinthenormalcourseofbusiness.Indeterminingwhetherapendingmatterissignificantforfinancialreportinganddisclosurepurposes,weconsiderbothquantitativeandqualitativefactorsinordertoassessmateriality.Weaccrueforcertainliabilityclaimstotheextentwecanformulateareasonableestimateoftheircostsandthereisareasonableprobabilityofincurringsignificantcostsorexpenses.AtDecember31,2018andDecember31,2017,wehadnoliabilitiesestablishedrelatedtolitigationastherewerenosignificantclaimswhichwereprobableandestimable.Wehavenothistoricallyhadanysignificantlitigationexpenseandarenotcurrentlysubjecttoasignificantclaim.
Note 16. Geographic Information
Weoperateasasingleoperatingsegmentengagedinthedevelopment,manufacturing,marketingandsalesofanimalhealthproductsworldwideforbothfoodanimalsandcompanionanimals.Consistentwithouroperationalstructure,ourPresidentandChiefExecutiveOfficer(CEO),asthechiefoperatingdecisionmaker,makesresourceallocationandbusinessprocessdecisionsgloballyacrossourconsolidatedbusiness.Strategicdecisionsaremanagedgloballywithglobalfunctionalleadersresponsiblefordeterminingsignificantcosts/investmentsandwithregionalleadersresponsibleforoverseeingtheexecutionoftheglobalstrategy.Ourglobalresearchanddevelopmentorganizationisresponsiblefordevelopmentofnewproducts.Ourmanufacturingorganizationisresponsibleforthemanufacturingandsupplyofproductsandfortheoptimizationofoursupplychain.Regionalleadersareresponsibleforthedistributionandsaleofourproductsandforlocaldirectcosts.Thebusinessisalsosupportedbyglobalcorporatestafffunctions.ManagingandallocatingresourcesattheglobalcorporatelevelenablesourCEOtoassesstheoveralllevelofresourcesavailableandhowtobestdeploytheseresourcesacrossfunctions,producttypes,regionalcommercialorganizationsandresearchanddevelopmentprojectsinlinewithouroverarchinglong-termcorporate-widestrategicgoals,ratherthanonaproductorgeographicbasis.Consistentwiththisdecision-makingprocess,ourCEOusesconsolidated,single-segmentfinancialinformationforpurposesofevaluatingperformance,allocatingresources,settingincentivecompensationtargets,aswellasforecastingfutureperiodfinancialresults.
F-37
2018 2017 2016 Incometaxexpense(benefit) $ (2.5) $ 2.5 $ 5.5
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 16. Geographic Information (Continued)
OurproductsincludeRumensin®,Optaflexx®,Denagard®,Tylan®,Maxiban®andotherproductsforlivestockandpoultry,aswellasTrifexis®,Interceptor®,Comfortis®andotherproductsforcompanionanimals.OurresultsfortheyearendedDecember31,2017includestheresultsofoperationsfromBIVIVP,whichwasacquiredonJanuary3,2017(Note6).
Wehaveasinglecustomerthataccountedfor11.9%,12.9%and11.7%ofrevenuefortheyearsendedDecember31,2018,2017and2016,respectively,andthatrepresentedaccountsreceivableof$96.4millionand$88.0millionasofDecember31,2018and2017,respectively.
Weareexposedtotheriskofchangesinsocial,politicalandeconomicconditionsinherentinforeignoperationsandourresultsofoperationsandthevalueofourforeignassetsareaffectedbyfluctuationsinforeigncurrencyexchangerates.
Selectedgeographicareainformationwasasfollows:
Note 17. Retirement Benefits
Shared Lilly Plans
OuremployeesparticipatedindefinedbenefitpensionandotherpostretirementplanssponsoredbyLilly,whichincludeparticipantsofLilly'sotherbusiness.Suchplansareaccountedforasmultiemployerplansinthesecombinedfinancialstatementsandasaresult,noassetorliabilitywasrecordedbytheCompanytorecognizethefundedstatusoftheseplans.
Werecordedexpenseof$4.0million,$73.7millionand$11.3millionfortheyearsendedDecember31,2018,2017and2016,respectively,relatingtoouremployees'participationinLillysponsoredplans.Theexpenseincluded$67.0millionrelatedtoacurtailmentlossandspecialterminationbenefitsforearlyretirementincentivesofferedbyLillytoouremployeesaspartofavoluntaryearlyretirementprogramfortheU.S.planandwhichhasbeenrecordedinassetimpairment,
F-38
2018 2017 2016 Geographic Information Revenue—tounaffiliatedcustomers(1): UnitedStates $ 1,483.2 $ 1,373.0 $ 1,361.6International 1,583.6 1,516.0 1,551.9
Revenue $ 3,066.8 $ 2,889.0 $ 2,913.5Long-livedassets(2): UnitedStates $ 602.6 $ 604.7 $ 463.8UnitedKingdom 187.5 204.4 190.6Otherforeigncountries 195.8 190.2 173.0
Long-livedassets $ 985.9 $ 999.3 $ 827.4
(1) Revenueisattributedtothecountriesbasedonthelocationofthecustomer.
(2) Long-livedassetsconsistofpropertyandequipment,net,andcertainnoncurrentassets.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 17. Retirement Benefits (Continued)
restructuringandotherspecialcharges.Nocontributionshavebeenrecognizedinthecombinedfinancialstatementsaswearenotrequiredtomakecontributionstotheseplans.
Pension Plans
TherearealsocertaindefinedbenefitpensionplansthatouremployeesparticipateinthatareeitherdedicatedtoouremployeesorwheretheplanassetsandliabilitiesthatrelatetoouremployeeswerelegallyrequiredtotransfertoElancoatthetimeofourseparationfromLilly.TheplansinSwitzerlandrepresentapproximately84percentofourglobalbenefitobligation.WeuseameasurementdateofDecember31todevelopthechangeinbenefitobligation,changeinplanassets,fundedstatusandamountsrecognizedinthecombinedbalancesheetsatDecember31forourdefinedbenefitpensionplans,whichwereasfollows:
F-39
2018 2017 Changeinbenefitobligation: Benefitobligationatbeginningofyear $ 258.6 $ 225.0Servicecost 11.3 10.5Interestcost 2.5 1.8Actuarial(gain)loss (44.7) 24.4Benefitspaid (2.7) (18.5)Foreigncurrencyexchangeratechangesandotheradjustments 9.8 15.4Benefitobligationatendofyear 234.8 258.6
Changeinplanassets: Fairvalueofplanassetsatbeginningofyear 131.5 123.7Actualreturnonplanassets (10.2) 13.3Employercontribution 5.7 3.9Benefitspaid (2.7) (18.5)Foreigncurrencyexchangeratechangesandotheradjustments 7.3 9.1Fairvalueofplanassetsatendofyear 131.6 131.5
Fundedstatus (103.2) (127.1)Unrecognizednetactuarialloss 0.5 29.1Unrecognizedpriorservicecost 0.8 0.7Netamountrecognized $ (101.9) $ (97.3)Amountsrecognizedinthecombinedbalancesheetconsistedof: Noncurrentassets $ 2.3 $ 2.4Othercurrentliabilities (0.3) (0.3)Accruedretirementbenefits (105.2) (129.2)Accumulatedothercomprehensivelossbeforeincometaxes 1.3 29.8Netamountrecognized $ (101.9) $ (97.3)
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 17. Retirement Benefits (Continued)
TheunrecognizednetactuariallossandunrecognizedpriorservicecostforthesepensionplanshavenotyetbeenrecognizedinnetperiodicpensioncostsandareincludedinaccumulatedothercomprehensivelossatDecember31,2018.
During2019,weexpectthefollowingcomponentsofaccumulatedothercomprehensivelosstoberecognizedascomponentsofnetperiodicbenefitcost:
Wedonotexpectanyplanassetstobereturnedtousin2019.
Thefollowingrepresentsourweighted-averageassumptionsrelatedtothesepensionplansasofDecember31:
Weannuallyevaluatetheexpectedreturnontheplanassetsinthesepensionplans.Inevaluatingtheexpectedrateofreturn,weconsidermanyfactors,withaprimaryanalysisofcurrentandprojectedmarketconditions;assetreturnsandassetallocations;andtheviewsofleadingfinancialadvisersandeconomists.Wemayalsoreviewourhistoricalassumptionscomparedwithactualresults,aswellastheassumptionsandtrendratesutilizedbysimilarplans,whereapplicable.
Thefollowingbenefitpayments,whichreflectexpectedfutureservice,asappropriate,areexpectedtobepaidasfollows:
AmountsrelatingtothesepensionplanswithprojectedbenefitobligationsinexcessofplanassetswereasfollowsatDecember31:
F-40
Unrecognizednetactuarialloss $ 0.5Unrecognizedpriorservicecost 0.8Total $ 1.3
(Percents) 2018 2017 2016 Discountrateforbenefitobligation 1.5% 1.1% 1.0%Discountratefornetbenefitcosts 1.1 1.0 1.0Rateofcompensationincreaseforbenefitobligation 2.2 2.1 3.1Rateofcompensationincreasefornetbenefitcosts 2.1 3.1 3.0Expectedreturnonplanassetsfornetbenefitcosts 4.0 4.4 4.9
2019 2020 2021 2022 2023 2024 - 2028 Benefitpayments $ 5.8 $ 6.4 $ 7.1 $ 6.1 $ 6.3 $ 35.9
2018 2017 Projectedbenefitobligation $ 229.2 $ 251.6Fairvalueofplanassets 124.1 121.8
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 17. Retirement Benefits (Continued)
AmountsrelatingtothesedefinedbenefitpensionplanswithaccumulatedbenefitobligationsinexcessofplanassetswereasfollowsatDecember31:
Thetotalaccumulatedbenefitobligationforthesedefinedbenefitpensionplanswas$199.9millionand$230.3millionatDecember31,2018and2017,respectively.
Netpensionexpenserelatedtotheseplansincludedthefollowingcomponents:
Thefollowingrepresentstheamountsrecognizedfortheseplansinothercomprehensiveloss:
Benefit Plan Investments
Ourbenefitplaninvestmentpoliciesaresetwithspecificconsiderationofreturnandriskrequirementsinrelationshiptotherespectiveliabilities.OurplanassetsinourSwitzerlandpensionplansrepresentapproximately87percentofourplanassetsforthesepensionplans.Giventhelong-termnatureofourliabilities,theseplanshavetheflexibilitytomanageanabove-averagedegreeofriskintheassetportfolios.Attheinvestment-policylevel,therearenospecificallyprohibitedinvestments.However,withinindividualinvestmentmanagermandates,restrictionsandlimitationsarecontractuallysettoalignwithourinvestmentobjectives,ensureriskcontrolandlimitconcentrations.
Wemanageourportfoliotominimizeconcentrationofriskbyallocatingfundswithinassetcategories.Inaddition,withinacategoryweusedifferentmanagerswithvariousmanagementobjectivestoeliminateanysignificantconcentrationofrisk.
F-41
2018 2017 Accumulatedbenefitobligation $ 194.3 $ 223.1Fairvalueofplanassets 124.1 121.8
2018 2017 2016 Servicecost $ 11.3 $ 10.5 $ 9.3Interestcost 2.5 1.8 1.8Expectedreturnonplanassets (6.2) (2.4) (3.4)Amortizationofpriorservicecost 0.2 0.1 0.1Amortizationofnetactuarialloss 1.9 1.4 1.0Other 0.5 — —Netpensionexpense $ 10.2 $ 11.4 $ 8.8
2018 2017 2016 Actuarialgain(loss)arisingduringperiod $ 28.3 $ (17.0) $ (6.1)Amortizationofpriorservicecostincludedinnetloss 0.2 0.1 0.1Amortizationofnetactuariallossincludedinnetloss 1.9 1.4 1.0Foreigncurrencyexchangeratechangesandother (1.9) 3.5 3.0Totalothercomprehensiveincome(loss)duringperiod $ 28.5 $ (12.0) $ (2.0)
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 17. Retirement Benefits (Continued)
Theinvestmentstrategyistodiversifyinfourmajorcategorieswithadesignatedpercentageinvestedineachincluding24%fixedincomesecurities,48%equitysecurities,ashareof11%inRealEstateSwitzerlandand17%inotheralternativeinvestments(seniorloans,hedgefundsandinsurance-linkedsecurities).Eachcategoryisdiversifiedandcomprisedofthefollowing:
• Fixed-incomesecurities—SwissBonds,GlobalAggregates,GlobalAggregateCorporatesandEmergingMarketsLocalCurrencies.
• Equityinvestments—SwissEquities,WorldEquitiesMSCI,LowVolatilityEquities(toreducerisk),EmergingMarketsEquitiesandrealestateinvestmenttrusts.
• RealEstateinSwitzerland—investmentfoundationsandfunds
• Otherinvestments—representsprimarilyprivateequitylikeinvestments,hedgefunds,insurance-linkedsecurities,cashandmark-to-marketderivatives.
Wedeterminethefairvalueoftheinvestmentsbasedonamarketapproachusingquotedmarketvalues,significantotherobservableinputsforidenticalorcomparableassetsorliabilities,ordiscountedcashflowanalysisforallinvestmentsexcepthedgefunds,privateequity-likeinvestmentsandrealestate.
Wedeterminethefairvalueofinvestmentsusingthevaluereportedbythepartnership,adjustedforknowncashflowsandsignificanteventsthroughourreportingdate.Valuesprovidedbythepartnershipsareprimarilybasedonanalysisofandjudgmentsabouttheunderlyinginvestments.InputstothesevaluationsincludeunderlyingNAVs,discountedcashflowvaluations,comparablemarketvaluations,andmayalsoincludeadjustmentsforcurrency,credit,liquidityandotherrisksasapplicable.Thevastmajorityoftheseprivatepartnershipsprovideuswithannualfinancialstatementsincludingtheircompliancewithfairvaluationproceduresconsistentwithapplicableaccountingstandards.
WedeterminethefairvalueofrealestateinvestmentsbasedontheNAVprovidedbythefundmanager.TheseNAVsaredevelopedwithinputsincludingdiscountedcashflow,independentappraisalandmarketcomparableanalyses.
F-42
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 17. Retirement Benefits (Continued)
ThefairvaluesofthesepensionplanassetsasofDecember31,2018byassetcategoryareasfollows:
NomaterialtransfersbetweenLevel1,Level2,orLevel3occurredduringtheyearendedDecember31,2018.TheactivityintheLevel3investmentsduringtheyearendedDecember31,2018wasnotmaterial.
F-43
Fair Value Measurements Using
Asset Class Total
Quoted Prices in Active
Markets for Identical Assets
(Level 1)
Significant Observable
Inputs (Level 2)
Significant Unobservable
Inputs (Level 3)
Investments Valued at Net Asset Value(1)
Publicequitysecurities $ 2.2 $ 1.0 $ — $ — $ 1.2Fixedincome: Developedmarkets 29.9 7.8 0.1 — 22.0Emergingmarkets 6.4 0.7 0.4 — 5.3
Privatealternativeinvestments: — Hedgefunds 6.6 — — — 6.6Equity-likefunds 49.0 — — — 49.0
Realestate 20.1 0.1 — — 20.0Other 17.4 0.3 2.3 — 14.8Total $ 131.6 $ 9.9 $ 2.8 $ — $ 118.9
(1) CertaininvestmentsthataremeasuredatfairvalueusingtheNAVpershare(oritsequivalent)asapracticalexpedienthavenotbeenclassifiedinthefairvaluehierarchy.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 17. Retirement Benefits (Continued)
ThefairvaluesofthesepensionplanassetsasofDecember31,2017byassetcategoryareasfollows:
NomaterialtransfersbetweenLevel1,Level2,orLevel3occurredduringtheyearendedDecember31,2017.TheactivityintheLevel3investmentsduringtheyearendedDecember31,2017wasnotmaterial.
Nocontributionstothesepensionplansareexpectedin2019.
Retiree Health Benefit Plan
TherearetworetireehealthbenefitplanwheretheplanliabilitiesthatrelatetoouremployeeswerelegallyrequiredtotransfertoElancoatthetimeofseparationfromLilly.Theaccruedretirementbenefitsfortheseplanswere$3.9millionand$9.8millionasofDecember31,2018and2017,respectively.
Defined Contribution Plans
Lillyhasdefinedcontributionsavingsplansthatincludecertainofouremployeesworldwide.Thepurposeoftheseplansisgenerallytoprovideadditionalfinancialsecurityduringretirementbyprovidingemployeeswithanincentivetosave.Ourcontributionstotheplansarebasedonouremployeecontributionsandthelevelofourmatch.Expensesrelatedtoouremployeesundertheplanstotaled$20.9million,$22.1millionand$19.6millionfortheyearsendedDecember31,2018,2017,and2016,respectively.
F-44
Fair Value Measurements Using
Asset Class Total
Quoted Prices in Active
Markets for Identical Assets
(Level 1)
Significant Observable
Inputs (Level 2)
Significant Unobservable
Inputs (Level 3)
Investments Valued at Net Asset Value(1)
Publicequitysecurities $ 0.8 $ 0.6 $ — $ — $ 0.2Fixedincome: Developedmarkets 29.9 8.2 0.1 — 21.6Emergingmarkets 7.2 0.6 0.3 — 6.3
Privatealternativeinvestments: Hedgefunds 6.8 — — — 6.8Equity-likefunds 52.7 — — — 52.7
Realestate 20.2 — — — 20.2Other 13.9 0.1 0.1 13.7Total $ 131.5 $ 9.5 $ 0.5 $ — $ 121.5
(1) CertaininvestmentsthataremeasuredatfairvalueusingtheNAVpershare(oritsequivalent)asapracticalexpedienthavenotbeenclassifiedinthefairvaluehierarchy.
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 18. Earnings Per Share
AsdiscussedinNote1,ElancoParentwasformedforthepurposeoffacilitatingtheIPO.LillyheldallsharesofElancoParentfromthetimeofformationuntiltheIPO.
PriortoIPO,therewereanaggregateof293,290,000sharesofourcommonstockheldbyLilly(whichrepresentsthe100sharesheldbyLillypriortogivingeffecttothe2,932,900-for-1stocksplitthatoccurredonSeptember19,2018).InconnectionwiththecompletionoftheIPO,anadditional72,335,000sharesofourcommonstockwereissued.
EarningspersharewascalculatedbasedontheweightedaveragesharesoutstandingduringeachperiodbasedontheassumptionthatthesharesheldbyLillywereoutstandingforallperiodspriortoIPO.
Note 19. Related Party Agreements and Transactions
Transactions with Lilly Subsequent to Separation and Related to the Separation
AsdescribedinNote1,inconnectionwiththeSeparation,Lillytransferredtoussubstantiallyallofitsanimalhealthbusinessesinexchangeforapproximately$4.2billion.ThisisreflectedasconsiderationtoLillyinourconsolidatedandcombinedstatementofequity.ThetermsofourseparationarecoveredbyamasterservicesagreemententeredwithLilly(MSA).UnderthetermsoftheMSA,throughaseriesoftransactions,LillytransferredtousthebusinessesthatwillcontinueaspartofElanco.
Foracertainportionofouroperations,thelegaltransferofournetassetsdidnotoccurpriortotheSeparationduetocertainregulatoryrequirementsineachofthesecountries.UndertheMSAenteredintowithLilly,weareresponsibleforthebusinessactivitiesconductedbyLillyonourbehalfandaresubjecttotherisksandentitledtothebenefitsgeneratedbytheseoperationsandassets.Asaresult,therelatedassetsandliabilitiesandresultsofoperationshavebeenreportedinourconsolidatedandcombinedfinancialstatements.Thetotalnetassetsassociatedwiththesejurisdictionsare$95.6millionandtheannualprofitsareinsignificant.AsofDecember31,2018,wehave$202.7millionofrestrictedcashonourconsolidatedandcombinedbalancesheetalongwithanoffsettingPayabletoLilly,whichreflectsthecashthatwillbeusedtofundthepurchaseofthelocalcountryassetsfromLilly.
AtthetimeoftheIPO,weenteredintoanumberofagreementsrelatedtoongoingactivitiesbetweenElancoandLillyincludingthefollowing:
• TransitionalServicesAgreement.Historically,Lillyhasprovidedussignificantsharedservicesandresourcesrelatedtocorporatefunctionssuchasexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations,whichwerefertocollectivelyasthe"LillyServices."UnderthetermsoftheTSA,wewillbeabletouseLillyServicesforafixedtermestablishedonaservice-by-servicebasis.WewillpayLillymutuallyagreed-uponfeesfortheLillyServicesprovidedundertheTSA,whichwillbebasedonLilly'scost(includingthird-partycosts)ofprovidingtheLillyServicesthroughMarch31,2021,andsubjecttoamark-upof7%thereafter,withadditionalinflation-basedescalationbeginningJanuary1,2020.ThefeesundertheTSAbecomepayableforallperiodsbeginningafterOctober1,2018.
F-45
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 19. Related Party Agreements and Transactions (Continued)
• IntellectualPropertyandTechnologyLicenseAgreement.WeenteredintoanintellectualpropertyandtechnologylicenseagreementwithLillyimmediatelypriortothecompletionoftheIPO.Undertheintellectualpropertyandtechnologylicenseagreement,LillygrantedElancoanexclusive,perpetuallicensetoexploitproductsintheanimalhealthfieldthatutilizeorusecertainofLilly'sintellectualproperty(excludingtrademarks).Inaddition,LillygrantedElanconon-exclusive,non-sublicensablelicensetoscreencertaincompoundsinLilly'scompoundlibrariestoexploitproductsintheanimalusecertainofLilly'sintellectualproperty.Thisscreeninglicensehasaninitialtermoftwoyears,subjecttothreeone-yearextensions,eachofwhichrequiresLilly'sconsent.
Wealsoenteredintoataxmattersagreement(TMA),anemployeemattersagreement,atollmanufacturingandsupplyagreementandaregistrationrightsagreementwithLillyinconnectionwiththeSeparation.
Ourconsolidatedandcombinedfinancialstatementofoperationsincludesrevenueof$7.0millionrelatedtoatollmanufacturingarrangementand$28millionrelatedtoTSAcharges.
AtDecember31,2018,wehaveapayabletoLillyof$66.0millionreflectedinPayabletoLillyonourconsolidatedandcombinedbalancesheetrelatedtoongoingtransactionswithLillyincludingthosetransactionsdescribedaboveandthereimbursementofcertaincostsLillyincurredonourbehalfduringtheperiod.
Transactions with Lilly Prior to Separation
PriortoIPO,wedidnotoperateasastandalonebusinessandhadvariousrelationshipswithLillywherebyLillyprovidedservicestous.Theimpactonourhistoricalcombinedfinancialstatementsincludesthefollowing:
Transfers to/from Lilly, net
Asdiscussedinthebasisofpresentation,netparentcompanyinvestmentisprimarilyimpactedbycontributionsfromLilly,whicharetheresultoftreasuryactivityandnetfundingprovidedbyordistributedtoLilly.FortheyearsendedDecember31,2018,2017and2016,thenettransfers(to)/fromLillywere$(226.3)million,$873.3millionand($129.2)million,respectively.Themostsignificantactivityimpactingthe2017transferwasthefinancingbyLillyofouracquisitionintheamountof$882.1millionforBoehringerIngelheimVetmedica,Inc.'sUnitedStatesfeline,canine,andrabiesvaccineportfolioandotherrelatedassetsin2017.Otheractivitiesthatimpactedthenettransfers(to)/fromLillyincludecorporateoverheadandotherallocations,incometaxes,retirementbenefits,andcentralizedcashmanagement.
Corporate Overhead and Other Allocations
Lillyprovidesuscertainservices,includingexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations.WeprovideLillycertainservicesrelatedtomanufacturingsupport.OurfinancialstatementsreflectanallocationofthesecostspriortoIPO.Whenspecificidentificationisnotpracticable,theremainderhavebeenallocatedprimarilyonaproportionalcostmethodonabasisofrevenueorheadcount.
F-46
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 19. Related Party Agreements and Transactions (Continued)
TheallocationsofservicesfromLilly,priortoIPO,touswerereflectedasfollowsinthecombinedstatementsofoperations:
WeprovideLillycertainservicesrelatedtomanufacturingsupport.AllocationsofmanufacturingsupportfromustoLilly$3.7million,$6.2millionand$5.5millionforthefortheyearsendedDecember31,2018,2017and2016,respectively,reducedthecostofsalesintheconsolidatedandcombinedstatementsofoperations.
Thefinancialinformationhereinmaynotnecessarilyreflectourconsolidatedfinancialposition,resultsofoperationsandcashflowsinthefutureorwhattheywouldhavebeenifwehadbeenaseparate,standaloneentityduringtheperiodspresented.Managementbelievesthatthemethodsusedtoallocateexpensesarereasonable.
Stock-based Compensation
AsdiscussedinNote13,ouremployeesparticipateinLillystock-basedcompensationplans,thecostsofwhichhavebeenallocatedtousandrecordedincostofsales,researchanddevelopment,andmarketing,sellingandadministrativeexpensesintheconsolidatedandcombinedstatementsofoperations.Thecostsofsuchplansrelatedtoouremployeeswere$26.0million,$25.0millionand$20.4millionfortheyearendedDecember31,2018,2017and2016,respectively.
Retirement Benefits
AsdiscussedinNote17,ouremployeesparticipateindefinedbenefitpensionandotherpostretirementplanssponsoredbyLilly,thecostsandbenefitsofwhichhavebeenrecordedintheconsolidatedandcombinedstatementofoperationsincostofsales,researchanddevelopment,andmarketing,sellingandadministrativeexpenses.thecosts/(benefits)ofsuchplansrelatedtotheCompany'semployeeswere$(6.3)million,$73.7millionand$11.3millionfortheyearsendedDecember31,2018,2017and2016,respectively.
Centralized Cash Management
Lillyusesacentralizedapproachtocashmanagementandfinancingofoperations.UntilSeparation,themajorityofourbusinesswaspartytoLilly'scashpoolingarrangementstomaximizeLilly'savailabilityofcashforgeneraloperatingandinvestingpurposes.Underthesecashpoolingarrangements,cashbalancesweresweptregularlyfromouraccountspriortoIPO.Cashtransfersto
F-47
2018(1) 2017 2016 Costofsales $ 21.8 $ 31.8 $ 32.5Researchanddevelopment 2.2 2.8 2.3Marketing,sellingandadministrative 81.2 117.1 110.5Total $ 105.2 $ 151.7 $ 145.3
(1) ThroughSeptember30,2018
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 19. Related Party Agreements and Transactions (Continued)
andfromLilly'scashconcentrationaccountsandtheresultingbalancesattheendofeachreportingperiodwerereflectedinnetparentcompanyinvestmentinthecombinedbalancesheets.
Debt
PriortoIPO,Lilly'sthird-partydebtandtherelatedinterestexpensewerenotallocatedtousforanyoftheperiodspresentedinthecombinedstatementofoperationsandbalancesheetsaswewerenotthelegalobligorofthedebtandLillyborrowingswerenotdirectlyattributabletoourbusiness.
Other Related Party Transactions
Wesellcertainproductstoandreceivecertaingoodsandservicesfromacustomer/vendor,whosechairmanandChiefExecutiveOfficerisamemberofLilly'sBoardofDirectors.Theseproductsalesresultedinrevenueof$23.5million,$24.8millionand$14.3millionfortheyearsendedDecember31,2018,2017and2016,respectively.Theproductsalesresultedinaccountsreceivableof$2.5millionand$2.0millionatDecember31,2018and2017,respectively.Thepurchaseofgoodsandservicesresultedincostofsalesandoperatingexpensesof$3.9million,$5.9millionand$7.1millionfortheyearsendedDecember31,2018,2017and2016,respectively.Thepurchaseofgoodsandservicesresultedinaccountspayableof$0.7millionand$0.4millionatDecember31,2018and2017,respectively.
Note 20. Selected Quarterly Data (unaudited)
F-48
2018 Fourth Third Second First Revenue $ 799.3 $ 761.1 $ 770.2 $ 736.2Costofsales 412.5 369.8 431.5 360.0Operatingexpenses(1) 246.2 237.9 252.5 245.2AssetImpairment,restructuring,andotherspecialcharges 46.0 12.4 68.0 2.4Interestexpense,netofcapitalizedinterest 21.0 8.6 — —Income(loss)beforeincometaxes (2.2) 78.8 (40.0) 77.5Incometaxes (18.6) 18.6 22.8 4.8Netincome(loss) 16.4 60.2 (62.8) 72.7Earnings(loss)pershare—basicanddiluted 0.04 0.20 (0.21) 0.25
TableofContents
Elanco Animal Health Incorporated
Notes to Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 20. Selected Quarterly Data (unaudited) (Continued)
F-49
2017 Fourth Third Second First Revenue $ 754.3 $ 697.1 $ 732.8 $ 704.8Costofsales 405.0 376.2 374.0 338.6Operatingexpenses(1) 258.8 256.6 257.8 258.3AssetImpairment,restructuring,andotherspecialcharges 185.8 23.7 58.8 106.8Interestexpense,netofcapitalizedinterest — — — —Income(loss)beforeincometaxes (155.4) (9.1) (15.2) (52.9)Incometaxes 6.1 11.6 15.0 45.4Netincome(loss) (161.5) (20.7) (30.2) (98.3)Earnings(loss)pershare—basicanddiluted (0.55) (0.07) (0.10) (0.34)
(1) Includesresearchanddevelopmentandmarketing,selling,andadministrativeexpenses.
TableofContents
Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined Statements of Operations
(Dollars and shares in millions, except per-share data)
Seenotestounauditedcondensedconsolidatedandcombinedfinancialstatements.
F-50
Three Months Ended
March 31, 2019 2018 Revenue $ 731.1 $ 736.2Costs,expensesandother: Costofsales 343.8 360.0Researchanddevelopment 64.1 65.2Marketing,sellingandadministrative 181.1 180.0Amortizationofintangibleassets 49.0 49.2Assetimpairments,restructuringandotherspecialcharges(Note6) 24.9 2.4Interestexpense,netofcapitalizedinterest 20.8 —Other—net,expense 2.6 1.9
686.3 658.7Incomebeforeincometaxes 44.8 77.5Incometaxexpense 13.3 4.8
Netincome $ 31.5 $ 72.7Earningspershare: Basic $ 0.09 $ 0.25Diluted $ 0.09 $ 0.25
Weightedaveragesharesoutstanding: Basic 365.7 293.3Diluted 366.0 293.3
TableofContents
Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined Statements of Comprehensive Income
(Dollars in millions)
Seenotestounauditedcondensedconsolidatedandcombinedfinancialstatements.
F-51
Three Months Ended
March 31, 2019 2018 Netincome $ 31.5 $ 72.7Othercomprehensiveincome(loss): Foreigncurrencytranslation (30.2) 119.2Definedbenefitpensionandretireehealthbenefitplans,netoftaxes 2.0 (0.6)
Othercomprehensiveincome(loss),netoftax (28.2) 118.6Comprehensiveincome $ 3.3 $ 191.3
TableofContents
Elanco Animal Health Incorporated
Unaudited Condensed Consolidated Balance Sheets
(Dollars in millions)
Seenotestounauditedcondensedconsolidatedandcombinedfinancialstatements.
F-52
March 31,
2019 December 31,
2018 (Unaudited) Assets Current Assets Cashandcashequivalents $ 272.1 $ 474.8Accountsreceivable,netofallowancesof$8.3(2019)and$8.4(2018) 684.1 651.8Otherreceivables 107.8 57.6Inventories(Note7) 1,035.5 1,004.1Prepaidexpensesandother 114.8 113.9ReceivablefromLilly(Note15) 35.5 —Restrictedcash(Note15) 28.5 202.7
Totalcurrentassets 2,278.3 2,504.9Noncurrent Assets Goodwill 2,933.1 2,958.0Otherintangibles,net 2,386.5 2,453.0Othernoncurrentassets 219.3 118.4Propertyandequipment,netofaccumulateddepreciation$909.3(2019)and$878.6(2018) 930.2 922.4
Totalassets $ 8,747.4 $ 8,956.7Liabilities and Equity Current Liabilities Accountspayable $ 252.1 $ 205.2Employeecompensation 64.2 98.9Salesrebatesanddiscounts 171.7 169.9Currentportionoflong-termdebt(Note8) 29.0 29.0Othercurrentliabilities 191.2 199.0PayabletoLilly(Note15) — 268.7
Totalcurrentliabilities 708.2 970.7Noncurrent Liabilities Long-termdebt(Note8) 2,436.6 2,443.3Accruedretirementbenefits 106.2 109.1Deferredtaxes(Note11) 131.8 114.6Othernoncurrentliabilities 168.4 121.5
Totalliabilities 3,551.2 3,759.2Commitments and Contingencies (Note 12) — —Equity Commonstock,noparvalue,5,000,000,000sharesauthorized,365,702,757and365,643,911sharesissuedandoutstandingasofMarch31,2019andDecember31,2018,respectively — —
Additionalpaid-incapital 5,398.7 5,403.3Retainedearnings 47.9 16.4Accumulatedothercomprehensiveloss (250.4) (222.2)
Totalequity 5,196.2 5,197.5Totalliabilitiesandequity $ 8,747.4 $ 8,956.7
TableofContents
Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined Statements of Equity
(Dollars and shares in millions)
Seenotestounauditedcondensedconsolidatedandcombinedfinancialstatements.
F-53
Accumulated Other Comprehensive
Income (Loss)
Common Stock
Defined Benefit Pension and
Retiree Health Benefit Plans
Additional Paid-in Capital
Net Parent Company Investment
Retained Earnings
Foreign Currency
Translation
Total Equity
Shares Amount Total December31,2017 293.3 $ — $ — $ 8,036.9 $ — $ (227.2) $ (29.4) $ (256.6) $ 7,780.3AdoptionofAccountingStandardsUpdate2016-16 — — — (0.3) — — — — (0.3)Netincome — — — 72.7 — — — — 72.7Othercomprehensiveincome(loss),netoftax — — — — — 119.2 (0.6) 118.6 118.6Transfers(to)/fromLilly,net — — — (69.2) — — — — (69.2)
March31,2018 293.3 $ — $ — $ 8,040.1 $ — $ (108.0) $ (30.0) $ (138.0) $ 7,902.1December31,2018 365.6 $ — $ 5,403.3 $ — $ 16.4 $ (218.2) $ (4.0) $ (222.2) $ 5,197.5Netincome — — — — 31.5 — — — 31.5Othercomprehensiveincome(loss),netoftax — — — — — (30.2) 2.0 (28.2) (28.2)Netcapitalcontributionsfrom/(distributionsto)Lilly(1) — — (7.0) — — — — — (7.0)Stockcompensation — — 2.4 — — — — — 2.4Issuanceofstockunderemployeestockplans,net 0.1 — — — — — — — —
March31,2019 365.7 $ — $ 5,398.7 $ — $ 47.9 $ (248.4) $ (2.0) $ (250.4) $ 5,196.2
(1) SeeNote15:RelatedPartyAgreementsandTransactionsforfurtherdiscussion.
TableofContents
Elanco Animal Health Incorporated
Unaudited Condensed Consolidated and Combined Statements of Cash Flows
(Dollars in millions)
Seenotestounauditedcondensedconsolidatedandcombinedfinancialstatements.
F-54
Three Months
Ended March 31, 2019 2018 Cash Flows from Operating Activities Netincome $ 31.5 $ 72.7
AdjustmentstoReconcileNetIncometoCashFlowsfromOperatingActivities: Depreciationandamortization 83.1 74.3Changeindeferredincometaxes 16.3 (2.4)Stock-basedcompensationexpense 7.7 6.9Assetimpairmentcharges 4.0 —Otherchangesinoperatingassetsandliabilities (127.6) (105.9)Othernon-cashoperatingactivities,net (9.4) 1.4
Net Cash Provided by Operating Activities 5.6 47.0Cash Flows from Investing Activities
Netpurchasesofpropertyandequipment (28.0) (32.7)Otherinvestingactivities,net (0.5) (1.7)
Net Cash Used for Investing Activities (28.5) (34.4)Cash Flows from Financing Activities
Repaymentsofborrowings(Note8) (7.5) —ConsiderationpaidtoLillyinconnectionwiththeSeparation(Note1) (175.1) —OthernetfinancingtransactionswithLilly (156.4) (76.1)Otherfinancingactivities,net (0.5) (0.4)
Net Cash Used for Financing Activities (339.5) (76.5)Effectofexchangeratechangesoncashandcashequivalents (14.5) 3.9Netdecreaseincash,cashequivalentsandrestrictedcash (376.9) (60.0)Cash,cashequivalentsandrestrictedcashatJanuary1 677.5 323.4Cash, cash equivalents and restricted cash at March 31 $ 300.6 $ 263.4
March 31, 2019 2018 Cashandcashequivalents $ 272.1 $ 263.4Restrictedcash(Note15) 28.5 —Cash, cash equivalents and restricted cash at March 31 $ 300.6 $ 263.4
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1. Nature of Business and Organization
Nature of Business
ElancoAnimalHealthIncorporated(ElancoParent)anditssubsidiaries(collectively,Elanco,theCompany,we,usorour)wasformedasawholly-ownedsubsidiaryofEliLillyandCompany(Lilly).Elancoisaglobalanimalhealthcompanythatinnovates,develops,manufacturesandmarketsproductsforcompanionandfoodanimals.Weofferadiverseportfolioofmorethan125brandstoveterinariansandfoodanimalproducersinmorethan90countries.
Organization
ElancoParentwasformedin2018,asawholly-ownedsubsidiaryofLilly,toserveastheultimateparentcompanyofsubstantiallyalloftheanimalhealthbusinessesofLilly.
OnSeptember24,2018,ElancoParentcompletedaninitialpublicofferingresultingintheissuanceof72.3millionsharesofitscommonstock(includingsharesissuedpursuanttotheunderwriters'optiontopurchaseadditionalshares),whichrepresented19.8%oftheoutstandingshares,at$24pershare(IPO)foratotalnetproceeds,afterunderwritingdiscountsandcommissions,of$1.7billion.InconnectionwiththecompletionoftheIPO,throughaseriesofequityandothertransactions,LillytransferredtoElancoParenttheanimalhealthbusinessesthatformitsbusinessgoingforward.InexchangeElancoParenthaspaid,orwillpay,toLillyapproximately$4.2billion,whichincludesthenetproceedsfromtheIPO,thenetproceedsfromthedebtofferingcompletedbyElancoParentinAugust2018andthetermloanfacilityenteredintobyElancoParentinSeptember2018(seeNote8).ThesetransactionsarecollectivelyreferredtohereinastheSeparation.
OnFebruary8,2019,LillyannouncedanexchangeofferwherebyLillyshareholderscouldexchangealloraportionofLillycommonstockforsharesofElancocommonstockownedbyLilly.ThedispositionofElancoshareswascompletedonMarch11,2019andresultedinthefullseparationofElancoanddisposalofLilly'sentireownershipandvotinginterestinElanco.
Note 2. Basis of Presentation
WehavepreparedtheaccompanyingunauditedcondensedconsolidatedandcombinedfinancialstatementsinaccordancewiththerequirementsofForm10-Qand,therefore,theydonotincludeallinformationandfootnotesnecessaryforafairpresentationoffinancialposition,resultsofoperations,andcashflowsinconformitywithaccountingprinciplesgenerallyacceptedintheUnitedStates(GAAP).Inouropinion,thefinancialstatementsreflectalladjustments(includingthosethatarenormalandrecurring)thatarenecessaryforafairpresentationoftheresultsofoperationsfortheperiodsshown.InpreparingfinancialstatementsinconformitywithGAAP,wemustmakeestimatesandassumptionsthataffectthereportedamountsofassets,liabilities,revenue,expenses,andrelateddisclosuresatthedateofthefinancialstatementsandduringthereportingperiod.Actualresultscoulddifferfromthoseestimates.
Certainreclassificationshavebeenmadetopriorperiodsintheunauditedcondensedconsolidatedandcombinedfinancialstatementsandaccompanyingnotestoconformwithcurrentpresentation.
F-55
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 2. Basis of Presentation (Continued)
TheinformationincludedinthisQuarterlyReportonForm10-QshouldbereadinconjunctionwithourcombinedfinancialstatementsandaccompanyingnotesfortheyearendedDecember31,2018includedinourAnnualReportonForm10-KfiledwiththeSEConFebruary20,2019.
FortheperiodsafterSeparation,thefinancialstatementsarepreparedonaconsolidatedbasisandreflecttheresultsofoperations,comprehensiveincome,financialposition,equityandcashflowsresultingfromouroperationsasanindependentcompany.ForperiodspriortotheSeparation,ourfinancialstatementsarecombined,havebeenpreparedonastandalonebasis,andarederivedfromLilly'sconsolidatedfinancialstatementsandaccountingrecords.Theconsolidatedandcombinedfinancialstatementsreflectthefinancialposition,resultsofoperationsandcashflowsrelatedtotheanimalhealthbusinessesthatweretransferredtoElancoParentandarepreparedinconformitywithGAAP.
ThecombinedfinancialstatementsincludetheattributionofcertainassetsandliabilitiesthathistoricallyhavebeenheldattheLillycorporatelevelbutwhicharespecificallyidentifiableorattributabletothebusinessesthathavebeentransferredtoElancoParent.AllintercompanytransactionsandaccountswithinElancohavebeeneliminated.AlltransactionsbetweenusandLillyareconsideredtobeeffectivelysettledinthecombinedfinancialstatementsatthetimetheintercompanytransactionisrecorded.Thetotalneteffectofthesettlementoftheseintercompanytransactionsisreflectedinthecombinedstatementsofcashflowsasafinancingactivityandinthecondensedconsolidatedandcombinedstatementofequityasnetparentcompanyinvestment.
PriortoSeparation,thesecombinedfinancialstatementsincludeanallocationofexpensesrelatedtocertainLillycorporatefunctions,includingexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations,priortoIPO.Theseexpenseshavebeenallocatedtousbasedondirectusageorbenefitwherespecificallyidentifiable,withtheremainderallocatedprimarilyonaproratabasisofrevenue,headcountandothermeasures.Weconsidertheexpensesmethodologyandresultstobereasonableforallperiodspresented.However,theallocationsmaynotbeindicativeoftheactualexpensethatwouldhavebeenincurredhadweoperatedasanindependent,publiclytradedcompanyfortheperiodspresented.ItisimpracticaltoestimatewhatthestandalonecostsofElancowouldhavebeeninthehistoricalperiods.AftertheSeparation,aTransitionalServicesAgreement(TSA)betweenLillyandElancowentintoeffect.UnderthetermsoftheTSA,wewillbeabletousetheseLillyservicesforafixedtermestablishedonaservice-by-servicebasis.WearepayingLillymutuallyagreeduponfeesfortheLillyservicesprovidedundertheTSA.OurconsolidatedandcombinedfinancialstatementsreflectthechargesforLillyservicesaftertheIPO.SeeNote15foradditionaldetails.
Theincometaxamountsinthecombinedfinancialstatementshavebeencalculatedbasedonaseparatereturnmethodologyandpresentedasifouroperationswereseparatetaxpayersintherespectivejurisdictions.WefileincometaxreturnsintheUnitedStates(U.S.)federaljurisdictionandvariousstate,localandnon-U.S.jurisdictions.CertainoftheseincometaxreturnsarefiledonaconsolidatedorcombinedbasiswithEliLillyandCompanyand/oritssubsidiaries.
PriortoSeparation,Lillymaintainedvariousbenefitandcombinedstock-basedcompensationplansatacorporatelevelandotherbenefitplansatacountrylevel.Ouremployeesparticipatedinsuchprogramsandtheportionofthecostofthoseplansrelatedtoouremployeesisincludedinour
F-56
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 2. Basis of Presentation (Continued)
financialstatements.However,thecondensedbalancesheetsdonotincludeanyequityissuedrelatedtostock-basedcompensationplansoranynetbenefitplanobligationsunlessthebenefitplancoversonlyourdedicatedemployeesorwherethelegalobligationassociatedwiththebenefitplantransferredtoElanco.UponLilly'sfulldivestitureofElancoinMarch2019,allLillyshare-basedawardsheldbyouremployeeswereconvertedintoawardsthatwillbesettledinElancoshares.
PriortoSeparation,theequitybalanceinthecombinedfinancialstatementsrepresentstheexcessoftotalassetsoverliabilities,includingintercompanybalancesbetweenElancoandLilly(netparentcompanyinvestment)andaccumulatedothercomprehensiveincome/(loss).NetparentcompanyinvestmentisprimarilyimpactedbycontributionsfromLillywhicharetheresultoftreasuryactivitiesandnetfundingprovidedbyordistributedtoLilly.SeeNote15forfurtherinformation.
Note 3. Impact of Separation
InconnectionwiththeSeparation,weissued$2.0billionaggregateprincipalamountofseniornotesinaprivateplacement,andwealsoenteredintoa$750.0millionseniorunsecuredrevolvingcreditfacilityand$500.0millionseniorunsecuredtermcreditfacility.InconnectionwiththeSeparation,weenteredintovariousagreementswithLilly,includingamasterseparationagreement,ataxmattersagreementandatransitionalservicesagreement.
WewillcontinuetohavecertainongoingrelationshipswithLillyasdescribedinNote15.
F-57
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 4. Implementation of New Financial Accounting Pronouncements
ThefollowingtableprovidesabriefdescriptionoftheaccountingstandardthatwaseffectiveJanuary1,2019andwasadoptedonthatdate:
F-58
Standard Description Effect on the financial statements
or other significant mattersAccountingStandardsUpdate2016-02,Leases Thisstandardwasissuedtoincreasetransparencyandcomparability
amongorganizationsbyrecognizingleaseassetsandleaseliabilities,includingleasesclassifiedasoperatingleasesunderpreviousGAAP,onthebalancesheetandrequiringadditionaldisclosuresaboutleasingarrangements.
WeadoptedthestandardonJanuary1,2019usingthemodifiedretrospectiveapproach,appliedatthebeginningoftheperiodofadoption,andweelectedthepackageoftransitionpracticalexpedients.Uponadoptionofthestandard,werecorded$84.9millionofright-of-useassetsand$85.3millionofoperatingleaseliabilitiesonourconsolidatedbalancesheet.AdoptionofthisstandarddidnothaveamaterialimpactonourconsolidatedstatementofoperationsforthethreemonthsendedMarch31,2019.SeeNote10:Leasesforfurtherinformation.
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 4. Implementation of New Financial Accounting Pronouncements (Continued)
Thefollowingtableprovidesabriefdescriptionoftheaccountingstandardsthathavenotyetbeenadoptedandcouldhaveamaterialeffectontheconsolidatedfinancialstatements:
Note 5. Revenue
Product Sales
Werecognizerevenueprimarilyfromproductsalestocustomers.Revenuefromsalesofproductsisrecognizedatthepointwherethecustomerobtainscontrolofthegoodsandwesatisfyourperformanceobligation,whichgenerallyisatthetimeweshiptheproducttothecustomer.Paymenttermsdifferbyjurisdictionandcustomer,butpaymenttermsinmostofourmajorjurisdictionstypicallyrangefrom30to100daysfromdateofshipment.Revenueforourproductsaleshasnotbeenadjustedfortheeffectsofafinancingcomponentasweexpect,atcontractinception,thattheperiodbetween
F-59
Standard Description Effective Date
Effect on the financial statements or
other significant mattersAccountingStandardsUpdate2016-13,Financial
Instruments—Credit Losses (Topic 326):Measurement of Credit Losses on FinancialInstruments
Thisstandardmodifiestheimpairmentmodelbyrequiringentitiestouseaforward-lookingapproachbasedonexpectedlossestoestimatecreditlossesoncertaintypesoffinancialinstruments,includingtradereceivables.Thismayresultintheearlierrecognitionofallowancesforlosses.
ThisstandardiseffectiveJanuary1,2020,withearlyadoptionpermitted.Weintendtoadoptthisstandardonthatdate.
Wearecurrentlyevaluatingtheeffectofthisstandardonourfinancialstatements.
AccountingStandardsUpdate2018-15,Intangibles—Goodwill and Other Internal-Use Software(Subtopic 350-40): Customer's Accounting forImplementation Costs Incurred in a CloudComputing Arrangement that is a ServiceContract
Thisguidancealignstherequirementsforcapitalizingimplementationcostsincurredinacloud-basedhostingarrangementthatisaservicecontractwiththerequirementsforcapitalizingimplementationcostsincurredtodeveloporobtaininternal-usesoftware.
ThisstandardiseffectiveJanuary1,2020,withearlyadoptionpermitted.Weintendtoadoptthisstandardonthatdate.
Wearecurrentlyevaluatingtheeffectofthisstandardonourfinancialstatements.
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 5. Revenue (Continued)
whenwetransfercontroloftheproductandwhenwereceivepaymentwillbeoneyearorless.Anyexceptionsareeithernotmaterialorwecollectinterestforpaymentsmadeaftertheduedate.Provisionsforrebatesanddiscounts,andreturnsareestablishedinthesameperiodtherelatedsalesarerecognized.Wegenerallyshipproductshortlyafterordersarereceived;therefore,wegenerallyonlyhaveafewdaysofordersreceivedbutnotyetshippedattheendofanyreportingperiod.Shippingandhandlingactivitiesareconsideredtobefulfillmentactivitiesandarenotconsideredtobeaseparateperformanceobligation.Weexcludefromthemeasurementofthetransactionpricealltaxesassessedbyagovernmentalauthoritythatareimposedonoursalesofproductandcollectedfromacustomer.
Significantjudgmentsmustbemadeindeterminingthetransactionpriceforsalesofproductsrelatedtoanticipatedrebatesanddiscounts,andreturns.Thefollowingdescribethemostsignificantofthesejudgments:
Sales Rebates and Discounts—Background and Uncertainties
• Mostofourproductsaresoldtowholesaledistributors.Weinitiallyinvoiceourcustomerscontractuallistprices.Contractswithdirectandindirectcustomersmayprovideforvariousrebatesanddiscountsthatmaydifferineachcontract.Asaconsequence,todeterminetheappropriatetransactionpriceforourproductsalesatthetimewerecognizeasaletoadirectcustomer,wemustestimateanyrebatesordiscountsthatultimatelywillbeduetothedirectcustomerandothercustomersinthedistributionchainunderthetermsofourcontracts.Judgmentsarerequiredinmakingtheseestimates.
• Therebateanddiscountamountsarerecordedasadeductiontoarriveatournetproductsales.Weestimatetheseaccrualsusinganexpectedvalueapproach.
• Indeterminingtheappropriateaccrualamount,weconsiderourhistoricalexperiencewithsimilarincentivesprogramsandcurrentsalesdatatoestimatetheimpactofsuchprogramsonrevenueandcontinuallymonitortheimpactofthisexperienceandadjustasnecessary.Althoughweaccruealiabilityforrebatesrelatedtotheseprogramsatthetimethesaleisrecorded,therebaterelatedtothatsaleistypicallypaiduptosixmonthsaftertherebateorincentiveperiodexpires.Becauseofthistimelag,inanyparticularperiodrebateadjustmentsmayincorporaterevisionsofaccrualsforseveralperiods.
OursalesrebatesanddiscountsarebasedonspecificagreementsandthemajorityrelatetosalesintheU.S.AsofMarch31,2019and2018,liabilityforsalesrebatesanddiscountsintheU.S.representsapproximately72%and69%,respectively,ofourtotalliabilitywiththenextlargestcountryrepresentingapproximately8%and5%,respectively,ofourtotalliability.
F-60
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 5. Revenue (Continued)
ThefollowingtablesummarizestheactivityinthesalesrebatesanddiscountsliabilityintheU.S.:
AdjustmentstorevenuerecognizedasaresultofchangesinestimatesforthejudgmentsdescribedaboveduringthethreemonthsendedMarch31,2019and2018forproductshippedinpreviousperiodswerenotmaterial.
Sales Returns—Background and Uncertainties
• Weestimateareserveforfutureproductreturnsrelatedtoproductsalesusinganexpectedvalueapproach.Thisestimateisbasedonseveralfactors,including:localreturnspoliciesandpractices;returnsasapercentageofrevenue;anunderstandingofthereasonsforpastreturns;estimatedshelflifebyproduct;andestimateoftheamountoftimebetweenshipmentandreturn.Adjustmentstothereturnsreservehavebeenandmayinthefutureberequiredbasedonrevisedestimatestoourassumptions,whichwouldhaveanimpactonourconsolidatedresultsofoperations.Werecordthereturnamountsasadeductiontoarriveatournetproductsales.
• Actualproductreturnswereapproximately0.3%and0.2%ofnetrevenueforthethreemonthsendedMarch31,2019and2018,respectively,andhavenotfluctuatedsignificantlyasapercentageofrevenue.
Disaggregation of Revenue
Thefollowingtablesummarizesourrevenuedisaggregatedbyproductcategory:
F-61
Three Months
Ended March 31, 2019 2018 Beginningbalance $ 118.5 $ 114.8Reductionofrevenue 65.7 44.5Payments (64.2) (68.2)
Endingbalance $ 120.0 $ 91.1
Three Months
Ended March 31, 2019 2018 CompanionAnimalDiseasePrevention $ 185.9 $ 201.3CompanionAnimalTherapeutics 81.4 62.3FoodAnimalFutureProtein&Health 167.2 166.7FoodAnimalRuminants&Swine 274.1 282.5StrategicExits(1) 22.5 23.4
Revenue $ 731.1 $ 736.2
(1) Representsrevenuefrombusinessactivitieswehaveeitherexitedormadeastrategicdecisiontoexit.
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 6. Asset Impairment, Restructuring and Other Special Charges
Ourtotalchargesrelatedtoassetimpairment,restructuringandotherspecialcharges,includingintegrationofacquiredbusinesses,intheunauditedcondensedconsolidatedandcombinedstatementsofoperationsconsistedofthefollowing:
Restructuring
WehistoricallyparticipatedinLilly'scost-reductioninitiatives,whichresultedinrestructuringchargesintheperiodpriortoourIPO.Therestructuringcostsincludeseveranceandothercostsincurredasaresultofactionstakentoreduceourcoststructure.
Integration
Integrationandothercostsprimarilyrepresentcostsrelatedtoourintegrationeffortsasaresultofouracquiredbusinessesandcoststostandourorganizationuptobeanindependentcompany.
Facility exit costs
Facilityexitcostsprimarilyrepresentcontractterminationcostsandreservesforcostsrelatedtofacilitieswhichwehaveexited.
Asset impairment
AssetimpairmentrecognizedduringthethreemonthsendedMarch31,2019resultedfromtheadjustmenttofairvalueofintangibleassetsthatweresubjecttoproductrationalization.
F-62
Three Months
Ended March 31, 2019 2018 Cashexpense: Severanceandother $ 0.5 $ 0.1Integration 20.4 2.8Facilityexitcosts — (0.5)
Totalcashexpense 20.9 2.4Non-cashexpense: Assetimpairment 4.0 —
Totalnon-cashexpense 4.0 —Totalexpense $ 24.9 $ 2.4
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 6. Asset Impairment, Restructuring and Other Special Charges (Continued)
Thefollowingtablesummarizestheactivityinourreservesestablishedinconnectionwiththeserestructuringactivities:
Substantiallyallofthereservesareexpectedtobepaidinthenexttwelvemonths.Webelievethatthereservesareadequate.
Note 7. Inventories
Westateallinventoriesatthelowerofcostornetrealizablevalue.Weusethelast-in,first-out(LIFO)methodforaportionofourinventorieslocatedinthecontinentalU.S.Otherinventoriesarevaluedbythefirst-in,first-out(FIFO)method.FIFOcostapproximatescurrentreplacementcost.
Inventoriesconsistedofthefollowing:
F-63
Facility exit
costs Severance Total BalanceatDecember31,2017 $ 34.9 $ 43.1 $ 78.0Charges — 0.1 0.1Reserveadjustments (0.2) — (0.2)Cashpaid (6.7) (13.6) (20.3)BalanceatMarch31,2018 $ 28.0 $ 29.6 $ 57.6BalanceatDecember31,2018 $ 9.3 $ 35.1 $ 44.4Charges — 0.5 0.5Cashpaid (0.3) (7.3) (7.6)BalanceatMarch31,2019 $ 9.0 $ 28.3 $ 37.3
March 31,
2019 December 31,
2018 Finishedproducts $ 415.5 $ 400.7Workinprocess 580.5 570.4Rawmaterialsandsupplies 83.7 80.4Total(approximatesreplacementcost) 1,079.7 1,051.5DecreasetoLIFOcost (44.2) (47.4)Inventories $ 1,035.5 $ 1,004.1
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 8. Debt
Long-termdebtconsistedofthefollowing:
Note 9. Financial Instruments and Fair Value
Financialinstrumentsthatarepotentiallysubjecttocreditriskconsistprincipallyoftradereceivables.Collateralisgenerallynotrequired.Theriskassociatedwiththisconcentrationismitigatedbyourongoingcredit-reviewproceduresandinsurance.
Alargeportionofourcashisheldbyafewmajorfinancialinstitutions.Wemonitortheexposurewiththeseinstitutionsanddonotexpectanyoftheseinstitutionstofailtomeettheirobligations.Allhighlyliquidinvestmentswithamaturityofthreemonthsorlessfromthedateofpurchaseareconsideredtobecashequivalents.Thecostoftheseinvestmentsapproximatesfairvalue.Wealsoconsiderthecarryingvalueofrestrictedcashbalancestoberepresentativeofitsfairvalue.
AsofMarch31,2019andDecember31,2018,wehad$15.7millionand$15.3million,respectively,ofequitymethodinvestmentsincludedinothernoncurrentassetsinourcondensedconsolidatedbalancesheet.
F-64
March 31,
2019 December 31,
2018 Termcreditfacility $ 485.0 $ 492.53.912%SeniorNotesdue2021 500.0 500.04.272%SeniorNotesdue2023 750.0 750.04.900%SeniorNotesdue2028 750.0 750.0Otherobligations 0.3 0.5Unamortizeddebtissuancecosts (19.7) (20.7)Totaldebt 2,465.6 2,472.3Lesscurrentportionoflong-termdebt 29.0 29.0Totallong-termdebt $ 2,436.6 $ 2,443.3
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 9. Financial Instruments and Fair Value (Continued)
ThefollowingtablesummarizesthefairvalueinformationatMarch31,2019andDecember31,2018forcontingentconsiderationliabilitiesandnetinvestmenthedgeliabilitymeasuredatfairvalueonarecurringbasisintherespectivebalancesheetlineitems:
WedetermineourLevel2fairvaluemeasurementsbasedonamarketapproachusingquotedmarketvalues,significantotherobservableinputsforidenticalorcomparableassetsorliabilities,ordiscountedcashflowanalysis.
ContingentconsiderationliabilitiesrelatetoGalliprantforwhichthefairvaluewasestimatedusingadiscountedcashflowanalysisandLevel3inputs,includingprojectionsrepresentativeofamarketparticipantviewfortheprobabilityofachievingpotentialfuturepaymentstoAratanaTherapeutics,Inc.andanestimateddiscountrate.Theamounttobepaidisdependentuponcertaindevelopment,success-basedregulatory,andsales-basedmilestones.Inaddition,theamountofroyaltiestobepaidiscalculatedasapercentageofnetsalesdependentuponthetimingandgeographyandwill,therefore,varydirectlywithincreasesanddecreasesinnetsalesofGalliprant.Thereisnocapontheamountthatmaybepaidpursuanttothisarrangement.
Wehavelongtermdebtof$2.5billionthatisrecordedatamortizedcostinourcondensedconsolidatedbalancesheetasofMarch31,2019andDecember31,2018.WeconsiderthecarryingvalueofthelongtermdebttoberepresentativeofitsfairvalueasofMarch31,2019andDecember31,2018.ThefairvalueofthislongtermdebtisestimatedbasedonquotedmarketpricesofsimilarliabilitiesandisclassifiedasLevel2.
F-65
Fair Value Measurements Using
Financial statement line item Carrying Amount
Quoted Prices in Active Markets for
Identical Assets (Level 1)
Significant Other Observable
Inputs (Level 2)
Significant Unobservable
Inputs (Level 3)
Fair Value
March31,2019 Othercurrentliabilities—contingentconsideration $ (9.2) $ — $ — $ (9.2) $ (9.2)Othernoncurrentliabilities—contingentconsideration (67.7) — — (67.7) (67.7)Othernoncurrentassets/(liabilities)—crosscurrencyinterestratecontractsdesignatedasnetinvestmenthedges 8.0 — 8.0 — 8.0
December31,2018 Othercurrentliabilities—contingentconsideration $ (5.1) $ — $ — $ (5.1) $ (5.1)Othernoncurrentliabilities—contingentconsideration (69.0) — — (69.0) (69.0)Othernoncurrentassets/(liabilities)—crosscurrencyinterestratecontractsdesignatedasnetinvestmenthedges (7.4) — (7.4) — (7.4)
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 9. Financial Instruments and Fair Value (Continued)
InOctober2018,weenteredintoacross-currencyfixedinterestrateswap,5-year,750millionSwissFranc(CHF),whichisdesignatedasanetinvestmenthedge(NIH)againstCHFdenominatedassetsforwhichthefairvaluewasestimatedbasedonquotedmarketvaluesofsimilarhedgesandisclassifiedasLevel2.TheNIHisexpectedtogenerateapproximately$25millionincashandanoffsettointerestexpenseonanannualbasis.DuringthethreemonthsendedMarch31,2019,ourinterestexpensewasoffsetby$6.1millionasaresultoftheNIH.Overthelifeofthederivative,gainsorlossesduetospotratefluctuationsarerecordedincumulativetranslationadjustment.DuringthethreemonthsendedMarch31,2019,werecordeda$12.2milliongain,netoftax,ontheNIH,whichisincludedinthechangeinthecumulativetranslationadjustmentinothercomprehensiveincome.Thereisapotentialforsignificant2023settlementexposureastheU.S.dollarfluctuatesagainsttheSwissFranc.TheriskmanagementobjectiveistomanageforeigncurrencyriskrelatingtonetinvestmentsincertainCHFdenominatedassets.ChangesinfairvalueofthederivativeinstrumentsarerecognizedinacomponentofAccumulatedOtherComprehensiveLosstooffsetthechangesinthevaluesofthenetinvestmentsbeinghedged.
Note 10. Leases
Wedetermineifanarrangementisaleaseatinception.Wehaveoperatingleasesforcorporateoffices,researchanddevelopmentfacilities,vehicles,andequipment.Ourleaseshaveremainingleasetermsofoneto10years,someofwhichhaveoptionstoextendorterminatetheleases.Financeleasesareincludedinpropertyandequipment,currentportionoflong-termdebt,andlong-termdebtinourcondensedconsolidatedbalancesheets.Financeleasesarenotmaterialtoourcondensedconsolidatedstatementsofoperations,condensedconsolidatedbalancesheets,orcondensedconsolidatedstatementsofcashflows.BeginningJanuary1,2019,operatingleasesareincludedinnoncurrentassets,othercurrentliabilities,andothernoncurrentliabilitiesinourconsolidatedbalancesheets.
Right-of-useassetsincludedinnoncurrentassetsrepresentourrighttouseanunderlyingassetfortheleasetermandleaseliabilitiesrepresentourobligationtomakeleasepaymentsarisingfromthelease.Right-of-useassetsandoperatingleaseliabilitiesarerecognizedatcommencementdatebasedonthepresentvalueofleasepaymentsovertheleaseterm.Asmostofourleasesdonotprovideanimplicitrate,weuseourincrementalborrowingratebasedontheinformationavailableatcommencementdateindeterminingthepresentvalueofleasepayments.Weusetheimplicitrateifitisreadilydeterminable.Theright-of-useassetalsoincludesanyleasepaymentsmadeandexcludesleaseincentives.Ourleasetermsmayincludeoptionstoextendorterminatetheleasewhenitisreasonablycertainandthereisasignificanteconomicincentivetoexercisethatoption.
Operatingleaseexpenseforright-of-useassetsisrecognizedonastraight-linebasisovertheleaseterm.Variableleasepayments,whichrepresentleasepaymentsthatvaryduetochangesinfactsorcircumstancesoccurringafterthecommencementdateotherthanthepassageoftime,areexpensedintheperiodinwhichtheobligationforthesepaymentswasincurred.VariableleaseexpenserecognizedinthethreemonthsendedMarch31,2019wasnotmaterial.
WeelectednottoapplytherecognitionrequirementsofASC842,Leases,toshort-termleases,whicharedeemedtobeleaseswithaleasetermof12monthsorless.Instead,werecognizedleasepaymentsinthecondensedconsolidatedstatementsofoperationsonastraight-linebasisovertheleasetermandvariablepaymentsintheperiodinwhichtheobligationforthesepaymentswasincurred.We
F-66
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 10. Leases (Continued)
electedthispolicyforallclassesofunderlyingassets.Short-termleaseexpenserecognizedinthethreemonthsendedMarch31,2019wasnotmaterial.Weelectednottoapplythepracticalexpedientrelatedtotheseparationofleaseandnon-leasecomponentsorthepracticalexpedientwhichallowsentitiestousehindsightwhendeterminingleaseterm.
Theimpactofoperatingleasestoourcondensedconsolidatedfinancialstatementswasasfollows:
Supplementalbalancesheetinformationrelatedtoouroperatingleasesisasfollows:
AsofMarch31,2019,theannualminimumleasepaymentsofouroperatingleaseliabilitieswereasfollows:
F-67
Three months ended
March 31, 2019
Lease cost Operatingleasecost $ 5.7Short-termleasecost 0.2Variableleasecost 0.5
Other information Operatingcashflowsfromoperatingleases 6.6Right-of-useassetsobtainedinexchangefornewoperatingleaseliabilities 0.1Weighted-averageremainingleaseterm—operatingleases 5yearsWeighted-averagediscountrate—operatingleases 4.2%
Balance Sheet Classification March 31,
2019 Right-of-useassets Othernoncurrentassets $ 80.7Currentoperatingleaseliabilities Othercurrentliabilities 21.8Non-currentoperatingleaseliabilities Othernoncurrentliabilities 59.4
Year1 $ 24.6Year2 19.6Year3 12.7Year4 9.5Year5 7.7AfterYear5 16.7Totalleasepayments 90.8Lessimputedinterest (9.6)Total $ 81.2
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 11. Income Taxes
Duringtheperiodspresentedintheconsolidatedandcombinedfinancialstatements,ouroperationsweregenerallyincludedinthetaxgroupingofotherLillyentitieswithintherespectiveentity'staxjurisdiction;however,incertainjurisdictions,wefiledseparatetaxreturns.PriortotheSeparation,theincometaxexpenseincludedinthesefinancialstatementshasbeencalculatedusingtheseparatereturnbasisasifElancofiledseparatetaxreturns.
InDecember2017,thePresidentoftheU.S.signedintolawtheTaxCutsandJobsAct(2017TaxAct).The2017TaxActincludessignificantchangestotheU.S.corporateincometaxsystem,suchasthereductioninthecorporateincometaxratefrom35percentto21percent,transitiontoaterritorialtaxsystem,changestobusinessrelatedexclusions,deductionsandcredits,andmodificationstointernationaltaxprovisions,includingaone-timerepatriationtransitiontax(alsoknownasthe'TollTax')onunremittedforeignearnings.
Wefinalizedouraccountingforthetaxeffectsofthe2017TaxActduring2018.Weexpectthatfurtherguidancewillcontinuetobeissuedin2019whichmayimpactourinterpretationsofthe2017TaxActandcouldmateriallyaffecttheestimatesused.The2017TaxActalsoincludesanewU.S.minimumtax,globalintangiblelow-taxedincome(GILTI),ontheearningsofourforeignsubsidiaries.WehaveelectedtoaccountforthetaxrelatedtoGILTIasaperiodcostintheyearthetaxisincurred.Deferredtaxesarerecognizedforthefuturetaxeffectsoftemporarydifferencesbetweenfinancialandincometaxreportingbasedonenactedtaxlawsandrates.Werecognizethetaxbenefitfromanuncertaintaxpositiononlyifitismorelikelythannotthatthetaxpositionwillbesustainedonexaminationbythetaxingauthorities,basedonthetechnicalmeritsoftheposition.Thetaxbenefitsrecognizedinthefinancialstatementsfromsuchapositionaremeasuredbasedonthelargestbenefitthathasagreaterthan50percentlikelihoodofbeingrealizeduponultimateresolution.
ForthethreemonthsendedMarch31,2019,weincurred$13.3millionofincometaxexpense.TheeffectiverateforthethreemonthsendedMarch31,2019,of29.7%wasdifferentfromthestatutoryincometaxrateprimarilyduetoaone-timeforeignexchangegainonthetransferofassetsuponseparationinadditiontotheimpactofstateincometaxes.
ForthethreemonthsendedMarch31,2018,weincurred$4.8millionofincometaxexpense.TheeffectivetaxrateforthethreemonthsendedMarch31,2018of6.2%wasdifferentfromthestatutoryincometaxrateprimarilyduetothebenefitofreleasingcertainvaluationallowances.ThesevaluationallowancesrelatedtonetoperatinglossesoperatedinpriorperiodsofElanco'sseparatecompanyfinancialstatements.Asoftheseparation,thosenetoperatinglossesremainedwith,andwereutilizedby,Lilly.
F-68
Three Months Ended
March 31, Provision for Taxes on Income 2019 2018 ProvisionforTaxesonIncome $ 13.3 $ 4.8EffectiveTaxRate 29.7% 6.2%
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 12. Contingencies
Wearepartytovariouslegalactionsinthenormalcourseofbusiness.Indeterminingwhetherapendingmatterissignificantforfinancialreportinganddisclosurepurposes,weconsiderbothquantitativeandqualitativefactorsinordertoassessmateriality.Werecordaliabilityforclaimstotheextentthatwecanformulateareasonableestimateoftheircostsandthereisareasonableprobabilityofincurringsignificantcostsorexpenses.AtMarch31,2019andDecember31,2018,wehadnoliabilitiesestablishedrelatedtolitigationastherewerenosignificantclaimswhichwereprobableandestimable.Wehavenothistoricallyhadanysignificantlitigationexpenseandarenotcurrentlysubjecttoasignificantclaim.
Note 13. Geographic Information
Weoperateasasingleoperatingsegmentengagedinthedevelopment,manufacturing,marketingandsalesofanimalhealthproductsworldwideforbothfoodanimalsandcompanionanimals.Consistentwithouroperationalstructure,ourPresidentandChiefExecutiveOfficer(CEO),asthechiefoperatingdecisionmaker,makesresourceallocationandbusinessprocessdecisionsgloballyacrossourconsolidatedbusiness.Strategicdecisionsaremanagedgloballywithglobalfunctionalleadersresponsiblefordeterminingsignificantcost/investmentsandwithregionalleadersresponsibleforoverseeingtheexecutionoftheglobalstrategy.Ourglobalresearchanddevelopmentorganizationisresponsiblefordevelopmentofnewproducts.Ourmanufacturingorganizationisresponsibleforthemanufacturingandsupplyofproductsandfortheoptimizationofoursupplychain.Regionalleadersareresponsibleforthedistributionandsaleofourproductsandforlocaldirectcosts.Thebusinessisalsosupportedbyglobalcorporatestafffunctions.ManagingandallocatingresourcesattheglobalcorporatelevelenablesourCEOtoassesstheoveralllevelofresourcesavailableandhowtobestdeploytheseresourcesacrossfunctions,producttypes,regionalcommercialorganizationsandresearchanddevelopmentprojectsinlinewithouroverarchinglong-termcorporate-widestrategicgoals,ratherthanonaproductorgeographicbasis.Consistentwiththisdecision-makingprocess,ourCEOusesconsolidated,single-segmentfinancialinformationforpurposesofevaluatingperformance,allocatingresources,settingincentivecompensationtargets,aswellasforecastingfutureperiodfinancialresults.
OurproductsincludeRumensin®,Optaflexx®,Denagard®,Tylan®,Maxiban®andotherproductsforlivestockandpoultry,aswellasTrifexis®,Interceptor®,Comfortis®,Galliprant®andotherproductsforcompanionanimals.
Wehaveasinglecustomerthataccountedfor12.3%and11.3%ofrevenueforthethreemonthsendedMarch31,2019and2018,respectively,andthatrepresentedaccountsreceivableof$83.5millionand$96.4millionasofMarch31,2019andDecember31,2018,respectively.
Weareexposedtotheriskofchangesinsocial,politicalandeconomicconditionsinherentinforeignoperationsandourresultsofoperationsandthevalueofourforeignassetsareaffectedbyfluctuationsinforeigncurrencyexchangerates.
F-69
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 13. Geographic Information (Continued)
Selectedgeographicareainformationwasasfollows:
Note 14. Earnings Per Share
AsdiscussedinNote1,ElancoParentwasformedforthepurposeoffacilitatingtheIPO.LillyheldallsharesofElancoParentfromthetimeofformationuntiltheIPO.
PriortoIPO,therewereanaggregateof293,290,000sharesofourcommonstockheldbyLilly(whichrepresentsthe100sharesheldbyLillypriortogivingeffecttothe2,932,900-for-1stocksplitthatoccurredonSeptember19,2018).InconnectionwiththecompletionoftheIPO,anadditional72,335,000shareswereissued.EarningspersharewascalculatedbasedontheassumptionthatthesharesheldbyLillywereoutstandingforallperiodspriortoIPO.
Wecomputebasicearningspersharebydividingnetearningsavailabletocommonshareholdersbytheactualweightedaveragenumberofcommonsharesoutstandingforthereportingperiod.Dilutedearningspersharereflectsthepotentialdilutionthatcouldoccurifholdersofunvestedrestrictedstockunitsandstockoptionsconvertedtheirholdingsintocommonstock.
Potentialcommonsharesthatwouldhavetheeffectofincreasingdilutedearningspershareareconsideredtobeanti-dilutiveandassuch,thesesharesarenotincludedinthecalculationofdilutedearningspershare.ForthethreemonthsendedMarch31,2019,approximately0.2millionofpotentialcommonshareswereexcludedfromthecalculationofdilutedearningspersharebecausetheireffectwasanti-dilutive.
F-70
Three Months Ended
March 31, 2019 2018 Revenue—tounaffiliatedcustomers(1) UnitedStates $ 383.9 $ 360.0International 347.2 376.2
Revenue $ 731.1 $ 736.2
March 31,
2019 December 31,
2018 Long-livedassets(2) UnitedStates $ 619.0 $ 602.6UnitedKingdom 192.3 187.5Otherforeigncountries 195.6 195.8
Long-livedassets $ 1,006.9 $ 985.9
(1) Revenueisattributedtothecountriesbasedonthelocationofthecustomer.
(2) Long-livedassetsconsistofpropertyandequipment,net,andcertainnoncurrentassets.
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 15. Related Party Agreements and Transactions
Transactions with Lilly Subsequent to Separation and Related to the Separation
Amountsduefrom/(dueto)LillyinconnectionwiththeSeparationandagreeduponserviceswereasfollows:
AsdescribedinNote1,wecompletedanIPOinSeptember2018andLillyfullydivestedofallownershipofElancoinMarch2019.InconnectionwiththeSeparation,weenteredintovariousagreementswithLillyrelatedtotheformofourseparationandcertainongoingactivitiesthatwillcontinueforaperiodoftime.Theseincluded,amongothers,amasterseparationagreement(MSA),atransitionalservicesagreement(TSA)andataxmattersagreement.Inaddition,therewasaportionofouroperationsforwhichthelegaltransferofournetassetsdidnotoccurpriortotheSeparationduetocertainregulatoryrequirementsineachofthesecountries.
Transitional Services Agreement (TSA)
Historically,Lillyhasprovidedussignificantsharedservicesandresourcesrelatedtocorporatefunctionssuchasexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations,whichwerefertocollectivelyasthe"LillyServices."UnderthetermsoftheTSA,wewillbeabletouseLillyServicesforafixedtermestablishedonaservice-by-servicebasis.WewillpayLillymutuallyagreed-uponfeesfortheLillyServicesprovidedundertheTSA,whichwillbebasedonLilly'scost(includingthird-partycosts)ofprovidingtheLillyServicesthroughMarch31,2021,andsubjecttoamark-upof7%thereafter,withadditionalinflation-basedescalationbeginningJanuary1,2022.ThefeesundertheTSAbecamepayableforallperiodsbeginningafterOctober1,2018.
Other Activities
WecontinuetosharecertainservicesandbackofficefunctionswithLilly,whichincertaininstancesresultinLillypayingcostsforElanco(e.g.,utilities,localcountryoperatingcosts,etc.)thatarethenpassedthroughtoElancoforreimbursement.Theseamountsareincludedincashflowsfromoperatingactivitiesinourcondensedconsolidatedandcombinedstatementsofcashflows.Inaddition,weoperatethroughasingletreasurysettlementprocessandpriortothelocalcountryassetpurchases(asdescribedbelow)continuedtotransactthroughLilly'sprocessesincertaininstances.Asaresultoftheseactivities,therewerecertainamountsoffinancingthatoccurredbetweenLillyandElancoduringthethree-monthperiodendedMarch31,2019.Theseamountsareincludedincashflowsfromfinancingactivitiesinourcondensedconsolidatedandcombinedstatementsofcashflows.
F-71
March 31,
2019 December 31,
2018 TSA $ (30.2) $ (28.0)Otheractivities 94.2 (38.0)Localcountryassetpurchases (28.5) (202.7)Totalreceivablefrom/(payableto)Lilly $ 35.5 $ (268.7)
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 15. Related Party Agreements and Transactions (Continued)
Local Country Asset Purchases
ThelegaltransferofcertainofournetassetsdidnotoccurpriortotheSeparationduetocertainregulatoryrequirementsineachofthesecountries.Therelatedassets,liabilities,andresultsofoperationshavebeenreportedinourcondensedconsolidatedandcombinedfinancialstatements,asweareresponsibleforthebusinessactivitiesconductedbyLillyonourbehalfandaresubjecttotherisksandentitledtothebenefitsgeneratedbytheseoperationsandassetsunderthetermsoftheMSA.Weheldrestrictedcash,andtheassociatedpayabletoLilly,atthedateofSeparationtofundtheacquisitionoftheseassets.AsofMarch31,2019,themajorityoftheseassetshavebeenlegallyacquiredandtheremainderareexpectedtobepurchasedduring2019.
Transactions with Lilly Prior to Separation
PriortoIPO,wedidnotoperateasastandalonebusinessandhadvariousrelationshipswithLillywherebyLillyprovidedservicestous.Theimpactonourhistoricalcombinedfinancialstatementsincludesthefollowing:
Transfers to/from Lilly, net
AsdiscussedinNote2:BasisofPresentation,netparentcompanyinvestmentisprimarilyimpactedbycontributionsfromLillywhicharetheresultoftreasuryactivityandnetfundingprovidedbyordistributedtoLilly.ForthethreemonthsendedMarch31,2018,nettransfers(to)/fromLillywere$(69.2)million.Activitiesthatimpactedthenettransfers(to)/fromLillyincludecorporateoverheadandotherallocations,incometaxes,retirementbenefits,andcentralizedcashmanagement.
Net capital contributions from/(distributions to) Lilly
ForthethreemonthsendedMarch31,2019,netcapitalcontributionsfrom/(distributionsto)Lillywere$(7.0)million.
Activitiesthatimpactednetcapitalcontributionsfrom/(distributionsto)Lillyincludeincometaxes,retirementbenefits,andcentralizedcashmanagement,priortofullseparation.
Corporate overhead and other allocations
Priortofullseparation,Lillyprovideduscertainservices,includingexecutiveoversight,treasury,legal,finance,humanresources,tax,internalaudit,financialreporting,informationtechnologyandinvestorrelations.WeprovideLillycertainservicesrelatedtomanufacturingsupport.Ourfinancialstatementsreflectedanallocationofthesecosts.Whenspecificidentificationisnotpracticable,theremainderhavebeenallocatedprimarilyonaproportionalcostmethodonabasisofrevenueorheadcount.
F-72
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 15. Related Party Agreements and Transactions (Continued)
TheallocationsofservicesfromLillytouswerereflectedasfollowsintheconsolidatedandcombinedstatementsofoperations:
WeprovideLillycertainservicesrelatedtomanufacturingsupport.AllocationsofmanufacturingsupportfromustoLillywere$1.2millionforthethreemonthsendedMarch31,2018,whichreducedthecostofsalesintheunauditedcondensedconsolidatedandcombinedstatementsofoperations.
Thefinancialinformationhereinmaynotnecessarilyreflectourconsolidatedfinancialposition,resultsofoperationsandcashflowsinthefutureorwhattheywouldhavebeenifwehadbeenaseparate,standaloneentityduringtheperiodspresented.Managementbelievesthatthemethodsusedtoallocateexpensesarereasonable.
Stock-based Compensation
Priortofullseparation,ouremployeesparticipatedinLillystock-basedcompensationplans,thecostsofwhichwereallocatedtousandrecordedincostofsales,researchanddevelopment,andmarketing,sellingandadministrativeexpensesintheunauditedcondensedconsolidatedandcombinedstatementsofoperations.Thecostsofsuchplansrelatedtoouremployeeswere$5.1millionand$6.7millionforthethreemonthsendedMarch31,2019and2018,respectively.
Retirement Benefits
Priortofullseparation,ouremployeesparticipatedindefinedbenefitpensionandotherpostretirementplanssponsoredbyLilly,thecostsandbenefitsofwhichwererecordedintheunauditedcondensedconsolidatedandcombinedstatementofoperationsincostofsales,researchanddevelopment,andmarketing,sellingandadministrativeexpenses.ForthethreemonthsendedMarch31,2018,thebenefitofsuchplansrelatedtoouremployeeswas$0.6million.
Centralized Cash Management
Lillyusesacentralizedapproachtocashmanagementandfinancingofoperations.UntilSeparation,themajorityofourbusinesswaspartytoLilly'scashpoolingarrangementstomaximizeLilly'savailabilityofcashforgeneraloperatingandinvestingpurposes.Underthesecashpoolingarrangements,cashbalancesweresweptregularlyfromouraccounts.CashtransferstoandfromLilly'scashconcentrationaccountsandtheresultingbalancesattheendofeachreportingperiodwerereflectedinnetparentcompanyinvestmentinthecondensedconsolidatedandcombinedstatementsofequity.
F-73
Three Months Ended
March 31, 2019 2018 Costofsales $ — $ 7.5Researchanddevelopment — 0.8Marketing,sellingandadministrative — 27.3Total $ — $ 35.6
TableofContents
Elanco Animal Health Incorporated
Notes to Unaudited Condensed Consolidated and Combined Financial Statements (Continued)
(Tables present dollars in millions, except per-share data)
Note 15. Related Party Agreements and Transactions (Continued)
Debt
Lilly'sthird-partydebtandtherelatedinterestexpensewerenotallocatedtousforanyoftheperiodspresentedaswewerenotthelegalobligorofthedebtandLillyborrowingswerenotdirectlyattributabletoourbusiness.
Other Related Party Transactions
Wesellcertainproductstoandreceivecertaingoodsandservicesfromacustomer/vendor,whosechairmanandChiefExecutiveOfficerisamemberofLilly'sBoardofDirectors,whichrepresentedrelatedpartytransactionspriortothefullseparation.Theseproductsalesresultedinrevenueof$4.2millionand$5.5millionforthethreemonthsendedMarch31,2019and2018,respectively.Theproductsalesresultedinaccountsreceivableof$1.2millionand$2.5millionatMarch31,2019andDecember31,2018,respectively.Thepurchaseofgoodsandservicesresultedincostofsalesandoperatingexpensesof$1.5millionand$0.8millionforthethreemonthsendedMarch31,2019and2018,respectively.Thepurchaseofgoodsandservicesresultedinaccountspayableof$0.9millionand$0.7millionatMarch31,2019andDecember31,2018,respectively.
Note 16. Subsequent Events
Aratana Acquisition
OnApril26,2019,weenteredintoanagreement(theMergerAgreement)toacquireAratanaTherapeutics,Inc.(Aratana).Aratanaisapettherapeuticscompanyfocusedoninnovativetherapiesfordogsandcats,andcreatorofthecanineosteoarthritismedicine,Galliprant®,therightstowhichweacquiredin2016.SubjecttothetermsandconditionssetforthintheMergerAgreement,upontheconsummationofthemerger,eachshareofAratanacommonstockwillbeconvertedintotherighttoreceive0.1481sharesofElanco'scommonstockplusonecontingentvalueright,whichshallrepresenttherighttoreceiveacontingentpaymentof$0.25incashupontheachievementofaspecifiedmilestoneasoutlinedintheMergerAgreement.BasedontheclosingpriceofashareofElancocommonstockonApril24,2019,thedateonwhichtheexchangeratiowasset,thestockportionofthemergerconsiderationrepresentedapproximately$234million.Themaximumaggregatecontingentpaymentisapproximately$12million.Thetransactionisexpectedtocloseinthemiddleof2019,subjecttocustomaryclosingconditions,includingtheregistrationofsharesofElancocommonstockissuableinthemerger,receiptofregulatoryapprovals,andapprovalbythestockholdersofAratana.
F-74
TableofContents
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 20. Indemnification of Directors and Officers
TheregistrantisanIndianacorporation.Theregistrant'sofficersanddirectorsareandwillbeindemnifiedunderIndianalawandtheamendedandrestatedarticlesofincorporationandamendedandrestatedbylawsoftheregistrantagainstcertainliabilities.Chapter37oftheIBCLrequireseveryIndianacorporationtoindemnifyanyofitsofficersordirectors(unlesslimitedbythearticlesofincorporationofthecorporation)whowerewhollysuccessful,onthemeritsorotherwise,inthedefenseofanyproceedingtowhichtheofficerordirectorwasapartybecausetheofficerordirectorisorwasanofficerordirectoroftheregistrantagainstreasonableexpensesincurredinconnectionwiththeproceeding.Acorporationmayalso,undercertaincircumstances,payfororreimbursethereasonableexpensesincurredbyanofficerordirectorwhoisapartytoaproceedinginadvanceoffinaldispositionoftheproceeding.Theregistrant'samendedandrestatedarticlesofincorporationdonotcontainanyprovisionlimitingsuchindemnification.
Chapter37oftheIBCLalsoauthorizeseveryIndianacorporationtoindemnifyitsofficersanddirectorsundercertaincircumstancesagainstliabilityincurredinconnectionwithanythreatened,pendingorcompletedaction,suitorproceeding,whethercivil,criminal,administrativeorinvestigativeandwhetherformalorinformal,towhichtheofficersordirectorsaremadeapartybyreasonoftheirrelationshiptothecorporation.Officersanddirectorsmaybeindemnifiedwheretheyhaveactedingoodfaith;inthecaseofofficialaction,theindividualreasonablybelievedthattheconductwasinthecorporation'sbestinterestsandinallothercases,theindividualreasonablybelievedthattheconductwasnotagainstthebestinterestsofthecorporation;andinthecaseofcriminalproceedings,theindividualeitherhadreasonablecausetobelievehisorherconductwaslawfulornoreasonablecausetobelievehisorherconductwasunlawful.Chapter37statesthattheindemnificationprovidedforthereinisnotexclusiveofanyotherrightstowhichapersonmaybeentitledunderthearticlesofincorporation,bylawsorresolutionsoftheboardofdirectorsorshareholders.
Theamendedandrestatedarticlesofincorporationandamendedandrestatedbylawsprovideforindemnification,tothefullestextentpermittedbytheIBCL,ofdirectors,officersandemployeesofthecorporationagainstliabilityandreasonableexpensethatmaybeincurredbythem,arisingoutofanythreatened,pendingorcompletedinvestigation,claim,suitorproceeding,whethercivil,administrative,investigativeorcriminal,inwhichtheymaybecomeinvolvedbyreasonofbeingorhavingbeenadirector,officeroremployee.Tobeentitledtoindemnification,(a)thosepersonsmusthavebeenwhollysuccessfulintheclaimoraction,or(b)theboardofdirectors,independentlegalcounselortheshareholdersmusthavedeterminedthatsuchpersonsactedingoodfaithinwhattheyreasonablybelievedtobeinthecorporation'sbestinterest,orinthecaseofconductnotintheindividual'sofficialcapacitywiththecorporation,didnotactinoppositiontothecorporation'sbestinterest.Inaddition,inanycriminalaction,suchpersonsmusthavehadnoreasonablecausetobelievethattheirconductwasunlawful.TheAmendedandRestatedBylawsprovideformandatoryadvancementofexpensestosuchpersonsprovidedcertainconditionsaremet,includingprovisionofawrittenundertakingtorepaysuchadvancements,shoulditbedeterminedthatthepersonisnotentitledtoindemnification.
TheIBCLpermitstheregistranttopurchaseinsuranceonbehalfofdirectors,officers,employeesandagentsagainstliabilitiesarisingoutoftheirpositionswiththecorporation,whetherornotsuchliabilitieswouldbewithintheaboveindemnificationprovisions.Pursuanttothisauthority,thecorporationwillmaintainsuchinsurancefordirectors,officersandemployees,subjecttocertainexclusionsanddeductibleandmaximumamounts,againstlossfromclaimsarisinginconnectionwiththeiractingintheirrespectivecapacities,includingclaimsundertheSecuritiesAct.
II-1
TableofContents
ITEM 21. Exhibits and Financial Statements Schedules
(a)Exhibits:Thelistofexhibitsissetforthunder"ExhibitIndex"attheendoftheregistrationstatementofwhichthisprospectusformaapartandisincorporatedbyreference.
(b)FinancialStatementSchedules:SeeIndextoCombinedFinancialStatementsandtherelatednotesthereto.
ITEM 22. Undertakings
(a)Theundersignedregistrantherebyundertakes:
(1)Tofile,duringanyperiodinwhichoffersorsalesarebeingmade,apost-effectiveamendmenttothisregistrationstatement:
(i)ToincludeanyprospectusrequiredbySection10(a)(3)oftheSecuritiesActof1933;
(ii)Toreflectintheprospectusanyfactsoreventsarisingaftertheeffectivedateofthisregistrationstatement(orthemostrecentpost-effectiveamendmentthereof)which,individuallyorintheaggregate,representafundamentalchangeintheinformationsetforthinthisregistrationstatement.Notwithstandingtheforegoing,anyincreaseordecreaseinvolumeofsecuritiesoffered(ifthetotaldollarvalueofsecuritiesofferedwouldnotexceedthatwhichwasregistered)andanydeviationfromtheloworhighendoftheestimatedmaximumofferingrangemaybereflectedintheformofprospectusfiledwiththeCommissionpursuanttoRule424(b)if,intheaggregate,thechangesinvolumeandpricerepresentnomorethan20percentchangeinthemaximumaggregateofferingpricesetforthinthe"CalculationofRegistrationFee"tableintheeffectiveregistrationstatement;
(iii)Toincludeanymaterialinformationwithrespecttotheplanofdistributionnotpreviouslydisclosedintheregistrationstatementoranymaterialchangetosuchinformationinthisregistrationstatement;
(2)That,forthepurposeofdetermininganyliabilityundertheSecuritiesActof1933,eachsuchpost-effectiveamendmentshallbedeemedtobeanewregistrationstatementrelatingtothesecuritiesofferedtherein,andtheofferingofsuchsecuritiesatthattimeshallbedeemedtobetheinitialbonafideofferingthereof.
(3)Toremovefromregistrationbymeansofapost-effectiveamendmentanyofthesecuritiesbeingregisteredwhichremainunsoldattheterminationoftheoffering.
(4)That,forpurposesofdeterminingliabilityundertheSecuritiesActof1933toanypurchaser,eachprospectusfiledpursuanttoRule424(b)aspartofaregistrationstatementrelatingtoanoffering,otherthanregistrationstatementsrelyingonRule430BorotherthanprospectusesfiledinrelianceonRule430A,shallbedeemedtobepartofandincludedintheregistrationstatementasofthedateitisfirstusedaftereffectiveness.Provided,however,thatnostatementmadeinaregistrationstatementorprospectusthatispartoftheregistrationstatementormadeinadocumentincorporatedordeemedincorporatedbyreferenceintotheregistrationstatementorprospectusthatispartoftheregistrationstatementwill,astoapurchaserwithatimeofcontractofsalepriortosuchfirstuse,supersedeormodifyanystatementthatwasmadeintheregistrationstatementorprospectusthatwaspartoftheregistrationstatementormadeinanysuchdocumentimmediatelypriortosuchdateoffirstuse
(5)That,forthepurposeofdeterminingliabilityoftheregistrantundertheSecuritiesActof1933toanypurchaserintheinitialdistributionofsecurities,theundersignedregistrantundertakesthatinaprimaryofferingofsecuritiesoftheundersignedregistrantpursuanttothisregistrationstatement,regardlessoftheunderwritingmethodusedtosellthesecuritiestothepurchaser,ifthe
II-2
TableofContents
securitiesareofferedorsoldtosuchpurchaserbymeansofanyofthefollowingcommunications,theundersignedregistrantwillbeasellertothepurchaserandwillbeconsideredtoofferorsellsuchsecuritiestosuchpurchaser:
(i)AnypreliminaryprospectusorprospectusoftheundersignedregistrantrelatingtotheofferingrequiredtobefiledpursuanttoRule424;
(ii)Anyfreewritingprospectusrelatingtotheofferingpreparedbyoronbehalfoftheundersignedregistrantorusedorreferredtobytheundersignedregistrant;
(iii)Theportionofanyotherfreewritingprospectusrelatingtotheofferingcontainingmaterialinformationabouttheundersignedregistrantoritssecuritiesprovidedbyoronbehalfoftheundersignedregistrant;and
(iv)Anyothercommunicationthatisanofferintheofferingmadebytheundersignedregistranttothepurchaser.
(b)InsofarasindemnificationforliabilitiesarisingundertheSecuritiesActmaybepermittedtodirectors,officersandcontrollingpersonsoftheregistrantpursuanttotheforegoingprovisions,orotherwise,theregistranthasbeenadvisedthatintheopinionoftheSecuritiesandExchangeCommissionsuchindemnificationisagainstpublicpolicyasexpressedintheSecuritiesActandis,therefore,unenforceable.Intheeventthataclaimforindemnificationagainstsuchliabilities(otherthanthepaymentbytheregistrantofexpensesincurredorpaidbyadirector,officerorcontrollingpersonoftheregistrantinthesuccessfuldefenseofanyaction,suitorproceeding)isassertedbysuchdirector,officerorcontrollingpersoninconnectionwiththesecuritiesbeingregistered,theregistrantwill,unlessintheopinionofitscounselthematterhasbeensettledbycontrollingprecedent,submittoacourtofappropriatejurisdictionthequestionwhethersuchindemnificationbyitisagainstpublicpolicyasexpressedintheSecuritiesActandwillbegovernedbythefinaladjudicationofsuchissue.
(c)Theundersignedregistrantherebyundertakestosupplybymeansofapost-effectiveamendmentallinformationconcerningatransaction,andthecompanybeingacquiredinvolvedtherein,thatwasnotthesubjectofandincludedinthisregistrationstatementwhenitbecameeffective.
EXHIBIT INDEX
II-3
Exhibit Number Description
2.1 AgreementandPlanofMerger,datedasofApril26,2019,byandamongElancoAnimalHealthIncorporated,ElancoAthensInc.andAratanaTherapeutics,Inc.(incorporatedbyreferencetoExhibit2.1toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonApril26,2019)
3.1 AmendedandRestatedArticlesofIncorporationoftheRegistrant(incorporatedbyreferencetoExhibit3.1toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
3.2 AmendedandRestatedBylawsoftheRegistrant(incorporatedbyreferencetoExhibit3.2toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
4.1 FormofCertificateofCommonStock(incorporatedbyreferencetoExhibit4.1toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))
TableofContents
II-4
Exhibit Number Description
4.2 Indenture,datedasofAugust28,2018,betweenElancoAnimalHealthIncorporatedandDeutscheBankTrustCompanyAmericas,astrustee(incorporatedbyreferencetoExhibit4.2toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))
4.3 FirstSupplementalIndenture,datedasofAugust28,2018,betweenElancoAnimalHealthIncorporatedandDeutscheBankTrustCompanyAmericas,astrustee(incorporatedbyreferencetoExhibit4.3toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))
4.4 ExchangeandRegistrationRightsAgreement,datedasofAugust28,2018,betweenElancoAnimalHealthIncorporatedandGoldmanSachs&Co.LLC,J.P.MorganSecuritiesLLCandMorganStanley&Co.LLC,asrepresentativesoftheinitialpurchasers(incorporatedbyreferencetoExhibit4.4toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))
5.1 OpinionofBryanCaveLeightonPaisnerLLP†
5.2 OpinionofBarnes&ThornburgLLP†
10.1 MasterSeparationAgreement,datedasofSeptember24,2018,byandbetweenElancoAnimalHealthIncorporatedandEliLillyandCompany(incorporatedbyreferencetoExhibit10.1toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
10.2 TransitionalServicesAgreement,datedasofSeptember24,2018,byandbetweenElancoAnimalHealthIncorporatedandEliLillyandCompany(incorporatedbyreferencetoExhibit10.2toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
10.3 TaxMattersAgreement,datedasofSeptember24,2018,byandbetweenElancoAnimalHealthIncorporatedandEliLillyandCompany(incorporatedbyreferencetoExhibit10.3toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
10.4 EmployeeMattersAgreement,datedasofSeptember24,2018,byandbetweenElancoAnimalHealthIncorporatedandEliLillyandCompany(incorporatedbyreferencetoExhibit10.4toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
10.5 TollManufacturingandSupplyAgreement,datedasofSeptember24,2018,byandbetweenElancoUKAHLimitedandEliLillyExportS.A.(incorporatedbyreferencetoExhibit10.5toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
10.6 RegistrationRightsAgreement,datedasofSeptember24,2018,byandbetweenElancoAnimalHealthIncorporatedandEliLillyandCompany(incorporatedbyreferencetoExhibit10.6toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
10.7 TransitionalTrademarkLicenseAgreement,datedasofSeptember24,2018,byandamongElancoAnimalHealthIncorporated,EliLillyandCompanyandElancoUSInc.(incorporatedbyreferencetoExhibit10.7toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
TableofContents
II-5
Exhibit Number Description
10.8 IntellectualPropertyandTechnologyLicenseAgreement,datedasofSeptember24,2018,byandamongElancoAnimalHealthIncorporated,EliLillyandCompanyandElancoUSInc.(incorporatedbyreferencetoExhibit10.7toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonSeptember26,2018)
10.9 2002LillyStockPlan,asamended(incorporatedbyreferencetoExhibit10.1toEliLillyandCompany'sReportonForm10-QforthequarterendedJune30,2018)*
10.10 TheEliLillyandCompanyBonusPlan,asamended(incorporatedbyreferencetoExhibit10.7toEliLillyandCompany'sReportonForm10-KfortheyearendedDecember31,2013)*
10.11 FormofPerformanceAwardunderthe2002LillyStockPlan(incorporatedbyreferencetoExhibit10.2toEliLillyandCompany'sReportonForm10-KfortheyearendedDecember31,2018)*
10.12 FormofShareholderValueAwardunderthe2002LillyStockPlan(incorporatedbyreferencetoExhibit10.3toEliLillyandCompany'sReportonForm10-KfortheyearendedDecember31,2018)*
10.13 TheLillyDeferredCompensationPlan,asamended(incorporatedbyreferencetoExhibit10.5toEliLillyandCompany'sReportonForm10-KfortheyearendedDecember31,2013)*
10.14 TheEliLillyandCompanyExecutiveOfferIncentivePlan(incorporatedbyreferencetoAppendixBtoEliLillyandCompany'sproxystatementonSchedule14AfiledonMarch7,2011(SECFileNo.001-06351,FilmNo.11666753))*
10.15 2007ChangeinControlSeverancePayPlan(incorporatedbyreferencetoExhibit10toEliLillyandCompany'sReportonForm10-QforthequarterendedSeptember30,2010(SECFileNo.001-06351,FilmNo.101149876))*
10.16 TheElancoCorporateBonusPlan(incorporatedbyreferencetoExhibit10.16toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))*
10.17 2018ElancoStockPlan(incorporatedbyreferencetoExhibit4.3toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-8(FileNo.333-227447))*
10.18 ElancoAnimalHealthIncorporatedDirectors'DeferralPlan(incorporatedbyreferencetoExhibit4.4toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-8(FileNo.333-227447))*
10.19 DirectorLetterAgreementbetweenEmuHoldingsCompanyandR.DavidHoover,datedasofMay25,2018(incorporatedbyreferencetoExhibit10.19toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))
10.20 Formof2018ChangeinControlSeverancePayPlanforSelectEmployees(incorporatedbyreferencetoExhibit10.20toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))*
10.21 FormofElancoAnimalHealthIncorporatedRestrictedStockUnitAwardsAgreement(incorporatedbyreferencetoExhibit10.21toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))*
TableofContents
II-6
Exhibit Number Description
10.22 FormofElancoAnimalHealthIncorporatedNonqualifiedStockOptionAwardAgreement(incorporatedbyreferencetoExhibit10.22toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))*
10.23 TheLillySeverancePayPlan(incorporatedbyreferencetoExhibit10.23toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))*
10.24 RevolvingLoanCreditAgreement,datedasofSeptember5,2018,amongElancoAnimalHealthIncorporated,asborrower,JPMorganChaseBank,N.A.,asadministrativeagentandtheotherLenderspartythereto(incorporatedbyreferencetoExhibit10.24toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))
10.25 TermLoanCreditAgreement,datedasofSeptember5,2018,amongElancoAnimalHealthIncorporated,asborrower,JPMorganChaseBank,N.A.,asadministrativeagentandtheotherLenderspartythereto(incorporatedbyreferencetoExhibit10.25toElancoAnimalHealthIncorporated'sregistrationstatementonFormS-1(FileNo.333-226536))
10.26 RetentionBonusAgreement,datedOctober18,2018,byandbetweenElancoUSInc.andToddS.Young(incorporatedbyreferencetoExhibit10.2toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonOctober30,2018)*
10.27 EmploymentOfferLetterwithMr.ToddS.Young,datedOctober15,2018,byandbetweenElancoUSInc.andToddS.Young(incorporatedbyreferencetoExhibit10.1toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonOctober30,2018)*
10.28 FormofPerformanceAwardAgreement(incorporatedbyreferencetoExhibit10.1toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonFebruary19,2019)*
10.29 FormofRestrictedStockUnitAwardAgreement(incorporatedbyreferencetoExhibit10.2toElancoAnimalHealthIncorporated'sReportonForm8-KfiledonFebruary19,2019)*
10.30 FormofRestrictedStockUnitAwardAgreement(incorporatedbyreferencetoExhibit10.22toElancoAnimalHealthIncorporated'sReportonForm10-KfortheyearendedDecember31,2018)*
10.31 FormofReplacementPerformanceAwardAgreementforCertainNamedExecutiveOfficers(incorporatedbyreferencetoExhibit10.23toElancoAnimalHealthIncorporated'sReportonForm10-KfortheyearendedDecember31,2018)*
10.32 FormofReplacementPerformanceAwardAgreementforJeffreyN.Simmons(incorporatedbyreferencetoExhibit10.24toElancoAnimalHealthIncorporated'sReportonForm10-KfortheyearendedDecember31,2018)*
10.33 FormofReplacementRestrictedStockUnitAwardAgreementforCertainNamedExecutiveOfficers(incorporatedbyreferencetoExhibit10.25toElancoAnimalHealthIncorporated'sReportonForm10-KfortheyearendedDecember31,2018)*
10.34 ElancoAnimalHealthIncorporatedDirectors'DeferralPlan(incorporatedbyreferencetoExhibit10.1toElancoAnimalHealthIncorporated'sReportonForm10-QforthequarterendedMarch31,2019)*
10.35 FormofElancoAnimalHealthIncorporatedRestrictedStockUnitAwardAgreementfornon-employeedirectorswithrespecttoannualawards(incorporatedbyreferencetoExhibit10.2toElancoAnimalHealthIncorporated'sReportonForm10-QforthequarterendedMarch31,2019)*
TableofContents
II-7
Exhibit Number Description
10.36 FormofElancoAnimalHealthIncorporatedRestrictedStockUnitAwardAgreementfornon-employeedirectorswithrespecttoone-timefounderaward(incorporatedbyreferencetoExhibit10.3toElancoAnimalHealthIncorporated'sReportonForm10-QforthequarterendedMarch31,2019)*
10.37 ElancoAnimalHealthIncorporatedReplacementRestrictedStockUnitAwardAgreement(incorporatedbyreferencetoExhibit10.4toElancoAnimalHealthIncorporated'sReportonForm10-QforthequarterendedMarch31,2019)*
21.1 SubsidiariesoftheRegistrant(incorporatedbyreferencetoExhibit21.1toElancoAnimalHealthIncorporated'sAnnualReportonForm10-KfortheyearendedDecember31,2018)
23.1 ConsentofErnst&YoungLLP†
23.2 ConsentofBryanCaveLeightonPaisnerLLP(includedinExhibit5.1)
23.3 ConsentofBarnes&ThornburgLLP(includedinExhibit5.2)
24.1 PowerofAttorney(includedaspartofsignaturepage)
25.1 StatementofEligibilityundertheTrustIndentureActof1939,asamended,oftheTrusteeundertheIndenture.†
99.1 FormofLetterofTransmittal†
99.2 FormofNoticeofGuaranteedDelivery†
99.3 FormofLettertoBrokers,Dealers,CommercialBanks,TrustCompanies,CustodiansandSimilarInstitutions†
99.4 FormofLettertoClients†
101.INS XBRLInstanceDocument†
101.SCH XBRLTaxonomyExtensionSchemaDocument†
101.CAL XBRLTaxonomyExtensionCalculationLinkbaseDocument†
101.DEF XBRLTaxonomyExtensionDefinitionLinkbaseDocument†
101.LAB XBRLTaxonomyExtensionLabelLinkbaseDocument†
101.PRE XBRLTaxonomyExtensionPresentationLinkbaseDocument†
† Filedherewith
* Managementcontractsorcompensatoryplansorarrangements
TableofContents
SIGNATURES
PursuanttotherequirementsoftheSecuritiesActof1933,asamended,theregistranthasdulycausedthisregistrationstatementonFormS-4tobesignedonitsbehalfbytheundersigned,thereuntodulyauthorized,intheCityofIndianapolis,StateofIndiana,onthe17thdayofMay,2019.
POWER OF ATTORNEY
We,theundersigneddirectorsandofficersofElancoAnimalHealthIncorporated,doherebyconstituteandappointJeffreyN.Simmons,ToddS.YoungandMichael-BryantHicks,andeachofthemactingindividually,asourtrueandlawfulattorneysandagents,withfullpowerofsubstitution,todoanyandallactsandthingsinournameandonourbehalfinourcapacitiesasdirectorsandofficersandtoexecuteanyandallinstrumentsforusandinournamesinthecapacitiesindicatedbelow,whichsaidattorneysandagents,oreitherofthem,maydeemnecessaryoradvisabletoenablesaidregistranttocomplywiththeSecuritiesActof1933,asamended,andanyrules,regulationsandrequirementsoftheSecuritiesandExchangeCommission,inconnectionwiththisregistrationstatement,includingspecifically,butwithoutlimitation,powerandauthoritytosignforusoranyofusinournamesinthecapacitiesindicatedbelow,thisregistrationstatementoranyandallamendmentstheretoandtofilethesame,withallrelevantexhibitsandotherdocumentsinconnectiontherewith,withtheSecuritiesandExchangeCommissionandwedoherebyratifyandconfirmthatsaidattorneysandagents,oranyofthem,shalldoorcausetobedonebyvirtuehereof.
PursuanttotherequirementsoftheSecuritiesActof1933,asamended,thisregistrationstatementhasbeensignedbythefollowingpersonsinthecapacitiesandonthedatesindicated.
II-8
ELANCO ANIMAL HEALTH INCORPORATED
By: /s/JEFFREYN.SIMMONS
Name: JeffreyN.Simmons Title: President and Chief Executive Officer
Name Title Date
/s/JEFFREYN.SIMMONS
JeffreyN.Simmons PresidentandChiefExecutiveOfficer(PrincipalExecutiveOfficer)
andDirector May17,2019
/s/TODDS.YOUNG
ToddS.Young ExecutiveVicePresidentandChiefFinancialOfficer(Principal
FinancialOfficer) May17,2019
/s/JAMESM.MEER
JamesM.Meer VicePresident,ChiefAccountingOfficer(PrincipalAccounting
Officer) May17,2019
/s/R.DAVIDHOOVER
R.DavidHoover Chairman May17,2019
TableofContents
II-9
Name Title Date
/s/KAPILAK.ANAND
KapilaK.Anand Director May17,2019
/s/JOHNP.BILBREY
JohnP.Bilbrey Director May17,2019
/s/ARTA.GARCIA
ArtA.Garcia Director May17,2019
/s/MICHAELJ.HARRINGTON
MichaelJ.Harrington Director May17,2019
/s/DEBORAHT.KOCHEVAR
DeborahT.Kochevar Director May17,2019
/s/LAWRENCEE.KURZIUS
LawrenceE.Kurzius Director May17,2019
/s/KIRKMCDONALD
KirkMcDonald Director May17,2019
/s/DENISESCOTS-KNIGHT
DeniseScots-Knight Director May17,2019
Exhibit5.1
[BryanCaveLeightonPaisnerletterhead]May17,2019ElancoAnimalHealthIncorporated2500InnovationWayGreenfield,Indiana46140LadiesandGentlemen:WehaveactedasspecialcounseltoElancoAnimalHealthIncorporated,anIndianacorporation(the“Company”),inconnectionwiththefilingoftheRegistrationStatementonFormS-4(the“RegistrationStatement”)bytheCompanywiththeSecuritiesandExchangeCommission(the“Commission”)undertheSecuritiesActof1933,asamended(the“Act”),relatingtotheoffersbytheCompany(the“ExchangeOffers”)toexchange(i)upto$500,000,000aggregateprincipalamountoftheCompany’s3.912%SeniorNotesdue2021(the“2021ExchangeNotes”)foralikeamountoftheCompany’soutstandingunregistered3.912%SeniorNotesdue2021(the“2021OriginalNotes”);(ii)upto$750,000,000aggregateprincipalamountoftheCompany’s4.272%SeniorNotesdue2023(the“2023ExchangeNotes”)foralikeamountoftheCompany’soutstandingunregistered4.272%SeniorNotesdue2023(the“2023OriginalNotes”);and(iii)upto$750,000,000aggregateprincipalamountoftheCompany’s4.900%SeniorNotesdue2028(the“2028ExchangeNotes”andtogetherwiththe2021ExchangeNotesandthe2023ExchangeNotes,the“ExchangeNotes”)foralikeamountoftheCompany’soutstandingunregistered4.900%SeniorNotesdue2028(the“2028OriginalNotes”andtogetherwiththe2021OriginalNotesandthe2023OriginalNotes,the“OriginalNotes”)undertheIndenture,datedasofAugust28,2018(the“BaseIndenture”),assupplementedbytheFirstSupplementalIndenture,datedasofAugust28,2018(the“SupplementalIndenture”andtogetherwiththeBaseIndenture,the“Indenture”),betweentheCompanyandDeutscheBankTrustCompanyAmericas,aNewYorkbankingcorporation,astrustee(the“Trustee”),ascontemplatedbytheExchangeandRegistrationRightsAgreement,datedAugust28,2018(the“RegistrationRightsAgreement”),byandamongtheCompanyandtheInitialPurchasers(asdefinedtherein).AllcapitalizedtermswhicharedefinedintheIndentureshallhavethesamemeaningswhenusedherein,unlessotherwisespecified.Inconnectionherewith,wehaveexamined:
(1)anexecutedcopyoftheBaseIndenture;
(2)anexecutedcopyoftheSupplementalIndenture;
(3)executedcopiesoftheOriginalNotes;
(4)anexecutedcopyoftheRegistrationRightsAgreement;
(5)theformsoftheExchangeNotes;
(6)theAmendedandRestatedArticlesofIncorporationoftheCompany,effectiveSeptember18,2018,ascertifiedbytheSecretaryofStateoftheStateofIndiana(the“Charter”);and
(7)theAmendedandRestatedBylawsoftheCompany,aseffectiveSeptember19,2018andineffectonthedatehereofandascertifiedbytheSecretaryorAssistantSecretaryoftheCompany(togetherwith
theCharter,the“OrganizationalDocuments”).Thedocumentsreferencedasitems(1)through(5)abovearecollectivelyreferredtohereinasthe“TransactionDocuments.”Wehavealsoexaminedoriginalsorcopies,certifiedorotherwiseidentifiedtooursatisfaction,ofsuchothercorporaterecords,agreementsandinstrumentsoftheCompany,certificatesofpublicofficialsandofficersoftheCompany,andsuchotherdocuments,recordsandinstruments,andwehavemadesuchlegalandfactualinquiries,aswehavedeemednecessaryorappropriateasabasisforustorendertheopinionshereinafterexpressed.InourexaminationoftheTransactionDocumentsandtheforegoing,wehaveassumedthegenuinenessofallsignatures,thelegalcompetenceandcapacityofnaturalpersons,theauthenticityofdocumentssubmittedtousasoriginalsandtheconformitywithauthenticoriginaldocumentsofalldocumentssubmittedtousascopiesorbyfacsimileorothermeansofelectronictransmission,orwhichweobtainedfromtheCommission’sElectronicDataGathering,AnalysisandRetrievalsystem(“Edgar”)orothersitesmaintainedbyacourtorgovernmentalauthorityorregulatorybodyandtheauthenticityoftheoriginalsofsuchlatterdocuments.Ifanydocumentweexaminedinprinted,wordprocessedorsimilarformhasbeenfiledwiththeCommissiononEdgarorsuchcourtorgovernmentalauthorityorregulatorybody,wehaveassumedthatthedocumentsofiledisidenticaltothedocumentweexaminedexceptforformattingchanges.Whenrelevantfactswerenotindependentlyestablished,wehavereliedwithoutindependentinvestigationastomattersoffactuponstatementsofgovernmentalofficialsanduponrepresentationsmadeinorpursuanttotheTransactionDocumentsandcertificatesandstatementsofappropriaterepresentativesoftheCompany.Inconnectionherewith,wehaveassumedthat(i)alloftheTransactionDocumentshavebeendulyauthorizedbyandhavebeendulyexecutedanddeliveredbyallofthepartiestosuchTransactionDocuments,(ii)otherthanwithrespecttotheCompany,alloftheTransactionDocumentsconstitutethevalid,bindingandenforceableobligationsofallofthepartiesthereto,and(iii)allofthesignatoriestosuchTransactionDocumentshavebeendulyauthorizedandallsuchpartiesaredulyorganizedandvalidlyexistingandhavethepowerandauthority(corporateorother)toexecute,deliverandperformsuchTransactionDocuments.Basedupontheforegoingandinreliancethereon,andsubjecttotheassumptions,comments,qualifications,limitationsandexceptionssetforthherein,weareoftheopinionthat,when(i)theRegistrationStatementhasbecomeeffectiveundertheActand(ii)theExchangeNotes(intheformexaminedbyus)havebeendulyexecutedbytheCompanyanddulyauthenticatedanddeliveredbytheTrusteeandissuedinexchangefortheOriginalNotesinaccordancewiththeprovisionsoftheIndentureuponconsummationofandotherwiseinaccordancewiththeExchangeOffers,theExchangeNoteswillconstitutevalidandbindingobligationsoftheCompany.Inadditiontotheassumptions,comments,qualifications,limitationsandexceptionssetforthabove,theopinionssetforthhereinarefurtherlimitedby,subjecttoandbaseduponthefollowingassumptions,comments,qualifications,limitationsandexceptions:
2
(a)Ouropinionshereinreflectonlytheapplicationof(i)applicableNewYorkStatelaw(excluding,withoutlimitation,(A)alllaws,rulesandregulationsofcities,countiesandotherpoliticalsubdivisionsof
suchStateand(B)thesecurities,bluesky,criminal,environmental,employeebenefit,pension,antitrustandtaxlawsofsuchState,astowhichweexpressnoopinion),and(ii)theFederallawsoftheUnitedStatesofAmerica(excluding,withoutlimitation,thefederalsecurities,commodities,criminal,environmental,employeebenefit,pension,taxandantitrustlaws,astowhichweexpressnoopinion).WenotethattheNotesandtheIndentureeachprovidethattheyaregovernedbyandaretobeconstruedinaccordancewiththelawsoftheStateofNewYork,withoutgivingeffecttoanychoiceoflaworconflictoflawprovisionorrulethatwouldcausetheapplicationofthelawsofanyotherjurisdiction.Wehaveassumedthatthechoiceoflawprovisionswouldbeenforcedbyanycourtinwhichenforcementthereofmaybesought.Theopinionssetforthhereinaremadeasofthedatehereofandaresubjectto,andmaybelimitedby,futurechangesinthefactualmatterssetforthherein,andweundertakenodutytoadviseyouofthesame.Theopinionsexpressedhereinarebaseduponthelawineffect(andpublishedorotherwisegenerallyavailable)onthedatehereof,andweassumenoobligationtoreviseorsupplementtheseopinionsshouldsuchlawbechangedbylegislativeaction,judicialdecisionorotherwise.Inrenderingouropinions,wehavenotconsidered,andherebydisclaimanyopinionasto,theapplicationorimpactofanylaws,cases,decisions,rulesorregulationsofanyotherjurisdiction,courtoradministrativeagency.
(b)Ouropinionscontainedhereinmaybelimitedby(i)applicablebankruptcy,insolvency,reorganization,receivership,moratoriumorsimilarlawsaffectingorrelatingtotherightsandremediesofcreditorsgenerallyincluding,withoutlimitation,lawsrelatingtofraudulenttransfersorconveyances,preferencesandequitablesubordination,(ii)generalprinciplesofequity(regardlessofwhetherconsideredinaproceedinginequityoratlaw),and(iii)animpliedcovenantofgoodfaithandfairdealing.
(c)Ouropinionsarefurthersubjecttotheeffectofgenerallyapplicablerulesoflawarisingfromstatutes,judicialandadministrativedecisions,andtherulesandregulationsofgovernmentalauthoritiesthat:(i)limitoraffecttheenforcementofprovisionsofacontractthatpurporttorequirewaiveroftheobligationsofgoodfaith,fairdealing,diligenceandreasonableness;(ii)limittheavailabilityofaremedyundercertaincircumstanceswhereanotherremedyhasbeenelected;(iii)limittheenforceabilityofprovisionsreleasing,exculpating,orexemptingapartyfrom,orrequiringindemnificationofapartyfor,liabilityforitsownactionorinaction,totheextenttheactionorinactioninvolvesnegligence,recklessness,willfulmisconductorunlawfulconduct;(iv)may,wherelessthanallofthecontractmaybeunenforceable,limittheenforceabilityofthebalanceofthecontracttocircumstancesinwhichtheunenforceableportionisnotanessentialpartoftheagreedexchange;and(v)governandaffordjudicialdiscretionregardingthedeterminationofdamagesandentitlementtoattorneys’fees.
(d)Weexpressnoopinionasto:
(i)theenforceabilityofanyprovisioninanyoftheTransactionDocumentspurportingorattemptingto(A)conferexclusivejurisdictionand/orvenueuponcertaincourtsorotherwisewaivethedefensesofforum non conveniens orimpropervenue,(B)confersubjectmatterjurisdictiononacourtnothavingindependentgroundstherefor,(C)modifyorwaivetherequirementsforeffectiveserviceofprocessforanyactionthatmaybebrought,(D)waivetherightoftheCompanyoranyotherpersontoatrialbyjury,(E)providethatremediesarecumulativeorthatdecisionsbyapartyareconclusive,(F)modifyorwaivetherightstonotice,legaldefenses,statutesoflimitationsandstatutesofrepose(includingthe
3
tollingofsame)orotherbenefitsthatcannotbewaivedunderapplicablelaw,(G)governchoiceoflaworconflictoflaws,or(H)providefororgrantapowerofattorney;or
(ii)theenforceabilityof(A)anyrightstoindemnificationorcontributionprovidedforintheTransactionDocumentswhichareviolativeofpublicpolicyunderlyinganylaw,ruleorregulation(includinganyFederalorstatesecuritieslaw,ruleorregulation)orthelegalityofsuchrights,(B)rightsofset-off,(C)anyprovisionspurportingtoprovidetotheTrusteeorHolderstherighttoreceivecostsandexpensesbeyondthosereasonablyincurredbythemor(D)provisionsintheTransactionDocumentswhosetermsareleftopenforlaterresolutionbytheparties.Wenotethat,withrespecttomatterspertainingtothelawsoftheStateofIndiana,wearerelyingontheopinionofBarnes&ThornburgLLP,datedthedatehereof,andweexpresslydisclaimanyopinionwithrespecttothelawsofsuchjurisdiction.Wedonotrenderanyopinionsexceptassetforthabove.ThisopinionletterisbeingdeliveredbyussolelyforyourbenefitpursuanttotheRegistrationStatement.WeherebyconsenttothefilingofthisopinionletterasExhibit5.1totheRegistrationStatementandtotheuseofournameunderthecaption“LegalMatters”intheprospectusfiledasapartthereof.WealsoconsenttoyourfilingcopiesofthisopinionletterasanexhibittotheRegistrationStatementwithagenciesofsuchstatesasyoudeemnecessaryinthecourseofcomplyingwiththelawsofsuchstatesregardingtheExchangeOffers.Ingivingsuchconsent,wedonottherebyconcedethatwearewithinthecategoryofpersonswhoseconsentisrequiredunderSection7oftheActortherulesandregulationsoftheCommissionthereunder.Verytrulyyours,/s/BryanCaveLeightonPaisnerLLP
4
Exhibit5.2
11S.MeridianStreet
Indianapolis,IN46204-3535317-236-1313
317-231-7433(Fax)www.btlaw.com
May17,2019
ElancoAnimalHealthIncorporated2500InnovationWayGreenfield,IN46140
Re:ElancoAnimalHealthIncorporatedRegistrationStatementonFormS-4
LadiesandGentlemen:
WehaveactedasspecialIndianacounseltoElancoAnimalHealthIncorporated,anIndianacorporation(“Elanco”),inconnectionwiththeRegistrationStatementonFormS-4(the“RegistrationStatement”)filedbyElancowiththeSecuritiesandExchangeCommission(the“Commission”)undertheSecuritiesActof1933,asamended(the“SecuritiesAct”).TheRegistrationStatementrelatestotheissuancebyElancoofupto(i)$500,000,000aggregateprincipalamountofnew3.912%SeniorNotesdue2021(the“2021ExchangeNotes”)foralikeamountofoutstandingunregistered3.912%SeniorNotesdue2021,(ii)$750,000,000aggregateprincipalamountofnew4.272%SeniorNotesdue2023(the“2023ExchangeNotes”)foralikeamountofoutstandingunregistered4.272%SeniorNotesdue2023,and(iii)$750,000,000aggregateprincipalamountofnew4.900%SeniorNotesdue2028(the“2028ExchangeNotes”and,collectivelywiththe2021ExchangeNotesandthe2023ExchangeNotes,the“ExchangeNotes”)foralikeamountofoutstandingunregistered4.900%SeniorNotesdue2028.AllcapitalizedtermsusedandnototherwisedefinedhereinshallhavethemeaningsassignedtosuchtermsintheRegistrationStatement.
TheExchangeNoteswillbeissuedunderanIndenturedatedasofAugust28,2018byandbetweenElancoandDeutscheBankTrustCompanyAmericas,astrustee(incorporatedbyreferencetoExhibit4.3ofElanco’sregistrationstatementonFormS-1(FileNo.333-226536))andFirstSupplementalIndenture,datedasofAugust28,2018,betweenElancoandDeutscheBankTrustCompanyAmericas,astrustee(incorporatedbyreferencetoExhibit4.3ofElanco’sregistrationstatementonFormS-1(FileNo.333-226536))(the“Indenture”).Wehaveassumed,withyourpermission,that(i)theIndenturehasnotbeenfurtheramended,modifiedorsupplementedand(ii)theExchangeNoteshavebeenissuedpursuanttotheIndentureandotherwiseincompliancewiththeprovisionsoftheIndenture.
Assuchcounselandforpurposesofouropinionssetforthbelow,wehaveexaminedoriginalsorcopies,certifiedorotherwiseidentifiedtooursatisfaction,ofsuchdocuments,corporaterecords,certificatesofpublicofficialsandotherinstrumentsaswehavedeemednecessaryorappropriateasabasisfortheopinionssetforthherein.
Insuchexaminationandinrenderingtheopinionsexpressedbelow,wehaveassumed,withoutinvestigation:(i)thedueauthorizationofallagreements,instrumentsandotherdocumentsbyallthepartiesthereto(otherthanthedueauthorizationofeachsuchagreement,instrumentanddocumentbyElanco);(ii)thedueexecutionanddeliveryofallagreements,instrumentsandotherdocumentsbyallthepartiesthereto(otherthanthedueexecutionanddeliveryofeachsuchagreement,instrumentand
documentbyElanco);(iii)thegenuinenessofallsignaturesonalldocumentssubmittedtous;(iv)theauthenticity,accuracyandcompletenessofalldocuments,corporaterecords,certificatesandotherinstrumentssubmittedtous;(v)thatphotocopy,electronic,certified,conformed,facsimileandothercopiessubmittedtousoforiginaldocuments,corporaterecords,certificatesandotherinstrumentsconformtotheoriginaldocuments,records,certificatesandotherinstruments,andthatallsuchoriginaldocumentswereauthenticandcomplete;(vi)thelegalcapacityofallindividualsexecutingdocuments;(vii)thattheExchangeNotesandtheIndentureexecutedinconnectionwiththetransactionscontemplatedtherebyarethevalidandbindingobligationsofeachofthepartiesthereto(otherthanElanco),enforceableagainstsuchparties(otherthanElanco)inaccordancewiththeirrespectivetermsandthatnoneoftheExchangeNotesandtheIndenturehasbeenamendedorterminatedorallyorinwritingexceptashasbeendisclosedtous;and(viii)thatthestatementscontainedinthecertificatesandcomparabledocumentsofpublicofficials,officersandrepresentativesofElancoandotherpersonsonwhichwehavereliedforthepurposesofthisopinionaretrueandcorrect.Astoallquestionsoffactmaterialtothisopinionandastothematerialityofanyfactorothermatterreferredtoherein,wehaverelied(withoutindependentinvestigation)uponcertificatesorcomparabledocumentsofofficersandrepresentativesofElanco.
Basedontheforegoingandinreliancethereon,andsubjecttothelimitations,qualificationsandexceptionssetforthherein,weareoftheopinionthat:
1.ElancoisacorporationdulyincorporatedandvalidlyexistingcorporationunderthelawsoftheStateofIndianaandhasallrequisitecorporatepowerandauthoritytoconductitsbusinessandtoownitsproperties(allasdescribedintheRegistrationStatement)andtoperformallofitsobligationsundertheExchangeNotesandtheIndenture.
2.Elancohasdulyauthorized,executedanddeliveredtheIndentureandhasdulyauthorizedtheissuanceoftheExchangeNotes.
Inrenderingtheforegoingopinionsweexpressnoopinionastotheeffect(ifany)oflawsofanyjurisdictionexceptthoseoftheStateofIndiana.ThisopinionletterhasbeenpreparedforyouruseinconnectionwiththeRegistrationStatementandmaynotberelieduponforanyotherpurpose.Thisopinionspeaksasofthedatehereof.WeassumenoobligationtoadviseyouofanychangesintheforegoingsubsequenttotheeffectivenessoftheRegistration.
WeherebyconsenttorelianceonthisopinionletterandtheopinionsprovidedhereinbythelawfirmBryanCaveLeightonPaisnerLLPinconnectionwiththelegalopinionprovidedbythatlawfirmthatisincludedasanexhibittotheRegistrationStatement.Weherebyconsenttothereferencestoourfirmunderthecaption“LegalMatters”intheRegistrationStatementandtotheinclusionofthisopinionasanexhibittotheRegistrationStatement.Ingivingthisconsent,wedonottherebyadmitthatwearewithinthecategoryofpersonswhoseconsentisrequiredunderSection7oftheSecuritiesAct,ortherulesandregulationsoftheCommissionthereunder.
Verytrulyyours,
/s/Barnes & Thornburg LLP
2
Exhibit23.1
ConsentofIndependentRegisteredPublicAccountingFirmWeconsenttothereferencetoourfirmunderthecaption“Experts”andtotheuseofourreportdatedFebruary20,2019,intheRegistrationStatement(FormS-4)andrelatedProspectusofElancoAnimalHealthIncorporated(the“Company”)fortheoffertoexchangeupto$500,000,000principalamountoftheCompany’s3.912%SeniorNotesdue2021registeredundertheSecuritiesActforanyandallofitsoutstanding3.912%SeniorNotesdue2021;upto$750,000,000principalamountoftheCompany’s4.272%SeniorNotesdue2023registeredundertheSecuritiesActforanyandallofitsoutstanding4.272%SeniorNotesdue2023;andupto$750,000,000principalamountoftheCompany’s4.900%SeniorNotesdue2028registeredundertheSecuritiesActforanyandallofitsoutstanding4.900%SeniorNotesdue2028.
/s/Ernst&YoungLLP Indianapolis,Indiana
May17,2019
Exhibit25.1
UNITEDSTATESSECURITIESANDEXCHANGECOMMISSION
WASHINGTON,D.C.20549
FORMT-1
STATEMENTOFELIGIBILITYUNDERTHETRUSTINDENTUREACTOF1939OFACORPORATIONDESIGNATEDTOACTASTRUSTEEooCHECKIFANAPPLICATIONTODETERMINEELIGIBILITYOFATRUSTEEPURSUANTTOSECTION305(b)(2)
DEUTSCHEBANKTRUSTCOMPANYAMERICAS(formerlyBANKERSTRUSTCOMPANY)
(Exactnameoftrusteeasspecifiedinitscharter)
NEWYORK
13-4941247(JurisdictionofIncorporationor
(I.R.S.EmployerorganizationifnotaU.S.nationalbank)
Identificationno.)
60WALLSTREET
NEWYORK,NEWYORK
10005(Addressofprincipal
(ZipCode)executiveoffices)
DeutscheBankTrustCompanyAmericas
Attention:CatherineWangLegalDepartment
60WallStreet,36thFloorNewYork,NewYork10005
(212)250—7544(Name,addressandtelephonenumberofagentforservice)
ElancoAnimalHealthIncorporated(Exactnameofobligorasspecifiedinitscharter)
Indiana
82-5497352(Stateorotherjurisdictionof
(I.R.S.Employerincorporationororganization)
IdentificationNo.)
2500InnovationWay
Greenfield,Indiana
46140(Addressofprincipalexecutiveoffices)
(Zipcode)
3.912%SeniorNotesdue20214.272%SeniorNotesdue20234.900%SeniorNotesdue2028(TitleoftheIndenturesecurities)
Item1.GeneralInformation.
Furnishthefollowinginformationastothetrustee.
(a)Nameandaddressofeachexaminingorsupervisingauthoritytowhichitissubject.
Name
Address FederalReserveBank(2ndDistrict)
NewYork,NYFederalDepositInsuranceCorporation
Washington,D.C.NewYorkStateBankingDepartment
Albany,NY
(b)Whetheritisauthorizedtoexercisecorporatetrustpowers.Yes.
Item2.AffiliationswithObligor.
IftheobligorisanaffiliateoftheTrustee,describeeachsuchaffiliation.
None.Item3.-15.NotApplicableItem16.ListofExhibits.
Exhibit1-RestatedOrganizationCertificateofBankersTrustCompanydatedAugust31,1998;CertificateofAmendmentoftheOrganizationCertificateofBankersTrustCompanydatedSeptember25,1998;CertificateofAmendmentoftheOrganizationCertificateofBankersTrustCompanydatedDecember18,1998;CertificateofAmendmentoftheOrganizationCertificateofBankersTrustCompanydatedSeptember3,1999;andCertificateofAmendmentoftheOrganizationCertificateofBankersTrustCompanydatedMarch14,2002,incorporatedhereinbyreferencetoExhibit1filedwithFormT-1Statement,RegistrationNo.333-201810.
Exhibit2-CertificateofAuthoritytocommencebusiness,incorporatedhereinbyreferencetoExhibit2filedwithFormT-1Statement,RegistrationNo.333-201810.Exhibit3-AuthorizationoftheTrusteetoexercisecorporatetrustpowers,incorporatedhereinbyreferencetoExhibit3filedwithFormT-1Statement,RegistrationNo.333-201810.Exhibit4-ExistingBy-LawsofDeutscheBankTrustCompanyAmericas,datedAugust30,2018,incorporatedhereinbyreferencetoExhibitS-4/AfiledwithFormT-1Statement,Registration
No.333-223415.Exhibit5-Notapplicable.Exhibit6-ConsentofBankersTrustCompanyrequiredbySection321(b)oftheAct,incorporatedhereinbyreferencetoExhibit6filedwithFormT-1Statement,RegistrationNo.333-201810.Exhibit7-Acopyofthelatestreportofconditionofthetrusteepublishedpursuanttolawortherequirementsofitssupervisingorexaminingauthority.Exhibit8-NotApplicable.Exhibit9-NotApplicable.
SIGNATURE
PursuanttotherequirementsoftheTrustIndentureActof1939,asamended,thetrustee,DeutscheBankTrustCompanyAmericas,acorporationorganizedandexistingunderthelawsoftheStateofNewYork,has
dulycausedthisstatementofeligibilitytobesignedonitsbehalfbytheundersigned,thereuntodulyauthorized,allinTheCityofNewYork,andStateofNewYork,onthis15thdayofMay,2019.
DEUTSCHEBANKTRUSTCOMPANYAMERICAS
By: /s/LukeRussell
Name:LukeRussell
Title:AssistantVicePresident
OMBNumber7100-0036OMBNumber3064-0052OMBNumber1557-0081ApprovalexpiresMarch31,2022Page1of87BoardofGovernorsoftheFederalReserveSystemFederalDepositInsuranceCorporationOfficeoftheComptrolleroftheCurrencyFederalFinancialInstitutionsExaminationCouncilConsolidatedReportsofConditionandIncomeforaBankwithDomesticOfficesOnly—FFIEC041ReportatthecloseofbusinessMarch31,2019Thisreportisrequiredbylaw:12U.S.C.§324(Statememberbanks);12U.S.C.§1817(Statenonmemberbanks);12U.S.C.§161(Nationalbanks);and12U.S.C.§1464(Savingsassociations).20190331(RCON9999)Unlessthecontextindicatesotherwise,theterm“bank”inthisreportformreferstobothbanksandsavingsassociations.ThisreportformistobefiledbybankswithdomesticofficesonlyandtotalconsolidatedassetsoflessthanthosebanksthatfiletheFFIEC051.$100billion,exceptNOTE:Eachbank’sboardofdirectorsandseniormanagementareresponsibleforestablishingandmaintaininganeffectivesystemofinternalcontrol,includingcontrolsovertheReportsofConditionandIncome.TheReportsofConditionandIncomearetobepreparedinaccordancewithfederalregulatoryauthorityinstructions.TheReportsofConditionandIncomemustbesignedbytheChiefFinanciaOfficer(CFO)ofthereportingbank(orbytheindividualperforminganequivalentfunction)andattestedtobynotlessthantwodirectors(trustees)forstatenonmemberbanksandthreedirectorsforstatememberbanks,nationalbanks,andsavingsassociations.schedules)forthisreportdatehavebeenmancewiththeinstructionsissuedbythepreparedinconfor-appropriateFederalregulatoryauthorityandaretrueandcorrecttothebestofmyknowledgeandbelief.We,theundersigneddirectors(trustees),attesttothecorrectnessoftheReportsofConditionandIncome(includingthesupportingschedules)forthisreportdateanddeclarethattheReportsofConditionandIncomehavebeenexaminedbyusandtothebestofourknowledgeandbeliefhavebeenpreparedinconformancewiththeinstructionsissuedbytheappropriateFederalregulatoryauthorityandaretrueandcorrect.I,theundersignedCFO(orequivalent)ofthenamedbank,attestthattheReportsofConditionandIncome(includingthesupportingDirector(Trustee)SignatureofChiefFinancialOfficer(orEquivalent)04/30/2019Director(Trustee)DateofSignatureDirector(Trustee)SubmissionofReportsEachbankmustfileitsReport)databyeither:ReportsofConditionandIncome(CallTofulfillthesignatureandattestationrequirementfortheReportsofConditionandIncomeforthisreportdate,attachyourbank’scompletedsignaturepage(oraphotocopyoracomputergener-atedversionofthispage)tothehard-copyrecordofthedatafilesubmittedtotheCDRthatyourbankmustplaceinitsfiles.(a)
UsingcomputersoftwaretoprepareitsCallReportandthensubmittingthereportdatadirectlytotheFFIEC’sCentralDataRepository(CDR),anInternet-basedsystemfordatacollec-tion(https://cdr.ffiec.gov/cdr/),orTheappearanceofyourbank’shard-copyrecordofthesubmitteddatafileneednotmatchexactlytheappearanceoftheFFIEC’ssamplereportforms,butshouldshowatleastthecaptionofeachCallReportitemandthereportedamount.(b)CompletingitsCallReportinpaperformandarrangingwithasoftwarevendororanotherpartytoconvertthedataintotheelectronicformatthatcanbeprocessedbytheCDR.Thesoftwarevendororotherpartythenmustelectronicallysubmitthebank’sdatafiletotheCDR.DEUTSCHEBANKTRUSTCOMPANYAMERICASLegalTitleofBank(RSSD9017)FortechnicalassistancewithsubmissionstotheCDR,pleasecontacttheCDRHelpDeskbytelephoneat(888)CDR-3111,byfaxat(703)774-3946,orbye-mailatCDR.Help@ffiec.gov.NewYorkCity(RSSD9130)FDICCertificateNumberNY10005StateAbbreviation(RSSD9200)LegalEntityIdentifier(LEI)ZipCode(RSSD9220)(RSSD9050)(ReportonlyifyourinstitutionalreadyhasanLEI.)(RCON9224)Theestimatedaverageburdenassociatedwiththisinformationcollectionis55.71hoursperrespondentandisexpectedtovarybyinstitution,dependingonindividualcircumstances.Burdenestimatesincludethetimeforreviewinginstructions,gatheringandmaintainingdataintherequiredform,andcompletingtheinformationcollection,butexcludethetimeforcompilingandmaintainingbusinessrecordsinthenormalcourseofarespondent’sactivities.AFederalagencymaynotconductorsponsor,andanorganization(oraperson)isnotrequiredtorespondtoacollectionofinformation,unlessitdisplaysacurrentlyvalidOMBcontrolnumber.CommentsconcerningtheaccuracyofthisburdenestimateandsuggestionsforreducingthisburdenshouldbedirectedtotheOfficeofInformationandRegulatoryAffairs,OfficeofManagementandBudget,Washington,DC20503,andtooneofthefollowing:Secretary,BoardofGovernorsoftheFederalReserveSystem,20thandCStreets,NW,Washington,DC20551;LegislativeandRegulatoryAnalysisDivision,OfficeoftheComptrolleroftheCurrency,Washington,DC20219;AssistantExecutiveSecretary,FederalDepositInsuranceCorporation,Washington,DC20429.03/20198EWQ2UQKS07AKK8ANH81623
FFIEC041Page17of87RC-1ConsolidatedReportofConditionforInsuredBanksandSavingsAssociationsforMarch31,2019Allschedulesaretobereportedinthousandsofdollars.Unlessotherwiseindicated,reporttheamountoutstandingasofthelastbusinessdayofthequarter.ScheduleRC—BalanceSheet1.a.1.b.2.a.2.b.2.c.3.a.3.b.4.a.4.b.4.c.4.d.5.6.7.8.9.10.11.12.RC-E)…………………220013.a.13.a.(1)13.a.(2)Interest-bearing…………………………………………………663614.a.14.b.15.16.………………………………………………………………32001.Includescashitemsinprocessofcollectionandunposteddebits.2.Includestimecertificatesofdepositnotheldfortrading.19.3.InstitutionsthathaveadoptedASU2016-13shouldreportinitem2.aamountsnetofanyapplicableallowanceforcreditlosses,anditem2.ashouldequalScheduleRC-B,item8,columnA,lessScheduleRI-B,PartII,item7,columnB.4.Item2.cistobecompletedonlybyinstitutionsthathaveadoptedASU2016-01,whichincludesprovisionsgoverningtheaccountingforinvestmentsinequitysecurities.SeetheinstructionsforfurtherdetailonASU2016-01.5.Includesallsecuritiesresaleagreements,regardlessofmaturity.6.InstitutionsthathaveadoptedASU2016-13shouldreportinitems3.band11amountsnetofanyapplicableallowanceforcreditlosses.7.InstitutionsthathaveadoptedASU2016-13shouldreportinitem4.ctheallowanceforcreditlossesonloansandleases.8.Includesnoninterest-bearingdemand,time,andsavingsdeposits.9.ReportovernightFederalHomeLoanBankadvancesinScheduleRC,item16,"Otherborrowedmoney."10.Includesallsecuritiesrepurchaseagreements,regardlessofmaturity.11.Includeslimited-lifepreferredstockandrelatedsurplus.03/2019DollarAmountsinThousandsRCONAmountAssets1.Cashandbalancesduefromdepositoryinstitutions(fromScheduleRC-A):a.Noninterest-bearingbalancesandcurrencyandcoin(1)…………………………….…….…...b.Interest-bearingbalances(2)………………………………………………………......................2.Securities:a.Held-to-maturitysecurities(fromScheduleRC-B,columnA)(3)……………………………......b.Available-for-salesecurities(fromScheduleRC-B,columnD)…………………….……..........c.Equitysecuritieswithreadilydeterminablefairvaluesnotheldfortrading(4)…………………3.Federalfundssoldandsecuritiespurchasedunderagreementstoresella.Federalfundssold……………………………………………………….......................................b.Securitiespurchasedunderagreementstoresell(5,6)………………………….......................4.Loansandleasefinancingreceivables(fromScheduleRC-C):a.Loansandleasesheldforsale………………………………………………………..……...........008133,000007116,966,000JJ34017730JA225,000B9870B98913,287,00053690b.Loansandleasesheldforinvestment………………...................c.LESS:Allowanceforloanandleaselosses……………..............B52810,109,00031239,000d.Loansandleasesheldforinvestment,netofallowance(item4.bminus4.c)(7)……….........5.Tradingassets(fromScheduleRC-D)…………………………………………………….…….........6.Premisesandfixedassets(includingcapitalizedleases)……………………………………..........7.Otherrealestateowned(fromScheduleRC-M)……………………………………………….........8.Investmentsinunconsolidatedsubsidiariesandassociatedcompanies…………………….........9.Directandindirectinvestmentsinrealestateventures...................................……......................10.Intangibleassets(fromScheduleRC-M)……………………………………………………………11.Otherassets(fromScheduleRC-F)(6)……………………………………………………………......12.Totalassets(sumofitems1through11)………………………………………………………..........Liabilities13.Deposits:a.Indomesticoffices(sumoftotalsofcolumnsAandCfromScheduleB52910,100,00035450214528,00021501,0002130036560214319,00021601,299,000217041,738,00028,602,000(1)Noninterest-bearing(8)………………………………………(2)663120,889,0007,713,000b.Notapplicable14.Federalfundspurchasedandsecuritiessoldunderagreementstorepurchase:a.Federalfundspurchased(9)………………………………………..…………............................b.Securitiessoldunderagreementstorepurchase(10)……………………………………………15.Tradingliabilities(fromScheduleRC-D)…………………………………………………..………….16.Otherborrowedmoney(includesmortgageindebtednessandobligationsundercapitalizedleases)(fromScheduleRC-M)……………………………………………………………17.and18.Notapplicable19.Subordinatednotesanddebentures(11)B993902,000B9950354803190856,0000
FFIEC041Page18of87RC-2ScheduleRC—Continued20.21.20)………………………………………………………………………294823.24.25.26.a.26.b.26.c.27.a.27.b.28.29.stock)………………………………………………..…………3839MemorandaTobereportedwiththeMarchReportofCondition.1.Indicateintheboxattherightthenumberofthestatementbelowthatbestdescribesthemostcomprehensivelevelofauditingworkperformedforthebankbyindependentexternalauditorsasofanydateduring2018……………………………………………………………………………………...............M.1.1a=Anintegratedauditofthereportinginstitution’sfinancialstatementsanditsinternalcontroloverfinancialreportingconductedinaccordancewiththestandardsoftheAmericanInstituteofCertifiedPublicAccountants(AICPA)orPublicCompanyAccountingOversightBoard(PCAOB)byanindepen-dentpublicaccountantthatsubmitsareportontheinstitution1b=Anauditofthereportinginstitution'sfinancialstatementsonlyconductedinaccordancewiththeauditingstandardsoftheAICPAorthePCAOBbyanindependentpublicaccountantthatsubmitsareportontheinstitution2a=Anintegratedauditofthereportinginstitution'sparentholdingcompany'sconsolidatedfinancialstatementsanditsinternalcontroloverfinancialreportingconductedinaccordancewiththestandardsoftheAICPAorthePCAOBbyanindependentpublicaccountantthatsubmitsareportontheconsolidatedholdingcompany(butnotontheinstitutionseparately)2b=Anauditofthereportinginstitution'sparentholdingcompany'sconsolidatedfinancialstatementsonlyconductedinaccordancewiththeauditingstandardsoftheAICPAorthePCAOBbyanindependentpublicaccountantthatsubmitsareportontheconsolidatedholdingcompany(butnotontheinstitutionseparately)3=Thisnumberisnottobeused4=Directors’examinationofthebankconductedinaccordancewithgenerallyacceptedauditingstandardsbyacertifiedpublicaccountingfirm(mayberequiredbystate-charteringauthority)5=Directors’examinationofthebankperformedbyotherexternalauditors(mayberequiredbystate-charteringauthority)6=Reviewofthebank’sfinancialstatementsbyexternalauditors7=Compilationofthebank’sfinancialstatementsbyexternalauditors8=Otherauditprocedures(excludingtaxpreparationwork)9=NoexternalauditworkTobereportedwiththeMarchReportofCondition.2.Bank'sfiscalyear-enddate(reportthedateinMMDDformat).....................................................................M.2.1.Includes,butisnotlimitedto,netunrealizedholdinggains(losses)onavailable-for-salesecurities,accumulatednetgains(losses)oncashflowhedges,andaccumulateddefinedbenefitpensionandotherpostretirementplanadjustments.2.IncludestreasurystockandunearnedEmployeeStockOwnershipPlanshares.03/2019RCONDate86781231RCONNumber67242aDollarAmountsinThousandsRCONAmountLiabilities—continued20.Otherliabilities(fromScheduleRC-G)…………………………………………………………………….………21.Totalliabilities(sumofitems13through22.NotapplicableEquityCapitalBankEquityCapital23.Perpetualpreferredstockandrelatedsurplus……………………………………………………………………24.Commonstock……………………………………………………………………………………………….………25.Surplus(excludeallsurplusrelatedtopreferred26.a.Retainedearnings………………………………………………………………………………………..………b.Accumulatedothercomprehensiveincome(1)………………………………………………………….……c.Otherequitycapitalcomponents(2)……………………………………………………………………………27.a.Totalbankequitycapital(sumofitems23through26.c)…………………………………………………..…b.Noncontrolling(minority)interestsinconsolidatedsubsidiaries…………………………………….…….....28.Totalequitycapital(sumofitems27.aand27.b)………………………………………………………..………29.Totalliabilitiesandequitycapital(sumofitems21and28)……………………………………………..………29301,977,00032,337,0003838032302,127,000752,00036326,523,000B530(1,000)A130032109,401,00030000G1059,401,000330041,738,000
QuickLinks--Clickheretorapidlynavigatethroughthisdocument
Exhibit 99.1
LETTER OF TRANSMITTAL
ELANCO ANIMAL HEALTH INCORPORATEDOffer to Exchange
$500,000,000 principal amount of 3.912% Senior Notes due 2021, registered under the Securities Act of 1933, for any and all outstanding 3.912% Senior Notes due 2021
(CUSIP Nos. 28414H AA1 and U2541F AA3)
$750,000,000 principal amount of 4.272% Senior Notes due 2023, registered under the Securities Act of 1933, for any and all outstanding 4.272% Senior Notes due 2023
(CUSIP Nos. 28414H AC7 and U2541F AC9)
$750,000,000 principal amount of 4.900% Senior Notes due 2028, registered under the Securities Act of 1933, for any and all outstanding 4.900% Senior Notes due 2028
(CUSIP Nos. 28414H AB9 and U2541F AB1)
Pursuant to the Prospectus dated , 2019
THE EXCHANGE OFFERS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON , 2019, UNLESS EXTENDED (SUCH TIME AND DATE, AS THE SAME MAY BEEXTENDED FROM TIME TO TIME, THE "EXPIRATION DATE"). TENDERS MAY BE WITHDRAWN AT ANY TIME PRIOR TO THE EXPIRATION DATE.
The Exchange Agent is:
DEUTSCHE BANK TRUST COMPANY AMERICAS
DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE OR TRANSMISSION TO A FACSIMILE NUMBER OTHER THAN THE ONELISTED ABOVE WILL NOT CONSTITUTE VALID DELIVERY TO THE EXCHANGE AGENT.
THE INSTRUCTIONS SET FORTH IN THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED.
Byexecutionhereof,theundersignedacknowledgesreceiptoftheprospectusdated,2019(the"Prospectus"),ofElancoAnimalHealthIncorporated,anIndianacorporation(the"Company"),andthisletteroftransmittalandtheinstructionshereto(the"LetterofTransmittal"),whichtogetherconstitutetheCompany'sofferstoexchange(the"ExchangeOffers")(i)upto$500,000,000aggregateprincipalamountoftheCompany's3.912%SeniorNotesdue2021(the"2021ExchangeNotes")foralikeamountoftheCompany'soutstandingunregistered3.912%SeniorNotesdue2021(the"2021OriginalNotes");(ii)upto$750,000,000aggregateprincipalamountoftheCompany's4.272%SeniorNotesdue2023(the"2023ExchangeNotes")foralikeamountoftheCompany'soutstandingunregistered4.272%SeniorNotesdue2023(the"2023OriginalNotes");and(iii)upto$750,000,000aggregateprincipalamountoftheCompany's4.900%SeniorNotesdue2028(the"2028ExchangeNotes"andtogetherwiththe2021ExchangeNotesandthe2023ExchangeNotes,the"ExchangeNotes")foralikeamountoftheCompany'soutstandingunregistered4.900%SeniorNotesdue2028(the"2028OriginalNotes"andtogetherwiththe2021OriginalNotesandthe2023OriginalNotes,the"OriginalNotes").RecipientsoftheProspectusshouldreadtherequirementsdescribedintheProspectuswithrespecttoeligibilitytoparticipateintheExchangeOffers.CapitalizedtermsusedbutnotdefinedhereinhavethemeaninggiventothemintheProspectus.
ForeachOriginalNoteacceptedforexchange,theholderofsuchOriginalNotewillreceiveanExchangeNotehavingaprincipalamountequaltothatofthesurrenderedOriginalNote.
By registered or certified mail, hand or overnight delivery:
Facsimile transactions: (For Eligible Institutions only)
DeutscheBankTrustCompanyAmericasc/oDBServicesAmericas,Inc.
Attn:ReorgDept.5022GateParkway,Suite200
Jacksonville,FL32256
615-866-3889Attention:ReorgDept.
To confirm by telephone:
877-843-9767
PLEASE READ THIS ENTIRE LETTER OF TRANSMITTAL CAREFULLY BEFORE CHECKING ANY BOX BELOW.
ThisLetterofTransmittalistobeusedbyaholderofOriginalNotes:
• ifcertificatesrepresentingtenderedOriginalNotesaretobeforwardedherewith;
• ifatenderofcertificatesforOriginalNotesistobemadebybook-entrytransfertotheaccountmaintainedbytheExchangeAgentattheDepositoryTrustCompany("DTC")pursuanttotheproceduressetforthin"TheExchangeOffers"sectionoftheProspectus;or
• ifatenderismadepursuanttotheguaranteeddeliveryproceduresinthesectionoftheProspectusentitled"TheExchangeOffers—ProceduresforTenderingOriginalNotes—GuaranteedDelivery."
HoldersofOriginalNotesthataretenderingbybook-entrytransfertotheaccountmaintainedbytheExchangeAgentatDTCcanexecutethetenderthroughtheAutomatedTenderOfferProgram("ATOP")forwhichtheExchangeOfferswillbeeligible.DTCparticipantsthatareacceptingtheExchangeOffersmusttransmittheiracceptancetoDTCwhichwillverifytheacceptanceandexecuteabook-entrydeliverytotheExchangeAgent'saccountatDTC.DTCwillthensendanagent'smessageformingpartofabook-entrytransferinwhichtheparticipantagreestobeboundbythetermsoftheLetterofTransmittal(an"Agent'sMessage")totheExchangeAgentforitsacceptance.
InordertoproperlycompletethisLetterofTransmittal,aholderofOriginalNotesmust:
• completetheboxentitled,"DescriptionofOriginalNotesTendered";
• ifappropriate,checkandcompletetheboxesrelatingtobook-entrytransfer,guaranteeddelivery,SpecialIssuanceInstructionsandSpecialDeliveryInstructions;
• signtheLetterofTransmittalbycompletingtheboxentitled"SignHeretoTenderYourOriginalNotesintheExchangeOffers";and
• completetheFormW-9orapplicableFormW-8.
EachholderofOriginalNotesshouldcarefullyreadthedetailedinstructionsbelowpriortocompletingtheLetterofTransmittal.
HoldersofOriginalNoteswhodesiretotendertheirOriginalNotesforexchange,but:
• suchholder'sOriginalNotesarenotimmediatelyavailable;
• suchholdercannotdeliveritsOriginalNotes,thisLetterofTransmittalandallotherdocumentsrequiredherebytotheExchangeAgent;or
• suchholdercannotcompletetheproceduresforbook-entrytransferonorpriortotheExpirationDate,
musttendertheirOriginalNotespursuanttotheguaranteeddeliveryproceduressetforthinthesectionoftheProspectusentitled"TheExchangeOffers—ProceduresforTenderingOriginalNotes—GuaranteedDelivery."SeeInstruction2.
DELIVERY OF DOCUMENTS TO DTC DOES NOT CONSTITUTE DELIVERY TO THE EXCHANGE AGENT. IN ORDER TO ENSURE PARTICIPATION IN THE EXCHANGE OFFERS,ORIGINAL NOTES MUST BE PROPERLY TENDERED PRIOR TO THE EXPIRATION DATE.
HoldersofOriginalNoteswhowishtotendertheirOriginalNotesforexchangemustcompletecolumns(1)through(4)intheboxbelowentitled"DescriptionofOriginalNotesTendered,"andsigntheboxbelowentitled"SignHeretoTenderYourOriginalNotesintheExchangeOffers."Ifonlythosecolumnsarecompleted,suchholderofOriginalNoteswillhavetenderedforexchangeall
2
OriginalNoteslistedincolumn(4)below.IftheholderofOriginalNoteswishestotenderforexchangelessthanallofsuchOriginalNotes,column(5)mustbecompletedinfull.Insuchcase,suchholderofOriginalNotesshouldrefertoInstruction5.
TheExchangeOffersmaybeextended,terminatedoramended,asprovidedintheProspectus.DuringanysuchextensionoftheExchangeOffers,allOriginalNotespreviouslytenderedandnotvalidlywithdrawnpursuanttotheExchangeOfferswillremainsubjecttosuchExchangeOffers.
TheundersignedherebytendersforexchangetheOriginalNotesdescribedintheboxentitled"DescriptionofOriginalNotesTendered"belowpursuanttothetermsandconditionsdescribedintheProspectusandthisLetterofTransmittal.
3
DESCRIPTION OF ORIGINAL NOTES TENDERED
(1) Name(s) and Address(es) of
Registered Owner(s) (Please fill in, if blank)
(2) Title of Security
(3) Certificate
Number(s)(A)
(4) Aggregate
Principal Amount Represented by Certificate(s)(B)
(5) Principal
Amount Tendered for Exchange (if less than all)(C)
Total:
(A) NeednotbecompletedifOriginalNotesarebeingtenderedbybook-entrytransfer.
(B) Unlessotherwiseindicated,anytenderingholderwillbedeemedtohavetenderedtheentireprincipalamountrepresentedbytheOriginalNotesindicatedin
thiscolumn.SeeInstruction5.
(C) Theminimumpermittedtenderis$2,000inprincipalamountofOriginalNotes.Alltendersinexcessofsuchamountmustbeintegralmultiplesof$1,000.See
Instruction5.
o CHECK HERE IF TENDERED ORIGINAL NOTES ARE ENCLOSED HEREWITH.o CHECK HERE IF TENDERED ORIGINAL NOTES ARE BEING DELIVERED BY DTC TO THE EXCHANGE AGENT'S ACCOUNT AT DTC AND COMPLETE THE FOLLOWING:
NameofTenderingInstitution:
DTCBook-EntryNumber:
TransactionCodeNumber:
o CHECK HERE IF TENDERED ORIGINAL NOTES ARE BEING DELIVERED PURSUANT TO A NOTICE OF GUARANTEED DELIVERY AND COMPLETE THE FOLLOWING (FOR USE BYELIGIBLE INSTITUTIONS ONLY):
Name(s)ofRegisteredHolders:
Name(s)ofRegisteredHolders:
DateofExecutionofNoticeofGuaranteedDelivery:
ByitsacceptanceoftheExchangeOffers,anybroker-dealerthatreceivesExchangeNotespursuanttotheExchangeOffersagreestonotifytheCompanybeforeusingtheProspectusinconnectionwiththesaleortransferoftheExchangeNotes.Seethesectiontitled"PlanofDistribution"intheProspectus.
OnlyregisteredholdersareentitledtotendertheirOriginalNotesforexchangeintheExchangeOffers.AnyfinancialinstitutionthatisaparticipantinDTC'ssystemandwhosenameappearsonasecuritypositionlistingastherecordowneroftheOriginalNotesandwhowishestomakebook-entrydeliveryofOriginalNotesasdescribedabovemustcompleteandexecuteaparticipant'sletter(whichwillbedistributedtoparticipantsbyDTC)instructingDTC'snomineetotendersuchOriginalNotesforexchange.
PersonswhoarebeneficialownersofOriginalNotesbutarenotregisteredholdersandwhoseektotenderOriginalNotesshould:
• promptlycontacttheregisteredholderofsuchOriginalNotesandinstructsuchregisteredholdertotenderonhisorherbehalf;
• obtainandincludewiththisLetterofTransmittalOriginalNotesproperlyendorsedfortransferbytheregisteredholderoraccompaniedbyaproperlycompletedbondpowerfromtheregisteredholder,withsignaturesontheendorsementorbondpowerguaranteedbyabank,broker,dealer,creditunion,savingsassociation,clearingagencyorotherinstitution,eachan"EligibleInstitution"thatisamemberofarecognizedsignatureguaranteemedallionprogramwithinthemeaningofRule17Ad-15undertheSecuritiesExchangeActof1934;or
• effectarecordtransferofsuchOriginalNotesfromtheregisteredholdertosuchbeneficialownerandcomplywiththerequirementsapplicabletoregisteredholdersfortenderingOriginalNotespriortotheExpirationDate.
Seethesectiontitled"TheExchangeOffers—ProceduresforTenderingOriginalNotes"intheProspectus.
SIGNATURES MUST BE PROVIDED BELOW.
4
NameofEligibleInstitution(asdefinedbelow)thatGuaranteedDelivery:
NameofTenderingInstitution:
DTCBook-EntryNumber:
TransactionCodeNumber:
o CHECK HERE IF YOU ARE A BROKER-DEALER WHO HOLDS ORIGINAL NOTES ACQUIRED FOR YOUR OWN ACCOUNT AS A RESULT OF MARKET-MAKING OR OTHER TRADINGACTIVITIES AND WISH TO RECEIVE COPIES OF THE PROSPECTUS AND COPIES OF ANY AMENDMENTS OR SUPPLEMENTS THERETO FOR USE IN CONNECTION WITH RESALES OFEXCHANGE NOTES RECEIVED FOR YOUR OWN ACCOUNT IN EXCHANGE FOR SUCH ORIGINAL NOTES.
Name:
Address:
AggregatePrincipalAmountofOriginalNotessoHeld:
PLEASE READ THE ACCOMPANYING INSTRUCTIONS CAREFULLY.
LadiesandGentlemen:
UponthetermsandsubjecttotheconditionsoftheExchangeOffers,theundersignedherebytenderstotheCompanyforexchangetheaggregateprincipalamountofOriginalNotesindicatedinthisLetterofTransmittal.Subjectto,andeffectiveupon,theacceptanceforexchangeoftheOriginalNotestenderedherewith,theundersignedherebysells,assigns,transfersandexchangesto,orupontheorderof,theCompanyallright,titleandinterestinandtoallsuchOriginalNotestenderedforexchangehereby.TheundersignedherebyirrevocablyconstitutesandappointstheExchangeAgentasthetrueandlawfulagentandattorney-in-factoftheundersigned(withfullknowledgethattheExchangeAgentalsoactsasagentoftheCompany)withrespecttosuchOriginalNotes,withfullpowerofsubstitutionandresubstitution(suchpowerofattorneybeingdeemedtobeanirrevocablepowercoupledwithaninterest)to:
• deliversuchOriginalNotesinregisteredcertificatedform,ortransferownershipofsuchOriginalNotesthroughbook-entrytransferatthebook-entrytransferfacility,toorupontheorderoftheCompany,uponreceiptbytheExchangeAgent,astheundersigned'sAgent,ofthesameaggregateprincipalamountoftheExchangeNotes;
• presentanddeliversuchOriginalNotesfortransferonthebooksoftheCompany;and
• receiveallbenefitsorotherwiseexerciseallrightsandincidentsofbeneficialownershipofsuchOriginalNotes,allinaccordancewiththetermsoftheExchangeOffers.
Theundersignedrepresentsandwarrantsthatithasfullpowerandauthoritytotender,sell,assign,exchange,andtransfertheOriginalNotestenderedherebyandthattheCompanywillacquiregood,marketableandunencumberedtitletothetenderedOriginalNotes,freeandclearofallsecurityinterests,liens,restrictions,chargesandencumbrances,conditionalsaleagreementsorotherobligationsrelatingtotheirsaleortransfer,andnotsubjecttoanyadverseclaimwhenthesameareacceptedbytheCompany.Theundersignedalsowarrantsthatitwill,uponrequest,executeanddeliveranyadditionaldocumentsdeemedbytheExchangeAgentortheCompanytobenecessaryordesirabletocompletetheexchange,assignmentandtransferoftenderedOriginalNotesortransferownershipofsuchOriginalNotesontheaccountbooksmaintainedbythebook-entrytransferfacility.TheundersignedfurtheragreesthatacceptanceofanyandallvalidlytenderedOriginalNotesbytheCompanyandtheissuanceofExchangeNotesinexchangethereforshallconstituteperformanceinfullbytheCompanyofitsobligationsundertheExchangeandRegistrationRightsAgreemententeredintowiththeinitialpurchasersnamedtherein,datedAugust28,2018(the"RegistrationRightsAgreement").
Bytendering,eachholderofOriginalNotesrepresentsthat:
• theExchangeNotestobeacquiredinconnectionwiththeExchangeOffersbytheholderandeachbeneficialowneroftheOriginalNotesarebeingacquiredbytheholderandeachbeneficialownerintheordinarycourseofbusinessoftheholderandeachbeneficialowner;
• theholderandeachbeneficialownerarenotparticipating,donotintendtoparticipate,andhavenoarrangementorunderstandingwithanypersontoparticipate,inthedistributionoftheExchangeNotes;
• theholderandeachbeneficialowneracknowledgeandagreethatanypersonparticipatingintheExchangeOffersforthepurposeofdistributingtheExchangeNotesmustcomplywiththeregistrationandprospectusdeliveryrequirementsoftheSecuritiesActof1933,asamended(the"SecuritiesAct"),inconnectionwithasecondaryresaletransactionandcannotrelyonthepositionofthestaffoftheSecuritiesandExchangeCommission(the"Commission")setforthintheapplicableno-actionletters,see"TheExchangeOffers—ResalesofExchangeNotes"inthe
5
Prospectus,andthatsuchasecondaryresaletransactionshouldbecoveredbyaneffectiveregistrationstatementcontainingthesellingsecurityholderinformationrequiredbyItem507or508,applicableofRegulationS-KoftheCommission;
• iftheholderisabroker-dealer,suchholderrepresentsthatitacquiredtheOriginalNotesforitsownaccountasaresultofmarketmakingorothertradingactivities(otherthanOriginalNotesacquireddirectlyfromtheCompany),andthatitwilldeliveraprospectusinconnectionwithanyresaleofExchangeNotesacquiredintheExchangeOffers;
• iftheholderisabroker-dealerandreceivesExchangeNotespursuanttotheExchangeOffersitshallnotifytheCompanybeforeusingtheProspectusinconnectionwithanysaleortransferoftheExchangeNotes;
• neithertheholdernoranybeneficialownerisan"affiliate,"asdefinedunderRule405oftheSecuritiesAct,oftheCompanyorofanyoftheCompany'ssubsidiaries;and
• inconnectionwithabook-entrytransfer,eachparticipantwillconfirmthatitmakestherepresentationsandwarrantiessetforthinthisLetterofTransmittal.
TheundersignedhasreadandagreestoallofthetermsoftheExchangeOffers.
TheundersignedalsoacknowledgesthattheCompanyismakingtheseExchangeOffersinrelianceonthepositionofthestaffoftheCommission,assetforthincertaininterpretivelettersissuedtothirdpartiesinothertransactions.BasedontheCommissioninterpretations,theCompanybelievesthattheExchangeNotesissuedinexchangefortheOriginalNotespursuanttotheExchangeOffersmaybeofferedforresale,resoldandotherwisetransferredbyholdersthereof(otherthanabroker-dealerwhopurchasedOriginalNotesdirectlyfromtheCompanyoranysuchholderthatisan"affiliate"oftheCompanyoranyofitssubsidiarieswithinthemeaningofRule405undertheprovisionsoftheSecuritiesAct)withoutfurthercompliancewiththeregistrationandprospectusdeliveryprovisionsoftheSecuritiesAct;providedthatsuchExchangeNotesareacquiredintheordinarycourseofsuchholders'businessandsuchholdersarenotengagedin,donotintendtoengagein,anddonothaveanarrangementorunderstandingwithanypersontoparticipateinadistributionofsuchExchangeNotes.However,theCompanydoesnotintendtorequesttheCommissiontoconsider,andtheCommissionhasnotconsidered,theExchangeOffersinthecontextofaninterpretiveletter,andtherecanbenoassurancethatthestaffoftheCommissionwouldmakeasimilardeterminationwithrespecttotheExchangeOffersasitdidininterpretativeletterstothirdpartiesinsimilarcircumstances.
Iftheundersignedisnotabroker-dealer,theundersignedrepresentsthatitisnotengagedin,anddoesnotintendtoengagein,adistributionofExchangeNotesandhasnoarrangementorunderstandingtoparticipateinadistributionofExchangeNotes.Ifanyholderisabroker-dealerthatacquiredanyofitsOriginalNotesdirectlyfromtheCompany,anaffiliateoftheCompanyoranyoftheCompany'ssubsidiaries,orisengagedinorintendstoengageinorhasanyarrangementorunderstandingwithrespecttothedistributionoftheExchangeNotestobeacquiredpursuanttotheExchangeOffers,suchholder(i)couldnotrelyontheapplicableinterpretationsofthestaffoftheCommissionand(ii)mustcomplywiththeregistrationandprospectusdeliveryrequirementsoftheSecuritiesActinconnectionwithanysecondaryresaletransaction.Iftheundersignedisabroker-dealerthatwillreceiveExchangeNotesforitsownaccountinexchangeforOriginalNotes,theundersignedrepresentsthattheOriginalNoteswereacquiredforitsownaccountasaresultofmarket-makingactivitiesorothertradingactivities,anditacknowledgesthatitwilldeliveraprospectusmeetingtherequirementsoftheSecuritiesActinconnectionwithanyresaleofExchangeNotesreceivedinrespectofsuchOriginalNotespursuanttotheExchangeOffers;however,bysoacknowledgingandbydeliveringaprospectus,theundersignedwillnotbedeemedtoadmitthatitisan"underwriter"withinthemeaningoftheSecuritiesAct.Inaddition,byitsacceptanceoftheExchangeOffers,anysuch
6
broker-dealerthatreceivesExchangeNotespursuanttotheExchangeOffersagreestonotifytheCompanybeforeusingtheProspectusinconnectionwiththesaleortransferofExchangeNotes.
TheCompanyhasagreedthat,subjecttotheprovisionsoftheRegistrationRightsAgreement,theProspectus,asitmaybeamendedorsupplementedfromtimetotime,ifrequestedbyabroker-dealerinconnectionwithresalesofExchangeNotesreceivedinexchangeforOriginalNoteswhichwereacquiredbysuchbroker-dealerforitsownaccountasaresultofmarket-makingorothertradingactivities,maybeusedbysuchabroker-dealerinconnectionwithsuchresalesforaperiodending180daysfromthedateonwhichtheExchangeOffersareconsummatedorsuchshorterperiodaswillterminatewhenabroker-dealerhassoldallExchangeNotesheldbysuchbroker-dealer.Inthatregard,eachbroker-dealerbytenderingsuchOriginalNotesandexecutingthisLetterofTransmittal,agreesthat,uponreceiptofnoticefromtheCompany:
• oftheoccurrenceofanyeventorthediscoveryofanyfactwhichmakesanystatementcontainedorincorporatedbyreferenceintheProspectusuntrueinanymaterialrespectorwhichcausestheProspectustoomittostateamaterialfactnecessaryinordertomakethestatementscontainedorincorporatedbyreferencetherein,inlightofthecircumstancesunderwhichtheyweremade,notmisleading,or
• thattheboardofdirectorsoftheCompany(oraduly-appointedcommitteeoftheboardofdirectorshavingpoweroverthesubjectmatter)determinesingoodfaiththatitisinthebestinterestsoftheCompanynottodisclosetheexistenceoforfactssurroundinganyproposedorpendingmaterialcorporatetransactioninvolvingtheCompany,
suchbroker-dealerwillsuspendthesaleofExchangeNotespursuanttotheProspectusuntiltheCompanyhasamendedorsupplementedtheProspectustocorrectsuchmisstatementoromissionortodisclosesuchtransactionandhasfurnishedcopiesoftheamendedorsupplementedProspectustothebroker-dealerortheCompanyhasgivenwrittennoticethatthesaleoftheExchangeNotesmayberesumed,asthecasemaybe.IftheCompanygivessuchnoticetosuspendthesaleoftheExchangeNotes,itshallextendthe180-dayperiodreferredtoaboveduringwhichsuchbroker-dealersareentitledtousetheProspectusinconnectionwiththeresaleofExchangeNotesbythenumberofdaysduringtheperiodfromandincludingthedateofthegivingofsuchnoticetoandincludingthedatewhensuchbroker-dealersshallhavereceivedcopiesofthesupplementedoramendedProspectusnecessarytopermitresalesoftheExchangeNotesortoandincludingthedateonwhichtheCompanyhasgivennoticethatthesaleofExchangeNotesmayberesumed,asthecasemaybe.Eachbroker-dealerbytenderingsuchOriginalNotesandexecutingthisLetterofTransmittalfurtheragreestoholdthefactthatithasreceivedtheforegoingsuspensionnotice,andanycommunicationfromtheCompanytosuchbroker-dealerrelatingtoaneventgivingrisetosuchsuspensionnotice,inconfidence.
AllauthorityconferredoragreedtobeconferredpursuanttothisLetterofTransmittalandeveryobligationoftheundersignedhereundershallbebindinguponthesuccessors,assigns,heirs,executors,administrators,trusteesinbankruptcy,andpersonalandlegalrepresentativesoftheundersignedandshallnotbeaffectedby,andshallsurvive,thedeathorincapacityoftheundersigned.OriginalNotesproperlytenderedmaybewithdrawnatanytimepriortotheExpirationDateinaccordancewiththetermsofthisLetterofTransmittal.
TheExchangeOffersaresubjecttocertainconditions,eachofwhichmaybewaivedormodifiedbytheCompany,inwholeorinpart,atanytimeandfromtimetotime,asdescribedintheProspectusunderthecaption"TheExchangeOffers—Conditions."TheundersignedrecognizesthatasaresultofsuchconditionstheCompanymaynotberequiredtoacceptforexchange,ortoissueExchangeNotesinexchangefor,anyoftheOriginalNotesproperlytenderedhereby.Insuchevent,thetenderedOriginalNotesnotacceptedforexchangewillbereturnedtotheundersignedwithoutcosttothe
7
undersignedattheaddressshownbelowtheundersigned'ssignature(s)unlessotherwiseindicatedunder"SpecialIssuanceInstructions"below.
Unlessotherwiseindicatedunder"SpecialIssuanceInstructions"below,pleasereturnanycertificatesrepresentingOriginalNotesnottenderedornotacceptedforexchangeinthename(s)oftheholdersappearingunder"DescriptionofOriginalNotesTendered."Similarly,unlessotherwiseindicatedunder"SpecialDeliveryInstructions,"pleasemailanycertificatesrepresentingOriginalNotesnottenderedornotacceptedforexchange(andaccompanyingdocumentsasappropriate)totheaddress(es)oftheholdersappearingunder"DescriptionofOriginalNotesTendered."Intheeventthatboththe"SpecialIssuanceInstructions"andthe"SpecialDeliveryInstructions"arecompleted,pleaseissuethecertificatesrepresentingtheExchangeNotesissuedinexchangefortheOriginalNotesacceptedforexchangeinthename(s)of,andreturnanyOriginalNotesnottenderedornotacceptedforexchangeto,thepersonorpersonssoindicated.Unlessotherwiseindicatedunder"SpecialIssuanceInstructions,"inthecaseofabook-entrydeliveryofOriginalNotes,pleasecredittheaccountmaintainedatDTCwithanyOriginalNotesnottenderedornotacceptedforexchange.TheundersignedrecognizesthattheCompanydoesnothaveanyobligationpursuanttotheSpecialIssuanceInstructions,totransferanyOriginalNotesfromthenameoftheholderthereofiftheCompanydoesnotacceptforexchangeanyoftheOriginalNotessotenderedorifsuchtransferwouldnotbeincompliancewithanytransferrestrictionsapplicabletosuchOriginalNotes.
8
SPECIAL ISSUANCE INSTRUCTIONS (See Instructions 1, 6, 7 and 8)
TobecompletedONLYif(i)ExchangeNotesissuedinexchangeforOriginalNotes,certificatesforOriginalNotesinaprincipalamountnotexchangedforExchangeNotes,orOriginalNotes(ifany)nottenderedforexchangearetobeissuedinthenameofsomeoneotherthantheundersigned,or(ii)OriginalNotestenderedbybook-entrytransferwhicharenotexchangedaretobereturnedbycredittoanaccountmaintainedatDTCotherthantheaccountindicatedaboveintheboxentitled,"DescriptionofOriginalNotesTendered."
SPECIAL DELIVERY INSTRUCTIONS (See Instructions 1, 6, 7 and 8)
TobecompletedONLYiftheExchangeNotesissuedinexchangeforOriginalNotes,certificatesforOriginalNotesinaprincipalamountnotexchangedforExchangeNotes,orOriginalNotes(ifany)nottenderedforexchangearetobesenttosomeoneotherthantheundersignedortotheundersignedatanaddressotherthanthatshownaboveintheboxentitled,"DescriptionofOriginalNotesTendered."
9
Issueto:
Name:
(Please Print)
Address:
(Include Zip Code)
TaxpayerIdentificationorSocialSecurityNumber:
CreditOriginalNotesnotexchangedanddeliveredbybook-entrytransfertotheDTCaccountsetforthbelow:
(Account Number)
Mailto:
Name:
(Please Print)
Address:
(Include Zip Code)
TaxpayerIdentificationorSocialSecurityNumber:
SIGN HERE TO TENDER YOUR ORIGINAL NOTES IN THE EXCHANGE OFFERS SIGNATURE(S) OF HOLDERS OF ORIGINAL NOTES
ThisLetterofTransmittalmustbesignedbytheregisteredholdersofOriginalNotesexactlyasthename(s)appear(s)oncertificate(s)representingtheOriginalNotesoronasecuritypositionlistingorbyperson(s)authorizedtobecomeregisteredholdersbycertificatesanddocumentstransmittedherewith.Ifsignatureisbyattorney-in-fact,executor,administrator,trustee,guardian,officerofacorporationorotherpersonactinginafiduciaryorrepresentativecapacity,pleaseprovidethefollowinginformationandseeInstruction6.
GUARANTEE OF SIGNATURE(S) (If required—see Instructions 1 and 6)
10
X Date:
X Date: (Signature of Owner)
Name(s): Address: (Please Print)
(Include Zip Code)
Capacity: TelephoneNumber: (Full Title) (Include Area Code)
Signature(s)Guaranteedby: (Authorized Signature)
(Title of Officer Signing this Guarantee)
(Name of Eligible Institution Guaranteeing Signatures—Please Print)
(Address and Telephone Number of Eligible Institution Guaranteeing Signatures)
Date:
INSTRUCTIONS
Forming Part of the Terms and Conditions of the Exchange Offers
1. Guarantee of Signatures. SignaturesonthisLetterofTransmittalneednotbeguaranteedif:
• tenderedOriginalNotesareregisteredinthenameofthesigneroftheLetterofTransmittal,unlesssuchholderhascompletedeithertheboxentitled"SpecialIssuanceInstructions"ortheboxentitled"SpecialDeliveryInstructions;"
• theExchangeNotestobeissuedinexchangefortheOriginalNotesaretobeissuedinthenameoftheholder;and
• anyuntenderedOriginalNotesaretobereissuedinthenameoftheholder.
Inanyothercase:
• thecertificatesrepresentingthetenderedOriginalNotesmustbeproperlyendorsedfortransferbytheregisteredholderorbeaccompaniedbyaproperlycompletedbondpowerfromtheregisteredholderorappropriatepowersofattorney,inaformsatisfactorytous;and
• signaturesontheendorsement,bondpowerorpowersofattorneymustbeguaranteedbyanEligibleInstitution.
IftheExchangeNotesorOriginalNotesnotexchangedaretobedeliveredtoanaddressotherthanthatoftheregisteredholderappearingonthenoteregistrarfortheOriginalNotes,thesignatureintheLetterofTransmittalmustbeguaranteedbyanEligibleInstitution.
PersonswhoarebeneficialownersofOriginalNotesbutarenottheregisteredholderandwhoseektotenderOriginalNotesforexchangeshould:
• promptlycontacttheregisteredholderofsuchOriginalNotesandinstructsuchregisteredholderstotenderonhisorherbehalf;
• obtainandincludewiththisLetterofTransmittal,OriginalNotesproperlyendorsedfortransferbytheregisteredholderoraccompaniedbyaproperlycompletedbondpowerfromtheregisteredholder,withsignaturesontheendorsementorbondpowerguaranteedbyanEligibleInstitution;or
• effectarecordtransferofsuchOriginalNotesfromtheregisteredholdertosuchbeneficialownerandcomplywiththerequirementsapplicabletoregisteredholdersfortenderingOriginalNotespriortotheExpirationDate.SeeInstruction6.
DO NOT SEND THIS LETTER OF TRANSMITTAL OR ANY ORIGINAL NOTES TO THE COMPANY.
2. Delivery of this Letter of Transmittal and Certificates for Original Notes or Book-Entry Confirmations; Guaranteed Delivery Procedures. ThisLetterofTransmittalistobecompletedbyregisteredholdersifcertificatesrepresentingOriginalNotesaretobeforwardedherewith.AllphysicallydeliveredOriginalNotes,aswellasaproperlycompletedanddulyexecutedLetterofTransmittal(ormanuallysignedfacsimilesthereof)andanyotherrequireddocuments,mustbereceivedbytheExchangeAgentatitsaddresssetforthonthecoverofthisLetterofTransmittalpriortotheExpirationDateorthetenderingholdermustcomplywiththeguaranteeddeliveryproceduressetforthbelow.DeliveryofthedocumentstoDTCdoesnotconstitutedeliverytotheExchangeAgent.
THE METHOD OF DELIVERY OF THIS LETTER OF TRANSMITTAL, ORIGINAL NOTES AND ALL OTHER REQUIRED DOCUMENTS TO THE EXCHANGE AGENT IS AT THE ELECTIONAND RISK OF THE HOLDER THEREOF. IF SUCH DELIVERY IS BY MAIL, IT IS SUGGESTED THAT HOLDERS USE PROPERLY INSURED REGISTERED MAIL, RETURN
11
RECEIPT REQUESTED, AND THAT THE MAILING BE SUFFICIENTLY IN ADVANCE OF THE EXPIRATION DATE, TO PERMIT DELIVERY TO THE EXCHANGE AGENT PRIOR TO SUCHDATE. EXCEPT AS OTHERWISE PROVIDED BELOW, THE DELIVERY WILL BE DEEMED MADE WHEN ACTUALLY RECEIVED OR CONFIRMED BY THE EXCHANGE AGENT. THIS LETTEROF TRANSMITTAL AND ORIGINAL NOTES TENDERED FOR EXCHANGE SHOULD BE SENT ONLY TO THE EXCHANGE AGENT, NOT TO THE COMPANY.
IfaholderdesirestotenderOriginalNotespursuanttotheExchangeOffersandsuchholder'sOriginalNotesare(i)notimmediatelyavailable;(ii)suchholdercannotdeliveritsOriginalNotes,thisLetterofTransmittalandallotherdocumentsrequiredherebytotheExchangeAgentpriortotheExpirationDate;or(iii)suchholdercannotcompletetheproceduresforbook-entrytransferonorpriortotheExpirationDate,suchholdermayeffectatenderofsuchOriginalNotesinaccordancewiththeguaranteeddeliveryproceduressetforthintheProspectusunder"TheExchangeOffers—ProceduresforTenderingOriginalNotes—GuaranteedDelivery."
Pursuanttotheguaranteeddeliveryprocedures:
• yourtenderofOriginalNotesmustbemadebyorthroughanEligibleInstitutionandyoumustproperlycompleteanddulyexecuteaNoticeofGuaranteedDelivery;
• onorpriortotheExpirationDate,theExchangeAgentmusthavereceivedfromyouandtheEligibleInstitutionaproperlycompletedanddulyexecutedNoticeofGuaranteedDelivery(byfacsimiletransmission,mailorhanddelivery)settingforththenameandaddressoftheholder,thecertificatenumberornumbersofthetenderedOriginalNotes,andtheprincipalamountoftenderedOriginalNotes,statingthatthetenderisbeingmadetherebyandguaranteeingthat,withinthree(3)businessdaysafterthedateofdeliveryoftheNoticeofGuaranteedDelivery,thetenderedOriginalNotes,adulyexecutedLetterofTransmittalandanyotherrequireddocumentswillbedepositedbytheEligibleInstitutionwiththeExchangeAgent;and
• suchproperlycompletedandexecuteddocumentsrequiredbytheLetterofTransmittalandthetenderedOriginalNotesinproperformfortransfer(orconfirmationofabook-entrytransferofsuchOriginalNotesintotheExchangeAgent'saccountatDTC)mustbereceivedbytheExchangeAgentwithinthree(3)businessdaysaftertheExpirationDate.
AnyholderwhowishestotenderitsOriginalNotespursuanttotheguaranteeddeliveryproceduresdescribedabovemustensurethattheExchangeAgentreceivestheNoticeofGuaranteedDeliveryrelatingtosuchOriginalNotespriorto5:00p.m.,NewYorkCitytime,ontheExpirationDate.
UnlessOriginalNotesbeingtenderedbytheabove-describedmethodaredepositedwiththeExchangeAgent,atenderwillbedeemedtohavebeenreceivedasofthedatewhenthetenderingholder'sproperlycompletedanddulysignedLetterofTransmittal,oraproperlytransmittedagent'smessage,accompaniedbytheOriginalNotesoraconfirmationofbook-entrytransferoftheOriginalNotesintotheExchangeAgent'saccountatthebook-entrytransferfacilityisreceivedbytheExchangeAgent.
IssuancesofExchangeNotesinexchangeforOriginalNotestenderedpursuanttoanoticeofguaranteeddeliverywillbemadeonlyagainstdepositofthisLetterofTransmittalandanyotherrequireddocumentsandthetenderedOriginalNotesoraconfirmationofbook-entryandanagent'smessage.
Alltenderingholders,byexecutionofthisLetterofTransmittal,waiveanyrighttoreceiveanynoticeoftheacceptanceoftheirOriginalNotesforexchange.
12
3. Inadequate Space. Ifthespaceprovidedintheboxentitled"DescriptionofOriginalNotesTendered"aboveisinadequate,thecertificatenumbersandprincipalamountsofOriginalNotestenderedshouldbelistedonaseparatesignedscheduleaffixedhereto.
4. Withdrawal of Tenders. AtenderofOriginalNotesmaybewithdrawnatanytimepriortotheExpirationDatebydeliveryofwrittenorfacsimile(receiptconfirmedbytelephone)noticeofwithdrawaltotheExchangeAgentattheaddresssetforthonthecoverofthisLetterofTransmittal.Tobeeffective,anoticeofwithdrawalmust:
• specifythenameofthepersonhavingtenderedtheOriginalNotestobewithdrawn(the"Depositor");
• identifytheOriginalNotestobewithdrawn(includingthecertificatenumberornumbersandprincipalamountofsuchOriginalNotes);
• specifytheprincipalamountofOriginalNotestobewithdrawn;
• includeastatementthatsuchholderiswithdrawinghisorherelectiontohavesuchOriginalNotesexchanged;
• besignedbytheholderinthesamemannerastheoriginalsignatureontheLetterofTransmittalbywhichsuchOriginalNotesweretenderedorasotherwisedescribedabove(includinganyrequiredsignatureguarantees)orbeaccompaniedbydocumentsoftransfersufficienttohavethetrusteeundertheIndentureregisterthetransferofsuchOriginalNotesintothenameofthepersonwithdrawingthetender;and
• specifythenameinwhichanysuchOriginalNotesaretoberegistered,ifdifferentfromthatoftheDepositor.
TheExchangeAgentwillreturntheproperlywithdrawnOriginalNotespromptlyfollowingreceiptofnoticeofwithdrawal.IfOriginalNoteshavebeentenderedpursuanttotheprocedureforbook-entrytransfer,anynoticeofwithdrawalmustspecifythenameandnumberoftheaccountatthebook-entrytransferfacility.Allquestionsastothevalidityofnoticesofwithdrawals,including,timeofreceipt,willbedeterminedbytheCompanyandsuchdeterminationwillbefinalandbindingonallparties.
AnyOriginalNotessowithdrawnwillbedeemednottohavebeenvalidlytenderedforexchangeforpurposesoftheExchangeOffers.AnyOriginalNoteswhichhavebeentenderedforexchangebutwhicharenotexchangedforanyreasonwillbereturnedtotheholderthereofwithoutcosttosuchholder(or,inthecaseofOriginalNotestenderedbybook-entrytransferintotheExchangeAgent'saccountatthebook-entrytransferfacilitypursuanttothebook-entrytransferproceduresdescribedabove,suchOriginalNoteswillbecreditedtoanaccountwithsuchbook-entrytransferfacilityspecifiedbytheholder)assoonaspracticableafterwithdrawal,rejectionoftenderorterminationoftheExchangeOffers.ProperlywithdrawnOriginalNotesmayberetenderedbyfollowingoneoftheproceduresdescribedunderthecaption"TheExchangeOffers—ProceduresforTenderingOriginalNotes"intheProspectusatanytimepriortotheExpirationDate.
5. Partial Tenders (Not Applicable to Holders of Original Notes that Tender by Book-Entry Transfer). TendersofOriginalNoteswillbeacceptedonlyindenominationsoftheprincipalamountof$2,000andintegralmultiplesof$1,000inexcessthereof.IfatenderforexchangeistobemadewithrespecttolessthantheentireprincipalamountofanyOriginalNotes,fillintheprincipalamountofOriginalNoteswhicharetenderedforexchangeincolumn(4)oftheboxentitled"DescriptionofOriginalNotesTendered,"asmorefullydescribedinthefootnotesthereto.Inthecaseofapartialtenderforexchange,newcertificates,infullyregisteredform,fortheremainderoftheprincipalamountoftheOriginalNotes,willbesenttotheholdersofOriginalNotesunlessotherwiseindicatedintheboxesentitled"SpecialIssuanceInstructions"or"SpecialDeliveryInstructions"above,assoonaspracticableaftertheexpirationorterminationoftheExchangeOffers.
13
6. Signatures on this Letter of Transmittal; Bond Powers and Endorsements. IfthisLetterofTransmittalissignedbytheregisteredholderoftheOriginalNotestenderedforexchangehereby,thesignature(s)mustcorrespondexactlywiththename(s)aswrittenonthefaceofthecertificate(s)withoutalteration,enlargementoranychangewhatsoever.
IfanyoftheOriginalNotestenderedherebyareownedofrecordbytwoormorejointowners,allsuchownersmustsignthisLetterofTransmittal.IfanytenderedOriginalNotesareregisteredindifferentnamesonseveralcertificates,itwillbenecessarytocomplete,signandsubmitasmanyseparatecopiesofthisLetterofTransmittalandanynecessaryorrequireddocumentsastherearenamesinwhichcertificatesareheld.
IfthisLetterofTransmittaloranycertificatesorbondpowersaresignedbytrustees,executors,administrators,guardians,attorneys-in-fact,officersofcorporationsorothersactinginafiduciaryorrepresentativecapacity,suchpersonsshouldsoindicatewhensigning,andproperevidencesatisfactorytotheCompanyoftheirauthoritysotoactmustbesubmitted,unlesswaivedbytheCompany.
IfthisLetterofTransmittalissignedbytheregisteredholderoftheOriginalNoteslistedandtransmittedhereby,noendorsementsofcertificatesorseparatebondpowersarerequiredunlesscertificatesforOriginalNotesnottenderedornotacceptedforexchangearetobeissuedorreturnedinthenameofapersonotherthanfortheregisteredholderthereof.SignaturesonsuchcertificatesmustbeguaranteedbyanEligibleInstitution(unlesssignedbyanEligibleInstitution).
IfthisLetterofTransmittalissignedbyapersonotherthantheregisteredholderoftheOriginalNotes,thecertificatesrepresentingsuchOriginalNotesmustbeproperlyendorsedfortransferbytheregisteredholderorbeaccompaniedbyaproperlycompletedbondpowerfromtheregisteredholderorappropriatepowersofattorney,inanycasesignedbysuchregisteredholderexactlyasthename(s)oftheregisteredholderoftheOriginalNotesappear(s)onthecertificates.SignaturesontheendorsementorbondpowermustbeguaranteedbyanEligibleInstitution(unlesssignedbyanEligibleInstitution).
7. Transfer Taxes. ExceptassetforthinthisInstruction7,theCompanywillpayorcausetobepaidanytransfertaxesapplicabletotheexchangeoftheOriginalNotespursuanttotheExchangeOffers.If,however,atransfertaxisimposedforanyreasonotherthantheexchangeofOriginalNotespursuanttotheExchangeOffers,thentheamountofanytransfertaxes(whetherimposedontheregisteredholdersoranyotherpersons)willbepayablebythetenderingholder.IfsatisfactoryevidenceofthepaymentofsuchtaxesorexemptionstherefromisnotsubmittedwiththisLetterofTransmittal,theamountofsuchtransfertaxeswillbebilleddirectlytosuchtenderingholder.
8. Special Issuance and Delivery Instructions. TenderingholdersofOriginalNotesshouldindicateintheapplicableboxthenameandaddresstowhichtheExchangeNotesissuedpursuanttotheExchangeOffersandanysubstitutecertificatesevidencingtheOriginalNotesnotexchangedaretobeissuedorsent,ifdifferentfromthenameoraddressofthepersonsigningthisLetterofTransmittal.Inthecaseofissuanceinadifferentname,theEmployerIdentificationorSocialSecurityNumberofthepersonnamedmustalsobeindicated.AholderofOriginalNotestenderingOriginalNotesbybook-entrytransfermayrequestthattheExchangeNotesandtheOriginalNotesnotexchangedbecreditedtosuchaccountmaintainedattheDTCassuchholderofOriginalNotesmaydesignate.Ifnosuchinstructionsaregiven,suchExchangeNotesandOriginalNotesnotexchangedwillbereturnedtothenameoraddressofthepersonsigningthisLetterofTransmittalorcreditedtotheaccountlistedbeneaththeboxentitled"DescriptionofOriginalNotes."
9. Irregularities. Allquestionsastotheformsofalldocumentsandthevalidityof(includingtimeofreceipt)andacceptanceofthetendersandwithdrawalsofOriginalNoteswillbedeterminedbytheCompany,initssolediscretion,whichdeterminationshallbefinalandbinding.TheCompanyreservestheabsoluterighttorejectanyoralltendersofOriginalNotesthatarenotinproperformor
14
theacceptanceofwhichwould,intheCompany'sopinionorthejudgmentoftheCompany'scounsel,beunlawful.TheCompanyalsoreservestherighttowaiveanydefects,irregularitiesorconditionsoftenderastoparticularOriginalNotes.TheCompany'sinterpretationsofthetermsandconditionsoftheExchangeOffers(includingtheinstructionsinthisLetterofTransmittal)willbefinalandbinding.AnydefectorirregularityinconnectionwithtendersofOriginalNotesmustbecuredwithinsuchtimeastheCompanydetermines,unlesswaivedbytheCompany.TendersofOriginalNotesshallnotbedeemedtohavebeenmadeuntilalldefectsorirregularitieshavebeenwaivedbytheCompanyorcured.NeithertheCompany,theExchangeAgent,noranyotherpersonwillbeunderanydutytogivenoticeofanydefectsorirregularitiesintendersofOriginalNotes,orwillincuranyliabilitytoregisteredholdersofOriginalNotesforfailuretogivesuchnotice.
10. Waiver of Conditions. Totheextentpermittedbyapplicablelaw,theCompanyreservestherighttowaiveanyandallconditionstotheExchangeOffersasdescribedunder"TheExchangeOffers—Conditions"intheProspectus,andacceptforexchangeanyOriginalNotestendered.
11. Tax Identification Number and Backup Withholding. FederalincometaxlawgenerallyrequiresthataholderofOriginalNoteswhosetenderedOriginalNotesareacceptedforexchangeorsuchholder'sassignee(ineithercase,the"Payee"),providetheExchangeAgent(the"Payor")withsuchPayee'scorrectTaxpayerIdentificationNumber("TIN")andcertainotherinformationonFormW-9,ortheappropriateFormW-8,andcertifyunderpenaltyofperjurythatsuchTINiscorrectandthatyouarenotsubjecttobackupwithholding.InthecaseofaPayeewhoisanindividual,theTINissuchPayee'ssocialsecuritynumber.Forcorporationsandotherentities,theTINistheEmployerIdentificationNumber.IfthePayorisnotprovidedwiththecorrectTINoranadequatebasisforanexemption,suchPayeemaybesubjecttoapenaltyimposedbytheInternalRevenueServiceandpaymentsmadewithrespecttotheOriginalNotesortheExchangeNotesmaybesubjecttobackupwithholding.Ifwithholdingresultsinanoverpaymentoftaxes,arefundmaybeobtained.
Topreventbackupwithholding,eachPayeemustprovidesuchPayee'scorrectTINbycompletingthe"FormW-9"attachedhereto,certifyingthattheTINprovidediscorrectandthat:
• thePayeeisexemptfrombackupwithholding;
• thePayeehasnotbeennotifiedbytheInternalRevenueServicethatsuchPayeeissubjecttobackupwithholdingasaresultofafailuretoreportallinterestordividends;or
• theInternalRevenueServicehasnotifiedthePayeethatsuchPayeeisnolongersubjecttobackupwithholding.
EachPayeemustalsocertifyitisaU.S.person(includingaU.S.residentalien),andcertifythatanyFATCAcodeenteredontheformindicatingthePayeeisexemptfromFATCAiscorrect.IfOriginalNotesand/orExchangeNotesareheldinmorethanonenameorarenotinthenameoftheactualowner,consulttheW-9instructionsforinformationonwhichTINtoreport.
ExemptPayees(including,amongothers,allcorporationsandcertainforeignindividuals)arenotsubjecttothesebackupwithholdingandreportingrequirements.Topreventpossibleerroneousbackupwithholding,anexemptPayeemustenteritscorrectTINinPartIoftheFormW-9andsignanddatetheform.SeetheinstructionsforfillingouttheFormW-9foradditionalguidance.APayeethatisaforeignpersonmayqualifyasexemptbysubmittingaproperlycompleted,appropriateIRSFormW-8(suchasanIRSFormW-8BEN),executedunderpenaltiesofperjury,certifyingsuchPayee'sexemptstatus.CopiesofIRSFormW-8BEN,FormW-8BEN-E,FormW-8ECIandFormW-8IMYcanbeobtainedfromtheIRSwebsiteatwww.irs.gov.Payeesareurgedtoconsulttheirowntaxadvisorstodeterminewhethertheyareexemptfromthesebackupwithholdingandreportingrequirements.
BackupwithholdingisnotanadditionalU.S.Federalincometax.Rather,theU.S.Federalincometaxliabilityofapersonsubjecttobackupwithholdingwillbereducedbytheamountoftaxwithheld.If
15
withholdingresultsinanoverpaymentoftaxes,arefundmaybeobtained,providedthattherequiredinformationisfurnishedtotheInternalRevenueService.
12. Mutilated, Lost, Stolen or Destroyed Original Notes. AnyholderwhoseOriginalNoteshavebeenmutilated,lost,stolenordestroyedshouldcontacttheExchangeAgentattheaddressortelephonenumbersetforthonthecoverofthisLetterofTransmittalforfurtherinstructions.
13. Requests for Assistance or Additional Copies. Requestsforassistancerelatingtotheprocedurefortendering,aswellasrequestsforadditionalcopiesoftheProspectus,thisLetterofTransmittalandtheNoticeofGuaranteedDeliverymaybedirectedtotheExchangeAgentatitsaddresssetforthonthecoverofthisLetterofTransmittal.
14. No Conditional Tenders. Noalternative,conditional,irregularorcontingenttenderswillbeaccepted.AlltenderingholdersofOriginalNotes,byexecutionofthisLetterofTransmittal,shallwaiveanyrighttoreceivenoticeoftheacceptanceoftheirOriginalNotesforexchange.
15. No Notice of Defect. NeithertheCompany,theExchangeAgentnoranyotherpersonisobligatedtogivenoticeofanydefectorirregularitywithrespecttoanytenderofOriginalNotesnorshallanyofthemincuranyliabilityforfailuretogiveanysuchnotice.
IMPORTANT—This Letter of Transmittal, together with certificates for tendered Original Notes and all other required documents, with any required signature guarantees and all other requireddocuments must be received by the Exchange Agent prior to the Expiration Date.
16
QuickLinks
Exhibit99.1
SPECIALISSUANCEINSTRUCTIONS(SeeInstructions1,6,7and8)SPECIALDELIVERYINSTRUCTIONS(SeeInstructions1,6,7and8)SIGNHERETOTENDERYOURORIGINALNOTESINTHEEXCHANGEOFFERSSIGNATURE(S)OFHOLDERSOFORIGINALNOTESGUARANTEEOFSIGNATURE(S)(Ifrequired—seeInstructions1and6)INSTRUCTIONSFormingPartoftheTermsandConditionsoftheExchangeOffers
QuickLinks--Clickheretorapidlynavigatethroughthisdocument
Exhibit 99.2
NOTICE OF GUARANTEED DELIVERY FOR
ELANCO ANIMAL HEALTH INCORPORATEDOffer to Exchange
$500,000,000 principal amount of 3.912% Senior Notes due 2021, registered under the Securities Act of 1933, for any and all outstanding 3.912% Senior Notes due 2021
(CUSIP Nos. 28414H AA1 and U2541F AA3)
$750,000,000 principal amount of 4.272% Senior Notes due 2023, registered under the Securities Act of 1933, for any and all outstanding 4.272% Senior Notes due 2023
(CUSIP Nos. 28414H AC7 and U2541F AC9)
$750,000,000 principal amount of 4.900% Senior Notes due 2028, registered under the Securities Act of 1933, for any and all outstanding 4.900% Senior Notes due 2028
(CUSIP Nos. 28414H AB9 and U2541F AB1)
Pursuant to the Prospectus dated , 2019
THE EXCHANGE OFFERS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON , 2019, UNLESS EXTENDED (SUCH TIME AND DATE, AS THE SAME MAY BE EXTENDEDFROM TIME TO TIME, THE "EXPIRATION DATE"). TENDERS MAY BE WITHDRAWN AT ANY TIME PRIOR TO THE EXPIRATION DATE.
The Exchange Agent is:
DEUTSCHE BANK TRUST COMPANY AMERICAS
DELIVERY OF THIS NOTICE OF GUARANTEED DELIVERY TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE OR TRANSMISSION TO A FACSIMILE NUMBER OTHER THAN THEONE LISTED ABOVE WILL NOT CONSTITUTE VALID DELIVERY TO THE EXCHANGE AGENT.
THIS FORM IS NOT TO BE USED TO GUARANTEE SIGNATURES. IF A SIGNATURE ON THE LETTER OF TRANSMITTAL IS REQUIRED TO BE GUARANTEED BY AN "ELIGIBLEINSTITUTION" UNDER THE INSTRUCTIONS THERETO, SUCH SIGNATURE GUARANTEE MUST APPEAR IN THE APPLICABLE SPACE PROVIDED IN THE LETTER OF TRANSMITTAL.
Thisformoronesubstantiallyequivalentheretomustbeusedbyaholderofthe(i)3.912%SeniorNotesdue2021(the"2021OriginalNotes");(ii)4.272%SeniorNotesdue2023(the"2023OriginalNotes");and(iii)4.900%SeniorNotesdue2028(the"2028OriginalNotes"andtogetherwiththe2021OriginalNotesandthe2023OriginalNotes,the"OriginalNotes")ofElancoAnimalHealthIncorporated,anIndianacorporation(the"Company"),toaccepttheCompany'sofferstoexchange(the"ExchangeOffers")the(i)3.912%SeniorNotesdue2021thathavebeenregisteredundertheSecuritiesActof1933,asamended(the"SecuritiesAct")(the"2021ExchangeNotes"),foranyandalloutstanding2021OriginalNotes;(ii)4.272%SeniorNotesdue2023thathavebeenregisteredunder
By registered or certified mail, hand or overnight delivery:
Facsimile transactions: (For Eligible Institutions only)
DeutscheBankTrustCompanyAmericasc/oDBServicesAmericas,Inc.
Attn:ReorgDept.5022GateParkway,Suite200
Jacksonville,FL32256
615-866-3889Attention:ReorgDept.
To confirm by telephone: 877-843-9767
theSecuritiesAct(the"2023ExchangeNotes")foranyandalloutstanding2023OriginalNotes;and(iii)4.900%SeniorNotesdue2028thathavebeenregisteredundertheSecuritiesAct(the"2028ExchangeNotes"andtogetherwiththe2021ExchangeNotesandthe2023ExchangeNotes,the"ExchangeNotes")foranyandalloutstanding2028OriginalNotes,madepursuanttotheProspectus,dated,2019(the"Prospectus"),andtherelatedLetterofTransmittalandtheinstructionsthereto(the"LetterofTransmittal")ifsuchholder'sOriginalNotesarenotimmediatelyavailable,suchholdercannotdeliveritsOriginalNotes,theLetterofTransmittalandallotherrequireddocumentstotheExchangeAgentpriortotheExpirationDate,orsuchholdercannotcompletetheproceduresforbook-entrytransferonorpriortotheExpirationDate.Thisformmaybedeliveredbymailorhanddeliveryortransmitted,viafacsimile,totheExchangeAgentassetforthabove.CapitalizedtermsusedbutnotdefinedhereinshallhavethemeaninggiventothemintheProspectusortheLetterofTransmittal.
2
LadiesandGentlemen:
TheundersignedherebytenderstotheCompanyuponthetermsandsubjecttotheconditionssetforthintheProspectusandtherelatedLetterofTransmittal(receiptofwhichisherebyacknowledged),theaggregateprincipalamountofOriginalNotesspecifiedbelowpursuanttotheguaranteeddeliveryproceduressetforthintheProspectusandinInstruction2oftheLetterofTransmittal.
BysotenderingtheOriginalNotes,theundersigneddoesherebymake,atandasofthedatehereof,therepresentationsandwarrantiesofatenderingholderofOriginalNotessetforthintheLetterofTransmittal.TheundersignedunderstandsthattendersofOriginalNotesmaybewithdrawnpursuanttoInstruction4oftheLetterofTransmittal.
AllauthorityconferredoragreedtobeconferredbythisNoticeofGuaranteedDeliveryshallnotbeaffectedby,andshallsurvive,thedeathorincapacityoftheundersigned,andeveryobligationoftheundersignedunderthisNoticeofGuaranteedDeliveryshallbebindingupontheheirs,executors,administrators,trusteesinbankruptcy,personalandlegalrepresentatives,successorsandassignsoftheundersigned.
TheundersignedherebytenderstheOriginalNoteslistedbelow:
3
Name(s), Address(es) and Telephone Number(s) of Registered Holder(s) Title of Security Certificate Number(s)
Aggregate Principal Amount of Original Notes Tendered
(if less than all)
Total Principal Amount of Original Notes Tendered:
IfOriginalNoteswillbedeliveredbybook-entrytransfertotheDepositoryTrustCompany,pleaseprovidetheaccountnumber.Accountnumber:
PLEASE SIGN AND COMPLETE
ThisNoticeofGuaranteedDeliverymustbesignedbytheregisteredholder(s)ofOriginalNotesexactlyastheirname(s)appear(s)oncertificate(s)representingtheOriginalNotesoronasecuritypositionlistingorbyperson(s)authorizedtobecomeregisteredholdersbycertificatesanddocumentstransmittedherewith.
Ifsignatureisbyattorney-in-fact,executor,administrator,trustee,guardian,officerofacorporationorotherpersonactinginafiduciaryorrepresentativecapacity,pleaseprovidethefollowinginformation.SeeInstruction2.
PLEASE PRINT NAME(S) AND ADDRESS(ES)
THE ACCOMPANYING GUARANTEE MUST BE COMPLETED.
4
X
Date:
X (Signature(s) of Registered Holder or Authorized Signatory)
Date:
Name(s):
Address:
Capacity: (Full Title)
(Include Zip Code)
Name(s):
Capacity: (Full Title) TelephoneNumber:
(Include Area Code)
GUARANTEE (Not to Be Used for Signature Guarantee)
Theundersigned,afirmorotherentityidentifiedinRule17Ad-15undertheSecuritiesExchangeActof1934,asamended(the"ExchangeAct"),asan"eligibleguarantorinstitution,"including(assuchtermsaredefinedtherein):(i)abank;(ii)abroker,dealer,municipalsecuritiesbroker,municipalsecuritiesdealer,governmentsecuritiesbroker,governmentsecuritiesdealer;(iii)acreditunion;(iv)anationalsecuritiesexchange,registeredsecuritiesassociationorclearingagency;or(v)asavingsassociation(each,an"EligibleInstitution"),hereby(i)representsthattheabove-namedpersonsaredeemedtoowntheOriginalNotestenderedherebywithinthemeaningofRule14e-4promulgatedundertheExchangeAct("Rule14e-4"),(ii)representsthatsuchtenderofOriginalNotescomplieswithRule14e-4and(iii)guaranteesthattheOriginalNotestenderedherebyinproperformfortransferorconfirmationofbook-entrytransferofsuchOriginalNotesintotheExchangeAgent'saccountatthebook-entrytransferfacility,ineachcasetogetherwithaproperlycompletedanddulyexecutedLetterofTransmittal(ormanuallysignedfacsimilethereof)withanyrequiredsignatureguaranteesandanyotherdocumentsrequiredbytheLetterofTransmittal,willbereceivedbytheExchangeAgentatitsaddresssetforthabovewithinthree(3)businessdaysafterthedateofexecutionhereof.
TheEligibleInstitutionthatcompletesthisformmustcommunicatetheguaranteetotheExchangeAgentandmustdelivertheLetterofTransmittalandOriginalNotestotheExchangeAgentwithinthetimeperiodshownherein.FailuretodosocouldresultinafinanciallosstosuchEligibleInstitution.
PLEASE PRINT NAME(S) AND ADDRESS(ES)
DO NOT SEND ORIGINAL NOTES WITH THIS FORM. ORIGINAL NOTES SHOULD BE SENT TO THE EXCHANGE AGENT TOGETHER WITH A PROPERLY COMPLETED AND DULYEXECUTED LETTER OF TRANSMITTAL.
5
NameofFirm: Address:
By:
(Authorized Signature)
Name: (Include Zip Code)
Title: TelephoneNumber:
(Full Title) (Include Area Code)
Date:
INSTRUCTIONS
1. Delivery of this Notice of Guaranteed Delivery.
AproperlycompletedanddulyexecutedcopyofthisNoticeofGuaranteedDeliveryandanyotherdocumentsrequiredbythisNoticeofGuaranteedDeliverymustbereceivedbytheExchangeAgentatitsaddresssetforthhereinpriortotheExpirationDate.ThemethodofdeliveryofthisNoticeofGuaranteedDeliveryandanyotherrequireddocumentstotheExchangeAgentisattheelectionandsoleriskoftheholder,andthedeliverywillbedeemedmadeonlywhenactuallyreceivedbytheExchangeAgent.Ifdeliveryisbymail,registeredmailwithreturnreceiptrequested,properlyinsured,isrecommended.Asanalternativetodeliverybymail,theholdersmaywishtoconsiderusinganovernightorhanddeliveryservice.Inallcases,sufficienttimeshouldbeallowedtoassuretimelydelivery.
2. Signatures on this Notice of Guaranteed Delivery.
IfthisNoticeofGuaranteedDeliveryissignedbytheregisteredholderoftheOriginalNotestenderedforexchangehereby,thesignature(s)mustcorrespondexactlywiththename(s)aswrittenonthefaceofthecertificatewithoutalteration,enlargement,oranychangewhatsoever.IfthisNoticeofGuaranteedDeliveryissignedbyaparticipantoftheDepositoryTrustCompanywhosenameappearsonasecuritypositionlistingastheowneroftheOriginalNotes,thesignaturemustcorrespondwiththenameshownonthesecuritypositionlistingastheowneroftheOriginalNotes.
IfthisNoticeofGuaranteedDeliveryissignedbyapersonotherthantheregisteredholderoftheOriginalNotesoraparticipantoftheDepositoryTrustCompany,thecertificatesrepresentingsuchOriginalNotesmustbeproperlyendorsedfortransferbytheregisteredholderorbeaccompaniedbyaproperlycompletedbondpowerfromtheregisteredholderorappropriatepowersofattorney,inanycasesignedbysuchregisteredholderexactlyasthename(s)oftheregisteredholderoftheOriginalNotesappear(s)onthecertificates.SignaturesontheendorsementorbondpowermustbeguaranteedbyanEligibleInstitution(unlesssignedbyanEligibleInstitution).
IfthisNoticeofGuaranteedDeliveryissignedbytrustees,executors,administrators,guardians,attorneys-in-fact,officersofcorporationsorothersactinginafiduciaryorrepresentativecapacity,suchpersonsshouldsoindicatewhensigning,andproperevidencesatisfactorytotheCompanyofitsauthoritysotoactmustbesubmitted,unlesswaivedbytheCompany.
3. Requests for Assistance or Additional Copies.
Requestsforassistancerelatingtotheprocedurefortendering,aswellasrequestsforadditionalcopiesoftheProspectusandtheNoticeofGuaranteedDeliverymaybedirectedtotheExchangeAgentatitsaddresssetforthonthecoverofthisNoticeofGuaranteedDelivery.
6
QuickLinks
PLEASESIGNANDCOMPLETEPLEASEPRINTNAME(S)ANDADDRESS(ES)THEACCOMPANYINGGUARANTEEMUSTBECOMPLETED.GUARANTEE(NottoBeUsedforSignatureGuarantee)PLEASEPRINTNAME(S)ANDADDRESS(ES)INSTRUCTIONS
QuickLinks--Clickheretorapidlynavigatethroughthisdocument
Exhibit 99.3
ELANCO ANIMAL HEALTH INCORPORATED Offer to Exchange
$500,000,000 principal amount of 3.912% Senior Notes due 2021, registered under the Securities Act of 1933, for any and all outstanding 3.912% Senior Notes due 2021
(CUSIP Nos. 28414H AA1 and U2541F AA3)
$750,000,000 principal amount of 4.272% Senior Notes due 2023, registered under the Securities Act of 1933, for any and all outstanding 4.272% Senior Notes due 2023
(CUSIP Nos. 28414H AC7 and U2541F AC9)
$750,000,000 principal amount of 4.900% Senior Notes due 2028, registered under the Securities Act of 1933, for any and all outstanding 4.900% Senior Notes due 2028
(CUSIP Nos. 28414H AB9 and U2541F AB1)
Pursuant to the Prospectus dated , 2019
THE EXCHANGE OFFERS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON , 2019, UNLESS EXTENDED (SUCH TIME AND DATE, AS THE SAME MAY BE EXTENDEDFROM TIME TO TIME, THE "EXPIRATION DATE"). TENDERS MAY BE WITHDRAWN AT ANY TIME PRIOR TO THE EXPIRATION DATE.
ToBrokers,Dealers,CommercialBanks,TrustCompanies,CustodiansandSimilarInstitutions:
WeareenclosingherewiththematerialslistedbelowrelatingtotheoffersbyElancoAnimalHealthIncorporated,anIndianacorporation(the"Company"),toexchange(i)upto$500,000,000aggregateprincipalamountoftheCompany's3.912%SeniorNotesdue2021(the"2021ExchangeNotes")foranyandalloftheCompany'soutstandingunregistered3.912%SeniorNotesdue2021(the"2021OriginalNotes");(ii)upto$750,000,000aggregateprincipalamountoftheCompany's4.272%SeniorNotesdue2023(the"2023ExchangeNotes")foranyandalloftheCompany'soutstandingunregistered4.272%SeniorNotesdue2023(the"2023OriginalNotes");and(iii)upto$750,000,000aggregateprincipalamountoftheCompany's4.900%SeniorNotesdue2028(the"2028ExchangeNotes"andtogetherwiththe2021ExchangeNotesandthe2023ExchangeNotes,the"ExchangeNotes")foranyandalloftheCompany'soutstandingunregistered4.900%SeniorNotesdue2028(the"2028OriginalNotes"andtogetherwiththe2021OriginalNotesandthe2023OriginalNotes,the"OriginalNotes"),uponthetermsandsubjecttotheconditionssetforthintheCompany'sprospectus,dated,2019(the"Prospectus")andtherelatedLetterofTransmittal(which,togetherwiththeProspectusconstitutethe"ExchangeOffers").
Enclosedherewitharecopiesofthefollowingdocuments:
1. Prospectus;
2. LetterofTransmittal;
3. NoticeofGuaranteedDelivery;and
4. LetterwhichmaybesenttoyourclientsforwhoseaccountyouholdOriginalNotesinyournameorinthenameofyournominee,withspaceprovidedforobtainingsuchclient'sinstructionwithregardtotheExchangeOffers.
Weurgeyoutocontactyourclientspromptly.PleasenotethattheExchangeOfferswillexpireontheExpirationDateunlessextended.
TheExchangeOffersarenotconditioneduponanyminimumnumberofOriginalNotesbeingtendered.
TheCompanywillnotpayanyfeeorcommissionstoanybrokerordealerortoanyotherpersons(otherthantheExchangeAgent)inconnectionwiththesolicitationoftendersofOriginalNotespursuanttotheExchangeOffers.TheCompanywillpayorcausetobepaidanytransfertaxespayableonthetransferofOriginalNotestoit,exceptasotherwiseprovidedinInstruction7oftheenclosedLetterofTransmittal.
AdditionalcopiesoftheenclosedmaterialmaybeobtainedfromtheExchangeAgentatitsaddresssetforthonthecoveroftheLetterofTransmittal.
2
QuickLinks
Exhibit99.3
ELANCOANIMALHEALTHINCORPORATED
QuickLinks--Clickheretorapidlynavigatethroughthisdocument
Exhibit 99.4
ELANCO ANIMAL HEALTH INCORPORATEDOffer to Exchange
$500,000,000 principal amount of 3.912% Senior Notes due 2021, registered under the Securities Act of 1933, for any and all outstanding 3.912% Senior Notes due 2021
(CUSIP Nos. 28414H AA1 and U2541F AA3)
$750,000,000 principal amount of 4.272% Senior Notes due 2023, registered under the Securities Act of 1933, for any and all outstanding 4.272% Senior Notes due 2023
(CUSIP Nos. 28414H AC7 and U2541F AC9)
$750,000,000 principal amount of 4.900% Senior Notes due 2028, registered under the Securities Act of 1933, for any and all outstanding 4.900% Senior Notes due 2028
(CUSIP Nos. 28414H AB9 and U2541F AB1)
Pursuant to the Prospectus dated , 2019
THE EXCHANGE OFFERS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON 2019, UNLESS EXTENDED (SUCH TIME AND DATE, AS THE SAME MAY BE EXTENDED FROMTIME TO TIME, THE "EXPIRATION DATE"). TENDERS MAY BE WITHDRAWN AT ANY TIME PRIOR TO THE EXPIRATION DATE.
To Our Clients:
WeareenclosingherewithaProspectus,dated,2019(the"Prospectus"),ofElancoAnimalHealthIncorporated,anIndianacorporation(the"Company"),andrelatedLetterofTransmittal(which,togetherwiththeProspectus,constitutethe"ExchangeOffers")relatingtotheoffersbytheCompanytoexchange(i)upto$500,000,000aggregateprincipalamountoftheCompany's3.912%SeniorNotesdue2021thathavebeenregisteredundertheSecuritiesActof1933,asamended(the"SecuritiesAct")(the"2021ExchangeNotes"),foralikeamountoftheCompany'soutstandingunregistered3.912%SeniorNotesdue2021(the"2021OriginalNotes");(ii)upto$750,000,000aggregateprincipalamountoftheCompany's4.272%SeniorNotesdue2023thathavebeenregisteredundertheSecuritiesAct(the"2023ExchangeNotes")foralikeamountoftheCompany'soutstandingunregistered4.272%SeniorNotesdue2023(the"2023OriginalNotes");and(iii)upto$750,000,000aggregateprincipalamountoftheCompany's4.900%SeniorNotesdue2028thathavebeenregisteredundertheSecuritiesAct(the"2028ExchangeNotes"andtogetherwiththe2021ExchangeNotesandthe2023ExchangeNotes,the"ExchangeNotes")foralikeamountoftheCompany'soutstandingunregistered4.900%SeniorNotesdue2028(the"2028OriginalNotes"andtogetherwiththe2021OriginalNotesandthe2023OriginalNotes,the"OriginalNotes"),uponthetermsandsubjecttotheconditionssetforthintheExchangeOffers.
TheExchangeOffersarenotconditioneduponanyminimumnumberofOriginalNotesbeingtendered.
WearetheholderofrecordofOriginalNotesheldbyusforyourownaccount.AtenderofsuchOriginalNotescanbemadeonlybyusastherecordholderandpursuanttoyourinstructions.TheLetterofTransmittalisfurnishedtoyouforyourinformationonlyandcannotbeusedbyyoutotenderOriginalNotesheldbyusforyouraccount.
WerequestinstructionsastowhetheryouwishtotenderanyoralloftheOriginalNotesheldbyusforyouraccountpursuanttothetermsandconditionsoftheExchangeOffers.WealsorequestthatyouconfirmthatwemayonyourbehalfmaketherepresentationscontainedintheLetterofTransmittal.
Instructions with Respect to the Exchange Offers
TheundersignedherebyacknowledgesreceiptoftheProspectusandtheaccompanyingLetterofTransmittalrelatingtotheexchangeoftheOriginalNotesfortheExchangeNotes,whichhavebeenregisteredundertheSecuritiesAct,uponthetermsandsubjecttotheconditionssetforthintheExchangeOffers.
Thiswillinstructyou,theregisteredholderand/orbook-entrytransferfacilityparticipant,astotheactiontobetakenbyyourelatingtotheExchangeOfferswithrespecttotheOriginalNotesheldbyyoufortheaccountoftheundersigned.
TheaggregateprincipalamountoftheOriginalNotesheldbyyoufortheaccountoftheundersignedis(fillinanamount):
$ofthe3.912%SeniorNotesdue2021
$ofthe4.272%SeniorNotesdue2023
$ofthe4.900%SeniorNotesdue2028
WithrespecttotheExchangeOffers,theundersignedherebyinstructsyou(check appropriate box ):
oTotenderthefollowingOriginalNotesheldbyyoufortheaccountoftheundersigned(insert aggregate principal amount of Original Notes to be tendered (if any):
$ofthe3.912%SeniorNotesdue2021
$ofthe4.272%SeniorNotesdue2023
$ofthe4.900%SeniorNotesdue2028
oNottotenderanyOriginalNotesheldbyyoufortheaccountoftheundersigned.
IftheundersignedinstructsyoutotendertheOriginalNotesheldbyyoufortheaccountoftheundersigned,itisunderstoodthatyouareauthorizedtomake,onbehalfoftheundersigned(andtheundersigned,byitssignaturebelow,herebymakestoyou),therepresentationsandwarrantiescontainedintheLetterofTransmittalthataretobemadewithrespecttotheundersignedasabeneficialowner,includingbutnotlimitedtherepresentationsthat:
• theExchangeNotestobeacquiredinconnectionwiththeExchangeOffersbyeachbeneficialowneroftheOriginalNotesarebeingacquiredbysuchbeneficialownerintheordinarycourseofbusinessofsuchbeneficialowner;
• eachbeneficialownerisnotparticipating,doesnotintendtoparticipate,andhasnoarrangementorunderstandingwithanypersontoparticipate,inthedistributionoftheExchangeNotes;
• eachbeneficialowneracknowledgesandagreesthatanypersonparticipatingintheExchangeOffersforthepurposeofdistributingtheExchangeNotesmustcomplywiththeregistrationandprospectusdeliveryrequirementsoftheSecuritiesActinconnectionwithasecondaryresaletransactionandcannotrelyonthepositionofthestaffoftheSecuritiesandExchangeCommission(the"Commission")setforthintheapplicableno-actionletters,see"TheExchangeOffers—ResalesofExchangeNotes"intheProspectus,andthatasecondaryresaletransactionshouldbecoveredbyaneffectiveregistrationstatementcontainingthesellingsecurityholderinformationrequiredbyItem507or508,asapplicable,ofRegulationS-KoftheCommission;
• ifthebeneficialholderisabroker-dealer,suchbeneficialholderrepresentsthatitacquiredtheOriginalNotesforitsownaccountasaresultofmarketmakingorothertradingactivities(other
2
thantheOriginalNotesacquireddirectlyfromtheCompany),andthatitwilldeliveraprospectusinconnectionwithanyresaleofExchangeNotesacquiredintheExchangeOffers;
• ifthebeneficialholderisabroker-dealerandreceivesExchangeNotespursuanttotheExchangeOffersitshallnotifytheCompanybeforeusingtheProspectusinconnectionwithanysaleortransferoftheExchangeNotes;
• nosuchbeneficialownerisan"affiliate,"asdefinedunderRule405oftheSecuritiesAct,oftheCompanyorofanyoftheCompany'ssubsidiaries;and
• inconnectionwithabook-entrytransfer,eachparticipantwillconfirmthatitmakestherepresentationsandwarrantiessetforthintheLetterofTransmittal.
3
Nameofbeneficialowner(s):
Signature(s):
Name(s)(pleaseprint):
Address:
TelephoneNumber:
TaxpayerIdentificationorSocialSecurityNumber:
Date:
QuickLinks
Exhibit99.4
InstructionswithRespecttotheExchangeOffers